FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Carnes, M Johnson, P Klein, W Jenkins, M Merz, CNB AF Carnes, Molly Johnson, Paula Klein, Wendy Jenkins, Marjorie Merz, C. Noel Bairey TI Advancing Women's Health and Women's Leadership With Endowed Chairs in Women's Health SO ACADEMIC MEDICINE LA English DT Article ID INSTITUTES-OF-HEALTH; GENDER BIAS; ACADEMIC MEDICINE; PHYSICIAN-RESEARCHERS; CAREER-DEVELOPMENT; CLINICAL-TRIALS; PAY GAP; SEX; ARTHROPLASTY; SPECIALTIES AB Gender-based bias and conflation of gender and status are root causes of disparities in women's health care and the slow advancement of women to leadership in academic medicine. More than a quarter of women physicians train in internal medicine and its subspecialties, and women physicians almost exclusively constitute the women's health focus within internal medicine. Thus, internal medicine has considerable opportunity to develop women leaders in academic medicine and promote women's health equity. To probe whether holding an endowed chair-which confers status-in women's health may be an effective way to advance women leaders in academic medicine and women's health, the authors explored the current status of endowed chairs in women's health in internal medicine. They found that the number of these endowed chairs in North America increased from 7 in 2013 to 19 in 2015, and all were held by women. The perceptions of incumbents and other women's health leaders supported the premise that an endowed chair in women's health would increase women's leadership, the institutional stature of women's health, and activities in women's health research, education, and clinical care. Going forward, it will be important to explore why not all recipients perceived that the endowed chair enhanced their own academic leadership, whether providing women's health leaders with fundraising expertise fosters future success in increasing the number of women's health endowed chairs, and how the conflation of gender and status play out (e.g., salary differences between endowed chairs) as the number of endowed chairs in women's health increases. C1 [Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Sch Med & Publ Hlth, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Sch Med & Publ Hlth, Madison, WI USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Womens Hlth, Madison, WI USA. [Johnson, Paula] Brigham & Womens Hosp, Connors Ctr Womens Hlth & Gender Biol, 75 Francis St, Boston, MA 02115 USA. [Johnson, Paula] Brigham & Womens Hosp, Dept Med, Div Womens Hlth, 75 Francis St, Boston, MA 02115 USA. [Johnson, Paula] Harvard Med Sch, Epidemiol, Boston, MA USA. [Johnson, Paula] Wellesley Coll, Wellesley, MA 02181 USA. [Klein, Wendy] Inst Womens Hlth, Richmond, VA USA. [Klein, Wendy] Virginia Commonwealth Univ, Richmond, VA USA. [Jenkins, Marjorie] Laura W Bush Inst Womens Hlth, Amarillo, TX USA. [Jenkins, Marjorie] Texas Tech Univ, Hlth Sci Ctr, Med, Amarillo, TX USA. [Merz, C. Noel Bairey] Barbra Streisand Womens Heart Ctr, Los Angeles, CA USA. [Merz, C. Noel Bairey] Cedars Sinai Heart Inst, Med, Los Angeles, CA USA. RP Carnes, M (reprint author), Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU NIGMS NIH HHS [R01 GM111002] NR 60 TC 1 Z9 1 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2017 VL 92 IS 2 BP 167 EP 174 DI 10.1097/ACM.0000000000001423 PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA EK1IA UT WOS:000393677800017 PM 27759706 ER PT J AU Piper, ME Vasilenko, SA Cook, JW Lanza, ST AF Piper, Megan E. Vasilenko, Sara A. Cook, Jessica W. Lanza, Stephanie T. TI What a difference a day makes: differences in initial abstinence response during a smoking cessation attempt SO ADDICTION LA English DT Article DE Anhedonia; craving; latent class analysis; person-centered analysis; relapse; smoking cessation; withdrawal ID ECOLOGICAL MOMENTARY ASSESSMENT; NICOTINE WITHDRAWAL SYMPTOMS; TOBACCO WITHDRAWAL; NEGATIVE AFFECT; QUIT ATTEMPT; TIME-COURSE; IMMEDIATE ANTECEDENTS; ANXIETY SENSITIVITY; WISCONSIN INVENTORY; DEPENDENCE MOTIVES AB Aims To (1) identify distinct classes of smokers based on quit day withdrawal symptoms and (2) explore the relations between withdrawal classes and demographics, tobacco dependence, treatment and smoking outcomes. Design Secondary data analysis of participants (n = 1504) in a randomized double-blind placebo-controlled multi-site smoking cessation trial who provided ecological momentary assessments of withdrawal symptoms on their quit day. Participants received smoking cessation counseling and were randomized to receive placebo or one of five active pharmacotherapies. Setting Research offices in Madison and Milwaukee, Wisconsin, USA. Participants Adult smokers (n = 1236; 58% female, 86% white), recruited from the community via advertisements, who abstained on their quit day. Measurements Demographics and tobacco dependence were assessed at baseline and participants carried palmtop computers to record withdrawal symptoms (craving, negative affect, difficulty concentrating, hunger and anhedonia) on their quit day. Point-prevalence abstinence and latency to relapse were assessed at 8 weeks and 6 months post-quit. Findings Latent class analysis identified four withdrawal classes [Akaike information criterion (AIC) = 70.09]: Moderate withdrawal (64% of sample), high craving-anhedonia (8% of sample), affective withdrawal (13% of sample) and hunger (15% of sample). The high craving-anhedonia class reported significantly higher dependence (P < 0.01), were less likely to have received combination nicotine replacement, reported lower week 8 abstinence rates and relapsed sooner than those in the moderate withdrawal class (P < 0.05). The affective withdrawal class reported higher levels of baseline negative affect and life-time psychopathology (P < 0.05) and relapsed more quickly than the moderate withdrawal class (P < 0.01). Conclusions While the majority of smokers report typical levels of withdrawal symptoms on their quit day, more than one-third report extreme craving or extreme negative affective or extreme hunger responses to initial abstinence. These distinct quit-day withdrawal symptom patterns are related to baseline characteristics, treatment and cessation success. C1 [Piper, Megan E.; Cook, Jessica W.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. [Piper, Megan E.; Cook, Jessica W.] Univ Wisconsin, Dept Med, Madison, WI USA. [Vasilenko, Sara A.; Lanza, Stephanie T.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Lanza, Stephanie T.] Penn State Univ, Dept Biobehav Hlth & Human Dev, University Pk, PA 16802 USA. RP Piper, ME (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM mep@ctri.wisc.edu FU NIH [P50DA0197, P50 DA039838, R01 CA168676]; US Department of Veterans Affairs [101CX00056]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development; [1KL2RR025012] FX This research was funded by NIH Grant P50DA0197 to the University of Wisconsin Center for Tobacco Research and Intervention and NIH grants P50 DA039838 and R01 CA168676 to the Pennsylvania State University. M.E.P. was funded in part by 1KL2RR025012. J.W.C. was funded in part by a VA Merit Review Award 101CX00056 from the US Department of Veterans Affairs, and by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development. Medication was provided to patients at no cost under a research agreement with GlaxoSmithKline. NR 63 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD FEB PY 2017 VL 112 IS 2 BP 330 EP 339 DI 10.1111/add.13613 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EK5RP UT WOS:000393983800029 PM 27633341 ER PT J AU Petrakis, IL Simpson, TL AF Petrakis, Ismene L. Simpson, Tracy L. TI Posttraumatic Stress Disorder and Alcohol Use Disorder: A Critical Review of Pharmacologic Treatments SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Review DE PTSD; Alcohol Use Disorder; Critical Review; Pharmacotherapy ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY; CLINICAL-TRIAL; PILOT TRIAL; ALPHA-1-ADRENERGIC ANTAGONIST; SERTRALINE TREATMENT; COMORBIDITY SURVEY; EXPOSURE THERAPY; HEALTH-CARE AB Treatment of alcohol use disorder (AUD) is complicated by the presence of psychiatric comorbidity including posttraumatic stress disorder (PTSD). This is a critical review of the literature to date on pharmacotherapy treatments of AUD and PTSD. A systematic literature search using PubMed MESH terms for alcohol and substance use disorders, PTSD, and treatment was undertaken to identify relevant randomized controlled trials (RCTs). The studies were independently evaluated (ILP and TLS) and those that evaluated the efficacy of a pharmacotherapy for individuals diagnosed with AUD and PTSD and were RCTs were selected. Studies were grouped in 3 categories: (i) those that evaluated first-line treatments for PTSD, (ii) those that evaluated medications to target AUD, and (iii) those that evaluated medications hypothesized to be effective in targeting alcohol consumption as well as PTSD symptoms. Nine RCTs were identified; 3 focused on medications to treat PTSD, 4 focused on AUD, and 3 to target both. One study included both a medication to treat PTSD and 1 to treat AUD so was discussed twice. All but 1 of the studies found that PTSD symptoms and drinking outcomes improved significantly over time. There is not 1 agent with clear evidence of efficacy in this comorbid group. The results for medications to treat PTSD are inconclusive because of contradictory results. There was weak evidence to support the use of medications to treat AUD among those with comorbidity with PTSD. Findings for medications that were hypothesized to treat both disorders were also contradictory. Most studies provided a combination of interventions to treat both disorders. Despite the contradictory results, this review suggests that individuals with AUD and comorbid PTSD can safely be prescribed medications used in noncomorbid populations and patients improve with treatment. C1 [Petrakis, Ismene L.] VA CT Healthcare Syst, Mental Illness Res & Clin Ctr MIRECC, West Haven, CT USA. [Petrakis, Ismene L.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care, CESATE, Seattle, WA USA. [Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Petrakis, IL (reprint author), VA Connecticut Healthcare Syst, 116-A,950 Campbell Ave, West Haven, CT 06516 USA. EM ismene.petrakis@yale.edu FU NIH/NIAAA [R01AA020252-01-Simpson] FX We gratefully acknowledge the contributions of Jessica Dascher, Erin Gandleman, and Diana Limoncelli. This work was funded in part by a grant from NIH/NIAAA (R01AA020252-01-Simpson). NR 66 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD FEB PY 2017 VL 41 IS 2 BP 226 EP 237 DI 10.1111/acer.13297 PG 12 WC Substance Abuse SC Substance Abuse GA EK4IV UT WOS:000393891200001 PM 28102573 ER PT J AU Lo, GH Driban, JB Kriska, AM McAlindon, TE Souza, RB Petersen, NJ Storti, KL Eaton, CB Hochberg, MC Jackson, RD Kwoh, CK Nevitt, MC Suarez-Almazor, ME AF Lo, Grace H. Driban, Jeffrey B. Kriska, Andrea M. McAlindon, Timothy E. Souza, Richard B. Petersen, Nancy J. Storti, Kristi L. Eaton, Charles B. Hochberg, Marc C. Jackson, Rebecca D. Kwoh, C. Kent Nevitt, Michael C. Suarez-Almazor, Maria E. TI Is There an Association Between a History of Running and Symptomatic Knee Osteoarthritis? A Cross-Sectional Study From the Osteoarthritis Initiative SO ARTHRITIS CARE & RESEARCH LA English DT Article ID ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; MEN; QUESTIONNAIRE; RUNNERS; DENSITY; RISK AB ObjectiveRegular physical activity, including running, is recommended based on known cardiovascular and mortality benefits. However, controversy exists regarding whether running can be harmful to knees. The purpose of this study is to evaluate the relationship of running with knee pain, radiographic osteoarthritis (OA), and symptomatic OA. MethodsThis was a retrospective cross-sectional study of Osteoarthritis Initiative participants (2004-2014) with knee radiograph readings, symptom assessments, and completed lifetime physical activity surveys. Using logistic regression, we evaluated the association of history of leisure running with the outcomes of frequent knee pain, radiographic OA, and symptomatic OA. Symptomatic OA required at least 1 knee with both radiographic OA and pain. ResultsOf 2,637 participants, 55.8% were female, the meanSD age was 64.3 +/- 8.9 years, and the mean +/- SD body mass index was 28.5 +/- 4.9 kg/m(2); 29.5% of these participants ran at some time in their lives. Unadjusted odds ratios of pain, radiographic OA, and symptomatic OA for those prior runners and current runners compared to those who never ran were 0.83 and 0.71 (P for trend=0.002), 0.83 and 0.78 (P for trend=0.01), and 0.81 and 0.64 (P for trend=0.0006), respectively. Adjusted models were similar, except radiographic OA results were attenuated. ConclusionThere is no increased risk of symptomatic knee OA among self-selected runners compared with nonrunners in a cohort recruited from the community. In those without OA, running does not appear to be detrimental to the knees. C1 [Lo, Grace H.; Petersen, Nancy J.] Baylor Coll Med, 1 Baylor Plaza,BCM 285, Houston, TX 77030 USA. [Lo, Grace H.] Michael E DeBakey Med Ctr, Houston, TX USA. [Driban, Jeffrey B.; McAlindon, Timothy E.] Tufts Med Ctr, Boston, MA USA. [Kriska, Andrea M.] Univ Pittsburgh, Pittsburgh, PA USA. [Souza, Richard B.; Nevitt, Michael C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Storti, Kristi L.] Indiana Univ Penn, Indiana, PA USA. [Eaton, Charles B.] Mem Hosp Rhode Isl, Pawtucket, RI USA. [Eaton, Charles B.] Brown Univ, Alpert Med Sch, Pawtucket, RI USA. [Hochberg, Marc C.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Jackson, Rebecca D.] Ohio State Univ, Columbus, OH 43210 USA. [Kwoh, C. Kent] Univ Arizona, Tucson, AZ USA. [Suarez-Almazor, Maria E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Lo, GH (reprint author), Baylor Coll Med, 1 Baylor Plaza,BCM 285, Houston, TX 77030 USA. EM ghlo@bcm.edu OI Driban, Jeffrey/0000-0001-6098-4273 FU NIH [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Merck Research Laboratories; Novartis Pharmaceuticals; GlaxoSmithKline; Pfizer; Foundation for the NIH; VA Health Services Research and Development [CIN-13-413]; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23-AR062127, K24-AR053593] FX This article was prepared using an Osteoarthritis Initiative (OAI) public-use data set, and its contents do not necessarily reflect the opinions or views of the OAI Study Investigators, the NIH, or the private funding partners of the OAI. The OAI is a public-private partnership between the NIH (contracts N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) and private funding partners (Merck Research Laboratories, Novartis Pharmaceuticals, GlaxoSmithKline, and Pfizer) and is conducted by the OAI Study Investigators. Private-sector funding for the OAI is managed by the Foundation for the NIH.; Supported in part by the VA Health Services Research and Development service that funds the Center for Innovations in Quality, Effectiveness and Safety, at the Michael E. DeBakey VA Medical Center in Houston, Texas (CIN-13-413). Drs. Lo and Suarez-Almazor's work is supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants K23-AR062127 and K24-AR053593, respectively). NR 25 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2017 VL 69 IS 2 BP 183 EP 191 DI 10.1002/acr.22939 PG 9 WC Rheumatology SC Rheumatology GA EK4CU UT WOS:000393875500004 PM 27333572 ER PT J AU Furie, R Khamashta, M Merrill, JT Werth, VP Kalunian, K Brohawn, P Illei, GG Drappa, J Wang, LW Yoo, S AF Furie, Richard Khamashta, Munther Merrill, Joan T. Werth, Victoria P. Kalunian, Kenneth Brohawn, Philip Illei, Gabor G. Drappa, Jorn Wang, Liangwei Yoo, Stephen CA CD1013 Study Investigators TI Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID DISEASE-ACTIVITY INDEX; I INTERFERON; REVISED CRITERIA; CLASSIFICATION; THERAPY; CLASI AB Objective. To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). Methods. Patients (n=305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or >= 10), oral corticosteroid dosage (<10 or >= 10 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay. The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained reduction of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24). Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]-based Composite Lupus Assessment [BICLA], modified SRI[6], and major clinical response) were assessed at week 52. The primary end point was analyzed in the modified intent-to-treat (ITT) population and type I IFN-high subpopulation. The study result was considered positive if the primary end point was met in either of the 2 study populations. The Type I error rate was controlled at 0.10 (2-sided), within each of the 2 study populations for the primary end point analysis. Results. The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P=0.014 for 300 mg and P=0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo-treated patients versus 36.0% [P=0.004] and 28.2% [P=0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively. At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P<0.001] and 53.8% [P=0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P<0.001] and 41.2% [P=0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P=0.002] and 44.7% [P=0.015], respectively), major clinical response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [P=0.012] and 17.3% [P=0.025], respectively), and several other global and organ-specific end points. Herpes zoster was more frequent in the anifrolumab-treated patients (2.0% with placebo treatment versus 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, respectively), as were cases reported as influenza (2.0% versus 6.1% and 7.6%, respectively), in the anifrolumab treatment groups. Incidence of serious adverse events was similar between groups (18.8% versus 16.2% and 17.1%, respectively). Conclusion. Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE. C1 [Furie, Richard] Northwell Hlth, Hofstra Northwell Sch Med, New York, NY USA. [Khamashta, Munther] Kings Coll London, London WC2R 2LS, England. [Khamashta, Munther] St Thomas Hosp, London, England. [Merrill, Joan T.] Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA. [Kalunian, Kenneth] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. [Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei] MedImmune, Gaithersburg, MD USA. [Yoo, Stephen] Regenxbio, Rockville, MD USA. RP Furie, R (reprint author), Northwell Hlth, Div Rheumatol, 865 Northern Blvd, Great Neck, NY 11021 USA. EM RFurie@northwell.edu FU MedImmune FX The study was funded by MedImmune. All authors interpreted the data, critically reviewed the manuscript for important intellectual content, approved the final draft, and agreed to its submission. Publication of the article was contingent upon approval by MedImmune. Writing assistance was provided by Katie Alexander, PhD (QXV Communications, an Ashfield business, part of UDG Healthcare, Macclesfield, UK) and fully funded by MedImmune. NR 32 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2017 VL 69 IS 2 BP 376 EP 386 DI 10.1002/art.39962 PG 11 WC Rheumatology SC Rheumatology GA EK4FK UT WOS:000393882300015 PM 28130918 ER PT J AU Singh, A Laribi, S Teerlink, JR Mebazaa, A AF Singh, Abhishek Laribi, Said Teerlink, John R. Mebazaa, Alexandre TI Agents with vasodilator properties in acute heart failure SO EUROPEAN HEART JOURNAL LA English DT Review DE Acute heart failure; Vasodilators; Clinical trials; Outcomes; Haemodynamics ID SOLUBLE GUANYLATE-CYCLASE; CHIMERIC NATRIURETIC PEPTIDE; 1ST CLINICAL-EXPERIENCE; ARRESTIN-BIASED LIGAND; CINACIGUAT BAY 58-2667; PRE-RELAX-AHF; BETA-ARRESTIN; RENAL-FUNCTION; CD-NP; CONTROLLED TRIAL AB Millions of patients worldwide are admitted for acute heart failure (AHF) each year and physicians caring for these patients are confronted with the short-term challenges of reducing symptoms while preventing end organ dysfunction without causing additional harm, and the intermediate- term challenges of improving clinical outcomes such as hospital readmission and survival. There are limited data demonstrating the efficacy of any currently available therapies for AHF to meet these goals. After diuretics, vasodilators are the most common intravenous therapy for AHF, but neither nitrates, nitroprusside, nor nesiritide have robust evidence supporting their ability to provide meaningful effects on clinical outcomes, except perhaps early symptom improvement. Recently, a number of novel agents with vasodilating properties have been developed for the treatment of AHF. These agents include serelaxin, natriuretic peptides (ularitide, cenderitide), beta-arrestin-biased angiotensin II type 1 receptor ligands (TRV120027), nitroxyl donors (CXL-1020, CXL-1427), soluble guanylate cyclase modulators (cinaciguat, vericiguat), shortacting calcium channel blockers (clevidipine), and potassium channel activators (nicorandil). These development programmes range from the stage of early dose-finding studies (e. g. TRV120027, CXL-1427) to large, multicentre mortality trials (e. g. serelaxin, ularitide). There is an urgent need for agents with vasodilating properties that will improve both in-hospital and post-discharge clinical outcomes, and these novel approaches may provide opportunities to address this need. C1 [Singh, Abhishek; Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. [Singh, Abhishek; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Laribi, Said; Mebazaa, Alexandre] INSERM, UMRS 942, Biomarkers & Cardiac Dis, F-75010 Paris, France. [Laribi, Said] St Louis Lariboisiere Hosp, AP HP, Emergency Dept, F-75010 Paris, France. [Mebazaa, Alexandre] Univ Paris Diderot, Sorbonne Paris Cite, F-75010 Paris, France. [Mebazaa, Alexandre] St Louis Lariboisiere Hosp, AP HP, Dept Anesthesiol & Crit Care, F-75010 Paris, France. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA.; Teerlink, JR (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. EM john.teerlink@ucsf.edu FU Servier; Actelion; Amgen; Bayer; Cytokinetics; Novartis; Sevier; Trevena FX S.L. received fees as a member of advisory board from Servier. J.T. has received research grants and consulting fees from Actelion, Amgen, Bayer, Cytokinetics, Novartis, Sevier and Trevena. A.M. received speaker's honoraria from Abbott, Novartis, Orion, Roche et Servier. A.M. received fee as member of advisory board and/or Steering Committee from Cardiorentis, Adrenomed, MyCartis, ZS Pharma and Critical Diagnostics. NR 88 TC 1 Z9 1 U1 3 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD FEB 1 PY 2017 VL 38 IS 5 BP 317 EP + DI 10.1093/eurheartj/ehv755 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EK6DH UT WOS:000394014700007 PM 28201723 ER PT J AU von Frankenberg, AD Marina, A Song, XL Callahan, HS Kratz, M Utzschneider, KM AF von Frankenberg, Anize D. Marina, Anna Song, Xiaoling Callahan, Holly S. Kratz, Mario Utzschneider, Kristina M. TI A high-fat, high-saturated fat diet decreases insulin sensitivity without changing intra-abdominal fat in weight-stable overweight and obese adults SO EUROPEAN JOURNAL OF NUTRITION LA English DT Article DE Dietary fat; Saturated fat; High-fat diet; Insulin sensitivity ID LIFE-STYLE INTERVENTION; ADIPOSE-TISSUE; LIVER FAT; POLYUNSATURATED FAT; CARBOHYDRATE DIET; GLYCEMIC CONTROL; ACID SYNTHESIS; HEALTHY-MEN; DE-NOVO; RESISTANCE AB We sought to determine the effects of dietary fat on insulin sensitivity and whether changes in insulin sensitivity were explained by changes in abdominal fat distribution or very low-density lipoprotein (VLDL) fatty acid composition. Overweight/obese adults with normal glucose tolerance consumed a control diet (35 % fat/12 % saturated fat/47 % carbohydrate) for 10 days, followed by a 4-week low-fat diet (LFD, n = 10: 20 % fat/8 % saturated fat/62 % carbohydrate) or high-fat diet (HFD, n = 10: 55 % fat/25 % saturated fat/27 % carbohydrate). All foods and their eucaloric energy content were provided. Insulin sensitivity was measured by labeled hyperinsulinemic-euglycemic clamps, abdominal fat distribution by MRI, and fasting VLDL fatty acids by gas chromatography. The rate of glucose disposal (Rd) during low- and high-dose insulin decreased on the HFD but remained unchanged on the LFD (Rd-low: LFD: 0.12 +/- 0.11 vs. HFD: -0.37 +/- 0.15 mmol/min, mean +/- SE, p < 0.01; Rd-high: LFD: 0.11 +/- 0.37 vs. HFD: -0.71 +/- 0.26 mmol/min, p = 0.08). Hepatic insulin sensitivity did not change. Changes in subcutaneous fat were positively associated with changes in insulin sensitivity on the LFD (r = 0.78, p < 0.01) with a trend on the HFD (r = 0.60, p = 0.07), whereas there was no association with intra-abdominal fat. The LFD led to an increase in VLDL palmitic (16:0), stearic (18:0), and palmitoleic (16:1n7c) acids, while no changes were observed on the HFD. Changes in VLDL n-6 docosapentaenoic acid (22:5n6) were strongly associated with changes in insulin sensitivity on both diets (LFD: r = -0.77; p < 0.01; HFD: r = -0.71; p = 0.02). A diet very high in fat and saturated fat adversely affects insulin sensitivity and thereby might contribute to the development of type 2 diabetes. NCT00930371. C1 [von Frankenberg, Anize D.; Marina, Anna; Kratz, Mario; Utzschneider, Kristina M.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, 1959 NE Pacific St, Seattle, WA 98195 USA. [von Frankenberg, Anize D.] Univ Fed Rio Grande do Sul, Sch Med, Postgrad Endocrinol Program, Porto Alegre, RS, Brazil. [Song, Xiaoling; Kratz, Mario] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA. [Song, Xiaoling; Kratz, Mario] Univ Washington, Dept Epidemiol, 1959 NE Pacific St, Seattle, WA 98195 USA. [Callahan, Holly S.] Univ Washington, Sch Med, 1959 NE Pacific St, Seattle, WA 98195 USA. [von Frankenberg, Anize D.; Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Endocrinol, 1660 S Columbian Way 151, Seattle, WA 98108 USA. RP von Frankenberg, AD (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, 1959 NE Pacific St, Seattle, WA 98195 USA.; von Frankenberg, AD (reprint author), Univ Fed Rio Grande do Sul, Sch Med, Postgrad Endocrinol Program, Porto Alegre, RS, Brazil.; von Frankenberg, AD (reprint author), VA Puget Sound Hlth Care Syst, Endocrinol, 1660 S Columbian Way 151, Seattle, WA 98108 USA. EM anize.frankenberg@gmail.com; annam45@hotmail.com; hcal@uw.edu; mkratz@fhcrc.org; kutzschn@u.washington.edu FU Department of Veteran Affairs, Diabetes Research Center [P30DK017047]; Institute for Translational Health Sciences [UL1TR000423]; Nutrition Obesity Research Center [P30 DK035816]; Diagnostic Imaging Sciences Center at the University of Washington; Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES) FX We are grateful to the study participants for their contribution and time. This study was supported by funding and resources from the Department of Veteran Affairs, Diabetes Research Center (P30DK017047), the Institute for Translational Health Sciences (UL1TR000423), the Nutrition Obesity Research Center (P30 DK035816), the Diagnostic Imaging Sciences Center at the University of Washington, and the Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES) (AF). NR 50 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1436-6207 EI 1436-6215 J9 EUR J NUTR JI Eur. J. Nutr. PD FEB PY 2017 VL 56 IS 1 BP 431 EP 443 DI 10.1007/s00394-015-1108-6 PG 13 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EK8IW UT WOS:000394168100038 PM 26615402 ER PT J AU Thorlacius, L Ingram, J Garg, A Villumsen, B Esmann, S Kirby, J Gottlieb, AB Merola, J Dellavalle, R Christensen, R Jemec, GBE AF Thorlacius, L. Ingram, J. Garg, A. Villumsen, B. Esmann, S. Kirby, J. Gottlieb, A. B. Merola, J. Dellavalle, R. Christensen, R. Jemec, G. B. E. TI Development of a core domain set for managing hidradenitis suppurativa: Protocol for identification using an international patient and provider combined Delphi survey SO EXPERIMENTAL DERMATOLOGY LA English DT Meeting Abstract CT 6th Conference of the European-Hidradenitis-Suppurativa-Foundatation-e-V (EHSF) CY FEB 08-10, 2017 CL Copenhagen, DENMARK SP European Hidradenitis Suppurativa Fdn C1 [Thorlacius, L.] Univ Copenhagen, Fac Hlth Sci, Roskilde, Denmark. [Thorlacius, L.; Christensen, R.] Capital Reg Denmark, Parker Inst, Bispebjerg & Frederiksberg Hosp, Musculoskeletal Stat Unit, Copenhagen, Denmark. [Thorlacius, L.; Esmann, S.; Jemec, G. B. E.] Zealand Univ Hosp, Dept Dermatol, Roskilde, Denmark. [Ingram, J.] Univ Wales Hosp, Inst Infect & Immun, Hlth Pk, Cardiff, S Glam, Wales. [Garg, A.] Hofstra Northwell Sch Med, Dept Dermatol, New Hyde Pk, NY USA. [Villumsen, B.] Patients Assoc HS Denmark, Copenhagen, Denmark. [Kirby, J.] Penn State Hershey Med Ctr, Dept Dermatol, Hershey, PA USA. [Gottlieb, A. B.] New York Med Coll, Dept Dermatol, Valhalla, NY 10595 USA. [Merola, J.] Brigham & Womens Hosp, Div Rheumatol, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA. [Merola, J.] Brigham & Womens Hosp, Dept Med, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA. [Merola, J.] Harvard Med Sch, Boston, MA USA. [Dellavalle, R.] US Dept Vet Affairs, Med Ctr, Dermatol Serv, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0906-6705 EI 1600-0625 J9 EXP DERMATOL JI Exp. Dermatol. PD FEB PY 2017 VL 26 SU 1 SI SI MA P015 BP 34 EP 35 PG 2 WC Dermatology SC Dermatology GA EK4PE UT WOS:000393908300070 ER PT J AU Shen, BJ Xu, Y Eisenberg, S AF Shen, Biing-Jiun Xu, Yue Eisenberg, Stacy TI Psychosocial and Physiological Predictors of Mortality in Patients of Heart Failure: Independent Effects of Marital Status and C-Reactive Protein SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Heart failure; Mortality; Marital status; C-reactive protein; Depression; Social support ID EVENT-FREE SURVIVAL; QUALITY-OF-LIFE; DEPRESSIVE SYMPTOMS; CLINICAL-OUTCOMES; SELF-EFFICACY; RISK-FACTOR; DISEASE; INFLAMMATION; READMISSION; PREVALENCE AB Few studies have examined the interplay between psychosocial and physiological variables in prediction of mortality in heart failure (HF) patients. This study investigated the prospective influence of marital status, social support, depression, and C-reactive protein (CRP) on the mortality of patients with chronic HF. In addition, it examined whether there was a mediating relationship between social support and marital status and whether depression and inflammation influenced one another to predict mortality of HF patients. The participants were 220 HF patients, among whom 48 were deceased over an average of 4.60 years. A number of psychosocial and biomedical variables were examined for their associations with mortality and their relationships between each other in hierarchical logistic regression analyses. After adjusting for New York Heart Association (NYHA) class, age, and gender, being unmarried predicted mortality (OR = 2.80, p = 0.004), whereas perceived social support did not. Higher CRP was not associated with depression, and it independently predicted mortality (OR = 1.92, p = 0.030). Depression predicted mortality only in the univariate analysis (OR = 1.02, p = 0.030), but the association was no longer significant either after removing somatic items or after adjusting for covariates. In the combined multivariate model, marital status (OR = 2.20, p = 0.047), CRP (OR = 1.91, p = 0.035), and NYHA class (OR = 2.41, p = 0.001) independently predicted mortality. Monitoring chronic HF patients who are unmarried, with elevated inflammation, or in higher NYHA class may help identify those at greater mortality risk to implement targeted intervention. C1 [Shen, Biing-Jiun; Xu, Yue] Nanyang Technol Univ, Div Psychol, 14 Nanyang Dr,HSS04-02, Singapore 637332, Singapore. [Shen, Biing-Jiun] Univ Delaware, Dept Psychol & Brain Sci, Newark, DE 19716 USA. [Eisenberg, Stacy] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Shen, BJ (reprint author), Nanyang Technol Univ, Div Psychol, 14 Nanyang Dr,HSS04-02, Singapore 637332, Singapore.; Shen, BJ (reprint author), Univ Delaware, Dept Psychol & Brain Sci, Newark, DE 19716 USA. EM bshen@alumni.uchicago.edu FU American Heart Association [0530052N] FX The study was funded by the American Heart Association (Grant no. 0530052N). NR 59 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 EI 1532-7558 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD FEB PY 2017 VL 24 IS 1 BP 83 EP 91 DI 10.1007/s12529-016-9579-2 PG 9 WC Psychology, Clinical SC Psychology GA EK8CP UT WOS:000394151800013 PM 27384414 ER PT J AU Aldiss, P Davies, G Woods, R Budge, H Sacks, HS Symonds, ME AF Aldiss, Peter Davies, Graeme Woods, Rachel Budge, Helen Sacks, Harold S. Symonds, Michael E. TI 'Browning' the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Review DE Epicardial adipose tissue; Perivascular adipose tissue; Brown adipose tissue; CVD ID CONJUGATED LINOLEIC-ACID; CORONARY-ARTERY-DISEASE; REDUCES BODY-FAT; BETA(3)-ADRENERGIC RECEPTOR AGONIST; DIET-INDUCED THERMOGENESIS; ENERGY-EXPENDITURE; EPICARDIAL FAT; INSULIN SENSITIVITY; METABOLIC SYNDROME; GENE-EXPRESSION AB Excess visceral adiposity, in particular that located adjacent to the heart and coronary arteries is associated with increased cardiovascular risk. In the pathophysiological state, dysfunctional adipose tissue secretes an array of factors modulating vascular function and driving atherogenesis. Conversely, brown and beige adipose tissues utilise glucose and lipids to generate heat and are associated with improved cardiometabolic health. The cardiac and thoracic perivascular adipose tissues are now understood to be composed of brown adipose tissue in the healthy state and undergo a brown-to-white transition i.e. during obesity which may be a driving factor of cardiovascular disease. In this review we discuss the risks of excess cardiac and vascular adiposity and potential mechanisms by which restoring the brown phenotype i.e. "re-browning" could potentially be achieved in clinically relevant populations. (C) 2016 The Authors. Published by Elsevier Ireland Ltd. C1 [Aldiss, Peter; Davies, Graeme; Woods, Rachel; Budge, Helen; Symonds, Michael E.] Univ Nottingham, Univ Hosp, Sch Med, Div Child Hlth Obstet & Gynaecol,Early Life Res U, Nottingham NG7 2UH, England. [Sacks, Harold S.] VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. [Sacks, Harold S.] David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Symonds, ME (reprint author), Univ Nottingham, Univ Hosp, Div Child Hlth Obstet & Gynaecol, Sch Med, Nottingham NG7 2UH, England. EM michael.symonds@nottingham.ac.uk OI Aldiss, Peter/0000-0002-1809-2092 FU British Heart Foundation [FS/15/4/31184]; University of Nottingham and Cardio-metabolic Research Foundation, Los Angeles; BBSRC [BBSRCBB/I016015/1] FX P. Aldiss is funded by the British Heart Foundation (FS/15/4/31184), G. Davies is funded by University of Nottingham and Cardio-metabolic Research Foundation, Los Angeles (CRFLAPhD2012) and R. Woods is funded by the BBSRC (BBSRCBB/I016015/1). NR 171 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD FEB 1 PY 2017 VL 228 BP 265 EP 274 DI 10.1016/j.ijcard.2016.11.074 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EJ7NJ UT WOS:000393408600044 PM 27865196 ER PT J AU Cook, JW Baker, TB Beckham, JC McFall, M AF Cook, Jessica W. Baker, Timothy B. Beckham, Jean C. McFall, Miles TI Smoking-Induced Affect Modulation in Nonwithdrawn Smokers With Posttraumatic Stress Disorder, Depression, and in Those With No Psychiatric Disorder SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE Smoking; PTSD; depression; psychiatric comorbidity ID ECOLOGICAL MOMENTARY ASSESSMENT; COMORBIDITY SURVEY REPLICATION; ACOUSTIC STARTLE RESPONSE; VIETNAM COMBAT VETERANS; NEGATIVE AFFECT; CIGARETTE-SMOKING; NICOTINE DEPENDENCE; PSYCHOPHYSIOLOGICAL ASSESSMENT; OUTCOME EXPECTANCIES; TOBACCO WITHDRAWAL AB This research sought to determine whether smoking influences affect by means other than withdrawal reduction. Little previous evidence suggests such an effect. We surmised that such an effect would be especially apparent in posttraumatic stress disorder (PTSD) and major depressive disorder (MDD), 2 disorders that are frequently comorbid with smoking and that involve dysregulated affect. Participants were U.S. veterans who were regular smokers (N = 159): 52 with PTSD (58% with comorbid MDD), 51 with MDD, and 56 controls with no psychiatric disorder. During 3 positive and 3 negative mood induction trials (scheduled over 2 sessions), nonwithdrawn participants smoked either a nicotine-containing cigarette (NIC+), a nicotine-free cigarette (NIC-), or held a pen. Positive and negative affect were each measured before and after mood induction. Results showed a significant 2-way interaction of Smoking Condition = Time on negative affect during the negative mood induction (F(6, 576) = 2.41, p = .03) in those with PTSD and controls. In these groups, both NIC+ and NIC-, relative to pen, produced lower negative affect ratings after the negative mood induction. There was also a 2-way interaction of Smoking Condition = Time on positive affect response to the positive mood induction among those with PTSD and controls (F(6, 564) = 3.17, p = .005) and among MDD and controls (F(6, 564) = 2.27, p = .036). Among all smokers, NIC+ enhanced the magnitude and duration of positive affect more than did NIC-. Results revealed affect modulation outside the context of withdrawal relief; such effects may motivate smoking among those with psychiatric diagnoses, and among smokers in general. C1 [Cook, Jessica W.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Beckham, Jean C.] Durham VA Med Ctr, Durham, NC USA. [Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. [McFall, Miles] Univ Washington, Dept Psychiat & Behav Sci, Sch Med & Publ Hlth, Seattle, WA 98195 USA. [McFall, Miles] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Cook, JW (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM jwcook@ctri.medicine.wisc.edu FU National Institutes of Health [K08DA02131, K05CA139871]; U.S. Department of Veterans Affairs [101CX00056]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development FX This research was supported by Grants K08DA02131 and K05CA139871 from National Institutes of Health and by VA Merit Review Award 101CX00056 from the U.S. Department of Veterans Affairs, and by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development. NR 96 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2017 VL 126 IS 2 BP 184 EP 198 DI 10.1037/abn0000247 PG 15 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA EM9WV UT WOS:000395663000004 PM 28004948 ER PT J AU Fang, YJ Zhao, L Xiao, HP Cook, KM Bai, Q Herrick, EJ Chen, XH Qin, CL Zhu, ZW Wakefield, MR Nicholl, MB AF Fang, Yujiang Zhao, Lei Xiao, Huaping Cook, Kathryn M. Bai, Qian Herrick, Elizabeth J. Chen, Xuhui Qin, Chenglu Zhu, Ziwen Wakefield, Mark R. Nicholl, Michael B. TI IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer SO MEDICAL ONCOLOGY LA English DT Article DE IL-33; Apoptosis; Proliferation ID THYROID EPITHELIAL-CELLS; EXPERIMENTAL AUTOIMMUNE-THYROIDITIS; INDUCED ARTHRITIS; TUMOR-GROWTH; MICE; APOPTOSIS; PATHWAY; ST2; PROTEIN; T1/ST2 AB IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. We found that the percentage of colonies of MIA PaCa-2 cells, PCNA+ cells and the OD value of cancer cells were all decreased in the presence of IL-33. TUNEL+ cells and the relative caspase-3 activity in cancer cells were increased in the presence of IL-33. We further found that its anti-proliferative effect on cancer cells correlated with downregulation of pro-proliferative molecules cdk2 and cdk4 and upregulation of anti-proliferative molecules p15, p21 and p53. Its pro-apoptotic effect correlated with downregulation of anti-apoptotic molecule FLIP and upregulation of pro-apoptotic molecule TRAIL. These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells. Thus, strength of IL-33/ST2 signal pathway might be a promising way to treat pancreatic cancer. C1 [Fang, Yujiang; Xiao, Huaping; Chen, Xuhui] Des Moines Univ, Coll Osteopath Med, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA. [Fang, Yujiang; Cook, Kathryn M.; Bai, Qian; Herrick, Elizabeth J.; Qin, Chenglu; Zhu, Ziwen; Wakefield, Mark R.; Nicholl, Michael B.] Univ Missouri, Sch Med, Dept Surg, Columbia, MO 65212 USA. [Zhao, Lei] Anhui Med Univ, Affiliated Hosp 1, Dept Infect Dis, Hefei, Anhui, Peoples R China. [Nicholl, Michael B.] South Texas Vet Hlth Care Syst, Dept Surg, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Xiao, Huaping] Xiangnan Univ, Affiliated Hosp, Chenzhou, Hunan, Peoples R China. [Chen, Xuhui; Qin, Chenglu] Luohu Hosp, Shenzhen, Peoples R China. RP Fang, YJ (reprint author), Des Moines Univ, Coll Osteopath Med, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA.; Fang, YJ; Nicholl, MB (reprint author), Univ Missouri, Sch Med, Dept Surg, Columbia, MO 65212 USA.; Nicholl, MB (reprint author), South Texas Vet Hlth Care Syst, Dept Surg, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM yujiang.fang@dmu.edu; michaelnicholl@gmail.com FU Des Moines University [ISF 16-8, IOER 05-14-01, IOER 112-3749, IOER 112-3104]; University of Missouri FX This study was partially supported by grants from Des Moines University for Yujiang Fang (Iowa Science Foundation Grant ISF 16-8, IOER 05-14-01, IOER 112-3749 and IOER 112-3104). This study was also supported by a grant from University of Missouri for Michael B. Nicholl and Yujiang Fang. NR 50 TC 0 Z9 0 U1 3 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1357-0560 EI 1559-131X J9 MED ONCOL JI Med. Oncol. PD FEB PY 2017 VL 34 IS 2 AR 23 DI 10.1007/s12032-016-0880-3 PG 9 WC Oncology SC Oncology GA EK1MF UT WOS:000393689000009 PM 28058630 ER PT J AU Covert, KL Mardis, CR Fleming, JN Pilch, NA Meadows, HB Mardis, BA Mohan, P Posadas-Salas, M Srinivas, T Taber, DJ AF Covert, Kelly L. Mardis, Caitlin R. Fleming, James N. Pilch, Nicole A. Meadows, Holly B. Mardis, Benjamin A. Mohan, Prince Posadas-Salas, Maria Srinivas, Titte Taber, David J. TI Development of a Predictive Model for Drug-Related Problems in Kidney Transplant Recipients SO PHARMACOTHERAPY LA English DT Article DE transplant; drug safety; outcomes; pharmacy practice; renal ID MEDICATION ERRORS; RISK-FACTORS; PHARMACIST; PATIENT; EVENTS; RECONCILIATION; PREVENTABILITY; DISCHARGE; LEVEL; TEAM AB Study ObjectiveDrug-related problems (DRPs) are associated with increased rates of infection, rejection, and graft loss in kidney transplant recipients. This study aimed to develop a model to predict which patients are at highest risk of DRPs to streamline pharmacists' workflow in a chronic kidney transplant clinic. DesignProspective observational study. SettingChronic kidney transplant clinic at a large, tertiary care, academic hospital. PatientsTwo hundred thirty-seven adults seen in the kidney transplant clinic between September 16, 2015, and November 30, 2015, who were at least 90 days posttransplantation at the time of their clinic visit. Measurements and Main ResultsProspective data detailing DRPs and a survey assessing baseline characteristics and patient-related outcomes were used to generate a predictive model to identify patients at risk of having six or more DRPs; the cutoff of six DRPs provided a threshold for identifying a subset of high-risk patients on whom the transplant pharmacists could focus their efforts. DRPs were categorized as nonadherence, overdosing or underdosing, duplication of therapy, preventable adverse drug reaction, missing medication, erroneous medication, conflicting provider information, undermonitoring or lack of monitoring, and wrong medication received. In total, 865 unique DRPs were identified, and the most common were erroneous medication, missing medication, and nonadherence, accounting for 38%, 21%, and 16% of the DRPs, respectively. A nine-variable model with a sensitivity of 62.5% and specificity of 66.7% (area under the receiver operating characteristic curve of 0.720) was developed to identify patients at risk of having six or more DRPs. The model included the following variables: age, Medicaid for prescription insurance, current employment status, medication affordability, difficulty or lack of difficulty obtaining medications from the pharmacy, negative impact of medications on quality of life, medication nonadherence, poor rating of current health status, and moderate or poor medication understanding. ConclusionThese results demonstrated that a straightforward, 5-minute survey completed by renal transplant recipients prior to their clinic visit may be capable of effectively determining those at risk of having six or more DRPs, potentially allowing use as a screening tool for transplant pharmacists' workflow prioritization. External validation is needed before this tool can be used in the outpatient setting. C1 [Covert, Kelly L.] East Tennessee State Univ, Bill Gatton Coll Pharm, Dept Pharm Practice, Johnson City, TN USA. [Mardis, Caitlin R.] Med Univ South Carolina, Transplant Serv Line, Charleston, SC USA. [Fleming, James N.; Pilch, Nicole A.; Meadows, Holly B.; Mardis, Benjamin A.] Med Univ South Carolina, Dept Pharm Serv, Charleston, SC USA. [Mohan, Prince; Posadas-Salas, Maria; Srinivas, Titte] Med Univ South Carolina, Dept Transplant Nephrol, Charleston, SC USA. [Taber, David J.] Med Univ South Carolina, Dept Surg, Charleston, SC USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. RP Covert, KL (reprint author), Maple Ave,Bldg 7,Room 312, Johnson City, TN 37614 USA. EM covertk@etsu.edu NR 26 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD FEB PY 2017 VL 37 IS 2 BP 159 EP 169 DI 10.1002/phar.1886 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EL4JV UT WOS:000394588400002 PM 27997676 ER PT J AU Frei, CR Rehani, S Lee, GC Boyd, NK Attia, E Pechal, A Britt, RS Mortensen, EM AF Frei, Christopher R. Rehani, Sylvie Lee, Grace C. Boyd, Natalie K. Attia, Erene Pechal, Ashley Britt, Rachel S. Mortensen, Eric M. TI Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy SO PHARMACOTHERAPY LA English DT Article DE evidence-based medicine; infectious disease; outcomes; pharmacy practice; pulmonary ID CARE-ASSOCIATED PNEUMONIA; MULTIDRUG-RESISTANT PATHOGENS; INFECTIOUS-DISEASES-SOCIETY; ACQUIRED PNEUMONIA; ANTIBIOTIC-THERAPY; THORACIC-SOCIETY; OUTCOMES; EPIDEMIOLOGY; AERUGINOSA; BACTERIA AB Study ObjectiveTo assess the impact of empiric Pseudomonas pharmacotherapy on 30-day mortality in hospitalized patients with community-onset pneumonia stratified according to their risk (low, medium, or high) of drug-resistant pathogens. DesignRetrospective cohort study. Data SourceVeterans Health Administration database. PatientsA total of 50,119 patients who were at least 65 years of age, hospitalized with pneumonia, and received antibiotics within 48 hours of admission between fiscal years 2002 and 2007. Patients were stratified into empiric Pseudomonas therapy (31,027 patients) and no Pseudomonas therapy (19,092 patients) groups based on antibiotics received during their first 48 hours of admission. Measurements and Main ResultsA clinical prediction scoring system developed in 2014 that stratifies patients with community-onset pneumonia according to their risk of drug-resistant pathogens was used to identify patients who were likely to benefit from empiric Pseudomonas therapy as well as those in whom antipseudomonal therapy could be spared; patients were classified into low-risk (68%), medium-risk (21%), and high-risk (11%) groups. Of the 50,119 patients, 62% received Pseudomonas therapy. All-cause 30-day mortality was the primary outcome. Empiric Pseudomonas therapy (adjusted odds ratio 0.72, 95% confidence interval 0.62-0.84) was associated with lower 30-day mortality in the high-risk group but not the low- or medium-risk groups. ConclusionApplication of a risk score for patients with drug-resistant pathogens can identify patients likely to benefit from empiric Pseudomonas therapy. Widespread use of this score could reduce overuse of anti-Pseudomonas antibiotics in low- to medium-risk patients and improve survival in high-risk patients. C1 [Frei, Christopher R.; Rehani, Sylvie; Lee, Grace C.; Boyd, Natalie K.; Attia, Erene; Pechal, Ashley; Britt, Rachel S.] Univ Texas Austin, Coll Pharm, Pharmacotherapy Div, Austin, TX 78712 USA. [Frei, Christopher R.; Rehani, Sylvie; Lee, Grace C.; Boyd, Natalie K.; Attia, Erene; Pechal, Ashley; Britt, Rachel S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Pharmacotherapy Educ & Res Ctr, 7703 Floyd Curl Dr,MSC 6220, San Antonio, TX 78229 USA. [Frei, Christopher R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. RP Frei, CR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Pharmacotherapy Educ & Res Ctr, 7703 Floyd Curl Dr,MSC 6220, San Antonio, TX 78229 USA. EM freic@uthscsa.edu FU University of Texas Southwestern Center for Patient-Centered Outcomes Research FX Dr. Mortensen was supported in part by the University of Texas Southwestern Center for Patient-Centered Outcomes Research. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health. NR 44 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD FEB PY 2017 VL 37 IS 2 BP 195 EP 203 DI 10.1002/phar.1891 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EL4JV UT WOS:000394588400006 PM 28035692 ER PT J AU Gerhard, F Deger, M Truccolo, W AF Gerhard, Felipe Deger, Moritz Truccolo, Wilson TI On the stability and dynamics of stochastic spiking neuron models: Nonlinear Hawkes process and point process GLMs SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID TIME-RESCALING THEOREM; TRAIN DATA-ANALYSIS; MOTOR CORTEX; POPULATION; ADAPTATION; CONNECTIVITY; VARIABILITY; INFERENCE; ENSEMBLE; SPECTRA AB Point process generalized linear models (PP-GLMs) provide an important statistical framework for modeling spiking activity in single-neurons and neuronal networks. Stochastic stability is essential when sampling from these models, as done in computational neuroscience to analyze statistical properties of neuronal dynamics and in neuro-engineering to implement closed-loop applications. Here we show, however, that despite passing common goodness-of-fit tests, PP-GLMs estimated from data are often unstable, leading to divergent firing rates. The inclusion of absolute refractory periods is not a satisfactory solution since the activity then typically settles into unphysiological rates. To address these issues, we derive a framework for determining the existence and stability of fixed points of the expected conditional intensity function (CIF) for general PP-GLMs. Specifically, in nonlinear Hawkes PP-GLMs, the CIF is expressed as a function of the previous spike history and exogenous inputs. We use a mean-field quasi-renewal (QR) approximation that decomposes spike history effects into the contribution of the last spike and an average of the CIF over all spike histories prior to the last spike. Fixed points for stationary rates are derived as self-consistent solutions of integral equations. Bifurcation analysis and the number of fixed points predict that the original models can show stable, divergent, and metastable (fragile) dynamics. For fragile models, fluctuations of the single-neuron dynamics predict expected divergence times after which rates approach unphysiologically high values. This metric can be used to estimate the probability of rates to remain physiological for given time periods, e.g., for simulation purposes. We demonstrate the use of the stability framework using simulated single-neuron examples and neurophysiological recordings. Finally, we show how to adapt PPGLM estimation procedures to guarantee model stability. Overall, our results provide a stability framework for data-driven PP-GLMs and shed new light on the stochastic dynamics of state-of-the-art statistical models of neuronal spiking activity. C1 [Gerhard, Felipe; Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Deger, Moritz] Ecole Polytech Fed Lausanne, Sch Comp & Commun Sci, Lausanne, Switzerland. [Deger, Moritz] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland. [Deger, Moritz] Univ Cologne, Inst Zool, Fac Math & Nat Sci, Cologne, Germany. [Truccolo, Wilson] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA. [Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI USA. RP Truccolo, W (reprint author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.; Truccolo, W (reprint author), Brown Univ, Inst Brain Sci, Providence, RI 02912 USA.; Truccolo, W (reprint author), US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI USA. EM Wilson_Truccolo@brown.edu RI Deger, Moritz/F-2191-2011 OI Deger, Moritz/0000-0002-2775-2611 FU National Institute of Neurological Disorders and Stroke (NINDS) [R01NS079533]; U.S. Department of Veterans Affairs, Merit Review Award [I01RX000668]; Pablo J. Salame '88 Goldman Sachs endowed Assistant Professorship of Computational Neuroscience at Brown University; Swiss National Science Foundation [P2ELP3-155278]; European Union [604102]; [200020_147200] FX We acknowledge support from the National Institute of Neurological Disorders and Stroke (NINDS), grant R01NS079533 (WT); the U.S. Department of Veterans Affairs, Merit Review Award I01RX000668 (WT); the Pablo J. Salame '88 Goldman Sachs endowed Assistant Professorship of Computational Neuroscience at Brown University (WT); the Swiss National Science Foundation, grant no. P2ELP3-155278 (FG) and grant no. 200020_147200 (MD); and the European Union Seventh Framework Program (FP7) under grant agreement no. 604102, Human Brain Project (MD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 0 Z9 0 U1 5 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD FEB PY 2017 VL 13 IS 2 AR e1005390 DI 10.1371/journal.pcbi.1005390 PG 31 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA EO0OW UT WOS:000396398700015 ER PT J AU de Oliveira, FL Carneiro, K Brito, JM Cabanel, M Pereira, JX Paiva, LD Syn, W Henderson, NC El-Cheikh, MC AF de Oliveira, Felipe Leite Carneiro, Katia Brito, Jose Marques Cabanel, Mariana Pereira, Jonathas Xavier Paiva, Ligia de Almeida Syn, Wingkin Henderson, Neil C. El-Cheikh, Marcia Cury TI Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Review ID EXPERIMENTAL MURINE SCHISTOSOMIASIS; MARROW-DERIVED MACROPHAGES; HEPATIC STELLATE CELLS; GRANULOMA-FORMATION; SONIC HEDGEHOG; T-CELLS; MANSONI; EXPRESSION; INHIBITORS; ACTIVATION AB Schistosomiasis affects approximately 240 million people in the world. Schistosoma mansoni eggs in the liver induce periportal fibrosis and hepatic failure driven by monocyte recruitment and macrophage activation, resulting in robust Th2 response. Here, we suggested a possible involvement of Galectin-3 (Gal-3), histone deacetylases (HDACs), and Hedgehog (Hh) signaling with macrophage activation during Th1/Th2 immune responses, fibrogranuloma reaction, and tissue repair during schistosomiasis. Gal-3 is highly expressed by liver macrophages (Kupffer cells) around Schistosoma eggs. HDACs and Hh regulate macrophage polarization and hepatic stellate cell activation during schistosomiasis-associated fibrogenesis. Previously, we demonstrated an abnormal extracellular matrix distribution in the liver that correlated with atypical monocyte-macrophage differentiation in S. mansoni-infected, Gal-3-deficient (Lgals3-/-) mice. New findings explored in this review focus on the chronic phase, when wild-type (Lgals3+/+) and Lgals3-/- mice were analyzed 90 days after cercariae infection. In Lgals3-/- infected mice, there was significant inflammatory infiltration with myeloid cells associated with egg destruction (hematoxylin and eosin staining), phagocytes (specifically Kupffer cells), numerically reduced and diffuse matrix extracellular deposition in fibrotic areas (Gomori trichrome staining), and severe disorganization of collagen fibers surrounding the S. mansoni eggs (reticulin staining). Granuloma-derived stromal cells (GR cells) of Lgals3-/- infected mice expressed lower levels of alpha smooth muscle actin (alpha-SMA) and eotaxin and higher levels of IL-4 than Lgals3+/+ mice (real-time PCR). The relevant participation of macrophages in these events led us to suggest distinct mechanisms of activation that culminate in defective fibrosis in the liver of Lgals3-/- infected mice. These aspects were discussed in this review, as well as the possible interference between Gal-3, HDACs, and Hh signaling during progressive liver fibrosis in S. mansoni-infected mice. Further studies focused on macrophage roles could elucidate these questions and clear the potential utility of these molecules as antifibrotic targets. C1 [de Oliveira, Felipe Leite; Carneiro, Katia; Brito, Jose Marques; Cabanel, Mariana; Pereira, Jonathas Xavier; El-Cheikh, Marcia Cury] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, Brazil. [Paiva, Ligia de Almeida] Inst Oswaldo Cruz, Dept Fisiologia Farmacodinamica, Rio De Janeiro, Brazil. [Syn, Wingkin] Gastroenterol Sect, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Syn, Wingkin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA. [Henderson, Neil C.] Univ Edinburgh, MRC Ctr Inflammat Res, Queens Med Res Inst, Edinburgh, Midlothian, Scotland. RP El-Cheikh, MC (reprint author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, Brazil. EM marcia@histo.ufrj.br FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [442308/2014-0]; FAPERJ (Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro) [E-26/203.217/2015]; CAPES (Coordenacao de Aperfeigoamento de Pessoal de Nivel Superior) FX Funding was provided by CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), grant number: 442308/2014-0; FAPERJ (Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro), grant number: E-26/203.217/2015; and CAPES (Coordenacao de Aperfeigoamento de Pessoal de Nivel Superior) to MC and JXP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2017 VL 11 IS 2 AR e0005137 DI 10.1371/journal.pntd.0005137 PG 17 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EN1AD UT WOS:000395741700004 PM 28231240 ER PT J AU Zumsteg, ZS Chen, ZN Howard, LE Amling, CL Aronson, WJ Cooperberg, MR Kane, CJ Terris, MK Spratt, DE Sandler, HM Freedland, SJ AF Zumsteg, Zachary S. Chen, Zinan Howard, Lauren E. Amling, Christopher L. Aronson, William J. Cooperberg, Matthew R. Kane, Christopher J. Terris, Martha K. Spratt, Daniel E. Sandler, Howard M. Freedland, Stephen J. TI Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database SO PROSTATE LA English DT Article DE prostate cancer; intermediate risk; unfavorable intermediate risk; favorable intermediate risk ID ANDROGEN DEPRIVATION THERAPY; POSITIVE SURGICAL MARGINS; AFRICAN-AMERICAN MEN; ACTIVE SURVEILLANCE; ONCOLOGIC OUTCOMES; RADIATION-THERAPY; DEATH; DISEASE; BIOPSY; RECURRENCE AB BACKGROUND. To validate and further improve the stratification of intermediate risk prostate cancer into favorable and unfavorable subgroups for patients undergoing radical prostatectomy. MATERIALS AND METHODS. The SEARCH database was queried for IR patients undergoing radical prostatectomy without adjuvant radiotherapy. UIR disease was defined any patient with at least one unfavorable risk factor (URF), including primary Gleason pattern 4, 50% of more biopsy cores containing cancer, or multiple National Comprehensive Cancer Network IR factors. RESULTS. One thousand five hundred eighty-six patients with IR prostate cancer comprised the study cohort. Median follow-up was 62 months. Patients classified as UIR were significantly more likely to have pathologic high-risk features, such as Gleason score 8 - 10, pT3-4 disease, or lymph node metastases, than FIR patients (P < 0.001). Furthermore, UIR patients had significantly higher rates of PSA-relapse (PSA, hazard ratio [HR] = 1.89, P < 0.001) and distant metastasis (DM, HR = 2.92, P = 0.001), but no difference in prostate cancer- specific mortality (PCSM) or all-cause mortality in multivariable analysis. On secondary analysis, patients with >= 2 URF had significantly worse PSA-RFS, DM, and PCSM than those with 0 or 1 URF. Moreover, 40% of patients with >= 2 URF had high- risk pathologic features. CONCLUSIONS. Patients with UIR prostate cancer are at increased risk of PSA relapse, DM, and pathologic upstaging following prostatectomy. However, increased risk of PCSM was only detected in those with >= 2 URF. This suggests that further refinement of the UIR subgroup may improve risk stratification. (C) 2016 Wiley Periodicals, Inc. C1 [Zumsteg, Zachary S.; Sandler, Howard M.; Freedland, Stephen J.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. [Zumsteg, Zachary S.; Sandler, Howard M.] Cedars Sinai Med Ctr, Dept Radiat Oncol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. [Chen, Zinan; Howard, Lauren E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Cooperberg, Matthew R.] UCSF, Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA. [Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Spratt, Daniel E.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Freedland, Stephen J.] Cedars Sinai Med Ctr, Dept Urol, Los Angeles, CA 90048 USA. RP Zumsteg, ZS (reprint author), Cedars Sinai Med Ctr, Dept Radiat Oncol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM zachary.zumsteg@cshs.org RI Cooperberg, Matthew/G-6249-2017 OI Cooperberg, Matthew/0000-0003-4339-6685 FU Department of Veterans Affairs; NIH [K24 CA160653] FX The SEARCH database is funded in part by the Department of Veterans Affairs and NIH K24 CA160653. NR 30 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD FEB 1 PY 2017 VL 77 IS 2 BP 154 EP 163 DI 10.1002/pros.23255 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA EK4JO UT WOS:000393893100003 PM 27683213 ER PT J AU Valle, JA Graham, L DeRussy, A Itani, K Hawn, MT Maddox, TM AF Valle, Javier A. Graham, Laura DeRussy, Aerin Itani, Kamal Hawn, Mary T. Maddox, Thomas M. TI Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery SO WORLD JOURNAL OF SURGERY LA English DT Article ID ATRIAL-FIBRILLATION PATIENTS; PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; ELUTING STENT IMPLANTATION; CARDIOLOGY WORKING GROUP; RHYTHM ASSOCIATION EHRA; ADVERSE CARDIAC EVENTS; ANTIPLATELET THERAPY; ANTICOAGULATION THERAPY; ORAL ANTICOAGULATION AB Triple therapy, or the use of anticoagulants with dual antiplatelet therapy (DAPT), is often used to protect against ischemic events in post-percutaneous coronary intervention (PCI) patients with indications for anticoagulation, but is associated with increased bleeding. As both ischemic and bleeding risks increase in the perioperative period, the impact of triple therapy may be especially pronounced in patients undergoing surgery. Outcomes in this population are currently unknown. We identified patients undergoing non-cardiac surgeries within 2 years of PCI in Veterans Affairs hospitals from 2004 to 2012. We compared perioperative major adverse cardiovascular and cerebrovascular events (MACCE: mortality, myocardial infarction, stroke, revascularization) and bleeding events (in-hospital bleeding, transfusion) between surgeries in patients prescribed triple therapy and DAPT, adjusting for clinical, demographic, and operative characteristics. Among 7811 surgeries, 391 (5.0 %) occurred in patients receiving triple therapy. 44 (11.3 %) MACCE and 107 (27.4 %) bleeding events occurred with surgeries in triple therapy patients, compared to 366 (4.9 %) MACCE and 980 (13.2 %) bleeding events in DAPT patients. After adjustment, surgery in triple therapy patients was associated with higher rates of MACCE [odds ratio (OR) 1.65, 95 % confidence interval (CI) 1.16-2.34] or bleeding (OR 1.52, 95 % CI 1.17-1.99) as compared to surgery in DAPT patients. One in twenty post-PCI patients undergoing non-cardiac surgery were on triple therapy. Surgery in these patients was associated with higher MACCE and bleeding events compared to surgery in patients on DAPT, independent of clinical and operative characteristics. These findings identify a high-risk population for surgery, which may warrant increased surveillance for adverse perioperative events. C1 [Valle, Javier A.; Maddox, Thomas M.] Univ Colorado, Sch Med, VA Eastern Colorado Hlth Care Syst, Denver, CO 80204 USA. [Graham, Laura; DeRussy, Aerin] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Itani, Kamal] Boston Univ, Vet Affairs Boston Hlth Care Syst, Boston, MA 02215 USA. [Itani, Kamal] Harvard Med Sch, Boston, MA USA. [Hawn, Mary T.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Valle, Javier A.] Univ Colorado Hosp, Div Cardiol, 12631 E 17th St,B130, Aurora, CO 80045 USA. RP Valle, JA (reprint author), Univ Colorado, Sch Med, VA Eastern Colorado Hlth Care Syst, Denver, CO 80204 USA.; Valle, JA (reprint author), Univ Colorado Hosp, Div Cardiol, 12631 E 17th St,B130, Aurora, CO 80045 USA. EM Javier.valle@ucdenver.edu FU NIH T32 training Grant at the University of Colorado, Aurora, CO [HL0782] FX There are no relationships with industry to disclose. Dr. Valle is supported by a NIH T32 training Grant HL0782 at the University of Colorado, Aurora, CO. NR 37 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 EI 1432-2323 J9 WORLD J SURG JI World J.Surg. PD FEB PY 2017 VL 41 IS 2 BP 423 EP 432 DI 10.1007/s00268-016-3725-5 PG 10 WC Surgery SC Surgery GA EK5LJ UT WOS:000393967600011 PM 27734083 ER PT J AU Hope, TA Pampaloni, MH Flavell, RR Nakakura, EK Bergsland, EK AF Hope, Thomas A. Pampaloni, Miguel Hernandez Flavell, Robert R. Nakakura, Eric K. Bergsland, Emily K. TI Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors SO CLINICAL AND TRANSLATIONAL IMAGING LA English DT Review DE Somatostatin receptor PET; PET/MRI; Neuroendocrine tumor; DOTA-TATE; DOTA-TOC ID DIFFUSION-WEIGHTED MRI; HEPATOCELLULAR-CARCINOMA; GA-68-DOTATATE PET/CT; RESPIRATORY MOTION; LIVER; QUANTIFICATION; CLASSIFICATION; METASTASES; UTILITY AB With the introduction of simultaneous PET/MRI scanners, concurrent acquisition of PET and MRI data is feasible, allowing for improved patient convenience and decreased radiation dose. Although PET/MRI has been used in many settings, not all cancers benefit from the combined modality. With the availability of somatostatin receptor-targeted PET tracers such as Ga-68-DOTA-TOC and Ga-68-DOTA-TATE, imaging of NET patients has refocused on targeted imaging, particularly with the development of peptide receptor radiotherapy. Nonetheless, there are many patients who continue to benefit from dedicated MR imaging, such as those with liver-predominant disease. In these patients, SSR PET/MRI is an important option for optimal imaging. Both diffusion-weighted imaging and hepatobiliary phase imaging provide improved lesion detection compared to conventional MRI and CT, and the results can effect therapeutic decisions. Additionally, the use of motion correction techniques can be used to leverage the additional PET data acquired in dedicated liver PET/MRI to remove respiratory artifacts. C1 [Hope, Thomas A.; Pampaloni, Miguel Hernandez; Flavell, Robert R.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave 0628, San Francisco, CA 94143 USA. [Hope, Thomas A.] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Nakakura, Eric K.] Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA 94143 USA. [Bergsland, Emily K.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA. RP Hope, TA (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave 0628, San Francisco, CA 94143 USA.; Hope, TA (reprint author), San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. EM thomas.hope@ucsf.edu FU Wylie J. Dodds Research Award; Society of Abdominal Radiology FX Dr. Hope received grant support from Wylie J. Dodds Research Award, Society of Abdominal Radiology, and is on the speakers' bureau for GE Healthcare. Drs. Pampaloni, Flavell, Nakakura, and Bergsland have no conflicts of interest. NR 40 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER-VERLAG ITALIA SRL PI MILAN PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY SN 2281-5872 EI 2281-7565 J9 CLIN TRANSL IMAGING JI Clin. Transl. Imaging PD FEB PY 2017 VL 5 IS 1 BP 63 EP 69 DI 10.1007/s40336-016-0193-8 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EK0WV UT WOS:000393648700006 ER PT J AU Lehavot, K Litz, B Millard, SP Hamilton, AB Sadler, A Simpson, T AF Lehavot, Keren Litz, Brett Millard, Steven P. Hamilton, Alison B. Sadler, Anne Simpson, Tracy TI Study adaptation, design, and methods of a web-based PTSD intervention for women Veterans SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Posttraumatic stress disorder; Clinical trial; Women veterans; Internet; Web-based intervention ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; OF-LIFE ENJOYMENT; MENTAL-HEALTH; FEMALE VETERANS; SATISFACTION QUESTIONNAIRE; NONINFERIORITY TRIAL; PERSON DELIVERY; SELF-MANAGEMENT AB Women Veterans are a rapidly growing population with high risk of exposure to potentially traumatizing events and PTSD diagnoses. Despite the dissemination of evidence-based treatments for PTSD in the VA, most women Veteran VA users underutilize these treatments. Web-based PTSD treatment has the potential to reach and engage women Veterans with PTSD who do not receive treatment in VA settings. Our objective is to modify and evaluate Delivery of Self Training and Education for Stressful Situations (DESTRESSS), a web-based cognitive-behavioral intervention for PTSD, to target PTSD symptoms among women Veterans. The specific aims are to: (1) obtain feedback about DESTRESS, particularly on its relevance and sensitivity to women, using semi-structured interviews with expert clinicians and women Veterans with PTSD, and make modifications based on this feedback; (2) conduct a pilot study to finalize study procedures and make further refinements to the intervention; and (3) conduct a randomized clinical trial (RCT) evaluating a revised, telephone-assisted DESTRESS compared to telephone monitoring only. We describe the results from the first two aims, and the study design and procedures for the ongoing RCT. This line of research has the potential to result in a gender-sensitive, empirically based, online treatment option for women Veterans with PTSD. Published by Elsevier Inc. C1 [Lehavot, Keren] Denver Seattle Ctr Innovat Vet Ctr Value Driven C, VA Puget Sound Hlth Serv Res & Dev, Seattle, WA USA. [Lehavot, Keren; Millard, Steven P.; Simpson, Tracy] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Lehavot, Keren; Simpson, Tracy] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lehavot, Keren] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Litz, Brett] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr, Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Hamilton, Alison B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Sadler, Anne] Iowa City VA Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat CA, Iowa City, IA USA. [Sadler, Anne] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA. [Simpson, Tracy] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. [Simpson, Tracy] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Lehavot, K (reprint author), 1660 South Columbian Way, Seattle, WA 98108 USA. EM keren.lehavot@va.gov FU CSR&D Service of the VA Office of Research and Development [IK2 CX000867] FX This work was supported by a VA Career Development Award from the CSR&D Service of the VA Office of Research and Development to Dr. Lehavot (IK2 CX000867). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans. NR 57 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD FEB PY 2017 VL 53 BP 68 EP 79 DI 10.1016/j.cct.2016.12.002 PG 12 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EK1ZA UT WOS:000393725200009 PM 27940187 ER PT J AU Kangovi, S Mitra, N Turr, L Huo, HR Grande, D Long, JA AF Kangovi, Shreya Mitra, Nandita Turr, Lindsey Huo, Hairong Grande, David Long, Judith A. TI A randomized controlled trial of a community health worker intervention in a population of patients with multiple chronic diseases: Study design and protocol SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Randomized controlled trial; Upstream medicine; Socioeconomic determinants ID AFRICAN-AMERICAN; SELF-MANAGEMENT; PRIMARY-CARE; BLOOD-PRESSURE; RISK REDUCTION; CLINICAL-TRIAL; SCREENING-TEST; OUTCOMES; ADULTS; ADOLESCENTS AB Upstream interventions - e.g. housing programs and community health worker interventions address socioeconomic and behavioral factors that influence health outcomes across diseases. Studying these types of interventions in clinical trials raises a methodological challenge: how should researchers measure the effect of an upstream intervention in a sample of patients with different diseases? This paper addresses this question using an illustrative protocol of a randomized controlled trial of collaborative-goal setting versus goal-setting plus community health worker support among patients multiple chronic diseases: diabetes, obesity, hypertension and tobacco dependence. At study enrollment, patients met with their primary care providers to select one of their chronic diseases to focus on during the study, and to collaboratively set a goal for that disease. Patients randomly assigned to a community health worker also received six months of support to address socioeconomic and behavioral barriers to chronic disease control. The primary hypothesis was that there Would be differences in patients' selected chronic disease control as measured by HbA1c, body mass index, systolic blood pressure and cigarettes per day, between the goal-setting alone and community health worker support arms. To test this hypothesis, we will conduct a stratum specific multivariate analysis of variance which allows all patients (regardless of their selected chronic disease) to be included in a single model for the primary outcome. Population health researchers can use this approach to measure clinical outcomes across diseases. (C) 2016 Elsevier Inc. All rights reserved. C1 [Kangovi, Shreya; Turr, Lindsey; Huo, Hairong; Grande, David; Long, Judith A.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Kangovi, Shreya] Penn Med, Penn Ctr Community Hlth Workers, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Long, Judith A.] Corporal Michael J Crescenz VA, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Kangovi, S (reprint author), Univ Penn, Perelman Sch Med, Div Gen Internal Med, 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu; nanditam@mail.med.upenn.edu; lindsey.turr@uphs.upenn.edu; huoh@mail.med.upenn.edu; dgrande@wharton.upenn.edu; jalong@mail.med.upenn.edu FU NHLBI NIH HHS [K23 HL128837] NR 54 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD FEB PY 2017 VL 53 BP 115 EP 121 DI 10.1016/j.cct.2016.12.009 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EK1ZA UT WOS:000393725200014 PM 27965180 ER PT J AU Grubbs, V Garcia, F Jue, BL Vittinghoff, E Ryder, M Lovett, D Carrillo, J Offenbacher, S Ganz, P Bibbins-Domingo, K Powe, NR AF Grubbs, Vanessa Garcia, Faviola Jue, Bonnie L. Vittinghoff, Eric Ryder, Mark Lovett, David Carrillo, Jacqueline Offenbacher, Steven Ganz, Peter Bibbins-Domingo, Kirsten Powe, Neil R. TI The Kidney and Periodontal Disease (KAPD) study: A pilot randomized controlled trial testing the effect of non-surgical periodontal therapy on chronic kidney disease SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE (max 6) chronic kidney disease; Periodontal disease; Non-surgical periodontal disease treatment; Periodontitis, oral health ID GELATINASE-ASSOCIATED LIPOCALIN; STAGE RENAL-DISEASE; FLOW-MEDIATED DILATION; ASYMMETRICAL DIMETHYLARGININE; FUNCTION DECLINE; RETROSPECTIVE COHORT; NEPHROPATHY; PROGRESSION; UPDATE; MARKER AB Introduction: Chronic kidney disease (CID) remains a prevalent public health problem that disproportionately affects minorities and the poor, despite intense efforts targeting traditional risk factors. Perioddntal diseases are common bacterial plaque-induced inflammatory conditions that can respond to treatment and have been implicated as a CKD risk factor. However there is limited evidence that treatment of periodontal disease slows the progression of CKD. Methods/design: We describe the protocol of the Kidney and Periodontal Disease (KAPD) study, a 12-month unblinded, randomized, controlled pilot trial with two intent-to-treat treatment arms: 1. immediate intensive nonsurgical periodontal treatment or 2. rescue treatment with delayed intensive treatment. The goals of this pilot study are to test the feasibility of conducting a larger trial in an ethnically and racially diverse, underserved population (mostly poor and/or low literacy) with both CKD and significant periodontal disease to determine the effect of intensive periodontal treatment on renal and inflammatory biotnarkers over a 12-mohth period. Results: To date, KAPD has identified 634 potentially eligible patients who were invited to in-person screening. Of the 83 (13.1%) of potentially eligible patients who attended in-person screening, 51 (61.4%) were eligible for participation and 46 enrolled in the study. The mean age of participants is 59.2 years (range 34 to 73). Twenty of the participants (43.5%) are Black and 22 (47.8%) are Hispanic. Discussion: Results from the KAPD study will provide needed preliminary evidence of the effectiveness of nonsurgical periodontal treatment to slow CKD progression and inform the design future clinical research trials. (C) 2016 Published by Elsevier Inc. C1 [Grubbs, Vanessa; Garcia, Faviola] Univ Calif San Francisco, Div Nephrol, 1001 Potrero Ave,Bldg 100,Room 342, San Francisco, CA 94110 USA. [Jue, Bonnie L.] Univ Calif San Francisco, Dept Prevent & Restorat Dent Sci, Div Oral Epidemiol & Dent Publ Hlth, 3333 Calif St,Ste 495, San Francisco, CA 94118 USA. [Vittinghoff, Eric] Univ Calif San Francisco, Div Epidemiol &Biostat, 550 16th St, San Francisco, CA 94158 USA. [Ryder, Mark] Univ Calif San Francisco, Sch Dent, Dept Orofacial Sci, Div Periodontol, 533 Parnassus Ave,UC Hall, San Francisco, CA 94143 USA. [Lovett, David] San Francisco VA Med Ctr, Div Nephrol, 4150 Clement St, San Francisco, CA 94121 USA. [Carrillo, Jacqueline] Univ Calif San Francisco, Div Gen Internal Med, 1001 Potrero Ave,Bldg 10, San Francisco, CA 94110 USA. [Offenbacher, Steven] UNC Sch Dent, Ctr Oral & System Dis, Dept Periodontol, Koury Hlth Sci Bldg,385 S Columbia St,Room 3501F, Chapel Hill, NC 27599 USA. [Ganz, Peter] Univ Calif San Francisco, Div Cardiol, 1001 Potrero Ave,Bldg 5, San Francisco, CA 94110 USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Div Gen Internal Med, 550 16th St, San Francisco, CA 94158 USA. [Powe, Neil R.] Univ Calif San Francisco, Dept Med, 1001 Potrero Ave,Bldg 5, San Francisco, CA 94110 USA. RP Grubbs, V (reprint author), Univ Calif San Francisco, Div Nephrol, 1001 Potrero Ave,Bldg 100,Room 342, San Francisco, CA 94110 USA. EM vanessa.grubbs@ucsf.edu; faviola.garcia@ucsf.edu; bonnie.jue@ucsf.edu; Eric.Vittinghoff@ucsf.edu; Mark.Ryder@ucsf.edu; David.Lovett@ucsf.edu; jacqueline.carrillo@ucsf.edu; steven_offenbacher@unc.edu; Peter.Ganz@ucsf.edu; Kirsten.bibbins-domingo@ucsf.edu; neil.powe@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD) [1K23DK093710-01A1]; Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, Princeton, NJ [P0045259] FX KAPD and VG are supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD) [grant number 1K23DK093710-01A1] and by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation (P0045259), Princeton, NJ. NR 43 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD FEB PY 2017 VL 53 BP 143 EP 150 DI 10.1016/j.cct.2016.12.017 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EK1ZA UT WOS:000393725200018 PM 28011387 ER PT J AU Cipres, D Seidman, D Cloniger, C Nova, C O'Shea, A Obedin-Maliver, J AF Cipres, Danielle Seidman, Dominika Cloniger, Charles, III Nova, Cyd O'Shea, Anita Obedin-Maliver, Juno TI Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco SO CONTRACEPTION LA English DT Article DE Transgender; Female-to-male; Contraception; Testosterone; Family planning; Reproductive health ID FEMALE; CARE AB Purpose: Although many transgender men may be able to conceive, their reproductive health needs are understudied. Methods: We retrospectively reviewed charts of transgender men presenting to a clinic for sex workers to describe the proportion at risk for pregnancy, pregnancy intentions, and contraceptive use. Results: Of 26 transgender men identified, half were at risk for pregnancy. Most desired to avoid pregnancy but used only condoms or no contraception. Two individuals desired pregnancy, were taking testosterone (a teratogen), and not using contraception. Conclusion: Further research is needed to explore how to best provide family planning services including preconception and contraception care to transgender men. (C) 2017 Elsevier Inc. All rights reserved. C1 [Cipres, Danielle] Univ Calif San Francisco, Sch Med, 513 Parnassus Ave, San Francisco, CA 94143 USA. [Seidman, Dominika; Obedin-Maliver, Juno] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 550 16th St, San Francisco, CA 94158 USA. [Cloniger, Charles, III] Univ Calif San Francisco, Dept Social & Behav Sci, 3333 Calif St, San Francisco, CA 94118 USA. [Cloniger, Charles, III] San Francisco Dept Publ Hlth, Populat Hlth Div, 25 Van Ness Ave,Suite 500, San Francisco, CA 94102 USA. [Cloniger, Charles, III; Nova, Cyd; O'Shea, Anita] St James Infirm, 234 Eddy St, San Francisco, CA 94102 USA. [Obedin-Maliver, Juno] San Francisco VA Med Ctr, Dept Med, Div Gen Internal Med, 4150 Clement St,Bldg 18,Room 111A1, San Francisco, CA 94121 USA. RP Seidman, D (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 550 16th St, San Francisco, CA 94158 USA. EM Danielle.cipres@ucsf.edu; Dominika.seidman@ucsf.edu; Chuck.sjimedical@yahoo.com; Registration@stjamesinfirmnary.org; Juno.obedin-maliver@ucsf.edu FU UCSF PROF-PATH program, National Institute on Minority Health and Health Disparities [R25MD006832] FX DC received support from the UCSF PROF-PATH program, National Institute on Minority Health and Health Disparities (R25MD006832). NR 10 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD FEB PY 2017 VL 95 IS 2 BP 186 EP 189 DI 10.1016/j.contraception.2016.09.005 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EJ0JU UT WOS:000392895300011 PM 27621044 ER PT J AU Kunitake, H Russell, MM Zheng, P Yothers, G Land, SR Petersen, L Fehrenbacher, L Giguere, JK Wickerham, DL Ko, CY Ganz, PA AF Kunitake, Hiroko Russell, Marcia M. Zheng, Ping Yothers, Greg Land, Stephanie R. Petersen, Laura Fehrenbacher, Louis Giguere, Jeffery K. Wickerham, D. Lawrence Ko, Clifford Y. Ganz, Patricia A. TI Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01 SO JOURNAL OF CANCER SURVIVORSHIP LA English DT Article DE Quality of life; Colorectal cancer; Survivors ID SURGICAL ADJUVANT BREAST; COLON-CANCER; HEALTH SURVEY; STAGE-II; PROJECT; VALIDATION; LEUCOVORIN; FATIGUE; FLUOROURACIL; CHEMOTHERAPY AB Purpose Little is known about health-related quality of life (HRQL) in long-term survivors (LTS) of colorectal cancer (CRC). Methods Long-term CRC survivors (>= 5 years) treated in previous National Surgical Adjuvant Breast and Bowel Project trials were recruited from 60 sites. After obtaining consent, a telephone survey was administered, which included HRQL instruments to measure physical health (Instrumental Activities of Daily Living [IADL], SF-12 Physical Component Scale [PCS], SF-36 Vitality Scale), mental health (SF-12 Mental Component Scale [MCS], Life Orientation Test, and Impact of Cancer), and clinical symptoms (Fatigue Symptom Inventory [FSI], European Organization for Research and Treatment of Cancer Colorectal Module [EORTC-CR38], and Brief Pain Inventory). A multivariable model identified predictors of overall quality of life (global health rating). Results Participants (N = 708) had significantly higher HRQL compared with age group-matched non-cancer controls with higher mean scores on SF-12 PCS (49.5 vs. 43.7, p = < 0.05), MCS (55.6 vs. 52.1, p = < 0.05), and SF-36 Vitality Scale (67.1 vs. 59.9, p = < 0.05). Multivariable modeling has demonstrated that better overall physical and mental health (PCS and MCS), positive body image (EORTC-CR38 scale), and less fatigue (FSI), were strongly associated with overall quality of life as measured by the global health rating. Interestingly, ability to perform IADLs, experience of cancer, gastrointestinal complaints, and pain, were not important predictors. Conclusions In long-term CRC survivors, overall physical and mental health was excellent compared with general population. Other disease-related symptoms did not detract from good overall health. Implications for cancer survivors LTS of CRC within the setting of a clinical trial have higher HRQL than the general population, and treatment regimens do not appear to be associated with any significant late effects on quality of life. Trial Registration: NSABP LTS-01: NCT00410579. C1 [Kunitake, Hiroko; Russell, Marcia M.; Wickerham, D. Lawrence; Ko, Clifford Y.; Ganz, Patricia A.] NRG Oncol, Natl Surg Adjuvant Breast & Bowel Project NSABP, Pittsburgh, PA 15213 USA. [Kunitake, Hiroko] Boston Univ, Sch Med, Boston, MA 02118 USA. [Russell, Marcia M.; Ko, Clifford Y.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, 11301 Wilshire Blvd,Mail Code 10H2, Los Angeles, CA 90073 USA. [Zheng, Ping; Yothers, Greg] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Yothers, Greg] Univ Pittsburgh, Pittsburgh, PA USA. [Land, Stephanie R.] NCI, Bethesda, MD 20892 USA. [Petersen, Laura] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. [Fehrenbacher, Louis] Kaiser Permanente Oncol Clin Trials Northern Cali, Vallejo, CA USA. [Giguere, Jeffery K.] Greenville Hlth Syst Canc Inst, Greenville, SC USA. [Wickerham, D. Lawrence] Allegheny Hlth Network Canc Inst, Pittsburgh, PA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, UCLA Sch Med, Los Angeles, CA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, UCLA Sch Publ Hlth, Los Angeles, CA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Yothers, Greg] NRG Oncol, Pittsburgh, PA USA. RP Russell, MM (reprint author), NRG Oncol, Natl Surg Adjuvant Breast & Bowel Project NSABP, Pittsburgh, PA 15213 USA.; Russell, MM (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, 11301 Wilshire Blvd,Mail Code 10H2, Los Angeles, CA 90073 USA. EM Marcia.Russell2@va.gov FU National Institutes of Health, US Department of Health and Human Services, Public Health Service [U10-CA180868, U10-CA180822, UG1CA189867]; American Cancer Society [RSGPB-05-236-01-CPPB] FX The National Cancer Institute at the National Institutes of Health, US Department of Health and Human Services, Public Health Service grants U10-CA180868 (NCTN), U10-CA180822 (NRG SDMC), and UG1CA189867 (NCORP), and grant RSGPB-05-236-01-CPPB from the American Cancer Society (UCLA) are acknowledged. NR 34 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 EI 1932-2267 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD FEB PY 2017 VL 11 IS 1 BP 111 EP 118 DI 10.1007/s11764-016-0567-y PG 8 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA EK1GZ UT WOS:000393675100013 PM 27562475 ER PT J AU Wheeler, DJ Mihara, K Chiovaro, J AF Wheeler, Daniel J. Mihara, Kip Chiovaro, Joe TI Seeing Wisely SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID MEDICAL-EDUCATION C1 [Wheeler, Daniel J.] Univ Minnesota, Sch Med, Dept Med, Mayo Mem Bldg,420 Delaware St SE,MMC 741, Minneapolis, MN 55455 USA. [Mihara, Kip] San Francisco VA Med Ctr, Emergency Dept, San Francisco, CA USA. [Mihara, Kip] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Chiovaro, Joe] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Chiovaro, Joe] Portland VA Med Ctr, Dept Med, Div Hosp Med, Portland, OR USA. RP Wheeler, DJ (reprint author), Univ Minnesota, Sch Med, Dept Med, Mayo Mem Bldg,420 Delaware St SE,MMC 741, Minneapolis, MN 55455 USA. EM wheel237@umn.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2017 VL 32 IS 2 BP 139 EP 139 DI 10.1007/s11606-016-3933-6 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EK2JL UT WOS:000393753500001 PM 27896695 ER PT J AU Oehler, A Chiovaro, J AF Oehler, Andrew Chiovaro, Joseph TI The Electrocardiogram Following Dynamic Cardiomyoplasty SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE heart failure; electrocardiography; cardiomyoplasty C1 [Oehler, Andrew; Chiovaro, Joseph] Oregon Hlth & Sci Univ, Dept Gen Internal Med, Portland, OR 97201 USA. [Chiovaro, Joseph] Portland VA Med Ctr, Div Hosp & Subspecialty Med, Portland, OR USA. RP Oehler, A (reprint author), Oregon Hlth & Sci Univ, Dept Gen Internal Med, Portland, OR 97201 USA. EM oehler@ohsu.edu NR 3 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2017 VL 32 IS 2 BP 223 EP 224 DI 10.1007/s11606-016-3827-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EK2JL UT WOS:000393753500023 PM 27488972 ER PT J AU Ffytche, DH Creese, B Politis, M Chaudhuri, KR Weintraub, D Ballard, C Aarsland, D AF Ffytche, Dominic H. Creese, Byron Politis, Marios Chaudhuri, K. Ray Weintraub, Daniel Ballard, Clive Aarsland, Dag TI The psychosis spectrum in Parkinson disease SO NATURE REVIEWS NEUROLOGY LA English DT Review ID DOPAMINERGIC-INDUCED HALLUCINATIONS; ANGIOTENSIN-CONVERTING ENZYME; ATTENTIONAL CONTROL NETWORKS; SLEEP BEHAVIOR DISORDER; DRUG-INDUCED PSYCHOSIS; LEWY BODY DEMENTIAS; VISUAL HALLUCINATIONS; RISK-FACTORS; ALZHEIMERS-DISEASE; GLUCOCEREBROSIDASE MUTATIONS AB In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD psychosis, and the causal and modifying effects of PD medication. We discuss recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages. In addition, we highlight novel risk factors-for example, autonomic dysfunction-that have emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The accumulating evidence raises novel questions and directions for future research to explore the clinical management and biomarker potential of PD psychosis. C1 [Ffytche, Dominic H.; Creese, Byron; Politis, Marios; Chaudhuri, K. Ray; Weintraub, Daniel; Ballard, Clive; Aarsland, Dag] Kings Coll London, Inst Psychiat Psychol & Neurosci, KCL PARCOG Grp, De Crespigny Pk, London SE5 8AF, England. [Ffytche, Dominic H.; Aarsland, Dag] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Old Age Psychiat, De Crespigny Pk, London SE5 8AF, England. [Creese, Byron; Ballard, Clive] Univ Exeter, Sch Med, Exeter EX1 2LU, Devon, England. [Politis, Marios] Kings Coll London, Inst Psychiat Psychol & Neurosci, Maurice Wohl Clin Neurosci Inst, Neurodegenerat Imaging Grp, 125 Coldharbour Lane, London SE5 9NU, England. [Chaudhuri, K. Ray] Kings Coll London, Kings Coll Hosp London, Natl Parkinson Fdn Ctr Excellence, Maurice Wohl Clin Neurosci Inst,Dept Basic & Clin, 5 Cutcombe Rd, London SE5 9RT, England. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, 3900 Woodland Ave, Philadelphia, PA 19104 USA. RP Ffytche, DH (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, KCL PARCOG Grp, De Crespigny Pk, London SE5 8AF, England.; Ffytche, DH (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Old Age Psychiat, De Crespigny Pk, London SE5 8AF, England. EM dominic.ffytche@kcl.ac.uk OI Aarsland, Dag/0000-0001-6314-216X FU European Union; Parkinson's UK; NIHR; Parkinson's Disease Non Motor group; Wolfson Foundation; Royal Society; National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre and Dementia Unit; NIHR Programme Grants [SHAPED RP-PG-0610-10100] FX The authors thank Dr Michael Haworth for help in preparing the final manuscript, Dr Rowena Carter for help preparing Figure 1, and the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre and Dementia Unit and NIHR Programme Grants for Applied Research (SHAPED RP-PG-0610-10100) for supporting their involvement in this work. K.R.C. acknowledges support from the European Union, Parkinson's UK, the NIHR and the Parkinson's Disease Non Motor group. D.A. is a Royal Society Wolfson Research Merit Award Holder and thanks the Wolfson Foundation and the Royal Society for their support. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. NR 188 TC 0 Z9 0 U1 10 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 EI 1759-4766 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD FEB PY 2017 VL 13 IS 2 BP 81 EP 95 DI 10.1038/nrneurol.2016.200 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA EK2CT UT WOS:000393735700007 PM 28106066 ER PT J AU Dolz-Marco, R Phasukkijwatana, N Sarraf, D Freund, KB AF Dolz-Marco, Rosa Phasukkijwatana, Nopasak Sarraf, David Freund, K. Bailey TI REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE age-related macular degeneration; AMD; choroidal neovascularization; OCT-A; OCT-angiography; type 1 neovascularization; type 2 neovascularization ID COHERENCE TOMOGRAPHY-ANGIOGRAPHY; ANTI-VEGF THERAPY; CHOROIDAL NEOVASCULARIZATION; EYES; RANIBIZUMAB; BEVACIZUMAB; MANAGEMENT; OUTCOMES AB Purpose: To study eyes with Type 2 (subretinal) neovascularization (NV) secondary to neovascular age-related macular degeneration (nAMD) that shows lesion regression into a Type 1 (subretinal pigment epithelium) pattern after treatment with intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Methods: Retrospective consecutive case series. Patients showing regression of Type 2 neovascularization into a Type 1 pattern after envelopment by retinal pigment epithelium were included in this analysis. A review of the clinical records and multimodal imaging of these cases was performed at baseline, 1, 3, 6, and 12 months. Demographic data, best-corrected visual acuity (BCVA), color fundus photography, fundus autofluorescence (FAF), fluorescein angiography, near-infrared reflectance (NIR), and structural spectral-domain optical coherence tomography (SD-OCT) were reviewed and analyzed. When available, optical coherence tomography angiography images were analyzed as well. Results: Ten eyes of 9 patients (6 males) diagnosed with treatment-naive pure Type 2 neovascularization secondary to nAMD were included. The mean age was 80.7 years (SD +/- 4.30). Mean best-corrected visual acuity expressed in logMAR (Snellen) was 0.45 +/- 0.20 (20/55) at baseline and significantly improved to 0.22 +/- 0.13 (20/32) at 3-month follow-up (P-value: 0.007). At baseline, color photographs and fundus autofluorescence showed a pigment ring around the neovascular lesion in 6 eyes. A hyperreflective ring was visible on NIR in all eyes at 3-month follow-up. Color photographs showed a tessellated fundus appearance in 9 of the 10 eyes. Serial structural spectral-domain optical coherence tomography scans showed the gradual regression of the Type 2 lesions into a Type 1 pattern with envelopment by the retinal pigment epithelium. En face and cross-sectional optical coherence tomography angiography showed baseline subretinal flow patterns which, after treatment, exhibited reduced flow beneath an intact hyperreflective retinal pigment epithelium (RPE) band. Conclusion: Pure Type 2 lesions are infrequent in nAMD, often leading to poor visual outcomes related to subretinal fibrosis. We describe an alternate regression pattern occurring in eyes with early Type 2 lesions treated with intravitreal anti-vascular endothelial growth factor therapy in which the neovascular tissue is enveloped by retinal pigment epithelium producing a Type 1 pattern. These eyes appear to have better visual outcomes than typically seen with Type 2 lesions related to reduced outer retinal damage. C1 [Dolz-Marco, Rosa; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA. [Dolz-Marco, Rosa] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA. EM kbfnyf@aol.com FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, NY; Macula Foundation Inc, New York, NY; Alcon; Allergan; Bayer; Heidelberg Engineering; Novartis; Thea; Genentech; Regeneron; Optovue FX This work was supported by a research grant from the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, NY, and The Macula Foundation Inc, New York, NY.; R. Dolz-Marco: Research grants from Alcon, Allergan, Bayer, Heidelberg Engineering, Novartis, Thea; N. Phasukkijwatana: None; D. Sarraf: Research grants from Genentech, Regeneron and Optovue. Consultant to Genentech and Optovue; K. B. Freund: Consultant to Genentech, Optos, Optovue, Heidelberg Engineering, and Bayer HealthCare. NR 26 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD FEB PY 2017 VL 37 IS 2 BP 222 EP 233 PG 12 WC Ophthalmology SC Ophthalmology GA EK1FO UT WOS:000393671400011 PM 27627752 ER PT J AU Tan, ACS Dansingani, KK Yannuzzi, LA Sarraf, D Freund, KB AF Tan, Anna C. S. Dansingani, Kunal K. Yannuzzi, Lawrence A. Sarraf, David Freund, K. Bailey TI TYPE 3 NEOVASCULARIZATION IMAGED WITH CROSS-SECTIONAL AND EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE type 3 neovascularization; optical coherence tomography angiography ID RETINAL ANGIOMATOUS PROLIFERATION; PIGMENT EPITHELIAL DETACHMENT; MACULAR DEGENERATION; ARTIFACTS; SPECTRUM AB Purpose: To study the cross-sectional and en face optical coherence tomography angiography (OCTA) findings in Type 3 neovascularization (NV). Methods: Optical coherence tomography angiography imaging of 27 eyes of 23 patients with Type 3 NV was analyzed with 9 eyes having consecutive follow-up OCTA studies. Results: Type 3 NV appeared as a linear high-flow structure on cross-sectional OCTA corresponding to a high-flow tuft of vessels seen on en face OCTA. Cross-sectional OCTA seemed to enable the distinction between vascular and nonvascular intraretinal hyper-reflective foci. Two patterns of flow were observed; Pattern 1 (11%): a flow signal confined to the neurosensory retina and Pattern 2 (74%): a flow signal extending through the retinal pigment epithelium. No definitive retinal-choroidal anastomosis was observed; however, projection artifacts confounded the interpretation of deeper structures. An increase in the intensity of the high-flow tuft was seen during the progression or recurrence of Type 3 NV. Intravitreal anti-vascular endothelial growth factor therapy caused a reduction in the intensity of the high-flow tuft which was not sustained. Conclusion: Compared with conventional imaging, OCTA may improve detection and delineation of vascular changes occurring in Type 3 NV. Cross-sectional and en face OCTA may prove useful in studying the pathogenesis and guiding the management of these lesions. C1 [Tan, Anna C. S.; Dansingani, Kunal K.; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA. [Tan, Anna C. S.; Dansingani, Kunal K.; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Tan, Anna C. S.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore. [Dansingani, Kunal K.] Moorfield Eye Hosp, London, England. [Dansingani, Kunal K.] Univ Nebraska, Truhlsen Eye Inst, Omaha, NE 68182 USA. [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA. EM kbfnyf@aol.com FU Allergan; Genenetch; Optoivue; Regeneron FX K. B. Freund is a consultant for Genentech, Optovue, Optos, Bayer Healthcare, and Heidelberg Engineering. D. Sarraf is a consultant for Genentech and Optovue and receives research grants from Allergan, Genenetch, Optoivue and Regeneron. The remaining authors have no financial/conflicting interests to disclose. NR 22 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD FEB PY 2017 VL 37 IS 2 BP 234 EP 246 PG 13 WC Ophthalmology SC Ophthalmology GA EK1FO UT WOS:000393671400012 PM 27749497 ER PT J AU Taber, DJ Gebregziabher, M Payne, EH Srinivas, T Baliga, PK Egede, LE AF Taber, David J. Gebregziabher, Mulugeta Payne, Elizabeth H. Srinivas, Titte Baliga, Prabhakar K. Egede, Leonard E. TI Overall Graft Loss Versus Death-Censored Graft Loss: Unmasking the Magnitude of Racial Disparities in Outcomes Among US Kidney Transplant Recipients SO TRANSPLANTATION LA English DT Article ID RENAL-ALLOGRAFT SURVIVAL; AFRICAN-AMERICANS; RISK-FACTORS; SCIENTIFIC REGISTRY; ETHNIC DISPARITIES; ACUTE REJECTION; UNITED-STATES; ACCESS; RACE; IMMUNOSUPPRESSION AB Background. Black kidney transplant recipients experience disproportionately high rates of graft loss. This disparity has persisted for 40 years, and improvements may be impeded based on the current public reporting of overall graft loss by US regulatory organizations for transplantation. Methods. Longitudinal cohort study of kidney transplant recipients using a data set created by linking Veterans Affairs and US Renal Data System information, including 4918 veterans transplanted between January 2001 and December 2007, with follow-up through December 2010. Multivariable analysis was conducted using 2-stage joint modeling of random and fixed effects of longitudinal data (linear mixed model) with time to event outcomes (Cox regression). Results. Three thousand three hundred six non-Hispanic whites (67%) were compared with 1612 non-Hispanic black (33%) recipients with 6.0 +/- 2.2 years of follow-up. In the unadjusted analysis, black recipients were significantly more likely to have overall graft loss (hazard ratio [HR], 1.19; 95% confidence interval [95% CI], 1.07-1.33), death-censored graft loss (HR, 1.67; 95% CI, 1.45-1.92), and lower mortality (HR, 0.83; 95% CI, 0.72-0.96). In fully adjusted models, only death-censored graft loss remained significant (HR, 1.38; 95% CI, 1.12-1.71; overall graft loss [HR, 1.08; 95% CI, 0.91-1.28]; mortality [HR, 0.84; 95% CI, 0.67-1.06]). A composite definition of graft loss reduced the magnitude of disparities in blacks by 22%. Conclusions. Non-Hispanic black kidney transplant recipients experience a substantial disparity in graft loss, but not mortality. This study of US data provides evidence to suggest that researchers should focus on using death-censored graft loss as the primary outcome of interest to facilitate a better understanding of racial disparities in kidney transplantation. C1 [Taber, David J.; Baliga, Prabhakar K.] Med Univ South Carolina, Div Transplant Surg, Coll Med, Charleston, SC USA. [Gebregziabher, Mulugeta; Payne, Elizabeth H.] Med Univ South Carolina, Dept Publ Hlth Sci, Coll Med, Charleston, SC USA. [Srinivas, Titte] Med Univ South Carolina, Div Transplant Nephrol, Coll Med, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach Innov, Charleston, SC USA. RP Taber, DJ (reprint author), Univ South Carolina, Coll Med, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440] FX Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK099440. NR 42 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD FEB PY 2017 VL 101 IS 2 BP 402 EP 410 DI 10.1097/TP.0000000000001119 PG 9 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA EK0WI UT WOS:000393647400036 PM 26901080 ER PT J AU Rinker, JA Fulmer, DB Trantham-Davidson, H Smith, ML Williams, RW Lopez, MF Randall, PK Chandler, LJ Miles, MF Becker, HC Mulholland, PJ AF Rinker, Jennifer A. Fulmer, Diana B. Trantham-Davidson, Heather Smith, Maren L. Williams, Robert W. Lopez, Marcelo F. Randall, Patrick K. Chandler, L. Judson Miles, Michael F. Becker, Howard C. Mulholland, Patrick J. TI Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking SO ALCOHOL LA English DT Article DE K+ channels; Alcohol use disorder; Pharmacogenetics; BXD mice; Prefrontal cortex; Nucleus accumbens ID UNION-OF-PHARMACOLOGY; CHRONIC INTERMITTENT ETHANOL; GENOME-WIDE ASSOCIATION; CA1 PYRAMIDAL NEURONS; NUCLEUS-ACCUMBENS; MOLECULAR RELATIONSHIPS; PREFRONTAL CORTEX; DRUG-ADDICTION; NMDA RECEPTOR; NALTREXONE RESPONSE AB Alcohol (ethanol) dependence is a chronic relapsing brain disorder partially influenced by genetics and characterized by an inability to regulate harmful levels of drinking. Emerging evidence has linked genes that encode Kv7, KIR, and K(ca)2 K+ channels with variation in alcohol-related behaviors in rodents and humans. This led us to experimentally test relations between K+ channel genes and escalation of drinking in a chronic intermittent ethanol (CIE) exposure model of dependence in BXD recombinant inbred strains of mice. Transcript levels for K+ channel genes in the prefrontal cortex (PFC) and nucleus accumbens (NAc) covary with voluntary ethanol drinking in a non-dependent cohort. Transcripts that encode Kv7 channels covary negatively with drinking in non-dependent BXD strains. Using a pharmacological approach to validate the genetic findings, C57BL/6J mice were allowed intermittent access to ethanol to establish baseline consumption before they were treated with retigabine, an FDA-approved Kv7 channel positive modulator. Systemic administration significantly reduced drinking, and consistent with previous evidence, retigabine was more effective at reducing voluntary consumption in high-drinking than low-drinking subjects. We evaluated the specific K+ channel genes that were most sensitive to CIE exposure and identified a gene subset in the NAc and PFC that were dysregulated in the alcohol-dependent BXD cohort. CIE-induced modulation of nine genes in the NAc and six genes in the PFC covaried well with the changes in drinking induced by ethanol dependence. Here we identified novel candidate genes in the NAc and PFC that are regulated by ethanol dependence and correlate with voluntary drinking in non-dependent and dependent BXD mice. The findings that Kcnq expression correlates with drinking and that retigabine reduces consumption suggest that Kv7 channels could be pharmacogenetic targets to treat individuals with alcohol addiction. (C) 2016 Elsevier Inc. All rights reserved. C1 [Rinker, Jennifer A.; Fulmer, Diana B.; Trantham-Davidson, Heather; Chandler, L. Judson; Mulholland, Patrick J.] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Lopez, Marcelo F.; Randall, Patrick K.; Becker, Howard C.; Mulholland, Patrick J.] Med Univ South Carolina, Charleston Alcohol Res Ctr, Addict Sci Div, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Smith, Maren L.; Miles, Michael F.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA. [Becker, Howard C.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Williams, Robert W.] Univ Tennessee, Hlth Sci Ctr, Dept Genet Genom & Informat, Memphis, TN 38163 USA. RP Mulholland, PJ (reprint author), Charleston Alcohol Res Ctr, Dept Neurosci, Addict Sci Div, 67 President St,462N,MSC861, Charleston, SC 29425 USA. EM mulholl@musc.edu OI Williams, Robert/0000-0001-8924-4447 FU NIH grants [AA020930, AA023288, AA020929, AA014095, AA010761, AA016667, AA016662, AA022701, AA022475] FX These studies were supported by NIH grants AA020930 (PJM), AA023288 (PJM), AA020929 (MFL), AA014095 (HCB), AA010761 (HCB), AA016667 (MFM), AA016662 (RWW), AA022701 (LJC), and AA022475 (HTD). The authors declare no conflict of interest. NR 88 TC 2 Z9 2 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD FEB PY 2017 VL 58 SI SI BP 33 EP 45 DI 10.1016/j.alcohol.2016.05.007 PG 13 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA EJ5KG UT WOS:000393256300006 PM 27432260 ER PT J AU Buck, KJ Chen, G Kozell, LB AF Buck, Kari J. Chen, Gang Kozell, Laura B. TI Limbic circuitry activation in ethanol withdrawal is regulated by a chromosome 1 locus SO ALCOHOL LA English DT Article DE Ethanol; c-Fos; Limbic; Amygdala; Withdrawal ID MEDIAL PREFRONTAL CORTEX; C-FOS EXPRESSION; GENOME-WIDE ASSOCIATION; PHASEOLUS-VULGARIS-LEUKOAGGLUTININ; ALCOHOL PHYSICAL-DEPENDENCE; RAT SUBSTANTIA-NIGRA; BASAL GANGLIA; INDUCED ANXIETY; NERVOUS-SYSTEM; MESSENGER-RNA AB Physiological dependence and associated withdrawal episodes are thought to constitute a motivational force sustaining alcohol use/abuse and contributing to relapse in alcoholics. Although no animal model exactly duplicates alcoholism, models for specific factors, including the withdrawal syndrome, are useful for identifying potential genetic and neural determinants of liability in humans. We previously identified highly significant quantitative trait loci (QTLs) with large effects on predisposition to withdrawal after chronic and acute alcohol exposure in mice and mapped these loci to the same region of chromosome 1 (Alcdp1 and Alcw1, respectively). The present studies utilize a novel Alcdp1/Alcw1 congenic model (in which an interval spanning Alcdp1 and Alcw1 from the C57BL/6J donor strain [build GRCm38 150.3 -174.6 Mb] has been introgressed onto a uniform inbred DBA/2J genetic background) known to demonstrate significantly less severe chronic and acute withdrawal compared to appropriate background strain animals. Here, using c-Fos induction as a high-resolution marker of neuronal activation, we report that male Alcdp1/Alcw1 congenic animals demonstrate significantly less alcohol withdrawal-associated neural activation compared to appropriate background strain animals in the prelimbic and cingulate cortices of the prefrontal cortex as well as discrete regions of the extended amygdala (i.e., basolateral) and extended basal ganglia (i.e., dorsolateral striatum, and caudal substantia nigra pars reticulata). These studies are the first to begin to elucidate circuitry by which this confirmed addiction-relevant QTL could influence behavior. This circuitry overlaps limbic circuitry involved in stress, providing additional mechanistic information. Alcdp1/Alcw1 maps to a region syntenic with human chromosome 1 q, where multiple studies find significant associations with risk for alcoholism. Published by Elsevier Inc. C1 [Buck, Kari J.; Kozell, Laura B.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA. [Chen, Gang] Nanjing Univ, Ctr Translat Syst Biol & Neurosci, Nanjing, Jiangsu, Peoples R China. RP Buck, KJ (reprint author), Vet Affairs Med Ctr, R&D40, Res Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM buckk@ohsu.edu OI Kozell, Laura/0000-0003-3059-2046 FU PHS [AA011114, AA010760, DA005228]; VA Merit grant [BX000222] FX Supported by PHS grants AA011114, AA010760, DA005228, and a VA Merit grant (BX000222). We are grateful to Dr. John Belknap, Dr. Robert Hitzemann, and Ms. Nicole Walter for helpful discussions of these experiments and comments on a draft of this manuscript. NR 51 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD FEB PY 2017 VL 58 SI SI BP 153 EP 160 DI 10.1016/j.alcohol.2016.09.030 PG 8 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA EJ5KG UT WOS:000393256300016 PM 27989609 ER PT J AU Winestone, LE Getz, KD Miller, TP Wilkes, JJ Sack, L Li, YM Huang, YS Seif, AE Bagatell, R Fisher, BT Epstein, AJ Aplenc, R AF Winestone, Lena E. Getz, Kelly D. Miller, Tamara P. Wilkes, Jennifer J. Sack, Leah Li, Yimei Huang, Yuan-Shung Seif, Alix E. Bagatell, Rochelle Fisher, Brian T. Epstein, Andrew J. Aplenc, Richard TI The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; FREESTANDING PEDIATRIC HOSPITALS; UNITED-STATES; CHILDHOOD-CANCER; MEDIATION ANALYSIS; CLINICAL-TRIALS; ONCOLOGY-GROUP; BREAST-CANCER; SOCIOECONOMIC POSITION; CARE UTILIZATION AB Black patients with acute myeloid leukemia (AML) experience higher mortality than White patients. We compared induction mortality, acuity of illness prior to chemotherapy, and insurance type between Black and White patients to assess whether acuity of presentation mediates the disparity. Within a retrospective cohort of 1,122 children with AML treated with two courses of standard induction chemotherapy between 2004 and 2014 in the Pediatric Health Information System (PHIS) database, the association between race (Black versus White) and inpatient mortality during induction was examined. Intensive Care Unit (ICU)-level resource utilization during the first 72 hours following admission for initial AML chemotherapy was evaluated as a potential mediator. The total effect of race on mortality during Induction I revealed a strong association (unadjusted HR 2.75, CI: 1.18, 6.41). Black patients had a significantly higher unadjusted risk of requiring ICU-level resources within the first 72 hours after initial presentation (17% versus 11%; RR 1.52, CI: 1.04, 2.24). Mediation analyses revealed the indirect effect of race through acuity accounted for 61% of the relative excess mortality during Induction I. Publicly insured patients experienced greater induction mortality than privately insured patients regardless of race. Black patients with AML have significantly greater risk of induction mortality and are at increased risk for requiring ICU-level resources soon after presentation. Higher acuity amongst Black patients accounts for a substantial portion of the relative excess mortality during Induction I. Targeting factors affecting acuity of illness at presentation may lessen racial disparities in AML induction mortality. C1 [Winestone, Lena E.; Getz, Kelly D.; Miller, Tamara P.; Wilkes, Jennifer J.; Sack, Leah; Seif, Alix E.; Bagatell, Rochelle; Aplenc, Richard] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [Winestone, Lena E.; Getz, Kelly D.; Miller, Tamara P.; Wilkes, Jennifer J.; Fisher, Brian T.; Aplenc, Richard] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA. [Winestone, Lena E.; Wilkes, Jennifer J.; Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Li, Yimei] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Huang, Yuan-Shung] Childrens Hosp Philadelphia, Healthcare Analyt Unit, Philadelphia, PA USA. [Seif, Alix E.; Bagatell, Rochelle; Aplenc, Richard] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Fisher, Brian T.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA USA. [Fisher, Brian T.; Aplenc, Richard] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. RP Winestone, LE (reprint author), CTRB 10305,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM winestonel@email.chop.edu OI Winestone, Lena/0000-0001-9982-1594 FU Pfizer; Merck FX Dr Brian Fisher receives research funding from Pfizer and Merck for projects unrelated to this research. NR 44 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD FEB PY 2017 VL 92 IS 2 BP 141 EP 148 DI 10.1002/ajh.24605 PG 8 WC Hematology SC Hematology GA EJ7TJ UT WOS:000393425200010 PM 27862214 ER PT J AU Rastegar, M Nagami, GT AF Rastegar, Mandana Nagami, Glenn T. TI Non-Anion Gap Metabolic Acidosis: A Clinical Approach to Evaluation SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Non-anion gap metabolic acidosis; urine anion gap; urine osmolal gap; renal acidification; acid-base; high volume ileostomy output; urinary ammonium ID URINE OSMOLAL GAP; AMMONIA PRODUCTION; BASE DISTURBANCES; ANGIOTENSIN-II; DIAGNOSIS; ELECTROLYTE; LIMITATIONS; MECHANISMS; DISORDERS; EXCRETION AB Acid-base disturbances can result from kidney or nonkidney disorders. We present a case of high-volume ileostomy output causing large bicarbonate losses and resulting in a non-anion gap metabolic acidosis. Non-anion gap metabolic acidosis can present as a form of either acute or chronic metabolic acidosis. A complete clinical history and physical examination are critical initial steps to begin the evaluation process, followed by measuring serum electrolytes with a focus on potassium level, blood gas, urine pH, and either direct or indirect urine ammonium concentration. The present case was selected to highlight the differential diagnosis of a non-anion gap metabolic acidosis and illustrate a systematic approach to this problem. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Rastegar, Mandana; Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Nephrol Sect, Los Angeles, CA 90095 USA. RP Nagami, GT (reprint author), VA Greater Los Angeles Healthcare Syst, Nephrol Sect 111L, 3, Los Angeles, CA 90073 USA. EM glenn.nagami@va.gov FU Department of Veterans Affairs FX This work was supported in part by the Department of Veterans Affairs. NR 40 TC 0 Z9 0 U1 14 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD FEB PY 2017 VL 69 IS 2 BP 296 EP 301 DI 10.1053/j.ajkd.2016.09.013 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA EJ2HS UT WOS:000393031300022 PM 28029394 ER PT J AU Dransfield, MT Kunisaki, KM Strand, MJ Anzueto, A Bhatt, SP Bowler, RP Criner, GJ Curtis, JL Hanania, NA Nath, H Putcha, N Roark, SE Wan, ES Washko, GR Wells, JM Wendt, CH Make, BJ AF Dransfield, Mark T. Kunisaki, Ken M. Strand, Matthew J. Anzueto, Antonio Bhatt, Surya P. Bowler, Russell P. Criner, Gerard J. Curtis, Jeffrey L. Hanania, Nicola A. Nath, Hrudaya Putcha, Nirupama Roark, Sarah E. Wan, Emily S. Washko, George R. Wells, J. Michael Wendt, Christine H. Make, Barry J. CA COPDGene Investigators TI Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; exacerbations; spirometry ID COPD EXACERBATION; FUNCTION DECLINE; EX-SMOKERS; SPIROMETRY; EPIDEMIOLOGY; PREDICTORS; MORTALITY; FREQUENCY; RECOVERY; HEALTH AB Rationale: Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase the risk of death and drive healthcare costs, but whether they accelerate loss of lung function remains controversial. Whether exacerbations in subjects with mild COPD or similar acute respiratory events in smokers without airflow obstruction affect lung function decline is unknown. Objectives: To determine the association between acute exacerbations of COPD (and acute respiratory events in smokers without COPD) and the change in lung function over 5 years of follow-up. Methods: We examined data on the first 2,000 subjects who returned for a second COPDGene visit 5 years after enrollment. Baseline data included demographics, smoking history, and computed tomography emphysema. We defined exacerbations (and acute respiratory events in those without established COPD) as acute respiratory symptoms requiring either antibiotics or systemic steroids, and severe events by the need for hospitalintion. Throughout the 5-year follow-up period, we collected self-reported acute respiratory event data at 6-month intervals. We used linear mixed models to fit FEV1 decline based on reported exacerbations or acute respiratory events. Measurements and Main Results: In subjects with COPD, exacerbations were associated with excess FEV1 decline, with the greatest effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbation was associated with an additional 23 ml/yr decline (95% confidence interval, 2-44; P = 0.03), and each severe exacerbation with an additional 87 ml/yr decline (95% confidence interval, 23-151; P = 0.008); statistically significant but smaller effects were observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects. In subjects without airflow obstruction, acute respiratory events were not associated with additional FEV1 decline. Conclusions: Exacerbations are associated with accelerated lung function loss in subjects with established COPD, particularly those with mild disease. Trials are needed to test existing and novel therapies in subjects with early/mild COPD to potentially reduce the risk of progressing to more advanced lung disease. C1 [Dransfield, Mark T.; Bhatt, Surya P.; Nath, Hrudaya; Wells, J. Michael] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA. [Dransfield, Mark T.; Wells, J. Michael] Birmingham VA Med Ctr, 422 THT 1900 Univ Blvd, Birmingham, AL 35294 USA. [Kunisaki, Ken M.; Wendt, Christine H.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Kunisaki, Ken M.; Wendt, Christine H.] Univ Minnesota, Minneapolis, MN USA. [Strand, Matthew J.; Bowler, Russell P.; Make, Barry J.] Natl Jewish Hlth, Denver, CO USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Pulm Crit Care, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Criner, Gerard J.] Temple Univ, Philadelphia, PA 19122 USA. [Curtis, Jeffrey L.; Roark, Sarah E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Curtis, Jeffrey L.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Hanania, Nicola A.] Baylor Coll Med, Houston, TX 77030 USA. [Putcha, Nirupama] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Wan, Emily S.; Washko, George R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Dransfield, MT (reprint author), Birmingham VA Med Ctr, 422 THT 1900 Univ Blvd, Birmingham, AL 35294 USA.; Dransfield, MT (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, 422 THT 1900 Univ Blvd, Birmingham, AL 35294 USA. EM mdransfield@uabmc.edu FU National Institutes of Health [R01HL089897, R01HL089856]; COPD Foundation; AstraZeneca; Pfizer; Novartis; Boehringer Ingelheim; Siemens; Sunovion; GlaxoSmithKline FX Supported by National Institutes of Health grants R01HL089897 and R01HL089856. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim, Siemens, Sunovion, and GlaxoSmithKline. The industry funders had no role in study design, collection/analysis/interpretation of the data, preparation of the manuscript, or decision to submit the manuscript for publication. This material is also the result of work supported with resources and the use of facilities at the Minneapolis VA and VA Ann Arbor Health Care Systems. The views expressed in this article are those of the authors and do not reflect the views of the United States Government, the Department of Veterans Affairs, the authors' affiliated institutions, or the funders of the study. NR 35 TC 2 Z9 2 U1 4 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2017 VL 195 IS 3 BP 324 EP 330 DI 10.1164/rccm.201605-1014OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EJ6VP UT WOS:000393358200012 PM 27556408 ER PT J AU Hess, KL Andorko, JI Tostanoski, LH Jewell, CM AF Hess, Krystina L. Andorko, James I. Tostanoski, Lisa H. Jewell, Christopher M. TI Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity SO BIOMATERIALS LA English DT Article DE Self-assembly; Polyplex; Toll-like receptor; Tolerance and autoimmunity; Nanoparticle; Immunology ID ANTIGEN-PRESENTING CELLS; MULTIPLE-SCLEROSIS; POLYELECTROLYTE MULTILAYERS; IMMUNOLOGICAL-TOLERANCE; DENDRITIC CELLS; T-CELLS; PENETRATING PEPTIDES; IMMUNE SIGNALS; STING ADAPTER; CPG MOTIFS AB Autoimmune diseases occur when the immune system incorrectly recognizes self-molecules as foreign; in the case of multiple sclerosis (MS), myelin is attacked. Intriguingly, new studies reveal toll-like receptors (TLRs), pathways usually involved in generating immune responses against pathogens, play a significant role in driving autoimmune disease in both humans and animal models. We reasoned polyplexes formed from myelin self-antigen and regulatory TLR antagonists might limit TLR signaling during differentiation of myelin-specific T cells, inducing tolerance by biasing T cells away from inflammatory phenotypes. Complexes were formed by modifying myelin peptide with cationic amino acids to create peptides able to condense the anionic nucleic-acid based TLR antagonist. These immunological polyplexes eliminate synthetic polymers commonly used to condense polyplexes and do not rely on gene expression; however, the complexes mimic key features of traditional polyplexes such as tunable loading and co-delivery. Using these materials and classic polyplex analysis techniques, we demonstrate condensation of both immune signals, protection from enzymatic degradation, and tunable physicochemical properties. We show polyplexes reduce TLR signaling, and in primary dendritic cell and T cell co-culture, reduce myelin-driven inflammation. During mouse models of MS, these tolerogenic polyplexes improve the progression, severity, and incidence of disease. (C) 2016 The Authors. Published by Elsevier Ltd. C1 [Hess, Krystina L.; Andorko, James I.; Tostanoski, Lisa H.; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, 8228 Paint Branch Dr, College Pk, MD 20742 USA. [Jewell, Christopher M.] Univ Maryland, Dept Microbiol & Immunol, Sch Med, 685 West Baltimore St, Baltimore, MD 21201 USA. [Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, 22 S Greene St, Baltimore, MD 21201 USA. [Jewell, Christopher M.] US Dept Vet Affairs, 10 North Greene St, Baltimore, MD 21201 USA. RP Jewell, CM (reprint author), Fischell Dept Bioengn, 2212 Jeong H Kim Engn Bldg,8228 Paint Branch Dr, College Pk, MD 20742 USA. EM cmjewell@umd.edu FU National Multiple Sclerosis Society Award [RG-1501-02968, PP2103]; NSF CAREER Award [1351688]; University of Maryland Venture Fund; ASD/RE; Defense National Defense Education Program (NDEP) [Wide/PE0601120D8Z, BA-1]; NIH [T32 AI089621]; American Association of Pharmaceutical Scientists Foundation; Damon Runyon Foundation [DRR3415]; Young Investigator of the Alliance for Cancer Gene Therapy [15051543]; Melanoma Research Alliance [348963] FX This work was supported in part by the National Multiple Sclerosis Society Award # RG-1501-02968 and # PP2103, NSF CAREER Award # 1351688, and the University of Maryland Venture Fund. K.LH. is a SMART Graduate Fellow funded by ASD/R&E, Defense Wide/PE0601120D8Z National Defense Education Program (NDEP)/BA-1, Basic Research. J.I.A. is a trainee on NIH Grant #T32 AI089621 and a Graduate Fellow supported by the American Association of Pharmaceutical Scientists Foundation. L.H.T. is a NSF Graduate Fellow (# DGE1322106). C.M.J. is a Damon Runyon-Rachleff Innovator supported by the Damon Runyon Foundation (# DRR3415), and a Young Investigator of the Alliance for Cancer Gene Therapy (# 15051543) and the Melanoma Research Alliance (# 348963). NR 65 TC 1 Z9 1 U1 10 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 EI 1878-5905 J9 BIOMATERIALS JI Biomaterials PD FEB PY 2017 VL 118 BP 51 EP 62 DI 10.1016/j.biomaterials.2016.11.052 PG 12 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA EJ5JQ UT WOS:000393254700004 PM 27940382 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI Premature closure? Not so fast SO BMJ QUALITY & SAFETY LA English DT Editorial Material ID DIAGNOSTIC-ACCURACY; INTERNAL-MEDICINE; CONTROLLED-TRIAL; RESIDENTS; BIAS; ERROR; THINK C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, Med Serv, 4150 Clement St, San Francisco, CA 94121 USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, Med Serv, 4150 Clement St, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@ucsf.edu NR 23 TC 2 Z9 2 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2017 VL 26 IS 2 BP 87 EP 89 DI 10.1136/bmjqs-2016-005267 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EJ4PI UT WOS:000393198900002 PM 26980778 ER PT J AU Pena-Polanco, JE Mor, MK Tohme, FA Fine, MJ Palevsky, PM Weisbord, SD AF Pena-Polanco, Julio E. Mor, Maria K. Tohme, Fadi A. Fine, Michael J. Palevsky, Paul M. Weisbord, Steven D. TI Acceptance of Antidepressant Treatment by Patients on Hemodialysis and Their Renal Providers SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID QUALITY-OF-LIFE; RECEIVING CHRONIC-HEMODIALYSIS; SYMPTOM MANAGEMENT STRATEGIES; RANDOMIZED CLINICAL-TRIAL; DISEASE PATIENTS; PSYCHOSOCIAL FACTORS; DEPRESSED-PATIENTS; DIALYSIS PATIENTS; PAIN; MORTALITY AB Background and objectives Depression is common in patients receiving chronic hemodialysis but seems to be ineffectively treated. We investigated the acceptance of antidepressant treatment by patients on chronic hemodialysis and their renal providers. Design, setting, participants, & measurements As part of a clinical trial of symptom management in patients on chronic hemodialysis conducted from 2009 to 2011, we assessed depression monthly using the Patient Health Questionnaire 9. For depressed patients (Patient Health Questionnaire 9 score-10), trained nurses generated treatment recommendations and helped implement therapy if patients and providers accepted the recommendations. We assessed patients' acceptance of recommendations, reasons for refusal, and provider willingness to implement antidepressant therapy. We analyzed data at the level of the monthly assessment. Results Of 101 patients followed for <= 12 months, 39 met criteria for depression (Patient Health Questionnaire 9 score >= 10 on one or more assessments). These 39 patients had depression on 147 of 373 (39%) monthly assessments. At 103 of these 147 (70%) assessments, patients were receiving antidepressant therapy, and at 51 of 70 (70%) assessments, patients did not accept nurses' recommendations to intensify treatment. At 44 assessments, patients with depression were not receiving antidepressant therapy, and in 40 (91%) instances, they did not accept recommendations to start treatment. The primary reason that patients refused the recommendations was athibution of their depression to an acute event, chronic illness, or dialysis (57%). In 11 of 18 (61%) instances in which patients accepted the recommendation, renal providers were unwilling to provide treatment. Conclusions Patients on chronic hemodialysis with depression are frequently not interested in modifying or initiating antidepressant treatment, commonly attributing their depression to a recent acute event, chronic illness, or dialysis. Renal providers are often unwilling to modify or initiate antidepressant therapy. Future efforts to improve depression management will need to address these patient- and provider-level obstacles to providing such care. C1 [Pena-Polanco, Julio E.; Tohme, Fadi A.; Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Fine, Michael J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Mor, Maria K.; Fine, Michael J.; Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Palevsky, Paul M.; Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu FU Department of Veterans Affairs Health Services Research and Development Merit Review award [IIR 07-190] FX This work was supported by Department of Veterans Affairs Health Services Research and Development Merit Review award IIR 07-190 (to S.D.W.). NR 29 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB PY 2017 VL 12 IS 2 BP 298 EP 303 DI 10.2215/CJN.07720716 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA EJ6VG UT WOS:000393357300013 PM 28126707 ER PT J AU Thenkondar, A Jafari, L Sooriash, R Hajsadeghi, F Berenji, GR Li, YX AF Thenkondar, Anuradha Jafari, Lida Sooriash, Robbie Hajsadeghi, Fereshteh Berenji, Gholam R. Li, Yuxin TI F-18-NaF PET Demonstrating Unusual Focal Tracer Activity in the Brain SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE F-18-NaF; PET/CT; brain; extraosseous; cerebral infarct ID TC-99M MDP UPTAKE; FLUORIDE; METASTASIS C1 [Thenkondar, Anuradha] Univ Calif Los Angeles, Dept Nucl Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Thenkondar, Anuradha] Univ Calif Los Angeles, David Geffen Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Thenkondar, A (reprint author), Univ Calif Los Angeles, Dept Nucl Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Thenkondar, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Anuradha.Thenkondar@va.gov NR 9 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD FEB PY 2017 VL 42 IS 2 BP 127 EP 128 DI 10.1097/RLU.0000000000001458 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EJ0UB UT WOS:000392924900028 PM 27879488 ER PT J AU Coley, JD Arenson, M Xu, Y Tanner, KD AF Coley, John D. Arenson, Melanie Xu, Yian Tanner, Kimberly D. TI Intuitive biological thought: Developmental changes and effects of biology education in late adolescence SO COGNITIVE PSYCHOLOGY LA English DT Article DE Intuitive biology; Science education; Conceptual change; Psychological essentialism; Anthropocentrism; Teleology ID FUNCTIONAL EXPLANATION; ESSENTIALIST BELIEFS; CONCEPTUAL CHANGE; CATEGORIES; EVOLUTION; KNOWLEDGE; CHILDREN; THINKING; DESIGN; ADULTS AB A large body of cognitive research has shown that people intuitively and effortlessly reason about the biological world in complex and systematic ways. We addressed two questions about the nature of intuitive biological reasoning: How does intuitive biological thinking change during adolescence and early adulthood? How does increasing biology education influence intuitive biological thinking? To do so, we developed a battery of measures to systematically test three components of intuitive biological thought: anthropocentric thinking, teleological thinking and essentialist thinking, and tested 8th graders and university students (both biology majors, and non-biology majors). Results reveal clear evidence of persistent intuitive reasoning among all populations studied, consistent but surprisingly small differences between 8th graders and college students on measures of intuitive biological thought, and consistent but again surprisingly small influence of increasing biology education on intuitive biological reasoning. Results speak to the persistence of intuitive reasoning, the importance of taking intuitive knowledge into account in science classrooms, and the necessity of interdisciplinary research to advance biology education. Further studies are necessary to investigate how cultural context and continued acquisition of expertise impact intuitive biology thinking. (C) 2016 Elsevier Inc. All rights reserved. C1 [Coley, John D.; Arenson, Melanie; Xu, Yian] Northeastern Univ, Dept Psychol, 125 Nightingale Hall,360 Huntington Ave, Boston, MA 02115 USA. [Arenson, Melanie] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Arenson, Melanie] San Francisco VA Med Ctr, San Francisco, CA USA. [Tanner, Kimberly D.] San Francisco State Univ, Dept Biol, San Francisco, CA 94132 USA. RP Coley, JD (reprint author), Northeastern Univ, Dept Psychol, 125 Nightingale Hall,360 Huntington Ave, Boston, MA 02115 USA. EM j.coley@northeastern.edu FU National Science Foundation EHR Core Research Grant [1535496] FX This research was funded by National Science Foundation EHR Core Research Grant #1535496 to J.D. Coley and K.D. Tanner. We thank Heather Krepelka, Rebeca Rosengaus and Fred Davis for their support making this research possible, Kathryn Hardin, Samantha Daoust and Nicole Betz for help in data collection, and Sarah Bissonnette for comments on the manuscript. NR 81 TC 0 Z9 0 U1 9 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0010-0285 EI 1095-5623 J9 COGNITIVE PSYCHOL JI Cogn. Psychol. PD FEB PY 2017 VL 92 BP 1 EP 21 DI 10.1016/j.cogpsych.2016.11.001 PG 21 WC Psychology; Psychology, Experimental SC Psychology GA EJ5NX UT WOS:000393266100001 PM 27865155 ER PT J AU Piper, ME Cook, JW Schlam, TR Smith, SS Bolt, DM Collins, LM Mermelstein, R Fiore, MC Baker, TB AF Piper, Megan E. Cook, Jessica W. Schlam, Tanya R. Smith, Stevens S. Bolt, Daniel M. Collins, Linda M. Mermelstein, Robin Fiore, Michael C. Baker, Timothy B. TI Toward precision smoking cessation treatment II: Proximal effects of smoking cessation intervention components on putative mechanisms of action SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Smoking cessation; Treatment; Mechanisms; Factorial design ID TOBACCO CESSATION; WITHDRAWAL SCALE; NICOTINE PATCH; CLINICAL-TRIAL; SELF-EFFICACY; BUPROPION; QUIT; VALIDATION; ABSTINENCE; REACTIVITY AB Background: Understanding how smoking cessation treatments exert their effects can inform treatment development and use. Factorial designs allow researchers to examine whether multiple intervention components affect hypothesized change mechanisms, and whether the affected mechanisms are related to cessation. Methods: This is a secondary data analysis of smokers recruited during primary care visits (N = 637, 55% women, 87% white) who were motivated to quit. Participants in this fractional factorial experiment were randomized to one level of each of six intervention factors: Prequit Nicotine Patch vs None, Pre-quit Nicotine Gum vs None, Preparation Counseling vs None, Intensive In-Person Counseling vs Minimal, Intensive Phone Counseling vs Minimal, and 16 vs 8 Weeks of Combination Nicotine Replacement (nicotine patch + nicotine gum). Data on putative mechanisms (e.g., medication use, withdrawal, self-efficacy) and smoking status were gathered using daily assessments and during follow-up assessment calls. Results: Some intervention components influenced hypothesized mechanisms. Prequit Gum and Patch each reduced prequit smoking and enhanced prequit coping and self-efficacy. In-Person Counseling increased prequit motivation to quit, postquit self-efficacy, and postquit perceived intratreatment support. Withdrawal reduction and reduced prequit smoking produced the strongest effects on cessation. The significant effect of combining Prequit Gum and In-Person Counseling on 26-week abstinence was mediated by increased prequit self-efficacy. Conclusions: This factorial experiment identified which putative treatment mechanisms were influenced by discrete intervention components and which mechanisms influenced cessation. Such information supports the combined use of prequit nicotine gum and intensive in-person counseling as cessation interventions that operate via increased prequit self-efficacy. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Piper, Megan E.; Cook, Jessica W.; Schlam, Tanya R.; Smith, Stevens S.; Fiore, Michael C.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St Suite 200, Madison, WI 53711 USA. [Piper, Megan E.; Cook, Jessica W.; Schlam, Tanya R.; Smith, Stevens S.; Fiore, Michael C.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gen Internal Med, Madison, WI 53706 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. RP Piper, ME (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St Suite 200, Madison, WI 53711 USA. EM mep@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; NIH [P50DA10075, R01DK097364, R01AA022931]; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; US Department of Veterans Affairs [101CX00056]; NSF [DMS-1305725] FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. Dr. Collins is also supported by NIH grants P50DA10075, R01DK097364, and R01AA022931. This work was carried out in part while Dr. Schlam was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. Dr. Cook is also supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. Dr. Loh is also supported by NSF grant DMS-1305725. NR 44 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2017 VL 171 BP 50 EP 58 DI 10.1016/j.drugalcdep.2016.11.027 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EK0QA UT WOS:000393630700007 PM 28013097 ER PT J AU Piper, ME Schlam, TR Cook, JW Smith, SS Bolt, DM Loh, WY Mermelstein, R Collins, LM Fiore, MC Baker, TB AF Piper, Megan E. Schlam, Tanya R. Cook, Jessica W. Smith, Stevens S. Bolt, Daniel M. Loh, Wei-Yin Mermelstein, Robin Collins, Linda M. Fiore, Michael C. Baker, Timothy B. TI Toward precision smoking cessation treatment I: Moderator results from a factorial experiment SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Smoking cessation; Treatment; Moderators; Factorial design; Psychiatric comorbidity ID NICOTINE REPLACEMENT THERAPY; RANDOMIZED CLINICAL-TRIAL; CIGARETTE-SMOKING; PSYCHIATRIC-DISORDERS; TOBACCO WITHDRAWAL; ABSTINENCE RATES; DEPENDENCE; EFFICACY; SMOKERS; INTERVENTIONS AB Background: The development of tobacco use treatments that are effective for all smokers is critical to improving clinical and public health. The Multiphase Optimization Strategy (MOST) uses highly efficient factorial experiments to evaluate multiple intervention components for possible inclusion in an optimized tobacco use treatment. Factorial experiments permit analyses of the influence of patient characteristics on main and interaction effects of multiple, relatively discrete, intervention components. This study examined whether person-factor and smoking characteristics moderated the main or interactive effects of intervention components on 26-week self-reported abstinence rates. Methods: This fractional factorial experiment evaluated six smoking cessation intervention components among primary care patients (N = 637): Prequit Nicotine Patch vs. None, Prequit Nicotine Gum vs. None, Preparation Counseling vs. None, Intensive Cessation In-Person Counseling vs. Minimal, Intensive Cessation Telephone Counseling vs. Minimal, and 16 vs. 8 Weeks of Combination Nicotine Replacement Therapy (NRT; nicotine patch + nicotine gum). Results: Both psychiatric history and smoking heaviness moderated intervention component effects. In comparison with participants with no self-reported history of a psychiatric disorder, those with a positive history showed better response to 16- vs. 8-weeks of combination NRT, but a poorer response to counseling interventions. Also, in contrast to light smokers, heavier smokers showed a poorer response to counseling interventions. Conclusions: Heavy smokers and those with psychiatric histories demonstrated a differential response to intervention components. This research illustrates the use of factorial designs to examine the interactions between person characteristics and relatively discrete intervention components. Future research is needed to replicate these findings. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Piper, Megan E.; Schlam, Tanya R.; Cook, Jessica W.; Smith, Stevens S.; Fiore, Michael C.; Baker, Timothy B.] Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. [Piper, Megan E.; Schlam, Tanya R.; Cook, Jessica W.; Smith, Stevens S.; Fiore, Michael C.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gen Internal Med, Madison, WI 53706 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53706 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. RP Piper, ME (reprint author), Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM mep@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; NIH [P50DA10075, R01 DK097364, R01AA022931]; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; NSF [DMS-1305725] FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. Dr. Collins is also supported by NIH grants P50DA10075, R01 DK097364, and R01AA022931. This work was carried out in part while Dr. Schlam was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. Dr. Cook is also supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. Dr. Loh is also supported by NSF grant DMS-1305725. NR 40 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2017 VL 171 BP 59 EP 65 DI 10.1016/j.drugalcdep.2016.11.025 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EK0QA UT WOS:000393630700008 PM 28013098 ER PT J AU Kelley, AS Covinsky, KE Gorges, RJ McKendrick, K Bollens-Lund, E Morrison, RS Ritchie, CS AF Kelley, Amy S. Covinsky, Kenneth E. Gorges, Rebecca J. McKendrick, Karen Bollens-Lund, Evan Morrison, R. Sean Ritchie, Christine S. TI Identifying Older Adults with Serious Illness: A Critical Step toward Improving the Value of Health Care SO HEALTH SERVICES RESEARCH LA English DT Article DE Medicare; population health; geriatrics; palliative medicine ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; PALLIATIVE CARE; END; CANCER; DISABILITY; COST AB ObjectiveTo create and test three prospective, increasingly restrictive definitions of serious illness. Data SourcesHealth and Retirement Study, 2000-2012. Study DesignWe evaluated subjects' 1-year outcomes from the interview date when they first met each definition: (A) one or more severe medical conditions (Condition) and/or receiving assistance with activities of daily living (Functional Limitation); (B) Condition and/or Functional Limitation and hospital admission in the last 12months and/or residing in a nursing home (Utilization); and (C) Condition and Functional Limitation and Utilization. Definitions are increasingly restrictive, but not mutually exclusive. Data CollectionOf 11,577 eligible subjects, 5,297 met definition A; 3,151 definition B; and 1,447 definition C. Principal FindingsOne-year outcomes were as follows: hospitalization 33 percent (A), 44 percent (B), 47 percent (C); total average Medicare costs $20,566 (A), $26,349 (B), and $30,828 (C); and mortality 13 percent (A), 19 percent (B), 28 percent (C). In comparison, among those meeting no definition, 12 percent had hospitalizations, total Medicare costs averaged $7,789, and 2 percent died. ConclusionsProspective identification of older adults with serious illness is feasible using clinically accessible criteria and may be a critical step toward improving health care value. These definitions may aid clinicians and health systems in targeting patients who could benefit from additional services. C1 [Kelley, Amy S.; McKendrick, Karen; Bollens-Lund, Evan; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, 1 Gustave Levy Pl,Box 1070, New York, NY 10029 USA. [Kelley, Amy S.; Morrison, R. Sean] James J Peters VA Med Ctr, Geriatr Res Educ Ctr, Bronx, NY USA. [Kelley, Amy S.; Morrison, R. Sean] James J Peters VA Med Ctr, Ctr Clin, Bronx, NY USA. [Covinsky, Kenneth E.; Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Gorges, Rebecca J.] Univ Chicago, Harris Sch Publ Policy, Chicago, IL 60637 USA. RP Kelley, AS (reprint author), Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, 1 Gustave Levy Pl,Box 1070, New York, NY 10029 USA. EM amy.kelley@mssm.edu FU National Institute on Aging (NIA) [1K23AG040774-01A1]; American Federation for Aging Research; National Palliative Care Research Center; NIA [1K07AG31779, 1K24 AG 22345-01] FX ASK receives support from the National Institute on Aging (NIA) (1K23AG040774-01A1), the American Federation for Aging Research, and the National Palliative Care Research Center. CSR receives support from the NIA (1K07AG31779). RSM receives support from the National Palliative Care Research Center and the NIA (1K24 AG 22345-01). The funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 27 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2017 VL 52 IS 1 BP 113 EP 131 DI 10.1111/1475-6773.12479 PG 19 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EJ9XC UT WOS:000393579500007 PM 26990009 ER PT J AU Schussler-Fiorenza Rose, SM Stineman, MG Pan, Q Bogner, H Kurichi, JE Streim, JE Xie, DW AF Schussler-Fiorenza Rose, Sophia Miryam Stineman, Margaret G. Pan, Qiang Bogner, Hillary Kurichi, Jibby E. Streim, Joel E. Xie, Dawei TI Potentially Avoidable Hospitalizations among People at Different Activity of Daily Living Limitation Stages SO HEALTH SERVICES RESEARCH LA English DT Article DE Ambulatory care; hospitalization; primary health care; health services accessibility; disabled persons ID CARE-SENSITIVE CONDITIONS; HEALTH-CARE; ELDERLY-PEOPLE; PREVENTABLE HOSPITALIZATIONS; HOME ACCESSIBILITY; MEDICARE CLAIMS; OLDER PERSONS; UNMET NEED; DISABILITIES; COMMUNITY AB ObjectiveTo determine whether higher activity of daily living (ADL) limitation stages are associated with increased risk of hospitalization, particularly for ambulatory care sensitive (ACS) conditions. Data SourceSecondary data analysis, including 8,815 beneficiaries from 2005 to 2006 Medicare Current Beneficiary Survey (MCBS). Study DesignADL limitation stages (0-IV) were determined at the end of 2005. Hospitalization rates were calculated for 2006 and age adjusted using direct standardization. Multivariate negative binomial regression, adjusting for baseline demographic and health characteristics, with the outcome hospitalization count was performed to estimate the adjusted rate ratio of ACS and non-ACS hospitalizations for beneficiaries with ADL stages > 0 compared to beneficiaries without limitations. Data CollectionBaseline ADL stage and health conditions were assessed using 2005 MCBS data and count of hospitalization determined using 2006 MCBS data. Principal FindingsReferenced to stage 0, the adjusted rate ratios (95 percent confidence interval) for stage I to stage IV ranged from 1.9 (1.4-2.5) to 4.1 (2.2-7.8) for ACS hospitalizations compared with from 1.6 (1.3-1.9) to 1.8 (1.4-2.5) for non-ACS hospitalizations. ConclusionsHospitalization rates for ACS conditions increased more dramatically with ADL limitation stage than did rates for non-ACS conditions. Adults with ADL limitations appear particularly vulnerable to potentially preventable hospitalizations for conditions typically manageable in ambulatory settings. C1 [Pan, Qiang; Bogner, Hillary; Kurichi, Jibby E.; Xie, Dawei] Univ Penn, Ctr Clin Epidemiol & Biostat, 907 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Schussler-Fiorenza Rose, Sophia Miryam] Dept Vet Affairs Palo Alto Hlth Care Syst, Spinal Cord Injury & Disorders Ctr, Palo Alto, CA USA. [Schussler-Fiorenza Rose, Sophia Miryam] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA. [Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Stineman, Margaret G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Kurichi, JE (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, 907 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jkurichi@mail.med.upenn.edu OI Schussler-Fiorenza Rose, Sophia Miryam/0000-0002-6311-6671 FU National Institute of Aging of the National Institutes of Health [AG032420-01A1, R01 AG 040105-01A1]; Ruth L. Kirschstein National Research Service Award Institutional Research Training grant [(T32) 5-T32-HD-007425]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Spinal Cord Injury Medicine; NIMH [MH082799, MH047447] FX This study was supported by grants from the National Institute of Aging of the National Institutes of Health (AG032420-01A1 and R01 AG 040105-01A1) for Drs. Stineman and Xie, Mr. Pan, and Ms. Kurichi. Dr. Schussler-Fiorenza Rose was supported by the Ruth L. Kirschstein National Research Service Award Institutional Research Training grant (T32) 5-T32-HD-007425 and the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Spinal Cord Injury Medicine. Dr. Bogner was supported by NIMH grants MH082799 and MH047447. The opinions and conclusions of the authors are not necessarily those of the sponsoring agencies. NR 69 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2017 VL 52 IS 1 BP 132 EP 155 DI 10.1111/1475-6773.12484 PG 24 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EJ9XC UT WOS:000393579500008 PM 26990312 ER PT J AU Kashner, TM Hettler, DL Zeiss, RA Aron, DC Bernett, DS Brannen, JL Byrne, JM Cannon, GW Chang, BK Dougherty, MB Gilman, SC Holland, GJ Kaminetzky, CP Wicker, AB Keitz, SA AF Kashner, T. Michael Hettler, Debbie L. Zeiss, Robert A. Aron, David C. Bernett, David S. Brannen, Judy L. Byrne, John M. Cannon, Grant W. Chang, Barbara K. Dougherty, Mary B. Gilman, Stuart C. Holland, Gloria J. Kaminetzky, Catherine P. Wicker, Annie B. Keitz, Sheri A. TI Has Interprofessional Education Changed Learning Preferences? A National Perspective SO HEALTH SERVICES RESEARCH LA English DT Article DE Health workforce training; survey research and questionnaire design; interprofessional care; patient-centered care; VA health care system ID LEARNERS PERCEPTIONS SURVEY; RESIDENT PHYSICIANS; HEALTH-PROFESSIONS; MEDICAL-STUDENTS; CARE PRACTICE; COLLABORATION; SATISFACTION; NURSES; ATTITUDES; TEAMWORK AB ObjectiveTo assess how changes in curriculum, accreditation standards, and certification and licensure competencies impacted how medical students and physician residents value interprofessional team and patient-centered care. Primary Data SourceThe Department of Veterans Affairs Learners' Perceptions Survey (2003-2013). The nationally administered survey asked a representative sample of 56,569 U.S. medical students and physician residents, with a comparison group of 78,038 nonphysician trainees, to rate satisfaction with 28 elements, in two overall domains, describing their clinical learning experiences at VA medical centers. Study DesignValue preferences were scored as independent adjusted associations between an element (interprofessional team, patient-centered preceptor) and the respective overall domain (clinical learning environment, faculty, and preceptors) relative to a referent element (quality of clinical care, quality of preceptor). Principal FindingsPhysician trainees valued interprofessional (14 percent vs. 37 percent, p<.001) and patient-centered learning (21 percent vs. 36 percent, p<.001) less than their nonphysician counterparts. Physician preferences for interprofessional learning showed modest increases over time (2.5 percent/year, p<.001), driven mostly by internal medicine and surgery residents. Preferences did not increase with trainees' academic progress. ConclusionsDespite changes in medical education, physician trainees continue to lag behind their nonphysician counterparts in valuing experience with interprofessional team and patient-centered care. C1 [Kashner, T. Michael; Hettler, Debbie L.; Zeiss, Robert A.; Brannen, Judy L.; Chang, Barbara K.; Dougherty, Mary B.; Gilman, Stuart C.; Holland, Gloria J.; Wicker, Annie B.] Dept Vet Affairs, Off Acad Affiliat, 810 Vermont Ave, Washington, DC 20006 USA. [Kashner, T. Michael; Byrne, John M.] Loma Linda Univ, Sch Med, Loma Linda, CA USA. [Hettler, Debbie L.] Salus Univ, Penn Coll Optometry, Elkins Pk, PA USA. [Hettler, Debbie L.] Salus Univ, Coll Hlth Sci, Elkins Pk, PA USA. [Aron, David C.] Louis Stokes Cleveland DVA Med Ctr, Cleveland, OH USA. [Aron, David C.] Case Western Reserve Univ, Weatherhead Sch Management, Sch Med, Cleveland, OH 44106 USA. [Bernett, David S.] VA Med Ctr, Off Acad Affiliat, St Louis, MO USA. [Brannen, Judy L.] Virginia Commonwealth Univ, Richmond, VA USA. [Byrne, John M.] Jerry L Pettis Mem VA Med Ctr, Loma Linda, CA USA. [Cannon, Grant W.] George E Wahlen VA Med Ctr, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Chang, Barbara K.] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. [Gilman, Stuart C.] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA. [Kaminetzky, Catherine P.] VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, Seattle, WA USA. [Kaminetzky, Catherine P.] Univ Washington, Sch Med, Seattle, WA USA. [Keitz, Sheri A.] Univ Massachusetts, UMass Mem Med Ctr, Dept Med, Worcester, MA 01605 USA. RP Kashner, TM (reprint author), Dept Vet Affairs, Off Acad Affiliat, 810 Vermont Ave, Washington, DC 20006 USA. EM michael.kashner@va.gov FU Office of Academic Affiliations (OAA); OAA National Evaluation Workgroup; Office of Academic Affiliations, Veterans Health Administration, Department of Veterans Affairs, Washington, DC FX Sincere gratitude is expressed for the support from the Office of Academic Affiliations (OAA), the OAA National Evaluation Workgroup (Sheri A. Keitz, M.D., Ph.D., Chair), Christopher T. Clarke, Ph.D., Terry V. Kruzan, George E. McKay, and Laura Stefanowycz of the OAA Data Management and Support Center in St. Louis, Missouri, and to the network of Designated Education Officers and Associated Chiefs of Staff for Education at VA Medical Centers. This study was supported, in part, by the Office of Academic Affiliations, Veterans Health Administration, Department of Veterans Affairs, Washington, DC. All statements and descriptions expressed herein do not necessarily reflect the opinions or positions of the Department of Veterans Affairs or its affiliated institutions. NR 66 TC 0 Z9 0 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2017 VL 52 IS 1 BP 268 EP 290 DI 10.1111/1475-6773.12485 PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EJ9XC UT WOS:000393579500015 PM 26990439 ER PT J AU Pekary, E Sattin, A AF Pekary, E. Sattin, A. TI TRH and TRH-Like Peptide Levels Co-Vary with Reproductive and Metabolic Rhythms SO HORMONE AND METABOLIC RESEARCH LA English DT Article DE thyrotropin-releasing hormone; reproduction; metabolism ID THYROTROPIN-RELEASING-HORMONE; RAT-BRAIN; PERIPHERAL-TISSUES; CIRCADIAN-RHYTHMS; RAPID MODULATION; LEYDIG-CELLS; BODY-WEIGHT; MOUSE-LIVER; FOOD-INTAKE; EXPRESSION AB Photoperiod-synchronized rhythms in non-CSN tissues persist in total darkness. Clock genes involved in maintaining regular biorhythms within the suprachiasmatic nucleus (SCN) of the hypothalamus are expressed in extra-CNS tissues and continue periodic expression in vitro. Understanding the details of how the SCN clock is coupled with peripheral clocks is only incompletely understood and may involve a multiplicity of feedback systems. The present study is an extension of our previous work showing that brain levels of TRH (pGlu-His-Pro-NH2) and TRH-like peptides (X-TRH: pGlu-X-Pro-NH2, where "X" can be any amino acid residue) fluctuate throughout the day-night cycle. Male rats were maintained in a stable environment, lights on 6-18 h. TRH and TRH-like peptides in liver, pancreas, testis, prostate, epididymis, and heart were measured at 3, 10, 16, and 22 h. The greatest change in peptide level was a 12-fold increase for TRH in prostate at 16 h relative to the corresponding value at 3 h. The TRH, Tyr-TRH and Phe-TRH levels in liver declined steadily to about 40 % of the 3-h values by 22 h. Changes, in the order of decreasing number of significant increases (up arrow) and/or decreases (down arrow), were: testis (5 up arrow, 1 down arrow), liver (3 down arrow), epididymis (2 up arrow), prostate (1 up arrow, 1 down arrow) and heart (1 up arrow). Peptide levels in liver and testis correlated with serum leptin and serum corticosterone, respectively, which are potent releasers of these peptides. Testosterone and glucose were also highly correlated. These tripeptides may participate in the regulation of metabolic and reproductive functions, which change during the day-night cycle. C1 [Pekary, E.; Sattin, A.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Pekary, E.] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA USA. [Pekary, E.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Sattin, A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Sattin, A.] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA USA. [Sattin, A.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Pekary, E (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Albert.Pekary@va.gov NR 78 TC 0 Z9 0 U1 2 U2 2 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0018-5043 EI 1439-4286 J9 HORM METAB RES JI Horm. Metab. Res. PD FEB PY 2017 VL 49 IS 2 BP 86 EP 94 DI 10.1055/s-0042-111012 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EJ4XU UT WOS:000393221400002 PM 27434852 ER PT J AU Hom, MA Chu, C Schneider, ME Lim, IC Hirsch, JK Gutierrez, PM Joiner, TE AF Hom, Melanie A. Chu, Carol Schneider, Matthew E. Lim, Ingrid C. Hirsch, Jameson K. Gutierrez, Peter M. Joiner, Thomas E. TI Thwarted belongingness as an explanatory link between insomnia symptoms and suicidal ideation: Findings from three samples of military service members and veterans SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Insomnia; Suicidal ideation; Loneliness; Thwarted belongingness; Military; Veterans ID COGNITIVE-BEHAVIORAL THERAPY; INTERPERSONAL-PSYCHOLOGICAL THEORY; OLDER-ADULTS; PERCEIVED BURDENSOMENESS; ANXIETY SENSITIVITY; EMOTION-REGULATION; SLEEP DISTURBANCE; YOUNG-ADULTS; US ARMY; NEEDS QUESTIONNAIRE AB Background: Although insomnia has been identified as a robust predictor of suicidal ideation and behaviors, little is known about the mechanisms by which sleep disturbances confer risk for suicide. We investigated thwarted belongingness as an explanatory link between insomnia symptoms and suicidal ideation across three military service member and veteran samples. Methods: Data were collected among United States military service members and veterans (N-1=937, N-2=3,386, N-3=417) who completed self-report measures of insomnia symptoms, thwarted belongingness, suicidal ideation, and related psychiatric symptoms (e.g., anxiety, hopelessness). Bias-corrected bootstrap mediation analyses were utilized to examine the indirect effects of insomnia symptoms on suicidal ideation through thwarted belongingness, controlling for related psychiatric symptoms. Results: Consistent with study hypotheses, thwarted belongingness significantly accounted for the relationship between insomnia and suicidal ideation across all three samples; however, insomnia symptoms did not significantly account for the relationship between thwarted belongingness and suicidal ideation, highlighting the specificity of our findings. Limitations: This study utilized cross-sectional self-report data. Conclusions: Insomnia may confer suicide risk for military service members and veterans, in part, through the pathway of thwarted belongingness. Additional prospective studies are warranted to further delineate this model of risk. Our results offer a potential therapeutic target for the prevention of suicide, via the promotion of belongingness, among service members and veterans experiencing insomnia symptoms. C1 [Hom, Melanie A.; Chu, Carol; Schneider, Matthew E.; Joiner, Thomas E.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. [Lim, Ingrid C.] Off Army Surg Gen, New York, NY USA. [Hirsch, Jameson K.] East Tennessee State Univ, Dept Psychol, Johnson City, TN 37614 USA. [Gutierrez, Peter M.] Denver Vet Affairs Med Ctr, Educ & Clin Ctr, Rocky Mt Mental Illness Res, Denver, CO USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA. RP Hom, MA (reprint author), Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. EM hom@psy.fsu.edu OI Gutierrez, Peter/0000-0001-8981-8404 FU NIMH NIH HHS [T32 MH093311] NR 92 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2017 VL 209 BP 114 EP 123 DI 10.1016/j.jad.2016.11.032 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EJ5EW UT WOS:000393241400019 PM 27898373 ER PT J AU Xie, K Gelfman, L Horton, JR Goldstein, NE AF Xie, Kira Gelfman, Laura Horton, Jay R. Goldstein, Nathan E. TI State of Research on Palliative Care in Heart Failure as Evidenced by Published Literature, Conference Proceedings, and NIH Funding SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; aging; morbidity; palliative care ID QUANTITY; MEDICINE AB Background: Heart failure (HF) is the most common diagnosis in hospitalized patients older than 65 years of age. Although these patients often need specialist-directed palliative care, <10% ever receive these services. This may be due to a lack of evidence examining the benefits of palliative care for these patients. To understand the current state of research on the interface of palliative care and HF, we examined trends in publications, presentations at national meetings, and National Institutes of Health (NIH) funding. Methods: Using key terms, we identified items about palliative care and HF in the following sources: (1) the tables of contents of nine leading cardiology journals, (2) abstracts of conference proceedings from four cardiology societies, and (3) all NIH grants from 2009 to 2013. Results: Of the journals reviewed, fewer than 1% of their publications related to palliative care. Less than 2% of HF-related sessions in conference proceedings mentioned palliative care. Of the NIH's $45 billion directed to HF research, only $14 million (0.03%) was spent on palliative care research. Conclusions: Despite calls for improving palliative care for patients with advanced HF, a lack of sufficient attention persists in research abstracts, concurrent sessions at national meetings, and NIH funding to increase the evidence base. Without these improvements, the ability to deliver high-quality specialist palliative care to patients with HF and their families will remain severely limited. C1 [Xie, Kira] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gelfman, Laura; Horton, Jay R.; Goldstein, Nathan E.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. [Gelfman, Laura; Goldstein, Nathan E.] James J Peters VA Med Ctr, Geriatr Res & Clin Care Ctr, Bronx, NY USA. RP Goldstein, NE (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. EM Nathan.Goldstein@mssm.edu FU Patricia S. Levinson Summer Fellowship from Icahn School of Medicine at Mount Sinai; Mount Sinai Claude D Pepper Older Americans Independence Center (National Institute on Aging) [2P30AG028741]; National Heart Lung and Blood Institute [5R01HL102084-05]; NIA [1 K23 AG049930-01A1] FX Ms. Xie was supported by a Patricia S. Levinson Summer Fellowship from Icahn School of Medicine at Mount Sinai. Drs. Goldstein, Horton, and Gelfman were supported by the Mount Sinai Claude D Pepper Older Americans Independence Center (National Institute on Aging 2P30AG028741). Dr. Goldstein was also supported by the National Heart Lung and Blood Institute (5R01HL102084-05) and Dr. Gelfman by the NIA (1 K23 AG049930-01A1). The content does not represent the views of the National Institutes of Health or the Veterans Affairs Health System. NR 13 TC 1 Z9 1 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD FEB PY 2017 VL 23 IS 2 BP 197 EP 200 DI 10.1016/j.cardfail.2016.10.013 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EJ9GT UT WOS:000393535300014 PM 27989871 ER PT J AU Hickman, SE Hammes, BJ Torke, AM Sudore, RL Sachs, GA AF Hickman, Susan E. Hammes, Bernard J. Torke, Alexia M. Sudore, Rebecca L. Sachs, Greg A. TI The Quality of Physician Orders for Life-Sustaining Treatment Decisions: A Pilot Study SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article DE advance directives; bioethics; geriatric palliative care end-of-life; nursing home ID TREATMENT PROGRAM; ADVANCE DIRECTIVES; TREATMENT PREFERENCES; NURSING FACILITIES; SERIOUS ILLNESS; CARE; STABILITY AB Background: Physician Orders for Life-Sustaining Treatment (POLST) forms are used to document patient treatment preferences as medical orders. Prior research demonstrates that use of POLST alters medical treatments in a way that is consistent with the POLST orders. However, there are minimal data about the quality of POLST decisions, including whether they reflect the current preferences of well-informed patients. Objective: Evaluate the quality of POLST decisions. Design: Chart abstraction; interviews. Subjects: Nursing home residents and healthcare agents of incapacitated nursing home residents (n = 28). Measurements: Characteristics of the POLST conversation were assessed. Brief vignettes were used to assess knowledge about how POLST orders guide medical treatment. Current treatment preferences were elicited and compared with the patient's POLST orders to assess discordance. Results: A majority (59%) of participants recognized the POLST form. Participants were generally accurate in their knowledge of how POLST orders guide treatment concerning cardiopulmonary resuscitation (CPR) (68%), antibiotics (74%), and artificial nutrition (79%), but less so for medical interventions (50%). Current treatment preferences were initially discordant with one or more POLST orders for 64% (18/28) of participants, but half of these discordances were resolved with further discussion (e. g., participant agreed with the existing order). Discordance by treatment decision was as follows: CPR (7%), level of medical intervention (18%), antibiotics (21%), and artificial nutrition (11%). Conclusions: Discordance between current preferences and POLST orders is complex. Interventions are needed to support high-quality POLST decisions that are informed and concordant with current preferences. C1 [Hickman, Susan E.] Indiana Univ, Sch Nursing, Dept Community & Hlth Syst, 600 Barnhill Dr,E419, Indianapolis, IN 46204 USA. [Hickman, Susan E.; Torke, Alexia M.; Sachs, Greg A.] Indiana Univ Purdue Univ Indianapolis, RESPECT Res Palliat & End of Life Commun & Traini, Indianapolis, IN USA. [Hammes, Bernard J.] Respecting Choices, Gundersen Hlth Syst, La Crosse, WI USA. [Torke, Alexia M.; Sachs, Greg A.] Indiana Univ Sch Med, Dept Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA. [Torke, Alexia M.; Sachs, Greg A.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA. [Torke, Alexia M.; Sachs, Greg A.] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Sudore, Rebecca L.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hickman, SE (reprint author), Indiana Univ, Sch Nursing, Dept Community & Hlth Syst, 600 Barnhill Dr,E419, Indianapolis, IN 46204 USA. EM hickman@iu.edu FU Indiana University School of Nursing Center for Enhancing Quality of Life in Chronic Illness FX This pilot research was funded by a grant from the Indiana University School of Nursing Center for Enhancing Quality of Life in Chronic Illness. The authors thank research assistant Rachel Podoski, MPH, for her assistance with data collection and oversight of the study. The authors are very grateful to the residents, family members, and nursing facilities that participated in this study. NR 29 TC 1 Z9 1 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2017 VL 20 IS 2 BP 155 EP 162 DI 10.1089/jpm.2016.0059 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EI9PC UT WOS:000392839600010 PM 27802064 ER PT J AU Borsari, B Apodaca, TR Yurasek, A Monti, PM AF Borsari, Brian Apodaca, Timothy R. Yurasek, Ali Monti, Peter M. TI Does mental status impact therapist and patient communication in emergency department brief interventions addressing alcohol use? SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Motivational interviewing; Emergency departments; Mental status; Alcohol use; Brief intervention ID TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; CLIENT CHANGE TALK; CARE; LANGUAGE; CONSUMPTION; METAANALYSIS; ADOLESCENTS; MECHANISMS; DISORDERS AB Motivational interviewing (MI) is often incorporated into screening, brief intervention, and referral to treatment (SBIRT) interventions in critical care settings to address alcohol and other drug use. However, cognitive status has been linked to differential response to MI sessions in emergency department (ED) settings. The current study examined one possible explanation for this differential response: whether higher versus lower mental status impacts patient response to clinician statements during MI sessions conducted in an ED. Participants were 126 patients receiving an MI-based single-session alcohol brief intervention, and 13 therapists who provided treatment. Participants completed a mental status exam (MSE) as part of the screening process. Intervention sessions were audio-taped, and transcribed and coded using the Motivational Interviewing Skills Code (MISC 2.0; Miller, Moyers, Ernst, & Amrhein, 2003). The MISC 2.0 coded therapist behaviors that are related to the use of motivational interviewing, and patient language reflecting movement toward (change talk) or away from (sustain talk) changing personal alcohol use. Overall, patients responded in a similar manner to therapist MI behaviors regardless of high versus low level of mental functioning at the time of the intervention. Group differences emerged on patient response to only three specific therapist skills: giving information, open questions, and complex reflection. Thus, the differential effects of SBIRT in critical care settings do not appear to be a result of differences in the therapist and patient communication process. (C) 2016 Elsevier Inc. All rights reserved. C1 [Borsari, Brian] San Francisco VA Med Ctr, Mental Hlth Serv 116B, 4150 Clement St, San Francisco, CA 94121 USA. [Borsari, Brian; Yurasek, Ali; Monti, Peter M.] Brown Univ, Dept Behav & Social Sci, Box G-S121-4, Providence, RI 02912 USA. [Borsari, Brian; Yurasek, Ali; Monti, Peter M.] Brown Univ, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA. [Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA. [Apodaca, Timothy R.] Childrens Mercy Kansas City, 2401 Gillham Rd, Kansas City, MO 64108 USA. [Apodaca, Timothy R.] Univ Missouri, Kansas City Sch Med, 3901 Rainbow Blvd, Kansas City, KS 66103 USA. RP Borsari, B (reprint author), San Francisco VA Med Ctr 116B, Bldg 8,Room 108,4150 Clement St, San Francisco, CA 94121 USA. EM Brian.Borsari.sfva.ucsf@gmail.com FU National Institute on Alcohol Abuse and Alcoholism [R01AA017427, K23AA015595, K05AA019681]; National Institute on Drug Abuse [T32 DA016184]; VISN1 Career Development Award [V1CDA2012-18] FX This manuscript was the result of a symposium presented at the Research Society on Alcoholism in June 2014 (Drs. Sayko-Adams, Organizer/Chair, Dr. Douglas Zatzick, Chair, Dr. Alana Conti, and Dr. Dennis Donovan, Discussant). This work was supported by National Institute on Alcohol Abuse and Alcoholism grants R01AA017427 to B. Borsari K23AA015595 to T. Apodaca, K05AA019681 to P. Monti, National Institute on Drug Abuse grant T32 DA016184 to A. Yurasek, and VISN1 Career Development Award V1CDA2012-18 to B. Borsari. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health, or the Department of Veterans Affairs or the United States Government. The authors would like to thank the patients and therapists from the parent intervention trial who allowed their audiotapes to be utilized for this study. We also wish to acknowledge the efforts of our diligent team of coders. NR 50 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD FEB PY 2017 VL 73 BP 1 EP 8 DI 10.1016/j.jsat.2016.10.002 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA EJ5OJ UT WOS:000393267300001 PM 28017179 ER PT J AU Bensley, KM Harris, AHS Gupta, S Rubinsky, AD Jones-Webb, R Glass, JE Williams, EC AF Bensley, Kara M. Harris, Alex H. S. Gupta, Shalini Rubinsky, Anna D. Jones-Webb, Rhonda Glass, Joseph E. Williams, Emily C. TI Racial/ethnic differences in initiation of and engagement with addictions treatment among patients with alcohol use disorders in the veterans health administration SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Treatment; Alcohol use disorder; Race; Ethnicity; Utilization, veterans ID SUBSTANCE-ABUSE TREATMENT; SCREENING SCORES; UNITED-STATES; CARE-SYSTEM; OUTPATIENT TREATMENT; PERFORMANCE-MEASURES; RACIAL DISPARITIES; PUBLIC-HEALTH; AFFAIRS; RISK AB Objective: Specialty addictions treatment can improve outcomes for patients with alcohol use disorders (AUD). Thus, initiation of and engagement with specialty addictions treatment are considered quality care for patients with AUD. Previous studies have demonstrated racial/ethnic differences in alcohol-related care but whether differences exist in initiation of and engagement with specialty addictions treatment among patients with clinically recognized alcohol use disorders is unknown. We investigated racial/ethnic variation in initiation of and engagement with specialty addictions treatment in a national sample of Black, Hispanic, and White patients with clinically recognized alcohol use disorders (AUD) from the US Veterans Health Administration (VA). Methods: National VA data were extracted for all Black, Hispanic, and White patients with a diagnosed AUD during fiscal year 2012. Mixed effects regression models estimated the odds of two measures of initiation (an initial visit within 180 days of diagnosis; and initiation defined consistent with Healthcare Effectiveness Data and Information Set (HEDIS) as a documented visit <= 14 days after index visit or inpatient admission), and three established measures of treatment engagement (>= 3 visits within first month after initiation; >= 2 visits in each of the first 3 months after initiation; and >= 2 visits within 30 days of HEDIS initiation) for Black and Hispanic relative to White patients after adjustment for facility- and patient-level characteristics. Results: Among 302,406 patients with AUD, 30% (90,879) initiated treatment within 180 days of diagnosis (38% Black, 32% Hispanic, and 27% White). Black patients were more likely to initiate treatment than Whites for both measures of initiation [odds ratio (OR) for initiation: 1.4, 95% confidence interval (CI) 1.41.4; OR for HEDIS initiation: 1.1, 95% CI: 1.11.1]. Hispanic patients were more likely than White patients to initiate treatment within 180 days (OR: 1.2, 95% CI 1.21.3) but HEDIS initiation did not differ between Hispanic and White patients. Engagement results varied depending on the measure but was more likely for Black patients relative to White for all measures (OR for engagement in first month: 1.1, 95% CI: 1.01.1; OR for engagement in first three months: 1.2, 95% CI: 1.11.2; OR for HEDIS measure: 1.1, 95% CI: 1.01.1), and did not differ between Hispanic and White patients. Conclusions: After accounting for facility- and patient-level characteristics, Black and Hispanic patients with AUD were more likely than Whites to initiate specialty addictions treatment, and Black patients were more likely than Whites to engage. Research is needed to understand underlying mechanisms and whether differences in initiation of and engagement with care influence health outcomes. Published by Elsevier Inc. C1 [Bensley, Kara M.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Magnuson Hlth Sci Ctr, 1959 NE Pacific St,Room H-680,Box 357660, Seattle, WA 98195 USA. [Bensley, Kara M.; Williams, Emily C.] Vet Hlth Adm VA, Denver Seattle Ctr Innovat Vet Ctr Value Driven C, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA. [Harris, Alex H. S.; Gupta, Shalini; Rubinsky, Anna D.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. [Jones-Webb, Rhonda] Univ Minnesota, Dept Epidemiol & Community Hlth, 1300 South Second St,Suite 300, Minneapolis, MN 55454 USA. [Glass, Joseph E.] Univ Wisconsin, 307 Sch Social Work,1350 Univ Ave, Madison, WI 53706 USA. RP Bensley, KM (reprint author), Univ Washington, Dept Hlth Serv, Magnuson Hlth Sci Ctr, 1959 NE Pacific St,Room H-680,Box 357660, Seattle, WA 98195 USA.; Bensley, KM (reprint author), Vet Hlth Adm VA, Denver Seattle Ctr Innovat Vet Ctr Value Driven C, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA. EM kbensley@uw.edu; Alexander.Harris2@va.gov; Shalini.Gupta2@va.gov; Anna.Rubinsky@va.gov; jones010@umn.edu; jglass2@wisc.edu; Emily.Williams3@va.gov FU Veterans Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI) locally initiated project [QLP 59-031]; AHRQ/NRSA T-32 training grant at the University of Washington; VA Puget Sound Health Services Research Development; VA Health Services Research Development [CDA 12-276, RCS-14-232]; National Institutes of Health [1R03AA023639] FX This study was funded by a Veterans Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI) locally initiated project (QLP 59-031). Ms. Bensley was supported by an AHRQ/NRSA T-32 training grant at the University of Washington and is currently supported by a Research Assistantship with VA Puget Sound Health Services Research & Development. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). Dr. Harris is supported by a Career Scientist Award from VA Health Services Research & Development (RCS-14-232). Dr. Glass is supported by National Institutes of Health award 1R03AA023639. NR 64 TC 0 Z9 0 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD FEB PY 2017 VL 73 BP 27 EP 34 DI 10.1016/j.jsat.2016.11.001 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA EJ5OJ UT WOS:000393267300004 PM 28017181 ER PT J AU Graber, CJ AF Graber, Christopher J. TI Clostridium difficile infection: stewardship's lowest hanging fruit? SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material ID METAANALYSIS C1 [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. RP Graber, CJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. EM christopher.graber@va.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD FEB PY 2017 VL 17 IS 2 BP 123 EP 124 DI 10.1016/51473-3099(16)30416-9 PG 2 WC Infectious Diseases SC Infectious Diseases GA EJ0NJ UT WOS:000392906000005 PM 27825596 ER PT J AU Harwood, JM Azocar, F Thalmayer, A Xu, HY Ong, MK Tseng, CH Wells, KB Friedman, S Ettner, SL AF Harwood, Jessica M. Azocar, Francisca Thalmayer, Amber Xu, Haiyong Ong, Michael K. Tseng, Chi-Hong Wells, Kenneth B. Friedman, Sarah Ettner, Susan L. TI The Mental Health Parity and Addiction Equity Act Evaluation Study Impact on Specialty Behavioral Health Care Utilization and Spending Among Carve-In Enrollees SO MEDICAL CARE LA English DT Article DE behavioral health care; health service research; policy evaluation; health insurance; claims data ID INTERRUPTED TIME-SERIES; USE DISORDER TREATMENT; REGRESSION-ANALYSIS; FEDERAL PARITY; SERVICES; MEDICAID; ACCESS; POLICY AB Objective: The federal Mental Health Parity and Addiction Equity Act (MHPAEA) sought to eliminate historical disparities between insurance coverage for behavioral health (BH) treatment and coverage for medical treatment. Our objective was to evaluate MHPAEA's impact on BH expenditures and utilization among "carve-in" enrollees. Methods: We received specialty BH insurance claims and eligibility data from Optum, sampling 5,987,776 adults enrolled in self-insured plans from large employers. An interrupted time series study design with segmented regression analysis estimated monthly time trends of per-member spending and use before (2008-2009), during (2010), and after (2011-2013) MHPAEA compliance (N = 179,506,951 member-month observations). Outcomes included: total, plan, patient out-of-pocket spending; outpatient utilization (assessment/diagnostic evaluation visits, medication management, individual and family psychotherapy); intermediate care utilization (structured outpatient, day treatment, residential); and inpatient utilization. Results: MHPAEA was associated with increases in monthly per-member total spending, plan spending, assessment/diagnostic evaluation visits [respective immediate increases of: $1.05 (P = 0.02); $0.88 (P = 0.04); 0.00045 visits (P = 0.00)], and individual psychotherapy visits [immediate increase of 0.00578 visits (P = 0.00) and additional increases of 0.00017 visits/mo (P = 0.03)]. Conclusions: MHPAEA was associated with modest increases in total and plan spending and outpatient utilization; for example, in July 2012 predicted per-enrollee plan spending was $4.92 without MHPAEA and $6.14 with MHPAEA. Efforts should focus on understanding how other barriers to BH care unaddressed by MHPAEA may affect access/utilization. Future research should evaluate effects produced by the Affordable Care Act's inclusion of BH care as an essential health benefit and expansion of MHPAEA protections to the individual and small group markets. C1 [Harwood, Jessica M.; Xu, Haiyong; Ong, Michael K.; Tseng, Chi-Hong; Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Azocar, Francisca; Thalmayer, Amber] Optum, United Hlth Grp, San Francisco, CA USA. [Ong, Michael K.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Wells, Kenneth B.] Univ Calif Los Angeles, Neuropsychiat Inst, Dept Psychiat, Los Angeles, CA 90024 USA. [Friedman, Sarah; Ettner, Susan L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Harwood, JM (reprint author), 911 Broxton Plaza, Los Angeles, CA 90024 USA. EM JHarwood@mednet.ucla.edu FU National Institute on Drug Abuse (NIDA) [1R01DA032619-01]; Optum, United Health Group FX Supported by the National Institute on Drug Abuse (NIDA, 1R01DA032619-01, PI: Ettner), and data from Optum.; F.A. is an employee of Optum, United Health Group and as such receives salary and stock options as part of her compensation. A.T. was a contractor for and received salary from Optum, United Health Group. The remaining authors declare no conflict of interest. NR 27 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2017 VL 55 IS 2 BP 164 EP 172 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EJ0RY UT WOS:000392919300015 PM 27632769 ER PT J AU Mays, VM Jones, AL Delany-Brumsey, A Coles, C Cochran, SD AF Mays, Vickie M. Jones, Audrey L. Delany-Brumsey, Ayesha Coles, Courtney Cochran, Susan D. TI Perceived Discrimination in Health Care and Mental Health/Substance Abuse Treatment Among Blacks, Latinos, and Whites SO MEDICAL CARE LA English DT Article DE race/ethnicity; provider discrimination; mental health; substance abuse ID QUALITY-OF-CARE; RACIAL-DISCRIMINATION; ETHNIC DISPARITIES; COLLABORATIVE CARE; AFRICAN-AMERICAN; UNITED-STATES; LIFE SURVEY; BORN BLACK; DRUG-ABUSE; US-BORN AB Background: Experiences of discrimination in health care settings may contribute to disparities in mental health outcomes for blacks and Latinos. We investigate whether perceived discrimination in mental health/substance abuse visits contributes to participants' ratings of treatment helpfulness and stopped treatment. Research Methods: We used data from 3 waves of the California Quality of Life Survey, a statewide population-based telephone survey assessing mental health/substance disorders and their treatment. In a sample of 1099 adults (age 18-72) who indicated prior year mental health/substance abuse visits, we examined: experiences of discrimination that occurred during health care and mental health/substance abuse visits, ratings of treatment helpfulness, and reports of stopping treatment early. Results: Fifteen percent of California adults reported discrimination during a health care visit and 4% specifically during mental health/substance abuse visits. Latinos, the uninsured, and those with past year mental disorders were twice as likely as others to report health care discrimination [adjusted odds ratio (AORs) = 2.08, 2.77, and 2.51]. Uninsured patients were 7 times more likely to report discrimination in mental health/substance abuse visits (AOR = 7.27, P < 0.01). The most commonly reported reasons for health care discrimination were race/ethnicity for blacks (52%) and Latinos (31%), and insurance status for whites (40%). Experiences of discrimination in mental health/substance abuse visits were associated with less helpful treatment ratings for Latinos (AOR = 0.09, P < 0.05) and whites (AOR = 0.25, P < 0.01), and early treatment termination for blacks (AOR = 13.38, P < 0.05). Conclusions: Experiences of discrimination are associated with negative mental health/substance abuse treatment experiences and stopped treatment, and could be a factor in mental health outcomes. C1 [Mays, Vickie M.; Coles, Courtney; Cochran, Susan D.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, 405 Hilgard Ave,POB 951563, Los Angeles, CA 90095 USA. [Mays, Vickie M.; Jones, Audrey L.; Delany-Brumsey, Ayesha; Coles, Courtney; Cochran, Susan D.] Univ Calif Los Angeles, Ctr Bridging Res, Innovat Training & Educ Minor Hlth Dispar Solut, 405 Hilgard Ave,POB 951563, Los Angeles, CA 90095 USA. [Jones, Audrey L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Delany-Brumsey, Ayesha] Vera Inst Justice, New York, NY USA. RP Mays, VM (reprint author), Univ Calif Los Angeles, Dept Psychol, Fielding Sch Publ Hlth, 405 Hilgard Ave,POB 951563, Los Angeles, CA 90095 USA. EM mays@ucla.edu FU National Institute of Drug Abuse [DA 15539, DA 20826]; National Institute of Minority Health Disparities [MD 00508, MD006923]; VA Office of Academic Affiliations Associated Health Professions FX Supported by funding from the National Institute of Drug Abuse (DA 15539; DA 20826) and National Institute of Minority Health Disparities (MD 00508, MD006923).; Dr Jones is supported as a VA Office of Academic Affiliations Associated Health Professions Post-doctoral Fellow in Health Services Research. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 50 TC 1 Z9 1 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2017 VL 55 IS 2 BP 173 EP 181 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EJ0RY UT WOS:000392919300016 PM 27753743 ER PT J AU Smallwood, AJ Schapira, MM Fedders, M Neuner, JM AF Smallwood, A. J. Schapira, M. M. Fedders, M. Neuner, J. M. TI A pilot randomized controlled trial of a decision aid with tailored fracture risk tool delivered via a patient portal SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Decision aids; Osteoporosis; Patient portal; Personalized risk; Shared decision making ID POSTMENOPAUSAL WOMEN; HIP FRACTURE; OSTEOPOROSIS; THERAPY AB We tested the feasibility of a fracture prevention decision aid in an online patient portal. The decision aid was acceptable for patients and successfully decreased decisional conflict. This study suggests the possible utility of leveraging the patient portal to enhance patient education and decision making in osteoporosis care. Although interventions have improved osteoporosis screening and/or treatment for certain populations of high-risk patients, recent national studies suggest that large-scale uptake of these interventions has been limited. We aimed to determine the feasibility and potential efficacy of a patient portal-based osteoporosis decision aid (DA). We conducted a pilot randomized controlled trial of primary care patients aged ae55 who were enrolled in a patient portal and had a T-score of <-1. Intervention subjects were provided a link to a patient DA. The DA contained a 10-year fracture risk calculator, summary of medication risks and benefits (prescription and nonprescription), and an elicitation of values. Subjects completed questionnaires assessing the primary outcomes of decisional conflict and preparation for decision making and secondary outcomes related to feasibility and planning for a larger trial. Charts were reviewed for physician-subject interactions and medication uptake. The DA was acceptable to subjects, but 17 % of the patients in the decision aid arm incorrectly entered their T-scores into FRAX-based risk calculator. Decisional conflict was lower post-intervention for those who were randomized to the decision aid arm compared to controls (17.8 vs. 47.1, p < .001), and there was a significant difference in the percentage of patients who made a treatment decision at 3 months. No significant differences were observed in medication uptake. A portal-based osteoporosis DA was acceptable and improved several measures of decision quality. Given its effect on improving the quality of patients' decisions, future studies should examine whether it improves physician guideline adherence or medication adherence uptake among treated patients. C1 [Smallwood, A. J.; Neuner, J. M.] Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA. [Schapira, M. M.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, 423 Guardian Ave, Philadelphia, PA 19104 USA. [Schapira, M. M.] Crescenz VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Fedders, M.] Froedtert, Clin Informat, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. [Fedders, M.] Med Coll Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. [Neuner, J. M.] Med Coll Wisconsin, Dept Med, Div Gen Internal Med, CLCC 5th Floor,9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. RP Smallwood, AJ (reprint author), Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA. EM asmallwood@mcw.edu FU Clinical and Translational Science Institute of Southeast Wisconsin [5,520,204] FX This study was funded by the Clinical and Translational Science Institute of Southeast Wisconsin (project number 5,520,204). NR 25 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2017 VL 28 IS 2 BP 567 EP 576 DI 10.1007/s00198-016-3767-4 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EK0VW UT WOS:000393646200014 PM 27647529 ER PT J AU Mori, T Crandall, CJ Ganz, DA AF Mori, T. Crandall, C. J. Ganz, D. A. TI Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Cost-effectiveness analysis; Falls prevention exercise; Fracture prevention; Oral bisphosphonate therapy; Osteoporosis ID QUALITY-OF-LIFE; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES; EXCESS MORTALITY; UNITED-STATES; METAANALYSIS; WOMEN; POPULATION; HEALTH AB We developed a Markov microsimulation model among hypothetical cohorts of community-dwelling US white women without prior major osteoporotic fractures over a lifetime horizon. At ages 75 and 80, adding 1 year of exercise to 5 years of oral bisphosphonate therapy is cost-effective at a conventionally accepted threshold compared with bisphosphonates alone. The purpose of this study was to examine the cost-effectiveness of the combined strategy of oral bisphosphonate therapy for 5 years and falls prevention exercise for 1 year compared with either strategy in isolation. We calculated incremental cost-effectiveness ratios [ICERs] (2014 US dollars per quality-adjusted life year [QALY]), using a Markov microsimulation model among hypothetical cohorts of community-dwelling US white women with different starting ages (65, 70, 75, and 80) without prior history of hip, vertebral, or wrist fractures over a lifetime horizon from the societal perspective. At ages 65, 70, 75, and 80, the combined strategy had ICERs of $202,020, $118,460, $46,870, and $17,640 per QALY, respectively, compared with oral bisphosphonate therapy alone. The combined strategy provided better health at lower cost than falls prevention exercise alone at ages 70, 75, and 80. In deterministic sensitivity analyses, results were particularly sensitive to the change in the opportunity cost of participants' time spent exercising. In probabilistic sensitivity analyses, the probabilities of the combined strategy being cost-effective compared with the next best alternative increased with age, ranging from 35 % at age 65 to 48 % at age 80 at a willingness-to-pay of $100,000 per QALY. Among community-dwelling US white women ages 75 and 80, adding 1 year of exercise to 5 years of oral bisphosphonate therapy is cost-effective at a willingness-to-pay of $100,000 per QALY, compared with oral bisphosphonate therapy only. This analysis will help clinicians and policymakers make better decisions about treatment options to reduce fracture risk. C1 [Mori, T.] Kameda Med Ctr, Dept Gen Internal Med, 929 Higashi Cho, Kamogawa City, Chiba 2968602, Japan. [Mori, T.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Primary Care & Med Educ, Tsukuba, Ibaraki, Japan. [Mori, T.] Univ Tsukuba, Dept Hlth Serv Res, Fac Med, Tsukuba, Ibaraki, Japan. [Crandall, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Ganz, D. A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Ganz, D. A.] Vet Affairs Greater Los Angeles Healthcare Syst, HSR&D Ctr Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Ganz, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Ganz, D. A.] RAND Corp, Hlth Unit, Santa Monica, CA USA. RP Mori, T (reprint author), Kameda Med Ctr, Dept Gen Internal Med, 929 Higashi Cho, Kamogawa City, Chiba 2968602, Japan.; Mori, T (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Primary Care & Med Educ, Tsukuba, Ibaraki, Japan.; Mori, T (reprint author), Univ Tsukuba, Dept Hlth Serv Res, Fac Med, Tsukuba, Ibaraki, Japan. EM takahiromori@outlook.com FU Veterans Affairs Special Fellowship in Advanced Geriatrics FX The authors (Takahiro Mori, Carolyn J. Crandall, and David A. Ganz) declare that they have no conflict of interest. Takahiro Mori was supported by the Veterans Affairs Special Fellowship in Advanced Geriatrics. The Department of Veterans Affairs had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 39 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2017 VL 28 IS 2 BP 585 EP 595 DI 10.1007/s00198-016-3772-7 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EK0VW UT WOS:000393646200016 PM 27726000 ER PT J AU Cornell, RF D'Souza, A Kassim, AA Costa, LJ Innis-Shelton, RD Zhang, MJ Huang, JX Abidi, M Aiello, J Akpek, G Bashey, A Bashir, Q Cerny, J Comenzo, R Diaz, MA Freytes, C Gale, RP Ganguly, S Hamadani, M Hashmi, S Holmberg, L Hossain, N Kamble, RT Kharfan-Dabaja, M Kindwall-Keller, T Kyle, R Kumar, S Lazarus, H Lee, C Maiolino, A Marks, DI Meehan, K Mikhael, J Nath, R Nishihori, T Olsson, RF Ramanathan, M Saad, A Seo, S Usmani, S Vesole, D Vij, R Vogl, D Wirk, BM Yared, J Krishnan, A Mark, T Nieto, Y Hari, P AF Cornell, Robert F. D'Souza, Anita Kassim, Adetola A. Costa, Luciano J. Innis-Shelton, Racquel D. Zhang, Mei-Jie Huang, Jiaxing Abidi, Muneer Aiello, Jack Akpek, Gorgun Bashey, Asad Bashir, Qaiser Cerny, Jan Comenzo, Raymond Angel Diaz, Miguel Freytes, Cesar Gale, Robert Peter Ganguly, Siddhartha Hamadani, Mehdi Hashmi, Shahrukh Holmberg, Leona Hossain, Nasheed Kamble, Rammurti T. Kharfan-Dabaja, Mohamed Kindwall-Keller, Tamila Kyle, Robert Kumar, Shaji Lazarus, Hillard Lee, Cindy Maiolino, Angelo Marks, David I. Meehan, Kenneth Mikhael, Joe Nath, Rajneesh Nishihori, Taiga Olsson, Richard F. Ramanathan, Muthalagu Saad, Ayman Seo, Sachiko Usmani, Saad Vesole, David Vij, Ravi Vogl, Dan Wirk, Baldeep M. Yared, Jean Krishnan, Amrita Mark, Tomer Nieto, Yago Hari, Parameswaran TI Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Myeloma; Transplantation; Survival; Relapse; Chemotherapy; Maintenance ID STEM-CELL TRANSPLANTATION; THALIDOMIDE PLUS DEXAMETHASONE; CONSOLIDATION THERAPY; RANDOMIZED PHASE-3; SURVIVAL; BORTEZOMIB; LENALIDOMIDE; TRIAL; ABNORMALITIES; HYBRIDIZATION AB Bortezomib (V), lenalidomide (R), cyclophosphamide (C), and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens before autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the United States. In this study we evaluated 693 patients receiving "upfront" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008 to 2013. Analysis was limited to those receiving a single AHCT after 1 line of induction therapy within 12 months from treatment initiation for MM. In multivariate analysis, progression-free survival (PFS) and overall survival were similar irrespective of induction regimen. However, high-risk cytogenetics and nonreceipt of post transplant maintenance/consolidation therapy were associated with higher risk of relapse. Patients receiving post-transplant therapy had significantly improved 3-year PFS versus no post-transplant therapy (55% versus 39%, P =.0001). This benefit was most evident in patients not achieving at least a complete response post-AHCT (P =.005). In patients receiving upfront AHCT, the choice of induction regimen (doublet or triplet therapies) appears to be of lower impact than use of post-transplant therapy. (C) 2017 American Society for Blood and Marrow Transplantation. C1 [Cornell, Robert F.; Kassim, Adetola A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [D'Souza, Anita; Zhang, Mei-Jie; Huang, Jiaxing; Hamadani, Mehdi; Hari, Parameswaran] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. [Costa, Luciano J.; Innis-Shelton, Racquel D.; Saad, Ayman] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Zhang, Mei-Jie] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA. [Abidi, Muneer] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Div BMT, Detroit, MI USA. [Akpek, Gorgun] Rush Univ, Med Ctr, Dept Internal Med, Stem Cell Transplantat & Cell Therapy, Chicago, IL 60612 USA. [Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. [Bashir, Qaiser; Nieto, Yago] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Stem Cell Transplantat, Houston, TX 77030 USA. [Cerny, Jan; Nath, Rajneesh; Ramanathan, Muthalagu] UMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA. [Comenzo, Raymond] Tufts Med Ctr, Boston, MA USA. [Angel Diaz, Miguel] Hosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain. [Freytes, Cesar] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gale, Robert Peter] Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. [Ganguly, Siddhartha] Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA. [Hashmi, Shahrukh; Kyle, Robert; Kumar, Shaji] Mayo Clin Rochester, Rochester, MN USA. [Holmberg, Leona] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Hossain, Nasheed] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Kamble, Rammurti T.] Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Kharfan-Dabaja, Mohamed; Nishihori, Taiga] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. [Kindwall-Keller, Tamila] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA. [Lazarus, Hillard] Univ Hosp, Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Lee, Cindy] Royal Adelaide Hosp, Adelaide, SA, Australia. [Maiolino, Angelo] Univ Fed Rio de Janeiro, Hosp Univ Clementinio Fraga Filho, Rio De Janeiro, Brazil. [Marks, David I.] Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England. [Meehan, Kenneth] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Mikhael, Joe] Mayo Clin Arizona, Phoenix, AZ USA. [Mikhael, Joe] Phoenix Childrens Hosp, Phoenix, AZ USA. [Olsson, Richard F.] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden. [Olsson, Richard F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Seo, Sachiko] East Hosp, Natl Canc Res Ctr, Chiba, Japan. [Usmani, Saad] Carolinas HealthCare Syst, Levine Canc Inst, Dept Med Hematol Oncol, Charlotte, NC USA. [Vesole, David] John Theurer Canc Ctr Hackensack UMC, Hackensack, NJ USA. [Vij, Ravi] Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA. [Vogl, Dan] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Wirk, Baldeep M.] Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA. [Yared, Jean] Univ Maryland, Dept Med, Div Hematol Oncol,Greenebaum Canc Ctr, Blood & Marrow Transplantat Program, Baltimore, MD 21201 USA. [Krishnan, Amrita] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Mark, Tomer] Weill Cornell Med Coll, Dept Med, New York, NY USA. RP D'Souza, A (reprint author), Med Coll Wisconsin, 9200 W Wisconsin Ave,Ste 5500, Milwaukee, WI 53226 USA. EM andsouza@mcw.edu OI Hari, Parameswaran/0000-0002-8800-297X; Saad, Ayman /0000-0003-0003-0130 FU Public Health Service Grant from the National Cancer Institute (NCI) [5U24-CA076518]; National Cancer Institute (NCI); National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases from NHLBI and NCI [5U10HL069294]; Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]; Office of Naval Research [N00014-15-1-0848, N00014-16-1-2020]; Alexion; *Amgen, Inc. FX The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from Alexion; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol-Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; *Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; The Leukemia and Lymphoma Society; Medac, GmbH; Medlmmune; The Medical College of Wisconsin; *Merck & Co., Inc.; Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd. - Japan; PCORI; Perkin Elmer, Inc.; Pfizer, Inc; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the HRSA, or any other agency of the U.S. Government. *Corporate Members. NR 35 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2017 VL 23 IS 2 BP 269 EP 277 DI 10.1016/j.bbmt.2016.11.011 PG 9 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA EJ0JK UT WOS:000392894300011 PM 27864161 ER PT J AU Hunter, LL Keefe, DH Feeney, MP Fitzpatrick, DF AF Hunter, Lisa L. Keefe, Douglas H. Feeney, M. Patrick Fitzpatrick, Denis F. TI Pressurized Wideband Acoustic Stapedial Reflex Thresholds: Normal Development and Relationships to Auditory Function in Infants SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Article DE middle ear muscle reflexes; acoustic stapedial reflex; middle ear; development ID TEST-RETEST RELIABILITY; MIDDLE-EAR PRESSURE; OTOACOUSTIC EMISSIONS; NORMAL-HEARING; REFLECTANCE; ADMITTANCE; TYMPANOMETRY; NEWBORN; PERFORMANCE; CHILDREN AB This study analyzed effects of pressurization on wideband acoustic stapedial-muscle reflex (ASR) tests in infants cared for in normal newborn (NN) and neonatal intensive care units (NICU). Effects of hearing-screening outcomes on ASR threshold measurements were also evaluated, and a subsequent longitudinal study established normative threshold ranges over the first year after birth. An initial experiment compared thresholds in newborns measured at ambient pressure in the ear canal and at the tympanometric peak pressure. ASR thresholds for broadband noise were higher for ears that did not pass newborn hearing screening and ASR threshold was 14 dB higher for real-ear compared to coupler conditions. Effects of pressurization were significant for ears that passed screening; thus, ASR testing in infants should be conducted at tympanometric peak pressure. ASR threshold was significantly higher for ears that referred on transient evoked otoacoustic emissions and Auditory Brainstem Response (ABR) screening tests and also for ears with conductive and sensorineural hearing loss diagnosed by ABR. Developmental ASR changes were significant over the first year for both normal and NICU infants. Wideband pressurized ASR thresholds are a clinically relevant measure of newborn hearing screening and diagnostic outcomes. C1 [Hunter, Lisa L.] Cincinnati Childrens Hosp, Med Ctr, Div Audiol, 3333 Burnet Ave, Cincinnati, OH 45213 USA. [Keefe, Douglas H.; Fitzpatrick, Denis F.] Boys Town Natl Res Hosp, 555 N 30th St, Omaha, NE 68131 USA. [Feeney, M. Patrick] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Feeney, M. Patrick] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. RP Hunter, LL (reprint author), Cincinnati Childrens Hosp, Med Ctr, Div Audiol, 3333 Burnet Ave, Cincinnati, OH 45213 USA. EM lisa.hunter@cchmc.org FU National Institute of Deafness and other Communication Disorders of the National Institutes of Health [R01 DC010202]; ARRA [DC010202-01S1] FX Funding Source Research reported in this publication was supported by the National Institute of Deafness and other Communication Disorders of the National Institutes of Health under Award Number R01 DC010202 and an ARRA supplement (DC010202-01S1). Co-author Keefe is involved in commercializing devices to assess middle-ear function in infants. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The content of this article does not represent the views of the Department of Veterans Affairs or of the United States Government. NR 30 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1525-3961 EI 1438-7573 J9 JARO-J ASSOC RES OTO JI JARO PD FEB PY 2017 VL 18 IS 1 BP 49 EP 63 DI 10.1007/s10162-016-0595-3 PG 15 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA EJ1BY UT WOS:000392946400003 PM 27928634 ER PT J AU Contrera, KJ Betz, J Deal, J Choi, JS Ayonayon, HN Harris, T Helzner, E Martin, KR Mehta, K Pratt, S Rubin, SM Satterfield, S Yaffe, K Simonsick, EM Lin, FR AF Contrera, Kevin J. Betz, Josh Deal, Jennifer Choi, Janet S. Ayonayon, Hilsa N. Harris, Tamara Helzner, Elizabeth Martin, Kathryn R. Mehta, Kala Pratt, Sheila Rubin, Susan M. Satterfield, Suzanne Yaffe, Kristine Simonsick, Eleanor M. Lin, Frank R. CA Hlth ABC Study TI Association of Hearing Impairment and Anxiety in Older Adults SO JOURNAL OF AGING AND HEALTH LA English DT Article DE hearing; anxiety; mental health; geriatrics ID NUTRITION EXAMINATION SURVEY; OF-THE-LITERATURE; PHYSICAL FUNCTION; BODY-COMPOSITION; NATIONAL-HEALTH; LOSS PREVALENCE; UNITED-STATES; RISK-FACTORS; US ADULTS; DEPRESSION AB Objective: The objective of the study is was investigate the association between hearing impairment and anxiety. Method: We conducted a cross-sectional analysis of 1,732 community-based adults aged 76 to 85 years who participated in the Health Aging and Body Composition (ABC) study. Logistic regression models were adjusted for demographic and cardiovascular risk factors. Hearing impairment was defined by the speech-frequency pure tone average. Anxiety was defined as reporting two symptoms of at least a little or one symptom quite a bit on the three-item Hopkins Symptom Checklist. Results: Compared with individuals with no hearing impairment, the odds of prevalent anxiety were higher among individuals with mild hearing impairment (odds ratio [OR] = 1.32, 95% confidence interval [CI] = [1.01, 1.73]) and moderate or greater hearing impairment (OR = 1.59, 95% CI = [1.14, 2.22]). Hearing aid use was not significantly associated with lower odds of anxiety. Discussion: Hearing impairment is independently associated with greater odds of anxiety symptoms in older adults. C1 [Contrera, Kevin J.; Betz, Josh; Deal, Jennifer; Choi, Janet S.; Pratt, Sheila; Lin, Frank R.] Johns Hopkins Univ, Baltimore, MD USA. [Ayonayon, Hilsa N.; Rubin, Susan M.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Harris, Tamara; Simonsick, Eleanor M.] NIA, Baltimore, MD 21224 USA. [Helzner, Elizabeth] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Martin, Kathryn R.] Sch Med & Dent, Inst Appl Hlth Sci, Aberdeen, Scotland. [Mehta, Kala; Pratt, Sheila] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. RP Lin, FR (reprint author), Johns Hopkins Univ, Johns Hopkins Ctr Aging & Hlth, 2024 E Monument St,Suite 2-700, Baltimore, MD 21205 USA. EM flin1@jhmi.edu OI Betz, Joshua/0000-0003-4488-9799 FU Eleanor Schwartz Charitable Foundation; Triological Society/American College of Surgeons Clinician Scientist Award; Johns Hopkins Institute for Clinical and Translational Research; National Institutes of Health (NIH) [K23DC011279, TL1 TR001078]; National Institute on Aging (NIA) [R01-AG028050, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institute of Nursing Research [R01-NR012459]; NIH Intramural Research Program FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article was supported in part by the Eleanor Schwartz Charitable Foundation; a Triological Society/American College of Surgeons Clinician Scientist Award; the Johns Hopkins Institute for Clinical and Translational Research; the National Institutes of Health (NIH; Grant Numbers K23DC011279, TL1 TR001078); the National Institute on Aging (NIA; Grant Number R01-AG028050, and Contract Numbers N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106); National Institute of Nursing Research (Grant Number R01-NR012459); and the NIH Intramural Research Program. NR 39 TC 0 Z9 0 U1 5 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 EI 1552-6887 J9 J AGING HEALTH JI J. Aging Health PD FEB PY 2017 VL 29 IS 1 BP 172 EP 184 DI 10.1177/0898264316634571 PG 13 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA EI9ZR UT WOS:000392868600008 ER PT J AU Bhambhvani, P Hage, FG Iskandrian, AE AF Bhambhvani, Pradeep Hage, Fadi G. Iskandrian, Ami E. TI A quick glance at selected topics in this issue SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material AB "A quick glance at selected topics in this issue" aims to highlight few randomly selected articles and provide a quick review to the readers. C1 [Bhambhvani, Pradeep] Univ Alabama Birmingham, Dept Radiol, Div Mol Imaging & Therapeut, Birmingham, AL 35294 USA. [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Bhambhvani, P (reprint author), Univ Alabama Birmingham, Dept Radiol, Div Mol Imaging & Therapeut, Birmingham, AL 35294 USA. EM pbhambhvani@uabmc.edu OI Hage, Fadi/0000-0002-1397-4942 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2017 VL 24 IS 1 BP 6 EP 8 DI 10.1007/s12350-016-0742-6 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EJ2RE UT WOS:000393057600003 PM 27995470 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Cardiovascular disease in the literature: A selection of recent original research papers SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 306,1900 Univ BLVD, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 306,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 3 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2017 VL 24 IS 1 BP 12 EP 14 DI 10.1007/s12350-016-0747-1 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EJ2RE UT WOS:000393057600005 PM 27943052 ER PT J AU Lee, PI Cheng, G Alavi, A AF Lee, Pei-Ing Cheng, Gang Alavi, Abass TI The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Cardiac sarcoidosis; FDG PET; standardized uptake value; metabolic volume product ID POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE; DISEASE-ACTIVITY; INVOLVEMENT; IDENTIFICATION; VOLUME; HEART AB The purpose of this study was to determine the feasibility of serial quantitative 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) to monitor the response of cardiac sarcoidosis to treatment. A total of 38 PET scan intervals (54 PET scans) were obtained in 16 patients with cardiac sarcoidosis who underwent serial FDG PET during treatment. FDG-avid lesions of the heart were interpreted quantitatively using 4 PET parameters: maximum standardized uptake value (SUVmax), partial volume corrected mean standardized uptake value (SUVmean), partial volume corrected metabolic volume product (MVP), and global metabolic volume product (gMVP). Clinical response to treatment (improved, stable, or progressive disease) was evaluated by clinical symptoms, NYHA class, and EKG in all the patients. SUVmax, SUVmean, MVP, and gMVP had significantly decreased value on repeat PET in patients who were either stable or showed clinical improvement between two serial PET scans, while none of them had significant change on repeat PET in patients who were clinically worse. Correlation analysis between PET findings and clinical assessment revealed that the changes of SUVmax and SUVmean on repeat PET were negatively correlated with patient's clinical outcome. Our results indicated that serial FDG PET is feasible to determine the extent of disease activity and to quantitatively assess the response of cardiac sarcoidosis to therapy. C1 [Lee, Pei-Ing] Koo Fdn, Dept Nucl Med, Sun Yat Sen Canc Ctr, Taipei, Taiwan. [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Cheng, Gang; Alavi, Abass] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. EM gangcheng99@yahoo.com; abass.alavi@uphs.upenn.edu NR 32 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2017 VL 24 IS 1 BP 19 EP 28 DI 10.1007/s12350-016-0682-1 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EJ2RE UT WOS:000393057600008 PM 27813028 ER PT J AU Velasco, A Reyes, E Hage, FG AF Velasco, Alejandro Reyes, Eliana Hage, Fadi G. TI Guidelines in review: Comparison of the 2014 ACC/AHA guidelines on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery and the 2014 ESC/ESA guidelines on noncardiac surgery: Cardiovascular assessment and management SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE C1 [Velasco, Alejandro; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 306,1900 Univ Blvd, Birmingham, AL 35294 USA. [Reyes, Eliana] Royal Brompton Hosp, London, England. [Reyes, Eliana] Harefield Hosp, London, England. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Lyons Harrison Res Bldg 306,1900 Univ Blvd, Birmingham, AL 35294 USA. EM fadihage@uab.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2017 VL 24 IS 1 BP 165 EP 170 DI 10.1007/s12350-016-0643-8 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EJ2RE UT WOS:000393057600033 PM 27549425 ER PT J AU Farag, AA Andrikopoulou, E Iskandrian, AE Germano, G Hage, FG AF Farag, Ayman A. Andrikopoulou, Efstathia Iskandrian, Ami E. Germano, Guido Hage, Fadi G. TI Detection of right ventricular ischemia by SPECT myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [Farag, Ayman A.; Andrikopoulou, Efstathia; Iskandrian, Ami E.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [Germano, Guido] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2017 VL 24 IS 1 BP 317 EP 318 DI 10.1007/s12350-016-0402-x PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EJ2RE UT WOS:000393057600059 PM 26818141 ER PT J AU Sutton, BS Pracht, E Williams, AR Alemi, F Williams, AE Levy, C AF Sutton, Bryce S. Pracht, Etienne Williams, Arthur R. Alemi, Farrokh Williams, Allison E. Levy, Cari TI Budget Impact Analysis of Veterans Affairs Medical Foster Homes versus Community Living Centers SO POPULATION HEALTH MANAGEMENT LA English DT Article ID LONG-TERM-CARE; HOSPITALIZATIONS; PROGRAM; MODELS; COSTS AB The objectives were to determine whether and by what amounts the US Department of Veterans Affairs (VA) use of Medical Foster Homes (MFH) rather than Community Living Centers (CLC) reduced budget impacts to the VA. This was a retrospective, matched, case-control study of veterans residing in MFH or CLC in the VA health care system from 2008 to 2012. Administrative data sets, nearest neighbor matching, generalized linear models, and a secondary analysis were used to capture and analyze budget impacts by veterans who used MFH or CLC exclusively in 2008-2012. Controls of 1483 veterans in CLC were matched to 203 cases of veterans in MFH. Use of MFH instead of CLC reduced budget impacts to the VA by at least $2645 per veteran per month. A secondary analysis of the data using different matching criteria and statistical methods produced similar results, demonstrating the robustness of the estimates of budget impact. When the average out-of-pocket payments made by MFH residents, not made by CLC residents, were included in the analysis, the net reduction of budget impact ranged from $145 to $2814 per veteran per month or a savings of $1740 to $33,768 per veteran per year. Even though outpatient costs of MFH are higher, much of the reduced budget impact of MFH use arises from lower inpatient or hospital costs. Reduced budget impacts on the VA system indicate that expansion of the MFH program may be cost-effective. Implications for further research are suggested. C1 [Sutton, Bryce S.; Williams, Arthur R.] James A Haley Vet Affairs Hosp, CINDRR, Tampa, FL USA. [Pracht, Etienne; Williams, Allison E.] Bay Pines Vet Affairs Med Ctr, Bay Pines, FL USA. [Alemi, Farrokh] Dist Columbia Vet Affairs Med Ctr, Washington, DC USA. [Levy, Cari] Univ Colorado Denver, Dept Med, Denver Vet Affairs Med Ctr, Denver, CO USA. [Williams, Arthur R.; Alemi, Farrokh] George Mason Univ, Dept Hlth Adm & Policy, Fairfax, VA 22030 USA. RP Sutton, BS (reprint author), Ctr Innovat Disabil & Rehabil Res, 8900 Grand Oak Circle 151R, Tampa, FL 33637 USA. EM bryce.sutton@va.gov FU US Department of Veterans Affairs, Office of Geriatrics and Extended Care [3620160] FX The authors received the following financial support: All aspects of this research were supported by appropriation #3620160 from the US Department of Veterans Affairs, Office of Geriatrics and Extended Care. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. NR 23 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD FEB PY 2017 VL 20 IS 1 BP 48 EP 54 DI 10.1089/pop.2015.0166 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EJ0DC UT WOS:000392877800008 PM 27128142 ER PT J AU Kamal, AH Bull, JH Swetz, KM Wolf, SP Shanafelt, TD Myers, ER AF Kamal, Arif H. Bull, Janet H. Swetz, Keith M. Wolf, Steven P. Shanafelt, Tait D. Myers, Evan R. TI Future of the Palliative Care Workforce: Preview to an Impending Crisis SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Kamal, Arif H.; Wolf, Steven P.; Myers, Evan R.] Duke Univ, Durham, NC 27708 USA. [Bull, Janet H.] Four Seasons, Flat Rock, NC USA. [Swetz, Keith M.] Univ Alabama Birmingham, Birmingham, AL USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Shanafelt, Tait D.] Mayo Clin, Rochester, MN USA. OI Swetz, Keith/0000-0001-9893-6517 NR 6 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD FEB PY 2017 VL 130 IS 2 BP 113 EP 114 DI 10.1016/j.amjmed.2016.08.046 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EI6RH UT WOS:000392623200018 PM 27687068 ER PT J AU Acierno, R Knapp, R Tuerk, P Gilmore, AK Lejuez, C Ruggiero, K Muzzy, W Egede, L Hernandez-Tejada, MA Foa, EB AF Acierno, Ron Knapp, Rebecca Tuerk, Peter Gilmore, Amanda K. Lejuez, Carl Ruggiero, Kenneth Muzzy, Wendy Egede, Leonard Hernandez-Tejada, Melba A. Foa, Edna B. TI A non-inferiority trial of Prolonged Exposure for posttraumatic stress disorder: In person versus home-based telehealth SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE PTSD; Prolonged exposure; Telehealth; Non-inferiority; RCT ID COGNITIVE PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; COMBAT VETERANS; AFGHANISTAN VETERANS; TELEMENTAL HEALTH; IRAQ; TELEMEDICINE; PTSD; CARE; CLINICIAN AB This is the first randomized controlled trial to evaluate non-inferiority of Prolonged Exposure (PE) delivered via home-based telehealth (HBT) compared to standard in-person (IP) PE. One-hundred thirty two Veterans recruited from a Southeastern Veterans Affairs Medical Center and affiliated University who met criteria for posttraumatic stress disorder (PTSD) were randomized to receive PE via HBT or PE via IP. Results indicated that PE-HBT was non-inferior to PE-IP in terms of reducing PTSD scores at posttreatment, 3 and 6 month follow-up. However, non-inferiority hypotheses for depression were only supported at 6 month follow-up. HBT has great potential to reduce patient burden associated with receiving treatment in terms of travel time, travel cost, lost work, and stigma without sacrificing efficacy. These findings indicate that telehealth treatment delivered directly into patients' homes may dramatically increase the reach of this evidence-based therapy for PTSD without diminishing effectiveness. Published by Elsevier Ltd. C1 [Acierno, Ron; Tuerk, Peter; Ruggiero, Kenneth; Muzzy, Wendy; Egede, Leonard; Hernandez-Tejada, Melba A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Acierno, Ron; Ruggiero, Kenneth; Muzzy, Wendy; Hernandez-Tejada, Melba A.] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Knapp, Rebecca] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Tuerk, Peter; Gilmore, Amanda K.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Lejuez, Carl] Univ Kansas, Coll Liberal Arts & Sci, Lawrence, KS 66045 USA. [Foa, Edna B.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Acierno, R (reprint author), Coll Nursing, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA. EM acierno@musc.edu FU Department of Veterans Affairs Health Services Research and Development grant [HX00152]; South Carolina Clinical & Translational Research (SCTR) Institute; Medical University of South Carolina through NIH/NCATS Grant [UL1 TR001450]; National Institute of Mental Health [T32 MH18869] FX This research was supported by the Department of Veterans Affairs Health Services Research and Development grant #HX00152 (PI: Acierno) and by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina through NIH/NCATS Grant Number UL1 TR001450. Manuscript preparation was partially supported by a grant from the National Institute of Mental Health (T32 MH18869; PIs: Kilpatrick & Danielson). NR 57 TC 0 Z9 0 U1 6 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD FEB PY 2017 VL 89 BP 57 EP 65 DI 10.1016/j.brat.2016.11.009 PG 9 WC Psychology, Clinical SC Psychology GA EI8SY UT WOS:000392779600007 PM 27894058 ER PT J AU Zhang, PP Andorko, JI Jewell, CM AF Zhang, Peipei Andorko, James I. Jewell, Christopher M. TI Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates SO BIOTECHNOLOGY AND BIOENGINEERING LA English DT Article DE vaccine; adjuvant; polyelectrolyte multilayer; immunology; nanotechnology; cancer ID DENDRITIC CELLS; TLR AGONISTS; ADJUVANTS; RESPONSES; EFFICACY; SYSTEM; CANCER; BIODISTRIBUTION; NANOPARTICLES; BIOMATERIALS AB Biomaterial vaccines offer new capabilities that can be exploited for both infectious disease and cancer. We recently developed a novel vaccine platform based on self-assembly of immune signals into immune polyelectrolyte multilayers (iPEMs). These iPEM vaccines are electrostatically assembled from peptide antigens and nucleic acid-based toll-like receptor agonists (TLRas) that serve as molecular adjuvants. Gold nanoparticles (AuNPs) coated with iPEMs stimulate effector cytokine secretion in vitro and expand antigen-specific T cells in mice. Here we investigated how the dose, injection route, and choice of molecular adjuvant impacts the ability of iPEMs to generate T cell immunity and anti-tumor response in mice. Three injection routesintradermal, subcutaneous, and intramuscularand three iPEM dosing levels were employed. Intradermal injection induced the most potent antigen-specific T cell responses and, for all routes, the level of response was dose-dependent. We further discovered that these vaccines generate durable memory, indicated by potent, antigen-specific CD8(+) T cell recall responses in mice challenged with vaccine 49 days after a prime-boost immunization regimen. In a common exogenous antigen melanoma model, iPEM vaccines slowed or stopped tumor growth more effectively than equivalent ad-mixed formulations. Further, iPEMs containing CpGa TLR9awere more potent compared with iPEMs containing polyIC, a TLR3a. These findings demonstrate the ability of iPEMs to enhance response to several different classes of vaccine cargos, supporting iPEMs as a simple vaccine platform that mimics attractive features of other nanoparticles using immune signals that can be self-assembled or coated on substrates. Biotechnol. Bioeng. 2017;114: 423-431. (c) 2016 Wiley Periodicals, Inc. C1 [Zhang, Peipei; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, 2212 Jeong H Kim Engn Bldg,8228 Paint Branch Dr, College Pk, MD 20742 USA. [Andorko, James I.; Jewell, Christopher M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. [Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Jewell, Christopher M.] US Dept Vet Affairs, Baltimore, MD 21201 USA. EM cmjewell@umd.edu FU NSF CAREER Award [1351688]; Alliance for Cancer Gene Therapy Young Investigator Award [15051543]; University of Maryland Division of Research (Tier 1); Damon Runyon Foundation [DRR3415]; Melanoma Research Alliance [348963]; NIH Grant [T32 AI089621]; American Association of Pharmaceutical Scientists Foundation FX Contract grant sponsor: NSF CAREER Award; Contract grant number: #1351688; Contract grant sponsor: Alliance for Cancer Gene Therapy Young Investigator Award; Contract grant number: #15051543; Contract grant sponsor: University of Maryland Division of Research (Tier 1); Contract grant sponsor: Damon Runyon Foundation; Contract grant number: #DRR3415; Contract grant sponsor: Melanoma Research Alliance; Contract grant number: #348963; Contract grant sponsor: NIH Grant; Contract grant number: #T32 AI089621; Contract grant sponsor: American Association of Pharmaceutical Scientists Foundation NR 37 TC 2 Z9 2 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0006-3592 EI 1097-0290 J9 BIOTECHNOL BIOENG JI Biotechnol. Bioeng. PD FEB PY 2017 VL 114 IS 2 BP 423 EP 431 DI 10.1002/bit.26083 PG 9 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA EI5MU UT WOS:000392539800017 PM 27567213 ER PT J AU Pandey, A Khan, H Newman, AB Lakatta, EG Forman, DE Butler, J Berry, JD AF Pandey, Ambarish Khan, Hassan Newman, Anne B. Lakatta, Edward G. Forman, Daniel E. Butler, Javed Berry, Jarett D. TI Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction The Health ABC Study (Health, Aging, and Body Composition) SO HYPERTENSION LA English DT Article DE arterial stiffness; ejection fraction; heart failure; hypertension; pulse wave velocity ID LEFT-VENTRICULAR HYPERTROPHY; PULSE-WAVE VELOCITY; CARDIOVASCULAR EVENTS; OLDER-ADULTS; DIASTOLIC DYSFUNCTION; DISEASE; ASSOCIATION; ATHEROSCLEROSIS; EXERCISE; POPULATION AB Higher arterial stiffness is associated with increased risk of atherosclerotic events. However, its contribution toward risk of heart failure (HF) and its subtypes, HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), independent of other risk factors is not well established. In this study, we included Health ABC study (Health, Aging, and Body Composition) participants without prevalent HF who had arterial stiffness measured as carotid-femoral pulse wave velocity (cf-PWV) at baseline (n=2290). Adjusted Cox-proportional hazards models were constructed to determine the association between continuous and data-derived categorical measures (tertiles) of cf-PWV and incidence of HF and its subtypes (HFpEF [ejection fraction >45%] and HFrEF [ejection fraction <= 45%]). We observed 390 HF events (162 HFpEF and 145 HFrEF events) over 11.4 years of follow-up. In adjusted analysis, higher cf-PWV was associated with greater risk of HF after adjustment for age, sex, ethnicity, mean arterial pressure, and heart rate (hazard ratio [95% confidence interval] for cf-PWV tertile 3 versus tertile 1 [ref] =1.35 [1.05-1.73]). However, this association was not significant after additional adjustment for other cardiovascular risk factors (hazard ratio [95% confidence interval], 1.14 [0.88-1.47]). cf-PWV velocity was also not associated with risk of HFpEF and HFrEF after adjustment for potential confounders (most adjusted hazard ratio [95% confidence interval] for cf-PWV tertile 3 versus tertile 1 [ref]: HFpEF, 1.06 [0.72-1.56]; HFrEF, 1.28 [0.83-1.97]). In conclusion, arterial stiffness, as measured by cf-PWV, is not independently associated with risk of HF or its subtypes after adjustment for traditional cardiovascular risk factors. Online Data Supplement C1 [Pandey, Ambarish; Berry, Jarett D.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX USA. [Berry, Jarett D.] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX USA. [Khan, Hassan] Emory Univ, Sch Med, Dept Internal Med, Atlanta, GA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Lakatta, Edward G.] NIA, Lab Cardiovasc Sci, Biomed Res Ctr, NIH, Baltimore, MD 21224 USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Sch Med, Sect Geriatr Cardiol,Div Geriatr, Pittsburgh, PA 15260 USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Sch Med, Sect Geriatr Cardiol,Div Cardiol, Pittsburgh, PA 15260 USA. [Butler, Javed] SUNY Stony Brook, Sch Med, Dept Internal Med, Div Cardiol, New York, NY USA. EM jarett.berry@utsouthwestern.edu FU Intramural Research Program of the National Institutes of Health (NIH), National Institute on Aging; National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; National Institute of Nursing Research [R01-NR012459] FX This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Institute on Aging. This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and National Institute of Nursing Research grant R01-NR012459. NR 50 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD FEB PY 2017 VL 69 IS 2 BP 267 EP + DI 10.1161/HYPERTENSIONAHA.116.08327 PG 12 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EI3QE UT WOS:000392405500011 PM 27993954 ER PT J AU Ascher, SB Scherzer, R Peralta, CA Tien, PC Grunfeld, C Estrella, MM Abraham, A Gustafson, DR Nowicki, M Sharma, A Cohen, MH Butch, AW Young, MA Bennett, MR Shlipak, MG AF Ascher, Simon B. Scherzer, Rebecca Peralta, Carmen A. Tien, Phyllis C. Grunfeld, Carl Estrella, Michelle M. Abraham, Alison Gustafson, Deborah R. Nowicki, Marek Sharma, Anjali Cohen, Mardge H. Butch, Anthony W. Young, Mary A. Bennett, Michael R. Shlipak, Michael G. TI Association of Kidney Function and Early Kidney Injury With Incident Hypertension in HIV-Infected Women SO HYPERTENSION LA English DT Article DE albuminuria; glomerular filtration rate; HIV; hypertension; kidney disease ID ACTIVE ANTIRETROVIRAL THERAPY; GLOMERULAR-FILTRATION-RATE; BLOOD-PRESSURE; GENERAL-POPULATION; FUNCTION DECLINE; DISEASE; ALBUMINURIA; PREVALENCE; RISK; MORTALITY AB Subclinical kidney disease is associated with developing hypertension in the general population, but data are lacking among HIV-infected people. We examined associations of kidney function and injury with incident hypertension in 823 HIV-infected and 267 HIV-uninfected women in the Women's Interagency HIV Study, a multicenter, prospective cohort of HIV-infected and uninfected women in the United States. Baseline kidney biomarkers included estimated glomerular filtration rate using cystatin C, urine albumin-to-creatinine ratio, and 7 urine biomarkers of tubular injury: alpha-1-microglobulin, interleukin-18, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, liver fatty acid-binding protein, N-acetyl-beta-D-glucosaminidase, and alpha 1-acid-glycoprotein. We used multivariable Poisson regression to evaluate associations of kidney biomarkers with incident hypertension, defined as 2 consecutive visits of antihypertensive medication use. During a median follow-up of 9.6 years, 288 HIV-infected women (35%) developed hypertension. Among the HIV-infected women, higher urine albumin-to-creatinine ratio was independently associated with incident hypertension (relative risk = 1.13 per urine albumin-to-creatinine ratio doubling, 95% confidence interval, 1.07-1.20), as was lower estimated glomerular filtration rate (relative risk = 1.10 per 10 mL/min/1.73 m(2) lower estimated glomerular filtration rate; 95% confidence interval, 1.04-1.17). No tubular injury and dysfunction biomarkers were independently associated with incident hypertension in HIV-infected women. In contrast, among the HIV-uninfected women, urine albumin-to-creatinine ratio was not associated with incident hypertension, whereas higher urine interleukin-18, alpha 1-acid-glycoprotein, and N-acetyl-beta-D-glucosaminidase levels were significantly associated with incident hypertension. These findings suggest that early glomerular injury and kidney dysfunction may be involved in the pathogenesis of hypertension in HIV-infected people. The associations of tubular markers with hypertension in HIV-uninfected women should be validated in other studies. Online Data Supplement C1 [Ascher, Simon B.; Scherzer, Rebecca; Peralta, Carmen A.; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA. [Peralta, Carmen A.; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, 4150 Clement St,111A1, San Francisco, CA 94121 USA. [Estrella, Michelle M.; Abraham, Alison] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Gustafson, Deborah R.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Nowicki, Marek] Univ Southern Calif, Dept Med, Los Angeles, CA USA. [Sharma, Anjali] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA. [Butch, Anthony W.] UCLA Hlth Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Young, Mary A.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. [Bennett, Michael R.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. EM michael.shlipak@ucsf.edu FU National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute on Drug Abuse; National Institute on Mental Health; National Institute of Dental and Craniofacial Research; National Institute on Alcohol Abuse and Alcoholism; National Institute on Deafness and other Communication Disorders; National Institutes of Health Office of Research on Women's Health; [R01AG034853-08] FX The WIHS (Women's Interagency HIV Study) is funded primarily by the National Institute of Allergy and Infectious Diseases, with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Mental Health. Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Deafness and other Communication Disorders, and the National Institutes of Health Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA) and UL1-TR000454 (Atlanta CTSA). MG Shlipak and R Scherzer are funded by R01AG034853-08. NR 46 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD FEB PY 2017 VL 69 IS 2 BP 304 EP + DI 10.1161/HYPERTENSIONAHA.116.08258 PG 18 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EI3QE UT WOS:000392405500015 PM 27993956 ER PT J AU Clark, PA Gaal, JT Strebe, JK Pasch, CA Deming, DA Kuo, JS Robins, HI AF Clark, Paul A. Gaal, Jordan T. Strebe, Joslyn K. Pasch, Cheri A. Deming, Dustin A. Kuo, John S. Robins, H. Ian TI The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Cancer stem cells; Glioblastoma; MGMT methylation; Temozolomide; Tumor treating fields ID ALTERNATING ELECTRIC-FIELDS; RANDOMIZED PHASE-III; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; TREATMENT MODALITY; CANCER; CONCOMITANT; THERAPY; CHEMOTHERAPY; RADIOTHERAPY AB A recent Phase 3 study of newly diagnosed glioblastoma (GBM) demonstrated the addition of tumor treating fields (TTFields) to temozolomide (TMZ) after combined radiation/TMZ significantly increased survival and progression free survival. Preliminary data suggested benefit with both methylated and unmethylated O-6-methylguanine-DNA methyl-transferase (MGMT) promoter status. To date, however, there have been no studies to address the potential interactions of TTFields and TMZ. Thus, the effects of TTFields and TMZ were studied in vitro using patient-derived GBM stem-like cells (GSCs) including MGMT expressing (TMZ resistant: 12.1 and 22 GSC) and non-MGMT expressing (TMZ sensitive: 33 and 114 GSC) lines. Dose-response curves were constructed using cell proliferation and sphere-forming assays. Results demonstrated a >= 10-fold increase in TMZ resistance of MGMT-expressing (12.1 GSCs: IC50 = 160 mu M; 22 GSCs: IC50 = 44 mu M) compared to MGMT non-expressing (33 GSCs: IC50 = 1.5 mu M; 114 GSCs: IC50 = 5.2 mu M) lines. TTFields inhibited 12.1 GSC proliferation at all tested doses (50-500 kHz) with an optimal frequency of 200 kHz. At 200 kHz, TTFields inhibited proliferation and tumor sphere formation of both MGMT GSC subtypes at comparable levels (12.1 GSC: 74 +/- 2.9% and 38 +/- 3.2%, respectively; 22 GSC: 61 +/- 11% and 38 +/- 2.6%, respectively; 33 GSC: 56 +/- 9.5% and 60 +/- 7.1%, respectively; 114 GSC: 79 +/- 3.5% and 41 +/- 4.3%, respectively). In combination, TTFields (200 kHz) and TMZ showed an additive anti-neoplastic effect with equal efficacy for TTFields in both cell types (i.e., +/- MGMT expression) with no effect on TMZ resistance. This is the first demonstration of the effects of TTFields on cancer stem cells. The expansion of such studies may have clinical implications. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Clark, Paul A.; Gaal, Jordan T.; Strebe, Joslyn K.; Kuo, John S.] Univ Wisconsin, Dept Neurol Surg, Sch Med & Publ Hlth UWSMPH, Madison, WI USA. [Pasch, Cheri A.; Deming, Dustin A.; Kuo, John S.; Robins, H. Ian] Univ Wisconsin, Carbone Canc Ctr, UWSMPH, Madison, WI USA. [Deming, Dustin A.; Robins, H. Ian] UWSMPH, Dept Med, Div Hematol & Oncol, Madison, WI USA. [Deming, Dustin A.] UWSMPH, Dept Oncol, McArdle Lab Canc Res, Madison, WI USA. [Deming, Dustin A.; Robins, H. Ian] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Robins, H. Ian] UWSMPH, Dept Neurol, Madison, WI USA. [Kuo, John S.; Robins, H. Ian] UWSMPH, Dept Human Oncol, Madison, WI USA. EM hirobins@wisc.edu FU National Institutes of Health (NIH) [P30 CA014520]; UW Carbone Cancer pilot grant; Semman Gray Matters Jam; UW (Carbone Cancer Center, Dept. of Medicine, School of Medicine and Public Health); UW (Graduate School through the Wisconsin Alumni Research Foundation); Novocure, Ltd. (Portsmouth, NH); Novocure, Ltd. (New York, NY); NIH [R01CA15880, R01NS75995]; Headrush Brain Tumor Research Professorship; Roger Loff Memorial Fund for GBM Research; Dept. of Neurological Surgery; Katheryn Reader Neuro-Oncology Fund; Steve Bolser Memorial Joggin for Noggin fund FX This research was supported by the National Institutes of Health (NIH) [Grant No. P30 CA014520], UW Carbone Cancer pilot grant, Semman Gray Matters Jam and Steve Bolser Memorial Joggin for Noggin fund. DAD was supported by start-up funds from the UW (Carbone Cancer Center, Dept. of Medicine, School of Medicine and Public Health, and the Graduate School through the Wisconsin Alumni Research Foundation). The in vitro TTFields cell culture equipment was provided by a grant from Novocure, Ltd. (Portsmouth, NH and New York, NY). JSK was partly supported by NIH R01CA15880, R01NS75995, Headrush Brain Tumor Research Professorship, Roger Loff Memorial Fund for GBM Research and the Dept. of Neurological Surgery. HIR was partly supported by the Katheryn Reader Neuro-Oncology Fund. NR 30 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 EI 1532-2653 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD FEB PY 2017 VL 36 BP 120 EP 124 DI 10.1016/j.jocn.2016.10.042 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EI5WN UT WOS:000392567100023 PM 27865821 ER PT J AU Adams, ZW McClure, EA Gray, KM Danielson, CK Treiber, FA Ruggiero, KJ AF Adams, Zachary W. McClure, Erin A. Gray, Kevin M. Danielson, Carla Kmett Treiber, Frank A. Ruggiero, Kenneth J. TI Mobile devices for the remote acquisition of physiological and behavioral biomarkers in psychiatric clinical research SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Biomarkers; Mobile health; Biosensors; Technology; Ecological momentary assessment; Clinical research ID SUBSTANCE USE DISORDERS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CONTINGENCY MANAGEMENT; SMOKING-CESSATION; CIGARETTE-SMOKING; BIPOLAR DISORDER; VOUCHER REINFORCEMENT; PRECISION MEDICINE; HEALTH-CARE; TECHNOLOGY AB Psychiatric disorders are linked to a variety of biological, psychological, and contextual causes and consequences. Laboratory studies have elucidated the importance of several key physiological and behavioral biomarkers in the study of psychiatric disorders, but much less is known about the role of these biomarkers in naturalistic settings. These gaps are largely driven by methodological barriers to assessing biomarker data rapidly, reliably, and frequently outside the clinic or laboratory. Mobile health (mHealth) tools offer new opportunities to study relevant biomarkers in concert with other types of data (e.g., self-reports, global positioning system data). This review provides an overview on the state of this emerging field and describes examples from the literature where mHealth tools have been used to measure a wide array of biomarkers in the context of psychiatric functioning (e.g., psychological stress, anxiety, autism, substance use). We also outline advantages and special considerations for incorporating mHealth tools for remote biomarker measurement into studies of psychiatric illness and treatment and identify several specific opportunities for expanding this promising methodology. Integrating mHealth tools into this area may dramatically improve psychiatric science and facilitate highly personalized clinical care of psychiatric disorders. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Adams, Zachary W.; McClure, Erin A.; Gray, Kevin M.; Danielson, Carla Kmett; Treiber, Frank A.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Coll Med, 67 President St, Charleston, SC USA. [Adams, Zachary W.] Indiana Univ Sch Med, Dept Psychiat, 410 West 10th St, Indianapolis, IN 46202 USA. [Treiber, Frank A.; Ruggiero, Kenneth J.] Med Univ South Carolina, Technol Applicat Ctr Healthful Lifestyles, Coll Nursing, 99 Jonathan Lucas St, Charleston, SC USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC USA. RP Adams, ZW (reprint author), 410 West 10th St,Suite 2000, Indianapolis, IN 46202 USA. EM zwadams@iu.edu FU National Institutes of Health [K23DA038257, K01DA036739, U01DA031779, K24DA039783, R01DA031285, T32MH018869, I21HX001729, R34MH096907, R01MH107641, R01DK098777, R01HL114957, R21HL118447]; Substance Abuse and Mental Health Services Administration; Veterans Administration; Duke Endowment; National Institutes of Health (NIH grant) [UL1RR029882] FX This work was supported primarily by National Institutes of Health (ZWA, grant number, K23DA038257; EAM, grant number K01DA036739; KMG, grant number U01DA031779; CKD, grant numbers K24DA039783, R01DA031285, and T32MH018869; KJR, grant numbers I21HX001729, R34MH096907, and R01MH107641; and FAT, grant numbers R01DK098777, R01HL114957, and R21HL118447; and NIH grant number UL1RR029882). Additional funding came from the Substance Abuse and Mental Health Services Administration (CKD), Veterans Administration (KJR), and the Duke Endowment (FAT). NR 108 TC 0 Z9 0 U1 12 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2017 VL 85 BP 1 EP 14 DI 10.1016/j.jpsychires.2016.10.019 PG 14 WC Psychiatry SC Psychiatry GA EI8QW UT WOS:000392773600001 ER PT J AU Gong, JJ Munoz, AR Pingali, S Payton-Stewart, F Chan, DE Freeman, JW Ghosh, R Kumar, AP AF Gong, Jingjing Munoz, Amanda R. Pingali, Subramanya Payton-Stewart, Florastina Chan, Daniel E. Freeman, James W. Ghosh, Rita Kumar, Addanki P. TI Downregulation of STAT3/NF-B potentiates gemcitabine activity in pancreatic cancer cells SO MOLECULAR CARCINOGENESIS LA English DT Article DE chemoresistance; pancreatic cancer; nexrutine; gemcitabine; STAT3; NFB ID NF-KAPPA-B; PROSTATE-CANCER; PLUS GEMCITABINE; MUC4 EXPRESSION; NEXRUTINE; BERBERINE; SURVIVAL; EXTRACT; MICROENVIRONMENT; CHEMORESISTANCE AB There is an unmet need to develop new agents or strategies against therapy resistant pancreatic cancer (PanCA). Recent studies from our laboratory showed that STAT3 negatively regulates NF-B and that inhibition of this crosstalk using Nexrutine (R) (Nx) reduces transcriptional activity of COX-2. Inhibition of these molecular interactions impedes pancreatic cancer cell growth as well as reduces fibrosis in a preclinical animal model. Nx is an extract derived from the bark of Phellodendron amurense and has been utilized in traditional Chinese medicine as antidiarrheal, astringent, and anti-inflammatory agent for centuries. We hypothesized that Nx-mediated inhibition of survival molecules like STAT3 and NF-B in pancreatic cancer cells will improve the efficacy of the conventional chemotherapeutic agent, gemcitabine (GEM). Therefore, we explored the utility of Nx, one of its active constituents berberine and its derivatives, to enhance the effects of GEM. Using multiple human pancreatic cancer cells we found that combination treatment with Nx and GEM resulted in significant alterations of proteins in the STAT3/NF-B signaling axis culminating in growth inhibition in a synergistic manner. Furthermore, GEM resistant cells were more sensitive to Nx treatment than their parental GEM-sensitive cells. Interestingly, although berberine, the Nx active component used, and its derivatives were biologically active in GEM sensitive cells they did not potentiate GEM activity when used in combination. Taken together, these results suggest that the natural extract, Nx, but not its active component, berberine, has the potential to improve GEM sensitivity, perhaps by down regulating STAT3/NF-B signaling. (c) 2016 Wiley Periodicals, Inc. C1 [Gong, Jingjing; Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Munoz, Amanda R.; Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Pingali, Subramanya; Payton-Stewart, Florastina] Xavier Univ Louisiana, Dept Chem, New Orleans, LA USA. [Chan, Daniel E.] Univ Colorado, Div Med Oncol, Aurora, CO USA. [Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Freeman, James W.; Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Freeman, James W.; Kumar, Addanki P.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kumara3@uthscsa.edu FU Veterans Affairs-Merit Award [I01 BX 000766-01, CPRIT RP 150166]; CTRC at UT Health Science Center San Antonio (UTHSCSA) [2P30 CA 054174-17]; CTRC; NIGMS-BUILD [8UL1GM118967]; RCMI [2G12MD007595-06]; [1R01AT007448] FX Grant sponsor: 1R01AT007448; Grant sponsor: Veterans Affairs-Merit Award; Grant numbers: I01 BX 000766-01; CPRIT RP 150166; Grant sponsor: CTRC at UT Health Science Center San Antonio (UTHSCSA); Grant number: #2P30 CA 054174-17; Grant sponsor: CTRC 40th Anniversary Distinguished Professor of Oncology Endowment; Grant sponsor: NIGMS-BUILD; Grant number: 8UL1GM118967; Grant sponsor: RCMI; Grant number: 2G12MD007595-06 NR 41 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD FEB PY 2017 VL 56 IS 2 BP 402 EP 411 DI 10.1002/mc.22503 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA EI5GH UT WOS:000392521800009 PM 27208550 ER PT J AU Gebregziabher, M AF Gebregziabher, Mulugeta TI Some comments on "The analysis of multivariate longitudinal data: A review" SO STATISTICAL METHODS IN MEDICAL RESEARCH LA English DT Letter DE hearing loss data; multivariate longitudinal data; shared random effects; separate random effects ID HEARING-LOSS; INFERENCE AB We provide a commentary on The analysis of multivariate longitudinal data: a review by Verbeke etal. The authors provide a comprehensive review of the issues in the analysis of multivariate longitudinal data and use examples to demonstrate the pros and cons of several approaches. In this commentary, we indicate some important omissions in their review paper. C1 [Gebregziabher, Mulugeta] Med Univ South Carolina, Dept Publ Hlth Sci Biostat, 135 Cannon St,MSC 835, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Gebregziabher, M (reprint author), Med Univ South Carolina, Dept Publ Hlth Sci Biostat, 135 Cannon St,MSC 835, Charleston, SC 29425 USA. EM gebregz@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institutes of Health, National Institute on Deafness and Other Communication Disorders (NIH/NIDCD) [P50 DC000422] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported (in part) by grant P50 DC000422 from the National Institutes of Health, National Institute on Deafness and Other Communication Disorders (NIH/NIDCD). NR 9 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0962-2802 EI 1477-0334 J9 STAT METHODS MED RES JI Stat. Methods Med. Res. PD FEB PY 2017 VL 26 IS 1 BP 108 EP 111 DI 10.1177/0962280214539863 PG 4 WC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Statistics & Probability SC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Mathematics GA EJ1KK UT WOS:000392968900007 PM 25847912 ER PT J AU Ma, YB Zhou, XH AF Ma, Yunbei Zhou, Xiao-Hua TI Treatment selection in a randomized clinical trial via covariate-specific treatment effect curves SO STATISTICAL METHODS IN MEDICAL RESEARCH LA English DT Article DE predictive biomarker; covariate-specific treatment effect curve; time-to-event outcome; pointwise confidence interval; simultaneous confidence interval; varying coefficient ID CONFIDENCE BANDS; SURVIVAL-DATA; COX MODEL; REGRESSION; COEFFICIENTS; SUBSETS AB For time-to-event data in a randomized clinical trial, we proposed two new methods for selecting an optimal treatment for a patient based on the covariate-specific treatment effect curve, which is used to represent the clinical utility of a predictive biomarker. To select an optimal treatment for a patient with a specific biomarker value, we proposed pointwise confidence intervals for each covariate-specific treatment effect curve and the difference between covariate-specific treatment effect curves of two treatments. Furthermore, to select an optimal treatment for a future biomarker-defined subpopulation of patients, we proposed confidence bands for each covariate-specific treatment effect curve and the difference between each pair of covariate-specific treatment effect curve over a fixed interval of biomarker values. We constructed the confidence bands based on a resampling technique. We also conducted simulation studies to evaluate finite-sample properties of the proposed estimation methods. Finally, we illustrated the application of the proposed method in a real-world data set. C1 [Ma, Yunbei] Southwestern Univ Finance & Econ, Sch Stat, Chengdu, Sichuan, Peoples R China. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] Peking Univ, Beijing Int Ctr Math Res, Beijing, Peoples R China. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98195 USA. EM azhou@washington.edu FU National Natural Science Foundation of China (NSFC) [11301424]; U.S. Department of Veterans Affairs HSR&D Research Career Scientist Award [RCS 05-196] FX Dr Ma's work was partially supported by the National Natural Science Foundation of China (NSFC) (No. 11301424), and Dr Zhou's work was supported in part by U.S. Department of Veterans Affairs HSR&D Research Career Scientist Award (RCS 05-196). NR 17 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0962-2802 EI 1477-0334 J9 STAT METHODS MED RES JI Stat. Methods Med. Res. PD FEB PY 2017 VL 26 IS 1 BP 124 EP 141 DI 10.1177/0962280214541724 PG 18 WC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Statistics & Probability SC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Mathematics GA EJ1KK UT WOS:000392968900010 PM 24996899 ER PT J AU Liu, JB Ko, CY AF Liu, Jason B. Ko, Clifford Y. TI Disparities in Rectal Cancer: Moving from Descriptions to Solutions SO ANNALS OF SURGICAL ONCOLOGY LA English DT Editorial Material ID HEALTH; CARE C1 [Liu, Jason B.; Ko, Clifford Y.] Amer Coll Surg, Chicago, IL 60611 USA. [Liu, Jason B.] Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90095 USA. RP Liu, JB (reprint author), Amer Coll Surg, Chicago, IL 60611 USA.; Liu, JB (reprint author), Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA. EM jliu@facs.org FU Department of Surgery, University of Chicago Hospitals; American College of Surgeons Clinical Scholar in Residence Program FX JBL is supported by a research fellowship from the Department of Surgery, University of Chicago Hospitals and the American College of Surgeons Clinical Scholar in Residence Program. NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2017 VL 24 IS 2 BP 299 EP 301 DI 10.1245/s10434-016-5628-y PG 3 WC Oncology; Surgery SC Oncology; Surgery GA EH7BA UT WOS:000391926600001 PM 27743226 ER PT J AU Artis, KA Dyer, E Mohan, V Gold, JA AF Artis, Kathryn A. Dyer, Edward Mohan, Vishnu Gold, Jeffrey A. TI Accuracy of Laboratory Data Communication on ICU Daily Rounds Using an Electronic Health Record SO CRITICAL CARE MEDICINE LA English DT Article DE attending rounds; communication; critical care; electronic health record; intensive care unit ID INTENSIVE-CARE-UNIT; DIAGNOSTIC ERRORS; MEDICAL-RECORD; INFORMATION; MORTALITY; SAFETY; IMPLEMENTATION; PARTICIPATION; SIMULATION; EVENTS AB Objectives: Accurately communicating patient data during daily ICU rounds is critically important since data provide the basis for clinical decision making. Despite its importance, high fidelity data communication during interprofessional ICU rounds is assumed, yet unproven. We created a robust but simple methodology to measure the prevalence of inaccurately communicated (misrepresented) data and to characterize data communication failures by type. We also assessed how commonly the rounding team detected data misrepresentation and whether data communication was impacted by environmental, human, and workflow factors. Design: Direct observation of verbalized laboratory data during daily ICU rounds compared with data within the electronic health record and on presenters' paper prerounding notes. Setting: Twenty-six-bed academic medical ICU with a well-established electronic health record. Subjects: ICU rounds presenter (medical student or resident physician), interprofessional rounding team. Interventions: None. Measurements and Main Results: During 301 observed patient presentations including 4,945 audited laboratory results, present. ers used a paper prerounding tool for 94.3% of presentations but tools contained only 78% of available electronic health record laboratory data. Ninty-six percent of patient presentations included at least one laboratory misrepresentation (mean, 6.3 per patient) and 38.9% of all audited laboratory data were inaccurately communicated. Most misrepresentation events were omissions. Only 7.8% of all laboratory misrepresentations were detected. Conclusion: Despite a structured interprofessional rounding script and a well-established electronic health record, clinician laboratory data retrieval and communication during ICU rounds at our institution was poor, prone to omissions and inaccuracies, yet largely unrecognized by the rounding team. This highlights an important patient safety issue that is likely widely prevalent, yet underrecognized. C1 [Artis, Kathryn A.; Dyer, Edward; Gold, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Artis, Kathryn A.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Div Hosp & Specialty Care, Portland, OR USA. [Mohan, Vishnu] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. RP Artis, KA (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA.; Artis, KA (reprint author), Portland VA Med Ctr, Sect Pulm & Crit Care Med, Div Hosp & Specialty Care, Portland, OR USA. EM artisk@ohsu.edu FU Agency for Healthcare Research and Quality (AHRQ) [R18 HS021367]; AHRQ FX Supported, in part, by Agency for Healthcare Research and Quality (AHRQ) R18 HS021367, AHRQ R01.; Dr. Artis disclosed other support from the Agency for Healthcare Research and Quality (AHRQ). Her institution received funding from the AHRQ. Dr. Mohan's institution received funding from the AHRQ. Dr. Gold's institution received funding from the AHRQ. Dr. Dyer has disclosed that he does not have any potential conflicts of interest. NR 37 TC 1 Z9 1 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2017 VL 45 IS 2 BP 179 EP 186 DI 10.1097/CCM.0000000000002060 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA EI4LF UT WOS:000392464500005 PM 27655323 ER PT J AU Skyler, JS Bakris, GL Bonifacio, E Darsow, T Eckel, RH Groop, L Groop, PH Handelsman, Y Insel, RA Mathieu, C McElvaine, AT Palmer, JP Pugliese, A Schatz, DA Sosenko, JM Wilding, JPH Ratner, RE AF Skyler, Jay S. Bakris, George L. Bonifacio, Ezio Darsow, Tamara Eckel, Robert H. Groop, Leif Groop, Per-Henrik Handelsman, Yehuda Insel, Richard A. Mathieu, Chantal McElvaine, Allison T. Palmer, Jerry P. Pugliese, Alberto Schatz, Desmond A. Sosenko, Jay M. Wilding, John P. H. Ratner, Robert E. TI Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis SO DIABETES LA English DT Article ID BETA-CELL FUNCTION; TRIAL-TYPE 1; IMPAIRED GLUCOSE-TOLERANCE; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; COTRANSPORTER 2 INHIBITOR; LIFE-STYLE INTERVENTION; ISLET AUTOIMMUNITY; GLYCEMIC CONTROL; KIDNEY-DISEASE AB The American Diabetes Association, JDRF, the European Association for the Study of Diabetes, and the American Association of Clinical Endocrinologists convened a research symposium, "The Differentiation of Diabetes by Pathophysiology, Natural History and Prognosis" on 10-12 October 2015. International experts in genetics, immunology, metabolism, endocrinology, and systems biology discussed genetic and environmental determinants of type 1 and type 2 diabetes risk and progression, as well as complications. The participants debated how to determine appropriate therapeutic approaches based on disease pathophysiology and stage and defined remaining research gaps hindering a personalized medical approach for diabetes to drive the field to address these gaps. The authors recommend a structure for data stratification to define the phenotypes and genotypes of subtypes of diabetes that will facilitate individualized treatment. C1 [Skyler, Jay S.; Pugliese, Alberto] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA. [Bakris, George L.] Univ Chicago Med, Chicago, IL USA. [Bonifacio, Ezio] Tech Univ Dresden, Dresden, Germany. [Darsow, Tamara; McElvaine, Allison T.; Ratner, Robert E.] Amer Diabet Assoc, Arlington, VA 22202 USA. [Eckel, Robert H.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. [Groop, Leif] Lund Univ, Skane Univ Hosp, Malmo, Sweden. [Groop, Per-Henrik] Univ Helsinki, Abdominal Ctr Nephrol, Helsinki, Finland. [Groop, Per-Henrik] Helsinki Univ Hosp, Helsinki, Finland. [Groop, Per-Henrik] Folkhalsan Res Ctr, Folkhalsan Inst Genet, Helsinki, Finland. [Groop, Per-Henrik] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Handelsman, Yehuda] Metab Inst Amer, Tarzana, CA USA. [Insel, Richard A.] JDRF, New York, NY USA. [Mathieu, Chantal] Katholieke Univ Leuven, Leuven, Belgium. [Palmer, Jerry P.] Univ Washington, Seattle, WA 98195 USA. [Palmer, Jerry P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Schatz, Desmond A.] Univ Florida, Coll Med, Gainesville, FL USA. [Sosenko, Jay M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Wilding, John P. H.] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England. RP McElvaine, AT (reprint author), Amer Diabet Assoc, Arlington, VA 22202 USA. EM amcelvaine@diabetes.org RI Wilding, John/A-7106-2008; Bonifacio, Ezio/E-7700-2010 OI Wilding, John/0000-0003-2839-8404; Bonifacio, Ezio/0000-0002-8704-4713 FU Novo Nordisk Inc. FX The authors gratefully acknowledge the Differentiation of Diabetes by Pathophysiology, Natural History and Prognosis research symposium steering committee members and speakers for the excellent presentations, discussions, and contributions to the conference. J.S.S., G.L.B., E.B., R.H.E., L.G., P.-H.G., R.A.I., C.M., J.P.P., A.P., D.A.S., J.M.S., J.P.H.W., and R.E.R. were presenters. Other faculty included Michael Bergman, New York University School of Medicine; Barbara E. Corkey, Boston University School of Medicine; James R. Gavin III, Emory University School of Medicine; Stanley Schwartz, University of Pennsylvania; and Kumar Sharma, University of California at San Diego. The conference was supported in part by an unrestricted educational grant from Novo Nordisk Inc. The sponsor had no influence on the selection of speakers, selection of writing group members, topics or content covered at the conference, or the content of this report. The authors thank Shirley Ash of the American Diabetes Association for assistance with the conference. NR 176 TC 2 Z9 2 U1 27 U2 27 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2017 VL 66 IS 2 BP 241 EP 255 DI 10.2337/db16-0806 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EI7PS UT WOS:000392691000002 PM 27980006 ER PT J AU Jha, P Bentley, B Behr, S Yee, J Zagoria, R AF Jha, Priyanka Bentley, Brian Behr, Spencer Yee, Judy Zagoria, Ronald TI Imaging of flank pain: readdressing state-of-the-art SO EMERGENCY RADIOLOGY LA English DT Review DE Renal stone; Low-dose CT; Ultrasound; MRI; Pregnancy; Imaging protocol; STONE score ID DUAL-ENERGY CT; CLINICAL-PREDICTION RULE; COMPUTED-TOMOGRAPHY; DIAGNOSTIC PERFORMANCE; URETERAL CALCULUS; STONE DISEASE; HELICAL CT; DOSE CT; UROLITHIASIS; US AB Pain resulting from renal and ureteral stones is a common cause for patients presenting in the acute setting. Since the late 1990s, computed tomography (CT) has been the initial imaging method of choice to evaluate patients with suspected ureteral stones; however, concerns regarding both radiation dose and cost-effectiveness have prompted investigations into a different imaging algorithm. Studies utilizing ultrasound have provided evidence indicating that it may be a more appropriate first step, with selective use of CT in selected cases, in the diagnostic work-up. Techniques have evolved with low-dose CT, dual-energy CT, and magnetic resonance urography emerging as useful in imaging of renal colic patients. This manuscript reviews the current literature on state-of-the-art imaging for acute flank pain and proposes a new imaging algorithm in the evaluation of patients with acute flank pain and suspected ureteral stones. C1 [Jha, Priyanka; Bentley, Brian; Behr, Spencer; Yee, Judy; Zagoria, Ronald] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 4150 Clement St,Bldg 200,Rm 2A-166, San Francisco, CA 94121 USA. [Yee, Judy] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Jha, P (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 4150 Clement St,Bldg 200,Rm 2A-166, San Francisco, CA 94121 USA. EM priyanka.jha@ucsf.edu NR 41 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1070-3004 EI 1438-1435 J9 EMERG RADIOL JI Emerg. Radiol. PD FEB PY 2017 VL 24 IS 1 BP 81 EP 86 DI 10.1007/s10140-016-1443-9 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EI2GL UT WOS:000392304800013 PM 27614885 ER PT J AU O'Donovan, A Ahmadian, AJ Neylan, TC Pacult, MA Edmondson, D Cohen, BE AF O'Donovan, Aoife Ahmadian, Ashkan J. Neylan, Thomas C. Pacult, Mark A. Edmondson, Donald Cohen, Beth E. TI Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Avoidance; C-reactive protein; Fibrinogen; Inflammation; Posttraumatic stress disorder; Threat reactivity; Threat sensitivity; Trauma; Veterans; White blood cell count ID C-REACTIVE PROTEIN; REPORTED PHYSICAL-ACTIVITY; QUALITY-OF-LIFE; PSYCHOLOGICAL STRESS; DEPRESSIVE SYMPTOMS; CONSTRUCT-VALIDITY; HEALTH BEHAVIORS; PROBLEM DRINKING; PTSD SYMPTOMS; WAR VETERANS AB Objective: Elevated inflammation has been repeatedly observed in posttraumatic stress disorder (PTSD), and it may drive the development of both psychiatric symptoms and physical comorbidities. However, it is not clear if elevated inflammation is a feature of both remitted and current PTSD, and little is known about relationships between specific clusters of PTSD symptoms and inflammation. Exaggerated threat sensitivity, as indexed by threat reactivity and avoidance of perceived threats, may be particularly closely associated with inflammation. Methods: We assessed PTSD symptoms and threat sensitivity using the Clinician Administered PTSD Scale in 735 Veterans Affairs patients (35% current PTSD; 16% remitted PTSD) who participated in the Mind Your Heart Study (mean age = 59 +/- 11; 94% male). High sensitivity C-reactive protein (hsCRP), white blood cell count (WBC), and fibrinogen were used as indices of inflammation. Analysis of covariance models with planned contrasts were used to examine differences in inflammation by PTSD status, adjusting for age, sex, race, kidney function and socioeconomic status. Results: Individuals with current PTSD had significantly higher hsCRP and WBC than patients with no history of PTSD, but there were no significant differences in inflammatory markers between those with remitted versus no history of PTSD. Within patients with current PTSD, higher threat reactivity was independently associated with higher h5CRP (beta = 0.16, p = 0.01) and WBC count (beta = 0.24, <0.001), and higher effortful avoidance was associated with higher fibrinogen (beta = 0.13, p = 0.04). Conclusion: Our data indicate that elevated inflammation may be a feature of current, but not remitted, PTSD. Within patients with PTSD, higher threat reactivity was also associated with elevated inflammation. A better understanding of the relationship between threat sensitivity and inflammation may inform interventions for patients with PTSD. (C) 2016 Elsevier Inc. All rights reserved. C1 [O'Donovan, Aoife; Ahmadian, Ashkan J.; Neylan, Thomas C.; Pacult, Mark A.; Cohen, Beth E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [O'Donovan, Aoife; Ahmadian, Ashkan J.; Neylan, Thomas C.; Pacult, Mark A.; Cohen, Beth E.] San Francisco VA Med Ctr, 4150 Clement St,116-C, San Francisco, CA 94121 USA. [O'Donovan, Aoife; Ahmadian, Ashkan J.; Neylan, Thomas C.; Pacult, Mark A.; Cohen, Beth E.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Edmondson, Donald] Columbia Univ, Med Ctr, New York, NY 10027 USA. RP O'Donovan, A (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116-C, San Francisco, CA 94121 USA. EM Aoife.ODonovan@ucsf.edu FU National Heart, Lung, and Blood Institute [K23 HL 094765-0]; Irene Perstein Foundation; American Heart Association Clinical Research Program; University of California, San Francisco; Society in Science - The Branco Weiss Fellowship; [NIH-KL2TR000143]; [NIH-K01MH109871] FX The Mind Your Heart Study is funded by the National Heart, Lung, and Blood Institute (K23 HL 094765-0), the Irene Perstein Foundation, the American Heart Association Clinical Research Program, and Departmental funds from the University of California, San Francisco. Society in Science - The Branco Weiss Fellowship and NIH-KL2TR000143 and NIH-K01MH109871 provided support to AOD. NR 66 TC 0 Z9 0 U1 9 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD FEB PY 2017 VL 60 BP 198 EP 205 DI 10.1016/j.bbi.2016.10.014 PG 8 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA EH6UA UT WOS:000391908200022 PM 27765647 ER PT J AU Yang, YS Marder, SR Green, MF AF Yang, Y. S. Marder, S. R. Green, M. F. TI Repurposing Drugs for Cognition in Schizophrenia SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article AB Currently approved treatments for schizophrenia only minimally affect the cognitive features of the illness that are the most closely related to disability. Hence, there is now considerable effort to repurpose drugs for schizophrenia, and to seek agents that can improve cognition by targeting receptor systems other than the dopaminergic system. The results of these studies have been mixed thus far; however, this continues to be a high-priority area of schizophrenia research and an important unmet need. C1 [Yang, Y. S.; Marder, S. R.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr VISN22, Los Angeles, CA 90073 USA. [Yang, Y. S.; Marder, S. R.; Green, M. F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. RP Yang, YS (reprint author), VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr VISN22, Los Angeles, CA 90073 USA.; Yang, YS (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. EM ysyang@mednet.ucla.edu FU Amgen; Forum; Neurocrine FX M.G. has been a consultant to: AbbVie, ACADIA, DSP, FORUM, Lundbeck, and Takeda; he is on the Scientific Board of Luc, and has received research support from Amgen and Forum. S.M. has been a consult to and on advisory boards for: Allergan, Takeda, Lundbeck, Otsuka, Neurocrine, and Boeringer Ingelheim, and has received research support from Forum and Neurocrine. Y.Y. has no disclosures to declare. NR 5 TC 2 Z9 2 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2017 VL 101 IS 2 BP 191 EP 193 DI 10.1002/cpt.529 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EH7FS UT WOS:000391938900026 PM 27706797 ER PT J AU Shah, FA Girard, TD Yende, S AF Shah, Faraaz Ali Girard, Timothy D. Yende, Sachin TI Limiting sedation for patients with acute respiratory distress syndrome - time to wake up SO CURRENT OPINION IN CRITICAL CARE LA English DT Review DE acute respiratory distress syndrome; outcomes; sedation ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; EXTRACORPOREAL MEMBRANE-OXYGENATION; TERM COGNITIVE IMPAIRMENT; ACUTE LUNG INJURY; NEUROMUSCULAR BLOCKING-AGENTS; CONFUSION ASSESSMENT METHOD; BREATHING CONTROLLED-TRIAL AB Purpose of review Critically ill patients with acute respiratory distress syndrome (ARDS) may require sedation in their clinical care. The goals of sedation in ARDS patients are to improve patient comfort and tolerance of supportive and therapeutic measures without contributing to adverse outcomes. This review discusses the current evidence for sedation management in patients with ARDS. Recent findings Deep sedation strategies should be avoided in the care of patients with ARDS because deep sedation has been associated with increased time on mechanical ventilation, longer ICU and hospital length of stay, and higher mortality in critically ill patients. Adoption of protocol-based, light-sedation strategies is preferred and improves patient outcomes. Although the optimal sedative agent for ARDS patients is unclear, benzodiazepines should be avoided because of associations with oversedation, delirium, prolonged ICU and hospital length of stay, and increased mortality. Minimizing sedation in patients with ARDS facilitates early mobilization and early discharge from the ICU, potentially aiding in recovery from critical illness. Strategies to optimize ventilation in ARDS patients, such as low tidal volume ventilation and high positive end-expiratory pressure can be employed without deep sedation; however, deep sedation is required if patients receive neuromuscular blockade, which may benefit some ARDS patients. Knowledge gaps persist as to whether or not prone positioning and extracorporeal membrane oxygenation can be tolerated with light sedation. Summary Current evidence supports the use of protocol-based, light-sedation strategies in critically ill patients with ARDS. Further research into sedation management specifically in ARDS populations is needed. C1 [Shah, Faraaz Ali] Univ Pittsburgh, CRISMA Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Girard, Timothy D.; Yende, Sachin] Univ Pittsburgh, CRISMA Ctr, Dept Crit Care Med, Pittsburgh, PA USA. [Yende, Sachin] VA Pittsburgh Healthcare Syst, Univ Dr C,Room 2A124, Pittsburgh, PA 15240 USA. RP Yende, S (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,Room 2A124, Pittsburgh, PA 15240 USA. EM yendes@upmc.edu OI Girard, Timothy/0000-0002-9833-4871 FU National Institutes of Health FX F.A.S., T.D.G., and S.Y. are supported by grants from the National Institutes of Health. NR 83 TC 0 Z9 0 U1 15 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1070-5295 EI 1531-7072 J9 CURR OPIN CRIT CARE JI Curr. Opin. Crit. Care PD FEB PY 2017 VL 23 IS 1 BP 45 EP 51 DI 10.1097/MCC.0000000000000382 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA EH7LM UT WOS:000391954500008 PM 27898439 ER PT J AU Lendon, JP AF Lendon, Jessica Penn TI A Decade of Love and Hate: Trajectories of Intergenerational Ambivalence Experienced by Two Cohorts of Older Parents and Adult Children SO JOURNAL OF FAMILY ISSUES LA English DT Article DE dyadic relationship; quality; satisfaction; quantitative; intergenerational; life course; parent-child relations ID AGING PARENTS; LIFE; MOTHERS AB The intergenerational ambivalence paradigm is a critical lens for understanding the complexities of aging families, and researchers have begun to explore the potential changes and implications of ambivalence over the life course. This study is one of few to examine trajectories of ambivalence over 13 years and is the first to include two birth cohorts of reciprocal parent-child dyads. This research uses five waves of the Longitudinal Study of Generations to assess changes in ambivalence and reciprocal influences among 903 parent-child dyads using latent growth models. Primary findings show an overall decline in ambivalence over time with different patterns by generation, cohort/life stage, and gender. Children experienced greater levels of ambivalence than parents. There is a reciprocal influence of ambivalence in parent-child dyads; parents and children have similar trajectories of ambivalence and the older generation of parents' ambivalence exerted influence on the change in their children's ambivalence over time. This study highlights the importance of using longitudinal data and reciprocal dyads in intergenerational research and adds to theory about the important influences of life stages, social contexts, and linked lives on intergenerational ambivalence. C1 [Lendon, Jessica Penn] Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Lendon, JP (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jessicapenn@gmail.com FU National Institute on Aging [RO1AG07977] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the National Institute on Aging, Grant No. RO1AG07977. NR 39 TC 0 Z9 0 U1 6 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-513X EI 1552-5481 J9 J FAM ISSUES JI J. Fam. Issues PD FEB PY 2017 VL 38 IS 3 BP 336 EP 357 DI 10.1177/0192513X16634763 PG 22 WC Family Studies SC Family Studies GA EH5GP UT WOS:000391800900003 ER PT J AU Sun, ZH Chen, FF Zhou, XH Zhang, QZ AF Sun, Zhihua Chen, Feifei Zhou, Xiaohua Zhang, Qingzhao TI Improved model checking methods for parametric models with responses missing at random SO JOURNAL OF MULTIVARIATE ANALYSIS LA English DT Article DE Empirical process; High dimensional covariates; Missing at random; Model checking; Projection ID PARTIAL LINEAR-MODEL; SINGLE-INDEX MODELS; OF-FIT TESTS; REGRESSION-MODELS; CONSISTENT TEST; BOOTSTRAP; ADEQUACY AB In this paper, we consider the lack-of-fit test of a parametric model when the response variable is missing at random. The popular imputation and inverse probability weighting methods are first employed to tackle the missing data. Then by employing the projection technique, we propose empirical-process-based testing methods to check the appropriateness of the parametric model. The asymptotic properties of the test statistics are obtained under the null and local alternative hypothetical models. It is shown that the proposed testing methods are consistent, and can detect local alternative hypothetical models converging to the null model at the parametric rate. To determine the critical values, a consistent bootstrap method is proposed, and its asymptotic properties are established. The simulation results show that the tests outperform the existing methods in terms of empirical sizes and powers, especially under the situation with high dimensional covariates. Analysis of a diabetes data set of Pima Indians is carried out to demonstrate the application of the testing procedures. (C) 2016 Elsevier Inc. All rights reserved. C1 [Sun, Zhihua] Univ Chinese Acad Sci, Beijing, Peoples R China. [Sun, Zhihua] Chinese Acad Sci, Key Lab Big Data Min & Knowledge Management, Beijing, Peoples R China. [Chen, Feifei] Renmin Univ China, Sch Stat, Beijing, Peoples R China. [Zhou, Xiaohua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiaohua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Tacoma, WA USA. [Zhang, Qingzhao] Xiamen Univ, Sch Econ, Xiamen, Peoples R China. [Zhang, Qingzhao] Xiamen Univ, Wang Yanan Inst Studies Econ, Xiamen, Peoples R China. RP Zhang, QZ (reprint author), Xiamen Univ, Sch Econ, Xiamen, Peoples R China.; Zhang, QZ (reprint author), Xiamen Univ, Wang Yanan Inst Studies Econ, Xiamen, Peoples R China. EM zhangqingzhao@amss.ac.cn FU National Natural Science Foundation of China [11571340, 11401561, U1430103, 10901162]; UCAS; Key Laboratory of Big Data Mining and Knowledge Management, Chinese Academy of Sciences FX The author would like to thank the Editor and the reviewer for their careful review and insightful comments that have led to significant improvement of this article. This research was supported by National Natural Science Foundation of China (Grant Nos. 11571340, 11401561, U1430103, 10901162), the President Fund of UCAS and the Open Project of Key Laboratory of Big Data Mining and Knowledge Management, Chinese Academy of Sciences. NR 27 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0047-259X J9 J MULTIVARIATE ANAL JI J. Multivar. Anal. PD FEB PY 2017 VL 154 BP 147 EP 161 DI 10.1016/j.jmva.2016.11.003 PG 15 WC Statistics & Probability SC Mathematics GA EH6TQ UT WOS:000391907200009 ER PT J AU Bryant, PA Baddley, JW AF Bryant, Paul A. Baddley, John W. TI Opportunistic Infections in Biological Therapy, Risk and Prevention SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Opportunistic infection; Biologics; Tuberculosis; Zoster; Histoplasmosis; Pneumocystosis ID NECROSIS-FACTOR ANTAGONISTS; PNEUMOCYSTIS-CARINII-PNEUMONIA; RHEUMATOID-ARTHRITIS PATIENTS; INFLAMMATORY-BOWEL-DISEASE; FACTOR-ALPHA ANTAGONISTS; ANTI-TNF-ALPHA; HERPES-ZOSTER; POSTMARKETING SURVEILLANCE; SERIOUS INFECTION; BRITISH-SOCIETY AB Patients being treated with biological therapies are at increased risk for serious infections, including opportunistic infections. Although more is known about opportunistic infection risk with older biologics, such as antitumor necrosis factor drugs, there is less knowledge of opportunistic infection risk with newer biological therapies. The incidence of certain opportunistic infections (tuberculosis, herpes zoster, pneumo-cystosis) has been rigorously evaluated in large observational studies. However, data are more limited for other infections (histoplasmosis, nontuberculous mycobacteria). Infectious morbidity and mortality may be preventable with screening and prophylaxis in select populations. C1 [Bryant, Paul A.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA. [Baddley, John W.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA. [Baddley, John W.] Med Serv, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Birmingham VA Med Ctr, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA.; Baddley, JW (reprint author), Med Serv, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA. EM jbaddley@uabmc.edu FU BMS FX P.A. Bryant: none; J.W. Baddley: consulting for Merck, Pfizer. Research grant from BMS. NR 77 TC 0 Z9 0 U1 5 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X EI 1558-3163 J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD FEB PY 2017 VL 43 IS 1 BP 27 EP + DI 10.1016/j.rdc.2016.09.005 PG 16 WC Rheumatology SC Rheumatology GA EG3ZP UT WOS:000390983500005 PM 27890172 ER PT J AU Habib, S Shaikh, OS AF Habib, Shahid Shaikh, Obaid S. TI Drug-Induced Acute Liver Failure SO CLINICS IN LIVER DISEASE LA English DT Article DE Drug hepatotoxicity; Liver failure; Cerebral edema; Encephalopathy; Liver transplantation ID FULMINANT HEPATIC-FAILURE; INTRACRANIAL-PRESSURE MONITORS; ADSORBENT RECIRCULATING SYSTEM; CEREBRAL-BLOOD-FLOW; CONTROLLED-TRIAL; MODERATE HYPOTHERMIA; N-ACETYLCYSTEINE; RENAL-FAILURE; BRAIN EDEMA; LUNG INJURY AB Drug-induced acute liver failure (ALF) disproportionately affects women and nonwhites. It is most frequently caused by antimicrobials and to a lesser extent by complementary and alternative medications, antiepileptics, antimetabolites, nonsteroidals, and statins. Most drug-induced liver injury ALF patients have hepatocellular injury pattern. Cerebral edema and intracranial hypertension are the most serious complications of ALF. Other complications include coagulopathy, sepsis, metabolic derangements, and renal, circulatory, and respiratory dysfunction. Although advances in intensive care have improved outcome, ALF has significant mortality without liver transplantation. Liver-assist devices may provide a bridge to transplant or to spontaneous recovery. C1 [Habib, Shahid] Southern Arizona Vet Affairs Healthcare Syst, Dept Med, 3601 S 6th Ave, Tucson, AZ 85723 USA. [Shaikh, Obaid S.] Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Gastroenterol Sect, Univ Dr C,FU 112, Pittsburgh, PA 15240 USA. [Shaikh, Obaid S.] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, 200 Lothrop St, Pittsburgh, PA 15213 USA. RP Shaikh, OS (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Gastroenterol Sect, Univ Dr C,FU 112, Pittsburgh, PA 15240 USA. EM obaid@pitt.edu NR 83 TC 0 Z9 0 U1 19 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1089-3261 EI 1557-8224 J9 CLIN LIVER DIS JI Clin. Liver Dis. PD FEB PY 2017 VL 21 IS 1 BP 151 EP + DI 10.1016/j.cld.2016.08.003 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EG0OA UT WOS:000390730900011 PM 27842769 ER PT J AU Jones, JD Scott, JC Calkins, ME Ruparel, K Moore, TM Gur, RC Gur, RE AF Jones, Jason D. Scott, J. Cobb Calkins, Monica E. Ruparel, Kosha Moore, Tyler M. Gur, Ruben C. Gur, Raquel E. TI Correspondence between adolescent and informant reports of substance use: Findings from the Philadelphia Neurodevelopmental Cohort SO ADDICTIVE BEHAVIORS LA English DT Article DE Adolescent substance use; Reporter agreement; Collateral informants; Substance use assessment; Philadelphia Neurodevelopmental Cohort ID PARENTAL AWARENESS; RISK INVOLVEMENT; AGREEMENT; ATTACHMENT; DEPRESSION; BEHAVIOR; ALCOHOL; SAMPLE; ABUSE; CHILD AB Inclusion of collateral informant reports is common in adolescent psychopathology research and clinical assessment, yet few studies have examined agreement on ratings of adolescent substance use or factors that may be associated with reporter agreement. The present study aimed to extend prior work on the correspondence between adolescent and informant reports of adolescent substance use with data from a large (n = 5214), diverse, community-based sample of youth aged 11-17 (mean age = 14.53, SD = 1.98; 52% female). Specifically, we examined: (a) agreement between adolescent and collateral informant reports of adolescent use of alcohol, marijuana, cocaine, inhalants, and stimulants and (b) potential correlates of reporter agreement. Agreement ranged from low (k = 0.007,p = 0.053) for inhalant use to moderate (k = 0.414, p < 0.001) for marijuana use. Disagreements were mainly driven by collateral underestimation of adolescent substance use. Older adolescent age was associated with poorer agreement across all substances (Odds Ratios [ORs] <= 0.80, ps < 0.05) except inhalants (OR = 128, p < 0.001). Reporter agreement on alcohol and marijuana use was lower for male than female adolescents (ORs <= 0.85, ps < 0.05). Adolescent psychopathology was associated with poorer agreement on all substances (ORs <= 0.62, ps < 0.01). For alcohol and marijuana, past year frequency of use was associated with better reporter agreement (ORs >= 1.54, ps < 0.001). For marijuana, older age at first use was related to poorer agreement (OR = 0.81, p = 0.01). Our results suggest that collateral reports of adolescent substance use may be ineffective proxies for adolescent self-reports in community samples, particularly for low base rate substances. Findings also highlight important factors to consider when collecting substance use information from multiple informants. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Jones, Jason D.; Scott, J. Cobb; Calkins, Monica E.; Ruparel, Kosha; Moore, Tyler M.; Gur, Ruben C.; Gur, Raquel E.] Univ Penn, Perelman School Med, Dept Psychiat, Neuropsychiat Sect, 3400 Spruce St,10th Floor Gates Bldg, Philadelphia, PA 19104 USA. [Scott, J. Cobb; Gur, Ruben C.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, 3900 Woodland Ave, Philadelphia, PA 19104 USA. RP Jones, JD; Gur, RE (reprint author), 3400 Spruce St,10th Floor,Gates Bldg, Philadelphia, PA 19104 USA. EM jasjones@upenn.edu; raquel@upenn.edu FU NIH [RC2 MH089983, MH089924, K08MH079364, T32MH019112, MH089983]; Dowshen Program for Neuroscience; Department of Veterans Affairs Career Development Award [IK2CX000772] FX This work was supported by the NIH (RC2 MH089983 and MH089924; K08MH079364; T32MH019112; NIDA supplement to MH089983) and the Dowshen Program for Neuroscience. Dr. Scott's participation was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772). We thank the participants of this study, and all the members of the Recruitment, Assessment, and Data Teams whose individual contributions collectively made this work possible. We also thank William G. Iacono for allowing use, modification, and computerization of the University of Minnesota Center for Twin and Family Research substance use measure, and Emily Bach for coding the family history of substance abuse questions. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 30 TC 1 Z9 1 U1 14 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2017 VL 65 BP 13 EP 18 DI 10.1016/j.addbeh.2016.09.006 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA EF1GT UT WOS:000390074000003 PM 27701026 ER PT J AU Schmidt, TP Pennington, DL Cardoos, SL Durazzo, TC Meyerhoff, DJ AF Schmidt, Thomas P. Pennington, David L. Cardoos, Stephanie L. Durazzo, Timothy C. Meyerhoff, Dieter J. TI Neurocognition and inhibitory control in polysubstance use disorders: Comparison with alcohol use disorders and changes with abstinence SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Addiction; Cognition; Impulsivity; Longitudinal; Recovery; Substance use disorders ID CHRONIC CIGARETTE-SMOKING; SUBSTANCE USE DISORDERS; DEPENDENT INDIVIDUALS; COGNITIVE IMPAIRMENTS; EXECUTIVE FUNCTIONS; DRUG-USE; RECOVERY; DEFICITS; DRINKERS; RISK AB Introduction: Intact neurocognition and early cognitive recovery during abstinence are important for substance use treatment outcome. Yet, little is known about them in the largest group of treatment seekers today, individuals with polysubstance use disorders (PSU). This study primarily contrasted PSU and individuals with an alcohol use disorder (AUD) on neurocognitive and inhibitory control measures and, secondarily, measured changes during abstinence in PSU. Method: At one month of abstinence from all substances except tobacco, 36 PSU and 69 AUD completed neurocognitive assessments of executive function, general intelligence, auditory-verbal learning/memory, visuospatial learning/memory/skills, processing speed, working memory, fine motor skills, and cognitive efficiency. The groups were also assessed on inhibitory control measures of self-reported impulsivity, risk-taking, and decision-making. Seventeen PSU repeated the assessments after approximately four months of abstinence. All cross-sectional and longitudinal analyses included smoking status as a possible confound. Results: At baseline, PSU performed significantly worse than AUD on auditory-verbal memory and on an inhibitory control measure of impulsivity. Polysubstance users showed trends to worse performance than AUD on general intelligence, auditory-verbal learning, and a decision-making task. Between one and four months of abstinence, PSU showed significant improvements on several neurocognitive and inhibitory control measures. Conclusions: Polysubstance users exhibit distinct differences in neurocognition and inhibitory control compared to AUD. Between one and four months of abstinence, neurocognition and inhibitory control improve in PSU. This neurocognitive recovery in some domains of abstinent PSU is influenced by smoking status. These results underscore the clinical value of select methods to augment neurocognitive recovery in PSU through appropriate interventions. C1 [Schmidt, Thomas P.; Pennington, David L.; Meyerhoff, Dieter J.] Northern Calif Inst Res & Educ, Dept Radiol, San Francisco, CA USA. [Schmidt, Thomas P.; Pennington, David L.; Cardoos, Stephanie L.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Pennington, David L.; Cardoos, Stephanie L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Durazzo, Timothy C.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Durazzo, Timothy C.] Vet Affairs Palo Alto Hlth Care Syst, Dept Psychiat, Palo Alto, CA USA. [Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Schmidt, TP (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM thomas.schmidt@ucsf.edu FU National Institutes of Health [AA10788, DA25202, DA21436] FX This work was supported by the National Institutes of Health [grant number AA10788 to D.J.M.], [grant number DA25202 to D.J.M.], [grant number DA21436 to T.C.D.], administered by the Northern California Institute for Research and Education; and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. NR 70 TC 0 Z9 0 U1 14 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1380-3395 EI 1744-411X J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD FEB PY 2017 VL 39 IS 1 BP 22 EP 34 DI 10.1080/13803395.2016.1196165 PG 13 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA EE3OH UT WOS:000389499700003 PM 27690739 ER PT J AU Auerbach, S Yaffe, K AF Auerbach, Sanford Yaffe, Kristine TI The link between sleep-disordered breathing and cognition in the elderly New opportunities? SO NEUROLOGY LA English DT Editorial Material ID POSITIVE AIRWAY PRESSURE; OLDER-ADULTS; APNEA; RISK; CPAP C1 [Auerbach, Sanford] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA. [Auerbach, Sanford] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Auerbach, Sanford] Boston Univ, Sch Med, Dept Behav Neurosci, Boston, MA 02215 USA. [Auerbach, Sanford] Boston Med Ctr, Sleep Disorders Ctr, Boston, MA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Auerbach, S (reprint author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.; Auerbach, S (reprint author), Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.; Auerbach, S (reprint author), Boston Univ, Sch Med, Dept Behav Neurosci, Boston, MA 02215 USA.; Auerbach, S (reprint author), Boston Med Ctr, Sleep Disorders Ctr, Boston, MA USA. EM sauerbac@bu.edu NR 11 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JAN 31 PY 2017 VL 88 IS 5 BP 424 EP 425 DI 10.1212/WNL.0000000000003577 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EP4HE UT WOS:000397340800006 PM 28039313 ER PT J AU Yaffe, K Freimer, D Chen, HL Asao, K Rosso, A Rubin, S Tranah, G Cummings, S Simonsick, E AF Yaffe, Kristine Freimer, Daniel Chen, Honglei Asao, Keiko Rosso, Andrea Rubin, Susan Tranah, Greg Cummings, Steve Simonsick, Eleanor TI Olfaction and risk of dementia in a biracial cohort of older adults SO NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; AFRICAN-AMERICANS; APOLIPOPROTEIN-E; RACIAL DISPARITIES; URBAN-COMMUNITY; IDENTIFICATION; ALLELE; CAUCASIANS; CONVERSION AB Objective: Prior studies indicate that olfactory function may be an early marker for cognitive impairment, but the body of evidence has been largely restricted to white populations. Methods: We studied 2,428 community-dwelling black and white older adults (baseline age 70-79 years) without dementia enrolled in the Health, Aging, and Body Composition (Health ABC) study. Olfaction was measured as odor identification (OI) with the 12-item Cross Cultural Smell Identification Test in year 3. We defined incident dementia over 12 years on the basis of hospitalization records, prescription for dementia medication, or 1.5-SD decline in race-stratified global cognition score. We assessed dementia risk associated with OI score (by tertile) using Cox proportional hazards models. All analyses were stratified by race. Results: Poorer OI in older adults without dementia was associated with increased risk of dementia. After adjustment for demographics, medical comorbidities, and lifestyle characteristics, white participants in the poor or moderate OI tertile had greater risk of dementia (adjusted hazard ratio [HR] 3.34, 95% confidence interval [CI] 2.45-4.54; and HR 1.84, 95% CI 1.33-2.54, respectively) compared to those in the good tertile of function. Among blacks, worse OI was associated with an increased risk of dementia, but the magnitude of the effect was weaker (p for interaction 5 0.04) for the poor OI tertile (adjusted HR 2.03, 95% CI 1.44-2.84) and for the moderate tertile (adjusted HR 1.42, 95% CI 0.97-2.10). There was no interaction between OI and APOE e4 and risk of dementia. Conclusions: While the magnitude of the association was stronger in whites, we found that poor OI was associated with increased risk of dementia among both black and white older adults. C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine; Rubin, Susan] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Yaffe, Kristine; Freimer, Daniel] NCIRE Vet Hlth Res Inst, San Francisco, CA 94121 USA. [Chen, Honglei] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. [Asao, Keiko] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Rosso, Andrea] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Tranah, Greg; Cummings, Steve] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Simonsick, Eleanor] NIA, Translat Gerontol Branch, Baltimore, MD 21224 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.; Yaffe, K (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Yaffe, K (reprint author), NCIRE Vet Hlth Res Inst, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu OI Chen, Honglei/0000-0003-3446-7779 FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, K24-AG031155]; National Institute of Nursing Research [R01-NR012459]; Intramural Research Program of the NIH, the National Institute of Environmental Health Sciences [Z01-ES101986] FX This research was supported by National Institute on Aging contracts N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, and K24-AG031155; and National Institute of Nursing Research grant R01-NR012459. The study was supported in part by the Intramural Research Program of the NIH, the National Institute of Environmental Health Sciences (Z01-ES101986). NR 46 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JAN 31 PY 2017 VL 88 IS 5 BP 456 EP 462 DI 10.1212/WNL.0000000000003558 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EP4HE UT WOS:000397340800011 PM 28039314 ER PT J AU Dizon, MP Linos, E Arron, ST Hills, NK Chren, MM AF Dizon, Matthew P. Linos, Eleni Arron, Sarah T. Hills, Nancy K. Chren, Mary-Margaret TI Comparing the Quality of Ambulatory Surgical Care for Skin Cancer in a Veterans Affairs Clinic and a Fee-For-Service Practice Using Clinical and Patient-Reported Measures SO PLOS ONE LA English DT Article ID SQUAMOUS-CELL CARCINOMA; MEDICAL-CARE; OF-LIFE; SUNLIGHT EXPOSURE; HEALTH-CARE; RISK; SATISFACTION; PERFORMANCE AB The Institute of Medicine has identified serious deficiencies in the measurement of cancer care quality, including the effects on quality of life and patient experience. Moreover, comparisons of quality in Veterans Affairs Medical Centers (VA) and other sites are timely now that many Veterans can choose where to seek care. To compare quality of ambulatory surgical care for keratinocyte carcinoma (KC) between a VA and fee-for-service (FFS) practice, we used unique clinical and patient-reported data from a comparative effectiveness study. Patients were enrolled in 1999-2000 and followed for a median of 7.2 years. The practices differed in a few process measures (e. g., median time between biopsy and treatment was 7.5 days longer at VA) but there were no substantial or consistent differences in clinical outcomes or a broad range of patient-reported outcomes. For example, 5-year tumor recurrence rates were equally low (3.6% [2.3-5.5] at VA and 3.4% [2.3-5.1] at FFS), and similar proportions of patients reported overall satisfaction at one year (78% at VA and 80% at FFS, P = 0.69). These results suggest that the quality of care for KC can be compared comprehensively in different health care systems, and suggest that quality of care for KC was similar at a VA and FFS setting. C1 [Dizon, Matthew P.; Linos, Eleni; Arron, Sarah T.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, Program Clin Res, San Francisco, CA 94143 USA. [Arron, Sarah T.; Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hills, Nancy K.] Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA. RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, Program Clin Res, San Francisco, CA 94143 USA.; Chren, MM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM chrenm@ucsf.edu OI Dizon, Matthew/0000-0001-6747-5973 FU University of California, San Francisco Resource Allocation Program for Trainees (RAPtr); University of California, San Francisco Resource Allocation Program (RAP); National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health [R01 AR054983, K24 AR052667] FX This study was supported in part by the University of California, San Francisco Resource Allocation Program for Trainees (RAPtr), University of California, San Francisco Resource Allocation Program (RAP), and grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (http://www.niams.nih.gov/), National Institutes of Health (R01 AR054983 and K24 AR052667). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 31 PY 2017 VL 12 IS 1 AR e0171253 DI 10.1371/journal.pone.0171253 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN6QW UT WOS:000396129500054 PM 28141817 ER PT J AU Bracamonte-Baran, W Florentin, J Zhou, Y Jankowska-Gan, E Haynes, WJ Zhong, WX Brennan, TV Dutta, P Claas, FHJ van Rood, JJ Burlingham, WJ AF Bracamonte-Baran, William Florentin, Jonathan Zhou, Ying Jankowska-Gan, Ewa Haynes, W. John Zhong, Weixiong Brennan, Todd V. Dutta, Partha Claas, Frans H. J. van Rood, Jon J. Burlingham, William J. TI Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE dendritic cells; exosomes; split tolerance; T cells; microchimerism ID MATERNAL HLA ANTIGENS; RHEUMATOID-ARTHRITIS; CORD BLOOD; INDUCTION; PATHWAY; MICE; TRANSPLANTATION; SENSITIZATION; MICROCLUSTERS; ALLOANTIGEN AB Maternal microchimerism (MMc) has been associated with development of allospecific transplant tolerance, antitumor immunity, and cross-generational reproductive fitness, but its mode of action is unknown. We found in a murine model that MMc caused exposure to the noninherited maternal antigens in all offspring, but in some, MMc magnitude was enough to cause membrane alloantigen acquisition (mAAQ; "cross-dressing") of host dendritic cells (DCs). Extracellular vesicle (EV)-enriched serum fractions from mAAQ(+), but not from non-mAAQ, mice reproduced the DC cross-dressing phenomenon in vitro. In vivo, mAAQ was associated with increased expression of immune modulators PD-L1 (programmed death-ligand 1) and CD86 by myeloid DCs (mDCs) and decreased presentation of allopeptide+self-MHC complexes, along with increased PD-L1, on plasmacytoid DCs (pDCs). Remarkably, both serum EV-enriched fractions and membrane microdomains containing the acquired MHC alloantigens included CD86, but completely excluded PD-L1. In contrast, EV-enriched fractions and microdomains containing allopeptide+self-MHC did not exclude PD-L1. Adoptive transfer of allospecific transgenic CD4 T cells revealed a "split tolerance" status in mAAQ+ mice: T cells recognizing intact acquired MHC alloantigens proliferated, whereas those responding to allopeptide+self-MHC did not. Using isolated pDCs and mDCs for in vitro culture with allopeptide+self-MHC-specific CD4 T cells, we could replicate their normal activation in non-mAAQ mice, and PD-L1-dependent anergy in mAAQ(+) hosts. We propose that EVs provide a physiologic link between microchimerism and split tolerance, with implications for tumor immunity, transplantation, autoimmunity, and reproductive success. C1 [Bracamonte-Baran, William; Florentin, Jonathan; Zhou, Ying; Jankowska-Gan, Ewa; Haynes, W. John; Burlingham, William J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Transplantat, Madison, WI 53792 USA. [Florentin, Jonathan; Dutta, Partha] Univ Pittsburgh, Med Ctr, Vasc Med Inst, Pittsburgh, PA 15213 USA. [Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Serv, Madison, WI 53705 USA. [Brennan, Todd V.] Duke Univ, Med Ctr, Dept Surg, Div Abdominal Transplantat, Durham, NC 27710 USA. [Claas, Frans H. J.; van Rood, Jon J.] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands. RP Burlingham, WJ (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Transplantat, Madison, WI 53792 USA.; van Rood, JJ (reprint author), Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands. EM Jon.vanRood@matchis.nl; burlingham@surgery.wisc.edu FU UW Carbone Cancer Center Flow Laboratory (University of Wisconsin Carbone Cancer Center Support Grant) [P30 CA014520]; NIH Grant [2R01-AI066219] FX We thank the WilliamS. Middleton Memorial Veterans Hospital Electron Microscopy Facility for EM assistance; Drs. Gilles Benichou, Jeremy Sullivan, and Dixon Kaufman for helpful suggestions on the manuscript; Dr. Luis Queiroz, Dr. John Verstegen (MOFA-Madison), and the personnel of the UW Carbone Cancer Center Flow Laboratory (University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520) for the technical support on flow cytometry and ImageStream experiments; and Dr. Douglas McNeel for providing the anti-PD-L1 antibody. This project was supported by NIH Grant 2R01-AI066219 (to W.J.B.). NR 38 TC 0 Z9 0 U1 5 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JAN 31 PY 2017 VL 114 IS 5 BP 1099 EP 1104 DI 10.1073/pnas.1618364114 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EJ4OI UT WOS:000393196300086 PM 28096390 ER PT J AU Singh, JA Dohm, M Choong, PF AF Singh, Jasvinder A. Dohm, Michael Choong, Peter F. TI Consensus on draft OMERACT core domains for clinical trials of Total Joint Replacement outcome by orthopaedic surgeons: a report from the International consensus on outcome measures in TJR trials (I-COMiTT) group SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE OMERACT; Core domain; Clinical trails; Total Joint Arthroplasty; TJR ID KNEE ARTHROPLASTY; MEASUREMENT SETS; FILTER 2.0; HIP AB Background: There are no core outcome domain or measurement sets for Total Joint Replacement (TJR) clinical trials. Our objective was to achieve an International consensus by orthopaedic surgeons on the OMERACT core domain/area set for TJR clinical trials. Methods: We conducted surveys of two orthopaedic surgeon cohorts, which included (1) the leadership of international orthopaedic societies and surgeons (IOS; cohort 1), and (2) the members of the American Academy of Orthopaedic Surgeons' Outcome Special Interest Group (AAOS-Outcome SIG), and/or the Outcome Research Interest Group of the Orthopaedic Research Society (ORS; cohort 2). Participants rated OMERACT-endorsed preliminary core area set for TJR clinical trials on a 1 to 9 scale, indicating 1-3 as domain of limited importance, 4-6 being important, but not critical, and 7-9 being critical. Results: Eighteen survey participants from the IOS group and 69 participants from the AAOS-Outcome SIG/ORS groups completed the survey questionnaire. The median (interquartile range [IQR]) scores were seven or higher for all six proposed preliminary core areas/domains across both groups, IOS and AAOS-Outcome SIG/ORS, respectively: pain, 8 [8, 9] and 8 [7, 9]; function, 8 [8, 8] and 8 [7, 9]; patient satisfaction, 8 [7, 9] and 8 [7, 8]; revision surgery, 7 [6, 9] and 8 [6, 8]; adverse events, 7 [5, 8] and 7 [6, 9]; and death, 7 [7, 9] and 8 [5, 9]. Respective median scores were lower for two additional optional domains: patient participation, 6.5 [5, 7] and 6 [5, 8]; and cost, 6 [5, 7] and 6 [5, 7]. Conclusions: This study showed that two independent surveys dervied from three groups of orthopaedic surgeons with international representation endorsed a preliminary/draft OMERACT core domain/area set for Joint Replacement clinical trials. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Dohm, Michael] Univ Arizona, Dept Orthopaed Surg, Tucson, AZ USA. [Choong, Peter F.] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia. [Choong, Peter F.] St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia. RP Singh, JA (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. EM jasvinder.md@gmail.com NR 11 TC 1 Z9 1 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD JAN 26 PY 2017 VL 18 AR 45 DI 10.1186/s12891-017-1409-4 PG 8 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA EM3DN UT WOS:000395194800003 PM 28125985 ER PT J AU Patel, B Ismahil, MA Hamid, T Bansal, SS Prabhu, SD AF Patel, Bindiya Ismahil, Mohamed Ameen Hamid, Tariq Bansal, Shyam S. Prabhu, Sumanth D. TI Mononuclear Phagocytes Are Dispensable for Cardiac Remodeling in Established Pressure-Overload Heart Failure SO PLOS ONE LA English DT Article ID DENDRITIC CELLS; MYOCARDIAL-INFARCTION; GENE-EXPRESSION; STEADY-STATE; MACROPHAGES; INFLAMMATION; MONOCYTES; MICE; CARDIOMYOPATHY; IDENTIFICATION AB Background Although cardiac and splenic mononuclear phagocytes (MPs), i.e., monocytes, macrophages and dendritic cells (DCs), are key contributors to cardiac remodeling after myocardial infarction, their role in pressure-overload remodeling is unclear. We tested the hypothesis that these immune cells are required for the progression of remodeling in pressure-overload heart failure (HF), and that MP depletion would ameliorate remodeling. Methods and Results C57BL/6 mice were subjected to transverse aortic constriction (TAC) or sham operation, and assessed for alterations in MPs. As compared with sham, TAC mice exhibited expansion of circulating LyC6(hi) monocytes and pro-inflammatory CD206(-) cardiac macrophages early (1 w) after pressure-overload, prior to significant hypertrophy and systolic dysfunction, with subsequent resolution during chronic HF. In contrast, classical DCs were expanded in the heart in a biphasic manner, with peaks both early, analogous to macrophages, and late (8 w), during established HF. There was no significant expansion of circulating DCs, or Ly6C(+) monocytes and DCs in the spleen. Periodic systemic MP depletion from 2 to 16 w after TAC in macrophage Fas-induced apoptosis (MaFIA) transgenic mice did not alter cardiac remodeling progression, nor did splenectomy in mice with established HF after TAC. Lastly, adoptive transfer of splenocytes from TAC HF mice into naive recipients did not induce immediate or long-term cardiac dysfunction in recipient mice. Conclusions Mononuclear phagocytes populations expand in a phasic manner in the heart during pressure-overload. However, they are dispensable for the progression of remodeling and failure once significant hypertrophy is evident and blood monocytosis has normalized. C1 [Patel, Bindiya; Ismahil, Mohamed Ameen; Hamid, Tariq; Bansal, Shyam S.; Prabhu, Sumanth D.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Patel, Bindiya; Ismahil, Mohamed Ameen; Hamid, Tariq; Bansal, Shyam S.; Prabhu, Sumanth D.] Univ Alabama Birmingham, Comprehens Cardiovasc Ctr, Birmingham, AL 35233 USA. [Prabhu, Sumanth D.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. RP Prabhu, SD (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA.; Prabhu, SD (reprint author), Univ Alabama Birmingham, Comprehens Cardiovasc Ctr, Birmingham, AL 35233 USA.; Prabhu, SD (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. EM sprabhu@uab.edu FU National Institutes of Health [1R01HL125735]; VA Merit Award [I01BX002706] FX This work was supported by National Institutes of Health grant 1R01HL125735 and a VA Merit Award I01BX002706 (both to SDP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 26 PY 2017 VL 12 IS 1 AR e0170781 DI 10.1371/journal.pone.0170781 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN7IT UT WOS:000396176100052 PM 28125666 ER PT J AU Szema, AM Forsyth, E Ying, B Hamidi, SA Chen, JJ Hwang, S Li, JC Dwyer, DS Ramiro-Diaz, JM Giermakowska, W Bosc, LVG AF Szema, Anthony M. Forsyth, Edward Ying, Benjamin Hamidi, Sayyed A. Chen, John J. Hwang, Sonya Li, Jonathan C. Dwyer, Debra Sabatini Ramiro-Diaz, Juan M. Giermakowska, Wieslawa Bosc, Laura V. Gonzalez TI NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease SO PLOS ONE LA English DT Article ID VASOACTIVE-INTESTINAL-PEPTIDE; ACTIVATED T-CELLS; CHRONIC HYPOXIA; ARTERIAL-HYPERTENSION; NUCLEAR FACTOR; SMOOTH-MUSCLE; UP-REGULATION; COPD; ANGIOGENESIS; INHIBITION AB Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are both debilitating lung diseases which can lead to hypoxemia and pulmonary hypertension (PH). Nuclear Factor of Activated T-cells (NFAT) is a transcription factor implicated in the etiology of vascular remodeling in hypoxic PH. We have previously shown that mice lacking the ability to generate Vasoactive Intestinal Peptide (VIP) develop spontaneous PH, pulmonary arterial remodeling and lung inflammation. Inhibition of NFAT attenuated PH in these mice suggesting a connection between NFAT and VIP. To test the hypotheses that: 1) VIP inhibits NFAT isoform c3 (NFATc3) activity in pulmonary vascular smooth muscle cells; 2) lung NFATc3 activation is associated with disease severity in IPF and COPD patients, and 3) VIP and NFATc3 expression correlate in lung tissue from IPF and COPD patients. NFAT activity was determined in isolated pulmonary arteries from NFAT-luciferase reporter mice. The% of nuclei with NFAT nuclear accumulation was determined in primary human pulmonary artery smooth muscle cell (PASMC) cultures; in lung airway epithelia and smooth muscle and pulmonary endothelia and smooth muscle from IPF and COPD patients; and in PASMC from mouse lung sections by fluorescence microscopy. Both NFAT and VIP mRNA levels were measured in lungs from IPF and COPD patients. Empirical strategies applied to test hypotheses regarding VIP, NFATc3 expression and activity, and disease type and severity. This study shows a significant negative correlation between NFAT isoform c3 protein expression levels in PASMC, activity of NFATc3 in pulmonary endothelial cells,expression and activity of NFATc3 in bronchial epithelial cells and lung function in IPF patients, supporting the concept that NFATc3 is activated in the early stages of IPF. We further show that there is a significant positive correlation between NFATc3 mRNA expression and VIP RNA expression only in lungs from IPF patients. In addition, we found that VIP inhibits NFAT nuclear translocation in primary human pulmonary artery smooth muscle cells (PASMC). Early activation of NFATc3 in IPF patients may contribute to disease progression and the increase in VIP expression could be a protective compensatory mechanism. C1 [Szema, Anthony M.; Dwyer, Debra Sabatini] SUNY Stony Brook, Coll Engn & Appl Sci, Dept Technol & Soc, Stony Brook, NY 11794 USA. [Szema, Anthony M.] John T Mather Mem Hosp, Stony Brook Med SUNY, Stony Brook Internal Med Residency Program, Port Jefferson, NY USA. [Szema, Anthony M.] Hofstra Univ, Dept Occupat Med Epidemiol & Prevent Med, Hofstra Northwell Sch Med, Hempstead, NY 11550 USA. [Szema, Anthony M.] Hofstra Univ, Dept Occupat Med Epidemiol & Prevent Med, Hofstra Northwell Sch Med, Manhasset, NY USA. [Szema, Anthony M.; Li, Jonathan C.] Three Village Allergy & Asthma PLLC, South Setauket, NY USA. [Szema, Anthony M.] Columbia Univ, Child Psychiat Epidemiol Grp, New York, NY USA. [Forsyth, Edward; Ying, Benjamin] SUNY Stony Brook, Sch Med, MD Scholarly Recognit Program, Stony Brook, NY 11794 USA. [Hamidi, Sayyed A.] Bronx Vet Affairs Med Ctr, Internal Med Residency Program, Dept Internal Med, Bronx, NY USA. [Chen, John J.] Univ Hawaii, Biostat & Data Management Core, John A Burns Sch Med, Honolulu, HI 96822 USA. [Hwang, Sonya] SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA. [Ramiro-Diaz, Juan M.; Giermakowska, Wieslawa; Bosc, Laura V. Gonzalez] Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA. RP Bosc, LVG (reprint author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA. EM lgonzalezbosc@salud.unm.edu FU NIH Lung Tissue Research Consortium (LTRC) [08-99-0002]; NIH [R01 HL088151-05]; Three Village Allergy Asthma, PLLC FX NIH Lung Tissue Research Consortium (LTRC) concept sheet number 08-99-0002. "Gene deficiency of Vasoactive Intestinal Peptide in COPD patients with pulmonary artery hypertension" to Anthony Szema, M.D (PI). NIH R01 HL088151-05 "NFATc3 in Chronic Pulmonary Hypertension" to Laura Gonzalez Bosc, Ph.D (PI). Three Village Allergy & Asthma, PLLC provided support in the form of salaries only for A.M.S., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section. NR 39 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 26 PY 2017 VL 12 IS 1 AR e0170606 DI 10.1371/journal.pone.0170606 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN7IT UT WOS:000396176100088 PM 28125639 ER PT J AU Surolia, R Li, FJ Wang, Z Li, HS Liu, G Zhou, Y Luckhardt, T Bae, S Liu, RM Rangarajan, S de Andrade, J Thannickal, VJ Antony, VB AF Surolia, Ranu Li, Fu Jun Wang, Zheng Li, Huashi Liu, Gang Zhou, Yong Luckhardt, Tracy Bae, Sejong Liu, Rui-ming Rangarajan, Sunad de Andrade, Joao Thannickal, Victor J. Antony, Veena B. TI 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs SO JCI INSIGHT LA English DT Article ID IDIOPATHIC PULMONARY-FIBROSIS; INVASIVE FIBROBLAST PHENOTYPE; FORCED VITAL CAPACITY; MODERATE IMPAIRMENT; LUNG FIBROBLASTS; PIRFENIDONE; NINTEDANIB; MYOFIBROBLASTS; INHIBITION; CRYOBIOPSY AB Idiopathic pulmonary fibrosis (IPF) is a fatal progressive fibrotic lung disease characterized by the presence of invasive myofibroblasts in the lung. Currently, there are only two FDA-approved drugs (pirfenidone and nintedanib) for the treatment of IPF. There are no defined criteria to guide specific drug therapy. New methodologies are needed not only to predict personalized drug therapy, but also to screen novel molecules that are on the horizon for treatment of IPF. We have developed a model system that exploits the invasive phenotype of IPF lung tissue. This ex vivo 3D model uses lung tissue from patients to develop pulmospheres. Pulmospheres are 3D spheroids composed of cells derived exclusively from primary lung biopsies and inclusive of lung cell types reflective of those in situ, in the patient. We tested the pulmospheres of 20 subjects with IPF and 9 control subjects to evaluate the responsiveness of individual patients to antifibrotic drugs. Clinical parameters and outcomes were also followed in the same patients. Our results suggest that pulmospheres simulate the microenvironment in the lung and serve as a personalized and predictive model for assessing responsiveness to antifibrotic drugs in patients with IPF. C1 [Surolia, Ranu; Li, Fu Jun; Wang, Zheng; Li, Huashi; Liu, Gang; Zhou, Yong; Luckhardt, Tracy; Liu, Rui-ming; Rangarajan, Sunad; de Andrade, Joao; Thannickal, Victor J.; Antony, Veena B.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Bae, Sejong] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [de Andrade, Joao; Thannickal, Victor J.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Antony, VB (reprint author), 1530 3rd Ave So,THT 422, Birmingham, AL 35294 USA. EM vantony@uabmc.edu FU NIH [P01 HL114470] FX This work was supported by NIH grant P01 HL114470 (to VJT and VBA). NR 42 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA SN 2379-3708 J9 JCI INSIGHT JI JCI Insight PD JAN 26 PY 2017 VL 2 IS 2 AR e91377 DI 10.1172/jci.insight.91377 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EK0BT UT WOS:000393592200015 PM 28138565 ER PT J AU Chatterton, Z Hartley, BJ Seok, MH Mendelev, N Chen, S Milekic, M Rosoklija, G Stankov, A Trencevsja-Ivanovska, I Brennand, K Ge, YC Dwork, AJ Haghighi, F AF Chatterton, Zac Hartley, Brigham J. Seok, Man-Ho Mendelev, Natalia Chen, Sean Milekic, Maria Rosoklija, Gorazd Stankov, Aleksandar Trencevsja-Ivanovska, Iskra Brennand, Kristen Ge, Yongchao Dwork, Andrew J. Haghighi, Fatemeh TI In utero exposure to maternal smoking is associated with DNA methylation alterations and reduced neuronal content in the developing fetal brain SO EPIGENETICS & CHROMATIN LA English DT Article DE Brain; DNA methylation; Epigenetics; Fetal; Neuron; Nicotine; Neurodevelopment; Prenatal; Smoking; Tobacco ID NICOTINE EXPOSURE; OXIDATIVE STRESS; SUCCINATE-DEHYDROGENASE; PROMOTER METHYLATION; INDUSTRIAL-CHEMICALS; PRENATAL EXPOSURE; PREGNANCY; SCHIZOPHRENIA; CHILDREN; TISSUE AB Background: Intrauterine exposure to maternal smoking is linked to impaired executive function and behavioral problems in the offspring. Maternal smoking is associated with reduced fetal brain growth and smaller volume of cortical gray matter in childhood, indicating that prenatal exposure to tobacco may impact cortical development and manifest as behavioral problems. Cellular development is mediated by changes in epigenetic modifications such as DNA methylation, which can be affected by exposure to tobacco. Results: In this study, we sought to ascertain how maternal smoking during pregnancy affects global DNA methylation profiles of the developing dorsolateral prefrontal cortex (DLPFC) during the second trimester of gestation. When DLPFC methylation profiles (assayed via Illumina, HM450) of smoking-exposed and unexposed fetuses were compared, no differentially methylated regions (DMRs) passed the false discovery correction (FDR = 0.05). However, the most significant DMRs were hypomethylated CpG Islands within the promoter regions of GNA15 and SDHAP3 of smoking-exposed fetuses. Interestingly, the developmental up-regulation of SDHAP3 mRNA was delayed in smoking-exposed fetuses. Interaction analysis between gestational age and smoking exposure identified significant DMRs annotated to SYCE3, C21orf56/LSS, SPAG1 and RNU12/POLDIP3 that passed FDR. Furthermore, utilizing established methods to estimate cell proportions by DNA methylation, we found that exposed DLPFC samples contained a lower proportion of neurons in samples from fetuses exposed to maternal smoking. We also show through in vitro experiments that nicotine impedes the differentiation of neurons independent of cell death. Conclusions: We found evidence that intrauterine smoking exposure alters the developmental patterning of DNA methylation and gene expression and is associated with reduced mature neuronal content, effects that are likely driven by nicotine. C1 [Chatterton, Zac; Hartley, Brigham J.; Seok, Man-Ho; Mendelev, Natalia; Chen, Sean; Brennand, Kristen; Haghighi, Fatemeh] Icahn Sch Med Mt Sinai, Friedman Brain Inst, 1425 Madison Ave, New York, NY 10029 USA. [Chatterton, Zac; Hartley, Brigham J.; Seok, Man-Ho; Mendelev, Natalia; Chen, Sean; Brennand, Kristen; Haghighi, Fatemeh] Icahn Sch Med Mt Sinai, Dept Neurosci, 1425 Madison Ave,Floor 10,Room 10-70D, New York, NY 10029 USA. [Hartley, Brigham J.; Seok, Man-Ho; Brennand, Kristen] Icahn Sch Med Mt Sinai, Dept Psychiat, 1425 Madison Ave, New York, NY 10029 USA. [Ge, Yongchao] Icahn Sch Med Mt Sinai, Dept Neurol, 1425 Madison Ave, New York, NY 10029 USA. [Milekic, Maria; Rosoklija, Gorazd; Dwork, Andrew J.] Columbia Univ, Dept Psychiat, New York, NY 10032 USA. [Dwork, Andrew J.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA. [Chatterton, Zac; Mendelev, Natalia; Chen, Sean; Haghighi, Fatemeh] James J Peters VA Med Ctr, Med Epigenet, Bronx, NY 10468 USA. [Rosoklija, Gorazd; Dwork, Andrew J.] Macedonian Acad Sci & Arts, Skopje, Macedonia. [Rosoklija, Gorazd; Stankov, Aleksandar] Sch Med, Skopje, Macedonia. [Trencevsja-Ivanovska, Iskra] Psychiat Hosp Skopje, Skopje, Macedonia. RP Haghighi, F (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosci, 1425 Madison Ave,Floor 10,Room 10-70D, New York, NY 10029 USA. EM fatemeh.haghighi@mssm.edu FU National Institute of Health (NIH) [R01MH094774]; NIDA T32 training grant in Drug Abuse Research from the NIH, USA; Brain and Behavior Research Foundation; NIH [R01 MH101454, R01 MH106056]; New York Stem Cell Foundation; Office of Research Infrastructure of the National Institutes of Health [S10OD018522] FX The Haghighi Laboratory is supported by the National Institute of Health (NIH) Grant R01MH094774. ZC is supported by a NIDA T32 training grant in Drug Abuse Research from the NIH, USA. Kristen J. Brennand is a New York Stem Cell Foundation-Robertson Investigator. The Brennand Laboratory is supported by the Brain and Behavior Research Foundation, NIH Grants R01 MH101454 and R01 MH106056, and the New York Stem Cell Foundation. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD018522. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 78 TC 0 Z9 0 U1 16 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-8935 J9 EPIGENET CHROMATIN JI Epigenetics Chromatin PD JAN 26 PY 2017 VL 10 AR 4 DI 10.1186/s13072-017-0111-y PG 11 WC Genetics & Heredity SC Genetics & Heredity GA EI7HV UT WOS:000392669300001 PM 28149327 ER PT J AU Triplette, M Attia, EF Akgun, KM Hoo, GWS Freiberg, MS Butt, AA Wongtrakool, C Goetz, MB Brown, ST Graber, CJ Huang, L Crothers, K AF Triplette, Matthew Attia, Engi F. Akgun, Kathleen M. Hoo, Guy W. Soo Freiberg, Matthew S. Butt, Adeel A. Wongtrakool, Cherry Goetz, Matthew Bidwell Brown, Sheldon T. Graber, Christopher J. Huang, Laurence Crothers, Kristina TI A Low Peripheral Blood CD4/CD8 Ratio Is Associated with Pulmonary Emphysema in HIV SO PLOS ONE LA English DT Article ID SPIROMETRY REFERENCE VALUES; OBSTRUCTIVE LUNG-DISEASES; T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY; DIFFUSING-CAPACITY; IMMUNOLOGICAL RECOVERY; LYMPHOCYTE SUBSETS; INFECTED PATIENTS; CD4CD8 RATIO; ADULTS AB Objectives The prevalence of emphysema is higher among HIV-infected (HIV+) individuals compared to HIV-uninfected persons. While greater tobacco use contributes, HIV-related effects on immunity likely confer additional risk. Low peripheral blood CD4+ to CD8+ T-lymphocyte (CD4/CD8) ratio may reflect chronic inflammation in HIV and may be a marker of chronic lung disease in this population. Therefore, we sought to determine whether the CD4/CD8 ratio was associated with chronic obstructive pulmonary disease (COPD), particularly the emphysema subtype, in a cohort of HIV+ subjects. Methods We performed a cross-sectional analysis of 190 HIV+ subjects enrolled in the Examinations of HIV Associated Lung Emphysema (EXHALE) study. Subjects underwent baseline laboratory assessments, pulmonary function testing and chest computed tomography (CT) analyzed for emphysema severity and distribution. We determined the association between CD4/CD8 ratio and emphysema, and the association between CD4/CD8 ratio and pulmonary function markers of COPD. Results Mild or greater emphysema (> 10% lung involvement) was present in 31% of subjects. Low CD4/CD8 ratio was associated with > 10% emphysema in multivariable models, adjusting for risk factors including smoking, current and nadir CD4 count and HIV RNA level. Those with CD4/CD8 ratio < 0.4 had 6.3 (1.1-39) times the odds of > 10% emphysema compared to those with a ratio > 1.0 in fully adjusted models. A low CD4/CD8 ratio was also associated with reduced diffusion capacity (DLCO). Conclusions A low CD4/CD8 ratio was associated with emphysema and low DLCO in HIV+ subjects, independent of other risk factors and clinical markers of HIV. The CD4/CD8 ratio may be a useful, clinically available, marker for risk of emphysema in HIV+ subjects in the antiretroviral therapy (ART) era. C1 [Triplette, Matthew; Attia, Engi F.; Crothers, Kristina] Univ Washington, Dept Med, Seattle, WA 98105 USA. [Akgun, Kathleen M.] Vet Affairs Connecticut Healthcare Syst, Dept Med, New Haven, CT USA. [Akgun, Kathleen M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Hoo, Guy W. Soo; Goetz, Matthew Bidwell; Graber, Christopher J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Hoo, Guy W. Soo; Goetz, Matthew Bidwell; Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Freiberg, Matthew S.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Butt, Adeel A.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Butt, Adeel A.] Hamad Healthcare Qual Inst & Med Corp, Doha, Qatar. [Wongtrakool, Cherry] Atlanta Vet Affairs Med Ctr, Dept Med, Atlanta, GA USA. [Wongtrakool, Cherry] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Dept Med, New York, NY USA. [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Huang, Laurence] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Triplette, M (reprint author), Univ Washington, Dept Med, Seattle, WA 98105 USA. EM mtrip@uw.edu FU National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) [R01 HL090342, 5R01HL126536, T32 HL007287-37, K24 HL087713]; National Institute on Alcohol Abuse and Alcoholism at NIH [U01 AA013566] FX This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) [R01 HL090342 and 5R01HL126536 to Dr. Crothers, T32 HL007287-37 supporting Dr. Triplette under Drs. Robb Glenny and J. Randall Curtis, K24 HL087713 to Dr. Huang] and the National Institute on Alcohol Abuse and Alcoholism at NIH [U01 AA013566]. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 25 PY 2017 VL 12 IS 1 AR e0170857 DI 10.1371/journal.pone.0170857 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN7FK UT WOS:000396167300008 PM 28122034 ER PT J AU Feng, S Shao, LJ Castro, P Coleman, I Nelson, PS Smith, PD Davies, BR Ittmann, M AF Feng, Shu Shao, Longjiang Castro, Patricia Coleman, Ilsa Nelson, Peter S. Smith, Paul D. Davies, Barry R. Ittmann, Michael TI Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors SO ONCOTARGET LA English DT Article DE prostate cancer; signal transduction; fibroblast growth factors; kinase inhibitor; AKT ID LUNG-CANCER; PI3K/AKT PATHWAY; GROWTH; PROGRESSION; EXPRESSION; PTEN; AZD5363; SENSITIVITY; PREDICT; MODELS AB Activation of the PI3K/AKT pathway occurs in the vast majority of advanced prostate cancers (PCas). Activation of fibroblast growth factor receptor (FGFR) signaling occurs in a wide variety of malignancies, including PCa. RNA-Seq of castration resistant PCa revealed expression of multiple FGFR signaling components compatible with FGFR signaling in all cases, with multiple FGF ligands expressed in 90% of cases. Immunohistochemistry confirmed FGFR signaling in the majority of xenografts and advanced PCas. AZD5363, an AKT kinase inhibitor and AZD4547, a FGFR kinase inhibitor are under active clinical development. We therefore sought to determine if these two drugs have additive effects in PCa models. The effect of both agents, singly and in combination was evaluated in a variety of PCa cell lines in vitro and in vivo. All cell lines tested responded to both drugs with decreased invasion, soft agar colony formation and growth in vivo, with additive effects seen with combination treatment. Activation of the FGFR, AKT, ERK and STAT3 pathways was examined in treated cells. AZD5363 inhibited AKT signaling and increased FGFR1 signaling, which partially compensated for decreased AKT kinase activity. While AZD4547 could effectively block the ERK pathway, combination treatment was needed to completely block STAT3 activation. Thus combination treatment with AKT and FGFR kinase inhibitors have additive effects on malignant phenotypes in vitro and in vivo by inhibiting multiple signaling pathways and mitigating the compensatory upregulation of FGFR signaling induced by AKT kinase inhibition. Our studies suggest that co-targeting these pathways may be efficacious in advanced PCa. C1 [Feng, Shu; Shao, Longjiang; Castro, Patricia; Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Feng, Shu; Shao, Longjiang; Castro, Patricia; Ittmann, Michael] Baylor Coll Med, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. [Coleman, Ilsa; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA. [Smith, Paul D.; Davies, Barry R.] AstraZeneca, Oncol iMED, Macclesfield, Cheshire, England. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.; Ittmann, M (reprint author), Baylor Coll Med, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. EM mittmann@bcm.edu FU Dept of Defense Prostate Cancer Research Program [W81XWH-13-1-0367]; Prostate Cancer Foundation; Dept of Veterans Affairs Merit Review program; National Cancer Institute [P50CA097186, R01CA165573]; Dan L. Duncan Cancer [P30 CA125123] FX This work was supported by grants from the Dept of Defense Prostate Cancer Research Program (W81XWH-13-1-0367; MI); the Prostate Cancer Foundation (PSN and MI); the Dept of Veterans Affairs Merit Review program (MI); the National Cancer Institute (P50CA097186 and R01CA165573; PSN) and to the Dan L. Duncan Cancer (P30 CA125123) supporting the Human Tissue Acquisition and Pathology Shared Resource and by the use of the facilities of the Michael E. DeBakey VAMC. NR 44 TC 0 Z9 0 U1 1 U2 1 PU IMPACT JOURNALS LLC PI ORCHARD PARK PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JAN 24 PY 2017 VL 8 IS 4 BP 6179 EP 6192 DI 10.18632/oncotarget.14049 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA EJ5WG UT WOS:000393289000065 PM 28008155 ER PT J AU Ahn, R Woodbridge, A Abraham, A Saba, S Korenstein, D Madden, E Boscardin, WJ Keyhani, S AF Ahn, Rosa Woodbridge, Alexandra Abraham, Ann Saba, Susan Korenstein, Deborah Madden, Erin Boscardin, W. John Keyhani, Salomeh TI Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID CONFLICTS-OF-INTEREST; MEDICAL-JOURNAL EDITORS; CLINICAL-TRIALS; INDUSTRY SPONSORSHIP; PHARMACEUTICAL-INDUSTRY; INTERNATIONAL-COMMITTEE; DRUG TRIALS; ASSOCIATION; AUTHORS; QUALITY AB OBJECTIVE To examine the association between the presence of individual principal investigators' financial ties to the manufacturer of the study drug and the trial's outcomes after accounting for source of research funding. DESIGN Cross sectional study of randomized controlled trials (RCTs). SETTING Studies published in "core clinical" journals, as identified by Medline, between 1 January 2013 and 31 December 2013. PARTICIPANTS Random sample of RCTs focused on drug efficacy. MAIN OUTCOME MEASURE Association between financial ties of principal investigators and study outcome. RESULTS A total of 190 papers describing 195 studies met inclusion criteria. Financial ties between principal investigators and the pharmaceutical industry were present in 132 (67.7%) studies. Of 397 principal investigators, 231 (58%) had financial ties and 166 (42%) did not. Of all principal investigators, 156 (39%) reported advisor/consultancy payments, 81 (20%) reported speakers' fees, 81 (20%) reported unspecified financial ties, 52 (13%) reported honorariums, 52 (13%) reported employee relationships, 52 (13%) reported travel fees, 41 (10%) reported stock ownership, and 20 (5%) reported having a patent related to the study drug. The prevalence of financial ties of principal investigators was 76% (103/136) among positive studies and 49% (29/59) among negative studies. In unadjusted analyses, the presence of a financial tie was associated with a positive study outcome (odds ratio 3.23, 95% confidence interval 1.7 to 6.1). In the primary multivariate analysis, a financial tie was significantly associated with positive RCT outcome after adjustment for the study funding source (odds ratio 3.57 (1.7 to 7.7). The secondary analysis controlled for additional RCT characteristics such as study phase, sample size, country of first authors, specialty, trial registration, study design, type of analysis, comparator, and outcome measure. These characteristics did not appreciably affect the relation between financial ties and study outcomes (odds ratio 3.37, 1.4 to 7.9). CONCLUSIONS Financial ties of principal investigators were independently associated with positive clinical trial results. These findings may be suggestive of bias in the evidence base. C1 [Ahn, Rosa] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Woodbridge, Alexandra; Abraham, Ann; Madden, Erin; Boscardin, W. John; Keyhani, Salomeh] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Saba, Susan] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Korenstein, Deborah] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Boscardin, W. John; Keyhani, Salomeh] Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Keyhani, S (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Keyhani, S (reprint author), Univ Calif San Francisco, San Francisco, CA 94121 USA. EM salomeh.keyhani@ucsf.edu FU National Institutes of Health [RO1 HL116522-01A1, RO1 HL114563-01A1]; Veterans Affairs Health Services Research and Development Service [1IP1HX001994]; National Cancer Institute [P30 CA008748] FX This project was not directly supported by any research funds. SK is funded by grants from the National Institutes of Health (RO1 HL116522-01A1, RO1 HL114563-01A1) and Veterans Affairs Health Services Research and Development Service (1IP1HX001994). DK's work on this paper was supported by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (award number P30 CA008748). NR 51 TC 3 Z9 3 U1 4 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD JAN 17 PY 2017 VL 356 AR i6770 DI 10.1136/bmj.i6770 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA EJ4CC UT WOS:000393162500004 PM 28096109 ER PT J AU Elnahal, SM Clancy, CM Shulkin, DJ AF Elnahal, Shereef M. Clancy, Carolyn M. Shulkin, David J. TI A Framework for Disseminating Clinical Best Practices in the VA Health System SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID CARE-SYSTEM C1 [Elnahal, Shereef M.; Clancy, Carolyn M.; Shulkin, David J.] US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. RP Clancy, CM (reprint author), US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM carolyn.clancy@va.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 17 PY 2017 VL 317 IS 3 BP 255 EP 256 DI 10.1001/jama.2016.18764 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EH9KC UT WOS:000392089200007 PM 28114562 ER PT J AU Mattison, JA Colman, RJ Beasley, TM Allison, DB Kemnitz, JW Roth, GS Ingram, DK Weindruch, R de Cabo, R Anderson, RM AF Mattison, Julie A. Colman, Ricki J. Beasley, T. Mark Allison, David B. Kemnitz, Joseph W. Roth, George S. Ingram, Donald K. Weindruch, Richard de Cabo, Rafael Anderson, Rozalyn M. TI Caloric restriction improves health and survival of rhesus monkeys SO NATURE COMMUNICATIONS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; MACAQUES MACACA-MULATTA; DIETARY RESTRICTION; NONHUMAN-PRIMATES; ENERGY-EXPENDITURE; DIABETES-MELLITUS; BODY-COMPOSITION; LIFE-SPAN; AGE; DISEASE AB Caloric restriction (CR) without malnutrition extends lifespan and delays the onset of age-related disorders in most species but its impact in nonhuman primates has been controversial. In the late 1980s two parallel studies were initiated to determine the effect of CR in rhesus monkeys. The University of Wisconsin study reported a significant positive impact of CR on survival, but the National Institute on Aging study detected no significant survival effect. Here we present a direct comparison of longitudinal data from both studies including survival, bodyweight, food intake, fasting glucose levels and age-related morbidity. We describe differences in study design that could contribute to differences in outcomes, and we report species specificity in the impact of CR in terms of optimal onset and diet. Taken together these data confirm that health benefits of CR are conserved in monkeys and suggest that CR mechanisms are likely translatable to human health. C1 [Mattison, Julie A.; de Cabo, Rafael] NIA, Translat Gerontol Branch, Baltimore, MD 21224 USA. [Colman, Ricki J.; Kemnitz, Joseph W.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Beasley, T. Mark; Allison, David B.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Beasley, T. Mark] Birmingham Atlanta Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, Birmingham, AL 35233 USA. [Kemnitz, Joseph W.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53792 USA. [Roth, George S.] GeroScience, Pylesville, MD 21323 USA. [Ingram, Donald K.] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA. [Weindruch, Richard; Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP de Cabo, R (reprint author), NIA, Translat Gerontol Branch, Baltimore, MD 21224 USA.; Anderson, RM (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53792 USA.; Anderson, RM (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. EM decabora@grc.nia.nih.gov; rmanderson5@wisc.edu FU NIH [P01AG011915, R01AG040178, R01AG037000]; Department of Medicine, School of Medicine and Public Health UW Madison; NCRR/ORIP grants [P51RR000167/P51OD011106]; NIA [HHSN-263-2013-00026C]; Intramural Research Program of the NIH, National Institute on Aging FX Thanks to animal care and research staff at both facilities including Scott Baum, Julie Adriansjach, Saverio Capuano, Casey Fitz, Heather Simmons at UW, and Rick Herbert, Edward Tilmont, Kelli Vaughan, Mark Szarowicz, Amanda Evans, Danielle Sedlak, Mark Bryant and Matt Starost at NIA for their tireless efforts and stalwart commitment over the years. Funding for the UW study was provided by NIH grants P01AG011915, R01AG040178, R01AG037000, and the Department of Medicine, School of Medicine and Public Health UW Madison. This publication was made possible in part by NCRR/ORIP grants P51RR000167/P51OD011106 to the Wisconsin National Primate Research Center, University of Wisconsin-Madison and the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The internet Primate Aging Database is funded by contract HHSN-263-2013-00026C from the NIA. The NIA study was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. NR 54 TC 2 Z9 2 U1 9 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JAN 17 PY 2017 VL 8 AR 14063 DI 10.1038/ncomms14063 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EH7GE UT WOS:000391940100001 PM 28094793 ER PT J AU Farris, GR Steinhilber, S AF Farris, Gary Ross Steinhilber, Starr TI An older patient with diabetes and severe foot pain SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Editorial Material ID DUAL-ENERGY CT; MANAGEMENT; GOUT; HYPERURICEMIA; DIAGNOSIS C1 [Farris, Gary Ross; Steinhilber, Starr] UAB Tinsley Harrison Internal Med Residency Progr, Birmingham, AL 35294 USA. [Steinhilber, Starr] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Farris, GR (reprint author), UAB Tinsley Harrison Internal Med Residency Progr, Birmingham, AL 35294 USA. EM grfarris1@uabmc.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0820-3946 EI 1488-2329 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD JAN 16 PY 2017 VL 189 IS 2 BP E73 EP E75 DI 10.1503/cmaj.160366 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EK2UQ UT WOS:000393782600006 ER PT J AU Durazzo, TC Murray, DE Meyerhoff, DJ AF Durazzo, Timothy C. Murray, Donna E. Meyerhoff, Dieter J. TI Reply to: On the Correction of Effects of Flip Angle in H-1 Magnetic Resonance Spectroscopy Signal Acquired Using Stimulated Echo Acquisition Mode Sequence SO BIOLOGICAL PSYCHIATRY LA English DT Letter C1 [Durazzo, Timothy C.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA USA. [Durazzo, Timothy C.] Vet Affairs Palo Alto Hlth Care Syst, Mental Illness Res & Educ Clin Ctr, Palo Alto, CA USA. [Durazzo, Timothy C.] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific War Related Illness & Injury Study, Palo Alto, CA USA. [Murray, Donna E.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Murray, Donna E.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. RP Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, Mental Illness Res & Educ Clin Ctr, War Related Illness & Injury Study Ctr, 151Y,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM tdurazzo@stanford.edu FU National Institutes of Health [DA24136, AA10788] FX This work was supported by grants from the National Institutes of Health (Grant Nos. DA24136 to TCD and AA10788 to DJM) administered by the Northern California Institute for Research and Education and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 15 PY 2017 VL 81 IS 2 BP E17 EP E17 DI 10.1016/j.biopsych.2016.02.025 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EO2JY UT WOS:000396524000004 PM 27063070 ER PT J AU Clancy, CJ Nguyen, MH AF Clancy, Cornelius J. Nguyen, M. Hong TI Emergence of Candida auris: An International Call to Arms SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE Candida auris; emergence; dissemination; outbreak; Centers for Disease Control and Prevention ID CLONAL STRAIN; INDIA; HAEMULONII C1 [Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. RP Clancy, CJ (reprint author), 3550 Terrace St,Scaife Hall 867, Pittsburgh, PA 15261 USA. EM cjc76@pitt.edu NR 24 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2017 VL 64 IS 2 BP 141 EP 143 DI 10.1093/cid/ciw696 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP1GB UT WOS:000397132300012 PM 27989986 ER PT J AU Hu, DP Ferro, F Yang, F Taylor, AJ Chang, WH Miclau, T Marcucio, RS Bahney, CS AF Hu, Diane P. Ferro, Federico Yang, Frank Taylor, Aaron J. Chang, Wenhan Miclau, Theodore Marcucio, Ralph S. Bahney, Chelsea S. TI Cartilage to bone transformation during fracture healing is coordinated by the invading vasculature and induction of the core pluripotency genes SO DEVELOPMENT LA English DT Article DE Endochondral ossification; Fracture repair; Pluripotency programs; Chondrocyte transformation ID MESENCHYMAL STEM-CELLS; OSTEOBLAST DIFFERENTIATION; GROWTH-PLATE; HYPERTROPHIC CHONDROCYTES; ENDOCHONDRAL OSSIFICATION; SELF-RENEWAL; IN-VIVO; SIGNALING CENTER; OCT4 EXPRESSION; CRE ACTIVITY AB Fractures heal predominantly through the process of endochondral ossification. The classic model of endochondral ossification holds that chondrocytes mature to hypertrophy, undergo apoptosis and new bone forms by invading osteoprogenitors. However, recent data demonstrate that chondrocytes transdifferentiate to osteoblasts in the growth plate and during regeneration, yet the mechanism(s) regulating this process remain unknown. Here, we show a spatially-dependent phenotypic overlap between hypertrophic chondrocytes and osteoblasts at the chondro-osseous border in the fracture callus, in a region we define as the transition zone (TZ). Hypertrophic chondrocytes in the TZ activate expression of the pluripotency factors [Sox2, Oct4 (Pou5f1), Nanog], and conditional knock-out of Sox2 during fracture healing results in reduction of the fracture callus and a delay in conversion of cartilage to bone. The signal(s) triggering expression of the pluripotency genes are unknown, but we demonstrate that endothelial cell conditioned medium upregulates these genes in ex vivo fracture cultures, supporting histological evidence that transdifferentiation occurs adjacent to the vasculature. Elucidating the cellular and molecular mechanisms underlying fracture repair is important for understanding why some fractures fail to heal and for developing novel therapeutic interventions. C1 [Hu, Diane P.; Ferro, Federico; Yang, Frank; Taylor, Aaron J.; Miclau, Theodore; Marcucio, Ralph S.; Bahney, Chelsea S.] Univ Calif San Francisco, 2550 23rd St,Bldg 9,3rd Floor, San Francisco, CA 94110 USA. [Hu, Diane P.; Ferro, Federico; Yang, Frank; Taylor, Aaron J.; Miclau, Theodore; Marcucio, Ralph S.; Bahney, Chelsea S.] San Francisco Gen Hosp, Orthopaed Trauma Inst, Dept Orthopaed Surg, 2550 23rd St,Bldg 9,3rd Floor, San Francisco, CA 94110 USA. [Chang, Wenhan] Univ Calif San Francisco, 1700 Owens St,4th Floor, San Francisco, CA 94158 USA. [Chang, Wenhan] San Francisco VA Med Ctr, Dept Med, 1700 Owens St,4th Floor, San Francisco, CA 94158 USA. RP Marcucio, RS; Bahney, CS (reprint author), Univ Calif San Francisco, 2550 23rd St,Bldg 9,3rd Floor, San Francisco, CA 94110 USA.; Marcucio, RS; Bahney, CS (reprint author), San Francisco Gen Hosp, Orthopaed Trauma Inst, Dept Orthopaed Surg, 2550 23rd St,Bldg 9,3rd Floor, San Francisco, CA 94110 USA. EM Ralph.Marcucio@UCSF.edu; Chelsea.Bahney@UCSF.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) [5F32AR062469, AR053645, AR057344, AR067291]; Musculoskeletal Transplant Foundation (MTF Junior Investigator Award); AO Foundation (Career Development Award) [S-14-114B]; UCSF Clinical and Translational Science Institute [UL1TR000004]; UCSF Core Center for Musculoskeletal Biology and Medicine [P30AR066262]; US Bone and Joint Initiative Young Investigator Program; Department of Veterans Affairs Program Project Award [IPIBX001599] FX Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) (5F32AR062469 to C.S.B.; AR053645 and AR057344 to T.M.; and AR067291 to W.C.). Additional research support was provided by the Musculoskeletal Transplant Foundation (MTF Junior Investigator Award to C.S.B.), the AO Foundation (Career Development Award, S-14-114B to C.S.B.), the UCSF Clinical and Translational Science Institute (UL1TR000004 to C.S.B.), UCSF Core Center for Musculoskeletal Biology and Medicine (P30AR066262 to C.S.B.), the US Bone and Joint Initiative Young Investigator Program (to C.S.B.) and Department of Veterans Affairs Program Project Award (IPIBX001599 to W.C.). Deposited in PMC for release after 12 months. NR 71 TC 0 Z9 0 U1 4 U2 4 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 EI 1477-9129 J9 DEVELOPMENT JI Development PD JAN 15 PY 2017 VL 144 IS 2 BP 221 EP 234 DI 10.1242/dev.130807 PG 14 WC Developmental Biology SC Developmental Biology GA EJ8DR UT WOS:000393455700005 PM 28096214 ER PT J AU Tromp, J ter Maaten, JM Damman, K O'Connor, CM Metra, M Dittrich, HC Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JGF Givertz, MM Bloomfield, DM van der Wal, MHL Jaarsma, T van Veldhuisen, DJ Hillege, HL Voors, AA van der Meer, P AF Tromp, Jasper ter Maaten, Jozine M. Damman, Kevin O'Connor, Christopher M. Metra, Marco Dittrich, Howard C. Ponikowski, Piot Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. F. Givertz, Michael M. Bloomfield, Daniel M. van der Wal, Martje H. L. Jaarsma, Tiny van Veldhuisen, Dirk J. Hillege, Hans L. Voors, Adriaan A. van der Meer, Peter TI Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID REDUCED EJECTION FRACTION; DIURETIC RESPONSE; RENAL-FUNCTION; HOSPITALIZATION; HYPERKALEMIA; MORTALITY; ROLOFYLLINE; PREDICTORS; ANTAGONIST; SURVIVAL AB Serum potassium is routinely measured at admission for acute heart failure (AHF), but information on association with clinical variables and prognosis is limited. Potassium measurements at admission were available in 1,867 patients with AHF in the original cohort of 2,033 patients included in the Patients Hospitalized with acute heart failure and Volume Overload to Assess Treatment Effect on Congestion and Renal FuncTion trial. Patients were grouped according to low potassium (<3.5 mEq/l), normal potassium (3.5 to 5.0 mEq/l), and high potassium (>5.0 mEq/l) levels. Results were verified in a validation cohort of 1,023 patients. Mean age of patients was 71 +/- 11 years, and 66% were men. Low potassium was present in 115 patients (6%), normal potassium in 1,576 (84%), and high potassium in 176 (9%). Potassium levels increased during hospitalization (0.18 +/- 0.69 mEq/l). Patients with high potassium more often used angiotensin-converting enzyme inhibitors and mineralocorticoid receptor antagonists before admission, had impaired baseline renal function and a better diuretic response (p = 0.005), independent of mineralocorticoid receptor antagonist usage. During 180-day follow-up, a total of 330 patients (18%) died. Potassium levels at admission showed a univariate linear association with mortality (hazard ratio [log] 2.36, 95% confidence interval 1.07 to 5.23; p = 0.034) but not after multivariate adjustment. Changes of potassium levels during hospitalization or potassium levels at discharge were not associated with outcome after multivariate analysis. Results in the validation cohort were similar to the index cohort. In conclusion, high potassium levels at admission are associated with an impaired renal function but a better diuretic response. Changes in potassium levels are common, and overall levels increase during hospitalization. In conclusion, potassium levels at admission or its change during hospitalization are not associated with mortality after multivariate adjustment. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativeconunons.org/licenses/by/4.0/). C1 [Tromp, Jasper; ter Maaten, Jozine M.; Damman, Kevin; van der Wal, Martje H. L.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.; van der Meer, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Metra, Marco] Univ Brescia, Dept Cardiol, Brescia, Italy. [Dittrich, Howard C.] Univ Iowa, Cardiovasc Res Ctr, Carver Coll Med, Iowa City, IA USA. [Ponikowski, Piot] Med Univ, Dept Heart Dis, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, Dept Cardiol, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G. F.] Univ Hull, Dept Cardiol, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Harvard Med Sch, Div Cardiovasc, Brigham & Womens Hosp, Boston, MA USA. [Bloomfield, Daniel M.] Merck & Co Inc, Kenilworth, NJ USA. [van der Wal, Martje H. L.; Jaarsma, Tiny] Linkoping Univ, Fac Hlth & Med Sci, Linkoping, Sweden. RP van der Meer, P (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. EM p.van.der.meer@umcg.nl FU NovaCardia; Merck Co., Inc. FX Dr. Cleland was, on the Steering Committee for the PROTECT trial, served on the advisory board for MSD, and received payments for both. Dr. O'Connor is a consultant to Merck & Co., Inc. Dr. Ponikowski has received honoraria from Merck & Co., Inc. Drs. Davison and Cotter are employees of Momentum Research Inc., which was contracted to perform work on the project by Merck & Co., Inc. Dr. Metra has received honoraria and reimbursements from NovaCardia, sponsors of the study, and Merck & Co., Inc. Dr. Givertz has received institutional research support and served on a scientific advisory board for Merck & Co., Inc. Dr. Teerlink has received research funds and consulting fees from Merck & Co., Inc. Dr. Bloomfield is an employee of Merck & Co., Inc. Dr. Dittrich served as a consultant to Merck & Co., Inc. Dr. Voors has received speaker and consultancy fees from Merck & Co., Inc. All other authors have reported that they have no conflict of interest to declare. NR 29 TC 0 Z9 0 U1 2 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 15 PY 2017 VL 119 IS 2 BP 290 EP 296 DI 10.1016/j.amjcard.2016.09.038 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EJ0KI UT WOS:000392896900020 PM 27823598 ER PT J AU Harmon, JL Gibbs, WS Whitaker, RM Schnellmann, RG Adkins, DL AF Harmon, Jennifer L. Gibbs, Whitney S. Whitaker, Ryan M. Schnellmann, Rick G. Adkins, DeAnna L. TI Striatal Mitochondrial Disruption following Severe Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE controlled cortical impact; mitochondria; oxidative stress; traumatic brain injury ID INFLAMMATION; MICRORNA-21; DYSFUNCTION; BIOGENESIS; CORTEX; DAMAGE; RAT; HIPPOCAMPUS; CIRCUIT; IMPACT AB Traumatic brain injury (TBI) results in oxidative stress and calcium dysregulation in mitochondria. However, little work has examined perturbations of mitochondrial homeostasis in peri-injury tissue. We examined mitochondrial homeostasis after a unilateral controlled cortical impact over the sensorimotor cortex in adult male rats. There was a significant reduction in peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha) messenger RNA (mRNA) at post-injury days 3 and 6 and a transient reduction in mitochondrial DNA copy number at 3 days post-injury that recovered by 6 days in the ipsi-injury striatum. In ipsilateral cortex, PGC-1a mRNA was reduced only at 6 days post-injury. Additionally, expression of mitochondrial-encoded mRNAs, cytochrome c oxidase subunit 1 and NADH dehydrogenase subunit 1, was decreased at 3 and 6 days post-injury in ipsilesional striatum and at 6 days post-injury in ipsilesional cortex. There was no observable decrease in nuclear-encoded mRNAs mitochondrial transcription factor A or NADH dehydrogenase (ubiquinone) Fe-S protein 1. We detected an acute increase in superoxide dismutase 2 mRNA expression, as well as an induction of microRNA (miR)-21 and miR-155, which have been previously demonstrated to disrupt mitochondrial homeostasis. Behaviorally, rats with TBI exhibited marked error rates in contrainjury forelimb performance on the ladder test. These findings reveal that there may be differential susceptibilities of various peri-injury brain structures to mitochondrial dysfunction and associated behavioral deficits, and that molecular pathways demonstrated to interfere with mitochondrial homeostasis and function are activated subacutely post-TBI. C1 [Harmon, Jennifer L.; Gibbs, Whitney S.; Whitaker, Ryan M.; Schnellmann, Rick G.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Adkins, DeAnna L.] Med Univ South Carolina, Dept Neurosci, 173 Ashley Ave,404D MSC510, Charleston, SC 29425 USA. [Adkins, DeAnna L.] Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Adkins, DeAnna L.] Med Univ South Carolina, Ctr Biomed Imaging, Charleston, SC 29425 USA. RP Adkins, DL (reprint author), Med Univ South Carolina, Dept Neurosci, 173 Ashley Ave,404D MSC510, Charleston, SC 29425 USA. EM adkinsdl@musc.edu FU National Institute of Neurological Disorders and Stroke [R01 NS065866]; National Institute of Diabetes and Digestive and Kidney Diseases [F30 DK091107, T32 DK083262]; National Institute of General Medical Sciences [GM084147, P20GM103542]; National Center for Research Resources [UL1-RR029882, C06-RR015455]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [5I01 BX-000851]; South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina FX This work was supported, in part, by the National Institute of Neurological Disorders and Stroke (R01 NS065866; to D.L.A.), National Institute of Diabetes and Digestive and Kidney Diseases (F30 DK091107 and T32 DK083262; to J.L.H.), and National Institute of General Medical Sciences (GM084147 [to R.G.S.] and P20GM103542 [to South Carolina COBRE in Oxidants, Redox Balance, and Stress Signaling]); National Center for Research Resources (UL1-RR029882); the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (5I01 BX-000851; to R.G.S.); and the South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina. Animal facilities were funded by the National Center for Research Resources (C06-RR015455). NR 38 TC 0 Z9 0 U1 2 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JAN 15 PY 2017 VL 34 IS 2 BP 487 EP + DI 10.1089/neu.2015.4395 PG 9 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA EH4QD UT WOS:000391754800024 PM 27321815 ER PT J AU Sharma, A Helft, G Garg, A Agrawal, S Chatterjee, S Lavie, CJ Goel, S Mukherjee, D Marmur, JD AF Sharma, Abhishek Helft, Gerard Garg, Aakash Agrawal, Sahil Chatterjee, Saurav Lavie, Carl J. Goel, Sunny Mukherjee, Debabrata Marmur, Jonathan D. TI Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Vorapaxar; Atherosclerotic vascular disease ID PERCUTANEOUS CORONARY INTERVENTION; PROTEASE-ACTIVATED RECEPTOR-1; DUAL ANTIPLATELET THERAPY; 2-DEGREES-P-TIMI 50 TRIAL; ELUTING STENT IMPLANTATION; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; ATHEROTHROMBOTIC EVENTS; ANTAGONIST VORAPAXAR; SCH 530348 AB Objective To study the cumulative evidence for vorapaxar use in patients with atherosclerotic cardiovascular disease. Methods A systematic review of randomized control trials in MEDLINE, EMBASE, EBSCO, CINAHL, Web of Science and Cochrane databases comparing vorapaxar with placebo was performed. Pre-specified efficacy endpoints were all-cause mortality, CV mortality, myocardial infarction (MI), ischemic stroke and repeat revascularization. The pre-specified safety endpoint was intracranial hemorrhage (ICH) and a composite of TIMI major and minor bleeding. Risk ratios were used as the metric of choice by applying random effects models. Results Five randomized controlled trials with 40,630 patients were included in final analysis. Compared with placebo, vorapaxar led to a statistically non-significant reduction in risk of MI [RR 0.86; 95% CI 0.80-0.93, p = 0.427] and ischemic stroke [RR 0.84; 95% CI 0.72-0.97, p = 0.920]. No differences were observed between vorapaxar and placebo with respect to all-cause mortality [RR 0.99; 95% CI 0.90-1.08, p = 0.620], cardiovascular mortality [RR 0.94; 95% CI 0.83-1.06, p = 0.351], repeat revascularization [RR 0.97; 95% CI 0.82-1.15, p = 0.236], and TIMI bleeding [RR 1.29; 95% CI 0.98-1.69, p = 0.126]. Vorapaxar was associated with a statistically non-significant higher risk of ICH [RR 2.36; 95% CI 1.40-3.96, p = 0.137] compared with placebo. Conclusion Addition of Vorapaxar to standard medical therapy in in patients with atherosclerotic disease led to a statistically non-significant reduction in the risk of MI and ischemic stroke at the cost of statistically non-significant increase in risk of ICH. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Sharma, Abhishek; Marmur, Jonathan D.] Suny Downstate Med Ctr, Div Cardiovasc Med, New York, NY USA. [Helft, Gerard] Univ Paris 06, Hop Pitie Salpetriere, AP HP, Inst Cardiol, Blvd Hop, Paris, France. [Helft, Gerard] Hop La Pitie Salpetriere, Inst Cardiometab & Nutr, Paris, France. [Garg, Aakash] Mt Sinai Sch Med, James J Peters VA Med Ctr, Dept Med, New York, NY USA. [Agrawal, Sahil] St Lukes Univ Hlth Network, Div Cardiol, Bethlehem, PA USA. [Chatterjee, Saurav] Mt Sinai Hlth Syst, St Lukes Roosevelt Hosp Ctr, Div Cardiovasc Dis, New York, NY USA. [Lavie, Carl J.] Univ Queensland, Sch Med, John Ochsner Heart end Vasc Inst, Dept Cardiovasc Dis,Ochsner Clin Sch, New Orleans, LA USA. [Goel, Sunny] Maimonides Hosp, Dept Cardiol, New York, NY USA. [Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, El Paso, TX USA. [Sharma, Abhishek] Inst Cardiovasc Res & Technol, Brooklyn, NY USA. RP Sharma, A (reprint author), Suny Downstate Med Ctr, Div Cardiol, Brooklyn, NY 11203 USA. EM abhisheksharma4mamc@gmail.com NR 33 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD JAN 15 PY 2017 VL 227 BP 617 EP 624 DI 10.1016/j.ijcard.2016.10.088 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EF6ZU UT WOS:000390480700105 PM 27810296 ER PT J AU Poindexter, EK Nazem, S Forster, JE AF Poindexter, Erin K. Nazem, Sarra Forster, Jeri E. TI Painful and provocative events scale and fearlessness about death among Veterans: Exploratory factor analysis SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Painful and provocative events; Fearlessness about death; Acquired capability ID INTERPERSONAL-PSYCHOLOGICAL THEORY; ACQUIRED CAPABILITY; PSYCHOMETRIC PROPERTIES; CONSTRUCT-VALIDITY; MILITARY PERSONNEL; SUICIDAL-BEHAVIOR; RISK; EXPERIENCES; TOLERANCE; SAMPLE AB Background: The interpersonal theory of suicide suggests three proximal risk factors for suicide: perceived burdensomeness, thwarted belongingness, and acquired capability. Previous literature indicates that repetitive exposure to painful and provocative events is related to increased acquired capability for suicide. Despite this, research related to the assessment of painful and provocative events has been insufficient. Research has inconsistently administered the Painful and Provocative Events Scale (PPES; a painful and provocative events assessment), and no study has examined the factor structure of the English PPES. This study explored the factor structure of the PPES and the relation between factors and fearlessness about death. Methods: The sample was a cross-sectional, self-report study comprised of 119 Veterans (Mage = 46.5, SD = 13.5). Results: Findings from an exploratory factor analysis indicated a four-factor solution for the PPES; however, no factor from the PPES significantly related to fearlessness about death (measured by the Acquired Capability for Suicide Scale Fearlessness About Death Scale; all p > .21). Limitations: Cross-sectional, small Veteran sample. Conclusions: Findings suggest that the PPES lacks the psychometric properties necessary to reliably investigate painful and provocative factors. Consequently, this measure may not reliably capture and explain how painful and provocative events relate to fearlessness about death, which is a barrier to improving suicide risk assessment and prediction. Recommendations for the construction of a new PPES are offered. C1 [Poindexter, Erin K.; Nazem, Sarra; Forster, Jeri E.] Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, Denver, CO USA. [Poindexter, Erin K.] Texas Tech Univ, Lubbock, TX 79409 USA. [Nazem, Sarra; Forster, Jeri E.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. RP Nazem, S (reprint author), Denver VAMC, Rocky Mt MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM Sarra.Nazem@va.gov FU Rocky Mountain MIRECC FX This work was supported by Rocky Mountain MIRECC pilot funding. NR 31 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 15 PY 2017 VL 208 BP 528 EP 534 DI 10.1016/j.jad.2016.10.030 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EG0OR UT WOS:000390732600076 PM 27817911 ER PT J AU Lamkin, J Lavner, JA Shaffer, A AF Lamkin, Joanna Lavner, Justin A. Shaffer, Anne TI Narcissism and observed communication in couples SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Narcissism; Communication; Observational; Couples; Dyadic ID PERSONALITY-INVENTORY; GENDER-DIFFERENCES; RELATIONSHIP SATISFACTION; ROMANTIC RELATIONSHIPS; SELF-ESTEEM; MODEL; LOVE; AGGRESSION; MARRIAGE; ANGER AB Narcissism is associated with dysfunction in interpersonal relationships. Empirically, limited information is available about how narcissism affects observed interactions in romantic relationships. In this study, we employed dyadic data analyses to investigate the effects of narcissism on relationship functioning. Young adult couples (N = 54 couples) participated in a neutral discussion task, and their communication behaviors (hostility, anger, and positive affect) were coded by observers. We also assessed self-reported relationship satisfaction and narcissism. Results of multilevel models revealed that women with higher levels of narcissism demonstrated significantly higher levels of hostility, as did their male partners. Men also displayed more anger if their female partner had higher levels of narcissism. Narcissism was not associated with observed positive affect in any of the analyses. Results are consistent with previous research on couples in highlighting that women's narcissism is associated with more difficulties in romantic relationships for women and their male partners. Findings are discussed with attention to better understanding the behaviors that lead to dissatisfaction and dysfunction in romantic relationships where narcissism is present. Published by Elsevier Ltd. C1 [Lamkin, Joanna; Lavner, Justin A.; Shaffer, Anne] Univ Georgia, Athens, GA 30602 USA. [Lamkin, Joanna] Baylor Coll Med, South Cent Mental Illness Res Educ & Clin Ctr MIR, VA HSR&D Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Lamkin, J (reprint author), 2002 Holcombe Blvd,MC 152, Houston, TX 77030 USA.; Lamkin, J (reprint author), Baylor Coll Med, South Cent Mental Illness Res Educ & Clin Ctr MIR, VA HSR&D Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM joannalamkin@bcm.edu NR 33 TC 0 Z9 0 U1 21 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD JAN 15 PY 2017 VL 105 BP 224 EP 228 DI 10.1016/j.paid.2016.09.046 PG 5 WC Psychology, Social SC Psychology GA ED3YF UT WOS:000388783700035 ER PT J AU Singh, JA Chen, J Inacio, MCS Namba, RS Paxton, EW AF Singh, Jasvinder A. Chen, Jason Inacio, Maria C. S. Namba, Robert S. Paxton, Elizabeth W. TI An underlying diagnosis of osteonecrosis of bone is associated with worse outcomes than osteoarthritis after total hip arthroplasty SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE Total hip replacement; Readmission; Osteoarthritis; Osteonecrosis; Arthroplasty; Joint replacement; Diagnosis; Risk factor ID RHEUMATOID-ARTHRITIS; RISK-FACTOR; REPLACEMENT; INFECTIONS; COHORT AB Background: Well-designed studies of complications and readmission rates in patients undergoing total hip arthroplasty (THA) with osteonecrosis are lacking. Our objective was to examine if a diagnosis of osteonecrosis was associated with complications, mortality and readmission rates after THA. Methods: We analyzed prospectively collected data from an integrated healthcare system's Total Joint Replacement Registry of adults with osteonecrosis vs. osteoarthritis (OA) undergoing unilateral primary THA during 2001-2012, in an observational cohort study. We examined mortality (90-day), revision (ever), deep (1 year) and superficial (30-day) surgical site infection (SSI), venous thromboembolism (VTE, 90-day), and unplanned readmission (90-day). Age, gender, race, body mass index, American Society of Anesthesiologists class, and diabetes were evaluated as confounders. We used logistic or Cox regression to calculate odds or hazard ratios (OR, HR) with 95% confidence intervals (CI). Results: Of the 47,523 primary THA cases, 45,252 (95.2%) had OA, and 2,271 (4.8%) had osteonecrosis. Compared to the OA, patients with osteonecrosis were younger (median age 55 vs. 67 years), and were less likely to be female (42.5% vs. 58.3%) or White (59.8% vs. 77.4%). Compared to the OA, the osteonecrosis cohort had higher crude incidence of 90-day mortality (0.7% vs. 0.3%), SSI (1.2% vs. 0.8%), unplanned readmission (9.6% vs. 5.2%) and revision (3.1% vs. 2.4%). After multivariable-adjustment, patients with osteonecrosis had a higher odds/hazard of mortality (OR: 2.48; 95% CI:1.31-4.72), SSI (OR: 1.67, 95% CI:1.11-2.51), unplanned 90-day readmissions (OR: 2.20; 95% CI:1.67-2.91) and a trend towards higher revision rate 1-year post-THA (HR: 1.32; 95% CI:0.94-1.84), than OA patients. Conclusions: Compared to OA, a diagnosis of osteonecrosis was associated with worse outcomes post-THA. A detailed preoperative discussion including the risk of complications is needed for informed consent from patients with osteonecrosis. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Sch Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. [Chen, Jason; Inacio, Maria C. S.; Paxton, Elizabeth W.] Kaiser Permanente, Dept Surg Outcomes & Anal, San Diego, CA USA. [Namba, Robert S.] Kaiser Permanente, Dept Orthopaed Surg, Irvine, CA USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Sch Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. EM Jasvinder.md@gmail.com NR 23 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD JAN 9 PY 2017 VL 18 AR 8 DI 10.1186/s12891-016-1385-0 PG 9 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA EM3BE UT WOS:000395188700001 PM 28068972 ER PT J AU Agamasu, C Ghanam, RH Xu, F Sun, Y Chen, YB Saad, JS AF Agamasu, Constance Ghanam, Ruba H. Xu, Fei Sun, Yong Chen, Yabing Saad, Jamil S. TI The Interplay between Calmodulin and Membrane Interactions with the Pleckstrin Homology Domain of Akt SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HUMAN BREAST-CANCER; PROTEIN-KINASE-B; PHOSPHOLIPID-BILAYER NANODISCS; HIGH-RESOLUTION STRUCTURE; HIV-1 MATRIX PROTEIN; TARGET RECOGNITION; PHOSPHATIDYLINOSITOL 3-KINASE; BIOPHYSICAL CHARACTERIZATION; INOSITOL PHOSPHATES; NMR-SPECTROSCOPY AB The Akt protein, a serine/threonine kinase, plays important roles in cell survival, apoptosis, and oncogenes. Akt is translocated to the plasma membrane for activation. Akt-membrane binding is mediated by direct interactions between its pleckstrin homology domain (PHD) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3). It has been shown that Akt activation in breast cancer cells is modulated by calmodulin (CaM). However, the molecular mechanism of the interplay between CaM and membrane binding is not established. Here, we employed nuclear magnetic resonance (NMR) and biochemical and biophysical techniques to characterize how PI(3,4,5)P-3, CaM, and membrane mimetics (nanodisc) bind to Akt(PHD). We show that PI(3,4,5)P-3 binding to Akt(PHD) displaces the C-terminal lobe of CaM but not the weakly binding N-terminal lobe. However, binding of a PI(3,4,5)P-3-embedded membrane nanodisc to Akt(PHD) with a 10(3)-fold tighter affinity than PI(3,4,5)P-3 is able to completely displace CaM. We also show that Akt(PHD) binds to both layers of the nanodisc, indicating proper incorporation of PI(3,4,5)P-3 on the nanodisc surface. No detectable binding has been observed between Akt(PHD) and PI(3,4,5)P-3-free nanodiscs, demonstrating that PI(3,4,5)P-3 is required for membrane binding, CaM displacement, and Akt activation. Using pancreatic cancer cells, we demonstrate that inhibition of Akt-CaM binding attenuated Akt activation. Our findings support a model by which CaM binds to Akt to facilitate its translocation to the membrane. Elucidation of the molecular details of the interplay between membrane and CaM binding to Akt may help in the development of potential targets to control the pathophysiological processes of cell survival. C1 [Agamasu, Constance; Ghanam, Ruba H.; Saad, Jamil S.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Xu, Fei; Sun, Yong; Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Sun, Yong; Chen, Yabing] Birmingham Vet Affairs Med Ctr, Res Dept, Birmingham, AL 35294 USA. RP Saad, JS (reprint author), 845 19th St South, Birmingham, AL 35294 USA. EM saad@uab.edu OI Saad, Jamil/0000-0001-9503-6484 FU National Institutes of Health [1S10RR026478] FX We thank the Comprehensive Cancer Center, University of Alabama at Birmingham, for supporting the High-Field NMR facility and the X-ray core facility that houses the Auto-ITC200 (acquired through National Institutes of Health Grant 1S10RR026478). NR 67 TC 0 Z9 0 U1 4 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 6 PY 2017 VL 292 IS 1 BP 251 EP 263 DI 10.1074/jbc.M116.752816 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EH2DQ UT WOS:000391578000022 PM 27872186 ER PT J AU Liu, SJ Horlbeck, MA Cho, SW Birk, HS Malatesta, M He, D Attenello, FJ Villalta, JE Cho, MY Chen, YW Mandegar, MA Olvera, MP Gilbert, LA Conklin, BR Chang, HY Weissman, JS Lim, DA AF Liu, S. John Horlbeck, Max A. Cho, Seung Woo Birk, Harjus S. Malatesta, Martina He, Daniel Attenello, Frank J. Villalta, Jacqueline E. Cho, Min Y. Chen, Yuwen Mandegar, Mohammad A. Olvera, Michael P. Gilbert, Luke A. Conklin, Bruce R. Chang, Howard Y. Weissman, Jonathan S. Lim, Daniel A. TI CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells SO SCIENCE LA English DT Article ID GENE-EXPRESSION; STEM-CELLS; DIFFERENTIATION; TRANSCRIPTION; EVOLUTION; CANCER; LNCRNA; INTERFERENCE; ACTIVATION; ENHANCERS AB The human genome produces thousands of long noncoding RNAs (lncRNAs)-transcripts >200 nucleotides long that do not encode proteins. Although critical roles in normal biology and disease have been revealed for a subset of lncRNAs, the function of the vast majority remains untested. We developed a CRISPR interference (CRISPRi) platform targeting 16,401 lncRNA loci in seven diverse cell lines, including six transformed cell lines and human induced pluripotent stem cells (iPSCs). Large-scale screening identified 499 lncRNA loci required for robust cellular growth, of which 89% showed growth-modifying function exclusively in one cell type. We further found that lncRNA knockdown can perturb complex transcriptional networks in a cell type-specific manner. These data underscore the functional importance and cell type specificity of many lncRNAs. C1 [Liu, S. John; Birk, Harjus S.; Malatesta, Martina; He, Daniel; Attenello, Frank J.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Liu, S. John; Birk, Harjus S.; Malatesta, Martina; He, Daniel; Attenello, Frank J.; Lim, Daniel A.] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Villalta, Jacqueline E.; Cho, Min Y.; Chen, Yuwen; Mandegar, Mohammad A.; Olvera, Michael P.; Gilbert, Luke A.; Conklin, Bruce R.; Weissman, Jonathan S.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Villalta, Jacqueline E.; Cho, Min Y.; Chen, Yuwen; Gilbert, Luke A.; Weissman, Jonathan S.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Villalta, Jacqueline E.; Cho, Min Y.; Chen, Yuwen; Gilbert, Luke A.; Weissman, Jonathan S.] Univ Calif San Francisco, Calif Inst Quantitat Biomed Res, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Villalta, Jacqueline E.; Cho, Min Y.; Chen, Yuwen; Gilbert, Luke A.; Weissman, Jonathan S.] Univ Calif San Francisco, Ctr RNA Syst Biol, San Francisco, CA 94143 USA. [Conklin, Bruce R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Conklin, Bruce R.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA. [Cho, Seung Woo; Chang, Howard Y.] Stanford Univ, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA. [Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Lim, DA (reprint author), Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.; Weissman, JS (reprint author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.; Weissman, JS (reprint author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.; Weissman, JS (reprint author), Univ Calif San Francisco, Calif Inst Quantitat Biomed Res, San Francisco, CA 94143 USA.; Weissman, JS (reprint author), Univ Calif San Francisco, Ctr RNA Syst Biol, San Francisco, CA 94143 USA.; Lim, DA (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM jonathan.weissman@ucsf.edu; daniel.lim@ucsf.edu FU NIH [1R01NS091544-01A1, F30 NS092319-01, P50 GM102706, U01 CA168370, R01 DA036858, R35-CA209919, P50-HG007735, U01HL100406, P01HL089707, R01HL130533]; VA grant [5I01 BX000252-07]; NIH Specialized Programs of Research Excellence Developmental Research Program subaward; Shurl and Kay Curci Foundation; LoGlio Foundation; Hana Jabsheh Initiative; Howard Hughes Medical Institutes; Gladstone Institutes; NIH/NCI Pathway to Independence Award [K99CA204602] FX We thank the members of the Lim and Weissman labs, particularly A. Fields, J. Dunn, M. DeVera, M. Cui, and D. Wu, for helpful discussions and assistance; A. Truong for assistance with iPS cell culturing; N. Salomonis for iPSC RNA-seq data; E. Chow and D. Bogdanoff of the UCSF Center for Advanced Technology for sequencing assistance; and L. Bruhn, D. Ryan, L. Fairbairn, and P. Tsang of Agilent Technologies for their assistance on the design and synthesis of oligonucleotide pools. Supported by NIH grant 1R01NS091544-01A1, VA grant 5I01 BX000252-07, NIH Specialized Programs of Research Excellence Developmental Research Program subaward, the Shurl and Kay Curci Foundation, the LoGlio Foundation, and the Hana Jabsheh Initiative (D.A.L.); NIH grant F30 NS092319-01 (S.J.L.); the Howard Hughes Medical Institutes and NIH grants P50 GM102706, U01 CA168370, and R01 DA036858 (M.A.H., J.E.V., M.Y.C., Y.C., L.A.G., and J.S.W.); NIH grants R35-CA209919 and P50-HG007735 (S.W.C. and H.Y.C.); the Gladstone Institutes and NIH grants U01HL100406, P01HL089707, and R01HL130533 (B.R.C. and M.A.M.); and NIH/NCI Pathway to Independence Award K99CA204602 (L.A.G.). Oligonucleotide pools were provided courtesy of the Innovative Genomics Initiative. M.A.H., L.A.G., and J.S.W. are inventors on patent application PCT/US15/40449 submitted by UCSF that covers CRISPRi library design. The human iPSC line WTC expressing the CRISPRi system (WTC-CRISPRi Gen IC) is available from B.R.C. under material transfer agreement from the Gladstone Institutes. The parental iPSC line (WTC) is available from the Coriell Biorepository #GM25256. The CRiNCL libraries are available from J.S.W. (via Addgene for academic users) under a material transfer agreement from UCSF and Agilent Technologies. M.A.H., L.A.G., and J.S.W. are inventors on patent application PCT/US15/40449 submitted by UCSF that covers CRISPRi library design. J.S.W. is a founder of KSQ Therapeutics, a company that uses CRISPR-based screening to identify therapeutic targets. H.Y.C. is a co-founder of Epinomics Inc. and served on the scientific advisory board of RaNA Therapeutics. M.A.H. and L.A.G. are consultants for KSQ Therapeutics. NR 61 TC 0 Z9 0 U1 26 U2 26 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD JAN 6 PY 2017 VL 355 IS 6320 AR aah7111 DI 10.1126/science.aah7111 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EH4KK UT WOS:000391739900002 ER PT J AU Han, S Jerome, JA Gregory, AD Mallampalli, RK AF Han, SeungHye Jerome, Jacob A. Gregory, Alyssa D. Mallampalli, Rama K. TI Cigarette smoke destabilizes NLRP3 protein by promoting its ubiquitination SO RESPIRATORY RESEARCH LA English DT Article DE NLRP3; Cigarette smoke; Ubiquitin ID NALP3 INFLAMMASOME; INDUCED EMPHYSEMA; TOBACCO-SMOKE; DEGRADATION; LUNG; ELASTASE; SYSTEM; AIRWAY; ALPHA; IL-18 AB Background: Cigarette smoke suppresses innate immunity, making smokers more susceptible to infection. The NLRP3 inflammasome is a multi-protein complex that releases interleukin (IL) -1 beta and IL -18. These cytokines are critical for a timely host response to pathogens. Whether cigarette smoke affects NLRP3 protein levels, and its ability to form an inflammasome, is not known. Methods and results: Using the human monocyte THP1 cell line and C57BL/6 mice, we show that cigarette smoke decreases NLRP3 levels in cells by increasing ubiquitin-mediated proteasomal processing. Half-life of NLRP3 is shortened with the exposure to cigarette smoke extract. Cigarette smoke extract reduces cellular NLRP3 protein abundance in the presence of lipopolysaccharide, a known inducer of NLRP3 protein, thereby decreasing the formation of NLRP3 inflammasomes. The release of IL-1 beta and IL-18 by inflammasome activation is also decreased with the exposure to cigarette smoke extract both in THP1 cells and primary human peripheral blood macrophages. Conclusions: Cigarette smoke extract decreased NLRP3 protein abundance via increased ubiquitin-mediated proteasomal processing. The release of IL-1 beta and IL-18 is also decreased with cigarette smoke extract. Our findings may provide mechanistic insights on immunosuppression in smokers and unique opportunities to develop a strategy to modulate immune function. C1 [Han, SeungHye; Jerome, Jacob A.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA. [Gregory, Alyssa D.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, 930 Scaife Hall, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA.; Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, 930 Scaife Hall, Pittsburgh, PA 15213 USA.; Mallampalli, RK (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. EM mallampallirk@upmc.edu FU Merit Review Award from the US Department of Veterans Affairs, National Institutes of Health R01 grants [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01HL114453]; American Heart Association Award [15POST25700096]; Breathe Pennsylvania Lung Health Research Grant; Flight Attendant Medical Research Institute FX This work was supported by a Merit Review Award from the US Department of Veterans Affairs, National Institutes of Health R01 grants HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01HL114453 (to R.K.M.); an American Heart Association Award 15POST25700096, Breathe Pennsylvania Lung Health Research Grant (to S.H.); and Flight Attendant Medical Research Institute (to A. D.G.). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. NR 31 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD JAN 5 PY 2017 VL 18 AR 2 DI 10.1186/s12931-016-0485-6 PG 8 WC Respiratory System SC Respiratory System GA EG9UP UT WOS:000391405300001 PM 28056996 ER PT J AU Ben-Ari, A Chansky, H Rozet, I AF Ben-Ari, Alon Chansky, Howard Rozet, Irene TI Preoperative Opioid Use Is Associated with Early Revision After Total Knee Arthroplasty A Study of Male Patients Treated in the Veterans Affairs System SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID CONTROLLED-TRIAL; GLYCEMIC CONTROL; PAIN MANAGEMENT; UNITED-STATES; RISK-FACTORS; REPLACEMENT; OUTCOMES; IMPACT; HIP AB Background: Opioid use is endemic in the U.S. and is associated with morbidity and mortality. The impact of long-term opioid use on joint-replacement outcomes remains unknown. We tested the hypothesis that use of opioids is associated with adverse outcomes after total knee arthroplasty (TKA). Methods: We performed a retrospective analysis of patients who had had TKA within the U.S. Veterans Affairs (VA) system over a 6-year period and had been followed for 1 year postoperatively. The length of time for which an opioid had been prescribed and the morphine equivalent dose were calculated for each patient. Patients for whom opioids had been prescribed for >3 months in the year prior to the TKA were assigned to the long-term opioid group. A natural language processing-based machine-learning classifier was developed to classify revisions due to infectious and non-infectious causes on the basis of the postoperative note. Survival curves for the time to knee revision or manipulation were used to compare the long-term opioid group with the patients who did not take opioids long-term. Hazard and odds ratios for knee revision and manipulation were obtained as well. Results: Of 32,636 patients (94.4% male; mean age [and standard deviation], 64.45 +/- 9.41 years) who underwent TKA, 12,772 (39.1%) were in the long-term opioid group and 734 (2.2%) had a revision within a year after the TKA. Chronic kidney disease, diabetes, and long-term opioid use were associated with revision within 1 year-with odds ratios (95% confidence intervals [CIs]) of 1.76 (1.37 to 2.22), 1.11 (0.93 to 1.31), and 1.40 (1.19 to 1.64), respectively-and were also the leading factors associated with a revision at any time after the index TKA-with odds ratios (95% CIs) of 1.61 (1.34 to 1.92), 1.21 (1.08 to 1.36), and 1.28 (1.15 to 1.43), respectively. Long-term opioid use had a hazard ratio of 1.19 (95% CI = 1.10 to 0.24) in the analysis of its relationship with knee revision, but the hazard was not significant in the analysis of its association with knee manipulation. The accuracy of the text classifier was 0.94, with the area under the receiver operating characteristic curve being 0.99. There was no association between long-term use of opioids and the specific cause for knee revision. Conclusions: Long-term opioid use prior to TKA was associated with an increased risk of knee revision during the first year after TKA among predominantly male patients treated in the VA system. C1 [Ben-Ari, Alon; Chansky, Howard; Rozet, Irene] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA USA. [Ben-Ari, Alon; Chansky, Howard; Rozet, Irene] Univ Washington, Dept Orthopaed Surg & Sports Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Ben-Ari, A (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA USA.; Ben-Ari, A (reprint author), Univ Washington, Dept Orthopaed Surg & Sports Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM alon.benari@gmail.com; chansky@uw.edu; irozet@uw.edu NR 38 TC 0 Z9 0 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02492 USA SN 0021-9355 EI 1535-1386 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN 4 PY 2017 VL 99 IS 1 BP 1 EP 9 DI 10.2106/JBJS.16.00167 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA EP0HM UT WOS:000397067900005 PM 28060227 ER PT J AU Ostrem, JL San Luciano, M Dodenhoff, KA Ziman, N Markun, LC Racine, CA de Hemptinne, C Volz, MM Heath, SL Starr, PA AF Ostrem, Jill L. San Luciano, Marta Dodenhoff, Kristen A. Ziman, Nathan Markun, Leslie C. Racine, Caroline A. de Hemptinne, Coralie Volz, Monica M. Heath, Susan L. Starr, Philip A. TI Subthalamic nucleus deep brain stimulation in isolated dystonia A 3-year follow-up study SO NEUROLOGY LA English DT Article ID PRIMARY GENERALIZED DYSTONIA; CRANIAL-CERVICAL DYSTONIA; SEGMENTAL DYSTONIA; BILATERAL PALLIDOTOMY; SECONDARY DYSTONIA; PARKINSON-DISEASE; IMPLANTATION; DURATION; TRIAL AB Objective: To report long-term safety and efficacy outcomes of a large cohort of patients with medically refractory isolated dystonia treated with subthalamic nucleus (STN) deep brain stimulation (DBS). Methods: Twenty patients (12 male, 8 female; mean age 49 +/- 16.3 years) with medically refractory isolated dystonia were studied (14 were followed for 36 months). The primary endpoints were change in Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score at 36 months compared to preoperative baseline. Multiple secondary outcomes were also assessed (ClinicalTrials.gov NCT00773604). Results: Eighteen of 20 patients showed improvement 12 months after STN DBS with sustained benefit persisting for 3 years (n = 14). At 36 months, BFMDRS motor scores improved 70.4% from a mean 17.9 +/- 8.5 to 5.3 +/- 5.6 (p = 0.0002) and total TWSTRS scores improved 66.6% from a mean 41.0 +/- 18.9 to 13.7 +/- 17.9 (p = 0.0002). Improvement at 36 months was equivalent to that seen at 6 months. Disability and quality of life measures were also improved. Three hardware-related and 24 stimulation-related nonserious adverse events occurred between years 1 and 3 (including 4 patients with dyskinesia). Conclusions: This study offers support for long-term tolerability and sustained effectiveness of STN DBS in the treatment of severe forms of isolated dystonia. Classification of evidence: This study provides Class IV evidence that STN DBS decreases long-term dystonia severity in patients with medically refractory isolated dystonia. C1 [Ostrem, Jill L.; San Luciano, Marta; Dodenhoff, Kristen A.; Ziman, Nathan; Markun, Leslie C.; Volz, Monica M.] Univ Calif San Francisco, Dept Neurol, Movement Disorders & Neuromodulat Ctr, San Francisco, CA 94143 USA. [Racine, Caroline A.; de Hemptinne, Coralie; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Ostrem, Jill L.; Markun, Leslie C.; Heath, Susan L.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. RP Ostrem, JL (reprint author), Univ Calif San Francisco, Dept Neurol, Movement Disorders & Neuromodulat Ctr, San Francisco, CA 94143 USA.; Ostrem, JL (reprint author), San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. EM jill.ostrem@ucsf.edu FU Bachmann Strauss Dystonia; Parkinson's Disease Foundation; Benign Essential Blepharospasm Research Foundation FX Supported by Bachmann Strauss Dystonia and Parkinson's Disease Foundation and the Benign Essential Blepharospasm Research Foundation. NR 36 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JAN 3 PY 2017 VL 88 IS 1 BP 25 EP 35 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA EI1OE UT WOS:000392246100009 PM 27903810 ER PT J AU DiNapoli, EA Pierpaoli, CM Shah, A Yang, X Scogin, F AF DiNapoli, Elizabeth A. Pierpaoli, Christina M. Shah, Avani Yang, Xin Scogin, Forrest TI Effects of Home-Delivered Cognitive Behavioral Therapy (CBT) for Depression on Anxiety Symptoms among Rural, Ethnically Diverse Older Adults SO CLINICAL GERONTOLOGIST LA English DT Article DE Anxiety; CBT; home-delivered intervention; rural ID QUALITY-OF-LIFE; PSYCHOLOGICAL TREATMENTS; RISK-FACTORS; DISORDERS; METAANALYSIS; TRIAL; PREVALENCE; VALIDATION; PEOPLE; IMPACT AB Background: We examined the effects of home-delivered cognitive-behavioral therapy (CBT) for depression on anxiety symptoms in an ethnically diverse, low resource, and medically frail sample of rural, older adults.Method: This was a secondary analysis of a randomized clincial trial with 134 rural-dwelling adults 65years and older with decreased quality of life and elevated psychological symptomatology. Anxiety symptoms were assessed with the anxiety and phobic anxiety subscales of the Symptom Checklist-90-Revised (SCL-90-R).Results: Compared to a minimal support control condition, CBT for depression resulted in significantly greater improvements in symptoms of anxiety and phobic anxiety from pre-treatment to post-treatment.Conclusion: Home-delivered CBT for depression can be an effective treatment for anxiety in a hard-to-reach older populations.Clinical Implications: Additional research should explore integrated anxiety and depression protocols and other treatment modalities, including bibliotherapy or telehealth models of CBT, to reduce costs associated with its in home delivery. Flexibility in administration and adaptations to the CBT protocol may be necessary for use with vulnerable, rural older adults. C1 [DiNapoli, Elizabeth A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [DiNapoli, Elizabeth A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Pierpaoli, Christina M.; Shah, Avani; Yang, Xin; Scogin, Forrest] Univ Alabama, Tuscaloosa, AL USA. RP Scogin, F (reprint author), Univ Alabama, Dept Psychol, Box 870348, Tuscaloosa, AL 35487 USA. EM fscogin@as.ua.edu FU National Institute on Aging [AG16311] FX This research was supported by the National Institute on Aging under Grant AG16311. NR 50 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0731-7115 EI 1545-2301 J9 CLIN GERONTOLOGIST JI Clin. Gerontol. PY 2017 VL 40 IS 3 BP 181 EP 190 DI 10.1080/07317115.2017.1288670 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA ES5JS UT WOS:000399575100005 PM 28452665 ER PT J AU Horton, LE Bridgwater, MA Haas, GL AF Horton, Leslie E. Bridgwater, Miranda A. Haas, Gretchen L. TI Emotion recognition and social skills in child and adolescent offspring of parents with schizophrenia SO COGNITIVE NEUROPSYCHIATRY LA English DT Article DE High-risk; schizophrenia; social skills; emotion recognition; facial affect recognition ID FACIAL AFFECT RECOGNITION; CLINICAL HIGH-RISK; 1ST-DEGREE RELATIVES; DEFICITS; PSYCHOSIS; INDIVIDUALS; PERCEPTION; SIBLINGS; PRECURSORS AB Introduction: Emotion recognition, a social cognition domain, is impaired in people with schizophrenia and contributes to social dysfunction. Whether impaired emotion recognition emerges as a manifestation of illness or predates symptoms is unclear. Findings from studies of emotion recognition impairments in first-degree relatives of people with schizophrenia are mixed and, to our knowledge, no studies have investigated the link between emotion recognition and social functioning in that population.Methods: This study examined facial affect recognition and social skills in 16 offspring of parents with schizophrenia (familial high-risk/FHR) compared to 34 age- and sex-matched healthy controls (HC), ages 7-19.Results: As hypothesised, FHR children exhibited impaired overall accuracy, accuracy in identifying fearful faces, and overall recognition speed relative to controls. Age-adjusted facial affect recognition accuracy scores predicted parent's overall rating of their child's social skills for both groups.Conclusions: This study supports the presence of facial affect recognition deficits in FHR children. Importantly, as the first known study to suggest the presence of these deficits in young, asymptomatic FHR children, it extends findings to a developmental stage predating symptoms. Further, findings point to a relationship between early emotion recognition and social skills. Improved characterisation of deficits in FHR children could inform early intervention. C1 [Horton, Leslie E.; Bridgwater, Miranda A.; Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Horton, LE (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. EM hortonle2@upmc.edu FU NARSAD Independent Investigator Grant from the Brain and Behavior Research Foundation [1098]; Department of Psychiatry of the University of Pittsburgh FX This work was supported, in part, by a NARSAD Independent Investigator Grant #1098 from the Brain and Behavior Research Foundation (formerly NARSAD) to the senior author (G. Haas), and infrastructure support funding from the Department of Psychiatry of the University of Pittsburgh. NR 30 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1354-6805 EI 1464-0619 J9 COGN NEUROPSYCHIATRY JI Cogn. Neuropsychiatry PY 2017 VL 22 IS 3 BP 175 EP 185 DI 10.1080/13546805.2017.1297223 PG 11 WC Psychiatry SC Psychiatry GA ES5MS UT WOS:000399584800001 PM 28288532 ER PT J AU Vaskinn, A Fiske, AP Green, MF AF Vaskinn, Anja Fiske, Alan P. Green, Michael F. TI Enhancing tolerability of a measure of social perception in schizophrenia: comparison of short and long Norwegian versions of the Relationships Across Domains test SO COGNITIVE NEUROPSYCHIATRY LA English DT Article DE Schizophrenia; social cognition; social perception; relationship perception; cross-cultural assessment ID COGNITION; SCALE AB Introduction: Relationship perception focuses on social interactions, is reduced in schizophrenia and is related to daily functioning. It can be assessed with the Relationships Across Domains (RAD) test, built on Relational Models Theory which states that people use four relational models to interpret social interaction. RAD is time consuming, low on tolerability and only used in English-speaking countries. We evaluated the psychometric properties of a translated, abbreviated Norwegian version.Methods: Sixty-two schizophrenia participants and 56 healthy controls underwent assessments of social and non-social cognition. The schizophrenia group completed functional and clinical measures. RAD's internal consistency was investigated with Cronbach's alphas, group differences with logistic regressions and associations between study variables with Pearson's correlations.Results: RAD was reduced from 25 (Cronbach's alpha=.809) to 12 vignettes (Cronbach's alpha=.815). Schizophrenia participants had significant impairments, with larger effect sizes for the full version. Associations of RAD with study variables were similar for the two versions: smaller for clinical measures and larger for functional and cognitive measures. Results were comparable to results for the English version.Conclusions: The length of the Norwegian RAD was reduced while retaining its psychometric properties, which were similar to the English version. This suggests the test's cross-cultural utility. C1 [Vaskinn, Anja] Univ Oslo, Dept Psychol, Oslo, Norway. [Vaskinn, Anja] Oslo Univ Hosp, NORMENT KG Jebsen Ctr Psychosis Res, Oslo, Norway. [Fiske, Alan P.] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA. [Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Vaskinn, A (reprint author), Univ Oslo, Dept Psychol, Oslo, Norway.; Vaskinn, A (reprint author), Oslo Univ Hosp, NORMENT KG Jebsen Ctr Psychosis Res, Oslo, Norway. EM anja.vaskinn@psykologi.uio.no FU South-Eastern Norway Regional Health Authority [2010007, 2013123]; Fulbright Foundation for Educational Exchange; Research Council of Norway [223273]; K.G. Jebsen Foundation FX This work was supported by the South-Eastern Norway Regional Health Authority (#2010007 to A.V., #2013123), the Fulbright Foundation for Educational Exchange (to A.V.), the Research Council of Norway (#223273) and the K.G. Jebsen Foundation. NR 22 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1354-6805 EI 1464-0619 J9 COGN NEUROPSYCHIATRY JI Cogn. Neuropsychiatry PY 2017 VL 22 IS 3 BP 254 EP 262 DI 10.1080/13546805.2017.1307174 PG 9 WC Psychiatry SC Psychiatry GA ES5MS UT WOS:000399584800005 PM 28346041 ER PT J AU Anzueto, A Miravitlles, M AF Anzueto, Antonio Miravitlles, Marc TI Pathophysiology of dyspnea in COPD SO POSTGRADUATE MEDICINE LA English DT Review DE COPD; dyspnea; lung; bronchodilator ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC RESPIRATORY SYMPTOMS; PATIENT-REPORTED OUTCOMES; QUALITY-OF-LIFE; LUNG HYPERINFLATION; EXERCISE TOLERANCE; STABLE COPD; PHYSICAL-ACTIVITY; DYNAMIC HYPERINFLATION; FLOW LIMITATION AB Dyspnea refers to the sensation of breathlessness, shortness of breath, or difficulty breathing that is commonly observed in patients with respiratory and cardiac disease. In the United States alone, dyspnea is reported in up to 4 million all-cause emergency room visits annually. Dyspnea can be a symptom of several different underlying physical conditions, typically involving the lung and heart. Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival. Currently there is no single physiological correlate that will accurately predict dyspnea, particularly because the mechanisms that contribute to respiratory discomfort can vary between diseases and between individuals experiencing breathlessness who have been diagnosed with the same disease. Therefore, various subjective clinical and psychophysical scales and questionnaires are typically used to measure or predict dyspnea. It is the goal of this review to discuss the pathophysiological mechanisms leading to dyspnea, particularly those associated with COPD, the physical and psychological impact on patients, assessment approaches, and modalities currently used to treat it. C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Pulmonol Sect, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Dept Med, Pulm Sect, San Antonio, TX USA. [Miravitlles, Marc] Hosp Univ Vall dHebron, Pneumonol Dept, Barcelona, Spain. [Miravitlles, Marc] CIBERES, Barcelona, Spain. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 4242 Med Dr, San Antonio, TX 78229 USA.; Miravitlles, M (reprint author), Vall dHebron Hosp, Dept Pneumonol, Barcelona 08035, Catalonia, Spain. EM anzueto@uthscsa.edu; marcm@separ.es FU AstraZeneca LP FX This paper was funded by AstraZeneca LP. NR 100 TC 0 Z9 0 U1 3 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PY 2017 VL 129 IS 3 BP 366 EP 374 DI 10.1080/00325481.2017.1301190 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA ES5DJ UT WOS:000399556700009 PM 28277858 ER PT J AU Bullman, TA Kang, HK Smolenski, DJ Skopp, NA Gahm, GA Reger, MA AF Bullman, Tim A. Kang, Han K. Smolenski, Derek J. Skopp, Nancy A. Gahm, Gregory A. Reger, Mark A. TI Risk of motor vehicle accident death among 1.3million veterans of the Iraq and Afghanistan wars SO TRAFFIC INJURY PREVENTION LA English DT Article DE Motor vehicle accidents; veterans; standardized mortality ratios; hazard ratios; Iraq and Afghanistan wars ID PERSIAN-GULF-WAR; MILITARY PERSONNEL; COMBAT RETURNEES; US VETERANS; MORTALITY; DEPLOYMENT; INJURY; ARMY; PTSD; LIFE AB Objective: We conducted a cohort study of recent wartime veterans to determine the postservice mortality risk due to motor vehicle accidents (MVAs).Methods: Veterans were identified from the Defense Manpower Data Center records. Deployment to te Iraq or Afghanistan war zone was determined from the Contingency Tracking System. Vital status of 317,581 deployed and 964,493 nondeployed veterans was followed from their discharge dates between 2001 to 2007 until earlier of date of death or December 31, 2009. Underlying causes of death were obtained from the National Death Index Plus.Results: Based on 9,353 deaths (deployed, 1,650; nondeployed, 7,703), of which 779 were MVA deaths as drivers (166; 613), both cohorts had 25 to 24% lower mortality risk from all causes but had 44 to 45% higher risk of MVA deaths relative to the U.S. general population. The higher MVA mortality risk was not associated with deployment to the war zone. After controlling for age, sex, race, marital status, branch of service, and rank, the risk for deployed veterans was comparable to that of nondeployed veterans (hazard ratio = 0.91; 95% confidence interval, 0.77-1.09).Conclusions: Veterans exhibit significantly higher risk of MVA deaths compared to the U.S. general population. However, deployment to the Iraq or Afghanistan war was not associated with the excess risk. C1 [Bullman, Tim A.] US Dept Vet Affairs, Off Publ Hlth, 810 Vermont Ave NW, Washington, DC 20420 USA. [Kang, Han K.] Inst Clin Res, Washington, DC USA. [Smolenski, Derek J.; Skopp, Nancy A.; Gahm, Gregory A.; Reger, Mark A.] US Dept Army, Natl Ctr Telehlth & Technol, Tacoma, WA USA. RP Bullman, TA (reprint author), US Dept Vet Affairs, Off Publ Hlth, 810 Vermont Ave NW, Washington, DC 20420 USA. EM tim.bullman@va.gov FU U.S. Army Medical Research and Materiel Command Military Operational Medicine Research Program-Suicide Prevention and Counseling Research [W81XWH-08-MOMRP-SPCR] FX This research was supported by Grant W81XWH-08-MOMRP-SPCR from the U.S. Army Medical Research and Materiel Command Military Operational Medicine Research Program-Suicide Prevention and Counseling Research. The content of this information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. The Washington VA Medical Center Institutional Review Board and Madigan Medical Center IRB approved this study. NR 30 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-9588 EI 1538-957X J9 TRAFFIC INJ PREV JI Traffic Inj. Prev. PY 2017 VL 18 IS 4 BP 369 EP 374 DI 10.1080/15389588.2016.1206201 PG 6 WC Public, Environmental & Occupational Health; Transportation SC Public, Environmental & Occupational Health; Transportation GA ES2LI UT WOS:000399359600006 PM 27589092 ER PT J AU Asuzu, CC Walker, RJ Williams, JS Egede, LE AF Asuzu, Christopher C. Walker, Rebekah J. Williams, Joni Strom Egede, Leonard E. TI Pathways for the relationship between diabetes distress, depression, fatalism and glycemic control in adults with type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Diabetes; Depression; Diabetes distress; Fatalism; HbA1c ID SELF-CARE; SOCIAL DETERMINANTS; MEDICATION ADHERENCE; METAANALYSIS; HEALTH; OUTCOMES; SCALE; PREVALENCE; MANAGEMENT; VALIDITY AB Background: The aim of this study was to examine the mechanism by which depressive symptoms, diabetes distress, and diabetes fatalism together influence diabetes outcomes using structured equation modeling. Methods: 615 adults with type 2 diabetes were recruited from two primary care clinics in the southeastern United States. Psychosocial factors found to be associated with diabetes outcomes were measured using validated questionnaires. Structured equation modeling (SEM) was used to investigate the relationship between diabetes fatalism, depressive symptoms, diabetes distress, self-care and glycemic control. Results: The final model (chi(2)(903) = 24,088.91, p < 0.0001, R-2 = 0.93, RMSEA = 0.05 and CFI = 0.90) showed that higher diabetes distress was directly significantly related to a decreased self-care (r = -0.69, p < 0.001) and increased HbA1c (r = 0.69, p < 0.001). There was no significant direct association between depressive symptoms or fatalism, and glycemic control or self-care. There was, however, an indirect association between increased depressive symptoms and increased fatalism, explained through the direct association with diabetes distress in that higher depressive symptoms (0.76, p < 0.001) and higher fatalism (0.11, p < 0.001) were significantly associated with higher diabetes distress. Conclusion: Diabetes distretc-serves as a pathway through which depressive symptoms and fatalism impact both glycemic control and self-care. In addition, pathways between diabetes distress and both self-care behaviors and glycemic control in patients with type 2 diabetes remained separate, suggesting the need to address both psychological and behavioral factors in standard diabetes care, rather than focusing on psyChological care primarily through support for self-management and treatment of depression. (C) 2017 Elsevier Inc. All rights reserved. C1 [Asuzu, Christopher C.] Med Univ South Carolina, Coll Med, Charleston, SC USA. [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Ralph H Johnson VAMC, Charleston VA HSR&D COIN, HEROIC, Charleston, SC USA. [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699] FX This study was supported by grant K24DK093699 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 34 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JAN PY 2017 VL 31 IS 1 BP 169 EP 174 DI 10.1016/j.jdiacomp.2016.09.013 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ES3MZ UT WOS:000399435000025 PM 27746088 ER PT J AU Cykert, DM Williams, JS Walker, RJ Davis, KS Egede, LE AF Cykert, David M. Williams, Joni S. Walker, Rebekah J. Davis, Kimberly S. Egede, Leonard E. TI The association of cumulative discrimination on quality of care, patient-centered care, and dissatisfaction with care in adults with type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Cumulative discrimination; Quality of care; Patient-centered care; Dissatisfaction with care; Adults; Diabetes ID PERCEIVED RACIAL-DISCRIMINATION; SELF-REPORTED DISCRIMINATION; GLYCEMIC CONTROL; HEALTH-CARE; LIFE; DISPARITIES; BEHAVIORS; SAMPLE AB Aims: Discrimination is linked to negative health outcomes, but little research has investigated how the cumulative effect of discrimination impacts perceptions of care. This study investigated the influence of cumulative perceived discrimination on quality of care, patient-centeredness, and dissatisfaction with care in adults with type 2 diabetes. Methods: Six hundred two patients from two primary care clinics in Charleston, SC. Linear regression models assessed associations between perceived discrimination and quality of care, patient-centered care, and dissatisfaction with care. The models control for race, site, age, gender, marital status, duration of diabetes, education, hours worked weekly, income, and health status. Results: The mean age was 61.5 years, with 66.3% non-Hispanic blacks, and 41.9% earning less than $20,000 annually. In final adjusted analyses, lower patient-centered care was associated with a higher discrimination score (beta = -0.28; p = 0.006), reporting at least 1 category of discrimination beta = -1.47; p = 0.002), and reporting at least 2 categories of discrimination (beta = -1.34; p = 0.004). Dissatisfaction with care was associated with at least 2 categories of discrimination (beta = 0.45; p = 0.002). No significant associations were seen with quality of care indicators. Conclusions: Increased cumulative discrimination was associated with decreased feeling of patient-centeredness and increased' dissatisfaction with care. However, these perceptions of discrimination were not significantly associated with quality indicators. (C) 2017 Elsevier Inc. All rights reserved. C1 [Cykert, David M.; Williams, Joni S.; Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA. [Cykert, David M.; Williams, Joni S.; Walker, Rebekah J.; Davis, Kimberly S.; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, 96 Jonathan Lucas St,Suite 803,MSC 623, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, 109 Bee St, Charleston, SC 29401 USA. RP Egede, LE (reprint author), Med Univ South Carolina, Hlth Equity & Rural Outreach Innovat Ctr, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM david.cykert@gmail.com; stromji@musc.edu; walkerrj@musc.edu; davisks@musc.edu; egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699] FX this study was supported by Grant K24DK093699 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 37 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JAN PY 2017 VL 31 IS 1 BP 175 EP 179 DI 10.1016/j.jdiacomp.2016.09.012 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ES3MZ UT WOS:000399435000026 PM 27769800 ER PT J AU Burke, RE Cumbler, E Coleman, EA Levy, C AF Burke, Robert E. Cumbler, Ethan Coleman, Eric A. Levy, Cari TI Post-Acute Care Reform: Implications and Opportunities for Hospitalists SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID SKILLED NURSING FACILITIES; QUALITY IMPROVEMENT PROJECT; ROOT CAUSE ANALYSES; FEE-FOR-SERVICE; OLDER-ADULTS; POSTACUTE CARE; INTERNAL-MEDICINE; HOME RESIDENTS; MEDICATION RECONCILIATION; DISCHARGE DESTINATION AB Nearly all practicing hospitalists have firsthand experience discharging patients to post-acute care (PAC), which is provided by inpatient rehabilitation facilities, skilled nursing facilities, or home healthcare providers. Many may not know that PAC is poised to undergo transformative change, spurred by recent legislation resulting in a range of reforms. These reforms have the potential to fundamentally reshape the relationship between hospitals and PAC providers. They have important implications for hospitalists and will open up opportunities for hospitalists to improve healthcare value. In this article, the authors explore the reasons for PAC reform and the scope of the reforms. Then they describe the implications for hospitalists and hospitalists' opportunities to Choose Wisely and improve healthcare value for the rapidly growing number of vulnerable older adults transitioning to PAC after hospital discharge. (C) 2017 Society of Hospital Medicine C1 [Burke, Robert E.; Levy, Cari] Denver VA Med Ctr, Res Sect, 1055 Clermont St, Denver, CO 80220 USA. [Burke, Robert E.] Denver VA Med Ctr, Hosp Med Sect, 1055 Clermont St, Denver, CO 80220 USA. [Burke, Robert E.; Cumbler, Ethan] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Coleman, Eric A.; Levy, Cari] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, Res Sect, 1055 Clermont St, Denver, CO 80220 USA.; Burke, RE (reprint author), Denver VA Med Ctr, Hosp Med Sect, 1055 Clermont St, Denver, CO 80220 USA. EM robert.burke5@va.gov FU VA Health Services Research and Development Service career development award; National Institute on Aging [R03 AG050885] FX Dr. Burke was supported by a VA Health Services Research and Development Service career development award and by National Institute on Aging grant R03 AG050885. The funders had no role in the design, conduct, interpretation, or presentation of the data. The other authors have nothing to report. The views represented here are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 99 TC 0 Z9 0 U1 0 U2 0 PU FRONTLINE MEDICAL COMMUNICATIONS PI THE WOODLANDS PA WRIGHTS MEDIA, 2407 TIMBERLOCH PLACE, SUITE B, THE WOODLANDS, TX 77386 USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2017 VL 12 IS 1 BP 46 EP 51 DI 10.1002/jhm.2673 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA ES5KJ UT WOS:000399577200009 PM 28125831 ER PT J AU Alfandre, D AF Alfandre, David TI Improving Quality in Against Medical Advice Discharges-More Empirical Evidence, Enhanced Professional Education, and Directed Systems Changes SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID RISK; LEAVE C1 [Alfandre, David] US Dept Vet Affairs, Natl Ctr Eth Hlth Care, Washington, DC USA. [Alfandre, David] NYU, Sch Med, Med & Populat Hlth, New York, NY USA. RP Alfandre, D (reprint author), 423 East 23rd St,10E1E, New York, NY 10010 USA. EM david.alfandre@va.gov NR 17 TC 0 Z9 0 U1 0 U2 0 PU FRONTLINE MEDICAL COMMUNICATIONS PI THE WOODLANDS PA WRIGHTS MEDIA, 2407 TIMBERLOCH PLACE, SUITE B, THE WOODLANDS, TX 77386 USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2017 VL 12 IS 1 BP 59 EP 60 DI 10.1002/jhm.2678 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA ES5KJ UT WOS:000399577200012 PM 28125834 ER PT J AU Connor, DM Conlon, PJ O'Brien, BC Chou, CL AF Connor, Denise M. Conlon, Paul J. O'Brien, Bridget C. Chou, Calvin L. TI Improving clerkship preparedness: a hospital medicine elective for pre-clerkship students SO MEDICAL EDUCATION ONLINE LA English DT Article DE Early clinical experience; curriculum/program evaluation; academic hospital medicine; medical education - clinical skills training; medical education - undergraduate ID PERCEPTIONS; STRESS; TIME AB Background: Medical students often struggle to apply their nascent clinical skills in clerkships. While transitional clerkships can orient students to new roles and logistics, students may benefit from developing clinical skills in inpatient environments earlier in their curriculum to improve readiness for clerkships. Intervention: Our four- to six-session elective provides pre-clerkship students with individualized learning in the inpatient setting with the aim of improving clerkship preparedness. Students work one-on-one with faculty who facilitate individualized learning through mentoring, deliberate practice, and directed feedback. Second-year medical students are placed on an attending-only, traditionally 'non-teaching' service in the hospital medicine division of a Veterans Affairs (VA) hospital for half-day sessions. Most students self-select into the elective following a class-wide advertisement. The elective also accepts students who are referred for remediation of their clinical skills. Outcome: In the elective's first two years, 25 students participated and 47 students were waitlisted. We compared participant and waitlisted (non-participant) students' self-efficacy in several clinical and professional domains during their first clerkship. Elective participants reported significantly higher clerkship preparedness compared to non-participants in the areas of physical exam, oral presentation, and formulation of assessments and plans. Conclusions: Students found the one-on-one feedback and personalized attention from attending physicians to be a particularly useful aspect of the course. This frequently cited benefit points to students' perceived needs and the value they place on individualized feedback. Our innovation harnesses an untapped resource - the hospital medicine 'non-teaching' service - and serves as an attainable option for schools interested in enhancing early clinical skill-building for all students, including those recommended for remediation. Abbreviations: A&P: Assessment and plan; H&P: History and physical; ILP: Individual learning plan C1 [Connor, Denise M.] San Francisco VA Med Ctr, Div Hosp Med, San Francisco, CA USA. [Connor, Denise M.; O'Brien, Bridget C.; Chou, Calvin L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Conlon, Paul J.] Med Coll Wisconsin, Sch Med, Milwaukee, WI 53226 USA. RP Connor, DM (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Denise.Connor@ucsf.edu FU University of California, San Francisco, School of Medicine and Academy of Medical Educator FX Innovations funding from the University of California, San Francisco, School of Medicine and Academy of Medical Educators was used to purchase gift cards to encourage survey completion. NR 21 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2017 VL 22 AR 1307082 DI 10.1080/10872981.2017.1307082 PG 6 WC Education & Educational Research SC Education & Educational Research GA ER3YU UT WOS:000398737000001 PM 28395598 ER PT J AU Last, BS Rubio, MJG Zhu, CW Cosentino, S Manly, JJ DeCarli, C Stern, Y Brickman, AM AF Last, Briana S. Rubio, Maria-Jose Garcia Zhu, Carolyn W. Cosentino, Stephanie Manly, Jennifer J. DeCarli, Charles Stern, Yaakov Brickman, Adam M. TI MEDICARE EXPENDITURE CORRELATES OF ATROPHY AND CEREBROVASCULAR DISEASE IN OLDER ADULTS SO EXPERIMENTAL AGING RESEARCH LA English DT Article ID MATTER HYPERINTENSITY VOLUME; VASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE; CARIBBEAN HISPANICS; NORTHERN MANHATTAN; AFRICAN-AMERICANS; UNITED-STATES; LIFE-STYLE; STROKE; BRAIN AB Background/Study Context: Magnetic resonance imaging (MRI) markers of cerebrovascular disease and atrophy are common in older adults and are associated with cognitive and medical burden. However, the extent to which they are related to health care expenditures has not been examined. We studied whether increased Medicare expenditures were associated with brain markers of atrophy and cerebrovascular disease in older adults. Methods: A subset of participants (n = 592; mean age = 80 years; 66% women) from the Washington Heights Inwood Columbia Aging Project (WHICAP), a community-based observational study of aging in upper Manhattan, received high-resolution MRI and had Medicare expenditure data on file. We examined the relationship of common markers of cerebrovascular disease (i.e., white matter hyperintensities and presence of infarcts) and atrophy (i.e., whole brain and hippocampal volume) with Medicare expenditure data averaged over a 10-year period. Main outcome measures were (a) mean Medicare payment per year across the 10-year interval; (b) mean payment for outpatient care per year; and (c) mean payment for inpatient care per year of visit. In addition, we calculated the ratio of mean inpatient spending to mean outpatient spending as well as the ratio of mean inpatient spending to mean total Medicare spending. Results: Increased Medicare spending was associated with higher white matter hyperintensity volume, presence of cerebral infarcts, and smaller total brain volume. When examining specific components of Medicare expenditures, we found that inpatient spending was strongly associated with white matter hyperintensity volume and that increased ratios of inpatient to outpatient and inpatient to total spending were associated with infarcts. Conclusion: Medicare costs are related to common markers of "silent" cerebrovascular disease and atrophy. C1 [Last, Briana S.; Rubio, Maria-Jose Garcia; Cosentino, Stephanie; Manly, Jennifer J.; Stern, Yaakov; Brickman, Adam M.] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, 630 West 168th St,P&S Box 16, New York, NY 10032 USA. [Zhu, Carolyn W.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Zhu, Carolyn W.] James J Peters VA Med Ctr, Bronx, NY USA. [Cosentino, Stephanie; Manly, Jennifer J.; Stern, Yaakov; Brickman, Adam M.] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY USA. [Cosentino, Stephanie; Manly, Jennifer J.; Stern, Yaakov; Brickman, Adam M.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA. [DeCarli, Charles] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. RP Brickman, AM (reprint author), Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, 630 West 168th St,P&S Box 16, New York, NY 10032 USA. EM amb2139@columbia.edu FU NIH [AG037212, AG007232, AG034189, AG029949, AG007370] FX This work was supported by NIH grants AG037212, AG007232, AG034189, AG029949, and AG007370. NR 39 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0361-073X EI 1096-4657 J9 EXP AGING RES JI Exp. Aging Res. PY 2017 VL 43 IS 2 BP 149 EP 160 DI 10.1080/0361073X.2017.1276376 PG 12 WC Geriatrics & Gerontology; Psychology SC Geriatrics & Gerontology; Psychology GA EQ3RL UT WOS:000397990100003 PM 28230421 ER PT J AU Hannon, PA Helfrich, CD Chan, KG Allen, CL Hammerback, K Kohn, MJ Parrish, AT Weiner, BJ Harris, JR AF Hannon, Peggy A. Helfrich, Christian D. Chan, K. Gary Allen, Claire L. Hammerback, Kristen Kohn, Marlana J. Parrish, Amanda T. Weiner, Bryan J. Harris, Jeffrey R. TI Development and Pilot Test of the Workplace Readiness Questionnaire, a Theory-Based Instrument to Measure Small Workplaces' Readiness to Implement Wellness Programs SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Readiness for Change; Measure Development; Workplace Health Promotion; Prevention Research ID HEALTH-SERVICES RESEARCH; ORGANIZATIONAL READINESS; LOW-WAGE; MODEL; INNOVATIONS; COMMITMENT; FRAMEWORK; EMPLOYERS AB Purpose. To develop a theory-based questionnaire to assess readiness for change in small workplaces adopting wellness programs. Design. In developing our scale, we first tested items via "think-aloud" interviews. We tested the revised items in a cross-sectional quantitative telephone survey. Setting. The study setting comprised small workplaces (20-250 employees) in low-wage industries. Subjects. Decision-makers representing small workplaces in King County, Washington (think-aloud interviews, n = 9), and the United States (telephone survey, n = 201) served as study subjects. Measures. We generated items for each construct in Weiner's theory of organizational readiness for change. We also measured workplace characteristics and current implementation of workplace wellness programs. Analysis. We assessed reliability by coefficient alpha for each of the readiness questionnaire subscales. We tested the association of all subscales with employers' current implementation of wellness policies, programs, and communications, and conducted a path analysis to test the associations in the theory of organizational readiness to change. Results. Each of the readiness subscales exhibited acceptable internal reliability (coefficient alpha range, .75-.88) and was positively associated with wellness program implementation (p < .05). The path analysis was consistent with the theory of organizational readiness to change, except change efficacy did not predict change-related effort. Conclusion. We developed a new questionnaire to assess small workplaces' readiness to adopt and implement evidence-based wellness programs. Our findings also provide empirical validation of Weiner's theory of readiness for change. C1 [Hannon, Peggy A.; Allen, Claire L.; Hammerback, Kristen; Kohn, Marlana J.; Parrish, Amanda T.; Harris, Jeffrey R.] Univ Washington, Hlth Promot Res Ctr, CDC Prevent Res Ctr, Sch Publ Hlth,Dept Hlth Serv, Seattle, WA 98105 USA. [Helfrich, Christian D.] Northwest Hlth Serv Res, Seattle, WA USA. [Helfrich, Christian D.] Dev Ctr Excellence, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Helfrich, Christian D.; Chan, K. Gary] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA. [Weiner, Bryan J.] Univ North Carolina Chapel Hill, UNC Gillings Global Sch Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA. RP Hannon, PA (reprint author), Univ Washington, Hlth Promot Res Ctr, CDC Prevent Res Ctr, Sch Publ Hlth,Dept Hlth Serv, Seattle, WA 98105 USA. FU National Cancer Institute [5R01CA160217] FX This project was supported by grant 5R01CA160217 from the National Cancer Institute. The authors would like to thank the employers who participated in the interviews and telephone survey. NR 32 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD JAN PY 2017 VL 31 IS 1 BP 67 EP 75 DI 10.4278/ajhp.141204-QUAN-604 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ER2JY UT WOS:000398621500009 ER PT J AU Jang, JH Chand, HS Bruse, S Doyle-Eisele, M Royer, C McDonald, J Qualls, C Klingelhutz, AJ Lin, Y Mallampalli, R Tesfaigzi, Y Nyunoya, T AF Jang, Jun-Ho Chand, Hitendra S. Bruse, Shannon Doyle-Eisele, Melanie Royer, Christopher McDonald, Jacob Qualls, Clifford Klingelhutz, Aloysius J. Lin, Yong Mallampalli, Rama Tesfaigzi, Yohannes Nyunoya, Toru TI Connective Tissue Growth Factor Promotes Pulmonary Epithelial Cell Senescence and Is Associated with COPD Severity SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE Airway epithelial cells; alveolar epithelial cells; cellular senescence; cigarette smoke; connective tissue growth factor; non-human primates ID SMOKE-INDUCED EMPHYSEMA; OXIDATIVE STRESS; DNA-DAMAGE; TELOMERE DYSFUNCTION; CIGARETTE-SMOKING; LUNG FIBROBLASTS; GENE-EXPRESSION; EXPOSED MICE; DISEASE; INFLAMMATION AB The purpose of this study was to determine whether expression of connective tissue growth factor (CTGF) protein in chronic obstructive pulmonary disease (COPD) is consistent in humans and animal models of COPD and to investigate the role of this protein in lung epithelial cells. CTGF in lung epithelial cells of ex-smokers with COPD was compared with ex-smokers without COPD by immunofluorescence. A total of twenty C57Bl/6 mice and sixteen non-human primates (NHPs) were exposed to cigarette smoke (CS) for 4 weeks. Ten mice of these CS-exposed mice and eight of the CS-exposed NHPs were infected with H3N2 influenza A virus (IAV), while the remaining ten mice and eight NHPs were mock-infected with vehicle as control. Both mRNA and protein expression of CTGF in lung epithelial cells of mice and NHPs were determined. The effects of CTGF overexpression on cell proliferation, p16 protein, and senescence-associated beta-galactosidase (SA-beta-gal) activity were examined in cultured human bronchial epithelial cells (HBECs). In humans, CTGF expression increased with increasing COPD severity. We found that protein expression of CTGF was upregulated in lung epithelial cells in both mice and NHPs exposed to CS and infected with IAV compared to those exposed to CS only. When overexpressed in HBECs, CTGF accelerated cellular senescence accompanied by p16 accumulation. Both CTGF and p16 protein expression in lung epithelia are positively associated with the severity of COPD in ex-smokers. These findings show that CTGF is consistently expressed in epithelial cells of COPD lungs. By accelerating lung epithelial senescence, CTGF may block regeneration relative to epithelial cell loss and lead to emphysema. C1 [Jang, Jun-Ho; Mallampalli, Rama; Nyunoya, Toru] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Jang, Jun-Ho; Mallampalli, Rama; Nyunoya, Toru] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Chand, Hitendra S.] Florida Int Univ, Dept Immunol, Herbert Wertheim Coll Med, Miami, FL 33199 USA. [Bruse, Shannon] Regeneron Genet Ctr, Tarrytown, NY USA. [Doyle-Eisele, Melanie; Royer, Christopher; McDonald, Jacob; Lin, Yong; Tesfaigzi, Yohannes] Lovelace Resp Res Inst, COPD Program, Albuquerque, NM USA. [Qualls, Clifford] Biomed Res Inst New Mexico, Albuquerque, NM USA. [Klingelhutz, Aloysius J.] Univ Iowa, Dept Med, Roy J & Lucille Carver Coll Med, Iowa City, IA 52242 USA. RP Nyunoya, T (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM nyunoyat@upmc.edu OI Chand, Hitendra/0000-0002-0574-9307 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development [CX001048, CTSC003-2]; LRRI Institutional Funds; National Institute of Health [AI117560]; American Lung Association Biomedical Research Grant [RG306208]; Flight Attendant Medical Research Institute; [HL068111]; [ES015482] FX This manuscript was supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development by a Merit Review award CX001048 and CTSC003-2 (to TN). This work was also supported by HL068111 and ES015482 (to YT), by LRRI Institutional Funds (to YT and HSC); National Institute of Health (AI117560) and American Lung Association Biomedical Research Grant (RG306208) (to HSC); Flight Attendant Medical Research Institute (to RM). NR 48 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1541-2555 EI 1541-2563 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PY 2017 VL 14 IS 2 BP 228 EP 237 DI 10.1080/15412555.2016.1262340 PG 10 WC Respiratory System SC Respiratory System GA EQ4GO UT WOS:000398033800013 PM 28026993 ER PT J AU Young, MRI AF Young, M. Rita I. TI Cancer Immunology with a Focus on Understudied Cancers as Targets for Immunotherapy SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Editorial Material ID CELLS; IMMUNOGENICITY; GLIOMAS C1 [Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. [Young, M. Rita I.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 173 Ashley Ave, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA.; Young, MRI (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 173 Ashley Ave, Charleston, SC 29425 USA. EM rita.young@va.gov NR 18 TC 0 Z9 0 U1 1 U2 1 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1422-0067 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD JAN PY 2017 VL 18 IS 1 AR 127 DI 10.3390/ijms18010127 PG 4 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary SC Biochemistry & Molecular Biology; Chemistry GA EJ2HL UT WOS:000393030600126 ER PT J AU Rasmussen, DD Kincaid, CL Froehlich, JC AF Rasmussen, Dennis D. Kincaid, Carrie L. Froehlich, Janice C. TI Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations SO ALCOHOL AND ALCOHOLISM LA English DT Article ID CORTICOTROPIN-RELEASING-FACTOR; CHRONIC DAILY ETHANOL; PREFERRING P RATS; DEPENDENT INDIVIDUALS; NORADRENERGIC SYSTEM; WITHDRAWAL; ABSTINENCE; DISORDERS; MODEL; NOREPINEPHRINE AB Aims: Stress-induced anxiety is a risk factor for relapse to alcohol drinking. The aim of this study was to test the hypothesis that the central nervous system (CNS)-active a1-adrenergic receptor antagonist, prazosin, would block the stress-induced increase in anxiety that occurs during alcohol deprivations. Methods: Selectively bred male alcohol-preferring (P) rats were given three cycles of 5 days of ad libitum voluntary alcohol drinking interrupted by 2 days of alcohol deprivation, with or without 1 h of restraint stress 4 h after the start of each of the first two alcohol deprivation cycles. Prazosin (1.0 or 1.5 mg/kg, IP) or vehicle was administered before each restraint stress. Anxiety-like behavior during alcohol deprivation following the third 5-day cycle of alcohol drinking (7 days after the most recent restraint stress similar to prazosin treatment) was measured by performance in an elevated plus-maze and in social approach/avoidance testing. Results: Rats that received constant alcohol access, or alcohol access and deprivations without stress or prazosin treatments in the first two alcohol deprivations did not exhibit augmented anxiety-like behavior during the third deprivation. In contrast, rats that had been stressed during the first two alcohol deprivations exhibited increased anxiety-like behavior (compared with control rats) in both anxiety tests during the third deprivation. Prazosin given before stresses in the first two cycles of alcohol withdrawal prevented increased anxiety-like behavior during the third alcohol deprivation. Conclusion: Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking. Short summary: Administration of prazosin before stresses during repetitive alcohol deprivations in male alcohol-preferring (P) rats prevents increased anxiety during a subsequent deprivation without further prazosin treatment. Prazosin treatment during repeated alcohol deprivations may prevent the increased anxiety that is a risk factor for relapse to alcohol drinking. C1 [Rasmussen, Dennis D.; Kincaid, Carrie L.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Mental Hlth Serv, Seattle, WA USA. [Rasmussen, Dennis D.] Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. [Froehlich, Janice C.] Indiana Univ Sch Med, Dept Med, Indinapolis, IN 46202 USA. RP Rasmussen, DD (reprint author), VA Med Ctr, MIRECC 116, 1660 S Columbian Way, Seattle, WA 98108 USA. EM drasmuss@u.washington.edu FU National Institutes of Health [AA018604, AA017839, AA007611] FX Supported by resources from VA Puget Sound Health Care System Mental Health Service, VISN 20 MIRECC and National Institutes of Health Grants AA018604 and AA017839 (Rasmussen); AA018604 and AA007611 (Froehlich). NR 37 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 EI 1464-3502 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD JAN 1 PY 2017 VL 52 IS 1 BP 5 EP 11 DI 10.1093/alcalc/agw082 PG 7 WC Substance Abuse SC Substance Abuse GA EP2ML UT WOS:000397217200002 PM 27797712 ER PT J AU Sultzer, DL Marder, SR AF Sultzer, David L. Marder, Stephen R. TI Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Editorial Material C1 [Sultzer, David L.; Marder, Stephen R.] VA Greater Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA. [Sultzer, David L.; Marder, Stephen R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Sultzer, DL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Psychiat Serv,Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. EM dsultzer@ucla.edu FU U.S. Department of Veterans Affairs; Eli Lilly and Company; Transition Therapeutics; Avanir; Otsuka; Astellas; Acadia; Insys; Neurocrine; Forum; Allergan; Teva; Lundbeck; Takeda; Roche FX This work was supported in part by the U.S. Department of Veterans Affairs.; Dr. Sultzer has received research support from Eli Lilly and Company, Transition Therapeutics, and Avanir and has received payment for research consultation from Otsuka, Astellas, Acadia, and Insys. Dr. Marder has received research support from Neurocrine and Forum and has received payment for consultation or other services from Allergan, Teva, Lundbeck, Otsuka, Takeda, Forum, and Roche. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JAN PY 2017 VL 25 IS 1 BP 11 EP 12 DI 10.1016/j.jagp.2016.10.002 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EO1UV UT WOS:000396484300002 PM 28231870 ER PT J AU Monin, JK Mota, N Levy, B Pachankis, J Pietrzak, RH AF Monin, Joan K. Mota, Natalie Levy, Becca Pachankis, John Pietrzak, Robert H. TI Older Age Associated with Mental Health Resiliency in Sexual Minority US Veterans SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Sexual minority status; veterans; mental health; aging ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-HEALTH; UNITED-STATES; CARE UTILIZATION; TRAUMA EXPOSURE; ADULTS; ORIENTATION; RISK; GAY; DEPRESSION AB Objectives: Objectives were to: (a) identify the mental health needs of older and younger sexual minority and heterosexual U.S. veterans and (b) examine whether sexual minority status confers vulnerability or resiliency in older adulthood. Support and trauma exposure were examined as potential mechanisms for age by sexual orientation differences. Methods: Participants were a nationally representative sample of 3,095 U.S. veterans (ages 21 to 96 years). Measures included demographics, military characteristics, sexual orientation (lesbian, gay, or bisexual; LGB), social support, trauma, and mental health indicators (lifetime and present depression and post-traumatic stress disorder (PTSD); lifetime anxiety and suicidal ideation). Results: Younger LGB veterans were most likely to report lifetime depression and/or PTSD and current depression compared with older LGB and younger and older heterosexual veterans. Older LGB veterans had low levels of mental health problems, but they reported the smallest social support networks. Conclusions: Older and younger LGB veterans have different mental health challenges. Younger LGB veterans are more vulnerable to mental health problems than their older LGB peers. Older LGB veterans are resilient, but they may be at greater risk of social isolation than their younger LGB peers. C1 [Monin, Joan K.; Levy, Becca; Pachankis, John] Yale Sch Publ Hlth, Social & Behav Sci Div, New Haven, CT 06520 USA. [Mota, Natalie] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzak, Robert H.] Yale Sch Med, Dept Psychiat, New Haven, CT USA. RP Monin, JK (reprint author), Yale Sch Publ Hlth, Social & Behav Sci Div, New Haven, CT 06520 USA. EM joan.monin@yale.edu FU Department of Veterans Affairs National Center for Post-traumatic Stress Disorder; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (NIA) [P30AG21342]; National Institutes of Health [R01AG032284, R01HL089314, K01 AG042450] FX This study was funded by the Department of Veterans Affairs National Center for Post-traumatic Stress Disorder. Preparation of this report was supported in part by a Research Career Development Award to Dr. Pietrzak from the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (NIA grant P30AG21342) and in part by National Institutes of Health grants (R01AG032284, R01HL089314) and to Dr. Monin from the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (NIA grant P30AG21342) and in part by National Institutes of Health grant (K01 AG042450). There are no disclosures to report. NR 40 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JAN PY 2017 VL 25 IS 1 BP 81 EP 90 DI 10.1016/j.jagp.2016.09.006 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EO1UV UT WOS:000396484300013 PM 27769835 ER PT J AU Banks, WA AF Banks, William A. TI Globalization of the Scientific Literature: CPD as a Case Study Foreword SO CURRENT PHARMACEUTICAL DESIGN LA English DT Editorial Material C1 [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Banks, WA (reprint author), Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 EI 1873-4286 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PY 2017 VL 23 IS 1 BP 1 EP 2 DI 10.2174/138161282301170213194403 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EL4DU UT WOS:000394572700001 PM 28292246 ER PT J AU Moheb, N Mendez, MF Kremen, SA Teng, E AF Moheb, Negar Mendez, Mario F. Kremen, Sarah A. Teng, Edmond TI Executive Dysfunction and Behavioral Symptoms Are Associated with Deficits in Instrumental Activities of Daily Living in Frontotemporal Dementia SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Frontotemporal lobar degeneration; Primary progressive aphasia; Semantic dementia; Progressive nonfluent aphasia; Cognition; Behavioral symptoms ID PRIMARY PROGRESSIVE APHASIA; UNIFORM DATA SET; ALZHEIMER-DISEASE; OLDER-ADULTS; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA; FUNCTIONAL STATUS; VARIANT; ASSESSMENTS; INVENTORY AB Background: Deficits in instrumental activities of daily living (ADLs) may be more prominent in behavioral variant frontotemporal dementia (bvFTD) than in nonfluent/agrammatic variant primary progressive aphasia (nfvPPA) or semantic variant primary progressive aphasia (svPPA). It is uncertain whether frontotemporal dementia (FTD) subgroups exhibit different patterns and/or predictors of functional impairment. Methods: We examined data from participants diagnosed with bvFTD (n = 607), svPPA (n = 132), and nfvPPA (n = 155) who were included in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) and assessed with the Functional Activities Questionnaire (FAQ). Stepwise multiple linear regression analyses were performed to identify associations between FAQ scores and cognitive/behavioral deficits using the NACC UDS neuropsychological testing battery and the Neuropsychiatric Inventory Questionnaire. Results: FAQ scores were higher in bvFTD than svPPA or nfvPPA. Functional deficits across FTD subtypes differed in severity, but not pattern, and were driven by executive dysfunction and behavioral symptoms. Conclusion: Executive dysfunction and behavioral symptoms underlie instrumental ADL deficits in FTD, which are most prominent in bvFTD. (C) 2017 S. Karger AG, Basel. C1 [Moheb, Negar; Mendez, Mario F.; Kremen, Sarah A.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Teng, E (reprint author), West Los Angeles VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@mednet.ucla.edu FU Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation; NIA/NIH grant [U01 AG016976]; NIA [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG047366, P30 AG010129, P50 AG016573]; [P50 AG016570]; [P50 AG005131]; [P50 AG023501]; [P30 AG035982]; [P30 AG028383]; [P30 AG010124]; [P50 AG005133]; [P50 AG005142]; [P30 AG012300]; [P50 AG005136]; [P50 AG033514]; [P50 AG005681]; [P50 AG047270] FX This research was supported by the Alzheimer's Disease Research Centers of California and the Sidell-Kagan Foundation. The NACC database is funded by NIA/NIH grant U01 AG016976. NACC data were contributed by the NIA-funded Alzheimer Disease Centers: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI Marie-Francoise Chesselet, MD, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD). NR 48 TC 0 Z9 0 U1 3 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 EI 1421-9824 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2017 VL 43 IS 1-2 BP 89 EP 99 DI 10.1159/000455119 PG 11 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA EM9XL UT WOS:000395664800009 PM 28103593 ER PT J AU Kocarnik, BM Moore, KP Smith, NL Boyko, EJ AF Kocarnik, Beverly M. Moore, Kathryn P. Smith, Nicholas L. Boyko, Edward J. TI Weight change after initiation of oral hypoglycemic monotherapy for diabetes predicts 5-year mortality: An observational study SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Weight change; Oral hypoglycemic medication; Mortality; Epidemiology; Prospective research ID ALL-CAUSE MORTALITY; BODY-MASS INDEX; OBESITY PARADOX; US ADULTS; MELLITUS; INDIVIDUALS; ASSOCIATION; COHORT; RISK AB Purpose: To investigate whether weight change in the first year after initiating an oral hypoglycemic agent (OHA) for type 2 diabetes treatment is associated with mortality in a national cohort. Procedures: We prospectively followed Veterans Health Administration patients with type 2 diabetes initiating treatment with an OHA and not receiving any other diabetes pharmacotherapy for at least one year. Information on OHAs, weight, co-morbidities, other medications, demographics, and laboratory measurements was obtained from electronic medical records. Logistic regression was used to estimate 5-year mortality odds by weight change during the first year after OHA treatment initiation. Findings: Patients (mean age 65 years, 97% male, mean BMI 32.3 kg/m2) initiating OHA monotherapy between 2003 and 2008 totaled 145,198 (metformin n = 89,111, glipizide n = 27,100, glyburide n = 25,226, rosiglitazone n = 3,761). Most patients (65%) maintained a stable weight (change <= 5% from baseline) during the first year after OHA initiation. Those losing >5% of baseline weight had a significantly higher odds of death over the subsequent 5-years ranging from 1.64 to 2.13 depending on OHA type. In the metformin group, weight gain >5% of baseline was also associated with higher odds of 5-year mortality. The same results were obtained after conducting three sensitivity analyses that excluded patients for the following reasons: weight loss in the one year prior to OHA initiation, weight change >100 lbs, or weight change >50 lbs. Conclusions: Weight loss was associated with higher odds of 5-year mortality among patients initiating an OHA, as was weight gain for metformin only. Published by Elsevier Ireland Ltd. C1 [Kocarnik, Beverly M.; Boyko, Edward J.] Gen Med & Hosp & Specialty Med Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Kocarnik, Beverly M.] Univ Washington, Dept Med, Div Endocrinol Metab & Nutr, Seattle, WA USA. [Kocarnik, Beverly M.; Moore, Kathryn P.; Smith, Nicholas L.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst S 123 PCC, 1660 South Columbian Way, Seattle, WA 98108 USA. EM eboyko@uw.edu OI Boyko, Edward/0000-0002-3695-192X FU Seattle Epidemiologic Research and Information Center (ERIC) of VA Puget Sound in Seattle; VA Advanced Fellowship in Geriatrics; NIH [2T32HL007028-36A1] FX This work was supported by the Seattle Epidemiologic Research and Information Center (ERIC) of VA Puget Sound in Seattle, and by facilities and services provided by the Diabetes Research Center (NIH DK-17047) at the University of Washington. VA Puget Sound Health Care System provided support for Drs. Boyko and Smith's involvement in this research. Dr. Kocarnik was supported by a VA Advanced Fellowship in Geriatrics and NIH Training Grant 2T32HL007028-36A1. The funding sources had no role in the conduct of the research or the preparation of the article. NR 27 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 EI 1872-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD JAN PY 2017 VL 123 BP 181 EP 191 DI 10.1016/j.diabres.2016.11.025 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EK5CO UT WOS:000393944700021 PM 28056429 ER PT J AU Becker, KL Arts, P Jaeger, M Plantinga, TS Gilissen, C van Laarhoven, A van Ingen, J Veltman, JA Joosten, LAB Hoischen, A Netea, MG Iseman, MD Chan, ED van de Veerdonk, FL AF Becker, Katharina L. Arts, Peer Jaeger, Martin Plantinga, Theodorus S. Gilissen, Christian van Laarhoven, Arjan van Ingen, Jakko Veltman, Joris A. Joosten, Leo A. B. Hoischen, Alexander Netea, Mihai G. Iseman, Michael D. Chan, Edward D. van de Veerdonk, Frank L. TI MST1R mutation as a genetic cause of Lady Windermere syndrome SO EUROPEAN RESPIRATORY JOURNAL LA English DT Letter ID MYCOBACTERIAL LUNG-DISEASE; NONTUBERCULOUS MYCOBACTERIA; INTERFERON-GAMMA; AVIUM COMPLEX; RECEPTOR; BODY C1 [Becker, Katharina L.; Jaeger, Martin; Plantinga, Theodorus S.; van Laarhoven, Arjan; Joosten, Leo A. B.; Netea, Mihai G.; van de Veerdonk, Frank L.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Dept Internal Med, Nijmegen, Netherlands. [Arts, Peer; Gilissen, Christian; Veltman, Joris A.; Hoischen, Alexander] Radboud Univ Nijmegen, Med Ctr, Donders Ctr Neurosci, Dept Human Genet, Nijmegen, Netherlands. [van Ingen, Jakko] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Dept Microbiol, Nijmegen, Netherlands. [Veltman, Joris A.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Clin Genet, Maastricht, Netherlands. [Iseman, Michael D.; Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Denver, CO USA. RP van de Veerdonk, FL (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Geert Grooteplein Zuid 8, NL-6525 GA Nijmegen, Netherlands. EM frank.vandeveerdonk@radboudumc.nl FU Netherlands Organisation for Scientific Research (NWO); European Research Council (ERC) [281964]; NWO; ERC [310372]; Euopean Research Area-Net for Research Programmes on Rare Diseases "EURO-CMC" FX A. Hoischen, C. Gilissen and F. van de Veerdonk are supported by Veni grants of the Netherlands Organisation for Scientific Research (NWO). J.A. Veltman was supported by a European Research Council (ERC) starting grant (281964). M.G. Netea is supported by Vici grants from the NWO and by an ERC consolidator grant (310372). F. van de Veerdonk is supported by the Euopean Research Area-Net for Research Programmes on Rare Diseases "EURO-CMC". Funding information for this article has been deposited with Open Funder registry. NR 14 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD JAN PY 2017 VL 49 IS 1 AR 1601478 DI 10.1183/13993003.01478-2016 PG 4 WC Respiratory System SC Respiratory System GA EP5MU UT WOS:000397423500029 ER PT J AU Luks, AM Swenson, ER Bartsch, P AF Luks, Andrew M. Swenson, Erik R. Baertsch, Peter TI Acute high-altitude sickness SO EUROPEAN RESPIRATORY REVIEW LA English DT Article ID ACUTE MOUNTAIN-SICKNESS; HYPOXIC PULMONARY VASOCONSTRICTION; TESTING IDENTIFIES SUBJECTS; EXHALED NITRIC-OXIDE; CEREBRAL EDEMA; NORMOBARIC HYPOXIA; ALVEOLAR HYPOXIA; INFLAMMATORY PROCESSES; EXERCISE PERFORMANCE; PROSPECTIVE COHORT AB At any point 1-5 days following ascent to altitudes. 2500 m, individuals are at risk of developing one of three forms of acute altitude illness: acute mountain sickness, a syndrome of nonspecific symptoms including headache, lassitude, dizziness and nausea; high-altitude cerebral oedema, a potentially fatal illness characterised by ataxia, decreased consciousness and characteristic changes on magnetic resonance imaging; and high-altitude pulmonary oedema, a noncardiogenic form of pulmonary oedema resulting from excessive hypoxic pulmonary vasoconstriction which can be fatal if not recognised and treated promptly. This review provides detailed information about each of these important clinical entities. After reviewing the clinical features, epidemiology and current understanding of the pathophysiology of each disorder, we describe the current pharmacological and nonpharmacological approaches to the prevention and treatment of these diseases. C1 [Luks, Andrew M.; Swenson, Erik R.] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA. [Baertsch, Peter] Univ Clin Heidelberg, Dept Internal Med, Heidelberg, Germany. RP Luks, AM (reprint author), Harborview Med Ctr, Div Pulm & Crit Care Med, 325 Ninth Ave,Box 359762, Seattle, WA 98104 USA. EM aluks@u.washington.edu NR 139 TC 0 Z9 0 U1 4 U2 4 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0905-9180 EI 1600-0617 J9 EUR RESPIR REV JI Eur. Respir. Rev. PD JAN 1 PY 2017 VL 26 IS 143 AR UNSP 160096 DI 10.1183/16000617.0096-2016 PG 14 WC Respiratory System SC Respiratory System GA EO9WH UT WOS:000397038300018 ER PT J AU Tyler, JM Teerlink, JR AF Tyler, Jeffrey M. Teerlink, John R. TI The safety of sacubitril-valsartan for the treatment of chronic heart failure SO EXPERT OPINION ON DRUG SAFETY LA English DT Review DE Cardiomyopathy; drug combination; drug safety; heart failure; LCZ696; pharmacology; sacubitril-valsartan ID NEPRILYSIN INHIBITOR LCZ696; NEUTRAL ENDOPEPTIDASE INHIBITOR; CONVERTING ENZYME-INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; BETA-AMYLOID PEPTIDE; NATRIURETIC-PEPTIDE; ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; EJECTION FRACTION; PARADIGM-HF AB Introduction: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor sacubitril and angiotensin II receptor blocker valsartan. In 2015, the US Food and Drug Administration approved sacubitril-valsartan for treatment of heart failure patients with reduced ejection fraction and New York Heart Association class II-IV symptoms following a large, Phase III clinical trial (PARADIGM-HF) that demonstrated a 20% reduction in the combined primary end-point of death from cardiovascular cause or hospitalization for heart failure compared to enalapril. Areas covered: This review discusses the clinical efficacy and safety of angiotensin receptor neprilysin inhibitor sacubitril-valsartan in heart failure with reduced ejection fraction. Expert opinion: Based on the PARADIGM-HF trial, sacubitril-valsartan offers compelling reductions in meaningful clinical endpoints, independent of age or severity of disease. The rate of adverse events was comparable between the enalapril and sacubitril-valsartan groups, although the absolute rates are likely underestimated due to the entry criteria and run-in period. Future trials and post-market surveillance are critical to better understand the risk of angioedema in high risk populations, particularly African-Americans, as well as long-term theoretical risks including the potential for increased cerebral amyloid plaque deposition with possible development of neurocognitive disease. Current trials are underway to evaluate potential benefit in patients with heart failure with preserved ejection fraction. C1 [Tyler, Jeffrey M.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr Cardiol, 111C4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu NR 48 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1474-0338 EI 1744-764X J9 EXPERT OPIN DRUG SAF JI Expert Opin. Drug Saf. PY 2017 VL 16 IS 2 BP 257 EP 263 DI 10.1080/14740338.2017.1279144 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EL4WB UT WOS:000394620500014 PM 28060547 ER PT J AU Robertson, DJ Lee, JK Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Rex, DK AF Robertson, Douglas J. Lee, Jeffrey K. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Rex, Douglas K. TI Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID OCCULT-BLOOD-TEST; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; AVERAGE-RISK POPULATION; SAMPLE RETURN TIME; ADENOMA DETECTION; ASYMPTOMATIC ADULTS; COLONOSCOPY SURVEILLANCE; AMBIENT-TEMPERATURE; SEASONAL-VARIATIONS AB The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed. C1 [Robertson, Douglas J.] VA Med Ctr, 215 N Main St, White River Jct, VT 05009 USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Lee, Jeffrey K.] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA. [Boland, C. Richard] Baylor Univ, Med Ctr, Dallas, TX USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Robertson, DJ (reprint author), VA Med Ctr, Gastroenterol 111E, 215 N Main St, White River Jct, VT 05009 USA. EM douglas.robertson@va.gov FU Olympus; Endochoice FX These authors disclose the following: David A. Johnson is a clinical investigator for Exact Sciences and Epigenomics. David Lieberman served on scientific advisory Board for Exact Sciences. Douglas K. Rex received consulting fees from Olympus and research support from Endochoice. Douglas J. Robertson is on the scientific advisory board for Medtronic. Tonya Kaltenbach served as Consultant for Olympus America. The remaining authors disclose no conflicts. NR 118 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2017 VL 85 IS 1 BP 2 EP + DI 10.1016/j.gie.2016.09.025 PG 23 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EO1YQ UT WOS:000396494200002 PM 27769516 ER PT J AU Guo, XY Yang, ZP Zhao, LN Leung, FL Luo, H Kang, XY Li, X Jia, H Yang, SY Tao, Q Pan, YL Guo, XG AF Guo, Xiaoyang Yang, Zhiping Zhao, Lina Leung, Felix Luo, Hui Kang, Xiaoyu Li, Xin Jia, Hui Yang, Shengye Tao, Qin Pan, Yanglin Guo, Xuegang TI Enhanced instructions improve the quality of bowel preparation for colonoscopy: a meta-analysis of randomized controlled trials SO GASTROINTESTINAL ENDOSCOPY LA English DT Review ID COLORECTAL-CANCER; POLYETHYLENE-GLYCOL; IMPACT; VALIDATION; EDUCATION; TELEPHONE; SOCIETY; SCALE; RISK AB Background and Aims: The success of a colonoscopy is highly dependent on the quality of bowel preparation (BP). Many patients have poor BP due to non-compliance with regular instructions. Reports concerning the effects of enhanced instructions on BP quality are inconsistent. The aim of this meta-analysis was to compare BP quality between patients receiving enhanced instructions in addition to regular instructions and those who received regular instructions only. Methods: MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched to identify relevant studies published for August 2015. The quality of BP (adequate/inadequate), adenoma detection rate, polyp detection rate, willingness to repeat preparation, and adverse events were estimated by using odds ratios (OR) and 95% confidence intervals (CI) with random effects models. Results: Eight randomized controlled trials (n = 3795) were included. Patients who received enhanced instructions showed significantly better BP quality than those receiving only regular instructions (OR, 2.35; 95% CI, 1.65-3.35; P < .001). Subgroup analysis showed that the beneficial effects of enhanced instructions on BP quality were consistent among patients receiving different purgative types, administration methods, or diet restriction (all P < .05). Patients in the enhanced instructions group showed more willingness to repeat the preparation (OR, 1.91; 95% CI, 1.20-3.04; P = .006). Conclusions: Enhanced instructions significantly improved the quality of BP and willingness to repeat the preparation in patients undergoing colonoscopy. Factors related to patient instructions appear to be as important as the preparation method itself in improving BP quality. C1 [Guo, Xiaoyang; Yang, Zhiping; Luo, Hui; Kang, Xiaoyu; Jia, Hui; Yang, Shengye; Tao, Qin; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. [Zhao, Lina] Fourth Mil Med Univ, Xijing Hosp, Dept Radiotherapy, Xian, Shaanxi, Peoples R China. [Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Div Gastroenterol, Sepulveda Ambulatory Care Ctr, 16111 Plummer St, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. [Li, Xin] Fourth Mil Med Univ, Dept Nursing, Xian, Shaanxi, Peoples R China. RP Pan, YL; Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. FU National Natural Science Foundation of China [81172288, 81570482] FX This work was supported in part by the National Natural Science Foundation of China (81172288 and 81570482). NR 28 TC 3 Z9 3 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2017 VL 85 IS 1 BP 90 EP + DI 10.1016/j.gie.2016.05.012 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EO1YQ UT WOS:000396494200010 PM 27189659 ER PT J AU Cadoni, S Falt, P Gallittu, P Liggi, M Smajstrla, V Leung, FW AF Cadoni, Sergio Falt, Premysl Gallittu, Paolo Liggi, Mauro Smajstrla, Vit Leung, Felix W. TI Impact of carbon dioxide insufflation and water exchange on postcolonoscopy outcomes in patients receiving on-demand sedation: a randomized controlled trial SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID UNSEDATED COLONOSCOPY; AIR INSUFFLATION; CO2 INSUFFLATION; DOUBLE-BLIND; PAIN; IMMERSION; INSERTION; TIME; COMPLICATIONS; METAANALYSIS AB Background and Aims: Water exchange (WE) is the least painful insertion method during colonoscopy. Its impact on postcolonoscopy discomfort has not been well-described. Carbon dioxide (CO2) insufflation consistently reduced postcolonoscopy discomfort. We compared postcolonoscopy outcomes of various combinations of insertion and withdrawal techniques (insertion-withdrawal modality): WE-CO2, WE-air insufflation (WE-AI), andCO(2)-CO2. Methods: A total of 240 patients undergoing on-demand sedation diagnostic colonoscopy were randomized to WE-CO2 (n = 79), WE-AI (n = 80), CO2-CO2 (n = 81), with postprocedural data collected up to 24 hours. The primary outcome was postcolonoscopy bloating. Other postcolonoscopy outcomes included pain scores, flatus and incontinence episodes, toilet use, interference with normal activities, patient satisfaction, and patient willingness to repeat the procedure. Results: Demographic and procedural data were comparable. Compared with WE-AI, WE-CO2 and CO2-CO2 resulted in significantly less bloating (all P < .0005) and lower pain scores (P values ranged from .008 to < .0005) up to 3 hours and fewer flatus episodes up to 6 hours (P values ranged from .003 to < .0005). WE-CO2 resulted in less interference with same-day activities compared with WE-AI (P = .043). The differences in postprocedural outcomes were significant, but the magnitude was small. Patient satisfaction and willingness to repeat the procedure were high and comparable among groups. WE was the least painful insertion technique (P < .0005). Conclusions: The combination WE-CO2 appears to be the optimal choice to decrease pain during the examination and to reduce bloating and other undesired procedural outcomes afterward. If a CO2 insufflator is already available, it seems advisable to adopt the combination WE-CO2. In the absence of a CO2 insufflator, the cost effectiveness of the addition of withdrawal CO2 to WE in diagnostic and nondiagnostic settings needs to be critically assessed. (Clinical trial registration number: NCT02409979.) C1 [Cadoni, Sergio; Gallittu, Paolo; Liggi, Mauro] St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. [Falt, Premysl; Smajstrla, Vit] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Czech Republic. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. EM cadonisergio@gmail.com NR 33 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2017 VL 85 IS 1 BP 210 EP + DI 10.1016/j.gie.2016.05.021 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EO1YQ UT WOS:000396494200028 PM 27207825 ER PT J AU Sun, Q Loughran, P Shapiro, R Shrivastava, IH Antoine, DJ Li, T Yan, ZZ Fan, J Billiar, TR Scott, MJ AF Sun, Qian Loughran, Patricia Shapiro, Richard Shrivastava, Indira H. Antoine, Daniel J. Li, Tunliang Yan, Zhengzheng Fan, Jie Billiar, Timothy R. Scott, Melanie J. TI Redox-Dependent Regulation of Hepatocyte Absent in Melanoma 2 Inflammasome Activation in Sterile Liver Injury in Mice SO HEPATOLOGY LA English DT Article ID GROUP BOX 1; ACETAMINOPHEN-INDUCED HEPATOTOXICITY; HEMORRHAGIC-SHOCK; CELL-DEATH; AIM2 INFLAMMASOME; DNA; HMGB1; AUTOPHAGY; RELEASE; PROTEIN AB Sterile liver inflammation, such as liver ischemia-reperfusion, hemorrhagic shock after trauma, and drug-induced liver injury, is initiated and regulated by endogenous mediators including DNA and reactive oxygen species. Here, we identify a mechanism for redox-mediated regulation of absent in melanoma 2 (AIM2) inflammasome activation in hepatocytes after redox stress in mice, which occurs through interaction with cytosolic high mobility group box 1 (HMGB1). We show that in liver during hemorrhagic shock in mice and in hepatocytes after hypoxia with reoxygenation, cytosolic HMGB1 associates with AIM2 and is required for activation of caspase-1 in response to cytosolic DNA. Activation of caspase-1 through AIM2 leads to subsequent hepatoprotective responses such as autophagy. HMGB1 binds to AIM2 at a non-DNAbinding site on the hematopoietic interferon-inducible nuclear antigen domain of AIM2 to facilitate inflammasome and caspase-1 activation in hepatocytes. Furthermore, binding of HMGB1 to AIM2 is stronger with fully reduced all-thiol HMGB1 than with partially oxidized disulfide-HMGB1, and binding strength corresponds to caspase-1 activation. These data suggest that HMGB1 redox status regulates AIM2 inflammasome activation. Conclusion: These findings suggest a novel and important mechanism for regulation of AIM2 inflammasome activation in hepatocytes during redox stress and may suggest broader implications for how this and other inflammasomes are activated and how their activation is regulated during cell stress, as well as the mechanisms of inflammasome regulation in nonimmune cell types. C1 [Sun, Qian; Loughran, Patricia; Li, Tunliang; Yan, Zhengzheng; Fan, Jie; Billiar, Timothy R.; Scott, Melanie J.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Loughran, Patricia] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA USA. [Shrivastava, Indira H.] Univ Pittsburgh, Computat & Syst Biol, Pittsburgh, PA USA. [Antoine, Daniel J.] Univ Liverpool, MRC Ctr Drug Safety Sci, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England. [Li, Tunliang] Xiangya Hosp Cent South Univ 3, Dept Anesthesiol, Xiangtan, Peoples R China. [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA USA. RP Scott, MJ (reprint author), Dept Surg Labs MUH, 3459 Fifth Ave, Pittsburgh, PA 3459 USA. EM scottm@upmc.edu FU National Institutes of Health [R01GM102146, R01HL079669] FX Supported by the National Institutes of Health (R01GM102146, to M.J.S., and R01HL079669, to J.F.). NR 43 TC 0 Z9 0 U1 3 U2 3 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD JAN PY 2017 VL 65 IS 1 BP 253 EP 268 DI 10.1002/hep.28893 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EP3RE UT WOS:000397298600023 PM 27774630 ER PT J AU Rodrigo, GJ Price, D Anzueto, A Singh, D Altman, P Bader, G Patalano, F Fogel, R Kostikas, K AF Rodrigo, Gustavo J. Price, David Anzueto, Antonio Singh, Dave Altman, Pablo Bader, Giovanni Patalano, Francesco Fogel, Robert Kostikas, Konstantinos TI LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE LABA/LAMA combinations; COPD; LAMA; LABA/ICS; meta-analysis ID OBSTRUCTIVE PULMONARY-DISEASE; FIXED-DOSE COMBINATION; UMECLIDINIUM/VILANTEROL 62.5/25 MCG; RANDOMIZED CONTROLLED-TRIALS; PARALLEL-GROUP; DOUBLE-BLIND; FLUTICASONE PROPIONATE/SALMETEROL; SALMETEROL-FLUTICASONE; NETWORK METAANALYSIS; COMPARATIVE EFFICACY AB Background: Randomized controlled trials (RCTs) indicate that long-acting bronchodilator combinations, such as beta 2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable efficacy compared with commonly used COPD treatments. The objective of this analysis was to compare the efficacy and safety of LABA/LAMA with LAMA or LABA/inhaled corticosteroid (ICS) in adults with stable moderate-to-very-severe COPD. Methods: This systematic review and meta-analysis (PubMed/MEDLINE, Embase, Cochrane Library and clinical trial/manufacturer databases) included RCTs comparing. 12 weeks' LABA/ LAMA treatment with LAMA and/or LABA/ICS (approved doses only). Eligible studies were independently selected by two authors using predefined data fields; the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Results: Eighteen studies (23 trials) were eligible (N= 20,185). LABA/LAMA significantly improved trough forced expiratory volume in 1 second (FEV1) from baseline to week 12 versus both LAMA and LABA/ICS (0.07 L and 0.08 L, P. 0.0001), with patients more likely to achieve clinically important improvements in FEV1 of. 100 mL (risk ratio[RR]: 1.33, 95% confidence interval[CI]:[1.20, 1.46] and RR: 1.44, 95% CI:[1.33, 1.56], respectively, the number needed to treat being eight and six, respectively). LABA/LAMA improved transitional dyspnea index and St George's Respiratory Questionnaire scores at week 12 versus LAMA (both P. 0.0001), but not versus LABA/ICS, and reduced rescue medication use versus both (P. 0.0001 and P= 0.001, respectively). LABA/LAMA significantly reduced moderate/severe exacerbation rate compared with LABA/ICS (RR 0.82, 95% CI:[0.75, 0.91]). Adverse event (AE) incidence was no different for LABA/LAMA versus LAMA treatment, but it was lower versus LABA/ICS (RR 0.94, 95% CI: [0.89, 0.99]), including a lower pneumonia risk (RR 0.59, 95% CI:[0.43, 0.81]). LABA/LAMA presented a lower risk for withdrawals due to lack of efficacy versus LAMA (RR: 0.66, 95% CI: [0.51, 0.87]) and due to AEs versus LABA/ICS (RR: 0.83, 95% CI:[0.69, 0.99]). Conclusion: The greater efficacy and comparable safety profiles observed with LABA/LAMA combinations versus LAMA or LABA/ICS support their potential role as first-line treatment options in COPD. These findings are of direct relevance to clinical practice because we included all currently available LABA/LAMAs and comparators, only at doses approved for clinical use. C1 [Rodrigo, Gustavo J.] Hosp Cent Fuerzas Armadas, Dept Emergencia, Ave 8 Octubre 3020, Montevideo 11300, Uruguay. [Price, David] Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Aberdeen, Scotland. [Price, David] Observat & Pragmat Res Inst, Singapore, Singapore. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Singh, Dave] Univ Manchester, Natl Inst Hlth Res Resp & Allergy Clin Res Facil, Univ Hosp South Manchester NHSNHS Fdn Trust, Med Evaluat Unit, Manchester, Lancs, England. [Altman, Pablo; Fogel, Robert] Novartis Pharmaceut, E Hanover, NJ USA. [Bader, Giovanni; Patalano, Francesco; Kostikas, Konstantinos] Novartis Pharma AG, Basel, Switzerland. RP Rodrigo, GJ (reprint author), Hosp Cent Fuerzas Armadas, Dept Emergencia, Ave 8 Octubre 3020, Montevideo 11300, Uruguay. EM gustavo.javier.rodrigo@gmail.com OI Price, David/0000-0002-9728-9992 FU Novartis; Novartis Pharma AG (Basel, Switzerland) FX The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing assistance was provided by Colette O'Sullivan, PhD, of Scriva Medical Communications Ltd, a professional medical writer funded by Novartis. Development of the manuscript was supported by Novartis Pharma AG (Basel, Switzerland). The authors received no compensation related to the development of the manuscript. NR 51 TC 0 Z9 0 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2017 VL 12 BP 907 EP 922 DI 10.2147/COPD.S130482 PG 16 WC Respiratory System SC Respiratory System GA EP5MR UT WOS:000397423200018 PM 28360514 ER PT J AU Waltz, P Zuckerbraun, BS AF Waltz, Paul Zuckerbraun, Brian S. TI Inferior Vena Cava Filters in Trauma Patients-For Whom the Benefit Tolls? SO JAMA SURGERY LA English DT Editorial Material C1 [Zuckerbraun, Brian S.] Univ Pittsburgh, Div Trauma & Gen Surg, 200 Lothrop St,Ste F1200, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Div Trauma & Gen Surg, 200 Lothrop St,Ste F1200, Pittsburgh, PA 15213 USA.; Zuckerbraun, BS (reprint author), Presbyterian Univ Hosp, Vet Affairs Pittsburgh Healthcare Syst, 200 Lothrop St,Ste F1200, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JAN PY 2017 VL 152 IS 1 BP 81 EP 81 DI 10.1001/jamasurg.2016.3121 PG 1 WC Surgery SC Surgery GA EL6GM UT WOS:000394718400018 PM 27681537 ER PT J AU Morgan, AE Wozniak, CJ Gulati, S Ge, L Grossi, EA Weinsaft, JW Ratcliffe, MB AF Morgan, Ashley E. Wozniak, Curtis J. Gulati, Sarthak Ge, Liang Grossi, Eugene A. Weinsaft, Jonathan W. Ratcliffe, Mark B. TI Association of Uneven MitraClip Application and Leaflet Stress in a Finite Element Model SO JAMA SURGERY LA English DT Letter ID REPAIR C1 [Morgan, Ashley E.] UCSF East Bay Surg Residency, San Francisco, CA USA. [Wozniak, Curtis J.] Univ Calif San Francisco, Dept Surg, Div Cardiac Surg, San Francisco, CA 94143 USA. [Wozniak, Curtis J.; Ge, Liang; Ratcliffe, Mark B.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Gulati, Sarthak] Univ Calif Los Angeles, Dept Cardiol, Los Angeles, CA USA. [Ge, Liang] Univ Calif San Francisco, Dept Surg & Bioengn, San Francisco, CA USA. [Grossi, Eugene A.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA. [Weinsaft, Jonathan W.] Weill Cornell Coll Med, Dept Med Cardiol, New York, NY USA. [Weinsaft, Jonathan W.] Weill Cornell Coll Med, Dept Radiol, New York, NY USA. [Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg & Bioengn, San Francisco, CA USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Mark.Ratcliffe@va.gov FU National Institutes of Health [R01 HL128278-01] FX An National Institutes of Health grant (No. R01 HL128278-01) provided salary support for Dr Morgan, who designed the study in conjunction with Dr Ratcliffe and Dr Wozniak; the grant provided further salary support to Dr Weinsaft, who reviewed the manuscript. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JAN PY 2017 VL 152 IS 1 BP 111 EP 114 DI 10.1001/jamasurg.2016.3360 PG 5 WC Surgery SC Surgery GA EL6GM UT WOS:000394718400028 PM 27706490 ER PT J AU Ibrahim, SA Blum, M Lee, GC Mooar, P Medvedeva, E Collier, A Richardson, D AF Ibrahim, Said A. Blum, Marissa Lee, Gwo-Chin Mooar, Pekka Medvedeva, Elina Collier, Aliya Richardson, Diane TI Effect of a Decision Aid on Access to Total Knee Replacement for Black Patients With Osteoarthritis of the Knee A Randomized Clinical Trial SO JAMA SURGERY LA English DT Article ID CORONARY-REVASCULARIZATION PROCEDURES; TOTAL HIP-ARTHROPLASTY; 1ST NATIONAL-HEALTH; OF-VETERANS-AFFAIRS; AFRICAN-AMERICAN; JOINT REPLACEMENT; UNITED-STATES; RACIAL-DIFFERENCES; RHEUMATOID-ARTHRITIS; ETHNIC-DIFFERENCES AB IMPORTANCE. Black patients with advanced osteoarthritis (OA) of the knee are significantly less likely than white patients to undergo surgery. No strategies have been proved to improve access to surgery for black patients with end-stage OA of the knee. OBJECTIVE To assess whether a decision aid improves access to total knee replacement (TKR)surgery for black patients with OA of the knee. DESIGN, SETTING, AND PARTICIPANTS. In a randomized clinical trial, 336 eligible participants who self-identified as black and 50 years or older with chronic and frequent knee pain, a Western Ontario McMaster Universities Osteoarthritis Index score of at least 39, and radiographic evidence of OA of the knee were recruited from December 1, 2010, to May 31, 2014, at 3 medical centers. Exclusion criteria were history of major joint replacement, terminal illness, inflammatory arthritis, prosthetic leg, cognitive impairment, lack of a telephone, or contraindications to elective replacement surgery. Data were analyzed on a per-protocol and intention-to-treat (ITT) basis. EXPOSURE. Access to a decision aid for OA of the knee, a 40-minute video that describes the risks and benefits of TKR surgery. MAIN OUTCOMES AND MEASURES. Receipt of TKR surgery within 12 months and/or a recommendation for TKR surgery from an orthopedic surgeon within 6 months after the intervention. RESULTS. Among 336 patients (101 men [30.1%]; 235 women [69.9%]; mean [SD] age, 59.1 [7.2] years) randomized to the intervention or control group, 13 of 168 controls (7.7%) and 25 of 168 intervention patients (14.9%) underwent TKR within 12 months (P =.04). These changes represent a 70% increase in the TKR rate, which increased by 86%(11 of 154 [7.1%] vs 23 of 150 [15.3%]; P =.02) in the per-protocol sample. Twenty-six controls (15.5%) and 34 intervention patients (20.2%) in the ITT analysis received a recommendation for surgery within 6 months (P =.25). The difference in the surgery recommendation rate between the controls (24 of 154 [15.6%]) and the intervention group (31 of 150 [20.7%]) in the per-protocol analysis also was not statistically significant (P =.25). Adjustment for study site yielded similar results: for receipt of TKR at 12 months, adjusted ORs were 2.10 (95% CI, 1.04-4.27) for the ITT analysis and 2.39 (95% CI, 1.12-5.10) for the per-protocol analysis; for recommendation of TKR at 6 months, 1.39 (95% CI, 0.79- 2.44) and 1.41 (95% CI, 0.78-2.55). CONCLUSIONS AND RELEVANCE. A decision aid increased rates of TKR among black patients. However, rates of recommendation for surgery did not differ significantly. A patient-centered counseling and educational intervention may help to address racial variations in the use of TKR for the management of end-stage OA of the knee. C1 [Ibrahim, Said A.; Collier, Aliya] Univ Penn, Dept Med, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ibrahim, Said A.; Medvedeva, Elina; Collier, Aliya; Richardson, Diane] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Blum, Marissa] Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19122 USA. [Lee, Gwo-Chin] Univ Penn, Dept Orthoped Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Mooar, Pekka] Temple Univ, Sch Med, Dept Orthoped Surg & Sports Med, Philadelphia, PA 19122 USA. RP Ibrahim, SA (reprint author), Univ Penn, Perelman Sch Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM said.ibrahim2@va.gov FU National Institute of Arthritis and Musculoskeletal Skin Diseases [1R01AR059615-0]; National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24AR055259] FX This study was supported by grant 1R01AR059615-0 from the National Institute of Arthritis and Musculoskeletal Skin Diseases, National Institutes of Health. Dr Ibrahim reports receiving Mid-Career Development Award K24AR055259 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. NR 54 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JAN PY 2017 VL 152 IS 1 AR e164225 DI 10.1001/jamasurg.2016.4225 PG 8 WC Surgery SC Surgery GA EL6GM UT WOS:000394718400034 ER PT J AU Sweerus, K Lachowicz-Scroggins, M Gordon, E LaFemina, M Huang, XZ Parikh, M Kanegai, C Fahy, JV Frank, JA AF Sweerus, Kelly Lachowicz-Scroggins, Marrah Gordon, Erin LaFemina, Michael Huang, Xiaozhu Parikh, Mihir Kanegai, Cindy Fahy, John V. Frank, James A. TI Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Asthma; epithelium; epithelial barrier function; tight junction; antigen sensitization; airway hyperresponsiveness ID INTRAEPITHELIAL MAST-CELLS; HUMAN TRACHEAL EPITHELIUM; TIGHT JUNCTION; ATOPIC-DERMATITIS; EXPRESSION; MICE; GENE; INTERLEUKIN-13; INFLAMMATION; EXPOSURE AB Background: Epithelial barrier dysfunction and increased permeability may contribute to antigen sensitization and disease progression in asthma. Claudin-18.1 is the only known lung-specific tight junction protein, but its contribution to airway barrier function or asthma is unclear. Objectives: We sought to test the hypotheses that claudin-18 is a determinant of airway epithelial barrier function that is downregulated by IL-13 and that claudin-18 deficiency results in increased aeroantigen sensitization and airway hyperresponsiveness. Methods: Claudin-18.1 mRNA levels were measured in airway epithelial brushings from healthy controls and patients with asthma. In patients with asthma, claudin-18 levels were compared with a three-gene-mean marker of T(H)2 inflammation. Airway epithelial permeability changes due to claudin-18 deficiency were measured in 16HBE cells and claudin-18 null mice. The effect of IL-13 on claudin expression was determined in primary human airway epithelial cells and in mice. Airway hyperresponsiveness and serum IgE levels were compared in claudin-18 null and wild-type mice following aspergillus sensitization. Results: Epithelial brushings from patients with asthma (n = 67) had significantly lower claudin-18 mRNA levels than did those from healthy controls (n = 42). Claudin-18 levels were lowest among T(H)2-high patients with asthma. Loss of claudin-18 was sufficient to impair epithelial barrier function in 16HBE cells and in mouse airways. IL-13 decreased claudin-18 expression in primary human cells and in mice. Claudin-18 null mice had significantly higher serum IgE levels and increased airway responsiveness following intranasal aspergillus sensitization. Conclusions: These data support the hypothesis that claudin-18 is an essential contributor to the airway epithelial barrier to aeroantigens. Furthermore, T(H)2 inflammation suppresses claudin-18 expression, potentially promoting sensitization and airway hyperresponsiveness. C1 [Sweerus, Kelly; Lachowicz-Scroggins, Marrah; Gordon, Erin; LaFemina, Michael; Huang, Xiaozhu; Parikh, Mihir; Kanegai, Cindy; Fahy, John V.; Frank, James A.] Univ Calif San Francisco, Div Pulm Crit Care Sleep & Allergy Med, San Francisco, CA 94143 USA. [Sweerus, Kelly; LaFemina, Michael; Parikh, Mihir; Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Sweerus, Kelly; LaFemina, Michael; Parikh, Mihir; Frank, James A.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Lachowicz-Scroggins, Marrah; Huang, Xiaozhu; Fahy, John V.] Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA 94143 USA. RP Frank, JA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA. EM James.frank@ucsf.edu OI Lachowicz-Scroggins, Marrah/0000-0002-3173-5662 FU National Institutes of Health/National Heart, Lung, and Blood Institute [R21HL111707] FX This study was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (grant no. R21HL111707 to J.A.F.). NR 42 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2017 VL 139 IS 1 BP 72 EP + DI 10.1016/j.jaci.2016.02.035 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA EK5WM UT WOS:000393996800009 PM 27215490 ER PT J AU Zhu, CW Cosentino, S Ornstein, KA Gu, Y Andrews, H Stern, Y AF Zhu, Carolyn W. Cosentino, Stephanie Ornstein, Katherine A. Gu, Yian Andrews, Howard Stern, Yaakov TI Interactive Effects of Dementia Severity and Comorbidities on Medicare Expenditures SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Health expenditure; Medicare; economics; comorbidities; longitudinal analysis ID MULTIPLE CHRONIC CONDITIONS; ALZHEIMERS-DISEASE; HEALTH-CARE; RETROSPECTIVE COHORT; ADMINISTRATIVE DATA; COSTS; PREVALENCE; MULTIMORBIDITY; CLAIMS; EPIDEMIOLOGY AB Background: Few studies have examined how dementia and comorbidities may interact to affect healthcare expenditures. Objective: To examine whether effects of dementia severity on Medicare expenditures differed for individuals with different levels of comorbidities. Methods: Data are drawn from the Washington Heights-Inwood Columbia Aging Project (WHICAP). Comprehensive clinical assessments of dementia severity were systematically carried out at similar to 18 month intervals. Dementia severity was measured by Clinical Dementia Rating (CDR). Comorbidities were measured by a modified Elixhauser comorbidities index. Generalized linear models examined effects of dementia severity, comorbidities, and their interactions on Medicare expenditures (1999-2010). Results: At baseline, 1,280 subjects were dementia free (CDR = 0, 66.4%), 490 had very mild dementia (CDR = 0.5, 25.4%), 108 had mild dementia (CDR = 1, 5.6%), and 49 had moderate/severe dementia (CDR = 2/3, 2.5%). Average annual Medicare expenditures for individuals with moderate/severe dementia were more than twice as high as those who were dementia free (CDR = 0: $9,108, CDR= 0.5/1: $11,664, CDR= 2: $19,604, p < 0.01). Expenditures were approximately 10 times higher among those with >= 3 comorbidities than among those with no comorbidities ($2,612 for those with no comorbidities, to $6,109 for those with 1, $10,656 for those with 2, and $30,244 for those with >= 3 comorbidities, p < 0.001). Dementia severity was associated with higher expenditures, but comorbidities were the most important predictor of expenditures. We did not find strong interaction effects between number of comorbidities and dementia severity. Conclusions: Increasing dementia severity and higher comorbidities are associated with higher Medicare expenditures. Care of individuals with dementia should focus on management of comorbidities. C1 [Zhu, Carolyn W.; Ornstein, Katherine A.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Zhu, Carolyn W.] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Cosentino, Stephanie; Gu, Yian; Stern, Yaakov] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, Med Ctr, Cognit Neurosci Div,Dept Neurol, New York, NY USA. [Andrews, Howard] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. RP Zhu, CW (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM carolyn.zhu@mssm.edu FU National Institute on Aging [AG07370, AG037212]; Department of Veterans Affairs, Veterans Health Administration FX This research was supported by grants from the National Institute on Aging (AG07370, AG037212). Dr. Zhu is also supported by the Department of Veterans Affairs, Veterans Health Administration. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 50 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2017 VL 57 IS 1 BP 305 EP 315 DI 10.3233/JAD-161077 PG 11 WC Neurosciences SC Neurosciences & Neurology GA EN8SQ UT WOS:000396270500026 PM 28222520 ER PT J AU Ismail, Z Agueera-Ortiz, L Brodaty, H Cieslak, A Cummings, J Fischer, CE Gauthier, S Geda, YE Herrmann, N Kanji, J Lanctot, KL Miller, DS Mortby, ME Onyike, CU Rosenberg, PB Smith, EE Smith, GS Sultzer, DL Lyketsos, C AF Ismail, Zahinoor Agueera-Ortiz, Luis Brodaty, Henry Cieslak, Alicja Cummings, Jeffrey Fischer, Corinne E. Gauthier, Serge Geda, Yonas E. Herrmann, Nathan Kanji, Jamila Lanctot, Krista L. Miller, David S. Mortby, Moyra E. Onyike, Chiadi U. Rosenberg, Paul B. Smith, Eric E. Smith, Gwenn S. Sultzer, David L. Lyketsos, Constantine CA NPS-PIA ISTAART TI The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre- Dementia Populations SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Behavioral and psychological symptoms of dementia; dementia; mild behavioral impairment; mild cognitive impairment; neuropsychiatric symptoms; preclinical dementia; prodromal dementia ID ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; CACHE COUNTY; PROSPECTIVE COHORT; INCIDENT DEMENTIA; RISK-FACTORS; INVENTORY; PROGRESSION; PREDICTORS; PSYCHOSIS AB Background: Mild behavioral impairment (MBI) is a construct that describes the emergence at = 50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a precursor to cognitive decline and dementia. MBI describes NPS of any severity, which are not captured by traditional psychiatric nosology, persist for at least 6 months, and occur in advance of or in concert with mild cognitive impairment. While the detection and description of MBI has been operationalized in the International Society to Advance Alzheimer's Research and Treatment -Alzheimer's Association (ISTAART-AA) research diagnostic criteria, there is no instrument that accurately reflects MBI as described. Objective: To develop an instrument based on ISTAART-AA MBI criteria. Methods: Eighteen subject matter experts participated in development using a modified Delphi process. An iterative process ensured items reflected the five MBI domains of 1) decreased motivation; 2) emotional dysregulation; 3) impulse dyscontrol; 4) social inappropriateness; and 5) abnormal perception or thought content. Instrument language was developed a priori to pertain to non-demented functionally independent older adults. Results: We present the Mild Behavioral Impairment Checklist (MBI-C), a 34-item instrument, which can easily be completed by a patient, close informant, or clinician. Conclusion: The MBI-C provides the first measure specifically developed to assess the MBI construct as explicitly described in the criteria. Its utility lies in MBI case detection, and monitoring the emergence of MBI symptoms and domains over time. Studies are required to determine the prognostic value of MBI for dementia development, and for predicting different dementia subtypes. C1 [Ismail, Zahinoor] Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada. [Ismail, Zahinoor] Cumming Sch Med, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada. [Ismail, Zahinoor; Cieslak, Alicja; Kanji, Jamila; Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB, Canada. [Ismail, Zahinoor; Cieslak, Alicja; Kanji, Jamila; Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Ron & Rene Ward Ctr Healthy Brain Aging Res, Calgary, AB, Canada. [Agueera-Ortiz, Luis] Univ 12 Octubre, Ctr Invest Biomed & Red Salud Mental CIBERSAM, Dept Psychiat, Madrid, Spain. [Agueera-Ortiz, Luis] Univ 12 Octubre, Res Inst i 12, Madrid, Spain. [Brodaty, Henry] Univ New South Wales, Ctr Healthy Brain Ageing, Sydney, NSW, Australia. [Brodaty, Henry] Univ New South Wales, Dementia Collaborat Res Ctr, Sydney, NSW, Australia. [Cummings, Jeffrey] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA. [Fischer, Corinne E.] Univ Toronto, St Michaels Hosp, Fac Med,Keenan Res Ctr Biomed Res, Li Ka Shing Knowledge Inst,Dept Psychiat, Toronto, ON, Canada. [Gauthier, Serge] McGill Ctr Studies Aging, Douglas Mental Hlth Res Inst, Montreal, PQ, Canada. [Geda, Yonas E.] Mayo Clin, Dept Psychiat & Neurol, Scottsdale, AZ USA. [Herrmann, Nathan] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Geriatr Psychiat, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Fac Med, Neuropsychopharmacol Res Program Sunnybrook Res I, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Fac Med, Dept Psychiat & Pharmacol Toxicol, Toronto, ON, Canada. [Miller, David S.] Bracket Global, Wayne, PA USA. [Mortby, Moyra E.] Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Res Sch Populat Hlth, NHMRC Natl Inst Dementia Res, Canberra, ACT, Australia. [Onyike, Chiadi U.; Rosenberg, Paul B.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD USA. [Smith, Gwenn S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Smith, Gwenn S.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA. [Sultzer, David L.] Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Sultzer, David L.] VA Greater Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. [Lyketsos, Constantine] Johns Hopkins Bayview & Johns Hopkins Med, Memory & Alzheimers Treatment Ctr, Baltimore, MD USA. [Lyketsos, Constantine] Johns Hopkins Bayview & Johns Hopkins Med, Alzheimers Dis Res Ctr, Dept Psychiat & Behav Sci, Baltimore, MD USA. RP Ismail, Z (reprint author), TRW Bldg 1st Floor,3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada. EM zahinoor@gmail.com FU Hotchkiss Brain Institute via the Alzheimer Society of Calgary; Katthy Taylor Chair in Vascular Dementia; CIHR; Department of Veterans Affairs; National Institute of Health [AG038893, AG041633]; National Institute of General Medical Sciences [P20GM109025]; Keep Memory Alive; Australian National Health and Medical Research Council (NHMRC); Australian Research Council (ARC) Dementia Research Development Fellowship [1102028]; Weston Brain Institute; NIH [P50AG005146] FX ZI is supported by the Hotchkiss Brain Institute via the Alzheimer Society of Calgary. EES is supported by the Katthy Taylor Chair in Vascular Dementia and CIHR. DS is supported in part by the Department of Veterans Affairs. GS is supported by National Institute of Health: AG038893 and AG041633. JC acknowledges funding from the National Institute of General Medical Sciences (Grant: P20GM109025) and support from Keep Memory Alive. MEM is supported by the Australian National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC) Dementia Research Development Fellowship #1102028. SG is supported by CIHR and the Weston Brain Institute. KGL is supported in part by NIH grant P50AG005146 for the Johns Hopkins ADRC. NR 45 TC 1 Z9 1 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2017 VL 56 IS 3 BP 929 EP 938 DI 10.3233/JAD-160979 PG 10 WC Neurosciences SC Neurosciences & Neurology GA EM1LK UT WOS:000395078900008 PM 28059789 ER PT J AU Joyce, KE Biggs, ML Djousse, L Ix, JH Kizer, JR Siscovick, DS Shores, MM Matsumoto, AM Mukamal, KJ AF Joyce, Katherine E. Biggs, Mary L. Djousse, Luc Ix, Joachim H. Kizer, Jorge R. Siscovick, David S. Shores, Molly M. Matsumoto, Alvin M. Mukamal, Kenneth J. TI Testosterone, Dihydrotestosterone, Sex Hormone-Binding Globulin, and Incident Diabetes Among Older Men: The Cardiovascular Health Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MIDDLE-AGED MEN; INSULIN SENSITIVITY; BODY-COMPOSITION; SKELETAL-MUSCLE; ELDERLY-MEN; RISK; ANDROGENS; WOMEN; STRENGTH; GLUCOSE AB Context: Although sex hormone-binding globulin (SHBG) and testosterone (T) have been inversely associated with risk of diabetes, few studies have examined dihydrotestosterone (DHT), a more potent androgen than T, in older adults, whose glycemic pathophysiology differs from younger adults. Objective: To determine the associations of SHBG, T, and DHT with insulin resistance and incident diabetes in older adult men. Design: In a prospective cohort study, we evaluated baseline levels of SHBG, T, and DHT using liquid chromatography-tandem mass spectrometry among 852 men free of diabetes and cardiovascular disease in the Cardiovascular Health Study in 1994. Main Outcome: Insulin resistance estimated by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and insulin sensitivity estimated by the Gutt index in 1996, and incident diabetes (n = 112) ascertained over a mean follow-up of 9.8 years. Results: In linear regression models adjusted for demographics, alcohol consumption, current smoking, body mass index, and other androgens, SHBG [HOMA-IR 0.30 units lower per doubling; 95% confidence interval (CI), 0.08 to 0.52; P = 0.01] and total DHT (HOMA-IR 0.18 units lower per doubling; 95% CI, 0.06 to 0.30; P = 0.01), but not free T (P = 0.33), were inversely associated with insulin resistance. In corresponding Cox proportional hazards models, total DHT was again inversely associated with risk of diabetes (adjusted hazard ratio per doubling, 0.69; 95% CI, 0.52 to 0.92; P = 0.01), but SHBG (hazard ratio, 1.09; 95% CI, 0.74 to 1.59; P = 0.66) and free T (hazard ratio, 1.15; 95% CI, 0.92 to 1.43; P = 0.23) were not. Conclusions: Among older men, higher levels of DHT were inversely associated with insulin resistance and risk of diabetes over the ensuing 10 years, whereas levels of T were not. Future studies are still needed to clarify the role of SHBG in risk of diabetes in this population. C1 [Joyce, Katherine E.; Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Biggs, Mary L.] Univ Washington, Dept Biostat, Seattle, WA 98115 USA. [Shores, Molly M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98115 USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Seattle, WA 98115 USA. [Djousse, Luc] Brigham & Womens Hosp, Div Aging, 75 Francis St, Boston, MA 02115 USA. [Djousse, Luc] Harvard Med Sch, Boston, MA 02115 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol Hypertens, San Diego, CA 92093 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92093 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA. [Siscovick, David S.] New York Acad Med, New York, NY 10029 USA. [Matsumoto, Alvin M.] Educ & Clin Ctr, Geriatr Res, Seattle, WA 98108 USA. [Shores, Molly M.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Mukamal, KJ (reprint author), Beth Israel Deaconess Med Ctr, 1309 Beacon St,2nd Floor, Brookline, MA 02446 USA. EM kmukamal@bidmc.harvard.edu RI Djousse, Luc/F-5033-2017 OI Djousse, Luc/0000-0002-9902-3047 FU National Heart, Lung, and Blood Institute [HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295, R01HL094555, R01HL091952]; National Institute on Aging [R01AG023629]; Veterans Affairs Research Service; Veterans Affairs Epidemiology Research and Information Center; Veterans Affairs Geriatric Research, Education and Clinical Center FX This research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295, R01HL094555, and R01HL091952 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurologic Disorders and Stroke. Additional support was provided by R01AG023629 from the National Institute on Aging, the Veterans Affairs Research Service, the Veterans Affairs Epidemiology Research and Information Center, and the Veterans Affairs Geriatric Research, Education and Clinical Center. A full list of principal CHS investigators and institutions can be found at www.chs-nhlbi.org. NR 29 TC 0 Z9 0 U1 1 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2017 VL 102 IS 1 BP 33 EP 39 DI 10.1210/jc.2016-2623 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP0IV UT WOS:000397071900006 PM 27732332 ER PT J AU Palladino, B Montgomery, AE Sommers, M Fargo, JD AF Palladino, B. Montgomery, A. E. Sommers, M. Fargo, J. D. TI Risk of Suicide Among Veterans with Traumatic Brain Injury Experiencing Homelessness SO JOURNAL OF MILITARY AND VETERANS HEALTH LA English DT Article C1 [Palladino, B.; Sommers, M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Montgomery, A. E.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19144 USA. [Fargo, J. D.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. RP Montgomery, AE (reprint author), US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19144 USA. EM ann.montgomery2@va.gov FU U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans FX This study was funded by the U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans. NR 10 TC 0 Z9 0 U1 0 U2 0 PU AUSTRALASIAN MILITARY MEDICINE ASSOC PI HOBART PA AMMA SECRETARIAT, 113 HARRINGTON ST, HOBART, TAS 7000, AUSTRALIA SN 1835-1271 EI 1839-2733 J9 J MIL VETERANS HEALT JI J. Mil. Veterans Health PD JAN PY 2017 VL 25 IS 1 BP 34 EP 38 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA EO0YV UT WOS:000396425500007 ER PT J AU Ortega, JM Gonzalez, NG Tejero, PC Monedero, MP Tolani, NB Martin, LN Montero, RS AF Martinez Ortega, J. Gomez Gonzalez, N. Castro Tejero, P. Pinto Monedero, M. Tolani, N. B. Nunez Martin, L. Sanchez Montero, R. TI A portal dosimetry dose prediction method based on collapsed cone algorithm using the clinical beam model SO MEDICAL PHYSICS LA English DT Article DE amorphous silicon; EPID dosimetry; IMRT; portal image prediction ID MODULATED RADIATION-THERAPY; VIVO EPID DOSIMETRY; AMORPHOUS-SILICON; IMAGING DEVICE; IMRT VERIFICATION; PRETREATMENT VERIFICATION; OPTIMAL BACKSCATTER; SYSTEM; IMAGER; RADIOTHERAPY AB Purpose: Amorphous silicon electronical portal imaging devices (EPIDs) are widely used for dosimetric measurements in Radiation Therapy. The purpose of this work was to determine if a portal dose prediction method can be utilized for dose map calculations based on the linear accelerator model within a commercial treatment planning system (Pinnacle 3 v8.0 m). Methods: The method was developed for a 6 MV photon beam on the Varian Clinac 21-EX, at a nominal dose rate of 400 MU/min. The Varian aS1000 EPID was unmounted from the linear accelerator and scanned to acquire CT images of the EPID. The CT images were imported into Pinnacle 3 and were used as a quality assurance phantom to calculate dose on the EPID setup at a source to detector distance of 105 cm. The best match of the dose distributions was obtained considering the image plane located at 106 cm from the source to detector plane. The EPID was calibrated according to the manufacturer procedure and corrections were made for output factors. Arm-backscattering effect, based on profile correction curves, has been introduced. Five low-modulated and three high-modulated clinical planned treatments were predicted and measured with the method presented here and with MatriXX (IBA Dosimetry, Schwarzenbruck, Germany). Results: A portal dose prediction method based on Pinnacle 3 was developed without modifying the commissioned parameters of the model in use in the clinic. CT images of the EPID were acquired and used as a quality assurance phantom. The CT images indicated a mean density of 1.16 g/cm(3) for the sensitive area of the EPID. Output factor measured with the EPID were lower for small fields and larger for larger fields (beyond 10 x 10 cm(2)). Arm-backscatter correction showed a better agreement at the target side of the EPID. Analysis of Gamma index comparison (3%, 3 mm) indicated a minimum of 97.4% pass rate for low modulated and 98.3% for high modulated treatments. Pass rates were similar for MatriXX measurements. Conclusions: The method developed here can be easily implemented into clinic, as neither additional modeling of the clinical energy nor an independent image prediction algorithm are necessary. The main advantage of this method is that portal dose prediction is calculated with the same algorithm and beam model used for patient dose distribution calculation. This method was independently validated with an ionization chamber matrix. (C) 2016 American Association of Physicists in Medicine C1 [Martinez Ortega, J.; Gomez Gonzalez, N.; Pinto Monedero, M.; Nunez Martin, L.] Hosp Univ Puerta Hierro, Dept Med Phys, C Manuel de Falla 1, Majadahonda 28222, Madrid, Spain. [Castro Tejero, P.] Hosp Univ La Princesa, Dept Radiat Oncol, Radiat Phys, C Diego de Leon 62, Madrid 28006, Spain. [Tolani, N. B.] ME DeBakey VA Med Ctr, Dept Radiotherapy, 2002 Holcombe Blvd, Houston, TX 77030 USA. [Sanchez Montero, R.] Univ Alcala De Henares, Signal Theory & Commun Dept, Campus Univ,Km 33-600, Alcala De Henares 28805, Madrid, Spain. RP Ortega, JM (reprint author), Hosp Univ Puerta Hierro, Dept Med Phys, C Manuel de Falla 1, Majadahonda 28222, Madrid, Spain. EM jaime.martinez@salud.madrid.org NR 40 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0094-2405 EI 2473-4209 J9 MED PHYS JI Med. Phys. PD JAN PY 2017 VL 44 IS 1 BP 333 EP 341 DI 10.1002/mp.12018 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EO9WJ UT WOS:000397038500032 ER PT J AU Herrick, KS Woltjer, R Pham, T Chalupsky, M Hiller, AL AF Herrick, Kory S. Woltjer, Randy Thao Pham Chalupsky, Megan Hiller, Amie L. TI Central Hypoventilation in Progressive Supranuclear Palsy SO MOVEMENT DISORDERS CLINICAL PRACTICE LA English DT Article DE progressive supranuclear palsy; primary hypoventilation; tauopathy ID MULTIPLE SYSTEM ATROPHY AB Central hypoventilation, also known as Ondine's curse, results from an impairment of the autonomic respiratory drive. It is characterized by an attenuated or absent respiratory response to hypoxemia and hypercapnia with preservation of volitional respiratory function. R.J. was a 75-year-old woman with a diagnosis of probably PSP who developed central hypoventilation approximately 4 years after her initial onset of symptoms. Brain MRI showed no evidence of medullary lesions, one of the more common causes of adult-onset central hypoventilation. The respiratory centers in the medulla, especially the ventral respiratory group (VRG) containing Botzinger and pre-Botzinger complex of neurons, appear critical for normal respiratory rhythm generation. R.J. was maintained on a portable ventilator after her diagnosis of central hypoventilation. Ten months after being placed on ventilation, she passed of unclear causes. R.J. showed pathological features consistent with a diagnosis of PSP, specifically loss of neurons, secondary demyelination, and tau-positive inclusions in both astrocytes and neurons, chiefly in the globus pallidus, midbrain, and brainstem. R.J. showed significant tauopathy in the region of the VRG in particular. We also examined this region in 16 other cases of PSP and found similar tauopathy in all but 1 case, which had significantly less involvement of this area. We had limited clinical data on these cases, but 1 had two episodes of unexplained hypoxia shortly before being placed on hospice. Central hypoventilation associated with tauopathy involving the VRG may be more common than often appreciated. C1 [Herrick, Kory S.; Woltjer, Randy; Thao Pham; Chalupsky, Megan; Hiller, Amie L.] Oregon Hlth & Sci Univ, Dept Neurol, Mail Code 32,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA. [Hiller, Amie L.] Portland VA Med Ctr, Portland, OR USA. RP Hiller, AL (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Mail Code 32,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA. EM peterami@ohsu.edu FU Alzheimer's Disease Center Neuropathology Core-NIH [NIA P30AG8017]; Portland VA Career Development Award-The Effects of Vitamin D on Balance in Parkinson's Disease; NINDS-Udall Study [P50 NS052684]; Michael J. Fox Foundation FX Dr. Woltjer has funding through the Alzheimer's Disease Center Neuropathology Core-NIH NIA P30AG8017. Dr. Hiller had funding through the Portland VA Career Development Award-The Effects of Vitamin D on Balance in Parkinson's Disease until November 2015. Dr. Hiller also receives funding through NINDS-Udall Study P50 NS052684 and the Michael J. Fox Foundation. NR 9 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2330-1619 J9 MOV DISORD CLIN PRAC JI MOV. DISORD. CLIN. PRACT. PD JAN-FEB PY 2017 VL 4 IS 1 BP 42 EP 45 DI 10.1002/mdc3.12348 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA EO0EF UT WOS:000396370400009 PM 28367478 ER PT J AU Singh, JA Bharat, A Khanna, D Aquino-Beaton, C Persselin, JE Duffy, E Elashoff, D Khanna, PP AF Singh, Jasvinder A. Bharat, Aseem Khanna, Dinesh Aquino-Beaton, Cleopatra Persselin, Jay E. Duffy, Erin Elashoff, David Khanna, Puja P. TI Racial differences in health-related quality of life and functional ability in patients with gout SO RHEUMATOLOGY LA English DT Article DE health-related quality of life; HRQOL; function; gout; race; disparity; racial ID RHEUMATOID-ARTHRITIS; ASSESSMENT QUESTIONNAIRE; RESOURCE USE; VETERANS-AFFAIRS; LOWERING THERAPY; CONTROLLED-TRIAL; OLDER-ADULTS; HYPERURICEMIA; HYPERTENSION; METHOTREXATE AB Objective. To compare the health-related quality of life (HRQOL) and the functional ability by race in patients with gout. Methods. In a 9-month prospective cohort multicentre study, patients with gout self-reported race, dichotomized as Caucasian or African American (others excluded). We calculated HRQOL/function scores adjusted for age, study site and college education for Short Form-36 (SF-36; generic HRQOL), Gout Impact Scale (GIS; disease-specific HRQOL) and HAQ-disability index (HAQ-DI; functional ability). Longitudinally adjusted scores were computed using multivariable mixed-effect regression models with a random patient effect and fixed sequential visit effect (3-monthly visits). Results. Compared with Caucasians (n = 107), African Americans (n = 60) with gout were younger (61.1 vs 67.3 years) and had higher median baseline serum urate (9.0 vs 7.9 mg/dl) (P < 0.01). African Americans with gout had worse HRQOL scores on three SF-36 domains, the mental component summary (MCS) and two of the five GIS scales than Caucasians [mean (S.E.); P <= 0.02 for all]: SF-36 mental health, 39.7 (1.1) vs 45.2 (0.9); SF-36 role emotional, 42.1 (4.2) vs 51.4 (4.2); SF-36 social functioning, 36.0 (1.1) vs 40.0 (0.9) (P = 0.04); SF-36 MCS, 43.2 (3.1) vs 50.0 (3.2); GIS unmet treatment need, 37.6 (1.6) vs 31.5 (1.4); and GIS concern during attacks, 53.3 (3.7) vs 47.4 (3.7). Differences between the respective HAQ-DI total scores were not statistically significant; 0.98 (0.1) vs 0.80 (1.0) (P = 0.11). Racial differences in SF-36 mental health, role emotional and MCS scales exceeded, and for HAQ-DI approached, the minimal clinically important difference thresholds. Conclusions. African Americans with gout have significantly worse HRQOL compared with Caucasians. Further research is necessary in the form of studies targeted at African Americans on how best to improve these outcomes. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Bharat, Aseem] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Bharat, Aseem] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Khanna, Dinesh; Khanna, Puja P.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Dept Biostat, Los Angeles, CA USA. [Duffy, Erin; Elashoff, David] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Khanna, Puja P.] VA Ann Arbor Healthcare Syst, Dept Med, Ann Arbor, MI USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Savient Pharmaceuticals Inc. FX This study was sponsored in part by an investigator-initiated study from Savient Pharmaceuticals Inc. NR 43 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD JAN PY 2017 VL 56 IS 1 BP 103 EP 112 DI 10.1093/rheumatology/kew356 PG 10 WC Rheumatology SC Rheumatology GA EP0AN UT WOS:000397049300014 PM 28028159 ER PT J AU Scheuner, MT Peredo, J Tangney, K Schoeff, D Sale, T Lubick-Goldzweig, C Hamilton, A Hilborne, L Lee, M Mittman, B Yano, EM Lubin, IM AF Scheuner, Maren T. Peredo, Jane Tangney, Kelly Schoeff, Diane Sale, Taylor Lubick-Goldzweig, Caroline Hamilton, Alison Hilborne, Lee Lee, Martin Mittman, Brian Yano, Elizabeth M. Lubin, Ira M. TI Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists SO GENETICS IN MEDICINE LA English DT Article ID FACTOR-V-LEIDEN; AXIAL SPONDYLOARTHRITIS; MANAGEMENT RECOMMENDATIONS; VENOUS THROMBOEMBOLISM; GENOMIC MEDICINE; CLINICAL UTILITY; CANCER-RISK; HEMOCHROMATOSIS; COMMUNICATION; VALIDATION AB Objective: To determine whether electronic health record (EHR) tools improve documentation of pre- and postanalytic care processes for genetic tests ordered by nongeneticists. Methods: We conducted a nonrandomized, controlled, pre-/postintervention study of EHR point-of-care tools (informational messages and template report) for three genetic tests. Chart review assessed documentation of genetic testing processes of care, with points assigned for each documented item. Multiple linear and logistic regressions assessed factors associated with documentation. Results: Preimplementation, there were no significant site differences (P > 0.05). Postimplementation, mean documentation scores increased (5.9 (2.1) vs. 5.0 (2.2); P = 0.0001) and records with clinically meaningful documentation increased (score >5: 59 vs. 47%; P = 0.02) at the intervention versus the control site. Pre and postimplementation, a score >5 was positively associated with abnormal test results (OR = 4.0; 95% CI: 1.8-9.2) and trainee provider (OR = 2.3; 95% CI: 1.2-4.6). Postimplementation, a score >5 was also positively associated with intervention site (OR = 2.3; 95% CI: 1.1-5.1) and specialty clinic (OR = 2.0; 95% CI: 1.1-3.6). There were also significantly fewer tests ordered after implementation (264/100,000 vs. 204/100,000; P = 0.03), with no significant change at the control site (280/100,000 vs. 257/100,000; P = 0.50). Conclusions: EHR point-of-care tools improved documentation of genetic testing processes and decreased utilization of genetic tests commonly ordered by nongeneticists. C1 [Scheuner, Maren T.; Peredo, Jane; Tangney, Kelly; Schoeff, Diane; Sale, Taylor; Lubick-Goldzweig, Caroline; Hamilton, Alison; Lee, Martin; Mittman, Brian; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Scheuner, Maren T.; Lubick-Goldzweig, Caroline] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Hamilton, Alison] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Hilborne, Lee] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Hilborne, Lee] Quest Diagnost, Madison, NJ USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Lubin, Ira M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Scheuner, MT (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.; Scheuner, MT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM maren.scheuner@va.gov FU Centers for Disease Control and Prevention Laboratory Training, Evaluation, and Quality Assurance Programs [CDC-RFA-CI10-100503CONT12, 5U47CI000823]; Centers for Disease Prevention and Control; VA HSR&D Senior Research Career Scientist Award [RCS 05-195] FX This study was funded by the Centers for Disease Control and Prevention Laboratory Training, Evaluation, and Quality Assurance Programs (CDC-RFA-CI10-100503CONT12; grant 5U47CI000823). This publication was supported by a cooperative agreement from the Centers for Disease Prevention and Control. E.M.Y.'s work was supported by a VA HSR&D Senior Research Career Scientist Award (RCS 05-195). The authors thank the VA staff who supported this project, including the following research team members: Albert Aparicio, Nui Brown, Austin Jones, Erica Ma, Russell Madison, Brian Tran, and Claudia Vaughn. The authors also thank the following members of the Advisory Board: Joanne Armstrong, Hawazin Faruki, W. Andrew Faucett, Matthew Goetz, Wayne Grody, Elaine Lyon, Laurence Meyer, Victoria Pratt, Sue Richards, Paul Schneider, Indira Subramanian, Tracy Trotter, Vickie Venne, An Weinreb, and Marc Williams. NR 40 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD JAN PY 2017 VL 19 IS 1 BP 112 EP 120 DI 10.1038/gim.2016.73 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA EH6VD UT WOS:000391911100016 PM 27362912 ER PT J AU Tave, TT Wyers, DR Schreiber-Jones, C Fogger, SA McGuinness, TM AF Tave, Tristan T. Wyers, Daniel R. Schreiber-Jones, Catherine Fogger, Susanne A. McGuinness, Teena M. TI Improving Quality Outcomes in Veteran-Centric Care SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-CARE; SUBSTANCE USE; PREVALENCE; SOLDIERS; SUICIDE; COMBAT; IRAQ AB The University of Alabama at Birmingham (UAB) School of Nursing and the Birmingham Veterans Affairs Medical Center (BVAMC) created a Psychiatric-Mental Health Nurse Practitioner (PMHNP) Residency Continuity Clinic tasked with providing Veteran-centric mental health outpatient treatment informed by measurement-based care (MBC) to provide quality outcomes. Approved by the BVAMC, the UAB Institutional Review Board also approved and exempted the project as quality improvement. PMHNP residents administered the Patient Stress Questionnaire (PSQ)-an MBC tool that incorporates validated tools for assessing depression, anxiety, posttraumatic stress, alcohol use, and pain-to each Veteran from March to August 2016. Patient outcomes focused on depression and anxiety. PSQ scores were reviewed retrospectively via descriptive statistics, paired t tests, and Wilcoxon signed ranks tests. Analysis showed improvement in depression and anxiety that approached significance, and in several national Veterans Affairs mental health performance measures, reinforcing the importance of using MBC in psychiatric assessment. C1 [Tave, Tristan T.] Alta Point Hlth Syst Adult Outpatient Serv, PMHNP, Mobile, AL 36617 USA. [Wyers, Daniel R.] Northwest Alabama Psychiat Services PC, PMHNP, Huntsville, AL USA. [Schreiber-Jones, Catherine] Birmingham Vet Affairs Med Ctr, PMHNP, 700 19th St South, Birmingham, AL USA. [Fogger, Susanne A.; McGuinness, Teena M.] Univ Alabama Birmingham, Dept Family Commun & Hlth Syst, Birmingham, AL USA. RP Schreiber-Jones, C (reprint author), Birmingham Vet Affairs Med Ctr, PMHNP, 700 19th St South, Birmingham, AL USA. EM Catherine.Schreiber-Jones2@va.gov FU Office of Academic Affiliations (OAA) through the Veterans Affairs (VA) Nursing Academy; Birmingham Veterans Affairs Medical Center; University of Alabama at Birmingham School of Nursing; VA's OAA, a component of the VA Nursing Academic Partnership-Graduate Education program FX The authors have disclosed no potential conflicts of interest, financial or otherwise. This publication was supported in part by the Office of Academic Affiliations (OAA) through the Veterans Affairs (VA) Nursing Academy, a partnership between the Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham School of Nursing. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Veterans Health Administration.; The PMHNP residents in the Resident Continuity Clinic were funded by trainee stipends from the VA's OAA, a component of the VA Nursing Academic Partnership-Graduate Education program. The OAA encourages scholarly work by NP residents in mental health or primary care settings. An OAA representative reviewed and approved this project, and made recommendations regarding dissemination. NR 31 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD JAN PY 2017 VL 55 IS 1 BP 37 EP 44 DI 10.3928/02793695-20170119-07 PG 8 WC Nursing SC Nursing GA EO9QP UT WOS:000397023500006 PM 28135390 ER PT J AU Valente, SM AF Valente, Sharon M. TI Managing Professional and Nurse-Patient Relationship Boundaries in Mental Health SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID VIOLATIONS; WORK AB Caring nurse-patient relationships in mental health settings are key components in helping patients recover. These professional relationships provide a safe, trustworthy, reliable, and secure foundation for therapeutic interactions; however, nurses face challenges in setting and maintaining relationship boundaries. Although patients ask for special privileges, romantic interactions, and social media befriending, or offer expensive gifts, nurses must recognize that these boundary violations may erode trust and harm patients. These violations may also trigger discipline for nurses. Professional relationship guidelines must be applied with thoughtful consideration, and nurses must monitor their emotions and reactions in these relationships. The current article is a sharing of personal experiences about boundaries augmented by evidence in the literature, and focuses on managing potential boundary violations (i. e., social media, sexuality, over-involvement, and gift giving) in mental health settings. C1 [Valente, Sharon M.] Greater Los Angeles Vet Adm Healthcare Syst, Res Continuum Care, 11301 Wilshire Blvd,Bldg 500, Los Angeles, CA 90073 USA. RP Valente, SM (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, Res Continuum Care, 11301 Wilshire Blvd,Bldg 500, Los Angeles, CA 90073 USA. EM sharon.valente@va.gov NR 19 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD JAN PY 2017 VL 55 IS 1 BP 45 EP 51 DI 10.3928/02793695-20170119-09 PG 7 WC Nursing SC Nursing GA EO9QP UT WOS:000397023500007 PM 28135391 ER PT J AU Robertson, DJ Lee, JK Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Rex, DK AF Robertson, Douglas J. Lee, Jeffrey K. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Rex, Douglas K. TI Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID OCCULT-BLOOD-TEST; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; AVERAGE-RISK POPULATION; SAMPLE RETURN TIME; ADENOMA DETECTION; ASYMPTOMATIC ADULTS; COLONOSCOPY SURVEILLANCE; AMBIENT-TEMPERATURE; SEASONAL-VARIATIONS AB The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed. C1 [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Lee, Jeffrey K.] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA. [Boland, C. Richard] Baylor Univ, Med Ctr, Dallas, TX USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Robertson, DJ (reprint author), VA Med Ctr, Gastroenterol 111E, 215N Main St, White River Jct, VT 05009 USA. EM douglas.robertson@va.gov FU Olympus; Endochoice FX This authors discloses the following: David A. Johnson is a clinical investigator for Exact Sciences and Epigenomics. David Lieberman served on scientific advisory Board for Exact Sciences. Douglas K. Rex received consulting fees from Olympus and research support from Endochoice. Douglas J. Robertson is on the scientific advisory board for Medtronic. Tonya Kaltenback served as Consultant for Olympus America. The remaining authors disclose no conflicts. NR 118 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2017 VL 112 IS 1 BP 37 EP 53 DI 10.1038/ajg.2016.492 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK7UX UT WOS:000394131800013 PM 27753435 ER PT J AU Freytes, IM LeLaurin, JH Zickmund, SL Resende, RD Uphold, CR AF Freytes, I. Magaly LeLaurin, Jennifer H. Zickmund, Susan L. Resende, Rosana D. Uphold, Constance R. TI Exploring the Post-Deployment Reintegration Experiences of Veterans With PTSD and Their Significant Others SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE post-deployment; family reintegration; family functioning; PTSD; TBI ID FAMILY; SYMPTOMS; COMBAT; HOME AB Veterans with family support have better functional recovery and reintegration outcomes. However, families' ability to support the veteran with PTSD's rehabilitation and reintegration oftentimes is hindered by interpersonal challenges. We report findings of a qualitative study that examined OEF/OIF veterans with PTSD/TBI and their significant others' (SOs') perceptions of family functioning. We conducted 24 in-depth interviews with 12 veteran/SO dyads using an adapted version of the Family Assessment Device Structured Interview. Descriptive qualitative analytic methods were used to analyze the data. Data show that the impact of deployment and the resulting changes in the individuals and the family dynamics lingered years after the veterans returned home and had a lasting influence on veterans' and SOs' perceptions of family functioning. Most couples acknowledged growth in their relationships several years postdeployment. However, many continued to struggle with disruptions generated by deployment. Four themes emerged from the data: individual changes, coping strategies, relationship changes, and a "new normal." Postdeployment family functioning was influenced by a dynamic interplay of individual and relationship factors and the development of coping strategies and a new normal. This study contributes to the understanding of the prolonged postdeployment family reintegration experiences of veterans and their SOs. Findings underscore the importance of continuing to advance the current knowledge base about the long-term impact of deployment on veterans and their families, especially factors that contribute to positive postdeployment family functioning. Additional empirical studies are needed to provide more in-depth understanding of the long-term postdeployment reintegration experiences of veterans and their families. C1 [Freytes, I. Magaly; LeLaurin, Jennifer H.] North Florida South Georgia Vet Hlth Syst, Ctr Innovat Disabil & Rehabil Res CINDRR, Gainesville, FL USA. [Zickmund, Susan L.] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Resende, Rosana D.] Univ Florida, Ctr Latin Amer Studies, Gainesville, FL 32611 USA. [Uphold, Constance R.] North Florida South Georgia Vet Hlth Syst, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA. [Uphold, Constance R.] Univ Florida, Coll Med, Dept Aging & Geriatr Res, Gainesville, FL 32611 USA. [Zickmund, Susan L.] VA Salt Lake City Informat Decis Enhancement & An, Ctr Innovat COIN, Salt Lake City, UT USA. [Zickmund, Susan L.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA. RP Freytes, IM (reprint author), North Florida South Georgia Vet Hlth Syst, 1601 SW Archer Rd 151B, Gainesville, FL 32608 USA. EM ivette.freytes@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Merit Award [D7801-P] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Merit Award D7801-P. We thank Justin Ahern, Latrice Jones, Tasnia Osmani, and Magda Schmitzberger for assistance with this research. NR 24 TC 1 Z9 1 U1 1 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PY 2017 VL 87 IS 2 SI SI BP 149 EP 156 DI 10.1037/ort0000211 PG 8 WC Psychiatry; Social Work SC Psychiatry; Social Work GA EN2SD UT WOS:000395859400005 PM 28206802 ER PT J AU Primack, JM Borsari, B Benz, MB Reddy, MK Shea, MT AF Primack, Jennifer M. Borsari, Brian Benz, Madeline B. Reddy, Madhavi K. Shea, M. Tracie TI Mental Health Treatment Utilization in OIF/OEF National Guard and Reserve Troops With and Without DSM Diagnoses SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE mental health; treatment utilization; military ID POSTTRAUMATIC-STRESS-DISORDER; TREATMENT ENGAGEMENT; TREATMENT-SEEKING; SOCIAL SUPPORT; PTSD TREATMENT; VETERANS; CARE; BARRIERS; IRAQ; SOLDIERS AB Military service members have an increased risk of developing mental health (MH) problems following deployment to Iraq or Afghanistan, yet only a small percentage seek mental health treatment. The aim of the present study was to explore patterns of MH service utilization within the first 12 months following return from combat deployment. Participants were 169 service members who had returned from war-zone deployment in either Iraq or Afghanistan and had assessments covering a 12-month period following their homecoming. The authors first examined the prevalence of mental health diagnoses and engagement with mental health treatment (e.g., visits to the emergency room, inpatient hospitalization, individual therapy, group therapy, family or couple therapy, medication appointments, and self-help). Regression analyses explored whether distress, functioning, diagnoses, or social support predicted treatment use. Findings indicated that 28 of 50 military service members (56%) who met diagnostic criteria for a mental health disorder accessed services in the year following their return from deployment. Individual treatment was the most common modality, and those with major depressive disorder (MDD) reported the most treatment contacts. Social support was not associated with use of mental health services. Baseline functioning and psychiatric distress predicted entry into treatment whereas only psychiatric distress predicted amount of mental health service use in the 12-month postdeployment period. Findings highlight the need for enhanced strategies to link those reporting psychiatric distress with MH treatment services and increase community connectedness regardless of whether they meet full criteria for a mental health diagnosis. C1 [Primack, Jennifer M.; Borsari, Brian; Shea, M. Tracie] Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02906 USA. [Primack, Jennifer M.; Reddy, Madhavi K.; Shea, M. Tracie] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA. [Borsari, Brian; Benz, Madeline B.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Reddy, Madhavi K.] Univ Texas Med Sch Houston, Houston, TX USA. [Borsari, Brian] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Primack, JM (reprint author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02906 USA. EM Jennifer_Primack@brown.edu FU Department of Defense [W81XWH-06-1-0573] FX This work was supported by a grant from the Department of Defense awarded to Tracie Shea (W81XWH-06-1-0573). The authors express their appreciation to the participating members of the National Guard and Reserves, the leadership of the Rhode Island National Guard, and to Walter Musto, Lauren Slater, and Melissa Platt for their work on this study. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 44 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PY 2017 VL 87 IS 2 SI SI BP 157 EP 165 DI 10.1037/ort0000226 PG 9 WC Psychiatry; Social Work SC Psychiatry; Social Work GA EN2SD UT WOS:000395859400006 PM 28206803 ER PT J AU Buehrle, DJ Shields, RK Clarke, LG Potoski, BA Clancy, CJ Nguyen, MH AF Buehrle, Deanna J. Shields, Ryan K. Clarke, Lloyd G. Potoski, Brian A. Clancy, Cornelius J. Nguyen, M. Hong TI Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article DE Pseudomonas aeruginosa; carbapenem resistance; bacteremia; mortality ID BLOOD-STREAM INFECTIONS; ACINETOBACTER-BAUMANNII; ANTIMICROBIAL THERAPY; KLEBSIELLA-PNEUMONIAE; MECHANISMS; STRAINS; ENTEROBACTERIACEAE; PREVALENCE; IMPACT; EPIDEMIOLOGY AB We reviewed 37 patients treated for bacteremia due to carbapenemresistant (CR) Pseudomonas aeruginosa. Although 65% of isolates were multiple-drug resistant, therapeutic options were available, as all were susceptible to >= 1 antibiotic. A total of 92% of patients received active antimicrobial therapy, but only 57% received early active therapy (within 48 h). Fourteen-day mortality was 19%. Microbiologic failure occurred in 29%. The Pitt bacteremia score (P = 0.046) and delayed active therapy (P = 0.027) were predictive of death and microbiologic failure, respectively. C1 [Buehrle, Deanna J.; Shields, Ryan K.; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Shields, Ryan K.; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA 15260 USA. [Clarke, Lloyd G.; Potoski, Brian A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA 15260 USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM cjc76@pitt.edu FU National Institutes of Health (NIH) [K08AI114883] FX R.K.S. is supported by the National Institutes of Health (NIH) under award K08AI114883. The content of this article is solely our responsibility and does not necessarily represent the official views of the NIH. NR 34 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2017 VL 61 IS 1 AR e01243-16 DI 10.1128/AAC.01243-16 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA EK7HC UT WOS:000394095800015 ER PT J AU Davidson, CL Anestis, MD Gutierrez, PM AF Davidson, Collin L. Anestis, Michael D. Gutierrez, Peter M. TI Ecological Momentary Assessment is a Neglected Methodology in Suicidology SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE suicide; Ecological Momentary Assessment; Experience Sampling Method ID BORDERLINE PERSONALITY-DISORDER; RANDOMIZED CONTROLLED-TRIAL; EXPERIENCE; BEHAVIOR; IDEATION; RISK; VALIDITY; IMPLICIT; RELAPSE; STATES AB Ecological momentary assessment (EMA) is a group of research methods that collect data frequently, in many contexts, and in real-world settings. EMA has been fairly neglected in suicidology. The current article provides an overview of EMA for suicidologists including definitions, data collection considerations, and different sampling strategies. Next, the benefits of EMA in suicidology (i.e., reduced recall bias, accurate tracking of fluctuating variables, testing assumptions of theories, use in interventions), participant safety considerations, and examples of published research that investigate self-directed violence variables using EMA are discussed. The article concludes with a summary and suggested directions for EMA research in suicidology with the particular aim to spur the increased use of this methodology among suicidologists. C1 [Davidson, Collin L.] Hennepin Cty Med Ctr, 700 Pk Ave S, Minneapolis, MN 55415 USA. [Anestis, Michael D.] Univ Southern Mississippi, Dept Psychol, Oxford, MS USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Denver VA Med Ctr, Denver, CO USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. RP Davidson, CL (reprint author), Hennepin Cty Med Ctr, 700 Pk Ave S, Minneapolis, MN 55415 USA. EM collin.davidson@hcmed.org OI Gutierrez, Peter/0000-0001-8981-8404 NR 37 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1381-1118 EI 1543-6136 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2017 VL 21 IS 1 BP 1 EP 11 DI 10.1080/13811118.2015.1004482 PG 11 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA EM1GV UT WOS:000395067000001 PM 26821811 ER PT J AU Bountress, KE Wei, W Sheerin, C Chung, DJ Amstadter, AB Mandel, H Wang, Z AF Bountress, Kaitlin E. Wei, Wei Sheerin, Christina Chung, Dongjun Amstadter, Ananda B. Mandel, Howard Wang, Zhewu TI Relationships between GAT1 and PTSD, Depression, and Substance Use Disorder SO BRAIN SCIENCES LA English DT Article DE GAT1; post-traumatic stress disorder; major depressive disorder; substance use disorder; veterans ID POSTTRAUMATIC-STRESS-DISORDER; ENVIRONMENTAL-INFLUENCES; GABA TRANSPORTER; MOOD DISORDERS; ALCOHOL-USE; MEMORY; COMORBIDITY; SYMPTOMS; GENETICS; ILLNESS AB Post-traumatic stress disorder (PTSD), Major Depressive Disorder (MDD), and Substance Use Disorder (SUD) have large public health impacts. Therefore, researchers have attempted to identify those at greatest risk for these phenotypes. PTSD, MDD, and SUD are in part genetically influenced. Additionally, genes in the glutamate and gamma-aminobutyric acid (GABA) system are implicated in the encoding of emotional and fear memories, and thus may impact these phenotypes. The current study examined the associations of single nucleotide polymorphisms in GAT1 individually, and at the gene level, using a principal components (PC) approach, with PTSD, PTSD comorbid with MDD, and PTSD comorbid with SUD in 486 combat-exposed veterans. Findings indicate that several GAT1 SNPs, as well as one of the GAT1 PCs, was associated with PTSD, with and without MDD and SUD comorbidity. The present study findings provide initial insights into one pathway by which shared genetic risk influences PTSD-MDD and PTSD-SUD comorbidities, and thus identify a high-risk group (based on genotype) on whom prevention and intervention efforts should be focused. C1 [Bountress, Kaitlin E.; Wang, Zhewu] Med Univ South Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Wei, Wei; Chung, Dongjun] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Sheerin, Christina; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23219 USA. [Mandel, Howard; Wang, Zhewu] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Wang, Z (reprint author), Med Univ South Carolina, Dept Psychiat, Charleston, SC 29425 USA.; Wang, Z (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. EM bountres@musc.edu; weiwe@musc.edu; Christina.sheerin@gmail.com; chungd@musc.edu; Ananda.Amstadter@vcuhealth.org; mandel@musc.edu; wanzh@musc.edu OI Chung, Dongjun/0000-0002-8072-5671 FU Ralph H. Johnson VA Medical Center; Clinical Sciences Program of the Department of Veterans Affairs Merit Review Grant [1I01CX000487-01A1]; National Institute of General Medical Sciences [GM122078]; National Cancer Institute [CA209848]; National Institute of Mental Health [MH18869, MH020030]; BBRF [20066, R21 MH103686, R01MH101518, P60MD002256]; [R01AA020179]; [K02 AA023239] FX This work was supported by Ralph H. Johnson VA Medical Center and the Clinical Sciences Program of the Department of Veterans Affairs Merit Review Grant (No. 1I01CX000487-01A1). Dongjun Chung is supported by the National Institute of General Medical Sciences R01 grant GM122078 and the National Cancer Institute R21 grant CA209848. Kaitlin E. Bountress and Christina Sheerin are supported by National Institute of Mental Health T32 grants MH18869 (KB) and MH020030 (CS). Ananda B. Amstadter is supported by grants R01AA020179, K02 AA023239, BBRF 20066, R21 MH103686, R01MH101518, and P60MD002256. NR 39 TC 0 Z9 0 U1 1 U2 1 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2076-3425 EI 2976-3425 J9 BRAIN SCI JI Brain Sci. PD JAN PY 2017 VL 7 IS 1 AR 6 DI 10.3390/brainsci7010006 PG 13 WC Neurosciences SC Neurosciences & Neurology GA EM7IC UT WOS:000395483700006 ER PT J AU Gonzalez, DA Soble, JR AF Gonzalez, David Andres Soble, Jason R. TI Corticobasal syndrome due to sporadic Creutzfeldt-Jakob disease: a review and neuropsychological case report SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Case report; review; corticobasal syndrome; Creutzfeldt-Jakob disease; CBS; CJD ID DEGENERATION; DIAGNOSIS; VARIANT; DEMENTIAS; ACCURACY; CRITERIA; FLUID; EEG AB Objective: Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, and fatal neurodegenerative disease with neuropsychological sequelae. This study highlighted a rare presentation of CJD (e.g. corticobasal syndrome [CBS]), reviewed updated diagnostic criteria and procedures for CJD (e.g. diffusion weighted imaging [DWI], real-time quaking-induced conversion [RT-QuIC]), and discussed differential diagnoses. Method: Case report methodology focused on a 68-year-old, Hispanic, right-handed man with 11years of education. He presented with a 1-2-month history of gait and motor difficulties (e.g. rigidity, myoclonus). Results: After evaluation, a cortical ribboning' pattern on DWI and positive RT-QuIC was integrated with performance on neurobehavioral exam (i.e. alien limb phenomenon, unilateral ideomotor apraxia) and neuropsychological testing (i.e. frontal-parietal dysfunction pattern) to reach a diagnosis of sCJD-CBS. The patient expired 3months after onset of symptoms. Conclusions: This literature review and case report highlighted the importance of staying abreast of developments in neurological literature and the added value of neuropsychology, when integrated with newer procedures, for confirming and excluding diagnostic considerations. C1 [Gonzalez, David Andres] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Gonzalez, David Andres; Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. RP Gonzalez, DA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.; Gonzalez, DA (reprint author), South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. EM gonzalezD15@uthscsa.edu NR 55 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2017 VL 31 IS 3 BP 676 EP 689 DI 10.1080/13854046.2016.1259434 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA EM5FX UT WOS:000395338500013 PM 27871202 ER PT J AU Singh, I Hershman, JM AF Singh, Ishita Hershman, Jerome M. TI Pathogenesis of Hyperthyroidism SO COMPREHENSIVE PHYSIOLOGY LA English DT Article ID HUMAN CHORIONIC-GONADOTROPIN; AMIODARONE-INDUCED THYROTOXICOSIS; MALIGNANT STRUMA OVARII; RECEPTOR CROSS-TALK; GRAVES-DISEASE; TSH RECEPTOR; THYROTROPIN RECEPTOR; SUBACUTE THYROIDITIS; SUPPURATIVE THYROIDITIS; AUTOIMMUNE-THYROIDITIS AB Hyperthyroidism is a form of thyrotoxicosis in which there is excess thyroid hormone synthesis and secretion. Multiple etiologies can lead to a common clinical state of "thyrotoxicosis," which is a consequence of the high thyroid hormone levels and their action on different tissues of the body. The most common cause of thyrotoxicosis is Graves' disease, an autoimmune disorder in which stimulating thyrotropin receptor antibodies bind to thyroid stimulating hormone (TSH) receptors on thyroid cells and cause overproduction of thyroid hormones. Other etiologies include: forms of thyroiditis in which inflammation causes release of preformed hormone, following thyroid gland insult that is autoimmune, infectious, mechanical or medication induced; secretion of human chorionic gonadotropin in the setting of transient gestational thyrotoxicosis and trophoblastic tumors; pituitary thyrotropin release, and exposure to extra-thyroidal sources of thyroid hormone that may be endogenous or exogenous. (C) 2017 American Physiological Society. C1 [Singh, Ishita; Hershman, Jerome M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA. [Singh, Ishita; Hershman, Jerome M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Hershman, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA.; Hershman, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 99 TC 0 Z9 0 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2040-4603 J9 COMPR PHYSIOL JI Compr. Physiol. PD JAN PY 2017 VL 7 IS 1 BP 67 EP 79 DI 10.1002/cphy.c160001 PG 13 WC Physiology SC Physiology GA EK8PQ UT WOS:000394186300003 ER PT J AU Anderson, LJ Albrecht, ED Garcia, JM AF Anderson, Lindsey J. Albrecht, Eliette D. Garcia, Jose M. TI Update on Management of Cancer-Related Cachexia SO CURRENT ONCOLOGY REPORTS LA English DT Review DE Cancer; Cachexia; Quality of life; Muscle loss; Body weight; Nutrition; Inflammation; Appetite; Ghrelin; Exercise; Therapy; Multimodal; Clinical management ID CELL LUNG-CANCER; QUALITY-OF-LIFE; III CLINICAL-TRIAL; DOUBLE-BLIND; MEGESTROL-ACETATE; PHASE-III; EICOSAPENTAENOIC ACID; ANDROGEN RECEPTOR; ESOPHAGEAL CANCER; GHRELIN AB Cachexia is a metabolic syndrome driven by inflammation and characterized by loss of muscle with or without loss of fat mass. In cancer cachexia, the tumor burden and host response induce increased inflammation, decreased anabolic tone, and suppressed appetite leading to the clinical presentation of reduced body weight and quality of life (QOL). There is no approved treatment for cancer cachexia, and commonly used nutritional and anti-inflammatory strategies alone have proven ineffective for management of symptoms. Several other pharmacological agents are currently in development and have shown promise as a clinical strategy in early-phase trials. Recently, it has been proposed that multimodal strategies, with an anabolic focus, initiated early in the disease/treatment progression may provide the most therapeutic potential for symptom management. Here we review the data from recent clinical trials in cancer cachexia including pharmacological, exercise, and nutritional interventions. C1 [Anderson, Lindsey J.; Albrecht, Eliette D.; Garcia, Jose M.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [Albrecht, Eliette D.] Yale Univ, New Haven, CT 06520 USA. [Garcia, Jose M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Garcia, JM (reprint author), VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA.; Garcia, JM (reprint author), Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. EM lindsey.anderson5@va.gov; eliette.albrecht@yale.edu; Jg77@uw.edu FU U.S. Dept. of Veterans Affairs (MERIT) [I01BX002807, I01 CX000174]; NIH [AG040583, AR067319, CA185349] FX This work was funded by the U.S. Dept. of Veterans Affairs (MERIT grants I01BX002807 and I01 CX000174, VA seed fund) and NIH Grants AG040583, AR067319, and CA185349 to JMG. We thank the University of Washington DERC (P30 DK017047) and NORC (P30 DK035816) for their help. NR 69 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3790 EI 1534-6269 J9 CURR ONCOL REP JI Curr. Oncol. Rep. PD JAN PY 2017 VL 19 IS 1 AR 3 DI 10.1007/s11912-017-0562-0 PG 11 WC Oncology SC Oncology GA EM2SF UT WOS:000395165200003 PM 28138933 ER PT J AU Morone, NE Greco, CM Moore, CG Rollman, BL Lane, B Morrow, LA Glynn, NW Weiner, DK AF Morone, N. E. Greco, C. M. Moore, C. G. Rollman, B. L. Lane, B. Morrow, L. A. Glynn, N. W. Weiner, D. K. TI A Mind-Body Program for Older Adults With Chronic Low Back Pain: A Randomized Clinical Trial SO DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR LA English DT Editorial Material ID MEDITATION; YOGA C1 [Morone, N. E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. Carolinas Hlth Care Syst, Dickson Adv Analyt, Charlotte, NC USA. Vet Affairs Pittsburgh Healthcare Syst, Penn Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Morone, NE (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0415-6412 EI 1439-4359 J9 DTSCH Z AKUPUNKT JI Dtsch. Z. Akupunkt. PY 2017 VL 60 IS 1 BP 30 EP 31 PG 2 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA EO4NO UT WOS:000396671800008 ER PT J AU Kokkinidis, DG Waldo, SW Armstrong, EJ AF Kokkinidis, Damianos G. Waldo, Stephen W. Armstrong, Ehrin J. TI Treatment of coronary artery in-stent restenosis SO EXPERT REVIEW OF CARDIOVASCULAR THERAPY LA English DT Review DE Coronary artery disease; in-stent restenosis; percutaneous coronary intervention; drug-eluting stents; drug-coated balloons ID DRUG-ELUTING STENT; BIORESORBABLE VASCULAR SCAFFOLD; PACLITAXEL-COATED BALLOON; OPTICAL COHERENCE TOMOGRAPHY; BARE-METAL STENTS; RANDOMIZED CONTROLLED-TRIAL; DUAL ANTIPLATELET THERAPY; INTRAVASCULAR ULTRASOUND ANALYSIS; GAMMA-RADIATION THERAPY; TERM-FOLLOW-UP AB Introduction: Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10% of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices. This article reviews the presentation, pathophysiology, and treatment of coronary artery ISR, with a focus on recent clinical data and emerging therapies for this difficult to treat clinical problem. Expert commentary: DCB and second-generation DES are the most effective treatment options for ISR. Most trials support a slight superiority of second-generation DES, while DCB have the advantage of not adding another metal layer. The role of bioresorbable vascular scaffolds will be determined in the near future. C1 [Kokkinidis, Damianos G.; Waldo, Stephen W.; Armstrong, Ehrin J.] Univ Colorado, Sch Med, Cardiol Sect, Aurora, CO USA. [Kokkinidis, Damianos G.; Waldo, Stephen W.; Armstrong, Ehrin J.] Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. RP Armstrong, EJ (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM ehrin.armstrong@ucdenver.edu NR 115 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1477-9072 EI 1744-8344 J9 EXPERT REV CARDIOVAS JI Expert Rev. Cardiovasc. Ther. PY 2017 VL 15 IS 3 BP 191 EP 202 DI 10.1080/14779072.2017.1284588 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EO7KW UT WOS:000396870600005 PM 28116914 ER PT J AU Khan, F Owens, MB Restrepo, M Povoa, P Martin-Loeches, I AF Khan, Faheem Owens, Mark B. Restrepo, Marcos Povoa, Pedro Martin-Loeches, Ignacio TI Tools for outcome prediction in patients with community acquired pneumonia SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY LA English DT Review DE Pneumonia; community acquired pneumonia; scores; APACHE; CURB; sepsis; treatment failure ID C-REACTIVE PROTEIN; RESPIRATORY-TRACT INFECTIONS; INTENSIVE-CARE-UNIT; RANDOMIZED-CONTROLLED-TRIAL; GERMAN COMPETENCE NETWORK; LOW-RISK PATIENTS; ANTIBIOTIC-THERAPY; TREATMENT FAILURE; CLINICAL STABILITY; PROCALCITONIN-GUIDANCE AB Introduction: Community-acquired pneumonia (CAP) is one of the most common causes of mortality world-wide. The mortality rate of patients with CAP is influenced by the severity of the disease, treatment failure and the requirement for hospitalization and/or intensive care unit (ICU) management, all of which may be predicted by biomarkers and clinical scoring systems. Areas covered: We review the recent literature examining the efficacy of established and newly-developed clinical scores, biological and inflammatory markers such as C-Reactive protein (CRP), procalcitonin (PCT) and Interleukin-6 (IL-6), whether used alone or in conjunction with clinical severity scores to assess the severity of CAP, predict treatment failure, guide acute in-hospital or ICU admission and predict mortality. Expert commentary: The early prediction of treatment failure using clinical scores and biomarkers plays a developing role in improving survival of patients with CAP by identifying high-risk patients requiring hospitalization or ICU admission; and may enable more efficient allocation of resources. However, it is likely that combinations of scoring systems and biomarkers will be of greater use than individual markers. Further larger studies are needed to corroborate the additive value of these markers to clinical prediction scores to provide a safer and more effective assessment tool for clinicians. C1 [Khan, Faheem; Owens, Mark B.; Martin-Loeches, Ignacio] St James Univ Hosp, Intens Care Med, POB 8, Dublin, Ireland. [Restrepo, Marcos] South Texas Vet Hlth Care Syst, Dept Resp Med, San Antonio, TX USA. [Restrepo, Marcos] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Povoa, Pedro] Sao Francisco Xavier Hosp, Ctr Hosp Lisboa Ocident, Dept Intens Care Med, Polyvalent Intens Care Unit, Lisbon, Portugal. [Povoa, Pedro] Univ Nova Lisboa, Nova Med Sch, CEDOC, Lisbon, Portugal. St James Hosp, Trin Coll, Welcome Trust HRB Clin Res Facil, Dept Clin Med, Dublin, Ireland. RP Martin-Loeches, I (reprint author), St James Univ Hosp, Intens Care Med, POB 8, Dublin, Ireland. EM drmartinloeches@gmail.com NR 101 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1751-2433 EI 1751-2441 J9 EXPERT REV CLIN PHAR JI Expert Rev. Clin. Pharmacol. PY 2017 VL 10 IS 2 BP 201 EP 211 DI 10.1080/17512433.2017.1268051 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EO7DM UT WOS:000396851400007 PM 27911103 ER PT J AU Deo, R Khodneva, YA Shlipak, MG Soliman, EZ Judd, SE McClellan, WM Brown, TM Rhodes, JD Gutierrez, OM Shah, SJ Albert, CM Safford, MM AF Deo, Rajat Khodneva, Yulia A. Shlipak, Michael G. Soliman, Elsayed Z. Judd, Suzanne E. McClellan, William M. Brown, Todd M. Rhodes, J. David Gutierrez, Orlando M. Shah, Sanjiv J. Albert, Christine M. Safford, Monika M. TI Albuminuria, kidney function, and sudden cardiac death: Findings from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study SO HEART RHYTHM LA English DT Article DE Albuminuria; Kidney function; Sudden cardiac death; Risk factor; Population health ID CORONARY-HEART-DISEASE; STAGE RENAL-DISEASE; UNEXPECTED DEATH; CYSTATIN C; RISK; ASSOCIATION; DEFIBRILLATOR; EPIDEMIOLOGY; DYSFUNCTION; ARREST AB BACKGROUND Moderate-to-severe kidney disease increases risk for sudden cardiac death (SCD). Limited studies have evaluated how mild degrees of kidney dysfunction impact SCD risk. OBJECTIVE The purpose of this study was to evaluate the association of albuminuria, which is one of the earliest biomarkers of kidney injury, and SCD. METHODS The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study is a prospective, population-based cohort of U.S. adults. Associations between albuminuria, which is categorized using urinary albumin-to-creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), and SCD were assessed independently and in combination. RESULTS After median follow-up of 6.1 years, we identified 335 SCD events. Compared to participants with ACR <15 mg/g, those with higher levels had an elevated adjusted risk of SCD (ACR 15-30 mg/g, hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.11-2.11; ACR >30 mg/g, HR 1.56, 95% CI 1.17-2.11). In contrast, compared to the group with eGFR >90 mL/min/1.73 m(2), the adjusted risk of SCD was significantly elevated only among those with eGFR <45 mL/min/1.73 m(2) (HR 1.66, 95% CI 1.06-2.58). The subgroup with eGFR <45 mL/min/1.73 m(2) (n = 1003) comprised 3.7% of REGARDS, whereas ACR 15-30 mg/g (n = 3089 [11.3%]) and ACR >30 mg/g (n = 4040 [14.8%] were far more common. In the analysis that combined ACR and eGFR categories, albuminuria consistently identified individuals with eGFR >60 mLmin/1.73 m(2) who were at significantly increased SCD risk. CONCLUSION Low levels of kidney injury as measured by ACR predict an increase in SCD risk. C1 [Deo, Rajat] Univ Penn, Perelman Sch Med, Div Cardiovasc Med, Electrophysiol Sect, Philadelphia, PA 19104 USA. [Khodneva, Yulia A.; Brown, Todd M.; Gutierrez, Orlando M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35487 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Soliman, Elsayed Z.] Epidemiol Cardiol Res Ctr EPICARE, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27109 USA. [Judd, Suzanne E.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [McClellan, William M.] Emory Univ, Rollins Sch Publ Hlth, Dept Med & Epidemiol, Atlanta, GA 30322 USA. [Rhodes, J. David] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35233 USA. [Shah, Sanjiv J.] Northwestern Univ, Div Cardiovasc Med, Chicago, IL 60611 USA. [Albert, Christine M.] Ctr Arrhythmia Prevent, Div Prevent Med, Boston, MA USA. [Albert, Christine M.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA. [Albert, Christine M.] Harvard Med Sch, Boston, MA USA. [Safford, Monika M.] Weill Cornell Med Coll, Dept Med, Div Gen Internal Med, New York, NY USA. RP Deo, R (reprint author), Univ Penn, Div Cardiovasc Med, Electrophysiol Sect, 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19104 USA. EM Rajat.Deo@uphs.upenn.edu FU National Institutes of Health [K23DK089118, R01 HL080477, K24 HL111154]; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service [U01 NS041588] FX Dr. Deo was supported by Grant K23DK089118 from the National Institutes of Health. This research project is supported by cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. The REGARDS-MI study was supported by National Institutes of Health Grants R01 HL080477 and K24 HL111154. NR 31 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 EI 1556-3871 J9 HEART RHYTHM JI Heart Rhythm PD JAN PY 2017 VL 14 IS 1 BP 65 EP 71 DI 10.1016/j.hrthm.2016.08.004 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EO1BQ UT WOS:000396433000020 PM 27523775 ER PT J AU Hser, YI Huang, D Saxon, AJ Woody, G Moskowitz, AL Matthews, AG Ling, W AF Hser, Yih-Ing Huang, David Saxon, Andrew J. Woody, George Moskowitz, Andrew L. Matthews, Abigail G. Ling, Walter TI Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine plus Naloxone and Methadone SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE buprenorphine; growth mixture model; methadone maintenance; opioid use trajectory ID ADDICTION SEVERITY INDEX; HEALTH AB Objectives: Uncovering heterogeneities in longitudinal patterns (trajectories) of opioid use among individuals with opioid use disorder can increase our understanding of disease progression and treatment responses to improve care. The present study aims to identify distinctive opioid use trajectories and factors associated with these patterns among participants randomized to treatment with methadone (MET) or buprenorphine+naloxone (BUP). Methods: Growth mixture modeling was applied to identify distinctive opioid use trajectories among 795 opioid users after their enrollment in a multisite trial during 2006 to 2009, with follow-up interviews conducted during 2011 to 2014. Results: Four distinctive trajectories were identified based on opioid use over the follow-up period: low use (42.0%), high use (22.3%), increasing use (17.1%), and decreasing use (18.6%). Greater odds of being in the high use group (relative to low use) was associated with Hispanics (relative to African American, odds ratio [OR] 3.21), injection drug use (OR 2.12), higher mental health functioning at baseline (OR 1.23), location on the West Coast (vs East Coast, OR 2.15), and randomization to BUP (relative to MET, OR 1.53). High use and increasing use groups had greater severity in problems related to drug, employment, legal, and social/family relationships, and worsened mental health functioning at follow-up. Participation in treatment significantly accounted for both within and betweengroup differences in opioid use. Conclusions: Continued treatment is necessary to reduce risk for opioid use and related adverse consequences, particularly among individuals (eg, injecting drug) at risk for consistently high level of opioid use. C1 [Hser, Yih-Ing; Huang, David; Moskowitz, Andrew L.; Ling, Walter] Univ Calif Los Angeles, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA 90025 USA. [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Woody, George] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Matthews, Abigail G.] EMMES Corp, Rockville, MD USA. RP Hser, YI (reprint author), Univ Calif Los Angeles, Integrated Subst Abuse Programs, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA 90025 USA. EM yhser@ucla.edu FU National Institute on Drug Abuse (NIDA) through the Clinical Trials Network (CTN) [U10 DA01714, U10 DA 015815, U10 DA13038, U10 DA13045, UG1 DA013035, U10 DA13043]; NIDA [P30DA016383] FX The main study funding was provided by the National Institute on Drug Abuse (NIDA) through the Clinical Trials Network (CTN) through a series of grants provided to each participating node: The Pacific Northwest Node (U10 DA01714); The Western States Node (U10 DA 015815); The New England Node (U10 DA13038); The Delaware Valley Node (U10 DA13043); The Pacific Region Node (U10 DA13045); The Greater New York Node (UG1 DA013035). Funding was also provided by NIDA through grant number P30DA016383. NR 17 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD JAN-FEB PY 2017 VL 11 IS 1 BP 63 EP 69 DI 10.1097/ADM.0000000000000274 PG 7 WC Substance Abuse SC Substance Abuse GA EL0JG UT WOS:000394308100010 PM 27898496 ER PT J AU Stein, BD Mendelsohn, J Gordon, AJ Dick, AW Burns, RM Sorbero, M Shih, RA Pacula, RL AF Stein, Bradley D. Mendelsohn, Joshua Gordon, Adam J. Dick, Andrew W. Burns, Rachel M. Sorbero, Mark Shih, Regina A. Pacula, Rosalie Liccardo TI Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE Opioid use disorders; benzodiazepines; opioids; social network analysis; prescribing behavior; Medicaid ID PRESCRIPTION DRUG OVERDOSES; SUBSTANCE USE; DEPENDENCE; RELAPSE; IMPACT; DOCTOR; BUPRENORPHINE; MAINTENANCE; BEHAVIOR; VIOLENCE AB Opioid analgesic and benzodiazepine use in individuals with opioid use disorders can increase the risk for medical consequences and relapse. Little is known about rates of use of these medications or prescribing patterns among communities of prescribers. The goal of this study was to examine rates of prescribing to Medicaid-enrollees in the calendar year after an opioid use disorder diagnosis, and to examine individual, county, and provider community factors associated with such prescribing. 2008 Medicaid claims data were used from 12 states to identify enrollees diagnosed with opioid use disorders, and 2009 claims data were used to identify rates of prescribing of each drug. Social network analysis was used to identify provider communities, and multivariate regression analyses was used to to identify patient, county, and provider community level factors associated with prescribing these drugs. The authors also examined variation in rates of prescribing across provider communities. Among Medicaid-enrollees identified with an opioid use disorder, 45% filled a prescription for an opioid analgesic, 37% filled a prescription for a benzodiazepine, and 21% filled a prescription for both in the year following their diagnosis. Females, older individuals, individuals with pain syndromes, and individuals residing in counties with higher rates of poverty were more likely to fill prescriptions. Prescribing rates varied substantially across provider communities, with rates in the highest quartile of prescribing communities over 2.5times the rates in the lowest prescribing communities. Prescribing opioid analgesics and benzodiazepines to individuals diagnosed with opioid use disorders may increase risk of relapse and overdose. Interventions should be considered that target provider communities with the highest rates of prescribing and individuals at the highest risk. C1 [Stein, Bradley D.; Burns, Rachel M.; Sorbero, Mark] RAND Corp, 4570 Fifth Ave, Pittsburgh, PA 15213 USA. [Stein, Bradley D.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Mendelsohn, Joshua; Pacula, Rosalie Liccardo] RAND Corp, Santa Monica, CA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Dick, Andrew W.] RAND Corp, Boston, MA USA. [Shih, Regina A.] RAND Corp, Arlington, VA USA. RP Stein, BD (reprint author), RAND Corp, 4570 Fifth Ave, Pittsburgh, PA 15213 USA. EM stein@rand.org FU National Institute on Drug Abuse of the National Institutes of Health (NIH) [1R01DA032881-01A1, RO1AG043960-01] FX The National Institute on Drug Abuse of the National Institutes of Health (NIH) provided support (award 1R01DA032881-01A1, PI: Stein and RO1AG043960-01, PI: Shih) for this study. NR 45 TC 0 Z9 0 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1055-0887 EI 1545-0848 J9 J ADDICT DIS JI J. Addict. Dis. PY 2017 VL 36 IS 1 BP 14 EP 22 DI 10.1080/10550887.2016.1211784 PG 9 WC Substance Abuse SC Substance Abuse GA EL2PR UT WOS:000394462400003 PM 27449904 ER PT J AU Kalapatapu, RK Ventura, MI Barnes, DE AF Kalapatapu, Raj K. Ventura, Maria I. Barnes, Deborah E. TI Lifetime alcohol use and cognitive performance in older adults SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE Alcohol; substance use; cognition; cognitive; older adult ID SUBSTANCE USE DISORDERS; RANDOMIZED-CONTROLLED-TRIAL; CAUSAL-DIAGRAMS; DRUG-USE; CONSUMPTION; AGE; IMPAIRMENT; PREVALENCE; COMMUNITY; AMERICANS AB Substance use is an important clinical issue in the older adult population. As older adults are susceptible to cognitive disorders, the intersection of the fields of substance use and cognitive neuroscience is an active area of research. Prior studies of alcohol use and cognitive performance are mixed, and inconsistencies may be due to under- or over-adjustment for confounders. This article adds to this literature by conducting a secondary analysis of self-reported lifetime history of alcohol use and cognitive performance in older adults (n = 133). It was hypothesized that current alcohol users would have poorer cognitive performance compared to never/minimal and former alcohol users. Older adult participants were classified into never/minimal alcohol users, former alcohol users, and current alcohol users. A neurocognitive battery included a global cognitive measure and individual measures of attention, memory, fluency, and executive function. A directed acyclic graph-based approach was used to select variables to be included in the multiple linear regression models. Though unadjusted analyses showed some significant associations between alcohol use and cognitive performance, all associations between alcohol use and cognitive performance were eliminated after adjusting for age, education, sex, race, and smoking pack years. Alcohol drink years were not significantly associated with cognitive performance among current and former alcohol users. These results suggest that lifetime alcohol use is not significantly associated with cognitive performance in older adults after adjustment for key confounders. Inconsistencies in prior studies may be due to uncontrolled confounding and/or unnecessary adjustment of mediators and/or colliders. C1 [Kalapatapu, Raj K.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kalapatapu, Raj K.; Ventura, Maria I.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kalapatapu, Raj K.; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kalapatapu, RK (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.; Kalapatapu, RK (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.; Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Opioid Treatment Program, Bldg 1,Ground Floor,Room 24,Mailstop 116F, San Francisco, CA 94121 USA. EM kalapatapu.raj.k@gmail.com FU National Institutes of Health [K01AG024069]; Alzheimer's Association [IIRG-06-27306]; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant [UL1 TR001872]; [K23DA034883] FX Dr. Kalapatapu is currently funded by K23DA034883. The MAX trial was funded by the National Institutes of Health (K01AG024069) and the Alzheimer's Association (IIRG-06-27306). This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 51 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1055-0887 EI 1545-0848 J9 J ADDICT DIS JI J. Addict. Dis. PY 2017 VL 36 IS 1 BP 38 EP 47 DI 10.1080/10550887.2016.1245029 PG 10 WC Substance Abuse SC Substance Abuse GA EL2PR UT WOS:000394462400006 PM 27719514 ER PT J AU Ho, L Legere, M Li, TB Levine, S Hao, K Valcarcel, B Pasinetti, GM AF Ho, Lap Legere, Marc Li, Tongbin Levine, Samara Hao, Ke Valcarcel, Breanna Pasinetti, Giulio M. TI Autonomic Nervous System Dysfunctions as a Basis for a Predictive Model of Risk of Neurological Disorders in Subjects with Prior History of Traumatic Brain Injury: Implications in Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; autonomic nervous system; biomarker; neurodegenerative disorders; risk factor; traumatic brain injury ID SYMPATHETIC HYPERACTIVITY; SELECTION AB Autonomic dysfunction is very common in patients with dementia, and its presence might also help in differential diagnosis among dementia subtypes. Various central nervous system structures affected in Alzheimer's disease (AD) are also implicated in the central autonomic nervous system (ANS) regulation. For example, deficits in central cholinergic function in AD could likely lead to autonomic dysfunction. We recently developed a simple, readily applicable evaluation for monitoring ANS disturbances in response to traumatic brain injury (TBI). This ability to monitor TBI allows for the possible detection and targeted prevention of long-term, detrimental brain responses caused by TBI that lead to neurodegenerative diseases such as AD. We randomly selected and extracted de-identified medical record information from subjects who have been assessed using the ANS evaluation protocol. Using machine learning strategies in the analysis of information from individual as well as a combination of ANS evaluation protocol components, we identified a novel prediction model that is effective in correctly segregating between cases with or without a documented history of TBI exposure. Results from our study support the hypothesis that trauma-induced ANS dysfunctions may contribute to clinical TBI features. Because autonomic dysfunction is very common in AD patients it is possible that TBI may also contribute to AD and/or other forms of dementia through these novel mechanisms. This study provides a novel prediction model to physiologically assess the likelihood of subjects with prior history of TBI to develop clinical TBI complications, such as AD. C1 [Ho, Lap; Levine, Samara; Valcarcel, Breanna; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Legere, Marc] PATCH Chiropract, Philadelphia, PA USA. [Li, Tongbin] AccuraSci, Johnston, IA USA. [Hao, Ke] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. RP Pasinetti, GM (reprint author), 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Icahn School of Medicine at Mount Sinai; Geriatric Research Education and Clinical Centers (GRECC) of the James J. Peters Veterans Affairs Medical Center; Career Scientist Award in the Research and Development unit; Altschul Foundation; VA Grant [1I01BX000870-01A2]; National Natural Science Foundation of China [21477087]; Ministry of Science and Technology of the People's Republic of China [2016YFC0206507] FX This study was supported by discretionary funding from the Icahn School of Medicine at Mount Sinai to Dr. Giulio Maria Pasinetti and by the Geriatric Research Education and Clinical Centers (GRECC) of the James J. Peters Veterans Affairs Medical Center. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The current study was supported, in part, by the Altschul Foundation and VA Grant 1I01BX000870-01A2 to Dr. Giulio Maria Pasinetti. Dr. Ke Hao is partially supported by the National Natural Science Foundation of China (Grant No. 21477087) and by the Ministry of Science and Technology of the People's Republic of China (Grant No. 2016YFC0206507). NR 33 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2017 VL 56 IS 1 BP 305 EP 315 DI 10.3233/JAD-160948 PG 11 WC Neurosciences SC Neurosciences & Neurology GA EK4GW UT WOS:000393886100025 PM 27911325 ER PT J AU Law, LL Schultz, SA Boots, EA Einerson, JA Dougherty, RJ Oh, JM Korcarz, CE Edwards, DF Koscik, RL Dowling, NM Gallagher, CL Bendlin, BB Carlsson, CM Asthana, S Hermann, BP Sager, MA Johnson, SC Cook, DB Stein, JH Okonkwo, OC AF Law, Lena L. Schultz, Stephanie A. Boots, Elizabeth A. Einerson, Jean A. Dougherty, Ryan J. Oh, Jennifer M. Korcarz, Claudia E. Edwards, Dorothy F. Koscik, Rebecca L. Dowling, N. Maritza Gallagher, Catherine L. Bendlin, Barbara B. Carlsson, Cynthia M. Asthana, Sanjay Hermann, Bruce P. Sager, Mark A. Johnson, Sterling C. Cook, Dane B. Stein, James H. Okonkwo, Ozioma C. TI Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer disease; cardiopulmonary exercise test; cardiovascular health; cognition; heart rate ID HEART-RATE RECOVERY; WHITE-MATTER HYPERINTENSITIES; CARDIORESPIRATORY FITNESS; WISCONSIN-REGISTRY; APOLIPOPROTEIN-E; CARDIAC-OUTPUT; BLOOD-PRESSURE; EXERCISE; MORTALITY; PREDICTOR AB The objective of this study was to examine the association of chronotropic response (CR) and heart rate (HR) recovery-two indices of cardiovascular function within the context of a graded exercise test-with cognitive performance in a cognitively healthy, late-middle-aged cohort at risk for Alzheimer's disease (AD). Ninety participants (age = 63.52 +/- 5.86 years; 65.6% female) from the Wisconsin Registry for Alzheimer's Prevention participated in this study. They underwent graded exercise testing and a comprehensive neuropsychological assessment that assessed the following four cognitive domains: Immediate Memory, Verbal & Learning Memory, Working Memory, and Speed & Flexibility. Regression analyses, adjusted for age, sex, and education, were used to examine the association between CR, HR recovery, and cognition. We found significant associations between CR and cognitive performance in the domains of Immediate Memory, Verbal Learning & Memory, and Speed & Flexibility. In contrast, HR recovery was not significantly associated with cognitive function. The association between CR and cognition persisted even after controlling for HR recovery. Together, these findings indicate that, in a cognitively normal, late-middle-aged cohort, CR is a stronger correlate of cognitive performance than HR recovery. Overall, this study reinforces the idea that cardiovascular health plays an important role in cognitive function, specifically in a cohort at risk for AD; and that interventions that promote vascular health may be a viable pathway to preventing or slowing cognitive decline due to AD. C1 [Law, Lena L.; Schultz, Stephanie A.; Boots, Elizabeth A.; Oh, Jennifer M.; Gallagher, Catherine L.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.; Okonkwo, Ozioma C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Law, Lena L.; Schultz, Stephanie A.; Boots, Elizabeth A.; Oh, Jennifer M.; Edwards, Dorothy F.; Gallagher, Catherine L.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Asthana, Sanjay; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Law, Lena L.; Schultz, Stephanie A.; Boots, Elizabeth A.; Oh, Jennifer M.; Edwards, Dorothy F.; Koscik, Rebecca L.; Bendlin, Barbara B.; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. [Dougherty, Ryan J.; Edwards, Dorothy F.; Cook, Dane B.] Univ Wisconsin, Sch Educ, Dept Kinesiol, Madison, WI 53792 USA. [Einerson, Jean A.; Korcarz, Claudia E.; Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiol, Madison, WI 53792 USA. [Dowling, N. Maritza] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Gallagher, Catherine L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53792 USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI 53705 USA. RP Okonkwo, OC (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53792 USA.; Okonkwo, OC (reprint author), Univ Wisconsin, Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA. EM ozioma@medicine.wisc.edu FU National Institute on Aging [K23 AG045957, R01 AG027161, R01 AG021155, P50 AG033514]; Clinical and Translational Science Award [UL1RR025011]; Alzheimer's Association; Extendicare Foundation; Wisconsin Alumni Research Foundation; Helen Bader Foundation; Northwestern Mutual Foundation; Veterans Administration FX This work was supported by the National Institute on Aging grants K23 AG045957 (OCO), R01 AG027161 (SCJ), R01 AG021155 (SCJ), and P50 AG033514 (SA); and by a Clinical and Translational Science Award (UL1RR025011) to the University of Wisconsin, Madison. Portions of this research were supported by the Alzheimer's Association, the Extendicare Foundation, the Wisconsin Alumni Research Foundation, the Helen Bader Foundation, Northwestern Mutual Foundation, and from the Veterans Administration, including facilities and resources at the Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI. We thank the staff and study participants of the Wisconsin Registry for Alzheimer's Prevention without whom this work would not be possible. NR 50 TC 0 Z9 0 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2017 VL 56 IS 1 BP 351 EP 359 DI 10.3233/JAD-160642 PG 9 WC Neurosciences SC Neurosciences & Neurology GA EK4GW UT WOS:000393886100029 PM 27911299 ER PT J AU Bramoweth, AD AF Bramoweth, Adam D. TI A Step in the Right Direction: Moving Toward Increased Access to Insomnia Care SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material C1 [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Bramoweth, AD (reprint author), VA Pittsburgh Healthcare Syst, Res Off Bldg 151R,Univ Dr, Pittsburgh, PA 15240 USA. EM adam.bramoweth@va.gov FU United States Department of Veterans Affairs Health Services Research and Development Service [13-260] FX Dr. Bramoweth has indicated no financial conflicts of interest. Dr. Bramoweth is supported by Career Development Award 13-260 from the United States Department of Veterans Affairs Health Services Research and Development Service. The views expressed are those of the author and do not necessarily represent the views of the United States Department of Veterans Affairs or the United States Government. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2017 VL 13 IS 2 BP 161 EP 162 DI 10.5664/jcsm.6432 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EP0AI UT WOS:000397048800003 PM 28095979 ER PT J AU Skaar, E Ranhoff, AH Nordrehaug, JE Forman, DE Schaufel, MA AF Skaar, Elisabeth Ranhoff, Anette Hylen Nordrehaug, Jan Erik Forman, Daniel E. Schaufel, Margrethe Aase TI Conditions for autonomous choice: a qualitative study of older adults' experience of decision-making in TAVR SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Article DE Aortic stenosis; Older adults; Patient-centered care; Shared decision-making; Trans-catheter aortic valve replacement ID AORTIC-VALVE IMPLANTATION; PREFERENCES; STENOSIS; CARE; INVOLVEMENT; DEMENTIA; SURGERY; TRUST; RISK AB Background Patient autonomy is a leading principle in bioethics and a basis for shared decision making. This study explores conditions for an autonomous choice experienced by older adults who recently underwent trans-catheter aortic valve replacement (TAVR). Methods Qualitative study entailing semi-structured interviews of a purposive sample of ten older (range 73-89, median 83.5 years) adults after TAVR (median 23 days). The study setting was a cardiac department at a university hospital performing TAVR since 2010. Analysis was by systematic text condensation. Results Even when choice seemed hard or absent, TAVR-patients deliberately took the chance offered them by processing risk assessment, ambivalence and fate. They regarded declining the treatment to be worse than accepting the risk related to the procedure. The experience of being thoroughly advised by their physician formed the basis of an autonomous trust. The trust they felt for the physicians' recommendations mitigated ambivalence about the procedure and risks. TAVR patients expressed feelings consistent with self-empowerment and claimed that it had to be their decision. Even so, choosing the intervention as an obligation to their family or passively accepting it was also reported. Conclusions Older TAVR patients' experience of an autonomous decision may encompass frank tradeoff; deliberate physician dependency as well as a resilient self-view. Physicians should be especially aware of how older adults' subtle cognitive declines and inclinations to preserve their identities which can influence their medical decision making when obtaining informed consent. Cardiologists and other providers may also use these insights to develop new strategies that better respond to such inherent complexities. C1 [Skaar, Elisabeth] Haukeland Hosp, Dept Heart Dis, POB 1400, N-5020 Bergen, Norway. [Skaar, Elisabeth; Ranhoff, Anette Hylen; Nordrehaug, Jan Erik] Univ Bergen, Dept Clin Sci, Bergen, Norway. [Skaar, Elisabeth; Ranhoff, Anette Hylen] Haraldsplass Deaconess Hosp, Kavli Res Ctr Geriatr & Dementia, Bergen, Norway. [Forman, Daniel E.] Univ Pittsburgh Med Ctr, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Schaufel, Margrethe Aase] Uni Res Hlth, Res Unit Gen Practice, Bergen, Norway. [Schaufel, Margrethe Aase] Haukeland Hosp, Dept Thorac Med, Bergen, Norway. RP Skaar, E (reprint author), Haukeland Hosp, Dept Heart Dis, POB 1400, N-5020 Bergen, Norway. EM elisabeth.skaar@helse-bergen.no FU Grieg Foundation; Department of Heart Disease; Haukeland University Hospital; Kavli Research Centre for Geriatrics and Dementia, Haraldsplass Deaconess Hospital, Bergen FX We would like to thank the participants in this study, and professor Kirsti Malterud for valuable comments. This study was mainly supported by Grants from Grieg Foundation, Department of Heart Disease, Haukeland University Hospital and Kavli Research Centre for Geriatrics and Dementia, Haraldsplass Deaconess Hospital, Bergen. NR 33 TC 0 Z9 0 U1 1 U2 1 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2017 VL 14 IS 1 BP 42 EP 48 DI 10.11909/j.issn.1671-5411.2017.01.007 PG 7 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA EN4QB UT WOS:000395990900007 PM 28270841 ER PT J AU Martin, JT Kim, DH Milby, AH Pfeifer, CG Smith, LJ Elliott, DM Smith, HE Mauck, RL AF Martin, John T. Kim, Dong Hwa Milby, Andrew H. Pfeifer, Christian G. Smith, Lachlan J. Elliott, Dawn M. Smith, Harvey E. Mauck, Robert L. TI In Vivo Performance of an Acellular Disc-Like Angle Ply Structure (DAPS) for Total Disc Replacement in a Small Animal Model SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE intervertebral disc; tissue engineering; acellular biomaterials; total disc replacement ID INTERVERTEBRAL DISC; LUMBAR DISC; ANNULUS FIBROSUS; CELL PHENOTYPE; MOUSE MODEL; DEGENERATION; COMPLICATIONS; MECHANICS; SCAFFOLDS; TRANSPORT AB Total intervertebral disc replacement with a biologic engineered disc may be an alternative to spinal fusion for treating end-stage disc disease. In previous work, we developed disc-like angle ply structures (DAPS) that replicate the structure and function of the native disc and a rat tail model to evaluate DAPS in vivo. Here, we evaluated a strategy in which, after in vivo implantation, endogenous cells could colonize the acellular DAPS and form an extracellular matrix organized by the DAPS topographical template. To do so, acellular DAPS were implanted into the caudal spines of rats and evaluated over 12 weeks by mechanical testing, histology, and microcomputed tomography. An external fixation device was used to stabilize the implant site and various control groups were included to evaluate the effect of immobilization. There was robust tissue formation within the DAPS after implantation and compressive mechanical properties of the implant matched that of the native motion segment. Immobilization provided a stable site for fibrous tissue formation after either a discectomy or a DAPS implantation, but bony fusion eventually resulted, with segments showing intervertebral bridging after long-term implantation, a process that was accelerated by the implanted DAPS. Thus, while compressive mechanical properties were replicated after DAPS implantation, methods to actively prevent fusion must be developed. Future work will focus on limiting fusion by remobilizing the motion segment after a period of integration, delivering pro-chondrogenic factors, and pre-seeding DAPS with cells prior to implantation. (C) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Martin, John T.; Kim, Dong Hwa; Milby, Andrew H.; Pfeifer, Christian G.; Smith, Lachlan J.; Smith, Harvey E.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, 426 B Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. [Martin, John T.; Milby, Andrew H.; Pfeifer, Christian G.; Smith, Lachlan J.; Smith, Harvey E.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. [Martin, John T.; Mauck, Robert L.] Univ Penn, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA. [Pfeifer, Christian G.] Univ Regensburg, Med Ctr, Dept Trauma Surg, Regensburg, Germany. [Smith, Lachlan J.; Smith, Harvey E.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Elliott, Dawn M.] Univ Delaware, Dept Biomed Engn, Newark, DE USA. [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, 426 B Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. EM Lemauck@mail.med.upenn.edu FU Department of Defense [OR090090]; Department of Veterans Affairs [I01 RX000211]; National Institutes of Health, through the Penn Center for Musculoskeletal Disorders [P30 AR050950] FX Grant sponsor: Department of Defense; Grant number: #OR090090; Grant sponsor: Department of Veterans Affairs; Grant number: #I01 RX000211; Grant sponsor: National Institutes of Health; Grant number: #P30 AR050950. NR 40 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD JAN PY 2017 VL 35 IS 1 BP 23 EP 31 DI 10.1002/jor.23310 PG 9 WC Orthopedics SC Orthopedics GA EK5SO UT WOS:000393986300003 PM 27227357 ER PT J AU Cooper, RA AF Cooper, Rory A. TI Commentary on WHO GATE Initiative SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Editorial Material C1 [Cooper, Rory A.] VA Pittsburgh Hlth Care Syst, Human Engn Resrch Lab, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Lab 151R 1, 7180 Highland Dr,Bldg 4,2nd Floor, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2017 VL 40 IS 1 BP 2 EP 4 DI 10.1080/10790268.2016.1224542 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EL5FX UT WOS:000394648100001 PM 27636193 ER PT J AU Wu, YK Liu, HY Kelleher, A Pearlman, J Ding, D Cooper, RA AF Wu, Yu-Kuang Liu, Hsin-Yi Kelleher, Annmarie Pearlman, Jonathan Ding, Dan Cooper, Rory A. TI Power seat function usage and wheelchair discomfort for power wheelchair users SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Wheelchairs; Rehabilitation ID SPINAL-CORD-INJURY; TILT-IN-SPACE; ASSESSMENT-TOOL; PRESSURE; RECLINE; LEGRESTS; FLEXION; EMG AB Objectives: To investigate correlations between power seat functions (PSFs) usage and wheelchair discomfort. Design: Quasi-experimental design: Time series design. Setting: In-home trial in participants' home/community. Participants: Thirteen power wheelchair users who independently used power wheelchairs equipped with PSFs as their primary means of mobility. Main Outcome Measures: PSF usage variables include the frequency of performing repositioning and using PSFs (tilt, recline, legrests and seat elevation), wheelchair occupancy, and driving distance. The Tool for Assessing Wheelchair disComfort (TAWC) were used to evaluate general discomfort and discomfort intensity. Results: Spearman correlation coefficient showed that the frequency of using tilt, recline, and legrest is significantly correlated with discomfort intensity. Multiple regression analysis with backward stepwise indicated that these functions can explain 43.8% of the variance (R2 =.438, F(3,33) = 8.588, P < 0.01) in the discomfort intensity score. The best-first decision tree shows that the frequency of using the legrest function was the top node, followed by recline and tilt functions. The overall accuracy of prediction with ten-fold cross validation for discomfort intensity was 79.4%. Conclusions: For people who used power wheelchairs equipped with PSFs, correlation analysis and regression modeling provided evidence from the quantitative data that increasing the frequency of using PSFs may decrease wheelchair discomfort. Future studies should include interventions to encourage people to use their PSFs appropriately. C1 [Wu, Yu-Kuang; Liu, Hsin-Yi; Kelleher, Annmarie; Pearlman, Jonathan; Ding, Dan; Cooper, Rory A.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Wu, Yu-Kuang; Liu, Hsin-Yi; Kelleher, Annmarie; Pearlman, Jonathan; Ding, Dan; Cooper, Rory A.] Vet Affairs Pittsburgh Healthcare Syst, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu FU National Science Foundation [EEC0540865]; VA RR& DVA RR&D (Merit Review Grant) [B6591R]; University of Pittsburgh FX This research was completed with the support of the National Science Foundation (Grant #EEC0540865 - Quality of Life Technology Engineering Research Center), VA RR&D (Merit Review Grant # B6591R - Powered Seating Function Usage among Veterans-Compliance and Coaching), and the University of Pittsburgh. NR 30 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2017 VL 40 IS 1 BP 62 EP 69 DI 10.1080/10790268.2016.1192360 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA EL5FX UT WOS:000394648100010 PM 27366954 ER PT J AU Altieri, L Hu, J Nguyen, A Cockburn, M Chiu, M Cotliar, J Kim, J Peng, D Crew, A AF Altieri, Lisa Hu, Jenny Nguyen, Andrew Cockburn, Myles Chiu, Melvin Cotliar, Jonathan Kim, Jenny Peng, David Crew, Ashley TI Interobserver reliability of teledermatology across all Fitzpatrick skin types SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article DE Telecare; teledermatology; telehealth; telemedicine; ehealth ID FORWARD TELEDERMATOLOGY; CONSULT SYSTEM; COST-BENEFIT; SAFETY-NET; REAL-TIME; MANAGEMENT; CARE; AGREEMENT; REFERRALS; DIAGNOSIS AB Introduction: Demand for dermatologic services in safety net hospitals, which disproportionately serve patients with darker coloured skin, is growing. Teledermatology has the potential to increase access and improve outcomes, but studies have yet to demonstrate the reliability of teledermatology for all Fitzpatrick skin types. Methods: We assessed the reliability of teledermatologists' diagnoses and management recommendations for store-and-forward teledermatology in patients with lightly pigmented (Fitzpatrick skin types I-III) versus darkly pigmented (Fitzpatrick skin types IV-VI) skin, when compared to in-person diagnosis and management decisions. This prospective study enrolled 232 adult patients, presenting with new, visible skin complaints in a Los Angeles county dermatology clinic. Forty-seven percent of patients were Fitzpatrick skin types I-III, and 53% were Fitzpatrick skin types IV-VI. Results: Percent concordance for the identical primary diagnosis was 53.2% in lighter (Fitzpatrick I-III) skin types and 56.0% in darker (Fitzpatrick IV-VI) skin types. There was no statistically significant difference in concordance rates between lighter and darker skin types for primary diagnosis. Concordance rates for diagnostic testing, clinic-based therapy, and treatments were similar in both groups of Fitzpatrick skin types. Discussion: These results suggest that teledermatology is reliable for the diagnosis and management of patients with all Fitzpatrick skin types. C1 [Altieri, Lisa] Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. [Hu, Jenny; Chiu, Melvin; Kim, Jenny] Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90024 USA. [Nguyen, Andrew; Cockburn, Myles] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Cockburn, Myles; Peng, David; Crew, Ashley] Univ Southern Calif, Dept Dermatol, Los Angeles, CA 90089 USA. [Chiu, Melvin; Kim, Jenny] Vet Affairs Greater Los Angeles Healthcare Syst, Dermatol Serv, Los Angeles, CA USA. [Cotliar, Jonathan] City Hope Natl Med Ctr, Div Dermatol, 1500 E Duarte Rd, Duarte, CA 91010 USA. RP Altieri, L (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM laltieri@mednet.ucla.edu NR 21 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1357-633X EI 1758-1109 J9 J TELEMED TELECARE JI J. Telemed. Telecare PD JAN PY 2017 VL 23 IS 1 BP 68 EP 73 DI 10.1177/1357633X15621226 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EK9QM UT WOS:000394259000009 PM 26729754 ER PT J AU Farrell, TW Widera, E Rosenberg, L Rubin, CD Naik, AD Braun, U Torke, A Li, I Vitale, C Shega, J AF Farrell, Timothy W. Widera, Eric Rosenberg, Lisa Rubin, Craig D. Naik, Aanand D. Braun, Ursula Torke, Alexia Li, Ina Vitale, Caroline Shega, Joseph CA Amer Geriatrics Soc TI AGS Position Statement: Making Medical Treatment Decisions for Unbefriended Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE unbefriended; capacity assessment; surrogate decision maker; substituted judgment; best interest; ethics committee; position statement ID HOSPITAL CARDIAC-ARREST; INDIVIDUALS; SURVIVAL; OUTCOMES; GUARDIANSHIP; SURROGATES; CAPACITY; CARE AB In this position statement, we define unbefriended older adults as patients who: (1) lack decisional capacity to provide informed consent to the medical treatment at hand; (2) have not executed an advance directive that addresses the medical treatment at hand and lack capacity to do so; and (3) lack family, friends or a legally authorized surrogate to assist in the medical decision-making process. Given the vulnerable nature of this population, clinicians, health care teams, ethics committees and other stakeholders working with unbefriended older adults must be diligent when formulating treatment decisions on their behalf. The process of arriving at a treatment decision for an unbefriended older adult should be conducted according to standards of procedural fairness and include capacity assessment, a search for potentially unidentified surrogate decision makers (including non-traditional surrogates) and a team-based effort to ascertain the unbefriended older adult's preferences by synthesizing all available evidence. A concerted national effort is needed to help reduce the significant state-to-state variability in legal approaches to unbefriended patients. Proactive efforts are also needed to identify older adults, including adult orphans, at risk for becoming unbefriended and to develop alternative approaches to medical decision making for unbefriended older adults.This document updates the 1996 AGS position statement on unbefriended older adults. C1 [Farrell, Timothy W.] Univ Utah, Sch Med, Salt Lake City, UT 84112 USA. [Farrell, Timothy W.] VA Salt Lake City Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA. [Widera, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Widera, Eric] San Francisco VA Med Ctr, San Francisco, CA USA. [Rosenberg, Lisa] Roseman Univ Hlth Sci, 2963 Kedleston St, Las Vegas, NV 89135 USA. [Rubin, Craig D.] Univ Texas Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Naik, Aanand D.; Braun, Ursula] Baylor Coll Med, Houston, TX 77030 USA. [Naik, Aanand D.; Braun, Ursula] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Torke, Alexia] Indiana Univ, 1101 West 10th St, Indianapolis, IN 46202 USA. [Li, Ina] Christiana Care Hlth Syst, N 1400 Washington St,Suite 327, Wilmington, DE 19801 USA. [Vitale, Caroline] Univ Michigan, Ann Arbor, MI 48109 USA. [Vitale, Caroline] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Shega, Joseph] VITAS Hosp Care Healthcare, Gotha, FL USA. [Shega, Joseph] Univ Cent Florida, Gotha, FL USA. [Farrell, Timothy W.] Univ Utah, Sch Med, VA Salt Lake City Geriatr Res Educ & Clin Ctr, 30 N 1900 E,AB 193 SOM, Salt Lake City, UT 84132 USA. [Widera, Eric] Univ Calif San Francisco, San Francisco VA Med Ctr, NHCU, SFVAMC Bldg 208, San Francisco, CA 94121 USA. [Naik, Aanand D.] Michael E DeBakey VA Med Ctr, 2002 Holcombe 152, Houston, TX 77030 USA. [Naik, Aanand D.] Baylor Coll Med, 2002 Holcombe 152, Houston, TX 77030 USA. [Braun, Ursula] Michael E DeBakey VA Med Ctr, 1 Baylor Plz,MS230, Houston, TX 77030 USA. [Braun, Ursula] Baylor Coll Med, 1 Baylor Plz,MS230, Houston, TX 77030 USA. [Vitale, Caroline] Univ Michigan, VA Ann Arbor Healthcare Syst, 2215 Fuller Rd,GRECC 11G, Ann Arbor, MI 48105 USA. [Shega, Joseph] Univ Cent Florida, VITAS Healthcare, Volunteer Fac, 9616 Lake Hugh Dr, Gotha, FL 34734 USA. [Shega, Joseph] Univ Cent Florida, Med, 9616 Lake Hugh Dr, Gotha, FL 34734 USA. RP Farrell, TW (reprint author), Univ Utah, Sch Med, Salt Lake City, UT 84112 USA.; Farrell, TW (reprint author), VA Salt Lake City Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA.; Farrell, TW (reprint author), Univ Utah, Sch Med, VA Salt Lake City Geriatr Res Educ & Clin Ctr, 30 N 1900 E,AB 193 SOM, Salt Lake City, UT 84132 USA. FU AGS operating budget FX Financial support for the development of this paper comes exclusively from the AGS operating budget. NR 35 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2017 VL 65 IS 1 BP 14 EP E5 DI 10.1111/jgs.14586 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EL3WZ UT WOS:000394551300003 ER PT J AU Sarkar, U Lyles, C Steinman, M Huang, ES Moffet, HH Whitmer, RA Warton, EM Karter, AJ AF Sarkar, Urmimala Lyles, Courtney Steinman, Michael Huang, Elbert S. Moffet, Howard H. Whitmer, Rachel A. Warton, E. Margaret Karter, Andrew J. TI Changes in Medication Use After Dementia Diagnosis in an Observational Cohort of Individuals with Diabetes Mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE polypharmacy; dementia; diabetes mellitus ID NORTHERN CALIFORNIA DISTANCE; DIFFERENCE-IN-DIFFERENCES; OLDER PATIENTS; GLYCEMIC CONTROL; SOCIAL SUPPORT; BLOOD-GLUCOSE; FOLLOW-UP; ADULTS; COMPLICATIONS; POPULATION AB ObjectivesTo assess changes in medication use after a diagnosis of dementia in individuals with type 2 diabetes mellitus. DesignDifference-in-differences analysis of changes in the number of dispensed chronic medications between individuals with and without newly diagnosed dementia. SettingIntegrated healthcare delivery system, Kaiser Permanente Northern California. ParticipantsIndividuals aged 50 and older without prevalent dementia with type 2 diabetes mellitus enrolled in a baseline survey. During 5 years of follow-up, 193 individuals with a new diagnosis of dementia were identified, and risk-set sampling was used to randomly select five reference subjects per case matched on 5-year age categories and sex (965 matched participants), resulting in an analytical sample of 1,158. MeasurementsThe exposure was new diagnosis of dementia. The primary outcome was change in number of current chronic medications (total, cardiovascular (blood pressure and lipid control), diabetes mellitus) at three times: 1 year before index date (preindex date), date of diagnosis of dementia or matched reference date (index date), and up to 1 year after index date or end of follow-up if censored before 1 year (postindex date). ResultsAfter adjustment, the number of chronic medications and the subset of cardiovascular medications declined after a dementia diagnosis in the overall cohort and in age-, sex-, and time-matched reference individuals, but the decline was significantly greater in the group with dementia (0.71 medications fewer than the reference group, P = .02). The number of diabetes mellitus medications declined in both groups, but the declines were not statistically different (0.18 medications fewer than the reference group, P = .008). ConclusionsUse of cardiometabolic medications fell after a diagnosis of dementia, as recommended in national guidelines. C1 [Sarkar, Urmimala; Lyles, Courtney] Univ Calif San Francisco, Div Gen Internal Med, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. [Steinman, Michael] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Huang, Elbert S.] Univ Chicago, Sch Med, Chicago, IL 60637 USA. [Moffet, Howard H.; Whitmer, Rachel A.; Warton, E. Margaret; Karter, Andrew J.] Kaiser Permanente, Div Res, Oakland, CA USA. RP Sarkar, U (reprint author), UCSF SFGH, 1001 Potrero Ave,Box 1364, San Francisco, CA 94110 USA. EM urmimala.sarkar@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases Grant [R01 DK081796]; Agency for Healthcare Research and Quality [K99022408]; National Institutes of Health [DK080726]; National Institute on Aging (NIA) Paul Beeson Career Development Award [1K23-AG030999]; NIA Claude Pepper Older Americans Independence Center Award [P30 AG044281]; [P30HS023558]; [P60MD006902]; [P30 DK092949]; [K24 DK105340] FX Dr. Urmimala Sarkar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This research was directly funded by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK081796 (Karter, Moffet, Warton, Huang). Other support included P30HS023558 (Sarkar), P60MD006902 (Karter), P30 DK092949 (Huang), K24 DK105340 (Huang), Agency for Healthcare Research and Quality K99022408 (Lyles), National Institutes of Health Grant DK080726 (Moffet), National Institute on Aging (NIA) Paul Beeson Career Development Award 1K23-AG030999 and NIA Claude Pepper Older Americans Independence Center Award P30 AG044281 (Steinman). NR 40 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2017 VL 65 IS 1 BP 77 EP 82 DI 10.1111/jgs.14429 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EL3WZ UT WOS:000394551300016 PM 27642180 ER PT J AU Soones, T Federman, A Leff, B Siu, AL Ornstein, K AF Soones, Tacara Federman, Alex Leff, Bruce Siu, Albert L. Ornstein, Katherine TI Two-Year Mortality in Homebound Older Adults: An Analysis of the National Health and Aging Trends Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE homebound; United States; epidemiology; cross-sectional studies; mortality ID LATE-LIFE DISABILITY; HOME-BASED PRIMARY; PRIMARY-CARE; RISK; SPACE; COMORBIDITY; POPULATION; IMPAIRMENT; PREVALENCE; DEPRESSION AB ObjectivesTo determine the association between homebound status and mortality. DesignCross-sectional. SettingAnnual, in-person interviews. ParticipantsA nationally representative sample of community-dwelling, Medicare beneficiaries aged 65 and older enrolled in the National Health and Aging Trends Study between 2011 and 2013 (N = 6,400). MeasurementsTwo-year mortality and prevalence of homebound status in the year before death are described using three categories of homebound status: homebound (never or rarely left home in the last month), semihomebound (left home with assistance, needed help or had difficulty), and nonhomebound (left home without help or difficulty). ResultsIn unadjusted analyses, 2-year mortality was 40.3% in homebound participants, 21.3% in those who were semihomebound and 5.8% in those who were nonhomebound. Homebound status was associated with greater 2-year mortality, adjusted for sociodemographic characteristics, comorbidities, and functional status (hazard ratio = 2.08; 95% confidence interval = 1.63-2.65, P < .001). Half of older community-dwelling Medicare beneficiaries were homebound in the year before death. ConclusionHomebound status is associated with greater risk of death independent of functional impairment and comorbidities. To improve outcomes for homebound older adults and the many older adults who will become homebound in the last year of life, providers and policymakers need to extend healthcare services from hospitals and clinics to the homes of vulnerable individuals. C1 [Soones, Tacara; Siu, Albert L.; Ornstein, Katherine] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave Levy Pl,Box 1070, New York, NY 10029 USA. [Federman, Alex; Ornstein, Katherine] Icahn Sch Med Mt Sinai, Div Gen Internal Med, Dept Med, New York, NY 10029 USA. [Leff, Bruce] Johns Hopkins Univ, Dept Med, Div Geriatr Med, Baltimore, MD USA. [Leff, Bruce] Johns Hopkins Univ, Dept Community & Publ Hlth, Sch Nursing, Baltimore, MD USA. [Leff, Bruce] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ornstein, Katherine] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. RP Soones, T (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave Levy Pl,Box 1070, New York, NY 10029 USA. EM tacara.soones@mssm.edu FU Voluntary Landmark Health; National Institute on Aging (NIA) [U01AG32947]; NIA [K01AG047923]; National Palliative Care Research Center FX Dr. Bruce Leff is on the boards of directors of the American Academy of Home Care Medicine and the Voluntary Alliance for Home Health Quality and Innovation. He is also a paid member of the advisory board of Voluntary Landmark Health.; NHATS is sponsored by Grant U01AG32947 from the National Institute on Aging (NIA). Dr. Ornstein was supported by Grant K01AG047923 from NIA and by the National Palliative Care Research Center. NR 40 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2017 VL 65 IS 1 BP 123 EP 129 DI 10.1111/jgs.14467 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EL3WZ UT WOS:000394551300022 PM 27641001 ER PT J AU Cohen, NA AF Cohen, Noam A. TI The Genetics of the Bitter Taste Receptor T2R38 in Upper Airway Innate Immunity and Implications for Chronic Rhinosinusitis SO LARYNGOSCOPE LA English DT Article DE T2R38; chronic rhinosinusitis; cilia; interkingdom signaling; host-pathogen interactions ID NONPOLYPOID CHRONIC RHINOSINUSITIS; BIOFILM-FORMING BACTERIA; NITRIC-OXIDE; PSEUDOMONAS-AERUGINOSA; CHEMOSENSORY CELLS; ANTIMICROBIAL ACTIVITY; CHRONIC SINUSITIS; PERCEPTION; INFLAMMATION; CILIOGENESIS AB Objective: Chronic rhinosinusitis (CRS) refractory to therapeutic intervention may involve a particularly resistant infection known as a bacterial biofilm. Critical to biofilm formation is the microbial process of quorum sensing whereby microbes secrete factors that regulate the expression of microbial genes involved in biofilm formation, persistence, and virulence. Here, we review recent work demonstrating that the bitter taste receptor T2R38, expressed on the apical surface of the sinonasal epithelium, serves a sentinel role in eavesdropping on microbial quorum-sensing communications and regulates localized innate biocidal defenses. Furthermore, studies investigating whether cilia are necessary for T2R38 expression and function in the upper airway are presented. Methods: Primary human sinonasal air-liquid interface cultures were used to elucidate cellular pathways responsive to quorum-sensing molecules, whereas clinical studies investigated the contribution of T2R38 polymorphisms to recalcitrant chronic rhinosinusitis. Results: T2R38 is stimulated by acyl-homoserine lactones, gram-negative quorum-sensing molecules, and subsequently activates nitric oxide-dependent innate immune responses. The formation of mature cilia is necessary for T2R38 expression and function, and polymorphisms that underlie T2R38 functionality appear to be involved in susceptibility to upper respiratory infection and recalcitrant CRS. Conclusion: Taste receptors are emerging as critical components of early-phase respiratory innate immunity, detecting molecules used by microbes to communicate and stimulating localized host defenses. Genetic polymorphisms are very common within the taste receptors, and recent linkage studies have demonstrated associations of taste receptor genetics with CRS. Lastly, ciliogenesis, which is often impacted in CRS, is critical for the functional expression of T2R38. C1 [Cohen, Noam A.] Univ Penn, Hosp Univ Penn, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Cohen, Noam A.] Monett Chem Senses Ctr, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Hosp Univ Penn, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU USPHS grant [R01DC013588] FX Funded in part by USPHS grant R01DC013588. The author has no other funding, financial relationships, or conflicts of interest to disclose. NR 53 TC 1 Z9 1 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2017 VL 127 IS 1 BP 44 EP 51 DI 10.1002/lary.26198 PG 8 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA EL9PB UT WOS:000394951400021 PM 27650657 ER PT J AU Love, MN Clark, DG Cochran, JN Den Beste, KA Geldmacher, DS Benzinger, TL Gordon, BA Morris, JC Bateman, RJ Roberson, ED AF Love, Marissa Natelson Clark, David G. Cochran, J. Nicholas Den Beste, Kyle A. Geldmacher, David S. Benzinger, Tammie L. Gordon, Brian A. Morris, John C. Bateman, Randall J. Roberson, Erik D. TI Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer's disease; Presenilin 1; PET scan; Elecrtoencephalography ID MISSENSE MUTATIONS; IN-VIVO; ONSET; GENE; BETA; MICE; A-BETA-42; MECHANISM; MRI; PET AB We present 2 cases of early-onset Alzheimer's disease due to a novel N135Y mutation in PSEN1. The proband presented with memory and other cognitive symptoms at age 32. Detailed clinical characterization revealed initial deficits in memory with associated dysarthria, progressing to involve executive dysfunction, spastic gait, and episodic confusion with polyspike discharges on long-term electroencephalography. Amyloid-and FDG-PET scans showed typical results of Alzheimer's disease. By history, the proband's father had developed cognitive symptoms at age 42 and died at age 48. Neuropathological evaluation confirmed Alzheimer's disease, with moderate to severe amyloid angiopathy. Skeletal muscle showed type 2 fiberepredominant atrophy with pale central clearing. Genetic testing of the proband revealed an N135Y missense mutation in PSEN1. This mutation was predicted to be pathogenic by in silico analysis. Biochemical analysis confirmed that the mutation caused an increased Ab42/Ab40 ratio, consistent with other PSEN1 mutations and with a loss of presenilin function. Published by Elsevier Inc. C1 [Love, Marissa Natelson; Clark, David G.; Geldmacher, David S.; Roberson, Erik D.] Univ Alabama Birmingham, Alzheimers Dis Ctr, Birmingham, AL USA. [Love, Marissa Natelson; Clark, David G.; Cochran, J. Nicholas; Den Beste, Kyle A.; Geldmacher, David S.; Roberson, Erik D.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Love, Marissa Natelson; Clark, David G.] Birmingham VA Med Ctr, Dept Neurol, Birmingham, AL USA. [Clark, David G.] Med Univ South Carolina, Ralph H Johnson VA Med Ctr, Dept Neurol, Charleston, SC USA. [Cochran, J. Nicholas; Den Beste, Kyle A.; Roberson, Erik D.] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Birmingham, AL USA. [Geldmacher, David S.; Roberson, Erik D.] Univ Alabama Birmingham, McKnight Brain Inst, Birmingham, AL USA. [Benzinger, Tammie L.; Gordon, Brian A.; Morris, John C.; Bateman, Randall J.] Washington Univ, Sch Med, Dept Neurol, Dominantly Inherited Alzheimers Network, St Louis, MO 63110 USA. [Benzinger, Tammie L.; Gordon, Brian A.] Washington Univ, Mallinckrodt Inst Radiol, Sch Med, St Louis, MO USA. RP Clark, DG (reprint author), 96 Jonathan Lucas St,301 CSB MSC 606, Charleston, SC 29425 USA. EM clarkda@musc.edu FU National Institutes of Health [R01NS075487, U19AG032438, U-01-AG042791]; National Institute on Aging [U19AG032438]; Veterans Administration [E6553W] FX This research was supported by the National Institutes of Health (R01NS075487, U19AG032438, and U-01-AG042791), the National Institute on Aging (U19AG032438), and the Veterans Administration (E6553W). NR 37 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JAN PY 2017 VL 49 AR 216.e7 DI 10.1016/j.neurobiolaging.2016.09.020 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA EK5PG UT WOS:000393977700028 ER PT J AU Markland, AD Burgio, KL Beasley, TM David, SL Redden, DT Goode, PS AF Markland, Alayne D. Burgio, Kathryn L. Beasley, T. Mark David, Shannon L. Redden, David T. Goode, Patricia S. TI Psychometric Evaluation of an Online and Paper Accidental Bowel Leakage Questionnaire: The ICIQ-B Questionnaire SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE accidental bowel leakage; fecal incontinence; functional bowel disorders; psychometric evaluation; quality of life; questionnaire ID QUALITY-OF-LIFE; FORM HEALTH SURVEY; FECAL INCONTINENCE; ANAL INCONTINENCE; CONCEPTUAL-FRAMEWORK; SEVERITY; PATIENT; SYMPTOM; EPIDEMIOLOGY; RELIABILITY AB Aims: To evaluate the psychometric properties of an online versus paper US-English version of the International Consultation on Incontinence Questionnaire-Bowel (ICIQ-B). Methods: The ICIQ-B includes 17 items under 3 domains: bowel pattern (5 items), bowel control (7 items), and quality of life (5 items). We recruited community-dwelling adults seeking treatment for >= monthly bowel leakage from specialty clinics within a VA medical center and university affiliate. An online versus paper version was evaluated at baseline, 2 weeks later, and 3 months after nonsurgical treatments per usual care. We assessed test-retest reliability (Pearson correlations) at 2 weeks, internal consistency (Cronbach's alpha), and convergent validity (Pearson correlations). Sensitivity to change was the difference between the baseline and post-treatment (3-month) scores. Results: Mean age was 58.0 +/- 11.9; 36% Veterans, 52% women. At baseline, 2 weeks, and 3 months, we found no differences in the online vs paper scores for the bowel control and quality of life domains. The ICIQ-B demonstrated fair internal consistency for the bowel pattern domain (Cronbach's alpha = 0.36-0.54). Internal consistency on the bowel pattern domain was better with the paper version than the online version at 2 weeks (P<0.05) and 3 months (P<0.01) with no difference at baseline. All other domains had good internal consistency (Cronbach's alpha>0.80), good retest reliability (r >= 0.70, P<0.001), domain-specific convergent validity for stool consistency (P<0.05), incontinence severity (P <= 0.002), and quality of life impact (P<0.05). After nonsurgical treatments, we found a reasonable response to change (P <= 0.05). Conclusions: Online and paper versions had robust psychometric data for use among U.S. men and women, including Veterans. (C) 2015 Wiley Periodicals, Inc. C1 [Markland, Alayne D.; Burgio, Kathryn L.; Beasley, T. Mark; Goode, Patricia S.] Univ Alabama Birmingham, Med Ctr, Birmingham Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA. [Markland, Alayne D.; Burgio, Kathryn L.; Goode, Patricia S.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Beasley, T. Mark; Redden, David T.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [David, Shannon L.] North Dakota State Univ, Dept Hlth Nutr & Exercise Sci, Fargo, ND USA. RP Markland, AD (reprint author), Birmingham VA Med Ctr, Div Gerontol Geriatr & Palliat Care, UAB Dept Med, GRECC 11-G,900 South 18th St, Birmingham, AL 35233 USA. EM amarkland@aging.uab.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development [I01 RX000315-01] FX Grant sponsor: Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Grant number: I01 RX000315-01 NR 24 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD JAN PY 2017 VL 36 IS 1 BP 166 EP 170 DI 10.1002/nau.22905 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA EL5MZ UT WOS:000394666500026 PM 26473313 ER PT J AU Brody, AL Zorick, T Hubert, R Hellemann, GS Balali, S Kawasaki, SS Garcia, LY Enoki, R Abraham, P Young, P McCreary, C AF Brody, Arthur L. Zorick, Todd Hubert, Robert Hellemann, Gerhard S. Balali, Shabnam Kawasaki, Sarah S. Garcia, Lizette Y. Enoki, Ryutaro Abraham, Paul Young, Paulina McCreary, Charles TI Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID NICOTINE REPLACEMENT THERAPY; SUSTAINED-RELEASE BUPROPION; PSYCHIATRIC RATING-SCALE; FAGERSTROM-TEST; MENTAL-ILLNESS; CLINICAL-TRIAL; CIGARETTE-SMOKING; BIPOLAR DISORDER; ATYPICAL ANTIPSYCHOTICS; TRANSDERMAL NICOTINE AB Introduction: The majority of people with schizophrenia have a diagnosis of tobacco dependence during their lifetime. A major obstacle to reducing the burden of cigarette smoking in this population is that these smokers have lower quit rates when undergoing standard treatment compared to smokers with no mental illness. We sought to determine if combination extended treatment (COMBEXT) and home visits (HV) would lead to improved outcomes in smokers with schizophrenia. Methods: Thirty-four cigarette smokers with schizophrenia completed either COMB-EXT with HV, COMB-EXT without HV, or treatment as usual (TAU) (random assignment). COMB-EXT consisted of group cognitive-behavioral therapy (CBT), bupropion, nicotine patch, and nicotine lozenge, which were initiated within 2 weeks and continued for 26 weekly visits. HV consisted of biweekly visits to the home with assessment of secondhand smoke (SHS) exposure and brief behavioral therapy with participants and others in the home environment. TAU consisted of group CBT plus serial single or combination medication trials as per standard care. Results: Smokers with schizophrenia who received COMB-EXT (with or without HV) had greater reductions in cigarettes per day than those treated with TAU (both ps <.01). In addition, 7-day point prevalence abstinence rates for the three groups were 45%, 20%, and 8%, respectively, which was significantly higher for COMB-EXT plus HV than TAU (.2(1) = 4.8, p =.03). Groups did not differ significantly in the number of adverse events, and HV were easily scheduled. Conclusion: COMB-EXT improves outcomes for smokers with schizophrenia. HV appeared to provide additional benefit for smoking cessation in this treatment-resistant population. Implications: The clear benefit found here of rapidly initiated, combination, extended treatment over TAU suggests that aggressive and extended treatment should be considered in clinical practice for smokers with schizophrenia. Furthermore, HV to address SHS exposure showed initial promise for assisting smokers with schizophrenia in maintaining abstinence, indicating that this intervention may be worthy of future research. C1 [Brody, Arthur L.; Zorick, Todd; Hubert, Robert; Hellemann, Gerhard S.; Balali, Shabnam; Garcia, Lizette Y.; Enoki, Ryutaro; Abraham, Paul; Young, Paulina; McCreary, Charles] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Brody, Arthur L.] Univ Calif San Diego, Dept Psychiat, 3350 La Jolla Village Dr 116A, San Diego, CA 92161 USA. [Kawasaki, Sarah S.] Hlth Care Homeless, Dept Primary Care, Baltimore, MD USA. RP Brody, AL (reprint author), Univ Calif San Diego, Dept Psychiat, 3350 La Jolla Village Dr 116A, San Diego, CA 92161 USA. EM abrody@ucsd.edu FU National Institute on Drug Abuse [R01 DA20872]; Department of Veterans Affairs Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; Tobacco-Related Disease Research Program [23XT-0002] FX This work was supported by the National Institute on Drug Abuse (grant number R01 DA20872), the Department of Veterans Affairs Office of Research and Development (CSR&D Merit Review Award I01 CX000412), and the Tobacco-Related Disease Research Program (grant number #23XT-0002). The funders had no role in the design, conduct, or reporting of this study. NR 87 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD JAN PY 2017 VL 19 IS 1 BP 68 EP 76 DI 10.1093/ntr/ntw190 PG 9 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA EP0DD UT WOS:000397056100009 PM 27613888 ER PT J AU Cuevas, AG O'Brien, K Saha, S AF Cuevas, Adolfo G. O'Brien, Kerth Saha, Somnath TI What is the key to culturally competent care: Reducing bias or cultural tailoring? SO PSYCHOLOGY & HEALTH LA English DT Article DE clinician-patient relationships; patient-centred care; cultural competency; health care disparities; ethnic minorities; focus groups ID PATIENT-CENTERED CARE; HEALTH-CARE; LANGUAGE BARRIERS; DISPARITIES; QUALITY; CLINICIAN; LATINOS; ACCESS; COMMUNICATION; PERCEPTIONS AB Objective: To gain a better understanding as to whether disparities in patient-provider relationships arise from ethnic minority patients being treated differently than European American patients while they would prefer to be treated the same, or whether disparities arise when ethnic minority patients are treated the same as European American patients while they would prefer to be treated differently. Method: African-American, Latina/Latino and European American community members were recruited to participate in one of 27 focus group discussions. Topics included what made a good or bad relationship with a doctor and what led one to trust a doctor. A thematic analysis was conducted using NVivo 10. Results: Patients of all groups described experiences that reflected the concepts of patient-centred care, such as wanting a clinician who is attentive to patients' needs. African-American patients reported experiences they viewed as discriminatory. Some African-American patients felt it was appropriate to racially/ethnically contextualise their care, and most Latina/Latino patients preferred language/culturally concordant clinicians. Conclusion: Health care disparities might be reduced through a patientcentred approach to cultural competency training, general knowledge of the cultural context of clinicians' patient population, and attention to the effects of racial bias and discrimination among both clinicians and non-clinical staff. C1 [Cuevas, Adolfo G.; O'Brien, Kerth] Portland State Univ, Dept Psychol, Portland, OR 97207 USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Publ Hlth & Prevent Med, Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Cuevas, Adolfo G.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA. RP Cuevas, AG (reprint author), Portland State Univ, Dept Psychol, Portland, OR 97207 USA.; Cuevas, AG (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA. EM acuevas@hsph.harvard.edu OI O'Brien, Kerth/0000-0002-1566-7364 FU Robert Wood Johnson Foundation; National Institute of Health [3R25CA057711] FX Project EQUALED was funded by a grant from the Robert Wood Johnson Foundation. The preparation of this article was supported by the National Institute of Health 3R25CA057711. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 40 TC 0 Z9 0 U1 3 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0887-0446 EI 1476-8321 J9 PSYCHOL HEALTH JI Psychol. Health PY 2017 VL 32 IS 4 BP 493 EP 507 DI 10.1080/08870446.2017.1284221 PG 15 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA EO5VU UT WOS:000396761800007 PM 28165767 ER PT J AU Richards, A Inslicht, SS Metzler, TJ Mohlenhoff, BS Rao, MN O'Donovan, A Neylan, TC AF Richards, Anne Inslicht, Sabra S. Metzler, Thomas J. Mohlenhoff, Brian S. Rao, Madhu N. O'Donovan, Aoife Neylan, Thomas C. TI Sleep and Cognitive Performance From Teens To Old Age: More Is Not Better SO SLEEP LA English DT Article DE Sleep duration; cognitive performance; aging; adolescence ID ADULT LIFE-SPAN; WORKING-MEMORY; VISUAL MEMORY; UNITED-STATES; DURATION; ADOLESCENTS; HEALTH; ASSOCIATION; SCHEDULES; BEHAVIORS AB Objectives: To determine the interaction of age and habitual sleep duration in predicting cognitive performance in a large sample of participants aged 15 to 89 years. Methods: This study is a cross-sectional analysis of performance data gathered between January 2012 and September 2013. First-time players ( N = 512 823) of three internet cognitive training games measuring processing speed, working memory, visuospatial memory, and arithmetic participated in the study. Results: Performance was based on a measure of speed and accuracy for each game. The relationship between performance and self-reported habitual sleep duration was examined in the sample as a whole and across 10-year age groups starting at age 15 and ending at 75 and older. Performance peaked at 7 h of sleep duration for all three games in the sample as a whole, and the decrements in performance for sleep durations greater than 7 h were either comparable or greater in the youngest as compared to the oldest age groups. Conclusions: These findings challenge the hypothesis that deteriorating cognitive performance with long sleep duration is driven by medical comorbidities associated with aging. Further, these data are consistent with an optimal dose model of sleep and suggest that the model for the homeostatic recovery of cognitive function as a function of sleep duration should incorporate a curvilinear decline with longer duration sleep, indicating that there may be a cost to increased sleep. Replication and further research is essential for clarifying the sleep duration-cognition relationship in youth and adults of all ages. C1 [Richards, Anne; Inslicht, Sabra S.; Mohlenhoff, Brian S.; Rao, Madhu N.; O'Donovan, Aoife; Neylan, Thomas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Richards, Anne; Inslicht, Sabra S.; Metzler, Thomas J.; Mohlenhoff, Brian S.; O'Donovan, Aoife; Neylan, Thomas C.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. RP Richards, A (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM anne.richards@ucsf.edu FU U.S. Department of Veteran Affairs [1IK2CX000871-01A2]; U.S. Department of Defense [W81XWH-16-1-0259] FX Work on this project was funded in part by grants to Dr. Richards from the U.S. Department of Veteran Affairs (1IK2CX000871-01A2) and the U.S. Department of Defense (W81XWH-16-1-0259). NR 51 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JAN 1 PY 2017 VL 40 IS 1 AR PII zsw029 DI 10.1093/sleep/zsw029 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EK7SO UT WOS:000394125700029 ER PT J AU Swetz, KM Barnett, MD Kamal, AH Mansel, JK AF Swetz, Keith M. Barnett, Michael D. Kamal, Arif H. Mansel, J. Keith TI Physician Aid in Dying in the US South: What Does the Future Hold? SO SOUTHERN MEDICAL JOURNAL LA English DT Editorial Material C1 Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham Vet Affairs Med Ctr, 1720 2nd Ave S,BDB 650, Birmingham, AL 35294 USA. Duke Univ, Duke Canc Inst, Durham, NC USA. Mayo Clin, Div Gen Internal Med, Sect Palliat Med, Rochester, MN USA. Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Swetz, KM (reprint author), Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave S,BDB 650, Birmingham, AL 35294 USA. EM kswetz@uabmc.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD JAN PY 2017 VL 110 IS 1 BP 9 EP 10 DI 10.14423/SMJ.0000000000000582 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EL1KS UT WOS:000394379900003 PM 28052167 ER PT J AU Vachhani, R Patel, T Centor, RM Estrada, CA AF Vachhani, Raj Patel, Toral Centor, Robert M. Estrada, Carlos A. TI Sensitivity for Diagnosing Group A Streptococcal Pharyngitis from Manufacturers is 10% Higher than Reported in Peer-Reviewed Publications SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE diagnostic test approval; pharyngitis; diagnosis; sensitivity and specificity; streptococcal infections; diagnosis; microbiology; techniques and procedures ID ANTIGEN-DETECTION TESTS; TEST ACCURACY; SORE THROAT; METAANALYSIS; REGRESSION AB Objectives Meta-analyses based on peer-reviewed publications report a sensitivity of approximately 85% for rapid antigen streptococcus tests to diagnose group A streptococcal (GAS) pharyngitis. Because these meta-analyses excluded package inserts, we examined the test characteristics of rapid antigen streptococcal tests and molecular methods that manufacturers report in their package inserts. Methods We included tests available in the US market (Food and Drug Administration, period searched 1993-2015) and used package insert data to calculate pooled sensitivity and specificity. To examine quality, we used the Quality Assessment of Diagnostic Accuracy Studies-2. We excluded 26 tests having different trade names but identical methods and data. Results The study design was prospective in 41.7% (10 of 24). The pooled sensitivity of the most commonly used method, lateral flow/immunochromatographic, was 95% (95% confidence interval [CI] 94-96) and the pooled specificity was 98% (96-98); 7108 patients. The pooled sensitivity of the polymerase chain reaction or molecular methods was 98% (95% CI 96-98) and the pooled specificity was 96% (95% CI 95-97); 5685 patients. Conclusions Package inserts include sponsored studies that overestimate the sensitivity of rapid tests to diagnose GAS pharyngitis by approximately 10%. Physicians should understand that package inserts overestimate diagnostic test utility; a negative test cannot be used to exclude GAS pharyngitis. C1 [Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, 732 FOT,510 20th St S, Birmingham, AL 35294 USA. Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, Div Gen Internal Med, 732 FOT,510 20th St S, Birmingham, AL 35294 USA. EM cestrada@uabmc.edu FU Justin E. Rodgers Foundation FX R.M.C. received funding from the Justin E. Rodgers Foundation. The remaining authors did not report any financial relationships or conflicts of interest. NR 19 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD JAN PY 2017 VL 110 IS 1 BP 59 EP 64 DI 10.14423/SMJ.0000000000000597 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EL1KS UT WOS:000394379900015 PM 28052179 ER PT J AU Suri, P Boyko, EJ Smith, NL Jarvik, JG Williams, FMK Jarvik, GP Goldberg, J AF Suri, Pradeep Boyko, Edward J. Smith, Nicholas L. Jarvik, Jeffrey G. Williams, Frances M. K. Jarvik, Gail P. Goldberg, Jack TI Modifiable risk factors for chronic back pain: insights using the co-twin control design SO SPINE JOURNAL LA English DT Article DE Activity; Alcohol; Depression; Low back pain; Musculoskeletal diseases; Obesity; Sleep; Smoking; Stress disorders; Twins ID ERA TWIN REGISTRY; POPULATION-BASED SAMPLE; LIFE-STYLE-FACTORS; PHYSICAL-ACTIVITY; PTSD CHECKLIST; PSYCHOMETRIC PROPERTIES; PSYCHIATRIC-DISORDERS; OBESITY; METAANALYSIS; HERITABILITY AB BACKGROUND: Inconsistent associations between modifiable risk factors and chronic back pain (CBP) may be due to the inability of traditional epidemiologic study designs to properly account for an array of potential genetic and environmental confounding factors. The co-twin control research design, comparing modifiable risk factors in twins discordant for CBP, offers a unique way to remove numerous confounding factors. PURPOSE: The study aimed to examine the association of modifiable lifestyle and psychological factors with lifetime CBP. STUDY DESIGN/SETTING: This is a cross-sectional co-twin control study in a nationwide sample of male twin members of the Vietnam Era Twin Registry. PATIENT SAMPLE: The sample is composed of 7,108 participants, including 1,308 monozygotic (MZ) pairs and 793 dizygotic pairs. OUTCOME MEASURE: The outcome measure is the self-reported lifetime history of CBP. METHODS: Lifestyle factors included body mass index (BMI), smoking history, alcohol consumption, habitual physical activity, and typical sleep duration. Psychological factors included depression (Patient Health Questionnaire-9) and posttraumatic stress disorder (PTSD) symptoms (PTSD Checklist). Covariates included age, race, education, and income. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated for the association of risk factors with lifetime CBP when considering twins as individuals, and a within-pair co-twin control analysis that accounted for familial and genetic factors. Funding was through VA Grant 5IK2RX001515; there were no study-specific conflicts of interest. RESULTS: The mean age of respondents was 62 years and the prevalence of lifetime CBP was 28%. All lifestyle factors were associated with CBP in the individual level analysis. However, none of these persisted in the within-pair analyses, except for severe obesity (BMI >= 35.0), which was associated with lifetime CBP in both individual-level (OR=1.6, 95% CI: 1.3-1.9) and within-pair analyses (MZ analysis: OR=3.7, 95% CI: 1.2-11.4). Symptoms of PTSD and depression were strongly associated with lifetime CBP in both the individual-level (moderate or severe depression: OR=4.2, 95% CI: 3.6-4.9, and severe PTSD: OR=4.8, 95% CI: 4.0-5.7) and within-pair (MZ) analyses (moderate or severe depression: OR=4.6, 95% CI: 2.4-8.7, and severe PTSD: OR=3.2, 95% CI: 1.6-6.5). CONCLUSIONS: Many associations between modifiable lifestyle risk factors and CBP are due to confounding by familial and genetic factors. Severe obesity, depression, and PTSD should be considered in the development of intervention strategies to reduce the prevalence of CBP. Published by Elsevier Inc. C1 [Suri, Pradeep; Boyko, Edward J.; Smith, Nicholas L.; Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, S-152 ERIC,1660 S Columbian Way, Seattle, WA 98108 USA. [Suri, Pradeep] Div Rehabil Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. [Suri, Pradeep] Univ Washington, Dept Rehabil Med, 325 Ninth Ave,Box 359612, Seattle, WA 98104 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. [Smith, Nicholas L.; Goldberg, Jack] Univ Washington, Dept Epidemiol, 1959 NE Pacific St Hlth Sci Bldg,Box 357236, Seattle, WA 98195 USA. [Jarvik, Jeffrey G.] Univ Washington, Comparat Effectiveness Cost & Outcomes Res Ctr, 4333 Brooklyn Ave NE,Box 359455, Seattle, WA 98195 USA. [Jarvik, Jeffrey G.] Univ Washington, Dept Radiol, 325 9th Ave, Seattle, WA 98104 USA. [Jarvik, Jeffrey G.] Univ Washington, Dept Neurol Surg, 325 9th Ave, Seattle, WA 98104 USA. [Jarvik, Jeffrey G.] Univ Washington, Dept Hlth Serv, 325 9th Ave, Seattle, WA 98104 USA. [Williams, Frances M. K.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England. [Jarvik, Gail P.] Dept Med Med Genet, 3720 15th Ave NE, Seattle, WA 98105 USA. [Jarvik, Gail P.] Univ Washington, Dept Genome Sci, 3720 15th Ave NE, Seattle, WA 98105 USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, S-152 ERIC,1660 S Columbian Way, Seattle, WA 98108 USA. EM pradeep.suri@va.gov OI Boyko, Edward/0000-0002-3695-192X FU VA Career Development Award from the US Department of Veterans Affairs Rehabilitation Research and Development Service [1IK2RX001515]; Cooperative Studies Program [569]; VA Puget Sound Health Care System FX This work was supported by VA Career Development Award #1IK2RX001515 from the US Department of Veterans Affairs Rehabilitation Research and Development Service. Funding for this study was also provided by Cooperative Studies Program #569. Dr Suri and Dr Boyko are staff physicians at the VA Puget Sound Health Care System in Seattle, Washington. Dr Goldberg and Dr Smith are research scientists at the VA Puget Sound Health Care System. The participation of Dr Suri, Dr Boyko, Dr Smith, and Dr Goldberg in this study was funded by the VA Puget Sound Health Care System. The contents of this work do not represent the views of the US Department of Veterans Affairs or the US Government. NR 67 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 EI 1878-1632 J9 SPINE J JI Spine Journal PD JAN PY 2017 VL 17 IS 1 BP 4 EP 14 DI 10.1016/j.spinee.2016.07.533 PG 11 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA EO1IL UT WOS:000396451800003 PM 27794503 ER PT J AU Gordon, AJ AF Gordon, Adam J. TI The 40th annual meeting of AMERSA: Highlights, abstracts, and awards SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15240 USA.; Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 2 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 1 EP 1 DI 10.1080/08897077.2017.1281646 PG 1 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600001 PM 28080324 ER PT J AU Gordon, AJ AF Gordon, Adam J. TI Abstracts of the 18th Annual Meeting of the International Society of Addiction Medicine (ISAM)-2016 SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15240 USA.; Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 2 EP 2 DI 10.1080/08897077.2017.1281044 PG 1 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600002 PM 28075715 ER PT J AU Kertesz, SG AF Kertesz, Stefan G. TI Turning the tide or riptide? The changing opioid epidemic SO SUBSTANCE ABUSE LA English DT Editorial Material DE Opioids; opioid use disorder; overdose; pain; prescriptions; primary care; treatment access ID UNITED-STATES; CHRONIC PAIN; ASSOCIATION; ADDICTION; THERAPY AB The US opioid epidemic has changed profoundly in the last 3 years, in ways that require substantial recalibration of the US policy response. This report summarizes the changing nature of overdose deaths in Jefferson County (home to Birmingham, Alabama) using data updated through June 30, 2016. Heroin and fentanyl have come to dominate an escalating epidemic of lethal opioid overdose, whereas opioids commonly obtained by prescription play a minor role, accounting for no more than 15% of reported deaths in 2015. Such local data, along with similar reports from other localities, augment the insights available from the Centers for Disease Control and Prevention's current overdose summary, which lacks data from 2015-2016 and lacks information regarding fentanyl in particular. The observed changes in the opioid epidemic are particularly remarkable because they have emerged despite sustained reductions in opioid prescribing and sustained reductions in prescription opioid misuse. Among US adults, past-year prescription opioid misuse is at its lowest level since 2002. Among 12th graders it is at its lowest level in 20 years. A credible epidemiologic account of the opioid epidemic is as follows: although opioid prescribing by physicians appears to have unleashed the epidemic prior to 2012, physician prescribing no longer plays a major role in sustaining it. The accelerating pace of the opioid epidemic in 2015-2016 requires a serious reconsideration of governmental policy initiatives that continue to focus on reductions in opioid prescribing. The dominant priority should be the assurance of subsidized access to evidencebased medication-assisted treatment for opioid use disorder. Such treatment is lacking across much of the United States at this time. Further aggressive focus on prescription reduction is likely to obtain diminishing returns while creating significant risks for patients. C1 [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Birmingham VA Med Ctr, 700 19th St South Mailstop 151, Birmingham, AL 35233 USA. RP Kertesz, SG (reprint author), Univ Alabama Birmingham, Sch Med, Birmingham VA Med Ctr, 700 19th St South Mailstop 151, Birmingham, AL 35233 USA. EM skertesz@uabmc.edu NR 50 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 3 EP 8 DI 10.1080/08897077.2016.1261070 PG 6 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600003 PM 27858590 ER PT J AU Das, S Shah, N Ghadiali, M AF Das, Smita Shah, Nina Ghadiali, Murtuza TI Intravenous use of intranasal naloxone: A case of overdose reversal SO SUBSTANCE ABUSE LA English DT Editorial Material DE Drug overdose; harm reduction; naloxone; opiate dependence ID OPIOID OVERDOSE; HEROIN OVERDOSE; DRUG-USERS; PARTICIPANTS; PREVENTION; MORTALITY; KNOWLEDGE; EDUCATION; EFFICACY; ACCESS AB Background: Opioid overdose is a growing concern in the United States and internationally. Prehospital or pre-medical personnel (layperson) administration of naloxone, an opioid antagonist, to reverse overdose, is an expanding mode of harm reduction. Recently, community clinics, methadone clinics, needle exchanges, some pharmacies, and other health care facilities have made naloxone available to the community. Case: This case describes heroin overdose reversal of a 28-year-old male who had been using about a gram of heroin intravenously for 3 years but recently reduced frequency of use in an attempt to stop. He was seen initially 1 week prior to a buprenorphine induction in our clinic. After the initial intake, he used intravenous heroin, a larger amount than over the past several weeks in anticipation of abstinence, lost consciousness, and was difficult to arouse. A friend with him noted the patient's respirations to become shallow and administered naloxone nasal spray that the patient had obtained from a needle exchange, but did so intravenously by attaching an unused drug needle to the syringe barrel in place of the nasal atomizer. The patient's overdose was reversed and he recovered. Discussion: This is the first known published case of a community-distributed naloxone nasal spray being used intravenously by a layperson (bystander). The case emphasizes the efficacy of naloxone in overdose reversal and also the need for education or instructions on naloxone use by others (not just the user). Finally, it highlights the risk of overdose in those entering treatment, seeking intoxication one last time. C1 [Das, Smita; Ghadiali, Murtuza] Univ Calif San Francisco, Dept Addict Psychiat, San Francisco, CA 94143 USA. [Das, Smita] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Das, Smita] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Das, Smita] San Francisco VA Med Ctr, San Francisco, CA USA. [Shah, Nina] Kaiser Permanente San Francisco Med Ctr, Chem Dependency Recovery Program, San Francisco, CA USA. [Ghadiali, Murtuza] Kaiser Permanente San Francisco Med Ctr, Dept Addict Med, San Francisco, CA USA. RP Das, S (reprint author), Univ Calif San Francisco, Addict Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM smidas@stanford.edu NR 27 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 18 EP 21 DI 10.1080/08897077.2016.1267686 PG 4 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600006 PM 27925864 ER PT J AU Gellad, WF Zhao, XH Thorpe, CT Thorpe, JM Sileanu, FE Cashy, JP Mor, M Hale, JA Radomski, T Hausmann, LRM Fine, MJ Good, CB AF Gellad, Walid F. Zhao, Xinhua Thorpe, Carolyn T. Thorpe, Joshua M. Sileanu, Florentina E. Cashy, John P. Mor, Maria Hale, Jennifer A. Radomski, Thomas Hausmann, Leslie R. M. Fine, Michael J. Good, Chester B. TI Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D SO SUBSTANCE ABUSE LA English DT Editorial Material DE Buprenorphine; opiate substitution treatment; opioid; veterans ID METHADONE; PROGRAMS; EPIDEMIC AB Background: Buprenorphine is a key tool in the management of opioid use disorder, but there are growing concerns about abuse, diversion, and safety. These concerns are amplified for the Department of Veterans Affairs (VA), whose patients may receive care concurrently from multiple prescribers within and outside VA. To illustrate the extent of this challenge, we examined overlapping prescriptions for buprenorphine, opioids, and benzodiazepines among veterans dually enrolled in VA and Medicare Part D. Methods: We constructed a cohort of all veterans dually enrolled in VA and Part D who filled an opioid prescription in 2012. We identified patients who received tablet or film buprenorphine products from either source. We calculated the proportion of buprenorphine recipients with any overlapping prescription (based on days supply) for a nonbuprenorphine opioid or benzodiazepine, focusing on veterans who received overlapping prescriptions from a different system than their buprenorphine prescription (Part D buprenorphine recipients receiving overlapping opioids or benzodiazepines from VA and vice versa). Results: There were 1790 dually enrolled veterans with buprenorphine prescriptions, including 760 (43%) from VA and 1091 (61%) from Part D (61 veterans with buprenorphine from both systems were included in each group). Among VA buprenorphine recipients, 199 (26%) received an overlapping opioid prescription and 11 (1%) received an overlapping benzodiazepine prescription from Part D. Among Part D buprenorphine recipients, 208 (19%) received an overlapping opioid prescription and 178 (16%) received an overlapping benzodiazepine prescription from VA. Among VA and Part D buprenorphine recipients with cross-system opioid overlap, 25% (49/199) and 35% (72/208), respectively, had > 90 days of overlap. Conclusions: Many buprenorphine recipients receive overlapping prescriptions for opioids and benzodiazepines from a different health care system than the one in which their buprenorphine was filled. These findings highlight a previously undocumented safety risk for veterans dually enrolled in VA and Medicare. C1 [Gellad, Walid F.; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Sileanu, Florentina E.; Cashy, John P.; Mor, Maria; Hale, Jennifer A.; Radomski, Thomas; Hausmann, Leslie R. M.; Fine, Michael J.; Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. [Gellad, Walid F.; Radomski, Thomas; Hausmann, Leslie R. M.; Fine, Michael J.; Good, Chester B.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. EM walid.gellad@va.gov FU VA Health Services Research & Development (HSRD) [I01 HX001765-01]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center Affairs [SDR 02-237, 98-004] FX This work was supported by VA Health Services Research & Development (HSR&D) I01 HX001765-01. Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (project numbers SDR 02-237 and 98-004). The funder had no role in the design and conduct of the study, collection, management, analysis, and interpretation of data, or preparation of the manuscript. This work represents the opinions of the authors alone and does not necessarily represent the views of the Department of Veterans Affairs or the United States Government. The authors declare they have no conflicts of interest. NR 19 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 22 EP 25 DI 10.1080/08897077.2016.1267071 PG 4 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600007 PM 27925868 ER PT J AU Mitchell, MA Broyles, LM Pringle, JL Kraemer, KL Childers, JW Buranosky, RA Gordon, AJ AF Mitchell, Michael A. Broyles, Lauren M. Pringle, Janice L. Kraemer, Kevin L. Childers, Julie W. Buranosky, Raquel A. Gordon, Adam J. TI Education for the mind and the heart? Changing residents' attitudes about addressing unhealthy alcohol use SO SUBSTANCE ABUSE LA English DT Editorial Material DE education; internship and residency; professional role; screening; unhealthy alcohol use ID STUDENTS-ATTITUDES; DISORDERS; PROGRAM AB Background: Screening and brief intervention counseling for unhealthy alcohol use are among the top 10 recommended clinical preventive services for US adults. Although federally funded training programs in alcohol screening, brief intervention, and referral to treatment (SBIRT) have focused on increasing physicians' professional readiness to address drinking with their patients, programs typically focus on knowledge and skill acquisition, with less attention to attitudinal change. The purpose of this study was to assess the impact of a multicomponent SBIRT training program on changes in internal medical residents' professional readiness for working with patients with unhealthy alcohol use. Methods: Between 2011 and 2013, first-year internal medicine residents (n = 80) at a large academic medical center participated in a 16-hour SBIRT training program, consisting of two 3-hour didactic sessions, online modules, and a half-day clinical experience, during the Ambulatory Care month of the residency training year. Residents completed a modified Alcohol and Problems Perceptions Questionnaire (AAPPQ) at the beginning and end of the residency year to assess changes in professional readiness to work with adults with unhealthy alcohol use across 6 domains: Role Adequacy, Role Legitimacy, Role Support, Motivation, Task-Specific Self-esteem, and Satisfaction. Wilcoxon signed-rank tests were used to evaluate changes in the 6 AAPPQ subscale scores over time. Results: Residents reported significant increases in Role Adequacy (alcoholrelated knowledge/skills; pre: 34 and post: 39.5; P <.0001) and Role Support (professional support; pre: 16 and post: 18; P D.005) scores. No significant differences in the remaining AAPPQ subscales were detected. Conclusions: Residents in the SBIRT training program indicated improvements in knowledge, skills, and professional role support but not in motivation, task-specific self-esteem, or satisfaction for working with patients with unhealthy alcohol use. Explicit curricular attention to these domains may be required to facilitate SBIRT skills application and sustained practice change. C1 [Mitchell, Michael A.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Adv Fellowship VA Interdisciplinary Addict Progra, Pittsburgh, PA USA. [Mitchell, Michael A.; Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Childers, Julie W.; Buranosky, Raquel A.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Gordon, Adam J.] Univ Pittsburgh, Ctr Res Healthcare, Pittsburgh, PA USA. [Pringle, Janice L.] Univ Pittsburgh, Sch Pharm, Program Evaluat & Res Unit, Pittsburgh, PA USA. RP Mitchell, MA (reprint author), Allegheny Cty Human Serv, Off Data Anal Res & Evaluat, One Smithfield St,Suite 400, Pittsburgh, PA 15222 USA. EM mike.mitchell@alleghenycounty.us FU Substance Abuse and Mental Health Service Administration (SAMHSA); Center for Substance Abuse Treatment (CSAT) [1TI020263-01]; US Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Addiction Treatment; Health Services Research and Development Service of the US Department of Veterans Affairs [CDA 10-014] FX The SMaRT project was originally funded through the Substance Abuse and Mental Health Service Administration (SAMHSA) and the Center for Substance Abuse Treatment (CSAT) (Award No. 1TI020263-01; Principal Investigator: J. Pringle). The funding agency was not involved in the work reported in the manuscript or in the composition of the submission. At the time this work was completed, Michael Mitchell was supported by the US Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Addiction Treatment. Dr. Broyles was supported by a Career Development Award (CDA 10-014) from the Health Services Research and Development Service of the US Department of Veterans Affairs. The material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 9 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 40 EP 42 DI 10.1080/08897077.2016.1185076 PG 3 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600011 PM 27163655 ER PT J AU Chung, T Ye, FF Hipwell, AE Stepp, SD Miller, E Borrero, S Hawk, M AF Chung, Tammy Ye, Feifei Hipwell, Alison E. Stepp, Stephanie D. Miller, Elizabeth Borrero, Sonya Hawk, Mary TI Alcohol and marijuana use in pathways of risk for sexually transmitted infection in white and black adolescent females SO SUBSTANCE ABUSE LA English DT Article DE Adolescent; alcohol; female; marijuana; risky sexual behavior; sexually transmitted infection ID BEHAVIOR; TRAJECTORIES; METAANALYSIS; INTERCOURSE; GROWTH; GIRLS; AGE AB Background: Some types of sexually transmitted infection (STI) have higher prevalence in females than males, and among black, relative to white, females. Identifying mechanisms of STI risk is critical to effective intervention. The authors tested a model in which alcohol and marijuana use serve as mediating factors in the associations between depression and conduct problems with sexual risk behavior (SRB) and STI in adolescent females. Methods: The Pittsburgh Girls Study is a longitudinal observational study of females who have been followed annually to track the course of mental and physical health conditions. The 3 oldest cohorts (N = 1750; 56.8% black, 43.2% white) provided self-reports of substance use, depression and conduct problems, SRB, and STI at ages 16-18. A path model tested alcohol and marijuana use at age 17 as mechanisms that mediate the associations of depression and conduct problems at age 16 with SRB and STI at age 18. Results: Race was involved in 2 risk pathways. In one pathway, white females reported greater alcohol use, which was associated with greater SRB. In another pathway, black females reported earlier sexual onset, which was associated with subsequent SRB. Public assistance use was independently associated with early sexual onset and STI. SRB, but not substance use, mediated the association of depression and conduct problems with STI. Conclusions: Differences by race in pathways of risk for SRB and STI, involving, for example, alcohol use and early sexual onset, were identified for young white and black females, respectively. Depression and conduct problems may signal risk for SRB and STI in young females, and warrant attention to improve health outcomes. C1 [Chung, Tammy; Hipwell, Alison E.; Stepp, Stephanie D.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, 3811 Ohara St, Pittsburgh, PA 15213 USA. [Ye, Feifei] Univ Pittsburgh, Sch Educ, Pittsburgh, PA 15260 USA. [Hipwell, Alison E.; Stepp, Stephanie D.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Miller, Elizabeth] Univ Pittsburgh, Sch Med, Div Adolescent & Young Adult Med, Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA USA. [Borrero, Sonya] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ & Promot, Pittsburgh, PA USA. [Hawk, Mary] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Chung, T (reprint author), Univ Pittsburgh, Med Ctr, Pittsburgh Adolescent Alcohol Res Ctr, Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM chungta@upmc.edu RI Chung, Tammy/B-9712-2017 OI Chung, Tammy/0000-0002-1527-2792 FU NIDA [R01 DA012237]; NIMH [R01 MH056630]; Office of Juvenile Justice and Delinquency Prevention [2013-JF-FX-0058]; FISA Foundation; Falk Fund FX This work was supported by NIDA R01 DA012237, NIMH R01 MH056630, The Office of Juvenile Justice and Delinquency Prevention (2013-JF-FX-0058), the FISA Foundation, and the Falk Fund. The funders had no role in design and conduct of the study; collection, management, analysis, or interpretation of the data; or review or approval of the manuscript. The authors have no conflicts of interest to declare. NR 24 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2017 VL 38 IS 1 BP 77 EP 81 DI 10.1080/08897077.2016.1263591 PG 5 WC Substance Abuse SC Substance Abuse GA EO3NN UT WOS:000396601600017 PM 27897467 ER PT J AU Wiederhold, NP Patterson, TF Srinivasan, A Chaturvedi, AK Fothergill, AW Wormley, FL Ramasubramanian, AK Lopez-Ribot, JL AF Wiederhold, Nathan P. Patterson, Thomas F. Srinivasan, Anand Chaturvedi, Ashok K. Fothergill, Annette W. Wormley, Floyd L. Ramasubramanian, Anand K. Lopez-Ribot, Jose L. TI Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi SO VIRULENCE LA English DT Article DE antifungal susceptibility; auranofin; repurposing; spectrum of action ID DRUG; INHIBITORS; BACTERIAL; AGENTS AB Repositioning old drugs can significantly decrease the time and effort that it takes to develop novel antifungal therapeutics, which represents a pressing and unmet clinical need due to the devastating nature of fungal infections. We have previously described the activity of auranofin, a gold thiol compound used to treat rheumatoid arthritis, against Candida albicans biofilms. Here we evaluate its antifungal spectrum of action and describe its activity against a variety of medically important fungi. C1 [Wiederhold, Nathan P.; Fothergill, Annette W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Srinivasan, Anand; Ramasubramanian, Anand K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biomed Engn, San Antonio, TX 78229 USA. [Srinivasan, Anand; Chaturvedi, Ashok K.; Wormley, Floyd L.; Ramasubramanian, Anand K.; Lopez-Ribot, Jose L.] Univ Texas San Antonio, South Texas Ctr Emerging Infect Dis, San Antonio, TX USA. [Chaturvedi, Ashok K.; Wormley, Floyd L.; Lopez-Ribot, Jose L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biol, San Antonio, TX 78229 USA. RP Lopez-Ribot, JL (reprint author), Univ Texas San Antonio, Dept Biol, MBT Room 1-242,One UTSA Circle, San Antonio, TX 78249 USA. EM jose.lopezribot@utsa.edu FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHS272201000018I, A06]; Army Research Office of the Department of Defense [W911NF-11-1-0136]; Clusters in Research Excellence grant from the San Antonio Life Science Institute (SALSI); Margaret Batts Tobin Foundation, San Antonio, TX FX This project utilized preclinical services funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract Nos. HHS272201000018I, Task Order A06. Additional support was provided by the Army Research Office of the Department of Defense under Contract No. W911NF-11-1-0136, by a Clusters in Research Excellence grant from the San Antonio Life Science Institute (SALSI) and by the Margaret Batts Tobin Foundation, San Antonio, TX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and the content is solely the responsibility of the authors. NR 21 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2150-5594 EI 2150-5608 J9 VIRULENCE JI Virulence PY 2017 VL 8 IS 2 BP 138 EP 142 DI 10.1080/21505594.2016.1196301 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EM5TY UT WOS:000395377700004 PM 27268469 ER PT J AU Crowley, ST Belcher, J Choudhury, D Griffin, C Pichler, R Robey, B Rohatgi, R Mielcarek, B AF Crowley, Susan T. Belcher, Justin Choudhury, Devasmita Griffin, Cassandra Pichler, Raymond Robey, Brooks Rohatgi, Rajeev Mielcarek, Bessie TI Targeting Access to Kidney Care Via Telehealth: The VA Experience SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Telemedicine; Health services; Access to health care; Kidney disease; Patient education as topic ID PREDIALYSIS NEPHROLOGY CARE; LIMITED HEALTH LITERACY; OF-VETERANS-AFFAIRS; PERITONEAL-DIALYSIS; UNITED-STATES; OUTCOMES; DISEASE; CKD; ASSOCIATIONS; TECHNOLOGY AB The Veterans Affairs (VA) is the largest integrated health care system in the United States and is responsible for the care of a population with a disproportionately high rate of CKD. As such, ensuring access to kidney health services is a VA imperative. One facet of the VA's strategy to reduce CKD is to leverage the use of teletechnology to expand the VA's outreach to Veterans with kidney disease. A wide array of teletechnology services have been deployed to both pull in Veterans and push out kidney health services to Veterans in their preferred health care venue. Teletechnology, thus, expands Veteran choice, facilitates their access to care, and furthers the goal of delivering patient-centered kidney specialty care. The VA has demonstrated the feasibility of virtual delivery of kidney specialty care services and education via synchronous and asynchronous approaches. The challenges ahead include determining the relative health care value of kidney telehealth services, identifying Veterans most likely to benefit from specific technologies and optimizing the adoption of effective kidney telehealth services by both providers and patients alike to ensure optimal and timely kidney health care delivery. C1 VA Connecticut Healthcare Syst, Dept Med, Nephrol Sect, West Haven, CT 06516 USA. Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06511 USA. Salem VA Med Ctr, Dept Med, Nephrol Sect, Salem, VA USA. Virginia Tech Caril Sch Med, Dept Med, Nephrol Sect, Roanoke, VA USA. VA Puget Sound Healthcare Syst, Dept Med, Nephrol Sect, Seattle, WA USA. Univ Washington, Sch Med, Div Nephrol, Seattle, WA 98195 USA. VA White River Junct VAMC, Dept Med, Nephrol Sect, White River Jct, VT USA. Dartmouth Med Sch, Dept Med, Nephrol Sect, Hanover, NH USA. VA Northport Healthcare Syst, Dept Med, Nephrol Sect, Northport, NY USA. SUNY Stony Brook, Sch Med, Dept Med, Nephrol Sect, Stony Brook, NY USA. RP Crowley, ST (reprint author), VA Connecticut Healthcare Syst 111F, VA Kidney Dis Natl Program, Renal Sect VA CT HCS, 950 Campbell Ave, West Haven, CT 06516 USA. EM susan.crowley@va.gov FU VA Puget Sound Health Care System; VA Office of Specialty Care; VA Office of Rural Health FX Support: Drs Pichler and Young received funding through the VA Puget Sound Health Care System and are supported by clinical grants from the VA Office of Specialty Care and the VA Office of Rural Health. The opinions expressed here are those of the authors and do not constitute policy of the US government. NR 36 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 EI 1548-5609 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD JAN PY 2017 VL 24 IS 1 BP 22 EP 30 DI 10.1053/j.ackd.2016.11.005 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA EN0UI UT WOS:000395725600006 PM 28224939 ER PT J AU Chang, TS Teng, E Elashoff, D Grill, JD AF Chang, Timothy S. Teng, Edmond Elashoff, David Grill, Joshua D. CA Alzheimer's Dis Neuroimaging TI Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; cognitive decline; clinical trial; enrichment; ADAS-Cog ID POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; FLORBETAPIR F 18; COGNITIVE IMPAIRMENT; ASSESSMENT SCALE; AMYLOID-BETA; PET; ASSOCIATION; DIAGNOSIS; DEMENTIA AB Recent clinical trials in mild Alzheimer disease (AD) have enriched for amyloid-specific positron emission tomography (PET) imaging and used extended versions of the AD Assessment Scale-Cognitive Subscale (ADAS-Cog) in an effort to increase the sensitivity to detect treatment effects. We used data from mild AD participants in the AD Neuroimaging Initiative to model trial effect sizes for 12- and 24-month trials using 3 versions of the ADAS-Cog and increased standardized uptake value ratio (SUVR) cutoffs for amyloid imaging inclusion criteria. For 12-month trials, extended ADAS-Cog versions improved effect sizes. The ADAS-Cog11 elicited larger effect sizes when enriching for SUVR 1.1 only, whereas the ADAS-Cog12 and ADAS-Cog13 were associated with larger effect sizes with higher SUVR thresholds. For 24-month trials, extended ADAS-Cog versions increased effect sizes for trials not enriched for amyloid and trials enriched for SUVR 1.1. Only enriching for higher SUVR thresholds (1.3 and 1.4, not 1.1) increased trial power. We conclude that extended versions of the ADAS-Cog improve mild AD trial effect sizes for both 12- and 24-month long studies, whereas amyloid imaging criteria may be most valuable for 12-month trials. C1 [Chang, Timothy S.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Grill, Joshua D.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, 3206 Biol Sci 3, Irvine, CA 92697 USA. RP Grill, JD (reprint author), Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, 3206 Biol Sci 3, Irvine, CA 92697 USA. EM jgrill@uci.edu FU NIA [AG016570, AG016573]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research FX J.D.G. and E.T. were supported by NIA AG016570. J.D.G. is currently supported by NIA AG016573. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development, LLC; Medpace Inc.; Merck & Co. Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. NR 30 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD JAN-MAR PY 2017 VL 31 IS 1 BP 19 EP 26 DI 10.1097/WAD.0000000000000150 PG 8 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA EM8JH UT WOS:000395556900004 PM 27196535 ER PT J AU Streng, KW ter Maaten, JM Cleland, JG O'Connor, CM Davison, BA Metra, M Givertz, MM Teerlink, JR Ponikowski, P Bloomfield, DM Dittrich, HC Hillege, HL van Veldhuisen, DJ Voors, AA van der Meer, P AF Streng, Koen W. ter Maaten, Jozine M. Cleland, John G. O'Connor, Christopher M. Davison, Beth A. Metra, Marco Givertz, Michael M. Teerlink, John R. Ponikowski, Piotr Bloomfield, Daniel M. Dittrich, Howard C. Hillege, Hans L. van Veldhuisen, Dirk J. Voors, Adriaan A. van der Meer, Peter TI Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE biomarkers; heart failure; mortality; obesity; prognosis ID REGIONAL PRO-ADRENOMEDULLIN; GLYCATION END-PRODUCTS; NATRIURETIC PEPTIDES; SOLUBLE RECEPTOR; OBESITY PARADOX; URIC-ACID; MORTALITY; RISK; ROLOFYLLINE; POPULATION AB Background-Plasma concentrations of natriuretic peptides decline with obesity in patients with heart failure. Whether this is true for other biomarkers is unknown. We investigated a wide range of biomarker profiles in acute heart failure across the body mass index (BMI) spectrum. Methods and Results-A total of 48 biomarkers, assessing multiple pathophysiological pathways, were measured in 2033 patients included in PROTECT (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function), a trial comparing the effects of rolofylline to placebo in patients with acute heart failure. Patients were classified into 4 groups according to BMI (<25, 25-30, 30-35, and >35 kg/m(2)). Of 2003 patients with known weight and height, mean age was 70 +/- 12 years and 67% were men. Patients with a higher BMI (> 35 kg/m2) had higher blood pressures, were younger, and were more often women. Median levels of brain natriuretic peptide were 550 pg/mL in patients with a BMI <25 kg/m(2) and 319 pg/mL in patients with a BMI >35 kg/m(2) (P<0.001). Multivariable regression revealed that brain natriuretic peptide (beta=-0.250; P<0.001) and receptor for advanced glycation endproducts (beta=-0.095; P<0.007) were inversely correlated to BMI, whereas higher levels of uric acid (beta=0.164; P<0.001), proadrenomedullin (beta=0.171; P<0.001), creatinine (beta=0.118; P=0.003), sodium (beta=0.101; P=0.006), and bicarbonate (beta=0.094; P=0.009) were associated with higher BMI. No significant interaction was seen between these 7 biomarkers and BMI on 180-day mortality. Conclusions-The plasma concentrations of several biomarkers are either positively or negatively influenced by BMI. These findings suggest that these markers should be interpreted with caution in patients with obesity. Although concentrations differ, their prognostic value for mortality up to 180 days did not differ. C1 [Streng, Koen W.; ter Maaten, Jozine M.; Hillege, Hans L.; van Veldhuisen, Dirk J.; Voors, Adriaan A.; van der Meer, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Cleland, John G.] Imperial Coll, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England. [Cleland, John G.] Imperial Coll, Natl Heart & Lung Inst, Harefield Hosp, London, England. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Davison, Beth A.] Momentum Res, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA 52242 USA. RP van der Meer, P (reprint author), Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM p.van.der.meer@umcg.nl FU NovaCardia of Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. NR 34 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2017 VL 10 IS 1 AR e003350 DI 10.1161/CIRCHEARTFAILURE.116.003350 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EL1NQ UT WOS:000394387500003 ER PT J AU Abreo, AP Dalrymple, LS Chertow, GM Kaysen, GA Herzog, CA Johansen, KL AF Abreo, Adrian P. Dalrymple, Lorien S. Chertow, Glenn M. Kaysen, George A. Herzog, Charles A. Johansen, Kirsten L. TI Predialysis volume overload and patient-reported sleep duration and quality in patients receiving hemodialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE End-stage renal disease; volume overload; sleep ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; MORTALITY RISK; OLDER ADULTS; FLUID SHIFT; DIALYSIS; INSOMNIA; APNEA; ASSOCIATION; COMPLAINTS AB Introduction: Previous studies of patients with end-stage renal disease have examined the role of fluid shifts on apnea-hypopnea episodes, but the association between volume overload and patient-reported sleep quality or duration has not been well-established. Methods: We studied the association between predialysis bioimpedance spectroscopy-derived volume estimates and self-reported sleep quality and duration in 638 patients in the United States Renal Data System ACTIVE/ADIPOSE study receiving hemodialysis from 2009 to 2011. We used questionnaires to assess self-reported sleep duration and quality. We used relative hydration status (fluid overload/extracellular water; FO/ECW) as the primary predictor and examined associations with hours of sleep duration using linear regression. We used multivariable ordinal logistic regression to determine the association between categories of relative hydration status (normal hydration [FO/ECW < 6.8%], mild overhydration [FO/ECW 6.8%-15%], and hyperhydration [FO/ECW > 15%]) and four levels of difficulty with falling asleep, waking, and returning to sleep. Findings: Higher relative hydration status was associated with fewer hours of sleep (-0.31 hours per 10%, 95% confidence interval (CI) -0.49 to -0.13). Compared to the normal hydration group, there was a statistically significant association between higher relative hydration status category and more frequent nighttime waking (OR: mild overhydration 1.92 [95% CI 1.23-2.99], hyperhydration 1.87 [95% CI 1.16-2.99]), a trend toward more difficulty returning to sleep (OR: mild overhydration 1.46 [95% CI 0.94-2.27], hyperhydration 1.52 [95% CI 0.95-2.43]), and no association between relative hydration category and difficulty falling asleep. Discussion: Hydration status was associated with self-reported sleep duration in patients on dialysis. Future studies should prospectively examine the effects of optimizing fluid status on sleep duration and quality. C1 [Abreo, Adrian P.] Louisiana State Univ, Hlth Sci Ctr, Div Nephrol, 1501 Kings Highway, Shreveport, LA 71103 USA. [Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Stanford, CA 94305 USA. [Kaysen, George A.] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA. [Herzog, Charles A.] Hennepin Cty Med Ctr, Div Cardiol, Minneapolis, MN 55415 USA. [Herzog, Charles A.] Univ Minnesota, Minneapolis, MN USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Abreo, AP (reprint author), Louisiana State Univ, Hlth Sci Ctr, Div Nephrol, 1501 Kings Highway, Shreveport, LA 71103 USA. EM aabreo@lsuhsc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [N01-DK-7-0005, N01-DK-7-5004, K24DK085153, K23 DK093584] FX This work was supported through contracts N01-DK-7-0005 and N01-DK-7-5004 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a K24DK085153 grant, and a K23 DK093584 (L.S.D.) grant. NR 30 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1492-7535 EI 1542-4758 J9 HEMODIAL INT JI Hemodial. Int. PD JAN PY 2017 VL 21 IS 1 BP 133 EP 141 DI 10.1111/hdi.12446 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA EK0KX UT WOS:000393616400021 PM 27346666 ER PT J AU Triplette, M Attia, E Akgun, K Campo, M Rodriguez-Barradas, M Pipavath, S Shahrir, S Wongtrakool, C Goetz, M Kim, J Hoo, GWS Brown, ST Crothers, K AF Triplette, Matthew Attia, Engi Akgun, Kathleen Campo, Monica Rodriguez-Barradas, Maria Pipavath, Sudhakar Shahrir, Shahida Wongtrakool, Cherry Goetz, Matthew Kim, Joon Hoo, Guy W. Soo Brown, Sheldon T. Crothers, Kristina TI The Differential Impact of Emphysema on Respiratory Symptoms and 6-Minute Walk Distance in HIV Infection SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE COPD; emphysema; HIV; 6-minute walk distance ID OBSTRUCTIVE PULMONARY-DISEASE; ANTIRETROVIRAL THERAPY ERA; IMMUNODEFICIENCY-VIRUS-INFECTION; SPIROMETRY REFERENCE VALUES; VETERANS AGING COHORT; RADIOGRAPHIC EMPHYSEMA; DIFFUSING-CAPACITY; RISK-FACTORS; MORTALITY; ASSOCIATION AB Background: Emphysema is more prevalent in HIV-infected (HIV+) patients independent of smoking behavior. Nonetheless, health effects of emphysema in this population are poorly understood. We determined whether emphysema is associated with a greater burden of pulmonary symptoms and a lower 6-minute walk distance (6MWD) in HIV+ compared with HIV-uninfected (HIV-) subjects. Methods: We performed a cross-sectional analysis of 170 HIV+ and 153 HIV- subjects in the Examinations of HIV-Associated Lung Emphysema (EXHALE) cohort study. Subjects completed a self-assessment of respiratory symptoms, pulmonary function testing, and 6MWD testing as well as a chest computed tomography to determine emphysema severity. We used regression models to determine the association of emphysema with respiratory symptoms and 6MWD in HIV+ subjects and compared this to HIV- subjects. Results: Models stratified by HIV status demonstrated an association between >10% radiographic emphysema and chronic cough and/or phlegm and 6MWD in HIV+ subjects. These associations persisted among the subset without airflow obstruction: those with emphysema had 4.2 (95% confidence interval: 1.3 to 14) times the odds of chronic cough and/or phlegm and walked 60 m (95% confidence interval: 26 to 93) less distance than those without emphysema. There was no association between >10% emphysema and symptoms or 6MWD in HIV- subjects. Conclusions: In our cohort,>10% radiographic emphysema was associated with chronic cough and/or phlegm and lower 6MWD in HIV+ but not HIV- subjects. These findings were robust even among HIV+ subjects with milder forms of emphysema and those without airflow obstruction, highlighting the clinical impact of emphysema in these patients. C1 [Triplette, Matthew; Attia, Engi; Campo, Monica; Shahrir, Shahida; Crothers, Kristina] Univ Washington, Dept Med, Seattle, WA USA. [Akgun, Kathleen] Yale Univ, Sch Med, Dept Internal Med, Vet Affairs Connecticut Healthcare, New Haven, CT 06510 USA. [Rodriguez-Barradas, Maria] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Pipavath, Sudhakar] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Wongtrakool, Cherry] Emory Univ, Sch Med, Dept Med, Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Goetz, Matthew; Hoo, Guy W. Soo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Kim, Joon; Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. RP Triplette, M (reprint author), Harborview Med Ctr, 325 Ninth Ave,Campus Box 359762, Seattle, WA 98104 USA. EM mtrip@uw.edu FU National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) [R01 HL090342, T32 HL007287-37]; National Institute on Alcohol Abuse and Alcoholism at the NIH [U01 AA013566]; University of Washington Center for AIDS Research, an NIH [P30-AI-027757]; National Institute of Allergy and Infectious Diseases; National Cancer Institute, National Institute of Mental Health; National Institute on Drug Abuse; Eunice Kennedy Shriver National Institute of Child Health and Human Development; NHLBI; National Institute on Aging; Boehringer Ingelheim; Department of Veterans Affairs Biomedical Laboratory Research and Development Program; Astra-Zeneca; National Institutes of Health FX Supported by the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) (R01 HL090342 to K.C., T32 HL007287-37 supporting M.T. under Drs. Robb Glenny and J. Randall Curtis) as well as the National Institute on Alcohol Abuse and Alcoholism at the NIH (U01 AA013566). This research was funded in part by a 2012 developmental grant from the University of Washington Center for AIDS Research, an NIH-funded program under award number P30-AI-027757, which is supported by the following NIH institutes and centers: National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institute of Mental Health, National Institute on Drug Abuse, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NHLBI, and National Institute on Aging.; S.P. reports receiving support from Boehringer Ingelheim as a consultant and expert advisor. C.W. discloses support from the Department of Veterans Affairs Biomedical Laboratory Research and Development Program, as well as support from Astra-Zeneca as a co-investigator on an industry sponsored clinical study. M.G. reports receiving support from the National Institutes of Health during the conduct of this study. The remaining authors have no funding or conflicts of interest to disclose. NR 48 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2017 VL 74 IS 1 BP E23 EP E29 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EN4RL UT WOS:000395994500004 PM 27716727 ER PT J AU Lakshmi, SP Reddy, AT Banno, A Reddy, RC AF Lakshmi, Sowmya P. Reddy, Aravind T. Banno, Asoka Reddy, Raju C. TI PPAR Agonists for the Prevention and Treatment of Lung Cancer SO PPAR RESEARCH LA English DT Review ID ACTIVATED RECEPTOR-GAMMA; SUPPRESSES TUMOR-GROWTH; NITRATED FATTY-ACIDS; CELL-GROWTH; ALPHA AGONIST; COLON-CANCER; BETA/DELTA; EXPRESSION; MICE; INHIBITION AB Lung cancer is the most common and most fatal of all malignancies worldwide. Furthermore, with more than half of all lung cancer patients presenting with distant metastases at the time of initial diagnosis, the overall prognosis for the disease is poor. There is thus a desperate need for new prevention and treatment strategies. Recently, a family of nuclear hormone receptors, the peroxisome proliferator-activated receptors (PPARs), has attracted significant attention for its role in various malignancies including lung cancer. Three PPARs, PPAR alpha., PPAR beta/delta, and PPARy, display distinct biological activities and varied influences on lung cancer biology. PPAR alpha activation generally inhibits tumorigenesis through its antiangiogenic and anti-inflammatory effects. Activated PPARy is also antitumorigenic and antimetastatic, regulating several functions of cancer cells and controlling the tumor microenvironment. Unlike PPAR alpha and PPAR gamma, whether PPAR beta/delta activation is anti-or protumorigenic or even inconsequential currently remains an open question that requires additional investigation. This review of current literature emphasizes the multifaceted effects of PPAR agonists in lung cancer and discusses how they may be applied as novel therapeutic strategies for the disease. C1 [Lakshmi, Sowmya P.; Reddy, Aravind T.; Banno, Asoka; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA. [Lakshmi, Sowmya P.; Reddy, Aravind T.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU US Department of Veterans Affairs; National Institutes of Health Grants [HL093196, AI125338] FX This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health Grants HL093196 and AI125338 (RCR). NR 74 TC 0 Z9 0 U1 2 U2 2 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND SN 1687-4757 EI 1687-4765 J9 PPAR RES JI PPAR Res. PY 2017 DI 10.1155/2017/8252796 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EN8JW UT WOS:000396247700001 ER PT J AU Guardado-Mendoza, R Chavez, AO Jimenez-Ceja, LM Hansis-Diarte, A DeFronzo, RA Folli, F Tripathy, D AF Guardado-Mendoza, Rodolfo Chavez, Alberto O. Jimenez-Ceja, Lilia M. Hansis-Diarte, Andrea DeFronzo, Ralph A. Folli, Franco Tripathy, Devjit TI Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus SO ACTA DIABETOLOGICA LA English DT Article DE Insulin secretion; Amylin; Hyperglycemic clamp ID BETA-CELL APOPTOSIS; ENDOPLASMIC-RETICULUM STRESS; PROHORMONE CONVERTASE PC2; INSULIN-SECRETION; AMYLIN RELEASE; ORAL GLUCOSE; HUMANS; PEPTIDE; MODEL; DETERMINANTS AB Pancreatic islet amyloid deposition is a characteristic feature of type 2 diabetes mellitus (T2DM). Islet amyloid polypeptide (IAPP) is co-secreted with insulin, but its secretion profile and relationship to insulin and C-peptide in response to glucose and non-glucose stimuli has not been clearly defined. Forty subjects (13 NGT, 12 IGT and 15 T2DM) participated in an OGTT and two-step hyperglycemic (225 and 400 mg/dl) clamp (80 min/step) followed by an IV arginine bolus. Acute insulin (AIR), C-peptide (ACPR) and IAPP (AIAR) responses during each hyperglycemic step and following arginine (AIR(Arg)) were assessed. AIR and ACPR during both hyperglycemic steps and after arginine progressively decreased from NGT to IGT to T2DM. Fasting IAPP concentrations were higher in T2DM compared to NGT and IGT subjects. The acute IAPP(0-10) was markedly decreased only in T2DM, while the acute IAPP(80-90) response during the second step (80-160 min) of hyperglycemic clamp and in response to arginine was markedly impaired in both IGT and T2DM. The ratio of IAPP/C-peptide during the first (225 mg/dl) and second step (400 mg/dl), and in response to arginine, was decreased in T2DM versus both NGT and IGT (p < 0.01). The acute IAPP(0-10) correlated with ACPR(0-10) (r = 0.665, p < 0.001) and AIR(0-10) (r = 0.543, p < 0.001). Basal IAPP secretion is higher in T2DM and IGT versus NGT but is reduced in response to hyperglycemia and arginine. The IAPP/C-peptide ratio is reduced with prolonged and more severe hyperglycemia in T2DM individuals. NCT00845182. C1 [Guardado-Mendoza, Rodolfo; Chavez, Alberto O.; Jimenez-Ceja, Lilia M.; Hansis-Diarte, Andrea; DeFronzo, Ralph A.; Folli, Franco; Tripathy, Devjit] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Guardado-Mendoza, Rodolfo; Jimenez-Ceja, Lilia M.] Univ Guanajuato, Div Hlth Sci, Dept Med & Nutr, Guanajuato, Mexico. [Guardado-Mendoza, Rodolfo; Jimenez-Ceja, Lilia M.] Hosp Reg Alta Especialidad Bajio, Dept Invest, Guanajuato, Mexico. [DeFronzo, Ralph A.; Tripathy, Devjit] South Texas Vet Hlth Care Syst, Audie L Murphy VA Hosp, San Antonio, TX USA. RP Tripathy, D (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.; Tripathy, D (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy VA Hosp, San Antonio, TX USA. EM tripathy@uthscsa.edu FU Takeda Pharmaceuticals FX We thank the nurses on the Bartter Research Unit (BRU) for their diligent care of our patients and especially James King, R.N. and John Kincade RN for carrying out the hyperglycemic clamp studies. The study was supported by a research grant from Takeda Pharmaceuticals to Devjit Tripathy. NR 48 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER-VERLAG ITALIA SRL PI MILAN PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY SN 0940-5429 EI 1432-5233 J9 ACTA DIABETOL JI Acta Diabetol. PD JAN PY 2017 VL 54 IS 1 BP 53 EP 61 DI 10.1007/s00592-016-0904-7 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EK3HF UT WOS:000393816500007 PM 27624579 ER PT J AU Durazzo, TC Meyerhoff, DJ AF Durazzo, Timothy C. Meyerhoff, Dieter J. TI Psychiatric, Demographic, and Brain Morphological Predictors of Relapse After Treatment for an Alcohol Use Disorder SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Relapse; Alcohol Use Disorders; Magnetic Resonance Imaging; Mood Disorders; Cigarette Smoking ID CHRONIC CIGARETTE-SMOKING; ANTERIOR CINGULATE CORTEX; SUBSTANCE USE DISORDERS; DEPENDENT PATIENTS; SURFACE-AREA; DRINKING; ABSTINENCE; DEPRESSION; RECOVERY; OUTCOMES AB Background: Relapse in alcohol use disorders (AUD) is related to a complex interplay among multiple biological, psychiatric, psychological, and psychosocial factors, which may change dynamically during and after treatment. At treatment entry for AUD, morphological abnormalities in anterior frontal regions and the insula have been observed in those who ultimately relapse following treatment. The goal of this study was to determine whether anterior frontal and insula measures of brain thickness, surface area, and volume predict posttreatment drinking status (i.e., relapser or abstainer) over an extended period after outpatient treatment for AUD, while concurrently considering common psychiatric, psychological, and psychosocial factors previously associated with relapse. Methods: Alcohol-dependent individuals (n = 129) were followed for 18 months after treatment to determine posttreatment drinking status (abstainers [n = 47] or relapsers [n = 82]). Brain morphometrics were derived from FreeSurfer. Receiver operating characteristic (ROC) curve analysis was used to identify the regional brain thickness, surface area, and volume (all scaled to intracranial volume), demographic, psychiatric, other substance use (e.g., cigarette smoking), and alcohol consumption variables, obtained at entry into treatment, that best predicted posttreatment drinking status. Survival analyses determined variables that were related to duration of abstinence after treatment. Results: ROC analyses indicated that mood disorders, education, and volumes of the right caudal anterior cingulate cortex (ACC), right rostral ACC, and total right frontal gray matter were significant predictors of posttreatment drinking status. Among relapsers, survival analyses showed smokers and individuals with a comorbid medical condition relapsed earlier after treatment. Additionally, a greater frequency of smokers relapsed within 6 months of AUD treatment. Conclusions: Results reinforce that relapse in AUD is a function of multiple biological, psychiatric, psychological, and psychosocial factors. Effective treatment of depressive disorders and cigarette smoking concurrent with AUD-focused interventions may promote better treatment outcomes. C1 [Durazzo, Timothy C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA. [Durazzo, Timothy C.] VA Palo Alto Hlth Care Syst, Mental Illness Res & Educ Clin Ctr, Palo Alto, CA USA. [Durazzo, Timothy C.] VA Palo Alto Hlth Care Syst, Sierra Pacific War Related Illness & Injury Study, Palo Alto, CA USA. [Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. RP Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, War Related Illness & Injury Study Ctr, Mental Illness Res & Educ Clin Ctr, 151Y,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM tdurazzo@stanford.edu FU National Institutes of Health [AA10788, DA24136] FX This study was supported by National Institutes of Health (AA10788 to DJM and DA24136 to TCD) and with resources and the use of facilities at the San Francisco VA Medical Center and the VA Palo Alto Health Care System. We thank Dr. Ellen Herbst, Ricky Chen, and colleagues of the Veterans Administration Substance Abuse Day Hospital and Dr. David Pating and colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in participant recruitment. We thank Drs. Stefan Gazdzinski and Anderson Mon for MR data acquisition and Thomas Schmidt for assistance with psychiatric assessments and cohort maintenance. We also wish to extend our gratitude to our participants, who made this research possible. NR 64 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JAN PY 2017 VL 41 IS 1 BP 107 EP 116 DI 10.1111/acer.13267 PG 10 WC Substance Abuse SC Substance Abuse GA EK4IQ UT WOS:000393890700012 PM 27883214 ER PT J AU Wordingham, SE Swetz, KM AF Wordingham, Sara E. Swetz, Keith M. TI Can Anyone Be Prepared Enough for Life With an LVAD-DT? SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material ID MECHANICAL CIRCULATORY SUPPORT; PALLIATIVE CARE C1 [Wordingham, Sara E.] Mayo Clin, Coll Med, Phoenix, AZ USA. [Swetz, Keith M.] Univ Alabama, Sch Med, UAB Ctr Palliat & Support Care, Tuscaloosa, AL 35487 USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Wordingham, SE (reprint author), Mayo Clin, Mayo Clin Arizona, Coll Med, Med,Palliat Med, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA. EM wordingham.sara@mayo.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1526-5161 EI 1536-0075 J9 AM J BIOETHICS JI Am. J. Bioeth. PY 2017 VL 17 IS 2 BP 14 EP 16 PG 3 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA EL5IN UT WOS:000394654900007 PM 28112619 ER PT J AU Kendrick, JB Zelnick, L Chonchol, MB Siscovick, D Hoofnagle, AN Ix, JH Sarnak, M Shlipak, MG Kestenbaum, B de Boer, IH AF Kendrick, Jessica B. Zelnick, Leila Chonchol, Michel B. Siscovick, David Hoofnagle, Andrew N. Ix, Joachim H. Sarnak, Mark Shlipak, Michael G. Kestenbaum, Bryan de Boer, Ian H. TI Serum Bicarbonate Is Associated with Heart Failure in the Multi-Ethnic Study of Atherosclerosis SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Cardiovascular disease; Bicarbonate; Heart failure; Arterial stiffness; Left ventricular mass ID INCIDENT CARDIOVASCULAR-DISEASE; CHRONIC KIDNEY-DISEASE; NUTRITION EXAMINATION SURVEY; STAGE RENAL-DISEASE; METABOLIC-ACIDOSIS; ANION GAP; VASCULAR CALCIFICATION; PLASMA BICARBONATE; BODY-COMPOSITION; NATIONAL-HEALTH AB Background: Low serum bicarbonate concentrations are associated with mortality and kidney disease progression. Data regarding associations between bicarbonate and cardiovascular disease (CVD) are scarce. Methods: We performed a cohort study of 6,229 adult participants from the Multi-Ethnic Study of Atherosclerosis, a community-based cohort free of CVD at baseline. Serum bicarbonate was measured at baseline. Cardiovascular outcomes were defined as: (1) subclinical CVD (left ventricular mass [LVM] and aortic pulse pressure [PP] measured at baseline), (2) incident atherosclerotic cardiovascular events (CVE; composite of myocardial infarction, resuscitated cardiac arrest, stroke, coronary heart disease death, and stroke death), and (3) incident heart failure. Results: During a median (interquartile range) follow-up of 8.5 (7.7-8.6) years, 331 (5.3%) participants had an incident CVE and 174 (2.8%) developed incident heart failure. We stratified analyses by use of diuretics because we observed a significant interaction between diuretic use and bicarbonate with study outcomes. Among diuretic nonusers, with adjustment, bicarbonate 25 mEq/L was associated with an estimated 3.0 g greater LVM (95% CI 0.5-5.0) and 1.0 mm Hg higher aortic PP (95% CI 0.4-2.0) compared to bicarbonate 23-24 mEq/L. Each 1 mEq/L of bicarbonate increase was associated with a 13% higher risk of incident heart failure (hazards ratio 1.13, 95% CI 1.01-2.11). Among diuretic users, higher bicarbonate was not associated with CVD. Bicarbonate was not associated with incident atherosclerotic CVE irrespective of diuretic use. Conclusion: Among nonusers of diuretics in a large community-based study, higher serum bicarbonate concentrations are associated with subclinical CVD and new heart failure. (C) 2016 S. Karger AG, Basel. C1 [Kendrick, Jessica B.; Chonchol, Michel B.] Univ Colorado, Sch Med, Div Renal Dis & Hypertens, Aurora, CO USA. [Kendrick, Jessica B.] Denver Hlth Med Ctr, Denver, CO USA. [Zelnick, Leila; Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Div Nephrol, Seattle, WA 98195 USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Siscovick, David] New York Acad Med, New York, NY USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92103 USA. [Sarnak, Mark] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Kendrick, JB (reprint author), Univ Colorado, Denver Hlth Med Ctr, Div Renal Dis & Hypertens, 660 Bannock St,Mail Code 4000, Denver, CO 80204 USA. EM Jessica.Kendrick@ucdenver.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K23 DK087859, 1R01DK081473, R01DK088762, R01DK099199, R01DK098234]; American Heart Association [14EIA18560026]; National Heart, Lung, and Blood Institute [R01HL096875, HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; NCRR [UL1-TR-000040, UL1-TR-001079] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Disease grants K23 DK087859, 1R01DK081473, R01DK088762, and R01DK099199, R01DK098234, National Heart, Lung, and Blood Institute grant R01HL096875, and an Established Investigator Award from the American Heart Association (14EIA18560026). This research was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161,N01-HC-95162,N01-HC-95163, N01-HC-95164, N01-HC-95165,N01-HC-95166,N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from NCRR. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. NR 43 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2017 VL 45 IS 2 BP 118 EP 126 DI 10.1159/000454783 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA EK4YR UT WOS:000393934600004 PM 27941322 ER PT J AU Cotton, AJ Shipley, LJ Glynn, LH Tracy, J Saxon, AJ AF Cotton, Ann J. Shipley, Leandra J. Glynn, Lisa H. Tracy, Josie Saxon, Andrew J. TI Methadone "callbacks" within a veterans affairs opioid treatment program: Detecting methadone misuse SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID BUPRENORPHINE AB Background and ObjectivesA callback requires patients to bring in take-home methadone doses for inspection. An opioid treatment program (OTP) quality-improvement project examined random versus for-cause callbacks. MethodEighty-two random callbacks and 60 for-cause callbacks were conducted among patients enrolled in an OTP (N=183). ResultsAmong patients with more take home doses, 6% of random callbacks versus 44% of for-cause callbacks were failed. Among patients with fewer take home doses, 36% of for-cause callbacks were failed. Discussion and ConclusionsFor-cause callbacks are more useful than random ones. Scientific SignificanceFor-cause callbacks based on clinical judgment detect methadone misuse. (Am J Addict 2017;26:50-52) C1 [Cotton, Ann J.; Shipley, Leandra J.; Glynn, Lisa H.; Tracy, Josie] US Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Cotton, Ann J.; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Shipley, Leandra J.; Glynn, Lisa H.; Tracy, Josie; Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. RP Cotton, AJ (reprint author), Univ Washington, VAPSHCS, Dept Psychiat & Behav Sci, MS 116-DDTP,1660 South Columbian, Seattle, WA 98108 USA. EM ann.cotton2@va.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2017 VL 26 IS 1 BP 50 EP 52 DI 10.1111/ajad.12479 PG 3 WC Substance Abuse SC Substance Abuse GA EK4FJ UT WOS:000393882200005 PM 28005315 ER PT J AU Carr, AR Samimi, MS Paholpak, P Jimenez, EE Mendez, MF AF Carr, Andrew R. Samimi, Mersal S. Paholpak, Pongsatorn Jimenez, Elvira E. Mendez, Mario F. TI Emotional quotient in frontotemporal dementia vs. Alzheimer's disease: the role of socioemotional agnosia SO COGNITIVE NEUROPSYCHIATRY LA English DT Article DE Socioemotional functioning; emotional intelligence; dementia; frontotemporal ID BEHAVIORAL VARIANT; NEURODEGENERATIVE DISEASE; DIAGNOSTIC-CRITERIA; SELF-AWARENESS; INTELLIGENCE; SCALE; RECOMMENDATIONS; CONSENSUS; INSIGHT; MIND AB Introduction: Socioemotional dysfunction distinguishes behavioural variant frontotemporal dementia (bvFTD) from other dementias. Patients with bvFTD not only have early social impairment and emotional blunting, but they also have agnosia of their socioemotional dysfunction.Methods: To investigate the relationship between agnosia and dysfunction, we assessed self-knowledge of socioemotional dysfunction with an emotional quotient (EQ) scale administered to 12 patients with bvFTD and a comparison group of 12 age-matched patients with Alzheimer's disease (AD), and compared these self-ratings to caregiver ratings of social dysfunction and emotional blunting.Results: The bvFTD patients self-rated as having higher EQs than the AD patients, particularly higher self-ratings of their Social Skills, an EQ subscale which correlated with increased emotional blunting. On within-groups analysis, the bvFTD patients' high self-ratings of their EQ Appraisal of Emotions correlated with increased socioemotional dysfunction, whereas all of the AD patients' self-ratings correlated appropriately with their degree of dysfunction.Conclusions: Large socioemotional agnosia scores (EQ minus function) distinguishes bvFTD from AD. Additionally, in bvFTD, agnosia specifically for their ability to appreciate others' emotions correlates with the degree of socioemotional dysfunction, suggesting a role for socioemotional agnosia in increasing socioemotional dysfunction. C1 [Carr, Andrew R.; Samimi, Mersal S.; Paholpak, Pongsatorn; Jimenez, Elvira E.; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Carr, Andrew R.; Samimi, Mersal S.; Paholpak, Pongsatorn; Jimenez, Elvira E.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Samimi, Mersal S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Dept Psychiat, Khon Kaen, Thailand. [Jimenez, Elvira E.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Carr, AR (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.; Carr, AR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM andrew.carr@va.gov FU National Institute of Aging [5R01AG050967]; V.A. Geriatrics Research, Education, and Clinical Care fellowship (ARC) FX This work was supported by the National Institute of Aging [grant number 5R01AG050967] and a V.A. Geriatrics Research, Education, and Clinical Care fellowship (ARC). NR 36 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1354-6805 EI 1464-0619 J9 COGN NEUROPSYCHIATRY JI Cogn. Neuropsychiatry PY 2017 VL 22 IS 1 BP 28 EP 38 DI 10.1080/13546805.2016.1259612 PG 11 WC Psychiatry SC Psychiatry GA EK6CL UT WOS:000394012500003 PM 27903133 ER PT J AU Rottman, BM Marcum, ZA Thorpe, CT Gellad, WF AF Rottman, Benjamin Margolin Marcum, Zachary A. Thorpe, Carolyn T. Gellad, Walid F. TI Medication adherence as a learning process: insights from cognitive psychology SO HEALTH PSYCHOLOGY REVIEW LA English DT Review DE Adherence; causal learning; value-expectancy; self-management ID CAUSAL INDUCTION; COMMON-SENSE; PRIMARY-CARE; ILL PATIENTS; MEDICINES; BELIEFS; DISEASE; PATIENT; MODEL; COVARIATION AB Non-adherence to medications is one of the largest contributors to sub-optimal health outcomes. Many theories of adherence include a value-expectancy' component in which a patient decides to take a medication partly based on expectations about whether it is effective, necessary, and tolerable. We propose reconceptualising this common theme as a kind of causal learning' - the patient learns whether a medication is effective, necessary, and tolerable, from experience with the medication. We apply cognitive psychology theories of how people learn cause-effect relations to elaborate this causal-learning challenge. First, expectations and impressions about a medication and beliefs about how a medication works, such as delay of onset, can shape a patient's perceived experience with the medication. Second, beliefs about medications propagate both top-down' and bottom-up', from experiences with specific medications to general beliefs about medications and vice versa. Third, non-adherence can interfere with learning about a medication, because beliefs, adherence, and experience with a medication are connected in a cyclic learning problem. We propose that by conceptualising non-adherence as a causal-learning process, clinicians can more effectively address a patient's misconceptions and biases, helping the patient develop more accurate impressions of the medication. C1 [Rottman, Benjamin Margolin] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Marcum, Zachary A.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Rottman, BM (reprint author), Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. EM rottman@pitt.edu FU NSF [1430439]; VA HSR&D Career Development Award; U.S. Department of Veterans Affairs [IIR 14-297] FX This research was supported by NSF 1430439 (Rottman) and a VA HSR&D Career Development Award (Gellad); U.S. Department of Veterans Affairs [IIR 14-297]. NR 78 TC 0 Z9 0 U1 4 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1743-7199 EI 1743-7202 J9 HEALTH PSYCHOL REV JI Health Psychol. Rev. PY 2017 VL 11 IS 1 BP 17 EP 32 DI 10.1080/17437199.2016.1240624 PG 16 WC Psychology, Clinical SC Psychology GA EM2CM UT WOS:000395124000002 PM 27707099 ER PT J AU Gvilia, I Suntsova, N Kostin, A Kalinchuk, A McGinty, D Basheer, R Szymusiak, R AF Gvilia, Irma Suntsova, Natalia Kostin, Andrey Kalinchuk, Anna McGinty, Dennis Basheer, Radhika Szymusiak, Ronald TI The role of adenosine in the maturation of sleep homeostasis in rats SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE sleep homeostasis; postweaning development; rats; adenosine; preoptic hypothalamus ID PREOPTIC AREA NEURONS; WAKING DISCHARGE PATTERNS; BASAL FOREBRAIN NEURONS; EYE-MOVEMENT SLEEP; CHOLINERGIC NEURONS; INFANT RATS; PROLONGED WAKEFULNESS; GABAERGIC NEURONS; A(2A) RECEPTORS; C-FOS AB Sleep homeostasis in rats undergoes significant maturational changes during postweaning development, but the underlying mechanisms of this process are unknown. In the present study we tested the hypothesis that the maturation of sleep is related to the functional emergence of adenosine (AD) signaling in the brain. We assessed postweaning changes in 1) wake-related elevation of extracellular AD in the basal forebrain (BF) and adjacent lateral preoptic area (LPO), and 2) the responsiveness of median preoptic nucleus (MnPO) sleep-active cells to increasing homeostatic sleep drive. We tested the ability of exogenous AD to augment homeostatic responses to sleep deprivation (SD) in newly weaned rats. In groups of postnatal day (P) 22 and P30 rats, we collected dialysate from the BF/LPO during baseline (BSL) wake-sleep, SD, and recovery sleep (RS). HPLC analysis of micro-dialysis samples revealed that SD in P30 rats results in significant increases in AD levels compared with BSL. P22 rats do not exhibit changes in AD levels in response to SD. We recorded neuronal activity in the MnPO during BSL, SD, and RS at P22/P30. MnPO neurons exhibited adult-like increases in waking neuronal discharge across SD on both P22 and P30, but discharge rates during enforced wake were higher on P30 vs. P22. Central administration of AD (1 nmol) during SD on P22 resulted in increased sleep time and EEG slow-wave activity during RS compared with saline control. Collectively, these findings support the hypothesis that functional reorganization of an adenosinergic mechanism of sleep regulation contributes to the maturation of sleep homeostasis. NEW & NOTEWORTHY Brain mechanisms that regulate the maturation of sleep are understudied. The present study generated first evidence about a potential mechanistic role for adenosine in the maturation of sleep homeostasis. Specifically, we demonstrate that early postweaning development in rats, when homeostatic response to sleep loss become adult like, is characterized by maturational changes in wake-related production/release of adenosine in the brain. Pharmacologically increased adenosine signaling in developing brain facilitates homeostatic responses to sleep deprivation. C1 [Gvilia, Irma; Suntsova, Natalia; Kostin, Andrey; McGinty, Dennis; Szymusiak, Ronald] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. [Gvilia, Irma; Suntsova, Natalia; Szymusiak, Ronald] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Gvilia, Irma] Ilia State Univ, Tbilisi, Rep of Georgia. [Kalinchuk, Anna; Basheer, Radhika] Harvard Med Sch, Dept Psychiat, Boston, MA USA. RP Gvilia, I (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. EM igvilia@ucla.edu FU Department of Veterans Affairs Medical Research Service Award [BX001556, 2I01BX001404]; National Institute of Mental Health Grant [MH-63323]; Shota Rustaveli National Science Foundation Grant [31/61]; National Institute of Neurological Disorders and Stroke Grant [NS-079866] FX This work was supported by the Department of Veterans Affairs Medical Research Service Award BX001556 (to R. Szymusiak), National Institute of Mental Health Grant MH-63323 (to R. Szymusiak), Shota Rustaveli National Science Foundation Grant 31/61 (to I. Gvilia), Department of Veterans Affairs Medical Research Service Award 2I01BX001404 (to R. Basheer), and National Institute of Neurological Disorders and Stroke Grant NS-079866 (to R. Basheer). NR 48 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN 1 PY 2017 VL 117 IS 1 BP 327 EP 335 DI 10.1152/jn.00675.2016 PG 9 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA EK3WZ UT WOS:000393860400029 PM 27784808 ER PT J AU Harrington, LB Marck, BT Wiggins, KL McKnight, B Heckbert, SR Woods, NF LaCroix, AZ Blondon, M Psaty, BM Rosendaal, FR Matsumoto, AM Smith, NL AF Harrington, L. B. Marck, B. T. Wiggins, K. L. McKnight, B. Heckbert, S. R. Woods, N. F. LaCroix, A. Z. Blondon, M. Psaty, B. M. Rosendaal, F. R. Matsumoto, A. M. Smith, N. L. TI Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE epidemiology; hemostasis; hormones; postmenopause; women ID VENOUS THROMBOSIS; REPLACEMENT THERAPY; ORAL-CONTRACEPTIVES; COAGULATION-FACTORS; EQUINE ESTROGEN; S LEVELS; RISK; PROTEIN; THROMBOEMBOLISM; PLASMA AB Background Oral use of exogenous estrogen/progestin alters hemostatic factor levels. The influence of endogenous hormones on these levels is incompletely characterized. Objectives Our study aimed to test whether, among postmenopausal women, high levels of estradiol (E2), estrone (E1), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), and androstenedione, and low levels of sex hormone-binding globulin (SHBG), are positively associated with measures of thrombin generation (TG), a normalized activated protein C sensitivity ratio (nAPCsr), and factor VII activity (FVIIc), and negatively associated with antithrombin activity (ATc) and total protein S antigen (PSAg). Methods This Heart and Vascular Health study cross-sectional analysis included 131 postmenopausal women without a prior venous thrombosis who were not currently using hormone therapy. Adjusted mean differences in TG, nAPCsr, FVIIc, ATc and PSAg levels associated with differences in hormone levels were estimated using multiple linear regression. We measured E2, E1, total T, DHEAS, DHEA and androstenedione levels by mass spectrometry, SHBG levels by immunoassay, and calculated the level of free T. Results One picogram per milliliter higher E1 levels were associated with 0.24% lower PSAg levels (95% Confidence Interval [CI]: -0.35, -0.12) and 1 g mL(-1) higher DHEAS levels were associated with 40.8 nm lower TG peak values (95% CI: -59.5, -22.2) and 140.7 nmxmin lower TG endogenous thrombin potential (ETP) (95% CI: -212.1, -69.4). After multiple comparisons correction, there was no evidence for other associations. Conclusions As hypothesized, higher E1 levels were associated with lower levels of the natural anticoagulant PSAg. Contrary to hypotheses, higher DHEAS levels were associated with differences in TG peak and ETP that suggest less generation of thrombin. C1 [Harrington, L. B.; Heckbert, S. R.; LaCroix, A. Z.; Blondon, M.; Psaty, B. M.; Smith, N. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Harrington, L. B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, 655 Huntington Ave,Bldg 2,Room 302, Boston, MA 02115 USA. [Marck, B. T.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Wiggins, K. L.; Psaty, B. M.] Univ Washington, Dept Med, Seattle, WA USA. [McKnight, B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Heckbert, S. R.; LaCroix, A. Z.; Psaty, B. M.; Smith, N. L.] Univ Washington, Grp Hlth Res Inst, Seattle, WA 98195 USA. [Woods, N. F.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [LaCroix, A. Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA. [Blondon, M.] Geneva Univ Hosp & Fac Med, Div Angiol & Hemostasis, Geneva, Switzerland. [Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Rosendaal, F. R.] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands. [Matsumoto, A. M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Smith, N. L.] Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs Off Res & Dev, Seattle, WA USA. RP Harrington, LB (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, 655 Huntington Ave,Bldg 2,Room 302, Boston, MA 02115 USA. EM lharring@hsph.harvard.edu FU National Institutes of Health [HL007902, HL098048, HL043201, HL060739, HL068986, HL073410, HL074745, HL085251, HL095080] FX This work was supported by National Institutes of Health grants HL007902 (D. S. Siscovick), HL098048 (E. B. Rimm), HL043201 (B. M. Psaty), HL060739 (B. M. Psaty), HL068986 (S. R. Heckbert), HL073410 (N. L. Smith), HL074745 (B. M. Psaty), HL085251 (B. M. Psaty), and HL095080 (N. L. Smith). NR 37 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JAN PY 2017 VL 15 IS 1 BP 80 EP 90 DI 10.1111/jth.13554 PG 11 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EK5OI UT WOS:000393975300012 PM 27797446 ER PT J AU Wilkerson, J Abdallah, K Hugh-Jones, C Curt, G Rothenberg, M Simantov, R Murphy, M Morrell, J Beetsch, J Sargent, DJ Scher, HI Lebowitz, P Simon, R Stein, WD Bates, SE Fojo, T AF Wilkerson, Julia Abdallah, Kald Hugh-Jones, Charles Curt, Greg Rothenberg, Mace Simantov, Ronit Murphy, Martin Morrell, Joseph Beetsch, Joel Sargent, Daniel J. Scher, Howard I. Lebowitz, Peter Simon, Richard Stein, Wilfred D. Bates, Susan E. Fojo, Tito TI Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis SO LANCET ONCOLOGY LA English DT Article ID CELL LUNG-CANCER; DOCETAXEL PLUS PREDNISONE; PHASE-III TRIAL; OPEN-LABEL; RATE CONSTANTS; DOUBLE-BLIND; SURVIVAL; CHEMOTHERAPY; MITOXANTRONE; PLACEBO AB Background We applied mathematical models to clinical trial data available at Project Data Sphere LLC (Cary, NC, USA), a non-profit universal access data-sharing warehouse. Our aim was to assess the rates of cancer growth and regression using the comparator groups of eight randomised clinical trials that enrolled patients with metastatic castration-resistant prostate cancer. Methods In this retrospective analysis, we used data from eight randomised clinical trials with metastatic castration-resistant prostate cancer to estimate the growth (g) and regression (d) rates of disease burden over time. Rates were obtained by applying mathematical models to prostate-specific antigen levels as the representation of tumour quantity. Rates were compared between study interventions (prednisone, mitoxantrone, and docetaxel) and off-treatment data when on-study treatment had been discontinued to understand disease behaviour during treatment and after discontinuation. Growth (g) was examined for association with a traditional endpoint (overall survival) and for its potential use as an endpoint to reduce sample size in clinical trials. Findings Estimates for g, d, or both were obtained in 2353 (88%) of 2678 patients with data available for analysis; g differentiated docetaxel (a US Food and Drug Administration-approved therapy) from prednisone and mitoxantrone and was predictive of overall survival in a landmark analysis at 8 months. A simulated sample size analysis, in which g was used as the endpoint, compared docetaxel data with mitoxantrone data and showed that small sample sizes were sufficient to achieve 80% power (16, 47, and 25 patients, respectively, in the three docetaxel comparator groups). Similar results were found when the mitoxantrone data were compared with the prednisone data (41, 39, and 41 patients in the three mitoxantrone comparator groups). Finally, after discontinuation of docetaxel therapy, median tumour growth (g) increased by nearly five times. Interpretation The application of mathematical models to existing clinical data allowed estimation of rates of growth and regression that provided new insights in metastatic castration-resistant prostate cancer. The availability of clinical data through initiatives such as Project Data Sphere, when combined with innovative modelling techniques, could greatly enhance our understanding of how cancer responds to treatment, and accelerate the productivity of clinical development programmes. C1 [Wilkerson, Julia] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD USA. [Abdallah, Kald; Curt, Greg] AstraZeneca, Gaithersburg, MD USA. [Hugh-Jones, Charles] Sanofi US, Bridgewater, NJ USA. [Rothenberg, Mace; Simantov, Ronit] Pfizer Inc, New York, NY USA. [Murphy, Martin; Morrell, Joseph] Project Data Sphere LLC, Cary, NC USA. [Beetsch, Joel] Celgene Corp, Summit, NJ USA. [Sargent, Daniel J.] Mayo Med Ctr, Rochester, MN USA. [Scher, Howard I.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Lebowitz, Peter] Johnson & Johnson, Janssen Pharmaceut Co, New Brunswick, NJ USA. [Simon, Richard] NCI, Biometr Res Program, NIH, Bethesda, MD USA. [Stein, Wilfred D.] Hebrew Univ Jerusalem, Silberman Inst Life Sci, Jerusalem, Israel. [Bates, Susan E.; Fojo, Tito] Columbia Univ, New York Presbyterian Hosp, Dept Med, Div Med Oncol, New York, NY USA. [Bates, Susan E.; Fojo, Tito] James J Peters VA Med Ctr, Bronx, NY USA. RP Fojo, T (reprint author), Univ Colombia, Div Med Oncol, Dept Med, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA. EM atf2116@cumc.columbia.edu NR 35 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD JAN PY 2017 VL 18 IS 1 BP 143 EP 154 DI 10.1016/S1470-2045(16)30633-7 PG 12 WC Oncology SC Oncology GA EN9SX UT WOS:000396341000055 PM 27979599 ER PT J AU Riggs, KR Knight, SJ AF Riggs, Kevin R. Knight, Sara J. TI The Language of Stewardship: Is the "Low-Value" Label Overused? SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID TOP 5 LISTS; PROSTATE-CANCER; HEALTH-CARE; COST; CLINICIAN; MEDICINE; NEED C1 [Riggs, Kevin R.] Univ Alabama Birmingham, Div Prevent Med, MT 610,1720 2nd Ave S, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Riggs, KR (reprint author), Univ Alabama Birmingham, Div Prevent Med, MT 610,1720 2nd Ave S, Birmingham, AL 35294 USA. EM kriggs@uab.edu FU National Institutes of Health [T32HL007180] FX This work was supported in part by grant T32HL007180 (K.R.R.) from the National Institutes of Health. NR 24 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JAN PY 2017 VL 92 IS 1 BP 11 EP 14 DI 10.1016/j.mayocp.2016.09.011 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA EK4QQ UT WOS:000393912300008 PM 27842705 ER PT J AU Heitmann, S Rule, M Truccolo, W Ermentrout, B AF Heitmann, Stewart Rule, Michael Truccolo, Wilson Ermentrout, Bard TI Optogenetic Stimulation Shifts the Excitability of Cerebral Cortex from Type Ito Type II: Oscillation Onset and Wave Propagation SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID NEURONAL NETWORKS; NEURAL-NETWORK; DYNAMICS; PULSES; MODEL AB Constant optogenetic stimulation targeting both pyramidal cells and inhibitory interneurons has recently been shown to elicit propagating waves of gamma-band (40-80 Hz) oscillations in the local field potential of non-human primate motor cortex. The oscillations emerge with non-zero frequency and small amplitude the hallmark of a type II excitable medium yet they also propagate far beyond the stimulation site in the manner of a type I excitable medium. How can neural tissue exhibit both type I and type II excitability? We investigated the apparent contradiction by modeling the cortex as a Wilson-Cowan neural field in which optogenetic stimulation was represented by an external current source. In the absence of any external current, the model operated as a type I excitable medium that supported propagating waves of gamma oscillations similar to those observed in vivo. Applying an external current to the population of inhibitory neurons transformed the model into a type II excitable medium. The findings suggest that cortical tissue normally operates as a type I excitable medium but it is locally transformed into a type II medium by optogenetic stimulation which predominantly targets inhibitory neurons. The proposed mechanism accounts for the graded emergence of gamma oscillations at the stimulation site while retaining propagating waves of gamma oscillations in the non-stimulated tissue. It also predicts that gamma waves can be emitted on every second cycle of a 100 Hz oscillation. That prediction was subsequently confirmed by re-analysis of the neurophysiological data. The model thus offers a theoretical account of how optogenetic stimulation alters the excitability of cortical neural fields. C1 [Heitmann, Stewart; Ermentrout, Bard] Univ Pittsburgh, Dept Math, Pittsburgh, PA 15260 USA. [Rule, Michael; Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI USA. RP Heitmann, S; Ermentrout, B (reprint author), Univ Pittsburgh, Dept Math, Pittsburgh, PA 15260 USA. EM heitmann@pitt.edu; bard@pitt.edu FU USA National Science Fund (NSF) [1219753]; National Institute of Neurological Disorders and Stroke (NINDS) [R01 NS25074]; K01 Career Award [NS057389]; Defense Advanced Research Projects Agency (DARPA REPAIR) [N66001-10-C-2010]; U.S. Department of Veterans Affairs, Merit Review Award [101RX000668]; Pablo J. Salame '88 Goldman Sachs endowed Assistant Professorship of Computational Neuroscience; National Science Foundation Graduate Research Fellowships Program (NSFGRFP) FX BE and SH were funded by USA National Science Fund (NSF) award 1219753. WT was supported by the National Institute of Neurological Disorders and Stroke (NINDS), R01 NS25074, K01 Career Award NS057389; Defense Advanced Research Projects Agency (DARPA REPAIR N66001-10-C-2010); U.S. Department of Veterans Affairs, Merit Review Award 101RX000668, and the Pablo J. Salame '88 Goldman Sachs endowed Assistant Professorship of Computational Neuroscience. MR was supported by National Science Foundation Graduate Research Fellowships Program (NSFGRFP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 18 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD JAN PY 2017 VL 13 IS 1 AR e1005349 DI 10.1371/journal.pcbi.1005349 PG 13 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA EK7ZT UT WOS:000394144400054 PM 28118355 ER PT J AU Loya, F Novakovic-Agopian, T Binder, D Rossi, A Rome, S Murphy, M Chen, AJW AF Loya, Fred Novakovic-Agopian, Tatjana Binder, Deborah Rossi, Annemarie Rome, Scott Murphy, Michelle Chen, Anthony J. -W. TI Long-Term Use and Perceived Benefits of Goal-Oriented Attentional Self-Regulation Training in Chronic Brain Injury SO REHABILITATION RESEARCH AND PRACTICE LA English DT Article ID EXECUTIVE DYSFUNCTION; REHABILITATION; INTERVENTIONS; MANAGEMENT; DISORDERS; AWARENESS; EFFICACY; BEHAVIOR; DEFICITS; PEOPLE AB Primary Objective. To investigate the long-term use and perceived benefit(s) of strategies included in Goal-Oriented Attentional Self-Regulation (GOALS) training (Novakovic-Agopian et al., 2011) by individuals with acquired brain injury (ABI) and chronic executive dysfunction. Research Design. Longitudinal follow-up of training. Methods and Procedures. Sixteen participants with chronic ABI participated in structured telephone interviews 20 months (range 11 to 31 months) following completion of GOALS training. Participants responded to questions regarding the range of strategies they continued to utilize, perceived benefit(s) of strategy use, situations in which strategy use was found helpful, and functional changes attributed to training. Results. Nearly all participants (94%) reported continued use of at least one trained strategy in their daily lives, with 75% of participants also reporting improved functioning resulting from training. However, there was considerable variability with respect to the specific strategies individuals found helpful as well as the perceived impact of training on overall functioning. Conclusions. GOALS training shows promising long-term benefits for individuals in the chronic phase of brain injury. Identifying individual-and injury-level factors that account for variability in continued strategy use and the perceived long-termbenefits of training will help with ongoing intervention development. C1 [Loya, Fred; Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Loya, Fred; Novakovic-Agopian, Tatjana; Binder, Deborah; Chen, Anthony J. -W.] VA Northern Calif Hlth Care Syst, Martinez, CA 94553 USA. [Loya, Fred; Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Loya, Fred; Chen, Anthony J. -W.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Novakovic-Agopian, Tatjana; Rossi, Annemarie; Rome, Scott] Calif Pacific Med Ctr, San Francisco, CA USA. [Murphy, Michelle] Laguna Honda Hosp, San Francisco, CA USA. RP Loya, F (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Loya, F (reprint author), VA Northern Calif Hlth Care Syst, Martinez, CA 94553 USA.; Loya, F (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Loya, F (reprint author), Univ Calif Berkeley, Berkeley, CA 94720 USA. EM fred.loya@va.gov FU VA Rehabilitation and Research Development Merit Awards (VANCHCS Project) [VA 1IO1RX001111-01A1, B7467I]; CPMC Foundation; Veterans Affairs Office of Academic Affiliations Advanced Postdoctoral Training Grant, Polytrauma/TBI Rehabilitation FX Aspects of this research were supported by the VA Rehabilitation and Research Development Merit Awards (VA 1IO1RX001111-01A1 and VANCHCS Project no. B7467I), CPMC Foundation Grant, and Veterans Affairs Office of Academic Affiliations Advanced Postdoctoral Training Grant, Polytrauma/TBI Rehabilitation. The authors thank Gary Abrams, MD, and Mark D'Esposito, MD, for their support and mentorship and their participants for contributing their time to their research program. NR 39 TC 0 Z9 0 U1 3 U2 3 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND SN 2090-2867 EI 2090-2875 J9 REHABIL RES PRACT JI Rehabil. Res. Pract. PY 2017 AR 8379347 DI 10.1155/2017/8379347 PG 8 WC Rehabilitation SC Rehabilitation GA EL8OQ UT WOS:000394880000001 ER PT J AU Ford, JM AF Ford, Judith M. TI Current Approaches to Studying Hallucinations: Overcoming Barriers to Progress SO SCHIZOPHRENIA BULLETIN LA English DT Editorial Material ID AUDITORY VERBAL HALLUCINATIONS; RDOC FRAMEWORK; SCHIZOPHRENIA C1 [Ford, Judith M.] San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM judith.ford@ucsf.edu FU NIMH [MH058262]; Veterans Administration [I01 CX000497] FX This work was supported by grants from NIMH (MH058262) and the Veterans Administration (I01 CX000497). NR 23 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2017 VL 43 IS 1 BP 21 EP 23 DI 10.1093/schbul/sbw149 PG 3 WC Psychiatry SC Psychiatry GA EK4LC UT WOS:000393897200008 PM 27872264 ER PT J AU Chang, JS Kushel, M Miaskowski, C Ceasar, R Zamora, K Hurstak, E Knight, KR AF Chang, Jamie Suki Kushel, Margot Miaskowski, Christine Ceasar, Rachel Zamora, Kara Hurstak, Emily Knight, Kelly R. TI Provider Experiences With the Identification, Management, and Treatment of Co-occurring Chronic Noncancer Pain and Substance Use in the Safety Net SO SUBSTANCE USE & MISUSE LA English DT Article DE Chronic noncancer pain; prescription opioids; safety net; primary care; provider-patient interactions; substance use treatment; qualitative research ID CHRONIC OPIOID THERAPY; UNITED-STATES; USE DISORDERS; PRIMARY-CARE; PATIENT; ABUSE; GUIDELINES; MEDICAID; HEALTH; TRENDS AB Background: In the United States and internationally, providers have adopted guidelines on the management of prescription opioids for chronic noncancer pain (CNCP). For high-risk patients with co-occurring CNCP and a history of substance use, guidelines advise that providers monitor patients using urine toxicology screening tests, develop opioid management plans, and refer patients to substance use treatment. Objective: We report primary care provider experiences in the safety net interpreting and implementing prescription opioid guideline recommendations for patients with CNCP and substance use. Methods: We interviewed primary care providers who work in safety net settings (N = 23) on their experiences managing CNCP and substance use. We analyzed interviews using a content analysis method. Results: Providers found management plans and urine toxicology screening tests useful for informing patients about clinic expectations of opioid therapy and substance use. However, they described that guideline-based clinic policies had unintended consequences, such as raising barriers to open, honest dialogue about substance use and treatment. While substance use treatment was recommended for high-risk patients, providers described lack of integration with and availability of substance use treatment programs. Conclusions: Our findings indicate that clinicians in the safety net found guideline-based clinic policies helpful. However, effective implementation was challenged by barriers to open dialogue about substance use and limited linkages with treatment programs. Further research is needed to examine how the context of safety net settings shapes the management and treatment of co-occurring CNCP and substance use. C1 [Chang, Jamie Suki] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Psychiat, 1001 Potrero Ave,Bldg 20,Suite 2100, San Francisco, CA 94110 USA. [Kushel, Margot; Hurstak, Emily] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Gen Hosp, San Francisco, CA 94143 USA. [Miaskowski, Christine] Univ Calif San Francisco, Physiol Nursing, San Francisco, CA 94143 USA. [Ceasar, Rachel] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Zamora, Kara] San Francisco VA Med Ctr, San Francisco, CA USA. [Knight, Kelly R.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. RP Chang, JS (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Psychiat, 1001 Potrero Ave,Bldg 20,Suite 2100, San Francisco, CA 94110 USA. EM jamie.chang@ucsf.edu FU National Institute of Drug Abuse [RO1DA034625]; Postdoctoral Training Program in Drug Abuse Treatment/Services Research [T32DA007250]; Career Investigator Award in Patient-Oriented Research [K24AG046372] FX This research was funded by a grant from the National Institute of Drug Abuse, RO1DA034625. Dr. Chang was supported in part by T32DA007250, Postdoctoral Training Program in Drug Abuse Treatment/Services Research. Dr. Kushel is supported in part by K24AG046372, Career Investigator Award in Patient-Oriented Research. NR 21 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2017 VL 52 IS 2 BP 251 EP 255 DI 10.1080/10826084.2016.1223138 PG 5 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA EK3GL UT WOS:000393814400013 PM 27754719 ER PT J AU Kazak, AE Nash, JM Hiroto, K Kaslow, NJ AF Kazak, Anne E. Nash, Justin M. Hiroto, Kimberly Kaslow, Nadine J. TI Psychologists in Patient-Centered Medical Homes (PCMHs): Roles, Evidence, Opportunities, and Challenges SO AMERICAN PSYCHOLOGIST LA English DT Article DE patient-centered medical home; psychology; health care delivery ID MENTAL-HEALTH-SERVICES; PRIMARY-CARE; BEHAVIORAL HEALTH; PROFESSIONAL PSYCHOLOGY; UNITED-STATES; ADULTS; PREFERENCES; COMPETENCES; DEPRESSION; MANAGEMENT AB The patient-centered medical home (PCMH) is an increasingly common model of health care delivery with many exciting opportunities for psychologists. The PCMH reflects a philosophy and model of care that is highly consistent with psychological science and practice. It strives to provide patient-centered, comprehensive, team-based, coordinated, accessible, and quality and safety-oriented health care delivery to individuals and families. Moreoever, in keeping with changes in the health care system more broadly, the PCMH model prioritizes the integration of behavioral and physical health care, and this emphasis lays the foundation for active and full engagement of psychologists in this context. This article provides an overview of the PCMH and the evidence and roles for psychologists across a range of pediatric, adult, and geriatric health care populations and settings. Current challenges to the necessary expansion of psychology in the PCMH are discussed, with particular attention to the needs for training and advocacy to support the contributions of behavioral health care in the PCMH. Psychology must embrace its rightful place as a health profession and appreciate and highlight the ways in which psychologists can play unique and critical roles in transforming present and future health care delivery models. C1 [Kazak, Anne E.] Nemours Childrens Hlth Syst, Nemours Ctr Healthcare Delivery Sci, Wilmington, DE USA. [Kazak, Anne E.] Thomas Jefferson Univ, Sidney Kimmel Med Sch, Dept Pediat, Philadelphia, PA 19107 USA. [Nash, Justin M.] Brown Univ, Warren Alpert Med Sch, Dept Family Med, Pawtucket, RI USA. [Nash, Justin M.] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Pawtucket, RI USA. [Nash, Justin M.] Mem Hosp Rhode Isl, Pawtucket, RI USA. [Hiroto, Kimberly] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Tacoma, WA USA. [Kaslow, Nadine J.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. RP Kazak, AE (reprint author), Nemours Ctr Healthcare Delivery Sci, 1701 Rockland Rd,Suite 160, Wilmington, DE 19803 USA. EM anne.kazak@nemours.org NR 68 TC 3 Z9 3 U1 3 U2 6 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X EI 1935-990X J9 AM PSYCHOL JI Am. Psychol. PD JAN PY 2017 VL 72 IS 1 BP 1 EP 12 DI 10.1037/a0040382 PG 12 WC Psychology, Multidisciplinary SC Psychology GA EK1GQ UT WOS:000393674200001 PM 26766761 ER PT J AU Cooper, CA Jain, N Gallagher, MD Weintraub, D Xie, SX Berlyand, Y Espay, AJ Quinn, J Edwards, KL Montine, T Van Deerlin, VM Trojanowski, J Zabetian, CP Chen-Plotkin, AS AF Cooper, Christine A. Jain, Nimansha Gallagher, Michael D. Weintraub, Daniel Xie, Sharon X. Berlyand, Yosef Espay, Alberto J. Quinn, Joseph Edwards, Karen L. Montine, Thomas Van Deerlin, Vivianna M. Trojanowski, John Zabetian, Cyrus P. Chen-Plotkin, Alice S. TI Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; ALPHA-SYNUCLEIN; RATING-SCALE; CLINICAL HETEROGENEITY; COGNITIVE IMPAIRMENT; GENETIC-VARIABILITY; PROSPECTIVE COHORT; CLUSTER-ANALYSIS; MOTOR SUBTYPE; ONSET AB Objective: Parkinson's disease (PD) presents clinically with several motor subtypes that exhibit variable treatment response and prognosis. Here, we investigated genetic variants for their potential association with PD motor phenotype and progression. Methods: We screened 10 SNPs, previously associated with PD risk, for association with tremor-dominant (TD) versus postural-instability gait disorder (PIGD) motor subtypes. SNPs that correlated with the TD/PIGD ratio in a discovery cohort of 251 PD patients were then evaluated in a multi-site replication cohort of 559 PD patients. SNPs associated with motor phenotype in both cross-sectional cohorts were next evaluated for association with (1) rates of motor progression in a longitudinal subgroup of 230 PD patients and (2) brain alpha-synuclein (SNCA) expression in the GTEx (Genotype-Tissue Expression project) consortium database. Results: Genotype at rs356182, near SNCA, correlated with the TD/PIGD ratio in both the discovery (Bonferroni-corrected P = 0.04) and replication cohorts (P = 0.02). The rs356182 GG genotype was associated with a more tremor-predominant phenotype and predicted a slower rate of motor progression (1-point difference in annual rate of UPDRS-III motor score change, P = 0.01). The rs356182 genotype was associated with SNCA expression in the cerebellum (P = 0.005). Interpretation: Our study demonstrates that the GG genotype at rs356182 provides molecular definition for a clinically important endophenotype associated with (1) more tremor-predominant motor phenomenology, (2) slower rates of motor progression, and (3) decreased brain expression of SNCA. Such molecularly defined endophenotyping in PD may benefit both clinical trial design and tailoring of clinical care as we enter the era of precision medicine. C1 [Cooper, Christine A.] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA. [Cooper, Christine A.; Jain, Nimansha; Gallagher, Michael D.; Berlyand, Yosef; Chen-Plotkin, Alice S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Berlyand, Yosef] Harvard Med Sch, Boston, MA USA. [Espay, Alberto J.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA. [Quinn, Joseph] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Edwards, Karen L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [Montine, Thomas] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Van Deerlin, Vivianna M.; Trojanowski, John] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zabetian, Cyrus P.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA 98195 USA. RP Chen-Plotkin, AS (reprint author), Dept Neurol, 3W Gates,3400 Spruce St, Philadelphia, PA 19104 USA. EM chenplot@mail.med.upenn.edu RI Gallagher, Michael/G-7113-2015 OI Gallagher, Michael/0000-0002-2109-1293 FU NIH [U01 NS082134, P50 NS062684, P50 NS053488, AG10124]; Burroughs Wellcome Fund; Pechenik Montague Award Fund; Benaroya Fund FX We thank Xiaoyan Han for her help with the statistical programming for Figure 2B. This work was supported by grants from the NIH (U01 NS082134, P50 NS062684, and P50 NS053488, and AG10124). Dr. Chen-Plotkin also receives research support from the Burroughs Wellcome Fund, the Pechenik Montague Award Fund, and the Benaroya Fund. NR 52 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2328-9503 J9 ANN CLIN TRANSL NEUR JI Ann. Clin. Transl. Neurol. PD JAN PY 2017 VL 4 IS 1 BP 15 EP 25 DI 10.1002/acn3.371 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EK1CY UT WOS:000393664600002 PM 28078311 ER PT J AU Merritt, FW Noble, MN Prochazka, AV Aagaard, EM Stickrath, CR AF Merritt, Frank W. Noble, Melissa N. Prochazka, Allan V. Aagaard, Eva M. Stickrath, Chad R. TI Attending rounds: What do the all-star teachers do? SO MEDICAL TEACHER LA English DT Article ID LEARNER-CENTERED MODEL; DUTY-HOUR REGULATIONS; INTERNAL-MEDICINE; TEACHING ROUNDS; BEDSIDE; EDUCATION; RESIDENT; CARE; ERA AB Aim: To examine differences in the types of teaching activities performed during rounds between the most effective and least effective inpatient teaching attendings.Methods: Participants included 56 attending physicians supervising 279 trainees. Trained observers accompanied teams during rounds and recorded the frequencies of educational activities that occurred. Students and residents then rated their satisfaction with the teaching on rounds.Results: Attending physicians with the highest learner satisfaction scores performed significantly more teaching activities per patient than attending physicians who were rated as average or less-effective (2.1 vs. 1.4 vs. 1.5; p=.03). There were significant differences in the frequencies of 3 out of the 9 specific teaching activities observed, including answering specific patient-care related questions (77% vs. 66% vs. 47%; p=.003), teaching on learner chosen topics (8% vs. 2% vs. 2%; p=.02), and providing feedback (31% vs. 10% vs. 0.1%; p=.001).Conclusions: Specific categories of teaching activitiespatient-specific teaching, teaching on learner-identified topics, and providing real-time feedbackare performed more frequently by the highest-rated attending physicians, which can guide faculty development. C1 [Merritt, Frank W.; Aagaard, Eva M.] Univ Colorado, Sch Med, Med, Aurora, CO USA. [Noble, Melissa N.; Stickrath, Chad R.] Univ Colorado, Sch Med, Aurora, CO USA. [Prochazka, Allan V.] Univ Colorado, Sch Med, Med, Div Gen Internal Med, Aurora, CO USA. [Prochazka, Allan V.] Univ Colorado, Sch Med, Mentored Scholarly Act, Aurora, CO USA. [Prochazka, Allan V.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Merritt, FW (reprint author), Hosp Med Grp, Leprino Bldg,4th Floor,12401 East 17th Ave, Aurora, CO 80045 USA. EM frank.merritt@ucdenver.edu NR 26 TC 0 Z9 0 U1 4 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0142-159X EI 1466-187X J9 MED TEACH JI Med. Teach. PD JAN PY 2017 VL 39 IS 1 BP 100 EP 104 DI 10.1080/0142159X.2017.1248914 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA EK4GT UT WOS:000393885800016 PM 27841061 ER PT J AU Koutroumpakis, E Slivka, A Furlan, A Dasyam, AK Dudekula, A Greer, JB Whitcomb, DC Yadav, D Papachristou, GI AF Koutroumpakis, Efstratios Slivka, Adam Furlan, Alessandro Dasyam, Anil K. Dudekula, Anwar Greer, Julia B. Whitcomb, David C. Yadav, Dhiraj Papachristou, Georgios I. TI Management and outcomes of acute pancreatitis patients over the last decade: A US tertiary-center experience SO PANCREATOLOGY LA English DT Article DE Acute pancreatitis; Management; Outcomes; Revised Atlanta classification ID DETERMINANT-BASED CLASSIFICATION; REVISED ATLANTA CLASSIFICATION; PERSISTENT ORGAN FAILURE; NECROTIZING PANCREATITIS; PROSPECTIVE COHORT; UNITED-STATES; INFLAMMATORY RESPONSE; INVASIVE-APPROACH; SEVERITY; MORTALITY AB Background/objectives: Acute pancreatitis (AP) management remains largely supportive and can be challenging in patients with severe disease. This study aims to describe a ten-year US tertiary-center experience in managing AP patients. Methods: Clinical management and outcomes of 400 prospectively enrolled AP patients stratified by the Revised Atlanta Classification were analyzed; trends in management between early (2004-2008) and late enrollment phase (2009-2014) were assessed. Results: Fifty-two% of patients were classified as mild AP (MAP); moderately severe (MoAP) and severe (SAP) grades contained 23.5% and 24.5% of participants. Intravenous fluid administration during the first 24 h (MAP 3.7, MoAP 4.7, and SAP 4.8 L), need for ICU (6%, 23%, 93%), and nutritional support (7%, 51%, 90%) increased significantly with greater AP severity (p < 0.001). One hundred fifty five (39%) patients developed necrotizing AP, of which 41% received prophylactic antibiotics, and 44% underwent pancreatic drainage/debridement. Prophylactic antibiotics (58% vs. 27%) and interventions (63% vs. 27%) were noted more frequently in SAP than MoAP (p < 0.001). Enteral nutrition (18% vs. 30%) and minimally invasive pancreatic interventions (19% vs. 41%) were more commonly used in the late phase (p < 0.05). The overall median length of hospitalization was 7 days reaching 29 days in SAP group. Mortality was 5%; all deaths occurred in SAP group. Conclusions: This study provides an extensive report on clinical management of AP and its trends overtime. Pancreatic intervention is required in less than 50% of patients with necrotizing pancreatitis. Utilization of enteral nutrition and minimally invasive pancreatic interventions has been increasing over time. Published by Elsevier B.V. on behalf of IAP and EPC. C1 [Koutroumpakis, Efstratios; Slivka, Adam; Greer, Julia B.; Whitcomb, David C.; Yadav, Dhiraj; Papachristou, Georgios I.] Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA. [Furlan, Alessandro; Dasyam, Anil K.] Univ Pittsburgh, Med Ctr, Dept Radiol, Div Abdominal Imaging, Pittsburgh, PA 15260 USA. [Dudekula, Anwar] Univ Pittsburgh, Med Ctr, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Dept Med, Div Gastroenterol, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), UPMC Presbyterian, 200 Lothrop St,3rd Floor, Pittsburgh, PA 15212 USA. EM papachri@pitt.edu FU Veterans Affairs Merit Review Award [PRO00000496] FX The study was supported by a Veterans Affairs Merit Review Award (PRO00000496; PI: G.I.P.). NR 31 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1424-3903 EI 1424-3911 J9 PANCREATOLOGY JI Pancreatology PD JAN-FEB PY 2017 VL 17 IS 1 BP 32 EP 40 DI 10.1016/j.pan.2016.10.011 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK0RG UT WOS:000393634200008 PM 28341116 ER PT J AU Badran, BW Austelle, CW Smith, NR Glusman, CE Froeliger, B Garland, EL Borckardt, JJ George, MS Short, B AF Badran, Bashar W. Austelle, Chris W. Smith, Nicole R. Glusman, Chloe E. Froeliger, Brett Garland, Eric L. Borckardt, Jeffrey J. George, Mark S. Short, Baron TI A Double-Blind Study Exploring the Use of Transcranial Direct Current Stimulation (tDCS) to Potentially Enhance Mindfulness Meditation (E-Meditation) SO BRAIN STIMULATION LA English DT Letter C1 [Badran, Bashar W.; Austelle, Chris W.; Smith, Nicole R.; Glusman, Chloe E.; Borckardt, Jeffrey J.; George, Mark S.; Short, Baron] Med Univ South Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Badran, Bashar W.; Austelle, Chris W.; Froeliger, Brett; George, Mark S.] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA. Med Univ South Carolina, Coll Med, Charleston, SC 29425 USA. [Froeliger, Brett] MUSC, Hollings Canc Ctr, Charleston, SC USA. [Garland, Eric L.] Univ Utah, Salt Lake City, UT USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Badran, BW (reprint author), MUSC Inst Psychiat, 67 President St,504N, Charleston, SC 29425 USA. EM basharwbadran@gmail.com FU MUSC Brain Stimulation Laboratory FX BWB is supported by the MUSC Brain Stimulation Laboratory and would like to thank Huda Nassori, William Stubbeman, and Zoe Fan for their early support and inspiration. NR 10 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD JAN-FEB PY 2017 VL 10 IS 1 BP 152 EP 154 DI 10.1016/j.brs.2016.09.009 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EJ5JO UT WOS:000393254500019 PM 27839723 ER PT J AU Davey, RA Russell, PK Fam, BC Mangiafico, S Clarke, MV Andrikopoulos, S Wiren, KM Zajac, JD AF Davey, Rachel A. Russell, Patricia K. Fam, Barbara C. Mangiafico, Salvatore Clarke, Michele V. Andrikopoulos, Sof Wiren, Kristine M. Zajac, Jeffrey D. TI Androgens act via the Androgen Receptor (AR) in progenitor cells residing within the bone marrow to reduce fat mass in male mice SO CLINICAL ENDOCRINOLOGY LA English DT Meeting Abstract C1 [Davey, Rachel A.; Russell, Patricia K.; Fam, Barbara C.; Mangiafico, Salvatore; Clarke, Michele V.; Andrikopoulos, Sof; Zajac, Jeffrey D.] Univ Melbourne, Dept Med, Austin Hlth, Heidelberg, Vic, Australia. [Wiren, Kristine M.] Portland VA Med Ctr, Bone & Mineral Res Unit, Portland, OR USA. [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0300-0664 EI 1365-2265 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD JAN PY 2017 VL 86 SU S1 MA 74 BP 6 EP 6 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EJ8DB UT WOS:000393453600017 ER PT J AU Fazio, RL Denning, JH Denney, RL AF Fazio, Rachel L. Denning, John H. Denney, Robert L. TI TOMM Trial 1 as a performance validity indicator in a criminal forensic sample SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Forensic neuropsychology; malingering; performance validity; response bias; Test of Memory Malingering ID TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ALBANY CONSISTENCY INDEX; RESPONSE BIAS SCALE; CLASSIFICATION ACCURACY; MENTAL-RETARDATION; COLLEGE-STUDENTS; RETENTION TRIAL; TEST FAILURE; WORD MEMORY AB Objective: To determine the effectiveness of the Test of Memory Malingering Trial 1 (TOMM1) as a freestanding Performance Validity Test (PVT) as compared to the full TOMM in a criminal forensic sample. Method: Participants included 119 evaluees in a Midwestern forensic hospital. Criterion groups were formed based on passing/failing scores on other freestanding PVTs. This resulted in three groups: +MND (Malingered Neurocognitive Dysfunction), who failed two or more freestanding PVTs; possible MND (pMND), who failed one freestanding PVT; and -MND, who failed no other freestanding PVTs. All three groups were compared initially, but only+MND and -MND groups were retained for final analyses. TOMM1 performance was compared to standard TOMM performance using Receiver Operating Characteristic (ROC) analyses. Results: TOMM1 was highly predictive of the standard TOMM decision rules (AUC=.92). Overall accuracy rate for TOMM1 predicting failure on 2 PVTs was quite robust as well (AUC=.80), and TOMM139 provided acceptable diagnostic statistics (Sensitivity=.68, Specificity=.89). These results were essentially no different from the standard TOMM accuracy statistics. In addition, by adjusting for those strongly suspected of being inaccurately placed into the -MND group (e.g. false negatives), TOMM1 diagnostics slightly improved (AUC=.84) at a TOMM140 (sensitivity=.71, specificity=.94). Conclusions: Results support use of TOMM1 in a criminal forensic setting where accuracy, shorter evaluation times, and more efficient use of resources are often critical in informing legal decision-making. C1 [Fazio, Rachel L.] Carter Psychol Ctr, Bradenton, FL 34207 USA. [Denning, John H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Denning, John H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Denney, Robert L.] Neuropsychol Associates Southwest Missouri, Springfield, MO USA. RP Fazio, RL (reprint author), Carter Psychol Ctr, Bradenton, FL 34207 USA. EM rlfazio@gmail.com NR 78 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2017 VL 31 IS 1 BP 251 EP 267 DI 10.1080/13854046.2016.1213316 PG 17 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA EK2VR UT WOS:000393785300016 PM 27456971 ER PT J AU Hu, QH Cho, MS Thiagarajan, P Aung, FM Sood, AK Afshar-Kharghan, V AF Hu, Qianghua Cho, Min Soon Thiagarajan, Perumal Aung, Fleur M. Sood, Anil K. Afshar-Kharghan, Vahid TI A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets SO PLATELETS LA English DT Article DE COX2; Platelets; COX1COX2; expression ID OVARIAN-CANCER CELLS; MEGAKARYOPOIESIS; INHIBITION; ASSAY AB Cyclooxygenase (COX) is the rate-limiting enzyme in conversion of arachidonic acid to prostanoids, COX2, Platelets, COX1C0X2, expression and has two isoforms, COX1 and COX2, which share similar to 65% amino acid homology. COX1 is universally expressed in many cell types including platelets; however, expression of COX2 is known to be more limited. We examined expression of COX2 mRNA and protein in platelets and platelet-derived microparticles (MPs); using quantitative RT-PCR, immunostaining, and Western blotting. We have detected a significant amount of COX2 in platelets, both at mRNA and protein levels. We found that COX1/COX2 mRNA and protein ratios in platelets were 370:1 and 17:1, respectively. Expression level of COX2 in platelets was less than COX1, but comparable to the expression of COX2 in malignant epithelial cells. Considering the important role of COX2 in tumorigenesis and thrombosis, and the large number of circulating platelets, we propose that platelet COX2 may play an important role in physiologic and pathologic conditions. C1 [Hu, Qianghua; Cho, Min Soon; Afshar-Kharghan, Vahid] Univ Texas MD Anderson Canc Ctr, Sect Benign Hematol, Houston, TX 77030 USA. [Thiagarajan, Perumal] Baylor Coll Med, Ctr Translat Res Inflammatory Dis, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Aung, Fleur M.] Univ Texas MD Anderson Canc Ctr, Lab Med, Houston, TX 77030 USA. [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA. RP Sood, AK (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.; Afshar-Kharghan, V (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Benign Hematol, Houston, TX 77030 USA. EM asood@mdanderson.org; vakharghan@mdanderson.org OI Thiagarajan, Perumal/0000-0003-2186-7036 FU NIH grant [CA177909]; Ovarian Cancer Research Fund Program Project Development Grant FX This work is supported in part by NIH grant CA177909 (V. Afshar-Kharghan and A.K. Sood) and Ovarian Cancer Research Fund Program Project Development Grant (V. Afshar-Kharghan and A.K. Sood). NR 18 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0953-7104 EI 1369-1635 J9 PLATELETS JI Platelets PD JAN PY 2017 VL 28 IS 1 BP 99 EP 102 DI 10.1080/09537104.2016.1203406 PG 4 WC Cell Biology; Hematology SC Cell Biology; Hematology GA EJ5OZ UT WOS:000393268900016 PM 27534811 ER PT J AU Minalyan, A Benhammou, JN Artashesyan, A Lewis, MS Pisegna, JR AF Minalyan, Artem Benhammou, Jihane N. Artashesyan, Aida Lewis, Michael S. Pisegna, Joseph R. TI Autoimmune atrophic gastritis: current perspectives SO CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY LA English DT Review DE autoimmune gastritis; pernicious anemia; gastric carcinoid ID HELICOBACTER-PYLORI INFECTION; IRON-DEFICIENCY ANEMIA; POLYPEPTIDE-EXPRESSING METAPLASIA; SUBACUTE COMBINED DEGENERATION; PARIETAL-CELL ANTIBODIES; PERNICIOUS-ANEMIA; INTESTINAL METAPLASIA; COBALAMIN DEFICIENCY; CHROMOGRANIN-A; ANTIGASTRIC AUTOANTIBODIES AB At present there is no universally accepted classification for gastritis. The first successful classification (The Sydney System) that is still commonly used by medical professionals was first introduced by Misiewicz et al in Sydney in 1990. In fact, it was the first detailed classification after the discovery of Helicobacter pylori by Warren and Marshall in 1982. In 1994, the Updated Sydney System was proposed during the International Workshop on the Histopathology of Gastritis followed by the publication in The American Journal of Surgical Pathology by Dixon et al. Using the new classification, distinction between atrophic and nonatrophic gastritis was revised, and the visual scale grading was incorporated. According to the Updated Sydney System Classification, atrophic gastritis is categorized into multifocal (H. pylori, environmental factors, specific diet) and corpus-predominant (autoimmune). Since metaplasia is a key histological characteristic in patients with atrophic gastritis, it has been recommended to use the word "metaplastic" in both variants of atrophic gastritis: autoimmune metaplastic atrophic gastritis (AMAG) and environmental metaplastic atrophic gastritis. Although there are many overlaps in the course of the disease and distinction between those two entities may be challenging, the aim of this review article was to describe the etiology, epidemiology, pathogenesis, diagnosis, clinical manifestations and treatment in patients with AMAG. However, it is important to mention that H. pylori is the most common etiologic factor for the development of gastritis in the world. C1 [Minalyan, Artem; Benhammou, Jihane N.; Artashesyan, Aida; Pisegna, Joseph R.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol Hepatol & Parenteral Nutr, Los Angeles, CA USA. [Lewis, Michael S.] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst 691 111C, Div Gastroenterol Hepatol & Parenteral Nutr, Dept Vet Affairs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu FU Department of Veterans Affairs RRD [I01 RX000194]; Human Studies CORE through CURE: Digestive Diseases Research Center by NIH [P30DK41301]; NIH NIDDK [T32 NIH5T32DK07180] FX This work received grant support from Department of Veterans Affairs RR&D Merit Review (JRP) I01 RX000194; Human Studies CORE through CURE: Digestive Diseases Research Center supported by NIH grant P30DK41301 and NIH NIDDK T32 NIH5T32DK07180 (JNB). NR 101 TC 0 Z9 0 U1 6 U2 6 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-7023 J9 CLIN EXP GASTROENTER JI Clin. Exp. Gastroenterol. PY 2017 VL 10 BP 19 EP 27 DI 10.2147/CEG.S109123 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EJ7ZQ UT WOS:000393441600001 PM 28223833 ER PT J AU Falavarjani, KG Iafe, NA Hubschman, JP Tsui, I Sadda, SR Sarraf, D AF Falavarjani, Khalil Ghasemi Iafe, Nicholas A. Hubschman, Jean-Pierre Tsui, Irena Sadda, Srinivas R. Sarraf, David TI Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE aflibercept; anti-VEGF; bevacizumab; diabetic retinopathy; foveal avascular zone; macular edema; optical coherence tomography angiography; retinal vein occlusion; ranibizumab; vessel density ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; FLUORESCEIN ANGIOGRAPHY; RANDOMIZED-TRIAL; VISUAL-ACUITY; NONPERFUSION; PROGRESSION; ISCHEMIA; RANIBIZUMAB; MANAGEMENT AB PURPOSE. To evaluate the changes in foveal avascular zone (FAZ) area and the retinal capillary density after a single intravitreal anti-VEGF injection for macular edema secondary to diabetic retinopathy or retinal vein occlusion. METHODS. In this prospective noncomparative case series, 18 eyes of 15 patients with diabetic macular edema (13 eyes) or macular edema secondary to central retinal vein occlusion (5 eyes) were included. Optical coherence tomography angiography (OCTA) images were obtained, and retinal capillary vessel density and FAZ area were measured in the foveal and parafoveal regions at the level of the superficial (SCP) and deep retinal capillary plexus (DCP) before and at the first visit after intravitreal injection. RESULTS. The mean interval between baseline and follow up OCTA was 32.5+/-9.4 (range, 2150) days. Foveal and parafoveal vessel density in the SCP and DCP were not significantly different before and after intravitreal injection (all P > 0.1), nor was FAZ area (P = 0.48 and P = 0.42, respectively). No significant difference was found between eyes with diabetic macular edema and those with retinal vein occlusion with respect to the mean change of vessel density and FAZ area (all P > 0.05). CONCLUSIONS. In this pilot study, retinal capillary density and FAZ area remained statistically unchanged in the short-term after a single intravitreal injection of an anti-VEGF agent. C1 [Falavarjani, Khalil Ghasemi; Iafe, Nicholas A.; Hubschman, Jean-Pierre; Tsui, Irena; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Falavarjani, Khalil Ghasemi; Sadda, Srinivas R.] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA. [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Tehran, Iran. [Iafe, Nicholas A.; Hubschman, Jean-Pierre; Tsui, Irena; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM sarraf@jsei.ucla.edu OI Ghasemi Falavarjani, Khalil/0000-0001-5221-1844 NR 25 TC 0 Z9 0 U1 2 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2017 VL 58 IS 1 BP 30 EP 34 DI 10.1167/iovs.16-20579 PG 5 WC Ophthalmology SC Ophthalmology GA EJ1EW UT WOS:000392954300004 ER PT J AU Armour, C Fried, EI Deserno, MK Tsai, J Pietrzak, RH AF Armour, Cherie Fried, Eiko I. Deserno, Marie K. Tsai, Jack Pietrzak, Robert H. TI A network analysis of DSM-5 posttraumatic stress disorder symptoms and correlates in US military veterans SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE PTSD; Depression; DSM-5; Veterans; Network analysis; Functioning; Quality of life (QoL); Suicide ID PTSD SYMPTOMS; LATENT STRUCTURE; DEPRESSION SYMPTOMS; SUICIDAL IDEATION; PRIMARY-CARE; COMORBIDITY; AFGHANISTAN; RISK; IRAQ; PREDICTORS AB Objective: Recent developments in psychometrics enable the application of network models to analyze psychological disorders, such as PTSD. Instead of understanding symptoms as indicators of an underlying common cause, this approach suggests symptoms co-occur in syndromes due to causal interactions. The current study has two goals: (1) examine the network structure among the 20 DSM-5 PTSD symptoms, and (2) incorporate clinically relevant variables to the network to investigate whether PTSD symptoms exhibit differential relationships with suicidal ideation, depression, anxiety, physical functioning/quality of life (QoL), mental functioning(QoL, age, and sex. Method: We utilized a nationally representative U.S. military veteran's sample; and analyzed the data from a subsample of 221 veterans who reported clinically significant DSM-5 PTSD symptoms. Networks were estimated using state-of-the-art regularized partial correlation models. Data and code are published along with the paper. Results: The 20-item DSM-5 PTSD network revealed that symptoms were positively connected within the network. Especially strong connections emerged between nightmares and flashbacks; blame of self or others and negative trauma-related emotions, detachment and restricted affect; and hypervigilance and exaggerated startle response. The most central symptoms were negative trauma-related emotions, flashbacks, detachment, and physiological cue reactivity. Incorporation of clinically relevant covariates into the network revealed paths between self-destructive behavior and suicidal ideation; concentration difficulties and anxiety, depression, and mental QoL; and depression and restricted affect. Conclusion: These results demonstrate the utility of a network approach in modeling the structure of DSM-5 PTSD symptoms, and suggest differential associations between specific DSM-5 PTSD symptoms and clinical outcomes in trauma survivors. Implications of these results for informing the assessment and treatment of this disorder, are discussed. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Armour, Cherie] Univ Ulster, Psychol Res Inst, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland. [Fried, Eiko I.] Univ Leuven, Fac Psychol & Educ Sci, Leuven, Belgium. [Deserno, Marie K.] Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands. [Tsai, Jack; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Pietrzak, Robert H.] Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, Clin Neurosci Div, West Haven, CT USA. RP Armour, C (reprint author), Univ Ulster, Psychol Res Inst, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland. EM armour.cherie@gmail.com FU U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder; European Research Council Consolidator Grant [647209] FX The National Health and Resilience in Veterans Study is supported by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. Dr. Fried is supported by the European Research Council Consolidator Grant no. 647209. NR 73 TC 1 Z9 1 U1 12 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JAN PY 2017 VL 45 BP 49 EP 59 DI 10.1016/j.janxdis.2016.11.008 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EI8YM UT WOS:000392794100007 PM 27936411 ER PT J AU Shakoor, N Felson, DT Niu, JB Nguyen, US Segal, NA Singh, JA Nevitt, MC AF Shakoor, Najia Felson, David T. Niu, Jingbo Nguyen, Uyen-Sa Segal, Neil A. Singh, Jasvinder A. Nevitt, Michael C. TI The Association of Vibratory Perception and Muscle Strength With the Incidence and Worsening of Knee Instability: The Multicenter Osteoarthritis Study SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID PHYSICAL FUNCTION; CONTROLLED-TRIAL; PROPRIOCEPTION; PAIN; ADOLESCENTS; LIMITATIONS; PREVALENCE; CHILDREN; EXERCISE; THERAPY AB Objective. To examine neuromuscular factors that predict the incidence and progression of knee instability symptoms in older adults with or at high risk of knee osteoarthritis (OA). Methods. At the 60-month clinic visit, participants in the Multicenter Osteoarthritis Study underwent evaluation of quantitative vibratory sense at the knee and isokinetic quadriceps muscle strength. At this 60-month visit, participants were also asked about knee buckling and sensations of knee shifting or slipping without buckling in the past 3 months and then were asked the same questions at the 72- and 84-month follow-up visits. We performed a person-based analysis using Poisson regression analysis with robust error variance to estimate adjusted relative risks (RRs) for the association of vibratory sense and muscle strength with the incidence and worsening of knee slipping/shifting, buckling, and overall knee instability symptoms (either buckling or knee shifting/slipping), with adjustment for relevant confounders. Results. A total of 1,803 participants (61% women) were included. Approximately one-third of the participants reported incident or worsening of instability symptoms over the study period. After adjustment for relevant confounders, better vibratory acuity (adjusted RR 0.78, 95% confidence interval [95% CI] 0.56-1.09), P=0.020 for trend) and greater quadriceps strength (adjusted RR 0.53, 95% CI 0.38-0.75, P<0.001) protected against incident knee instability symptoms. Greater quadriceps strength (adjusted RR 0.73, 95% CI 0.58-0.92, P=0.008) also protected against worsening of knee instability symptoms. Conclusion. Vibratory acuity and quadriceps muscle strength are important predictors of the incidence and worsening of knee instability over 2 years. These neuromuscular factors are potentially modifiable and should be considered in interventional studies of instability in persons with or at risk of knee OA. C1 [Shakoor, Najia] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Felson, David T.; Niu, Jingbo] Boston Univ, Sch Med, Boston, MA 02215 USA. [Felson, David T.] Univ Manchester, Manchester, Lancs, England. [Nguyen, Uyen-Sa] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Segal, Neil A.] Univ Kansas, Kansas City, KS 66045 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Nevitt, Michael C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. EM Najia_shakoor@rush.edu FU NIH (National Institute on Aging) [AG-18820, AG-18832, AG-18947, AG-19069] FX Supported by the NIH (National Institute on Aging grants AG-18820, AG-18832, AG-18947, and AG-19069). NR 29 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JAN PY 2017 VL 69 IS 1 BP 94 EP 102 DI 10.1002/art.39821 PG 9 WC Rheumatology SC Rheumatology GA EI5AJ UT WOS:000392505500012 PM 27564789 ER PT J AU Domsic, RT Lucas, M Nihtyanova, SI Denton, CP Wisniewski, SR Fine, MJ Kwoh, CK Medsger, TA AF Domsic, Robyn T. Lucas, Mary Nihtyanova, Svetlana I. Denton, Christopher P. Wisniewski, Stephen R. Fine, Michael J. Kwoh, C. Kent Medsger, Thomas A. TI Statistical considerations in the development of clinical predictive scores: comment on the article by Domsic et al Reply SO ARTHRITIS & RHEUMATOLOGY LA English DT Letter C1 [Domsic, Robyn T.; Lucas, Mary; Medsger, Thomas A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Nihtyanova, Svetlana I.; Denton, Christopher P.] UCL, Royal Free Hosp, Sch Med, London, England. [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare, Vet Affairs Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA. FU NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [K23-AR-057845] FX Dr. Domsic's work was supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K23-AR-057845). NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JAN PY 2017 VL 69 IS 1 BP 242 EP 242 DI 10.1002/art.39853 PG 1 WC Rheumatology SC Rheumatology GA EI5AJ UT WOS:000392505500031 PM 27589673 ER PT J AU Eggers, S Barker, A Valentine, S Hess, T Duster, M Safdar, N AF Eggers, Shoshannah Barker, Anna Valentine, Susan Hess, Timothy Duster, Megan Safdar, Nasia TI Impact of Probiotics for Reducing Infections in Veterans (IMPROVE): Study protocol for a double-blind, randomized controlled trial to reduce carriage of Staphylococcus aureus SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Clinical trial; Staphylococcus aureus; MRSA; Lactobacilli; Probiotics; Veterans ID LACTOBACILLUS-RHAMNOSUS HN001; BIFIDOBACTERIUM-LACTIS HN019; VENTILATOR-ASSOCIATED PNEUMONIA; GRAM-NEGATIVE BACILLI; TERM-CARE FACILITY; METHICILLIN-RESISTANT; NASAL COLONIZATION; ACIDOPHILUS HN017; ANTIBIOTIC-THERAPY; ACID BACTERIA AB Background: Staphylococcus aureus (S. aureus) is an organism of great public health importance, causing 20,000 deaths annually. Decolonization of patients with S. aureus may prevent infections, yet current options are limited to antimicrobials that promote antibiotic resistance and can cause adverse side effects. Probiotics have potential to reduce colonization of pathogenic bacteria, representing a promising alternative for S. aureus decolonization, but thus far lack rigorous evaluation. Methods: Potential subjects were recruited from inpatient and outpatient settings within a VA medical center and screened for S. aureus gastrointestinal (GI) or extra-GI colonization using swabs at multiple body sites. Positive, eligible, consenting participants were stratified by colonization site and randomized in a 1:1 ratio to 4-Weeks of daily placebo or Lactobacillus rhamnosus (L. rhamnosus) HN001 probiotic treatment. Blood and stool samples, and treatment adherence reports were collected from each subject throughout the study, along with a final set of swabs at study completion to detect S. aureus carriage. The outcomes of this study are GI or extra-GI carriage by S. aureus at the end of 4 weeks of therapy, change in phagocytic activity of polymorphonticlear cells from pre-intervention to post-intervention, and symptomatic S. aureus infection at any site during the study period. Conclusion: 114 participants have been recruited for this study. Analysis of outcomes is underway. This is the first clinical trial to examine the efficacy of L. rhamnosus HN001 for decolonization of S. aureus, and investigates the mechanism by which L rhamnosus HN001 mediates its effect on S. aureus colonization. Published by Elsevier Inc. C1 [Eggers, Shoshannah; Valentine, Susan; Hess, Timothy; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA. [Eggers, Shoshannah; Hess, Timothy; Duster, Megan] Univ Wisconsin Madison, Sch Med & Publ Hlth, Madison, WI USA. [Eggers, Shoshannah; Barker, Anna; Safdar, Nasia] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. EM nasia.safdar@va.gov RI IB/USP, Genetica e Biologia /G-1755-2017 FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX007080]; National Institute of Health [UL1TR000427, TL1TR000429] FX This work was supported by the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (Award Number I01BX007080). The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. AB is supported under National Institute of Health (awards UL1TR000427 and TL1TR000429, administered by the University of Wisconsin-Madison's Institute for Clinical and Translational Research). These funding sources had no role in the design or implementation of this study, and will have no role in data analysis, in of data, or the decision to submit results. NR 61 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD JAN PY 2017 VL 52 BP 39 EP 45 DI 10.1016/j.cct.2016.11.004 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EI5VZ UT WOS:000392565700006 PM 27836508 ER PT J AU Markland, AD Jelovsek, JE Whitehead, WE Newman, DK Andy, UU Dyer, K Harm-Ernandes, I Cichowski, S McCormick, J Rardin, C Sutkin, G Shaffer, A Meikle, S AF Markland, A. D. Jelovsek, J. E. Whitehead, W. E. Newman, D. K. Andy, U. U. Dyer, K. Harm-Ernandes, I. Cichowski, S. McCormick, J. Rardin, C. Sutkin, G. Shaffer, A. Meikle, S. CA Pelvic Floor Disorders Network TI Improving biofeedback for the treatment of fecal incontinence in women: implementation of a standardized multi-site manometric biofeedback protocol SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE anal sphincter exercises; anorectal manometry; factorial design; fecal incontinence; manometry-assisted biofeedback; pelvic floor disorders; randomized placebo-controlled trial; treatment fidelity; urge resistance training ID OBJECTIVE STRUCTURED ASSESSMENT; RANDOMIZED CONTROLLED-TRIAL; ANAL INCONTINENCE; TECHNICAL SKILL; SURGICAL RESIDENTS; NATIONAL INSTITUTE; EXERCISES; TRAINEES; WORKSHOP; DESIGN AB BackgroundStandardized training and clinical protocols using biofeedback for the treatment of fecal incontinence (FI) are important for clinical care. Our primary aims were to develop, implement, and evaluate adherence to a standardized protocol for manometric biofeedback to treat FI. MethodsIn a Pelvic Floor Disorders Network (PFDN) trial, participants were enrolled from eight PFDN clinical centers across the United States. A team of clinical and equipment experts developed biofeedback software on a novel tablet computer platform for conducting standardized anorectal manometry with separate manometric biofeedback protocols for improving anorectal muscle strength, sensation, and urge resistance. The training protocol also included education on bowel function, anal sphincter exercises, and bowel diary monitoring. Study interventionists completed online training prior to attending a centralized, standardized certification course. For the certification, expert trainers assessed the ability of the interventionists to perform the protocol components for a paid volunteer who acted as a standardized patient. Postcertification, the trainers audited interventionists during trial implementation to improve protocol adherence. Key ResultsTwenty-four interventionists attended the in-person training and certification, including 46% advanced practice registered nurses (11/24), 50% (12/24) physical therapists, and 4% physician assistants (1/24). Trainers performed audio audits for 88% (21/24), representing 84 audited visits. All certified interventionists met or exceeded the prespecified 80% pass rate for the audit process, with an average passing rate of 93%. Conclusions & InferencesA biofeedback protocol can be successfully imparted to experienced pelvic floor health care providers from various disciplines. Our process promoted high adherence to a standard protocol and is applicable to many clinical settings. C1 [Markland, A. D.; McCormick, J.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, 700 19th St South, Birmingham, AL 35294 USA. [Markland, A. D.; McCormick, J.] Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Jelovsek, J. E.] Cleveland Clin, Obstet Gynecol & Womens Hlth Inst, Cleveland, OH 44106 USA. [Whitehead, W. E.] Univ North Carolina Chapel Hill, Div Gastroenterol & Hepatol, Dept Med, Chapel Hill, NC USA. [Whitehead, W. E.] Univ North Carolina Chapel Hill, Div Urogynecol, Dept Obstet & Gynecol, Chapel Hill, NC USA. [Newman, D. K.] Univ Penn, Dept Surg, Perelman Sch Med, Div Urol, Philadelphia, PA 19104 USA. [Andy, U. U.] Univ Penn, Dept Obstet & Gynecol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Dyer, K.] Kaiser Permanente, Dept Obstet & Gynecol, San Diego, CA USA. [Harm-Ernandes, I.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA. [Cichowski, S.] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA. [Cichowski, S.] Univ New Mexico, Hlth Sci Ctr, Dept Surg, Albuquerque, NM 87131 USA. [Rardin, C.] Brown Univ, Alpert Med Sch, Dept Obstet & Gynecol, Providence, RI 02912 USA. [Sutkin, G.] Univ Pittsburgh, Med Ctr, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Shaffer, A.] RTI Int, Res Triangle Pk, NC USA. [Meikle, S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. EM amarkland@uabmc.edu OI Markland, Alayne/0000-0002-6567-6744 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [U10 HD054215, U10 HD041261, U10 HD069013, U10 HD054214, U10 HD041267, U10 HD069025, U10 HD069010, U10 HD069006, U01 HD069031]; National Institutes of Health Office of Research on Women's Health FX Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10 HD054215, U10 HD041261, U10 HD069013, U10 HD054214, U10 HD041267, U10 HD069025, U10 HD069010, U10 HD069006, U01 HD069031) and the National Institutes of Health Office of Research on Women's Health. NR 19 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1350-1925 EI 1365-2982 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD JAN PY 2017 VL 29 IS 1 AR UNSP e12906 DI 10.1111/nmo.12906 PG 7 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA EI4YM UT WOS:000392500000009 ER PT J AU Brown, WJ Wilkerson, AK Milanak, ME Tuerk, PW Uhde, TW Cortese, BM Grubaugh, AL AF Brown, Wilson J. Wilkerson, Allison K. Milanak, Melissa E. Tuerk, Peter W. Uhde, Thomas W. Cortese, Bernadette M. Grubaugh, Anouk L. TI An examination of sleep quality in veterans with a dual diagnosis of PTSD and severe mental illness SO PSYCHIATRY RESEARCH LA English DT Article DE PTSD; Severe mental illness; Sleep; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; BIPOLAR DISORDER; MILITARY VETERANS; OF-LIFE; DISTURBANCES; INSOMNIA; SYMPTOMS; INDEX; VALIDATION; DEPRESSION AB Poor sleep quality is one of the most frequently reported symptoms by veterans with Posttraumatic Stress Disorder (PTSD) and by veterans with severe mental illness (SMI; i.e., schizophrenia spectrum disorders, bipolar disorder, major depression with or without psychotic features). However, little is known about the compounding effects of co-occurring PTSD/SMI on sleep quality in this population. Given the high rates of comorbidity and poor functional outcomes associated with sleep dysfunction, there is a need to better understand patterns of poor sleep quality in this population. The present study provides a description of sleep quality in veterans with a dual diagnosis of PTSD/SMI relative to veterans with PTSD only. Results indicated that, despite similar reports of PTSD symptom severity between the groups, veterans with PTSD/SMI reported higher levels of poor sleep quality than veterans only diagnosed with PTSD. Specifically, veterans with PTSD/SMI reported significantly greater difficulties with sleep onset and overall more sleep disturbance than their non-SMI counterparts. Implications of the findings are discussed within the context of an existing model of insomnia and suggest that more comprehensive sleep assessment and the provision of targeted sleep interventions may be helpful for those with a dual diagnosis of PTSD/SMI. C1 [Brown, Wilson J.] Penn State Univ, Behrend Coll, Erie, PA 16563 USA. [Wilkerson, Allison K.; Milanak, Melissa E.; Tuerk, Peter W.; Uhde, Thomas W.; Cortese, Bernadette M.; Grubaugh, Anouk L.] Med Univ South Carolina, Charleston, SC USA. [Tuerk, Peter W.; Grubaugh, Anouk L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Brown, WJ (reprint author), Penn State Univ, Behrend Coll, Sch Humanities & Social Sci, 4701 Coll Dr, Erie, PA 16563 USA. EM wilsonbrown@psu.edu FU Veterans Affairs Health Services Research & Development grants [CD207015, IIR 11-306] FX This study was supported by Veterans Affairs Health Services Research & Development grants CD207015 and IIR 11-306 awarded to Anouk L. Grubaugh, Ph.D. NR 44 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD JAN PY 2017 VL 247 BP 15 EP 20 DI 10.1016/j.psychres.2016.07.062 PG 6 WC Psychiatry SC Psychiatry GA EI8QK UT WOS:000392772400004 PM 27863313 ER PT J AU Ruzek, JI Eftekhari, A Crowley, J Kuhn, E Karlin, BE Rosen, CS AF Ruzek, J. I. Eftekhari, A. Crowley, J. Kuhn, E. Karlin, B. E. Rosen, C. S. TI Post-training Beliefs, Intentions, and Use of Prolonged Exposure Therapy by Clinicians in the Veterans Health Administration SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Post-training beliefs; Intentions; Use of prolonged exposure therapy by clinicians in the veterans health administration; Posttraumatic stress disorder; Training; Implementation ID POSTTRAUMATIC-STRESS-DISORDER; EVIDENCE-BASED-PSYCHOTHERAPIES; PSYCHOLOGICAL TREATMENTS; PTSD TREATMENT; IMPLEMENTATION; CARE; DISSEMINATION; ATTITUDES; BEHAVIORS; EFFICACY AB To examine how changes in beliefs during the training process predict adoption of prolonged exposure therapy (PE) by veterans health administration clinicians who received intensive training in this evidence-based treatment. Participants completed a 4-day PE workshop and received expert consultation as they used PE with two or more training cases. Participants were surveyed prior to the workshop, after the workshop, after case consultation (n = 1.034), and 6 months after training (n = 810). Hierarchical regression was used to assess how pre-training factors, and changes in beliefs during different stages of training incrementally predicted post-training intent to use PE and how many patients clinicians were treating with PE 6 months after training. Post-training intent to use PE was high (mean = 6.2, SD = 0.81 on a 1-7 scale), yet most participants treated only 1 or 2 patients at a time with PE. Pre-training factors predicted intent to use and actual use of PE. Changes in beliefs during the workshop had statistically significant yet modest effects on intent and use of PE. Changes in beliefs during case consultation had substantial effects on intent and actual use of PE. Pre-training factors and changes in beliefs during training (especially during case consultation) influence clinicians' adoption of PE. Use of PE was influenced not only by its perceived clinical advantages/disadvantages, but also by contextual factors (working in a PTSD specialty clinic, perceived control over one's schedule, and ability to promote PE to patients and colleagues). C1 [Ruzek, J. I.; Eftekhari, A.; Crowley, J.; Kuhn, E.; Rosen, C. S.] VA Palo Alto Hlth Care Syst, Disseminat & Training Div, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Ruzek, J. I.] Palo Alto Univ, Palo Alto, CA USA. [Ruzek, J. I.; Kuhn, E.; Rosen, C. S.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Karlin, B. E.] Educ Dev Ctr Inc, New York, NY USA. [Karlin, B. E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Karlin, B. E.] US Dept Vet Affairs, Cent Off, Mental Hlth Serv, Washington, DC USA. RP Ruzek, JI (reprint author), VA Palo Alto Hlth Care Syst, Disseminat & Training Div, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.; Ruzek, JI (reprint author), Palo Alto Univ, Palo Alto, CA USA.; Ruzek, JI (reprint author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. EM josef.ruzek@va.gov; afsoon.eftekhari@va.gov; jill.crowley@va.gov; eric.kuhn@va.gov; bradkarlin@gmail.com; craig.rosen@va.gov NR 42 TC 2 Z9 2 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X EI 1573-3289 J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD JAN PY 2017 VL 44 IS 1 BP 123 EP 132 DI 10.1007/s10488-015-0689-y PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EI3IL UT WOS:000392383600012 PM 26487392 ER PT J AU Maleki-Yazdi, MR Singh, D Anzueto, A Tombs, L Fahy, WA Naya, I AF Maleki-Yazdi, M. Reza Singh, Dave Anzueto, Antonio Tombs, Lee Fahy, William A. Naya, Ian TI Assessing Short-term Deterioration in Maintenance naive Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials SO ADVANCES IN THERAPY LA English DT Article DE Chronic obstructive pulmonary disease; Clinically important deterioration; Respiratory; Umeclidinium; Vilanterol ID OBSTRUCTIVE PULMONARY-DISEASE; EFFICACY; SAFETY AB Introduction: Dual bronchodilator therapy is reserved as a second-line treatment in patients with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function and health status versus monotherapy. The aim of this study was to determine whether early initiation of a dual bronchodilator versus monotherapy reduced the risk of deterioration in COPD. Methods: This post hoc pooled analysis investigated the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg/day compared with tiotropium (TIO) 18 mcg/day in a maintenance-naive (MN) subgroup of patients relative to the intent-to-treat (ITT) population from three 6-month active comparator studies (n = 1747). Other treatment arms (UMEC/VI 125/25, VI 25 and UMEC 125) comprised 850 patients in total but were not included in this analysis. The primary endpoint was trough forced expiratory volume in 1 s (FEV1). St George's Respiratory Questionnaire (SGRQ) score, rescue medication use, and a novel composite endpoint of short-term clinically important deterioration (CID; C >= 100 ml decrease in trough FEV1, >= 4-unit increase in SGRQ score, or a COPD exacerbation) were also assessed. Results: UMEC/VI improved trough FEV1 versus TIO at day 169 [least squares mean (95% confidence interval): MN: 146 ml (102-189) and ITT: 95 ml (71-118); both P < 0.001]. Both UMEC/VI and TIO improved SGRQ and rescue use in the two populations, with greater improvements in rescue use with UMEC/VI versus TIO. UMEC/VI reduced the risk of short-term clinically important deterioration versus TIO [hazard ratio; 95% confidence interval: MN: 0.66 (0.51-0.85); ITT: 0.62 (0.54-0.71), both P <= 0.001]. Adverse events were similar across both populations and treatments. Conclusions: Early use of dual-bronchodilator therapy has superior efficacy on lung function and may reduce the risk of short-term deterioration compared to monotherapy in symptomatic patients with COPD. C1 [Maleki-Yazdi, M. Reza] Univ Toronto, Div Resp Med, Womens Coll Hosp, Toronto, ON, Canada. [Singh, Dave] Univ Manchester, Univ Hosp South Manchester Fdn Trust, Med Evaluat Unit, Manchester, Lancs, England. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Tombs, Lee] Precise Approach LTD, Birmingham, W Midlands, England. [Fahy, William A.; Naya, Ian] GSK, Resp Med Dev Ctr, Stockley Pk, Middx, England. RP Maleki-Yazdi, MR (reprint author), Univ Toronto, Div Resp Med, Womens Coll Hosp, Toronto, ON, Canada. EM maleki.pccrc@on.aibn.com FU GSK FX This study was funded by GSK. NR 19 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0741-238X EI 1865-8652 J9 ADV THER JI Adv. Ther. PD JAN PY 2017 VL 33 IS 12 BP 2188 EP 2199 DI 10.1007/s12325-016-0430-6 PG 12 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EI0CS UT WOS:000392140300008 PM 27796912 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID XANTHINE-OXIDASE INHIBITION; CONGESTIVE-HEART-FAILURE; LEFT-VENTRICULAR MASS; ALL-CAUSE MORTALITY; TERM-FOLLOW-UP; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION; BLOOD-PRESSURE; UNITED-STATES AB Objective To assess the effect of allopurinol use on the risk of incident atrial fibrillation (AF) in the elderly. Methods We used the 5% random Medicare Claims data from 2006 to 2012 to examine the association of allopurinol use and incident AF in a cohort of patients with an absence of AF at baseline (at least 365 days). Multivariable-adjusted Cox regression analyses compared allopurinol exposed and non-exposed periods for the risk of AF, controlling for age, sex, race, Charlson-Romano comorbidity index and use of statins, diuretics, ACE inhibitors and beta-blockers. HR with 95% CIs was calculated. Sensitivity analyses considered a longer baseline period (365 days vs 183 days) and individual comorbidities. Results There were 9244 episodes of incident allopurinol use in 8569 beneficiaries, of which 1366 episodes (14.8%) had incident AF. In multivariable-adjusted analyses, allopurinol use was associated with an HR of 0.83 (95% CI 0.74 to 0.93) for incident AF. In a separate multivariable-adjusted model, compared with no allopurinol use, longer allopurinol use durations were associated with a lower HR of AF: 180 days-2 years, 0.85 (95% CI 0.73 to 0.99) and >2 years, 0.65 (95% CI 0.52 to 0.82). Other factors significantly associated with a higher hazard of AF were: age 75-<85 years and >= 85 years, higher Charlson index score and current beta-blocker use. Sensitivity analyses confirmed these findings with minimal/no attenuation of HRs. Conclusions Allopurinol use was associated with a reduced risk of incident AF in the elderly, especially its use for >6 months duration. Future studies should assess the mechanisms underlying this beneficial effect of allopurinol. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Dept Med, Sch Med, Birmingham, AL USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Div Epidemiol, Sch Publ Hlth, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU UAB Division of Rheumatology; Birmingham VA Medical Center; National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) [P50 AR060772] FX This material is the result of work supported by research funds from the UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. JAS is also supported by a grant from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) P50 AR060772. NR 49 TC 2 Z9 2 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JAN PY 2017 VL 76 IS 1 BP 72 EP 78 DI 10.1136/annrheumdis-2015-209008 PG 7 WC Rheumatology SC Rheumatology GA EI3XG UT WOS:000392425200011 PM 27165177 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID CHRONIC KIDNEY-DISEASE; CLINICAL COMORBIDITY INDEX; RHEUMATIC CONDITIONS; UNITED-STATES; GOUT; HYPERURICEMIA; PROGRESSION; FEBUXOSTAT; ARTHRITIS; ISCHEMIA AB Objective To assess the effect of allopurinol dose/duration on the risk of renal failure in the elderly with allopurinol use. Methods We used the 5% random Medicare claims data from 2006 to 2012. Multivariable-adjusted Cox regression analyses assessed the association of allopurinol dose/duration with subsequent risk of developing incident renal failure or end-stage renal disease (ESRD) (no prior diagnosis in last 183 days) in allopurinol users, controlling for age, sex, race and Charlson-Romano comorbidity index. HRs with 95% CIs were calculated. Sensitivity analyses considered a longer baseline period (365 days), controlled for gout or used more specific codes. Results Among the 30 022 allopurinol treatment episodes, 8314 incident renal failure episodes occurred. Compared with 1-199 mg/day, allopurinol dose of 200299 mg/day (HR 0.81; 95% CI 0.75 to 0.87) and >= 300 mg/day, 0.71 (0.67 to 0.76), had significantly lower hazard of renal failure in multivariable-adjustment model, confirmed in multiple sensitivity analyses. Longer allopurinol use duration was significantly associated with lower hazards in sensitivity analyses (365-day look-back; reference, <0.5 year): 0.5-1 year, 1.00 (0.88, 1.15); >1-2 years, 0.85 (0.73 to 0.99); and >2 years, 0.81 (0.67 to 0.98). Allopurinol >= 300 mg/day was also associated with significantly lower risk of acute renal failure and ESRD with HR of 0.89 (0.83 to 0.94) and 0.57 (0.46 to 0.71), respectively. Conclusions Higher allopurinol dose is independently protective against incident renal failure in the elderly allopurinol users. A longer duration of allopurinol use may be associated with lower risk of incident renal failure. Potential mechanisms of these effects need to be examined. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Div Epidemiol, Dept Med, Sch Med,Sch Publ Hlth, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU UAB Division of Rheumatology; Birmingham VA Medical Center FX This material is the result of work supported by research funds from UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. NR 42 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JAN PY 2017 VL 76 IS 1 BP 133 EP 139 DI 10.1136/annrheumdis-2015-209046 PG 7 WC Rheumatology SC Rheumatology GA EI3XG UT WOS:000392425200019 PM 27296322 ER PT J AU Neogi, T Dalbeth, N Stamp, L Castelar, G Fitzgerald, J Gaffo, A Mikuls, TR Singh, J Vazquez-Mellado, J Edwards, NL AF Neogi, Tuhina Dalbeth, Nicola Stamp, Lisa Castelar, Geraldo Fitzgerald, John Gaffo, Angelo Mikuls, Ted R. Singh, Jasvinder Vazquez-Mellado, Janitzia Edwards, N. Lawrence TI Renal dosing of allopurinol results in suboptimal gout care SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Letter ID ADVERSE EVENTS; HYPERURICEMIA; IMPAIRMENT; FEBUXOSTAT C1 [Neogi, Tuhina] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA. [Dalbeth, Nicola] Univ Auckland, Dept Immunol, Auckland, New Zealand. [Stamp, Lisa] Univ Otago, Dept Med, Canterbury, New Zealand. [Castelar, Geraldo] Pedro Ernesto Univ Hosp, Dept Rheumatol, Rio De Janeiro, Brazil. [Fitzgerald, John] Univ Calif Los Angeles, David Geffen Sch Med, Med Rheumatol, Los Angeles, CA 90095 USA. [Gaffo, Angelo] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. [Gaffo, Angelo; Singh, Jasvinder] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Dept Med, Omaha, NE USA. [Vazquez-Mellado, Janitzia] Hosp Gen Mexico City, Serv Reumatol, Mexico City, DF, Mexico. [Edwards, N. Lawrence] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA. RP Edwards, NL (reprint author), Univ Florida, Gainesville, FL 32610 USA. EM edwarni@medicine.ufl.edu OI Neogi, Tuhina/0000-0002-9515-1711 NR 12 TC 1 Z9 1 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JAN PY 2017 VL 76 IS 1 BP E1 EP + DI 10.1136/annrheumdis-2016-210352 PG 2 WC Rheumatology SC Rheumatology GA EI3XG UT WOS:000392425200045 PM 27582422 ER PT J AU Rundell, SD Goode, AP Suri, P Heagerty, PJ Comstock, BA Friedly, JL Gold, LS Bauer, Z Avins, AL Nedeljkovic, SS Nerenz, DR Kessler, L Jarvik, JG AF Rundell, Sean D. Goode, Adam P. Suri, Pradeep Heagerty, Patrick J. Comstock, Bryan A. Friedly, Janna L. Gold, Laura S. Bauer, Zoya Avins, Andrew L. Nedeljkovic, Srdjan S. Nerenz, David R. Kessler, Larry Jarvik, Jeffrey G. TI Effect of Comorbid Knee and Hip Osteoarthritis on Longitudinal Clinical and Health Care Use Outcomes in Older Adults With New Visits for Back Pain SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Back pain; Comorbidity; Osteoarthritis; Patient outcome assessment; Rehabilitation ID PATIENT-REPORTED OUTCOMES; LUMBAR SPINE; RHEUMATIC CONDITIONS; RESEARCH PRIORITIES; AFRICAN-AMERICANS; UNITED-STATES; PREVALENCE; IMPACT; REPLACEMENT; DISORDERS AB Objective: To examine if a comorbid diagnosis of knee or hip osteoarthritis (OA) in older adults with new back pain visits is associated with long-term patient-reported outcomes and back-related health care use. Design: Prospective cohort study. Setting: Three integrated health systems forming the Back pain Outcomes using Longitudinal Data cohort. Participants: Participants (N=5155) were older adults (>= 65y) with a new visit for back pain and a complete electronic health record data. Interventions: Not applicable; we obtained OA diagnoses using diagnostic codes in the electronic health record 12 months prior to the new back pain visit. Main Outcome Measures: The Roland-Morris Disability Questionnaire (RDQ) and the EuroQol-5D (EQ-5D) were key patient-reported outcomes. Health care use, measured by relative-value units (RVUs), was summed for the 12 months after the initial visit. We used linear mixed-effects models to model patient-reported outcomes. We also used generalized linear models to test the association between comorbid knee or hip OA and total back-related RVUs. Results: Of the 5155 participants, 368 (7.1%) had a comorbid knee OA diagnosis, and 94 (1.8%) had a hip OA diagnosis. Of the participants, 4711 (91.4%) had neither knee nor hip OA. In adjusted models, the 12-month RDQ score was 1.23 points higher (95% confidence interval [CI], 0.72-1.74) for patients with knee OA and 1.26 points higher (95% CI, 0.24-2.27) for those with hip OA than those without knee or hip OA, respectively. A lower EQ-5D score was found among participants with knee OA (.02 lower; 95% CI, -.04 to -.01) and hip OA diagnoses (.03 lower; 95% CI,-.05 to -.01) compared with those without knee or hip OA, respectively. Comorbid knee or hip OA was not significantly associated with total 12-month back-related resource use. Conclusions: Comorbid knee or hip OA in older adults with a new back pain visit was associated with modestly worse long-term disability and health-related quality of life. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Rundell, Sean D.; Suri, Pradeep; Friedly, Janna L.] Univ Washington, Dept Rehabil Med, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. [Rundell, Sean D.; Suri, Pradeep; Friedly, Janna L.; Gold, Laura S.; Bauer, Zoya; Jarvik, Jeffrey G.] Univ Washington, Comparat Effectiveness Cost & Outcomes Res Ctr, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. [Goode, Adam P.] Duke Univ, Dept Orthopaed, Durham, NC USA. [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Heagerty, Patrick J.; Comstock, Bryan A.] Univ Washington, Ctr Biomed Stat, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. [Gold, Laura S.; Bauer, Zoya; Jarvik, Jeffrey G.] Univ Washington, Dept Radiol, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. [Avins, Andrew L.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Nedeljkovic, Srdjan S.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA. [Nedeljkovic, Srdjan S.] Harvard Vanguard Med Associates, Spine Unit, Boston, MA USA. [Nerenz, David R.] Henry Ford Hosp, Inst Neurosci, Detroit, MI 48202 USA. [Kessler, Larry; Jarvik, Jeffrey G.] Univ Washington, Dept Hlth Serv, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. [Jarvik, Jeffrey G.] Univ Washington, Dept Neurol Surg, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. RP Rundell, SD (reprint author), Univ Washington, Box 359455,4333 Brooklyn Ave NE, Seattle, WA 98105 USA. EM srundell@uw.edu FU Agency for Healthcare Research and Quality [1R01HS01922201, 1R01HS022972-01]; K12 grant from Agency for Healthcare Research and Quality [1K12HS022982-01] FX Supported by the Agency for Healthcare Research and Quality (grant nos. 1R01HS01922201 and 1R01HS022972-01), and a K12 grant from the Agency for Healthcare Research and Quality (grant no. 1K12HS022982-01). NR 49 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JAN PY 2017 VL 98 IS 1 BP 43 EP 50 DI 10.1016/j.apmr.2016.06.022 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA EI4JN UT WOS:000392460000005 PM 27519927 ER PT J AU Dizon, M Linos, E Arron, ST Abuabara, K de Luzuriaga, AMR Jin, C Boscardin, WJ Chren, MM AF Dizon, M. Linos, E. Arron, S. T. Abuabara, K. de Luzuriaga, A. M. Ruiz Jin, C. Boscardin, W. J. Chren, M. -M. TI Comparisons of patients' satisfaction should take expectations into account SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Letter ID CARE C1 [Dizon, M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Linos, E.; Arron, S. T.; Abuabara, K.; Chren, M. -M.] Univ Calif San Francisco, Dept Dermatol, Program Clin Res, San Francisco, CA 94143 USA. [Jin, C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Boscardin, W. J.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Arron, S. T.; Chren, M. -M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [de Luzuriaga, A. M. Ruiz] Univ Chicago, Dept Med, Dermatol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA. RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, Program Clin Res, San Francisco, CA 94143 USA.; Chren, MM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM chrenm@ucsf.edu OI Dizon, Matthew/0000-0001-6747-5973 FU University of California; San Francisco Resource Allocation Program for Trainees (RAPtr); San Francisco Resource Allocation Program (RAP); National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health [R01 AR 054983, K24 AR052667] FX This study was supported, in part, by the University of California, San Francisco Resource Allocation Program for Trainees (RAPtr), University of California, San Francisco Resource Allocation Program (RAP) and grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (R01 AR 054983 and K24 AR052667). NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JAN PY 2017 VL 176 IS 1 BP 252 EP 254 PG 3 WC Dermatology SC Dermatology GA EI4OV UT WOS:000392474100062 PM 27203511 ER PT J AU George, MD Shah, R Kreider, M Miller, WT Merkel, PA Werth, VP AF George, M. D. Shah, R. Kreider, M. Miller, W. T., Jr. Merkel, P. A. Werth, V. P. TI Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Letter ID GENE 5; MANIFESTATIONS; POLYMYOSITIS C1 [George, M. D.; Merkel, P. A.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Miller, W. T., Jr.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Shah, R.; Kreider, M.] Univ Penn, Div Pulm & Crit Care Med, Philadelphia, PA 19104 USA. [Shah, R.] Univ Calif San Francisco, Div Pulm Allergy & Crit Care Med, San Francisco, CA 94143 USA. [Merkel, P. A.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP George, MD (reprint author), Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. EM michael.george@uphs.upenn.edu OI George, Michael/0000-0002-0398-2308 FU National Institutes of Health [NIH 5T32AR007442-28, NIH R21 AR066286]; Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) FX M.D.G. is supported by the National Institutes of Health (NIH 5T32AR007442-28). V.P.W. is supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and by the National Institutes of Health (NIH R21 AR066286). The funders had no involvement in the study design, data collection, data analysis, manuscript preparation and/or publication decisions. NR 11 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JAN PY 2017 VL 176 IS 1 BP 262 EP 264 DI 10.1111/bjd.14771 PG 3 WC Dermatology SC Dermatology GA EI4OV UT WOS:000392474100065 PM 27229750 ER PT J AU Walling, AM Ahluwalia, SC Wenger, NS Booth, M Roth, CP Lorenz, K Kanwal, F Dy, S Asch, SM AF Walling, A. M. Ahluwalia, S. C. Wenger, N. S. Booth, M. Roth, C. P. Lorenz, K. Kanwal, F. Dy, S. Asch, S. M. CA Palliative Care Cirrhosis Quality TI Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Palliative care; End-stage liver disease; Quality ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; APPROPRIATENESS METHOD; HOSPITALIZED-PATIENTS; ADVANCED CANCER; HEALTH-CARE; MANAGEMENT; OUTCOMES; DEATH AB There are guidelines for the medical management of cirrhosis and associated quality indicators (QIs), but QIs focusing on standards for palliative aspects of care are needed. We convened a 9-member, multidisciplinary expert panel and used RAND/UCLA modified Delphi methods to develop palliative care quality indicators for patients with cirrhosis. Experts were provided with a report based on a systematic review of the literature that contained evidence concerning the proposed candidate QIs. Panelists rated QIs prior to a planned meeting using a standard 9-point RAND appropriateness scale. These ratings guided discussion during a day-long phone conference meeting, and final ratings were then provided by panel members. Final QI scores were computed and QIs with a final median score of greater than or equal to 7, and no disagreement was included in the final set. Among 28 candidate QIs, the panel rated 19 as valid measures of quality care. These 19 quality indicators cover care related to information and care planning (13) and supportive care (6). These QIs are evidence-based process measures of care that may be useful to improve the quality of palliative care. Research is needed to better understand the quality of palliative care provided to patients with cirrhosis. C1 [Walling, A. M.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Walling, A. M.; Wenger, N. S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Walling, A. M.; Ahluwalia, S. C.; Wenger, N. S.; Booth, M.; Roth, C. P.] RAND Hlth, Santa Monica, CA 90401 USA. [Kanwal, F.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Kanwal, F.] Baylor Coll Med, Div Gastroenterol, Houston, TX 77030 USA. [Dy, S.] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. [Lorenz, K.; Asch, S. M.] Palo Alto VA Hlth Syst, Palo Alto, CA USA. [Lorenz, K.; Asch, S. M.] Div Gen Med Disciplines, Stanford, CA USA. [Ahluwalia, S. C.] UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Walling, AM (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA.; Walling, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.; Walling, AM (reprint author), RAND Hlth, Santa Monica, CA 90401 USA. EM awalling@mednet.ucla.edu FU HIV/Hepatitis QUERI; Veterans Administration; VA HSRD [PPO 14-372]; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant [UL1TR000124]; NIH loan repayment program FX This project was supported by the HIV/Hepatitis QUERI, Veterans Administration and VA HSR&D (PPO 14-372). Dr. Walling was also supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number (UL1TR000124) and the NIH loan repayment program. NR 34 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 2017 VL 62 IS 1 BP 84 EP 92 DI 10.1007/s10620-016-4339-3 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI2JE UT WOS:000392312200015 PM 27804005 ER PT J AU Greenstein, RJ Cameron, DW Brown, ST AF Greenstein, Robert J. Cameron, D. William Brown, Sheldon T. TI A Data-Based Hypothesis Explicating Thiopurine Therapeutic Failure in Biologic-Naive UC SO DIGESTIVE DISEASES AND SCIENCES LA English DT Letter ID AVIUM SUBSPECIES PARATUBERCULOSIS; PULMONARY TUBERCULOSIS; MYCOBACTERIUM; 6-MERCAPTOPURINE; DISEASE; DRUGS C1 [Greenstein, Robert J.; Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Cameron, D. William] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. RP Greenstein, RJ (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. EM bgaxis@aol.com NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 2017 VL 62 IS 1 BP 282 EP 283 DI 10.1007/s10620-016-4360-6 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI2JE UT WOS:000392312200037 PM 27812848 ER PT J AU Alday, PH Doggett, JS AF Alday, P. Holland Doggett, Joseph Stone TI Drugs in development for toxoplasmosis: advances, challenges, and current status SO DRUG DESIGN DEVELOPMENT AND THERAPY LA English DT Review DE Toxoplasma gondii; therapeutics; preclinical medicine; experimental medicine; mechanism of action; Apicomplexa ID PROTEIN-KINASE 1; CENTRAL-NERVOUS-SYSTEM; IN-VIVO ACTIVITIES; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CELL TRANSPLANT RECIPIENTS; HIGH-AFFINITY INHIBITOR; HIV-INFECTED PATIENTS; FATTY-ACID SYNTHESIS; PLASMODIUM-FALCIPARUM; UNITED-STATES AB Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis. C1 [Alday, P. Holland; Doggett, Joseph Stone] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Doggett, Joseph Stone] Portland VA Med Ctr, Portland, OR USA. RP Doggett, JS (reprint author), Vet Affairs Med Ctr, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA. EM doggettj@ohsu.edu FU United States Department of Veterans Affairs Biomedical Laboratory Research and Development [BX002440] FX This work was supported by Career Development Award #BX002440 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development. NR 172 TC 0 Z9 0 U1 3 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-8881 J9 DRUG DES DEV THER JI Drug Des. Dev. Ther. PY 2017 VL 11 BP 273 EP 293 DI 10.2147/DDDT.S60973 PG 21 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EI7CV UT WOS:000392656000001 PM 28182168 ER PT J AU Simonetti, JA Rowhani-Rahbar, A Rivara, FP AF Simonetti, Joseph A. Rowhani-Rahbar, Ali Rivara, Frederick P. TI The Road Ahead for Personalized Firearms SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Simonetti, Joseph A.] Univ Colorado, Sch Med, Div Gen Internal Med, Denver, CO USA. [Simonetti, Joseph A.] Vet Affairs Eastern Colorado Healthcare Syst, Hosp Med Program, Denver, CO USA. [Rowhani-Rahbar, Ali; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. [Rowhani-Rahbar, Ali] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA. [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. RP Simonetti, JA (reprint author), Denver VA Med Ctr, 4E-129,1055 Clermont St, Denver, CO 80220 USA. EM joseph.simonetti@ucdenver.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2017 VL 177 IS 1 BP 9 EP 10 DI 10.1001/jamainternmed.2016.6718 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EI0WN UT WOS:000392196200003 PM 27893047 ER PT J AU Bagenski, AL Sink, J Rusiecki, J AF Bagenski, Amy L. Sink, Jacquelyn Rusiecki, Jennifer TI Thinking Beyond the Ostomy A Teachable Moment SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID HUNTINGTONS-DISEASE C1 [Bagenski, Amy L.] Univ Pittsburgh, Med Ctr, Presbyterian Montefiore Hosp, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sink, Jacquelyn] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sink, Jacquelyn] Metropolitan Hosp Ctr, New York Med Ctr, New York, NY 10029 USA. [Rusiecki, Jennifer] Univ Chicago, Gen Internal Med, Chicago, IL 60637 USA. RP Bagenski, AL (reprint author), UPMC Presbyterian Montefiore Hosp, 200 Lothrop St, Pittsburgh, PA 15213 USA.; Bagenski, AL (reprint author), VA Pittsburgh Healthcare Syst, 200 Lothrop St, Pittsburgh, PA 15213 USA. EM bagenskial@upmc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2017 VL 177 IS 1 BP 13 EP 14 DI 10.1001/jamainternmed.2016.6868 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EI0WN UT WOS:000392196200005 PM 27820609 ER PT J AU Okonkwo, OC Asthana, S AF Okonkwo, Ozioma C. Asthana, Sanjay TI Dementia Trends in the United States Read Up and Weigh Inle SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID ALZHEIMERS-DISEASE C1 [Okonkwo, Ozioma C.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Okonkwo, Ozioma C.; Asthana, Sanjay] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Okonkwo, Ozioma C.] Univ Wisconsin, Wisconsin Alzheimers Inst, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Okonkwo, Ozioma C.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Asthana, S (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Geriatr Res Educ & Clin Ctr, 2870 Univ Ave,Ste 106, Madison, WI 53705 USA. EM sa@medicine.wisc.edu FU National Institute on Aging (NIA) [K23 AG045957, P50 AG033514] FX This work was supported by National Institute on Aging (NIA) grants K23 AG045957 and P50 AG033514. NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2017 VL 177 IS 1 BP 58 EP 60 DI 10.1001/jamainternmed.2016.7073 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA EI0WN UT WOS:000392196200016 PM 27893015 ER PT J AU Danielson, CK Cohen, JR Adams, ZW Youngstrom, EA Soltis, K Amstadter, AB Ruggiero, KJ AF Danielson, Carla Kmett Cohen, Joseph R. Adams, Zachary W. Youngstrom, Eric A. Soltis, Kathryn Amstadter, Ananda B. Ruggiero, Kenneth J. TI Clinical Decision-Making Following Disasters: Efficient Identification of PTSD Risk in Adolescents SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY LA English DT Article DE Stress disorders; Evidence-based assessment; Traumatic stress; Adolescents; PTSD risk assessment ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; DEPRESSIVE REACTIONS; NATIONAL SAMPLE; INTERNALIZING SYMPTOMS; HURRICANE-ANDREW; BIPOLAR DISORDER; SUBSTANCE-ABUSE; TASK BART; CHILDREN AB The present study aimed to utilize a Receiver Operating Characteristic (ROC) approach in order to improve clinical decision-making for adolescents at risk for the development of psychopathology in the aftermath of a natural disaster. Specifically we assessed theoretically-driven individual, interpersonal, and event-related vulnerability factors to determine which indices were most accurate in forecasting PTSD. Furthermore, we aimed to translate these etiological findings by identifying clinical cut-off recommendations for relevant vulnerability factors. Our study consisted of structured phone-based clinical interviews with 2000 adolescent-parent dyads living within a 5-mile radius of tornados that devastated Joplin, MO, and northern Alabama in Spring 2011. Demographics, tornado incident characteristics, prior trauma, mental health, and family support and conflict were assessed. A subset of youth completed two behavioral assessment tasks online to assess distress tolerance and risk-taking behavior. ROC analyses indicated four variables that significantly improved PTSD diagnostic efficiency: Lifetime depression (AUC = .90), trauma history (AUC = .76), social support (AUC = .70), and family conflict (AUC = .72). Youth were 2-3 times more likely to have PTSD if they had elevated scores on any of these variables. Of note, event-related characteristics (e.g., property damage) were not related to PTSD diagnostic status. The present study adds to the literature by making specific recommendations for empirically-based, efficient disaster-related PTSD assessment for adolescents following a natural disaster. Implications for practice and future trauma-related developmental psychopathology research are discussed. C1 [Danielson, Carla Kmett; Adams, Zachary W.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St, Charleston, SC 29425 USA. [Cohen, Joseph R.] Univ Illinois, Dept Psychol, Champaign, IL USA. [Youngstrom, Eric A.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [Soltis, Kathryn] Univ Memphis, Dept Psychol, Memphis, TN 38152 USA. [Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. [Ruggiero, Kenneth J.] Med Univ South Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Danielson, CK (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St, Charleston, SC 29425 USA. EM danielso@musc.edu FU National Institute of Mental Health (NIMH) [1R21MH086313, 1R01MH081056]; National Institute on Drug Abuse (NIDA) [R01DA031285]; National Institute on Alcohol Abuse and Alcoholism (NIAAA) [P50AA010761]; NIMH [T32MH018869] FX This work was supported by 1R21MH086313 (PI: Danielson) and 1R01MH081056 (PI: Ruggiero) from the National Institute of Mental Health (NIMH). The preparation of this manuscript was supported by R01DA031285 (PI: Danielson) from the National Institute on Drug Abuse (NIDA), P50AA010761 (PI: Becker) from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and T32MH018869 (PIs: Danielson & Kilpatrick) from the NIMH. Views expressed herein are those of the authors and do not necessarily represent the official views of NIMH, NIDA, or NIAAA. NR 78 TC 0 Z9 0 U1 15 U2 15 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0627 EI 1573-2835 J9 J ABNORM CHILD PSYCH JI J. Abnorm. Child Psychol. PD JAN PY 2017 VL 45 IS 1 BP 117 EP 129 DI 10.1007/s10802-016-0159-3 PG 13 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA EH9DM UT WOS:000392071900010 PM 27103002 ER PT J AU Steinhilber, S Estrada, CA AF Steinhilber, Starr Estrada, Carlos A. TI Exercises in Clinical Reasoning: A Retrospective SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID ABDOMINAL-PAIN; WOMAN C1 [Steinhilber, Starr; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Steinhilber, Starr; Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Steinhilber, S (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA. EM ssteinhilber@uabmc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2017 VL 32 IS 1 BP 1 EP 2 DI 10.1007/s11606-016-3906-9 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0ZB UT WOS:000392203200001 PM 27798776 ER PT J AU Gupta, N Feingold, K Dhaliwal, G AF Gupta, Neha Feingold, Kenneth Dhaliwal, Gurpreet TI Stressing Signal Versus Noise: An Exercise in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical reasoning; problem representation; signal detection theory ID PARANEOPLASTIC CUSHINGS-SYNDROME; CELL LUNG-CANCER C1 [Gupta, Neha; Feingold, Kenneth; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, 505 Parnasus Ave, San Francisco, CA 94143 USA. [Feingold, Kenneth; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Gupta, N (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnasus Ave, San Francisco, CA 94143 USA. EM neha616@gmail.com NR 12 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2017 VL 32 IS 1 BP 122 EP 126 DI 10.1007/s11606-016-3887-8 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0ZB UT WOS:000392203200026 PM 27798784 ER PT J AU Judson, T Mihara, K AF Judson, Timothy Mihara, Kip TI Minocycline-induced Hyperpigmentation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical image; dermatology; pharmaceutical care C1 [Mihara, Kip] San Francisco VA Med Ctr, Emergency Dept, 4150 Clement St,Mail Code 111A3, San Francisco, CA 94121 USA. [Judson, Timothy; Mihara, Kip] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. RP Mihara, K (reprint author), San Francisco VA Med Ctr, Emergency Dept, 4150 Clement St,Mail Code 111A3, San Francisco, CA 94121 USA. EM Kip.mihara@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2017 VL 32 IS 1 BP 133 EP 133 DI 10.1007/s11606-016-3735-x PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0ZB UT WOS:000392203200029 PM 27173498 ER PT J AU Storzbach, D Twamley, EW Roost, MS Golshan, S Williams, RM O'Neil, M Jak, AJ Turner, AP Kowalski, HM Pagulayan, KF Huckans, M AF Storzbach, Daniel Twamley, Elizabeth W. Roost, Mai S. Golshan, Shahrokh Williams, Rhonda M. O'Neil, Maya Jak, Amy J. Turner, Aaron P. Kowalski, Halina M. Pagulayan, Kathleen F. Huckans, Marilyn TI Compensatory Cognitive Training for Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans With Mild Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE cognitive training; mild traumatic brain injury; OEF/OIF/OND Veterans ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; MEMORY QUESTIONNAIRE PRMQ; OF-THE-LITERATURE; NEUROPSYCHOLOGICAL OUTCOMES; RETROSPECTIVE MEMORY; MILITARY PERSONNEL; OIF/OEF VETERANS; LATENT STRUCTURE; NORMATIVE DATA AB Objective: The purpose of the study was to evaluate the efficacy of group-based compensatory cognitive training (CCT) for Operation Enduring Freedom (OEF)/Operation Iraqi Freedom(OIF)/Operation New Dawn (OND) Veterans with a history of mild traumatic brain injury. Method: One hundred nineteen OEF/OIF/OND Veterans with history of mild traumatic brain injury participated at 3 sites, and 50 of the Veterans were randomized to CCT group, while 69 Veterans were randomized to the usual care control group. The CCT group participated in 10 weeks of CCT. Both CCT and usual care groups were assessed at baseline, 5 weeks (midway through CCT), 10 weeks (immediately following CCT), and 15 weeks (5-week follow-up) on measures of subjective cognitive complaints, use of cognitive strategies, psychological functioning, and objective cognitive performance. Results: Veterans who participated in CCT reported significantly fewer cognitive and memory difficulties and greater use of cognitive strategies. They also demonstrated significant improvements on neurocognitive tests of attention, learning, and executive functioning, which were 3 of the cognitive domains targeted in CCT. Conclusions: Findings indicate that training in compensatory cognitive strategies facilitates behavioral change (ie, use of cognitive strategies) as well as both subjective and objective improvements in targeted cognitive domains. C1 [Storzbach, Daniel; Roost, Mai S.; O'Neil, Maya; Kowalski, Halina M.; Huckans, Marilyn] VA Portland Healthcare Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Storzbach, Daniel; O'Neil, Maya; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Storzbach, Daniel] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Twamley, Elizabeth W.; Jak, Amy J.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Twamley, Elizabeth W.; Golshan, Shahrokh; Jak, Amy J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Williams, Rhonda M.; Turner, Aaron P.; Pagulayan, Kathleen F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Williams, Rhonda M.; Turner, Aaron P.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Pagulayan, Kathleen F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Storzbach, D (reprint author), VA Portland Healthcare Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM daniel.storzbach@va.gov FU VA Merit Review Award [D7217-R]; Veterans Affairs Health Services Research and Development Center of Innovation grant; Center to Improve Veteran Involvement in Care [CIN 13-404]; Agency for Healthcare Research and Quality [1 K12 HS019456 01] FX This work was supported by VA Merit Review Award #D7217-R to Daniel Storzbach and Elizabeth Twamley from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development. Author Maya O'Neil is currently receiving funding from a Veterans Affairs Health Services Research and Development Center of Innovation grant, Center to Improve Veteran Involvement in Care, Award #CIN 13-404, and an Agency for Healthcare Research and Quality-funded PCOR K12 award to MEO (#1 K12 HS019456 01). For the remaining authors, none were declared. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Medical Centers in Portland, Oregon, San Diego, California, and Seattle, Washington. NR 49 TC 2 Z9 2 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2017 VL 32 IS 1 BP 16 EP 24 DI 10.1097/HTR.0000000000000228 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EI2GH UT WOS:000392304400002 PM 27022961 ER PT J AU Peltz, CB Gardner, RC Kenney, K Diaz-Arrastia, R Kramer, JH Yaffe, K AF Peltz, Carrie B. Gardner, Raquel C. Kenney, Kimbra Diaz-Arrastia, Ramon Kramer, Joel H. Yaffe, Kristine TI Neurobehavioral Characteristics of Older Veterans With Remote Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE cognitive impairment; psychiatric disorders; traumatic brain injury; veterans ID LONG-TERM OUTCOMES; ALZHEIMERS-DISEASE; HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; RISK; DEPRESSION; PREVALENCE; SOLDIERS; HISTORY; SCALE AB Objective: While traumatic brain injury (TBI) is common across the life span, the detailed neurobehavioral characteristics of older adults with prior TBI remain unclear. Our goal was to compare the clinical profile of older independently living veterans with and without prior TBI. Setting: Two veterans' retirement communities. Participants: Seventy-five participants with TBI and 71 without (mean age = 78 years). Design: Cross-sectional. Main Measures: TBI history was determined by the Ohio State University TBI Questionnaire. We assessed psychiatric and medical history via interviews and chart review and conducted measures assessing functional/lifestyle, psychiatric, and cognitive outcomes. Regression analyses (adjusted for demographics, diabetes, prior depression, substance abuse, and site) were performed to compare between TBI and non-TBI participants. Results: Compared with veterans without TBI, those with TBI had greater functional impairment (adjusted P = .05), endorsed more current depressive (adjusted P = .04) and posttraumatic stress disorder symptoms (adjusted P = .01), and had higher rates of prior depression and substance abuse (both adjusted Ps < .01). While composite memory and language scores did not differ between groups, participants with TBI performed worse on tests of executive functioning/processing speed (adjusted P = .01). Conclusions: Our results suggest that TBI may have adverse long-term neurobehavioral consequences and that TBI-exposed adults may require careful screening and follow-up. C1 [Peltz, Carrie B.; Gardner, Raquel C.; Yaffe, Kristine] San Francisco VA Med Ctr, 4150 Clement St,116H, San Francisco, CA 94121 USA. [Peltz, Carrie B.; Yaffe, Kristine] NCIRE, San Francisco, CA USA. [Gardner, Raquel C.; Kramer, Joel H.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kenney, Kimbra; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Rockville, MD USA. RP Peltz, CB (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116H, San Francisco, CA 94121 USA. EM carrie.peltz2@va.gov FU Department of Defense [W81XWH-12-1-0581]; National Institute of Neurological Disorders and Stroke [K23 NS095755]; American Federation for Aging Research; UCSF Pepper Center; Center for Neuroscience and Regenerative Medicine; Military Clinical Neurosciences Center of Excellence; Department of Defense; VA [W81XWH-12-PHTBI-CENC, W81XHW-14-2-0137]; NIA [K24 AG031155] FX This project was supported by the Department of Defense (W81XWH-12-1-0581). R.C.G. receives support from the National Institute of Neurological Disorders and Stroke (K23 NS095755), the American Federation for Aging Research, and the UCSF Pepper Center. K.K. and R.D.-A. receive support from the Center for Neuroscience and Regenerative Medicine and the Military Clinical Neurosciences Center of Excellence. K. Y. receives support from the Department of Defense and VA (W81XWH-12-PHTBI-CENC, W81XHW-14-2-0137) and NIA (K24 AG031155). The authors thank their research participants, the Armed Forces Retirement Home in Washington, District of Columbia, the Veterans Home of California in Yountville, California, and their dedicated study staff including Kim Kelley, Ross Passo, and Leah Harburg. NR 44 TC 2 Z9 2 U1 8 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2017 VL 32 IS 1 BP E8 EP E15 DI 10.1097/HTR.0000000000000245 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EI2GH UT WOS:000392304400015 PM 27323220 ER PT J AU Ge, LS Vujanovic, NL AF Ge, Lisheng Vujanovic, Nikola L. TI Soluble TNF Regulates TACE via AP-2 alpha Transcription Factor in Mouse Dendritic Cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ALPHA-CONVERTING-ENZYME; NECROSIS-FACTOR-ALPHA; NATURAL-KILLER-CELLS; FACTOR-RECEPTOR; HUMAN-MELANOMA; EGFR LIGANDS; CANCER CELLS; EXPRESSION; GROWTH; INFLAMMATION AB Dendritic cells (DCs), the essential immunoregulatory and APCs, are major producers of the central mediator of inflammation, soluble TNF-alpha (sTNF). sTNF is generated by TNF-alpha converting enzyme (TACE) proteolytic release of the transmembrane TNF (tmTNF) ectodomain. The mechanisms of TACE and sTNF regulation in DCs remain elusive. This study newly defines that sTNF regulates TACE in mouse DCs by engaging the AP-2 alpha transcription factor. We found that the expression of AP-2 alpha was higher, whereas the expression and activity of TACE were lower, in wild-type DCs (wtDCs) than in TNF knockout (TNFko) DCs. Exogenous sTNF rapidly and simultaneously induced increases of AP-2 alpha expression and decreases of TACE expression and activity in wtDCs and TNFko DCs, indicating that AP-2 alpha and TACE are inversely dependent on sTNF and are functionally associated. To define this functional association, we identified an AP-2 alpha binding site in TACE promoter and demonstrated, using EMSAs and chromatin immunoprecipitation assays, that AP-2 alpha could bind to TACE promoter in a TNF-dependent manner. Additionally, sTNF simultaneously enhanced AP-2 alpha expression and decreased TACE promoter luciferase activity in DCs. Similarly, transfection of AP-2 alpha cDNA decreased TACE promoter luciferase activity, TACE expression, and TACE enzymatic activity in wtDCs or TNFko DCs. In contrast, transfection of AP-2 alpha small interfering RNA increased TACE promoter luciferase activity, TACE expression, and TACE enzymatic activity in wtDCs. These results show that TACE is a target of, and is downregulated by, sTNF-induced AP-2 alpha transcription factor in DCs. C1 [Ge, Lisheng; Vujanovic, Nikola L.] Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15232 USA. [Vujanovic, Nikola L.] Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA 15232 USA. [Vujanovic, Nikola L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. RP Vujanovic, NL (reprint author), Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, G 17d,5117 Ctr Ave, Pittsburgh, PA 15213 USA. EM vujanovicnl@upmc.edu FU National Institutes of Health [R01 DE14775, R01 DE17150]; U.S. Department of Veterans Affairs Merit Award [1-I01-BX000993-01/VUJ-ONCA-053-12S] FX This work was supported by National Institutes of Health Grants R01 DE14775 and R01 DE17150 and by U.S. Department of Veterans Affairs Merit Award Grant 1-I01-BX000993-01/VUJ-ONCA-053-12S (to N.L.V.). NR 44 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2017 VL 198 IS 1 BP 417 EP 427 DI 10.4049/jimmunol.1600524 PG 11 WC Immunology SC Immunology GA EI3ON UT WOS:000392400800042 PM 27852742 ER PT J AU Mitsuki, YY Tuen, M Hioe, CE AF Mitsuki, Yu-Ya Tuen, Michael Hioe, Catarina E. TI Differential effects of HIV transmission from monocyte-derived dendritic cells vs. monocytes to IL-17(+)CD4(+) T cells SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE Th17; Th1; HIV envelope ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVATED-RECEPTOR-GAMMA; HUMAN TH17 CELLS; IMMUNE ACTIVATION; INFECTED PATIENTS; TYPE-1 INFECTION; TRANS-INFECTION; CCR5 LIGANDS; HELPER-CELLS; TH2 CELLS AB HIV infection leads to CD4 helper T cell (Th) loss, but not all Th cells are equally depleted. The contribution of other immune cells in the Th depletion also remains unclear. This study investigates HIV transmission from monocyte-derived dendritic cells (MDDCs) vs. monocytes to Th17 and Th1 cells using an allogeneic coculture model. The addition of HIV to MDDCs increased the expression of the negative regulatory molecule PD-L1 and decreased the expression of the activation markers HLA-DR and CD86, whereas the virus up-regulated HLA-DR and CD86, but not PD-L1, on monocytes. Coculturing of CD4(+) T cells with MDDCs pretreated with HIV led to the decline of Th17, but not Th1, responses. In contrast, pretreatment of monocytes with HIV increased Th17 without affecting Th1 responses. The enhanced Th17 responses in the cocultures with HIV-treated monocytes were also accompanied by high numbers of virus-infected CD4(+) T cells. The Th17 expansion arose from memory CD4(+) T cells with minimal contribution from naive CD4(+) T cells. The Th17-enhancing activity was mediated by the HIV envelope and did not require productive virus infection. Comparison of MDDCs and monocytes further showed that, although HIV-treated MDDCs reduced Th proliferation and increased the activation of the apoptosis mediator caspase-3, HIV-treated monocytes enhanced Th proliferation without increasing the active caspase-3 levels. This study indicates the potential role of distinct myeloid cell populations in shaping Th17 responses during HIV infection. C1 [Mitsuki, Yu-Ya; Hioe, Catarina E.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, One Gustave L Levy Pl, New York, NY 10029 USA. [Tuen, Michael] Vet Affairs New York Harbor Healthcare Syst, New York, NY USA. [Tuen, Michael] NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA. [Hioe, Catarina E.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Hioe, CE (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, One Gustave L Levy Pl, New York, NY 10029 USA. EM catarina.hioe@mssm.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Department of Veterans Affairs Merit Review Award; U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases [AI093210, AI102740, AI114520] FX This study was supported in part by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, the Department of Veterans Affairs Merit Review Award (C.E.H.) and by U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases Grants AI093210, AI102740, and AI114520 (to C.E.H.). We thank Dr. Paul D. Bieniasz (Aaron Diamond AIDS Research Center) for providing the MT-4TMZR5 cell line, Dr. Susan Zolla-Pazner (Icahn School of Medicine at Mount Sinai) for providing monoclonal anti-HIV envelope Abs, and Ms. Radhika Wikramanayake for editing the manuscript. NR 65 TC 1 Z9 1 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JAN PY 2017 VL 101 IS 1 BP 339 EP 350 DI 10.1189/jlb.4A0516-216R PG 12 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA EI0FN UT WOS:000392148500031 PM 27531931 ER PT J AU Counts, SE Ikonomovic, MD Mercado, N Vega, IE Mufson, EJ AF Counts, Scott E. Ikonomovic, Milos D. Mercado, Natosha Vega, Irving E. Mufson, Elliott J. TI Biomarkers for the Early Detection and Progression of Alzheimer's Disease SO NEUROTHERAPEUTICS LA English DT Review DE Alzheimer's disease; Mild cognitive impairment; Biomarker; Cerebrospinal fluid; Positron emission tomography; Amyloid ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; CEREBROSPINAL-FLUID BIOMARKERS; CEREBRAL AMYLOID ANGIOPATHY; NEUROIMAGING INITIATIVE SUBJECTS; LINKED-IMMUNOSORBENT-ASSAY; BETA-PROTEIN PRECURSOR; MEMORY CLINIC COHORT; PHF-TAU RADIOLIGAND AB The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may reflect the fact that the enrolled participants in clinical trials are already too advanced to derive a clinical benefit. Thus, well-validated biomarkers for the early detection and accurate diagnosis of the preclinical stages of AD will be crucial for therapeutic advancement. The combinatorial use of biomarkers derived from biological fluids, such as cerebrospinal fluid (CSF), with advanced molecular imaging and neuropsychological testing may eventually achieve the diagnostic sensitivity and specificity necessary to identify people in the earliest stages of the disease when drug modification is most likely possible. In this regard, positive amyloid or tau tracer retention on positron emission tomography imaging, low CSF concentrations of the amyloid-beta 1-42 peptide, high CSF concentrations in total tau and phospho-tau, mesial temporal lobe atrophy on magnetic resonance imaging, and temporoparietal/precuneus hypometabolism or hypoperfusion on 18F-fluorodeoxyglucose positron emission tomography have all emerged as biomarkers for the progression to AD. However, the ultimate AD biomarker panel will likely involve the inclusion of novel CSF and blood biomarkers more precisely associated with confirmed pathophysiologic mechanisms to improve its reliability for detecting preclinical AD. This review highlights advancements in biological fluid and imaging biomarkers that are moving the field towards achieving the goal of a preclinical detection of AD. C1 [Counts, Scott E.; Mercado, Natosha; Vega, Irving E.] Michigan State Univ, Dept Translat Sci & Mol Med, Grand Rapids, MI USA. [Counts, Scott E.] Michigan State Univ, Dept Family Med, Grand Rapids, MI USA. [Counts, Scott E.] Mercy Hlth St Marys Hosp, Hauenstein Neurosci Ctr, Grand Rapids, MI USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Mufson, Elliott J.] Barrow Neurol Inst, Dept Neurobiol & Neurol, Phoenix, AZ 85013 USA. RP Mufson, EJ (reprint author), Barrow Neurol Inst, Dept Neurobiol & Neurol, Phoenix, AZ 85013 USA. EM elliott.mufson@dignityhealth.org FU National Institutes of Health [PO1AG14449, RO1AG043375, AG025204, AG052528, R21AG026032, R21AG042146]; Saint Mary's Foundation, Miles for Memories of Battle Creek, MI; Barrow Neurological Institute Barrow and Beyond FX This study was supported by National Institutes of Health grants PO1AG14449, RO1AG043375, AG025204, AG052528, R21AG026032, and R21AG042146; the Saint Mary's Foundation, Miles for Memories of Battle Creek, MI; and Barrow Neurological Institute Barrow and Beyond. NR 289 TC 0 Z9 0 U1 26 U2 26 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1933-7213 EI 1878-7479 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD JAN PY 2017 VL 14 IS 1 BP 35 EP 53 DI 10.1007/s13311-016-0481-z PG 19 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA EI2NW UT WOS:000392325200005 PM 27738903 ER PT J AU Gullbrand, SE Malhotra, NR Schaer, TP Zawacki, Z Martin, JT Bendigo, JR Milby, AH Dodge, GR Vresilovic, EJ Elliott, DM Mauck, RL Smith, LJ AF Gullbrand, S. E. Malhotra, N. R. Schaer, T. P. Zawacki, Z. Martin, J. T. Bendigo, J. R. Milby, A. H. Dodge, G. R. Vresilovic, E. J. Elliott, D. M. Mauck, R. L. Smith, L. J. TI A large animal model that recapitulates the spectrum of human intervertebral disc degeneration SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Goat; Caprine; Preclinical animal model; Disc degeneration; Chondroitinase ABC; Nucleotomy ID HUMAN LUMBAR DISC; NUCLEUS PULPOSUS; IN-VIVO; CHONDROITINASE-ABC; NEEDLE PUNCTURE; INJURY; GOAT; INJECTION; MOTION; CANINE AB Objective: The objective of this study was to establish a large animal model that recapitulates the spectrum of intervertebral disc degeneration that occurs in humans and which is suitable for pre-clinical evaluation of a wide range of experimental therapeutics. Design: Degeneration was induced in the lumbar intervertebral discs of large frame goats by either inti-adiscal injection of chondroitinase ABC (ChABC) over a range of dosages (0.1U, 1U or 5U) or subtotal nucleotomy. Radiographs were used to assess disc height changes over 12 weeks. Degenerative changes to the discs and endplates were assessed via magnetic resonance imaging (MRI), semi-quantitative histological grading, microcomputed tomography (mu CT), and measurement of disc biomechanical properties. Results: Degenerative changes were observed for all interventions that ranged from mild (0.1U ChABC) to moderate (1U ChABC and nucleotomy) to severe (5U ChABC). All groups showed progressive reductions in disc height over 12 weeks. Histological scores were significantly increased in the 1U and 5U ChABC groups. Reductions in T2 and T1 rho, and increased Pfirrmann grade were observed on MRI. Resorption and remodeling of the cortical honey endplate adjacent to ChABC-injected discs also occurred. Spine segment range of motion (ROM) was greater and compressive modulus was lower in 1U ChABC and nucleotomy discs compared to intact. Conclusions: A large animal model of disc degeneration was established that recapitulates the spectrum of structural, compositional and biomechanical features of human disc degeneration. This model may serve as a robust platform for evaluating the efficacy of therapeutics targeted towards varying degrees of disc degeneration. (C) 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Gullbrand, S. E.; Martin, J. T.; Bendigo, J. R.; Dodge, G. R.; Mauck, R. L.; Smith, L. J.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Gullbrand, S. E.; Martin, J. T.; Bendigo, J. R.; Milby, A. H.; Dodge, G. R.; Mauck, R. L.; Smith, L. J.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA USA. [Malhotra, N. R.; Bendigo, J. R.; Smith, L. J.] Univ Penn, Dept Neurosurg, 424 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA. [Schaer, T. P.; Zawacki, Z.] Univ Penn, Sch Vet Med, Comparat Orthopaed Res Lab, Kennett Sq, PA 19348 USA. [Vresilovic, E. J.] Penn State Univ, Penn State Hershey Bone & Joint Inst, Hershey, PA USA. [Elliott, D. M.] Univ Delaware, Dept Biomed Engn, Newark, DE USA. RP Smith, LJ (reprint author), Univ Penn, Dept Neurosurg, 424 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA. EM lachlans@mail.med.upenn.edu FU Department of Veterans Affairs (RRD) [I01RX00132]; Orthopaedic Research and Education Foundation; Sharpe Foundation; Departments of Neurosurgery and Orthopaedic Surgery at the University of Pennsylvania FX This work was supported by the Department of Veterans Affairs (RR&D I01RX00132). The authors would also like to acknowledge the Orthopaedic Research and Education Foundation (resident grant), the Sharpe Foundation, and the Departments of Neurosurgery and Orthopaedic Surgery at the University of Pennsylvania for financial support. Core equipment used in this study was provided by the Penn Center for Musculoskeletal Disorders (NIH P30AR050950) and the Center for Magnetic Resonance Imaging & Spectroscopy (CAMRIS). The authors would also like to acknowledge the veterinary staff at the New Bolton Center for their assistance with animal care and management throughout the study. NR 53 TC 0 Z9 0 U1 11 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 EI 1522-9653 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD JAN PY 2017 VL 25 IS 1 BP 146 EP 156 DI 10.1016/j.joca.2016.08.006 PG 11 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA EI2XN UT WOS:000392353100019 PM 27568573 ER PT J AU Halbert, CH Gattoni-Celli, S Savage, S Prasad, SM Kittles, R Briggs, V Delmoor, E Rice, LJ Jefferson, M Johnson, JC AF Halbert, Chanita Hughes Gattoni-Celli, Sebastiano Savage, Stephen Prasad, Sandip M. Kittles, Rick Briggs, Vanessa Delmoor, Ernestine Rice, LaShanta J. Jefferson, Melanie Johnson, Jerry C. TI Ever and Annual Use of Prostate Cancer Screening in African American Men SO AMERICAN JOURNAL OF MENS HEALTH LA English DT Article DE PSA testing; health care utilization; health education ID HEALTH-CARE; DECISION-MAKING; COLLECTIVE EFFICACY; SOCIETY GUIDELINES; RACIAL-DIFFERENCES; TRIAL; KNOWLEDGE; WOMEN; RATES; COMPREHENSION AB Since prostate cancer continues to disproportionately affect African American men in terms of incidence, morbidity, and mortality, prostate-specific antigen (PSA) screening plays an important role in early detection, especially when men engage in informed decision making to accept or decline this test. The authors evaluated utilization of PSA testing among African American men based on factors that are important components of making informed decisions. Utilization of PSA testing was evaluated based on whether men had ever had PSA testing and PSA testing during the past year in a community-based sample of African American men ages 50 to 75 (n = 132). Overall, 64% of men (n = 85) reported that they had ever had a PSA test; the mean (SD) age for first use of PSA testing was 47.7 (SD = 7.4). The likelihood of ever having a PSA test increased significantly with physician communication (odds ratio [OR] = 14.2; 95% confidence interval [CI] = 4.20, 48.10; p = .0001) and with having an annual household income that was greater than $20,000 (OR = 9.80; 95% CI = 3.15, 30.51; p = 0001). The odds of ever having a PSA test were also decreased with each unit increase in future temporal orientation (OR = 0.66; 95% CI = 0.47, 0.93; p = .02). Of the men who had ever had PSA testing, 57% were screened during the past year. Only health insurance status had a significant independent association with having annual PSA testing (OR = 5.10; 95% CI = 1.67, 15.60; p = .004). Different factors were associated significantly with ever having PSA testing and annual testing among African American men. African American men may not be making an informed decision about prostate cancer screening. C1 [Halbert, Chanita Hughes; Gattoni-Celli, Sebastiano; Savage, Stephen; Prasad, Sandip M.; Rice, LaShanta J.; Jefferson, Melanie] Med Univ South Carolina, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Halbert, Chanita Hughes; Gattoni-Celli, Sebastiano; Savage, Stephen; Prasad, Sandip M.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Kittles, Rick] Univ Arizona, Tucson, AZ USA. [Briggs, Vanessa] Hlth Promot Council Southeastern Penn, Philadelphia, PA USA. [Delmoor, Ernestine] Natl Black Leadership Initiat Canc, Philadelphia Chapter, Philadelphia, PA USA. [Johnson, Jerry C.] Univ Penn, Philadelphia, PA 19104 USA. RP Halbert, CH (reprint author), Med Univ South Carolina, 68 President St,Suite BE103, Charleston, SC 29425 USA. EM hughesha@musc.edu FU National Cancer Institute [R01CA100254]; National Institute on Minority Health and Health Disparities [R24MD001594]; Veterans Health Administration; Charleston Health Equity and Rural Outreach Innovation Center; [CIN 13-410] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by Grant No. R01CA100254 from the National Cancer Institute and Grant No. R24MD001594 from the National Institute on Minority Health and Health Disparities, and CIN 13-410, Veterans Health Administration, Charleston Health Equity and Rural Outreach Innovation Center. NR 44 TC 1 Z9 1 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1557-9883 EI 1557-9891 J9 AM J MENS HEALTH JI Am. J. Mens Health PD JAN PY 2017 VL 11 IS 1 SI SI BP 99 EP 107 DI 10.1177/1557988315596225 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EH1QO UT WOS:000391542300011 ER PT J AU Switzer, GE Bruce, J Kiefer, DM Kobusingye, H Drexler, R Besser, RM Confer, DL Horowitz, MM King, RJ Shaw, BE Riches, M Hayes-Lattin, B Linenberger, M Bolwell, B Rowley, SD Litzow, MR Pulsipher, MA AF Switzer, Galen E. Bruce, Jessica Kiefer, Deidre M. Kobusingye, Hati Drexler, Rebecca Besser, RaeAnne M. Confer, Dennis L. Horowitz, Mary M. King, Roberta J. Shaw, Bronwen E. Riches, Marcie Hayes-Lattin, Brandon Linenberger, Michael Bolwell, Brian Rowley, Scott D. Litzow, Mark R. Pulsipher, Michael A. TI Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (> 60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Hematopoietic stem cell (HSC) donation; Related donation; HSC donor health-related quality of life (HRQoL) ID BONE-MARROW DONATION; UNRELATED DONORS; TRANSPLANTATION; AGE; RECOMMENDATIONS; ATTRITION; IMPACT AB The increasing number of older adults with blood-related disorders and the introduction of reduced intensity conditioning regimens has led to increases in hematopoietic stem cell (HSC) transplantation among older adults and a corresponding increase in the age of siblings who donate HSCs to these patients. Data regarding the donation-related experiences of older donors are lacking. The Related Donor Safety Study aimed to examine/compare health-related quality of life (HRQoL) of older versus younger HSC donors. Sixty peripheral blood stem cell (PBSC) donors ages 18 to 60 years and 104 PBSC donors age >60 years completed validated questionnaires before donation and 4 weeks and 1 year after donation. Before donation, older donors had poorer general physical health (t = 3.27; P=.001) but better mental health (t = 2.11; P<.05). There were no age differences in multiple other donation-related factors. At 4 weeks after donation, there were no group differences in general physical/mental health, but older donors were less likely to report donation-related pain (t=-2.26; P<.05) and concerns (t=-3.38; P=.001). At both 4 weeks and 1 year after donation, there were no significant differences in the percentage of each age group feeling physically back to normal or in the number of days it took donors to feel completely well. There was no evidence that increasing age within the older donor group was associated with poorer donation-related HRQoL. Taken together, these data support the current practice of HSC donation by sibling donors above age 60, providing no evidence of worsening HRQoL up to 1 year after donation in individuals up to age 76. (C) 2017 American Society for Blood and Marrow Transplantation. C1 [Switzer, Galen E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Switzer, Galen E.; Bruce, Jessica] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Kiefer, Deidre M.; Kobusingye, Hati; Drexler, Rebecca; Besser, RaeAnne M.; Confer, Dennis L.; King, Roberta J.] Be The Match, Natl Marrow Donor Program, Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Horowitz, Mary M.; Shaw, Bronwen E.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Riches, Marcie] Univ North Carolina Chapel Hill, Div Hematol Oncol, Chapel Hill, NC USA. [Hayes-Lattin, Brandon] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Linenberger, Michael] Univ Washington, Div Hematol, Seattle, WA 98195 USA. [Bolwell, Brian] Cleveland Clin, Lerner Sch Med, Cleveland, OH 44106 USA. [Rowley, Scott D.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Rowley, Scott D.] Georgetown Univ, Sch Med, Dept Med, Washington, DC USA. [Litzow, Mark R.] Mayo Clin, Rochester, NY USA. [Pulsipher, Michael A.] Univ Calif Los Angeles, Div Hematol Oncol & BMT, Los Angeles, CA USA. RP Switzer, GE (reprint author), Univ Pittsburgh, 3501 Forbes Ave,Oxford Bld Suite 410, Pittsburgh, PA 15213 USA. EM SwitzerGE@upmc.edu OI Switzer, Galen/0000-0001-8541-9449 FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL085707] FX Supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI R01 HL085707). NR 23 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD JAN PY 2017 VL 23 IS 1 BP 165 EP 171 DI 10.1016/j.bbmt.2016.10.008 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA EH8ST UT WOS:000392043300025 PM 27751935 ER PT J AU Wood, JN Griffis, HM Taylor, CM Strane, D Harb, GC Mi, LY Song, LH Lynch, KG Rubin, DM AF Wood, Joanne N. Griffis, Heather M. Taylor, Christine M. Strane, Douglas Harb, Gerlinde C. Mi, Lanyu Song, Lihai Lynch, Kevin G. Rubin, David M. TI Under-ascertainment from healthcare settings of child abuse events among children of soldiers by the US Army Family Advocacy Program SO CHILD ABUSE & NEGLECT LA English DT Article DE Child maltreatment; Child abuse; Family Advocacy Program (FAP); Military ID EMERGENCY-DEPARTMENT VISITS; PHYSICAL ABUSE; UNITED-STATES; HEAD TRAUMA; MALTREATMENT; FRACTURES; HOSPITALS; MILITARY; IDENTIFICATION; DEPLOYMENT AB In cases of maltreatment involving children of U.S. Army service members, the U.S. Army Family Advocacy Program (FAP) is responsible for providing services to families and ensuring child safety. The percentage of cases of maltreatment that are known to FAP, however, is uncertain. Thus, the objective of this retrospective study was to estimate the percentage of U.S. Army dependent children with child maltreatment as diagnosed by a military or civilian medical provider who had a substantiated report with FAP from 2004 to 2007. Medical claims data were used to identify 0-17 year old child dependents of soldiers who received a medical diagnosis of child maltreatment. Linkage rates of maltreatment medical diagnoses with corresponding substantiated FAP reports were calculated. Bivariate and multivariable analyses examined the association of child, maltreatment episode, and soldier characteristics with linkage to substantiated FAP reports. Across 5945 medically diagnosed maltreatment episodes, 20.3% had a substantiated FAP report. Adjusting for covariates, the predicted probability of linkage to a substantiated FAP report was higher for physical abuse than for sexual abuse, 25.8%, 95% CI (23.4, 28.3) versus 14.5%, 95% CI (11.2, 17.9). Episodes in which early care was provided at civilian treatment facilities were less likely to have a FAP report than those treated at military facilities, 9.8%, 95% CI (7.3, 12.2) versus 23.6%, 95% CI (20.8, 26.4). The observed low rates of linkage of medically diagnosed child maltreatment to substantiated FAP reports may signal the need for further regulation of FAP reporting requirements, particularly for children treated at civilian facilities. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Wood, Joanne N.; Griffis, Heather M.; Taylor, Christine M.; Strane, Douglas; Rubin, David M.] Childrens Hosp Philadelphia, PolicyLab, CHOP North,Room 1544,3535 Market St,15th Floor, Philadelphia, PA 19104 USA. [Wood, Joanne N.; Rubin, David M.] Childrens Hosp Philadelphia, Div Gen Pediat, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA. [Wood, Joanne N.; Rubin, David M.] Univ Penn, Dept Pediat, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. [Harb, Gerlinde C.; Lynch, Kevin G.] Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Mi, Lanyu; Song, Lihai] Childrens Hosp Philadelphia, HAU, 3535 Market St,15th Floor, Philadelphia, PA 19104 USA. [Lynch, Kevin G.] Univ Penn, Dept Psychiat, Perelman Sch Med, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. RP Rubin, DM (reprint author), Childrens Hosp Philadelphia, PolicyLab, CHOP North,Room 1544,3535 Market St,15th Floor, Philadelphia, PA 19104 USA. EM woodjo@email.chop.edu; griffish@email.chop.edu; taylorc2@email.chop.edu; straned@email.chop.edu; gharb@upenn.edu; mil@email.chop.edu; songl@email.chop.edu; lynch3@mail.med.upenn.edu; rubin@email.chop.edu FU Department of the Army [W81XWH-11-2-0100]; U.S. Army Medical Research Acquisition Activity, Fort Detrick MD [21702-5014] FX This work was sponsored by the Department of the Army (award number: W81XWH-11-2-0100). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 was the awarding and administering acquisition office. The information in this manuscript does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. NR 34 TC 0 Z9 0 U1 8 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 EI 1873-7757 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD JAN PY 2017 VL 63 BP 202 EP 210 DI 10.1016/j.chiabu.2016.11.007 PG 9 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA EH6VC UT WOS:000391911000020 PM 27955871 ER PT J AU Handelsman, DJ Matsumoto, AM Gerrard, DF AF Handelsman, David J. Matsumoto, Alvin M. Gerrard, David F. TI Doping Status of DHEA Treatment for Female Athletes with Adrenal Insufficiency SO CLINICAL JOURNAL OF SPORT MEDICINE LA English DT Review DE DHEA; doping; adrenal disease; adrenal insufficiency; female athlete; therapeutic ID ANABOLIC-ANDROGENIC STEROIDS; CLINICAL-PRACTICE GUIDELINE; QUALITY-OF-LIFE; DEHYDROEPIANDROSTERONE DHEA; ORAL DEHYDROEPIANDROSTERONE; POSTMENOPAUSAL WOMEN; FREE TESTOSTERONE; MASS-SPECTROMETRY; HYPOADRENAL WOMEN; BODY-COMPOSITION AB Objective: To review the doping status of dehydroepiandrosterone (DHEA) for female athletes with adrenal insufficiency within the framework of Therapeutic Use Exemption (TUE) applications for this proandrogen, which is included on the World Anti-Doping Agency (WADA)'s Prohibited List. Data Sources and Main Results: Current knowledge of adrenal pathophysiology with a focus on the physiological role and pharmacological effects of DHEA in female athletes including placebo-controlled clinical trials of DHEA and consensus clinical practice and prescribing guidelines. Conclusions: Because there is no convincing clinical evidence to support the use of DHEA replacement therapy in women with adrenal failure, a TUE for DHEA is not justified by definite health benefit for either secondary or primary adrenal failure. This is consistent with the 2014 update of the US Endocrine Society guidelines, meta-analyses of DHEA treatment in women with or without adrenal failure, current WADA TUE guidance document for adrenal insufficiency and recent case law of WADA's Court of Arbitration for Sport. C1 [Handelsman, David J.] Univ Sydney, Concord Hosp, ANZAC Res Inst, Sydney, NSW 2139, Australia. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Gerrard, David F.] Univ Otago, Dunedin Sch Med, WADA TUE Expert Grp, New Zealand Chair, Dunedin, New Zealand. RP Handelsman, DJ (reprint author), Univ Sydney, Concord Hosp, ANZAC Res Inst, Sydney, NSW 2139, Australia. EM djh@anzac.edu.au NR 91 TC 0 Z9 0 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1050-642X EI 1536-3724 J9 CLIN J SPORT MED JI Clin. J. Sport Med. PD JAN PY 2017 VL 27 IS 1 BP 78 EP 85 PG 8 WC Orthopedics; Physiology; Sport Sciences SC Orthopedics; Physiology; Sport Sciences GA EH9OP UT WOS:000392101000014 PM 26844622 ER PT J AU Jakien, KM Kampel, SD Gordon, SY Gallun, FJ AF Jakien, Kasey M. Kampel, Sean D. Gordon, Samuel Y. Gallun, Frederick J. TI The Benefits of Increased Sensation Level and Bandwidth for Spatial Release From Masking SO EAR AND HEARING LA English DT Article DE Aging; Bandwidth; Binaural hearing; Head-related-transfer-functions; Hearing aids; Hearing loss; Sensation level; Spatial release from masking ID INTERAURAL TIME DIFFERENCES; HEARING-LOSS; SPEECH; SEPARATION; RECEPTION; INTELLIGIBILITY; NOISE; MODEL; TASK AB Objective: Spatial release from masking (SRM) can increase speech intelligibility in complex listening environments. The goal of the present study was to document how speech-in-speech stimuli could be best processed to encourage optimum SRM for listeners who represent a range of ages and amounts of hearing loss. We examined the effects of equating stimulus audibility among listeners, presenting stimuli at uniform sensation levels (SLs), and filtering stimuli at two separate bandwidths. Design: Seventy-one participants completed two speech intelligibility experiments (36 listeners in experiment 1; all 71 in experiment 2) in which a target phrase from the coordinate response measure (CRM) and two masking phrases from the CRM were presented simultaneously via earphones using a virtual spatial array, such that the target sentence was always at 0 degree azimuth angle and the maskers were either colocated or positioned at +/-45 degrees. Experiments 1 and 2 examined the impacts of SL, age, and hearing loss on SRM. Experiment 2 also assessed the effects of stimulus bandwidth on SRM. Results: Overall, listeners' ability to achieve SRM improved with increased SL. Younger listeners with less hearing loss achieved more SRM than older or hearing-impaired listeners. It was hypothesized that SL and bandwidth would result in dissociable effects on SRM. However, acoustical analysis revealed that effective audible bandwidth, defined as the highest frequency at which the stimulus was audible at both ears, was the best predictor of performance. Thus, increasing SL seemed to improve SRM by increasing the effective bandwidth rather than increasing the level of already audible components. Conclusions: Performance for all listeners, regardless of age or hearing loss, improved with an increase in overall SL and/or bandwidth, but the improvement was small relative to the benefits of spatial separation. C1 [Jakien, Kasey M.; Gallun, Frederick J.] Oregon Hlth & Sci Univ, Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Jakien, Kasey M.; Kampel, Sean D.; Gordon, Samuel Y.; Gallun, Frederick J.] Portland VA Med Ctr, Dept Vet Affairs, Natl Ctr Rehabil Auditory Res, Portland, OR USA. RP Jakien, KM (reprint author), VA Portland Hlth Care Syst, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Kasey.Jakien@va.gov FU National Institutes of Health's National Institute for Deafness and Communication Disorders [R01 DC011828]; VA RR&D National Center for Rehabilitative Auditory Research at the VA Portland Health Care System Medical Center FX Supported by the National Institutes of Health's National Institute for Deafness and Communication Disorders (R01 DC011828) and by the VA RR&D National Center for Rehabilitative Auditory Research, which is located at the VA Portland Health Care System Medical Center. The contents of this article are the private views of the authors and should not be assumed to represent the views of the Department of Veterans Affairs or the United States Government. NR 26 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-0202 EI 1538-4667 J9 EAR HEARING JI Ear Hear. PD JAN-FEB PY 2017 VL 38 IS 1 BP E13 EP E21 DI 10.1097/AUD.0000000000000352 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA EH2WV UT WOS:000391630200002 PM 27556520 ER PT J AU Conway, CR George, MS Sackeim, HA AF Conway, Charles R. George, Mark S. Sackeim, Harold A. TI Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression When Enough Is Enough SO JAMA PSYCHIATRY LA English DT Editorial Material ID OUTCOMES; TERM C1 [Conway, Charles R.] Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8134, St Louis, MO 63110 USA. [Conway, Charles R.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [George, Mark S.] Med Univ South Carolina, Charleston, SC USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Sackeim, Harold A.] Columbia Univ, New York, NY USA. RP Conway, CR (reprint author), Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8134, St Louis, MO 63110 USA. EM conwayc@psychiatry.wustl.edu FU Bristol-Myers Squibb; Stanley Medical Research Institute; National Institute of Mental Health; NeoSync; Cyberonics; Taylor Family Institute for Innovative Psychiatric Research; August Busch IV Foundation; Barnes-Jewish Hospital Foundation; Brainsway; Cervel/NeoStim; MECTA; Neuronetics FX Dr Conway has received research support from Bristol-Myers Squibb, the Stanley Medical Research Institute, the National Institute of Mental Health, NeoSync, Cyberonics, Taylor Family Institute for Innovative Psychiatric Research, August Busch IV Foundation, and Barnes-Jewish Hospital Foundation. He previously served as a speaker for Bristol-Myers Squibb and Otsuka Pharmaceuticals. He has served as an unpaid consultant to Cyberonics. Dr George has no equity ownership in any device or pharmaceutical company. He does occasionally consult with industry, although he has not accepted consulting fees from anyone who manufactures a transcranial magnetic stimulation device, because of his role in National Institutes of Health and US Department of Veterans Affairs studies evaluating this technology. His total industry-related compensation per year is less than 10% of his total university salary. He has consulted (unpaid) to BrainSonix, Brainsway, Cervel/NeoStim, MECTA, Neuronetics, NeoSync, and Nervive. He has consulted to PureTech Ventures and is a data and safety monitoring board member of MicroTransponder. He has received research grant funding or equipment from Brainsway, Cervel/NeoStim, MECTA, Neuronetics, and NeoSync. He is a journal editor for Elsevier Press. Dr Sackeim has consulted to Brainsway, Cyberonics, Eli Lilly, Magstim, MECTA, Neosync, Neuronetics, NeuroPace, Novartis, and Pfizer. NR 7 TC 2 Z9 2 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2017 VL 74 IS 1 BP 9 EP 10 DI 10.1001/jamapsychiatry.2016.2586 PG 2 WC Psychiatry SC Psychiatry GA EH9UQ UT WOS:000392117300003 PM 27784055 ER PT J AU Resick, PA Wachen, JS Dondanville, KA Pruiksma, KE Yarvis, JS Peterson, AL Mintz, J AF Resick, Patricia A. Wachen, Jennifer Schuster Dondanville, Katherine A. Pruiksma, Kristi E. Yarvis, Jeffrey S. Peterson, Alan L. Mintz, Jim CA STRONG STAR Consortium TI Effect of Group vs Individual Cognitive Processing Therapy in Active-Duty Military Seeking Treatment for Posttraumatic Stress Disorder A Randomized Clinical Trial SO JAMA PSYCHIATRY LA English DT Article ID PSYCHOTHERAPY; PTSD; VETERANS; HEALTH; METAANALYSIS; AFGHANISTAN; SURVIVORS; EFFICACY; VIOLENCE; VICTIMS AB IMPORTANCE Cognitive processing therapy (CPT), an evidence-based treatment for posttraumatic stress disorder (PTSD), has not been tested as an individual treatment among active-duty military. Group CPT may be an efficient way to deliver treatment. OBJECTIVE To determine the effects of CPT on PTSD and co-occurring symptoms and whether they differ when administered in an individual or a group format. DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, 268 active-duty servicemembers consented to assessment at an army medical center from March 8, 2012, to September 23, 2014, and were randomized to group or individual CPT. Inclusion criteria were PTSD after military deployment and stable medication therapy. Exclusion criteria consisted of suicidal or homicidal intent or psychosis. Data collection was completed on June 15, 2015. Analysis was based on intention to treat. INTERVENTIONS Participants received CPT (the version excluding written accounts) in 90-minute group sessions of 8 to 10 participants (15 cohorts total; 133 participants) or 60-minute individual sessions (135 participants) twice weekly for 6 weeks. The 12 group and individual sessions were conducted concurrently. MAIN OUTCOMES AND MEASURES Primary measures were scores on the Posttraumatic Symptom Scale-Interview Version (PSS-I) and the stressor-specific Posttraumatic Stress Disorder Checklist (PCL-S); secondary measures were scores on the Beck Depression Inventory-II (BDI-II) and the Beck Scale for Suicidal Ideation (BSSI). Assessments were completed by independent evaluators masked to treatment condition at baseline and 2 weeks and 6 months after treatment. RESULTS Among the 268 participants (244 men [91.0%]; 24women [9.0%]; mean [SD] age, 33.2 [7.4] years), improvement in PTSD severity at posttreatment was greater when CPT was administered individually compared with the group format (mean [SE] difference on the PSS-I, -3.7 [1.4]; Cohen d = 0.6; P=.006). Significant improvements were maintained with the individual (mean [SE] PSS-I, -7.8 [1.0]; Cohen d = 1.3; mean [SE] PCL-S, -12.6 [1.4]; Cohen d = 1.2) and group (mean [SE] PSS-I, -4.0 [0.97]; Cohen d = 0.7; mean [SE] PCL-S, -6.3 [1.4]; Cohen d = 0.6) formats, with no differences in remission or severity of PTSD at the 6-month follow-up. Symptoms of depression and suicidal ideation did not differ significantly between formats. CONCLUSIONS AND RELEVANCE Individual treatment resulted in greater improvement in PTSD severity than group treatment. Depression and suicidal ideation improved equally with both formats. However, even among those receiving individual CPT, approximately 50% still had PTSD and clinically significant symptoms. In the military population, improving existing treatments such as CPT or developing new treatments is needed. C1 [Resick, Patricia A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 1121 W Chapel Hill St,Ste 201, Durham, NC 27701 USA. [Wachen, Jennifer Schuster] Vet Affairs Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. [Wachen, Jennifer Schuster] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Dondanville, Katherine A.; Pruiksma, Kristi E.; Peterson, Alan L.; Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Dondanville, Katherine A.; Pruiksma, Kristi E.; Peterson, Alan L.; Mintz, Jim] South Texas Vet Hlth Care Syst, Off Res & Dev, San Antonio, TX USA. [Yarvis, Jeffrey S.] Carl R Darnall Army Med Ctr, Dept Behav Hlth, Ft Hood, TX USA. [Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychol, San Antonio, TX 78229 USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Resick, PA (reprint author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 1121 W Chapel Hill St,Ste 201, Durham, NC 27701 USA. EM patricia.resick@duke.edu FU US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs; Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-02-0116, W81XWH-08-02-109, W81XWH-08-02-0114] FX This study was supported by the US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, and awards W81XWH-08-02-0116 (Dr Resick), W81XWH-08-02-109 (Dr Peterson), and W81XWH-08-02-0114 (Brett Litz, PhD) from the Psychological Health and Traumatic Brain Injury Research Program. NR 40 TC 1 Z9 1 U1 11 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2017 VL 74 IS 1 BP 28 EP 36 DI 10.1001/jamapsychiatry.2016.2729 PG 9 WC Psychiatry SC Psychiatry GA EH9UQ UT WOS:000392117300009 PM 27893032 ER PT J AU Thomas, ML Green, MF Hellemann, G Sugar, CA Tarasenko, M Calkins, ME Greenwood, TA Gur, RE Gur, RC Lazzeroni, LC Nuechterlein, KH Radant, AD Seidman, LJ Shiluk, AL Siever, LJ Silverman, J Sprock, J Stone, WS Swerdlow, NR Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL Light, GA AF Thomas, Michael L. Green, Michael F. Hellemann, Gerhard Sugar, Catherine A. Tarasenko, Melissa Calkins, Monica E. Greenwood, Tiffany A. Gur, Raquel E. Gur, Ruben C. Lazzeroni, Laura C. Nuechterlein, Keith H. Radant, Allen D. Seidman, Larry J. Shiluk, Alexandra L. Siever, Larry J. Silverman, JeremyM. Sprock, Joyce Stone, William S. Swerdlow, Neal R. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. Light, Gregory A. TI Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia SO JAMA PSYCHIATRY LA English DT Article ID MISMATCH NEGATIVITY DEFICITS; RANDOMIZED CONTROLLED-TRIAL; SOCIAL COGNITION; NEUROCOGNITIVE DEFICITS; WORKING-MEMORY; VERBAL MEMORY; PERFORMANCE; SYMPTOMS; BIOMARKERS; MMN AB IMPORTANCE Neurophysiologic measures of early auditory information processing (EAP) are used as endophenotypes in genomic studies and biomarkers in clinical intervention studies. Research in schizophrenia has established correlations among measures of EAP, cognition, clinical symptoms, and functional outcome. Clarifying these associations by determining the pathways through which deficits in EAP affect functioning would suggest when and where to therapeutically intervene. OBJECTIVES To characterize the pathways from EAP to outcome and to estimate the extent to which enhancement of basic information processing might improve cognition and psychosocial functioning in schizophrenia. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional data were analyzed using structural equation modeling to examine the associations among EAP, cognition, negative symptoms, and functional outcome. Participants were recruited from the community at 5 geographically distributed laboratories as part of the Consortium on the Genetics of Schizophrenia 2 from July 1, 2010, through January 31, 2014. This well-characterized cohort of 1415 patients with schizophrenia underwent EAP, cognitive, and thorough clinical and functional assessment. MAIN OUTCOME AND MEASURES Mismatch negativity, P3a, and reorienting negativity were used to measure EAP. Cognition was measured by the Letter Number Span test and scales from the California Verbal Learning Test-Second Edition, the Wechsler Memory Scale-Third Edition, and the Penn Computerized Neurocognitive Battery. Negative symptoms were measured by the Scale for the Assessment of Negative Symptoms. Functional outcome was measured by the Role Functioning Scale. RESULTS Participants included 1415 unrelated outpatients diagnosed with schizophrenia or schizoaffective disorder (mean [SD] age, 46 [11] years; 979 males [69.2%] and 619 white [43.7%]). Early auditory information processing had a direct effect on cognition (beta = 0.37, P<.001), cognition had a direct effect on negative symptoms (beta = -0.16, P<.001), and both cognition (beta = 0.26, P <.001) and experiential negative symptoms (beta = -0.75, P <.001) had direct effects on functional outcome. The indirect effect of EAP on functional outcome was significant as well (beta = 0.14, P <.001). Overall, EAP had a fully mediated effect on functional outcome, engaging general rather than modality-specific cognition, with separate pathways that involved or bypassed negative symptoms. CONCLUSIONS AND RELEVANCE The data support a model in which EAP deficits lead to poor functional outcome via impaired cognition and increased negative symptoms. Results can be used to help guide mechanistically informed, personalized treatments and support the strategy of using EAP measures as surrogate end points in early-stage procognitive intervention studies. C1 [Thomas, Michael L.; Tarasenko, Melissa; Greenwood, Tiffany A.; Shiluk, Alexandra L.; Sprock, Joyce; Swerdlow, Neal R.; Tsuang, Debby W.; Braff, David L.; Light, Gregory A.] Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,MC 0738, La Jolla, CA 92093 USA. [Thomas, Michael L.; Tarasenko, Melissa; Light, Gregory A.] Vet Affairs VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, San Diego, CA USA. [Green, Michael F.; Hellemann, Gerhard; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Green, Michael F.; Hellemann, Gerhard] VA Greater Los Angeles Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, Los Angeles, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Radant, Allen D.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. [Seidman, Larry J.; Stone, William S.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Seidman, Larry J.; Stone, William S.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA. [Siever, Larry J.; Silverman, JeremyM.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; Silverman, JeremyM.] James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 3, New York, NY USA. [Tsuang, Ming T.] Univ Calif San Diego, Ctr Behav Genom, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. [Tsuang, Ming T.] VA Puget Sound Hlth Care Syst, VISN Geriatr Res Educ & Clin Ctr 20, Seattle, WA USA. RP Thomas, ML (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,MC 0738, La Jolla, CA 92093 USA. EM mlthomas@ucsd.edu FU University of California, San Diego [R01-MH065571, R01-MH042228, R01-MH079777, K01-MH087889, K23-MH102420]; Mount Sinai School of Medicine [R01-MH065554]; University of California, Los Angeles [R01-MH65707]; University of Pennsylvania [R01-MH65578]; University of Washington [R01-MH65558] FX This work was supported in part by grants R01-MH065571 (Dr Braff), R01-MH042228 (Dr Braff), R01-MH079777 (Dr Light), K01-MH087889 (Dr Greenwood), and K23-MH102420 (Dr Thomas) from the University of California, San Diego; grant R01-MH065554 (Dr Siever) from Mount Sinai School of Medicine; grant R01-MH65707 (Dr Green) from University of California, Los Angeles; grant R01-MH65578 (Dr R. C. Gur) from the University of Pennsylvania; and grant R01-MH65558 (Dr Tsuang) from the University of Washington. NR 83 TC 1 Z9 1 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2017 VL 74 IS 1 BP 37 EP 46 DI 10.1001/jamapsychiatry.2016.2980 PG 10 WC Psychiatry SC Psychiatry GA EH9UQ UT WOS:000392117300010 PM 27926742 ER PT J AU Sato, N Lam, CSP Teerlink, JR Greenberg, BH Tsutsui, H Oh, BH Zhang, J Lefkowitz, M Hua, TA Holbro, T Marshood, M Wang, XL Ge, JB AF Sato, Naoki Lam, Carolyn S. P. Teerlink, John R. Greenberg, Barry H. Tsutsui, Hiroyuki Oh, Byung-Hee Zhang, Jian Lefkowitz, Martin Hua, Tsushung A. Holbro, Thomas Marshood, Miriam Wang, Xing Li Ge, Junbo TI Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Serelaxin; efficacy; Asian; acute heart failur ID RECOMBINANT HUMAN RELAXIN-2; GLOMERULAR-FILTRATION-RATE; EUROPEAN-SOCIETY; EJECTION FRACTION; RENAL-FUNCTION; TASK-FORCE; ASSOCIATION; CONGESTION; CARDIOLOGY; DISEASE AB Background: Acute heart failure (AHF), a common and growing health concern worldwide, is associated with high risk of post-discharge rehospitalization and mortality. Existing evidence indicates potential therapeutic benefits of serelaxin in Caucasian AHF patients, but corresponding data in Asians remain scarce. RELAX-AHF-ASIA, a multinational, randomized, double-blind, placebo-controlled, phase III trial, will evaluate the effects of serelaxin on symptom relief and clinical outcomes in Asian AHF patients, with the use of novel assessments. Methods and Results: Patients with AHF, systolic blood pressure >= 125 mm Hg, and mild to moderate renal dysfunction will be randomized within 16 hours of presentation to receive 48-hour intravenous infusion of 30 mu g . kg(-1) . d(-1) serelaxin or placebo in addition to standard therapy. The composite primary end point includes: (1) treatment success (moderate/marked improvement in patient-reported dyspnea and physician-assessed signs of congestion on day 2); (2) treatment failure (in-hospital worsening of signs and/ or symptoms of heart failure [HF] requiring intensification of intravenous HF therapy or mechanical ventilation, renal/circulatory support, rehospitalization due to HF/renal-failure, or death through day 5); and (3) unchanged status. Secondary end points include time to in-hospital worsening HF through day 5 and all cause and cardiovascular deaths through day 180. Conclusions: RELAX-AHF-ASIA, the largest randomized clinical trial in Asian AHF patients to date, has a novel composite primary end point and the potential to become a hallmark of AHF trials. C1 [Sato, Naoki] Musashi Kosugi Hosp, Nippon Med Sch, Cardiol & Intens Care Unit, Kawasaki, Kanagawa, Japan. [Lam, Carolyn S. P.] Natl Heart Ctr Singapore, Singapore, Singapore. [Lam, Carolyn S. P.] Duke NUS, Singapore, Singapore. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Los Angeles, CA USA. [Greenberg, Barry H.] Univ Calif San Diego, Div Cardiol, La Jolla, CA 92093 USA. [Tsutsui, Hiroyuki] Kyushu Univ, Fac Med Sci, Dept Cardiovasc Med, Fukuoka, Japan. [Oh, Byung-Hee] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea. [Zhang, Jian] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Beijing, Peoples R China. [Zhang, Jian] Peking Union Med Coll, Beijing, Peoples R China. [Lefkowitz, Martin; Hua, Tsushung A.; Marshood, Miriam; Wang, Xing Li] Novartis Pharmaceut, E Hanover, NJ USA. [Holbro, Thomas] Novartis Pharmaceut, Basel, Switzerland. [Ge, Junbo] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai, Peoples R China. RP Sato, N (reprint author), Musashi Kosugi Hosp, Nippon Med Sch, Cardiol & Intens Care Unit, Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan. EM nms-ns@nms.ac.jp FU Novartis Pharma FX This study is sponsored by Novartis Pharma. NR 43 TC 0 Z9 0 U1 2 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD JAN PY 2017 VL 23 IS 1 BP 63 EP 71 DI 10.1016/j.cardfail.2016.10.016 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EH8SE UT WOS:000392041800010 PM 27825893 ER PT J AU Moussaoui, N Jacobs, JP Larauche, M Biraud, M Million, M Mayer, E Tache, Y AF Moussaoui, Nabila Jacobs, Jonathan P. Larauche, Muriel Biraud, Mandy Million, Mulugeta Mayer, Emeran Tache, Yvette TI Chronic Early-life Stress in Rat Pups Alters Basal Corticosterone, Intestinal Permeability, and Fecal Microbiota at Weaning: Influence of Sex SO JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE Corticosterone; Microbiota; Permeability; Stress; psychological; Weaning ID IRRITABLE-BOWEL-SYNDROME; PITUITARY-ADRENAL AXIS; MATERNAL SEPARATION; CHILDHOOD TRAUMA; NEONATAL STRESS; RODENT MODELS; GUT; DEPRESSION; INSIGHTS; BEHAVIOR AB Background/Aims Wistar rat dams exposed to limited nesting stress (LNS) from post-natal days (PND) 2 to 10 display erratic maternal behavior, and their pups show delayed maturation of the hypothalamic-pituitary-adrenal axis and impaired epithelial barrier at PND10 and a visceral hypersensitivity at adulthood. little is known about the impact of early life stress on the offspring before adulthood and the influence of sex. We investigated whether male and female rats previously exposed to LNS displays at weaning altered corticosterone, intestinal permeability, and microbiota. Methods Wistar rat dams and litters were maintained from PND2 to 10 with limited nesting/bedding materials and thereafter reverted to normal housing up to weaning (PND21). Control litters had normal housing. At weaning, we monitored body weight, corticosterone plasma levels (enzyme immunoassay), in vivo intestinal to colon permeability (fluorescein isothiocyanate-dextran 4 kDa) and fecal microbiota (DNA extraction and amplification of the V4 region of the 16S ribosomal RNA gene). Results At weaning, LNS pups had hypercorticosteronemia and enhanced intestinal permeability with females > males while body weights were similar. LNS decreased fecal microbial diversity and induced a distinct composition characterized by increased abundance of Gram positive cocci and reduction of fiber-degrading, butyrate-producing, and mucus-resident microbes. Conclusions These data indicate that chronic exposure to LNS during the first week post-natally has sustained effects monitored at weanirig including hypercorticosteronemia, a leaky gut, and dysbiosis. These alterations may impact on the susceptibility to develop visceral hypersensitivity in adult rats and have relevance to the development of irritable bowel syndrome in childhood. C1 Univ Calif Los Angeles, G Oppenheimer Ctr Neurobiol Stress & Resilience, CURE Digest Dis Res Ctr, Vatche & Tamar Manoukian Div Digest Dis,Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Moussaoui, N (reprint author), CURE VA GLAHS, Bldg 115,Rm 111,1301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM NMoussaoui@mednet.ucla.edu FU National Institute of Health [P50 DK-64539, DK-41301, R01 DK-57238, K01 DK088937]; VA Career Scientist Award FX This work was supported by National Institute of Health grants P50 DK-64539 and Center grant DK-41301 (Animal Model Core), R01 DK-57238, K01 DK088937, and VA Career Scientist Award. NR 52 TC 2 Z9 2 U1 7 U2 7 PU KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY PI GANGNAM-GU PA RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU, SEOUL 135-839, SOUTH KOREA SN 2093-0879 EI 2093-0887 J9 J NEUROGASTROENTEROL JI J. Neurogastroenterol. Motil. PD JAN PY 2017 VL 23 IS 1 BP 135 EP 143 DI 10.5056/jnm16105 PG 9 WC Gastroenterology & Hepatology; Clinical Neurology SC Gastroenterology & Hepatology; Neurosciences & Neurology GA EH4XH UT WOS:000391776700019 PM 27829577 ER PT J AU de Boer, IH Kahn, SE AF de Boer, Ian H. Kahn, Steven E. TI SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease? SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material C1 [de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Kahn, Steven E.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [de Boer, Ian H.; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP de Boer, IH (reprint author), Univ Washington, Med Nephrol, Box 359606,325 9th Ave, Seattle, WA 98104 USA. EM deboer@u.washington.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK088762, R01DK099199]; American Diabetes Association [4-15-CKD-20]; Department of Veterans Affairs [I01BX001060]; NIDDK [P30DK017047]; VA Puget Sound Health Care System FX I.H.d.B. receives support from grants R01DK088762 and R01DK099199 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), grant 4-15-CKD-20 from the American Diabetes Association, an unrestricted gift from the Northwest Kidney Centers to the Kidney Research Institute, and the Veterans Affairs (VA) Puget Sound Health Care System. S.E.K. receives support from grant I01BX001060 from the Department of Veterans Affairs, grant P30DK017047 from the NIDDK, and the VA Puget Sound Health Care System. NR 15 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2017 VL 28 IS 1 BP 7 EP 10 DI 10.1681/ASN.2016060650 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA EH3CW UT WOS:000391647700004 PM 27539605 ER PT J AU Clark, AM Wheeler, SE Young, CL Stockdale, L Neiman, JS Zhao, W Stolz, DB Venkataramanan, R Lauffenburger, D Griffith, L Wells, A AF Clark, A. M. Wheeler, S. E. Young, C. L. Stockdale, L. Neiman, J. Shepard Zhao, W. Stolz, D. B. Venkataramanan, R. Lauffenburger, D. Griffith, L. Wells, A. TI A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties SO LAB ON A CHIP LA English DT Article ID HUMAN BREAST-CANCER; EXTRACELLULAR-MATRIX; MALIGNANT PHENOTYPE; CARCINOMA; STIFFNESS; CULTURE; GROWTH; TISSUE; PROGRESSION; MICROENVIRONMENTS AB Distant metastasis is the major cause of breast cancer-related mortality, commonly emerging clinically after 5 or more years of seeming 'cure' of the primary tumor, indicating a quiescent dormancy. The lack of relevant accessible model systems for metastasis that recreate this latent stage has hindered our understanding of the molecular basis and the development of therapies against these lethal outgrowths. We previously reported on the development of an all-human 3D ex vivo hepatic microphysiological system that reproduces several features of liver physiology and enables spontaneous dormancy in a subpopulation of breast cancer cells. However, we observed that the dormant cells were localized primarily within the 3D tissue, while the proliferative cells were in contact with the polystyrene scaffold. As matrix stiffness is known to drive inflammatory and malignant behaviors, we explored the occurrence of spontaneous tumor dormancy and inflammatory phenotype. The microphysiological system was retrofitted with PEGDa-SynKRGD hydrogel scaffolding, which is softer and differs in the interface with the tissue. The microphysiological system incorporated donor-matched primary human hepatocytes and non-parenchymal cells (NPCs), with MDA-MB-231 breast cancer cells. Hepatic tissue in hydrogel scaffolds secreted lower levels of pro-inflammatory analytes, and was more responsive to inflammatory stimuli. The proportion of tumor cells entering dormancy was markedly increased in the hydrogel-supported tissue compared to polystyrene. Interestingly, an unexpected differential response of dormant cells to varying chemotherapeutic doses was identified, which if reflective of patient pathophysiology, has important implications for patient dosing regimens. These findings highlight the metastatic microphysiological system fitted with hydrogel scaffolds as a critical tool in the assessment and development of therapeutic strategies to target dormant metastatic breast cancer. C1 [Clark, A. M.; Wheeler, S. E.; Stolz, D. B.; Venkataramanan, R.; Wells, A.] Univ Pittsburgh, Dept Pathol, S711 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Wells, A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. [Young, C. L.; Stockdale, L.; Neiman, J. Shepard; Lauffenburger, D.; Griffith, L.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Zhao, W.; Venkataramanan, R.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA. [Stolz, D. B.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA. [Wells, A.] VA Pittsburgh Healthcare Syst, Pittsburgh VA Med Ctr, Pittsburgh, PA 15240 USA. [Stolz, D. B.; Wells, A.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA. [Stolz, D. B.] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA. [Young, C. L.] Appl BioMath LLC, Lincoln, MA USA. RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, S711 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.; Wells, A (reprint author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA.; Wells, A (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh VA Med Ctr, Pittsburgh, PA 15240 USA.; Wells, A (reprint author), Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA. EM wellsa@upmc.edu RI Zhao, Wenchen/D-1867-2017 OI Zhao, Wenchen/0000-0002-0501-8459 FU NIH [1UH3TR000496]; VA Merit Award; DARPA [BAA-11-73, W911NF-12-2-0039] FX The authors thank other members of their laboratories for thoughtful discussions as well as Dr. Jonathan Coppeta (The Charles Stark Draper Laboratory, LLC) for his helpful suggestions with respect to the hydrogel scaffolds. The work described within is funded by grants from the NIH (1UH3TR000496), a VA Merit Award, and DARPA (BAA-11-73 Microphysiological Systems: W911NF-12-2-0039). NR 59 TC 0 Z9 0 U1 9 U2 9 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 EI 1473-0189 J9 LAB CHIP JI Lab Chip PY 2017 VL 17 IS 1 BP 156 EP 168 DI 10.1039/c6lc01171c PG 13 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA EH2NH UT WOS:000391604000013 ER PT J AU Taber, DJ Fleming, JN Fominaya, CE Gebregziabher, M Hunt, KJ Srinivas, TR Baliga, PK McGillicuddy, JW Egede, LE AF Taber, David J. Fleming, James N. Fominaya, Cory E. Gebregziabher, Mulugeta Hunt, Kelly J. Srinivas, Titte R. Baliga, Prabhakar K. McGillicuddy, John W. Egede, Leonard E. TI The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Kidney transplant; Non-adherence; Acute rejection; Graft survival ID SOLID-ORGAN TRANSPLANTATION; ASSESSING MEDICATION ADHERENCE; RENAL-TRANSPLANTATION; CLAIMS DATA; RECIPIENTS; FAILURE; REGIMEN; IMMUNOSUPPRESSANTS; NONCOMPLIANCE; THERAPY AB Background: Non-adherence to medication is a well-studied and known cause of late allograft loss, but it is difficult to measure and prospectively monitor. The aim of this study was to assess if appointment non-adherence was correlated with medication non-adherence and a predictor of graft outcomes. Methods: This was a longitudinal cohort study that used the National United States Renal Data System and veterans affairs health records data with time-to-event analyses conducted to assess the impact on graft and patient survival. Results: The number of transplants that were included in the analysis was 4,646 (3,656 with complete records); 14.6% of patients had an appointment no show rate of = 12% (non-adherence). Appointment and medication non-adherence were highly correlated and both were significant independent predictors of outcomes. Those with appointment non-adherence had 1.5 times the risk of acute rejection (22.0 vs. 14.7%, p < 0.0001) and a 65% higher risk of graft loss (adjusted hazards ratio (aHR) 1.65, 95% CI 1.38-1.97, p < 0.0001). There was a significant interaction between appointment and medication non-adherence; those with appointment and medication non-adherence were at very high risk of graft loss (aHR 4.18, 95% CI 3.39-5.15, p < 0.0001), compared to those with only appointment non-adherence (aHR 1.39, 95% CI 0.97-2.01, p = 0.0766) or only medication non-adherence (aHR 2.44, 95% CI 2.11-2.81, p < 0.0001). Conclusion: These results demonstrate that non-adherence to health care appointments is a significant and independent risk factor for graft loss. (C) 2016 S. Karger AG, Basel C1 [Taber, David J.; Baliga, Prabhakar K.; McGillicuddy, John W.] Med Univ South Carolina, Coll Med, Div Transplant Surg, Charleston, SC USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ South Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC USA. [Srinivas, Titte R.] Med Univ South Carolina, Coll Med, Div Transplant Nephrol, Charleston, SC USA. [Fleming, James N.] Med Univ South Carolina, Dept Pharm Serv, Charleston, SC USA. [Taber, David J.; Fominaya, Cory E.] Ralph H Johnson VAMC, Dept Pharm Serv, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach Innov, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ South Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440] FX Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award number K23DK099440. NR 30 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2017 VL 45 IS 1 BP 91 EP 98 DI 10.1159/000453554 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA EH0CB UT WOS:000391428900014 PM 27907919 ER PT J AU Dubin, RF Deo, R Bansal, N Anderson, AH Yang, P Go, AS Keane, M Townsend, R Porter, A Budoff, M Malik, S He, J Rahman, M Wright, J Cappola, T Kallem, R Roy, J Sha, DH Shlipak, MG AF Dubin, Ruth F. Deo, Rajat Bansal, Nisha Anderson, Amanda H. Yang, Peter Go, Alan S. Keane, Martin Townsend, Ray Porter, Anna Budoff, Matthew Malik, Shaista He, Jiang Rahman, Mahboob Wright, Jackson Cappola, Thomas Kallem, Radhakrishna Roy, Jason Sha, Daohang Shlipak, Michael G. CA CRIC Study Investigators TI Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID LEFT-VENTRICULAR HYPERTROPHY; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS; DIASTOLIC FUNCTION; DIALYSIS PATIENTS; ESRD PATIENTS; RISK; MASS; RECOMMENDATIONS; METAANALYSIS AB Background and objectives Heart failure is the most frequent cardiac complication of CKD. Left ventricular hypertrophy is common and develops early in CKD, but studies have not adequately evaluated the association of left ventricular mass index with heart failure incidence among men and women with CKD. Design, setting, participants, & measurements We evaluated echocardiograms of 2567 participants without self reported heart failure enrolled in the Chronic Renal Insufficiency Cohort Study. Two-dimensional echocardiograms were performed at the year 1 study visit and interpreted at a central core laboratory. Left ventricular mass index was calculated using the linear method, indexed to height(2.7), and analyzed using sex-specific quartiles. The primary outcomes of incident heart failure and all-cause mortality were adjudicated over a median of 6.6 (interquartile range, 5.7-7.6) years. Results Among 2567 participants, 45% were women, and 54% were nonwhite race; mean (SD) age was 59 +/- 11 years old, and mean eGFR was 44 +/- 17 ml/min per 1.73 m(2). During a median follow-up period of 6.6 years, 262 participants developed heart failure, and 470 participants died. Compared with participants in the first quartile of left ventricular mass index, those in the highest quartile had higher rates of incident heart failure (hazard ratio, 3.96; 95% confidence interval, 1.96 to 8.02) and mortality (hazard ratio, 1.86; 95% confidence interval, 1.22 to 2.85), even after adjustment for B type natriuretic peptide, troponin T, mineral metabolism markers, and other cardiovascular disease risk factors. Those in the lowest quartile of ejection fraction had higher rates of incident heart failure (hazard ratio, 3.01; 95% confidence interval, 1.94 to 4.67) but similar mortality rates (hazard ratio, 1.18; 95% confidence interval, 0.89 to 1.57) compared with those in the highest quartile. Diastolic dysfunction was not significantly associated with heart failure or death. Conclusions Among persons with CKD and without history of cardiovascular disease, left ventricular mass index is strongly associated with incident heart failure, even after adjustment for major cardiovascular risk factors and biomarkers. C1 [Dubin, Ruth F.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Deo, Rajat; Anderson, Amanda H.; Yang, Peter; Townsend, Ray; Cappola, Thomas; Kallem, Radhakrishna; Roy, Jason; Sha, Daohang] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bansal, Nisha] Univ Washington, Seattle, WA 98195 USA. [Go, Alan S.] Kaiser Permanente, Div Clin Res, Oakland, CA USA. [Keane, Martin; Malik, Shaista] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA. [Porter, Anna] Univ Calif Irvine, Irvine, CA USA. [Budoff, Matthew] Univ Calif Los Angeles, Los Angeles, CA USA. [He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Rahman, Mahboob; Wright, Jackson] Univ Hosp Case Med Ctr, Cleveland, OH USA. RP Dubin, RF (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM ruth.dubin@ucsf.edu FU National Institutes of Health (NIH) [K23 DK092354, R03DK104013, 5R01DK066488, 1R01DK098234]; National Institute of Diabetes and Digestive and Kidney Diseases [U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902]; Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences (NCATS) grant [UL1TR000003]; Johns Hopkins University [UL1 TR-000424]; University of Maryland General Clinical Research Center [M01 RR-16500]; Clinical and Translational Science Collaborative of Cleveland; NCATS component of the NIH [UL1TR000439]; NIH Roadmap for Medical Research; Michigan Institute for Clinical and Health Research [UL1TR000433]; University of Illinois at Chicago Clinical and Translational Science Award [UL1RR029879]; Tulane University Translational Research in Hypertension and Renal Biology grant [P30GM103337]; Kaiser Permanente NIH/National Center for Research Resources University California San Francisco-Clinical and Translational Science Institute [L1 RR-024131] FX This work was supported by National Institutes of Health (NIH) research grants K23 DK092354 (to R.F.D.), R03DK104013 (to R.F.D.), 5R01DK066488 (to M.G.S.), and 1R01DK098234 (to M.G.S.). Funding for the Chronic Renal Insufficiency Cohort Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported, in part, by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences (NCATS) grant UL1TR000003, Johns Hopkins University grant UL1 TR-000424, University of Maryland General Clinical Research Center grant M01 RR-16500, the Clinical and Translational Science Collaborative of Cleveland, grant UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research grant UL1TR000433, University of Illinois at Chicago Clinical and Translational Science Award grant UL1RR029879, Tulane University Translational Research in Hypertension and Renal Biology grant P30GM103337, and Kaiser Permanente NIH/National Center for Research Resources University California San Francisco-Clinical and Translational Science Institute grant L1 RR-024131. NR 33 TC 0 Z9 0 U1 4 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2017 VL 12 IS 1 BP 60 EP 68 DI 10.2215/CJN.02700316 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA EG9YD UT WOS:000391416700010 PM 28062676 ER PT J AU Taber, DJ Hunt, KJ Gebregziabher, M Srinivas, T Chavin, KD Baliga, PK Egede, LE AF Taber, David J. Hunt, Kelly J. Gebregziabher, Mulugeta Srinivas, Titte Chavin, Kenneth D. Baliga, Prabhakar K. Egede, Leonard E. TI A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID AFRICAN-AMERICAN RECIPIENTS; RENAL-ALLOGRAFT SURVIVAL; LONG-TERM; ACUTE REJECTION; RECEIVING SIROLIMUS; SURVEILLANCE BIOPSY; GRAFT OUTCOMES; FLOW-CYTOMETRY; DOUBLE-BLIND; TACROLIMUS AB Background and objectives There is continued debate whether early steroid withdrawal is safe to use in high immunologic risk patients, such as blacks. The goal of this study was to use comparative effectiveness methodology to elucidate the safety of early steroid withdrawal in blacks with kidney transplants. Design, setting, participants, & measurements Our cohort study used United Network of Organ Sharing data including all adult black kidney transplant recipients from 2000 to 2009 followed through 2014. Propensity score matching was used to equalize baseline risk between continued steroid and early steroid withdrawal groups. Interaction terms were used to assess if the effect of early steroid withdrawal on outcomes varied by baseline and post-transplant factors. Of 26,582 eligible black patients with kidney transplants (5825 [21.9%] with early steroid withdrawal), 5565 patients with early steroid withdrawal were matched to 5565 blacks on continued steroid use. Results Black patients with early steroid withdrawal had similar risk of graft loss (hazard ratio, 0.98; 95% confidence interval, 0.92 to 1.04; P=0.42) and lower risk of death (hazard ratio, 0.91; 95% confidence interval, 0.84 to 0.99; P=0.02), primarily driven by a late mortality advantage (>4 years post-transplant). Delayed graft function, cytolytic induction, tacrolimus, and mycophenolate significantly modified the effect of early steroid withdrawal on outcomes (P<0.05). Acute rejection rates were slightly higher in the continued steroid group (13.0% versus 11.3%, respectively; P<0.01), but this was not associated with graft or patient survival. Conclusions Overall, early steroid withdrawal in black kidney transplant recipients was not associated with graft loss but seemed to be associated with better long term patient survival. Early steroid withdrawal in blacks not receiving cytolytic induction, tacrolimus, and mycophenolate or those with delayed graft function was associated with higher risk of graft loss and death. C1 [Taber, David J.; Chavin, Kenneth D.; Baliga, Prabhakar K.] Med Univ South Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Srinivas, Titte] Med Univ South Carolina, Div Transplant Nephrol, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Hunt, Kelly J.; Gebregziabher, Mulugeta] Med Univ South Carolina, Coll Med, Dept Publ Hlth Sci, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Vet Affairs Hlth Serv Res & Dev, Dept Pharm Serv, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Vet Affairs Hlth Serv Res & Dev, Dept Med, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ South Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440] FX Research reported in this publication was supported by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health award K23DK099440. NR 38 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2017 VL 12 IS 1 BP 131 EP 139 DI 10.2215/CJN.04880516 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA EG9YD UT WOS:000391416700018 PM 27979979 ER PT J AU Safdar, N Sengupta, S Musuuza, JS Juthani-Mehta, M Drees, M Abbo, LM Milstone, AM Furuno, JP Varman, M Anderson, DJ Morgan, DJ Miller, LG Snyder, GM AF Safdar, Nasia Sengupta, Sharmila Musuuza, Jackson S. Juthani-Mehta, Manisha Drees, Marci Abbo, Lilian M. Milstone, Aaron M. Furuno, Jon P. Varman, Meera Anderson, Deverick J. Morgan, Daniel J. Miller, Loren G. Snyder, Graham M. CA SHEA Res Comm TI Status of the Prevention of Multidrug-Resistant Organisms in International Settings: A Survey of the Society for Healthcare Epidemiology of America Research Network SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID STAPHYLOCOCCUS-AUREUS; INFECTIONS; PREVALENCE; HOSPITALS; BACTERIA AB OBJECTIVE. To examine self-reported practices and policies to reduce infection and transmission of multidrug-resistant organisms (MDRO) in healthcare settings outside the United States. DESIGN. Cross-sectional survey. PARTICIPANTS. International members of the Society for Healthcare Epidemiology of America (SHEA) Research Network. METHODS. Electronic survey of infection control and prevention practices, capabilities, and barriers outside the United States and Canada. Participants were stratified according to their country's economic development status as defined by the World Bank as low-income, lower-middle-income, upper-middle-income, and high-income. RESULTS. A total of 76 respondents (33%) of 229 SHEA members outside the United States and Canada completed the survey questionnaire, representing 30 countries. Forty (53%) were high-, 33 (43%) were middle-, and 1 (1%) was a low-income country. Country data were missing for 2 respondents (3%). Of the 76 respondents, 64 (84%) reported having a formal or informal antibiotic stewardship program at their institution. High-income countries were more likely than middle-income countries to have existing MDRO policies (39/64 [61%] vs 25/64 [39%], P=.003) and to place patients with MDRO in contact precautions (40/72 [56%] vs 31/72 [44%], P=.05). Major barriers to preventing MDRO transmission included constrained resources (infrastructure, supplies, and trained staff) and challenges in changing provider behavior. CONCLUSIONS. In this survey, a substantial proportion of institutions reported encountering barriers to implementing key MDRO prevention strategies. Interventions to address capacity building internationally are urgently needed. Data on the infection prevention practices of low income countries are needed. C1 [Safdar, Nasia] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Dept Infect Dis, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Sengupta, Sharmila] Medanta Medicity, Sect 38, Gurgaon, Haryana, India. [Musuuza, Jackson S.] Univ Wisconsin, Inst Clin & Translat Res, Madison, WI USA. [Juthani-Mehta, Manisha] Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06510 USA. [Drees, Marci] Christiana Care Hlth Syst, Dept Med, Newark, DE USA. [Drees, Marci] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA. [Abbo, Lilian M.] Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA. [Milstone, Aaron M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Infect Dis, Baltimore, MD 21205 USA. [Furuno, Jon P.] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Dept Pharm Practice, Portland, OR 97201 USA. [Varman, Meera] Creighton Univ, Med Ctr, Dept Pediat, Div Infect Dis, Omaha, NE USA. [Anderson, Deverick J.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA. [Morgan, Daniel J.] Univ Maryland, Sch Med, Vet Affairs Maryland Healthcare Syst, Baltimore, MD 21201 USA. [Morgan, Daniel J.] Ctr Dis Dynam Econ & Policy, Washington, DC USA. [Miller, Loren G.] Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA. [Snyder, Graham M.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. RP Safdar, N (reprint author), UWMF Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu NR 18 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JAN PY 2017 VL 38 IS 1 BP 53 EP 60 DI 10.1017/ice.2016.242 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EG7QD UT WOS:000391243000009 PM 27817759 ER PT J AU Hope, TA Truillet, C Ehman, EC Afshar-Oromieh, A Aggarwal, R Ryan, CJ Carroll, PR Small, EJ Evans, MJ AF Hope, Thomas A. Truillet, Charles Ehman, Eric C. Afshar-Oromieh, Ali Aggarwal, Rahul Ryan, Charles J. Carroll, Peter R. Small, Eric J. Evans, Michael J. TI Ga-68-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE oncology: GU; PET; androgen receptor; PSMA PET; prostate cancer ID RESISTANT PROSTATE-CANCER; MEMBRANE ANTIGEN; DEPRIVATION THERAPY; PSMA; EXPRESSION; SURVIVAL; MARKER; CELLS AB The purpose of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged using 68Ga-PSMA-11 PET in a mouse xenograft model and in a patient with castration-sensitive prostate cancer. Methods: We imaged 3 groups of 4 mice bearing LNCaPAR xenografts before and 7 d after treatment with ARN-509, orchiectomy, or control vehicle. Additionally, we imaged one patient with castration-sensitive prostate cancer before and 4 wk after treatment with androgen deprivation therapy (ADT). Uptake on pre-and posttreatment imaging was measured and compared. Results: PSMA uptake increased 1.5-to 2.0-fold in the xenograft mouse model after treatment with both orchiectomy and ARN-509 but not with vehicle. Patient imaging demonstrated a 7-fold increase in PSMA uptake after the initiation of ADT. Thirteen of 22 lesions in the imaged patient were visualized on PSMA PET only after treatment with ADT. Conclusion: Inhibition of the AR can increase PSMA expression in prostate cancer metastases and increase the number of lesions visualized using PSMA PET. The effect seen in cell and animal models can be recapitulated in humans. A better understanding of the temporal changes in PSMA expression is needed to leverage this effect for both improved diagnosis and improved therapy. C1 [Hope, Thomas A.; Truillet, Charles; Evans, Michael J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 185 Berry St,Lobby 6,Ste 350, San Francisco, CA 94107 USA. [Hope, Thomas A.] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Hope, Thomas A.; Aggarwal, Rahul; Ryan, Charles J.; Carroll, Peter R.; Small, Eric J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Ehman, Eric C.] Mayo Clin, Dept Radiol, Rochester, MN USA. [Afshar-Oromieh, Ali] Univ Heidelberg Hosp, Dept Nucl Med, Heidelberg, Germany. [Aggarwal, Rahul; Ryan, Charles J.; Small, Eric J.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA. [Carroll, Peter R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. RP Evans, MJ (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 185 Berry St,Lobby 6,Ste 350, San Francisco, CA 94107 USA. EM michael.evans@ucsf.edu FU Radiological Society of North America; Department of Radiology and Biomedical Imaging, UCSF; GE Healthcare; Prostate Cancer Foundation; National Institutes of Health [R00CA172695, 1R01CA17661]; Department of Defense Idea Development Award [PC140107]; UCSF Academic Senate; Department of Defense Prostate Cancer Research Program [PC151060]; National Cancer Institute of the National Institutes of Health [P30CA082103]; ORIC Pharmaceuticals, Inc. FX Dr. Hope receives grant support, is on the speaker's bureau for GE Healthcare, and was supported by the Radiological Society of North America and the Department of Radiology and Biomedical Imaging, UCSF. Dr. Evans receives consulting fees, owns shares in ORIC Pharmaceuticals, Inc., and was supported by the 2013 David H. Koch Young Investigator Award from the Prostate Cancer Foundation, the National Institutes of Health (R00CA172695, 1R01CA17661), a Department of Defense Idea Development Award (PC140107), the UCSF Academic Senate, and GE Healthcare. Dr. Truillet was supported by a postdoctoral fellowship from the Department of Defense Prostate Cancer Research Program (PC151060). Research from UCSF reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under award P30CA082103. No other potential conflict of interest relevant to this article was reported. NR 25 TC 1 Z9 1 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD JAN PY 2017 VL 58 IS 1 BP 81 EP 84 DI 10.2967/jnumed.116.181800 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EG8YM UT WOS:000391343400022 PM 27660139 ER PT J AU Leventhal, JS Wyatt, CM Ross, MJ AF Leventhal, Jeremy S. Wyatt, Christina M. Ross, Michael J. TI Recycling to discover something new: the role of autophagy in kidney disease SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID FIBROSIS; MUTANTS AB This year, the Nobel Prize in Physiology or Medicine was awarded to Yoshinori Ohsumi for his groundbreaking work in dissecting the mechanisms of autophagy, a cellular process resulting in the organized degradation of cytoplasmic components. Ohsumi's work paved the way for subsequent studies that demonstrated critical roles for autophagy in modulating both acute and chronic kidney injury. This work may lead to future therapeutic approaches that target the autophagy system to prevent or treat kidney diseases. C1 [Leventhal, Jeremy S.; Wyatt, Christina M.; Ross, Michael J.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. [Leventhal, Jeremy S.; Ross, Michael J.] James J Peters Bronx VA Med Ctr, Renal Div, Bronx, NY USA. RP Leventhal, JS (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM Jeremy.leventhal@mssm.edu FU NIDDK NIH HHS [K08 DK090217, R01 DK101338, R01 DK108346] NR 8 TC 1 Z9 1 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2017 VL 91 IS 1 BP 4 EP 6 DI 10.1016/j.kint.2016.11.004 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA EG6NH UT WOS:000391162700001 PM 28003091 ER PT J AU Boedhoe, PSW Schmaal, L Abe, Y Ameis, SH Arnold, PD Batistuzzo, MC Benedetti, F Beucke, JC Bollettini, I Bose, A Brem, S Calvo, A Cheng, YQ Cho, KIK Dallaspezia, S Denys, D Fitzgerald, KD Fouche, JP Gimenez, M Gruner, P Hanna, GL Hibar, DP Hoexter, MQ Hu, H Huyser, C Ikari, K Jahanshad, N Kathmann, N Kaufmann, C Koch, K Kwon, JS Lazaro, L Liu, Y Lochner, C Marsh, R Martinez-Zalacain, I Mataix-Cols, D Menchon, JM Minuzzi, L Nakamae, T Nakao, T Narayanaswamy, JC Piras, F Piras, F Pittenger, C Reddy, YCJ Sato, JR Simpson, HB Soreni, N Soriano-Mas, C Spalletta, G Stevens, MC Szeszko, PR Tolin, DF Venkatasubramanian, G Walitza, S Wang, Z van Wingen, GA Xu, J Xu, XF Yun, JY Zhao, Q Thompson, PM Stein, DJ van den Heuvel, OA AF Boedhoe, Premika S. W. Schmaal, Lianne Abe, Yoshinari Ameis, Stephanie H. Arnold, Paul D. Batistuzzo, Marcelo C. Benedetti, Francesco Beucke, Jan C. Bollettini, Irene Bose, Anushree Brem, Silvia Calvo, Anna Cheng, Yuqi Cho, Kang Ik K. Dallaspezia, Sara Denys, Damiaan Fitzgerald, Kate D. Fouche, Jean-Paul Gimenez, Monica Gruner, Patricia Hanna, Gregory L. Hibar, Derrek P. Hoexter, Marcelo Q. Hu, Hao Huyser, Chaim Ikari, Keisuke Jahanshad, Neda Kathmann, Norbert Kaufmann, Christian Koch, Kathrin Kwon, Jun Soo Lazaro, Luisa Liu, Yanni Lochner, Christine Marsh, Rachel Martinez-Zalacain, Ignacio Mataix-Cols, David Menchon, Jose M. Minuzzi, Luciano Nakamae, Takashi Nakao, Tomohiro Narayanaswamy, Janardhanan C. Piras, Fabrizio Piras, Federica Pittenger, Christopher Reddy, Y. C. Janardhan Sato, Joao R. Simpson, H. Blair Soreni, Noam Soriano-Mas, Caries Spalletta, Gianfranco Stevens, Michael C. Szeszko, Philip R. Tolin, David F. Venkatasubramanian, Ganesan Walitza, Susanne Wang, Zhen van Wingen, Guido A. Xu, Jian Xu, Xiufeng Yun, Je-Yeon Zhao, Qing Thompson, Paut M. Stein, Dan J. van den Heuvel, Odile A. CA ENIGMA OCD Working Grp TI Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A Worldwide Meta- and Mega-Analysis SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID OBSESSIVE-COMPULSIVE DISORDER; VOXEL-BASED MORPHOMETRY; MANUAL SEGMENTATION; AMYGDALA VOLUMES; BRAIN-REGIONS; METAANALYSIS; MRI; HIPPOCAMPAL; RELIABILITY; FREESURFER AB Objective: Structural brain imaging studies in obsessive compulsive disorder (OCD) have produced inconsistent findings. This may be partially due to limited statistical power from relatively small samples and clinical heterogeneity related to variation in illness profile and developmental stage. To address these limitations, the authors conducted meta and mega-analyses of data from OCD sites worldwide. Method: T-1 images from 1,830 OCD patients and 1,759 control subjects were analyzed, using coordinated and standardized processing, to identify subcortical brain volumes that differ between OCD patients and healthy subjects. The authors performed a meta analysis on the mean of the left and right hemisphere measures of each subcortical structure, and they performed a mega-analysis by pooling these volumetric measurements from each site. The authors additionally examined potential modulating effects of clinical characteristics on morphological differences in OCD patients. Results: The meta-analysis indicated that adult patients had significantly smaller hippocampal volumes (Cohen's d=-0.13; % difference=-2.80) and larger pallidum volumes (d=0.16; % difference=3.16) compared with adult controls. Both effects were stronger in medicated patients compared with controls (d=-0.29, % difference=-4.18, and d=0.29, % difference=4.38, respectively). Unmedicated pediatric patients had significantly larger thalamic volumes (d=0.38, % difference=3.08) compared with pediatric controls. None of these findings were mediated by sample characteristics, such as mean age or scanning field strength. The mega-analysis yielded similar results. Conclusions: The results indicate different patterns of sub cortical abnormalities in pediatric and adult OCD patients. The patlidum and hippocampus seem to be of importance in adult OCD, whereas the thalamus seems to be key in pediatric OCD. These findings highlight the potential importance of neurodevelopmental alterations in OCD and suggest that further research on neuroplasticity in OCD may be useful. C1 [Boedhoe, Premika S. W.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands. Vrije Univ Amsterdam, Med Ctr, Dept Anat & Neurosci, Amsterdam, Netherlands. Free Univ Amsterdam, VU Univ, Med Ctr, Neurosci Campus Amsterdam, Amsterdam, Netherlands. Kyoto Prefectural Univ Med, Dept Psychiat, Grad Sch Med Sci, Kyoto, Japan. Ctr Addict & Mental Hlth, Toronto, ON, Canada. Hosp Sick Children, Toronto, ON, Canada. Univ Calgary, Cumming Sch Med, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada. Univ Sao Paulo, Sch Med, Dept Psychiat, Inst Psychiat, Sao Paulo, Brazil. Osped San Raffaele, Inst Sci, Clin Res Grp Psychiat & Clin Psychobiol, Div Neurosci, Milan, Italy. Humboldt Univ, Dept Psychol, Berlin, Germany. Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Obsess Compuls Disorder Clin, Bangalore, Karnataka, India. Univ Zurich, Hosp Psychiat, Dept Child & Adolescent Psychiat & Psychotherapy, Zurich, Switzerland. Inst Invest Biomed August Pi I Sunyer IDIBAPS, Magnet Resonance Image Core Facil, Barcelona, Spain. Kunming Med Univ, Affiliated Hosp 1, Dept Psychiat, Kunming, Peoples R China. Seoul Natl Univ, Coll Nat Sci, Dept Brain & Cognit Sci, Seoul, South Korea. Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Amsterdam, Netherlands. Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. Univ Cape Town, Dept Psychiat, Cape Town, South Africa. Univ Stellenbosch, Dept Psychiat, Cape Town, South Africa. Bellvitge Biomed Res Inst IDIBELL, Bellvitge Univ Hosp, Dept Psychiat, Barcelona, Spain. Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. Univ Southern Calif, Keck Sch Med, Mark & Mary Stevens Inst Neuroimaging & Informat, Imaging Genet Ctr, Marina Del Rey, CA USA. De Bascule, Acad Ctr Child & Adolescent Psychiat, Amsterdam, Netherlands. Univ Amsterdam, Acad Med Ctr, Dept Child & Adolescent Psychiat, Amsterdam, Netherlands. Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka, Japan. Tech Univ Munich, Dept Neuroradiol, Klinikum Rechts Isar, Munich, Germany. Tech Univ Munich, TUM Neuroimaging Ctr TUM NIC, Klinikum Rechts Isar, Munich, Germany. Seoul Natl Univ, Dept Psychiat, Coll Med, Seoul, South Korea. Hosp Clin Univ, Inst Neurosci, Dept Child & Adolescent Psychiat & Psychol, Barcelona, Spain. Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain. Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain. Univ Stellenbosch, Dept Psychiat, SU UCT MRC Unit Anxiety & Stress Disorders, Cape Town, South Africa. Columbia Univ, Med Ctr, New York, NY USA. New York State Psychiat Inst & Hosp, Div Child & Adolescent Psychiat, New York, NY USA. Columbia Univ, New York, NY USA. Karolinska Inst, Ctr Psychiat Res & Educ, Dept Clin Neurosci, Stockholm, Sweden. Univ Barcelona, Dept Clin Sci, Barcelona, Spain. St Josephs HealthCare, Mood Disorders Clin, Hamilton, ON, Canada. St Josephs HealthCare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. ATR Brain Informat Commun Res Lab Grp, Dept Neural Computat Decis Making, Kyoto, Japan. IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, Lab Neuropsychiat, Rome, Italy. Univ Fed ABC, Ctr Math Computat & Cognit, Santo Andre, Brazil. New York State Psychiat Inst & Hosp, Ctr OCD & Related Disorders, New York, NY 10032 USA. Univ Autonoma Barcelona, Dept Psychobiol & Methodol Hlth Sci, Barcelona, Spain. Baylor Coll Med, Beth K & Stuart C Yudofsky Div Neuropsychiat, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. Olin Neuropsychiat Res Ctr, Clin Neurosci & Dev Lab, Hartford, CT USA. Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY USA. Hartford Hosp, Inst Living, Hartford, CT USA. Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai, Peoples R China. Shanghai Key Lab Psychot Disorders, Shanghai, Peoples R China. Kunming Med Univ, Affiliated Hosp 1, Dept Internal Med, Kunming, Peoples R China. RP Boedhoe, PSW (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands. EM p.boedhoe@vumc.nl RI Batistuzzo, Marcelo/H-7790-2015 OI Benedetti, Francesco/0000-0003-4949-856X; Brem, Silvia/0000-0002-8031-1305 FU NIH BD2K [U54 EB020403-02]; Neuroscience Campus Amsterdam; IPB-grant; Hartmann Muller Foundation [1460]; International Obsessive-Compulsive Disorder Foundation Research Award; Deutsche Forschungsgemeinschaft [KO 3744/2-1]; Marato TV3 Foundation [01/2010, 091710]; Wellcome Trust; South London and Maudsley Trust, London [064846]; Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT KAKENHI) [26461753]; Government of India of the Department of Science and Technology [SR/S0/HS/0016/2011, IFA12-LSBM-26]; Government of India of the Department of Biotechnology [BT/PR13334/Med/30/259/2009, BT/06/IYBA/2012]; Wellcome-DBT India Alliance grant [500236/Z/11/Z]; Carlos III Health Institute [CP10/00604, PI13/00918, PI13/01958, PI14/00413/PI040829]; FEDER funds/European Regional Development Fund, AGAUR [2014 SGR 1672, 2014 SGR 489]; "Miguel Server" contract from the Carlos III Health Institute [CP10/00604]; Italian Ministry of Health [RC10-11-12-13-14-15A]; Swiss National Science Foundation [320030_130237]; Netherlands Organization for Scientific Research [NWO VIDI 917-15-318]; AB-Biotics; Ferrer; GlaxoSmithKline; Janssen; Lundbeck; Medtronic; Otsuka; Spanish Ministry of Science and Innovation (CIBERSAM); Alternative Funding Plan Innovation Fund; Brain and Behavioral Foundation; Canadian Institutes of Health Research; Hamilton Health Sciences Foundation; Ontario Brain Institute; Ontario Mental Health Foundation; Swiss National Science Foundation; German Research Foundation; Hochspezialisierte Medizin of the Canton of Zurich; German Federal Ministry of Education and Research; AMBRF; Biocodex; Cipla; National Responsible Gambling Foundation; Novartis; Servier; Sun; PhotoPharmics FX The ENIGMA OCD Working Group gratefully acknowledges support from the NIH BD2K award U54 EB020403-02 (principal investigator, Dr. Thompson). Supported by the Neuroscience Campus Amsterdam, IPB-grant to Dr. Schmaal and Dr. van den Heuvel; the Hartmann Muller Foundation (No. 1460 to Dr. Brem); the International Obsessive-Compulsive Disorder Foundation Research Award to Dr. Gruner; the Deutsche Forschungsgemeinschaft (KO 3744/2-1 to Dr. Koch); the Marato TV3 Foundation grants 01/2010 and 091710 to Dr. Lazaro; the Wellcome Trust and a pump priming grant from the South London and Maudsley Trust, London (project grant no. 064846) to Dr. Mataix-Cols; the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT KAKENHI No. 26461753 to Dr. Nakamae); Government of India grants to Prof. Reddy (SR/S0/HS/0016/2011) and Dr. Narayanaswamy (DST INSPIRE faculty grant -IFA12-LSBM-26) of the Department of Science and Technology; the Government of India grants to Prof. Reddy (No.BT/PR13334/Med/30/259/2009) and Dr. Narayanaswamy (BT/06/IYBA/2012) of the Department of Biotechnology; the Wellcome-DBT India Alliance grant to Dr. Venkatasubramanian (500236/Z/11/Z); the Carlos III Health Institute (CP10/00604, PI13/00918, PI13/01958, PI14/00413/PI040829); FEDER funds/European Regional Development Fund, AGAUR (2014 SGR 1672 and 2014 SGR 489); a "Miguel Server" contract (CP10/00604) from the Carlos III Health Institute to Dr. Soriano-Mas; the Italian Ministry of Health (RC10-11-12-13-14-15A to Dr. Spalletta); the Swiss National Science Foundation (No. 320030_130237 to Dr. Walitza); and the Netherlands Organization for Scientific Research (NWO VIDI 917-15-318 to Dr. van Wingen).; Dr. Menchon has received grants and served as consultant, adviser, or speaker for AB-Biotics, Ferrer, GlaxoSmithKline, Janssen, Lundbeck, Medtronic, Otsuka, and the Spanish Ministry of Science and Innovation (CIBERSAM). Dr. Minuzzi has received grant or research support from the Alternative Funding Plan Innovation Fund, the Brain and Behavioral Foundation, the Canadian Institutes of Health Research, the Hamilton Health Sciences Foundation, the Ontario Brain Institute, and the Ontario Mental Health Foundation; he has served as a consultant or speaker for Bristol-Myers Squibb, the Canadian Psychiatric Association, the Canadian Network for Mood and Anxiety Treatments, and Lundbeck. Dr. Simpson receives royalties from Cambridge University Press and UpToDate. Prof. Dr. Walitza has received lecture honoraria from Opopharma and Eli Lilly; her work and research have been partially supported by the Swiss National Science Foundation, the German Research Foundation, Hochspezialisierte Medizin of the Canton of Zurich, and the German Federal Ministry of Education and Research. Dr. Stein has received research grants or consultancy honoraria from AMBRF, Biocodex, Cipla, Lundbeck, the National Responsible Gambling Foundation, Novartis, Servier, and Sun. Dr. van den Heuvel has received research funding (sponsor-initiated clinical trial) from PhotoPharmics and has served as a speaker for Lundbeck. The other authors report no financial relationships with commercial interests. NR 38 TC 2 Z9 2 U1 7 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JAN PY 2017 VL 174 IS 1 BP 60 EP 69 DI 10.1176/appi.ajp.2016.16020201 PG 10 WC Psychiatry SC Psychiatry GA EG4BB UT WOS:000390987300012 PM 27609241 ER PT J AU de Andrade, JA Luckhardt, T AF de Andrade, Joao A. Luckhardt, Tracy TI What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike! SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID USUAL INTERSTITIAL PNEUMONIA; DIAGNOSIS; SURVIVAL C1 [de Andrade, Joao A.; Luckhardt, Tracy] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [de Andrade, Joao A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP de Andrade, JA (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.; de Andrade, JA (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. NR 12 TC 0 Z9 0 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 1 PY 2017 VL 195 IS 1 BP 10 EP 12 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG3ZB UT WOS:000390982100007 PM 28035849 ER PT J AU Eapen, BC Murphy, DP Cifu, DX AF Eapen, Blessen C. Murphy, Douglas P. Cifu, David X. TI Neuroprosthetics in amputee and brain injury rehabilitation SO EXPERIMENTAL NEUROLOGY LA English DT Review DE Neuroprosthetics; Rehabilitation; Brain injury; Amputee ID TRANSCRANIAL MAGNETIC STIMULATION; CONTROLLED-TRIAL; EARLY HISTORY; LIMB; DISORDERS; ATTENTION; CONSCIOUSNESS; PROSTHESES; NEUROPLASTICITY; EPIDEMIOLOGY AB The goals of rehabilitation medicine programs are to promote health, restore functional impairments and improve quality of life. The field of neuroprosthetics has evolved over the last decade given an improved understanding of neuroscience and the incorporation of advanced biotechnology and neuroengineering in the rehabilitation setting to develop adaptable applications to help facilitate recovery for individuals with amputations and brain injury. These applications may include a simple cognitive prosthetics aid for impaired memory in brain-injured individuals to myoelectric prosthetics arms with artificial proprioceptive feedback for those with upper extremity amputations. The integration of neuroprosthetics into the existing framework of current rehabilitation approaches not only improves quality-of-care and outcomes but help broadens current rehabilitation treatment paradigms. Although, we are in the infancy of the understanding the true benefit of neuroprosthetics and its clinical applications in the rehabilitation setting there is tremendous amount of promise for future research and development of tools to help facilitate recovery and improve quality of life in individuals with disabilities. Published by Elsevier Inc. C1 [Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Phys Med & Rehabil Serv, Polytrauma Rehabil Ctr, San Antonio, TX USA. [Eapen, Blessen C.; Cifu, David X.] VA DoD Chron Effects Neurotrauma Consortium, Richmond, VA USA. [Murphy, Douglas P.; Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. [Murphy, Douglas P.; Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA. RP Eapen, BC (reprint author), South Texas Vet Hlth Care Syst, Phys Med & Rehabil Serv, Polytrauma Rehabil Ctr, San Antonio, TX USA.; Eapen, BC (reprint author), VA DoD Chron Effects Neurotrauma Consortium, Richmond, VA USA. EM blessen.eapen2@va.gov; Douglas.Murphy3@va.gov; david.cifu@vcuhealth.org NR 69 TC 0 Z9 0 U1 24 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD JAN PY 2017 VL 287 SI SI BP 479 EP 485 DI 10.1016/j.expneurol.2016.08.004 PN 4 PG 7 WC Neurosciences SC Neurosciences & Neurology GA EG6LU UT WOS:000391158800006 PM 27519275 ER PT J AU Lugea, A Waldron, RT AF Lugea, Aurelia Waldron, Richard T. TI Exosome-Mediated Intercellular Communication Between Stellate Cells and Cancer Cells in Pancreatic Ductal Adenocarcinoma SO PANCREAS LA English DT Editorial Material ID MESSENGER-RNAS; MICRORNAS; MICROENVIRONMENT; PROGRESSION; CARCINOMA C1 Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Med, Div Gastroenterol, Los Angeles, CA 90048 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Hepatol, VA Greater Los Angeles Hlth Syst, Los Angeles, CA 90095 USA. RP Lugea, A (reprint author), Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. EM lugeaa@cshs.org FU NCI NIH HHS [P01 CA163200]; NIAAA NIH HHS [R01 AA019954]; NIDDK NIH HHS [P01 DK098108, U01 DK108314] NR 22 TC 0 Z9 0 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD JAN PY 2017 VL 46 IS 1 BP 1 EP 4 DI 10.1097/MPA.0000000000000686 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EG3JU UT WOS:000390940700001 PM 27977625 ER PT S AU Composto, AM Reisner, LA Pandya, AK Edelman, DA Jacobs, KL Bagian, TM AF Composto, Anthony M. Reisner, Luke A. Pandya, Abhilash K. Edelman, David A. Jacobs, Katrina L. Bagian, Tandi M. BE Duffy, VG Lightner, N TI Methods to Characterize Operating Room Variables in Robotic Surgery to Enhance Patient Safety SO ADVANCES IN HUMAN FACTORS AND ERGONOMICS IN HEALTHCARE SE Advances in Intelligent Systems and Computing LA English DT Proceedings Paper CT 7th International Conference on Applied Human Factors and Ergonomics / International Conference on Human Factors and Ergonomics in Healthcare CY JUL 27-31, 2016 CL Bay Lake, FL DE Task analysis; Robotic surgery; Patient safety; Clinical teams; Veterans health administration; Best practices ID OUTCOMES; MANAGEMENT; ERROR AB Surgical team experience is an important determinant of operative outcome. However, even the most experienced team will not be familiar with all potential variability that could be encountered during a surgical procedure. Robotic surgery adds further complexity through advanced technology, additional equipment, intricate process steps, etc. One method that is crucial to understanding a robotic procedure is surgical observation, which can be used to identify the process flow and involved objects. Another method is task excursion analysis, a proactive approach to understanding system variability and key factors that may affect system performance and patient safety. Finally, a method must be used to efficiently present the gathered information to surgical teams. As rapidly evolving technology is introduced into health care systems, the adoption of these types of methods is necessary to ensure patient safety. This paper describes the proposed methodology for analyzing robotic surgery variability and provides some example data. C1 [Composto, Anthony M.; Reisner, Luke A.; Pandya, Abhilash K.] Wayne State Univ, Dept Elect & Comp Engn, Wayne, NJ 48202 USA. [Edelman, David A.] Wayne State Univ, Dept Surg, Wayne, NJ 48202 USA. [Jacobs, Katrina L.; Bagian, Tandi M.] US Dept Vet Affairs, Natl Ctr Patient Safety, Ann Arbor, MI 48107 USA. RP Bagian, TM (reprint author), US Dept Vet Affairs, Natl Ctr Patient Safety, Ann Arbor, MI 48107 USA. EM aj6568@wayne.edu; lreisner@wayne.edu; apandya@ece.eng.wayne.edu; dedelman@med.wayne.edu; Katrina.Jacobs@va.gov; Tandi.Bagian@va.gov NR 12 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2194-5357 BN 978-3-319-41652-6; 978-3-319-41651-9 J9 ADV INTELL SYST PY 2017 VL 482 BP 215 EP 223 DI 10.1007/978-3-319-41652-6_21 PG 9 WC Computer Science, Artificial Intelligence; Public, Environmental & Occupational Health; Medical Informatics SC Computer Science; Public, Environmental & Occupational Health; Medical Informatics GA BG6SE UT WOS:000390838700021 ER PT J AU Tsuang, DW Bird, TD AF Tsuang, Debby W. Bird, Thomas D. TI Genetic factors in neurodegenerative diseases SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Editorial Material C1 [Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Tsuang, Debby W.] Univ Washington, Dept Med Genet, Seattle, WA 98195 USA. [Tsuang, Debby W.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Tsuang, DW (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.; Tsuang, DW (reprint author), Univ Washington, Dept Med Genet, Seattle, WA 98195 USA.; Tsuang, DW (reprint author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.; Tsuang, DW (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. EM dwt1@uw.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JAN PY 2017 VL 174 IS 1 BP 3 EP 4 DI 10.1002/ajmg.b.32504 PG 2 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA EF9PB UT WOS:000390661000001 PM 27770499 ER PT J AU Shah, C DeMichele-Sweet, MAA Sweet, RA AF Shah, Chintan DeMichele-Sweet, Mary Ann A. Sweet, Robert A. TI Genetics of psychosis of Alzheimer disease SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Review DE Alzheimer disease; psychosis; genome-wide association; heritability ID COPY-NUMBER VARIATION; INCREASED FAMILIAL RISK; GENOME-WIDE SCAN; NEUROPSYCHIATRIC SYMPTOMS; PSYCHOLOGICAL SYMPTOMS; RECEPTOR POLYMORPHISM; SEROTONIN TRANSPORTER; VARIATION ASSOCIATION; AGGRESSIVE-BEHAVIOR; APOLIPOPROTEIN-E AB Psychotic symptoms, comprised of delusions and hallucinations, occur in about half of individuals with Alzheimer disease (AD with psychosis, AD+P). These individuals have greater agitation, aggression, depression, functional impairment, and mortality than individuals without psychosis (AD-P). Although the exact etiopathogenesis of AD+P is unclear, the rapidly developing field of genomics continues to expand our understanding of this disease. Several independent studies have demonstrated familial aggregation and heritability of AD+P. Linkage studies have been suggestive of loci on several chromosomes associated with AD+P. Association studies examining apolipoprotein E gene, the best established genetic risk factor for late-onset AD, did not find any significant association of this gene with AD+P. Other candidate gene studies focusing on monoamine neurotransmitter systems have yielded equivocal results. A genome-wide association study and studies examining copy number variations recently have detected suggestive associations, but have been underpowered. Approaches to increase sizes of AD+P samples for genome wide association studies are discussed. (c) 2016 Wiley Periodicals, Inc. C1 [Shah, Chintan; DeMichele-Sweet, Mary Ann A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat & Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Hlth Illness Res Educ & Clin Ctr MIRE, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat & Neurol, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU NIA NIH HHS [P50 AG005133, R01 AG027224] NR 86 TC 1 Z9 1 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JAN PY 2017 VL 174 IS 1 BP 27 EP 35 DI 10.1002/ajmg.b.32413 PG 9 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA EF9PB UT WOS:000390661000003 PM 26756273 ER PT J AU Domoto-Reilly, K Davis, MY Keene, CD Bird, TD AF Domoto-Reilly, Kimiko Davis, Marie Y. Keene, C. Dirk Bird, Thomas D. TI Unusually long duration and delayed penetrance in a family with FTD and mutation in MAPT (V337M) SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE dementia; frontotemporal dementia; MAPT; tau; penetrance ID FRONTOTEMPORAL DEMENTIA; PRESENILE-DEMENTIA; ALZHEIMER-DISEASE; TAU GENE; APOE; CHROMOSOME-17; DEGENERATION; CARRIERS; ONSET AB Mutations in the MAPT gene coding for the tau protein are one of the most common causes of familial frontotemporal dementia (FTD). In a previously described family with the V337M mutation in MAPT, we now report an affected woman who died at age 92 with a >40 year duration of symptoms, more than three times the mean disease duration in her family (13.8 years). Neuropathology showed the typical findings of a diffuse tauopathy. Conversely, her 67-year-old son with the same mutation remains asymptomatic more than 15 years beyond the mean age of onset in the family (51.5 years). These two cases demonstrate the marked variability in onset and duration of familial FTD and underscore the difficulties of discussing these issues with patients and families. The presumed genetic and environmental factors influencing these parameters remain largely unknown. (c) 2016 Wiley Periodicals, Inc. C1 [Domoto-Reilly, Kimiko; Davis, Marie Y.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Keene, C. Dirk] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Bird, TD (reprint author), 1660 SColumbian Way,S-182 GRECC, Seattle, WA 98108 USA. EM tomnroz@uw.edu FU NIH/NIA ADRC [P50-AG005136]; VA Research Funds FX Grant sponsor: NIH/NIA ADRC; Grant number: P50-AG005136; Grant sponsor: VA Research Funds. NR 19 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JAN PY 2017 VL 174 IS 1 BP 70 EP 74 DI 10.1002/ajmg.b.32443 PG 5 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA EF9PB UT WOS:000390661000005 PM 26990251 ER PT J AU Mata, IF Davis, MY Lopez, AN Dorschner, MO Martinez, E Yearout, D Cholerton, BA Hu, SC Edwards, KL Bird, TD Zabetian, CP AF Mata, Ignacio F. Davis, Marie Y. Lopez, Alexis N. Dorschner, Michael O. Martinez, Erica Yearout, Dora Cholerton, Brenna A. Hu, Shu-Ching Edwards, Karen L. Bird, Thomas D. Zabetian, Cyrus P. TI The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot (vol 171, pg 925, 2016) SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Correction C1 [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu NR 2 TC 1 Z9 1 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JAN PY 2017 VL 174 IS 1 BP 113 EP 113 DI 10.1002/ajmg.b.32510 PG 1 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA EF9PB UT WOS:000390661000008 PM 27943640 ER PT J AU Birtolo, C Pham, H Morvaridi, S Chheda, C Go, VLW Ptasznik, A Edderkaoui, M Weisman, MH Noss, E Brenner, MB Larsonr, B Guindi, M Wang, Q Pandol, SJ AF Birtolo, Chiara Pham, Hung Morvaridi, Susan Chheda, Chintan Go, Vay Liang W. Ptasznik, Andrzej Edderkaoui, Mouad Weisman, Michael H. Noss, Erika Brenner, Michael B. Larsonr, Brent Guindi, Maha Wang, Qiang Pandol, Stephen J. TI Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID DUCTAL ADENOCARCINOMA; POTENTIAL ROLE; IN-VIVO; ADHESION; EXPRESSION; CARCINOMA; FIBROSIS; GENE; METASTASIS; INVASION AB Chronic pancreatitis is a prominent risk factor for the development of pancreatic ductal adenocarcinoma. In both conditions, the activation of myofibroblast-like pancreatic stellate cells (PSCs) plays a predominant role in the formation of desmoplastic reaction through the synthesis of connective tissue and extracellular matrix, inducing local pancreatic fibrosis and an inflammatory response. Yet the signaling events involved in chronic pancreatitis and pancreatic cancer progression and metastasis remain poorly defined. Cadherin-11 (Cad-11, also known as OB cadherin or CDH11) is a cell-to-cell adhesion molecule implicated in many biological functions, including tissue morphogenesis and architecture, extracellular matrix-mediated tissue remodeling, cytoskeletal organization, epithelial-to-mesenchymal transition, and cellular migration. In this study, we show that, in human chronic pancreatitis and pancreatic cancer tissues, Cad-11 expression was significantly increased in PSCs and pancreatic cancer cells. In particular, an increased expression of Cad-11 can be detected on the plasma membrane of activated PSCs isolated from chronic pancreatitis tissues and in pancreatic cancer cells Metastasized to the Liver. Moreover, knockdown of Cad-11 in cancer cells reduced pancreatic Cancer cell migration. Taken together, our data underline the potential role of Cad-11 in PSC activation and pancreatic cancer metastasis. C1 [Birtolo, Chiara; Pham, Hung; Morvaridi, Susan; Chheda, Chintan; Ptasznik, Andrzej; Edderkaoui, Mouad; Weisman, Michael H.; Wang, Qiang; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. [Larsonr, Brent; Guindi, Maha] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA. [Birtolo, Chiara] Univ Bologna, S Orsola Malpighi Hosp, Dept Internal Med, Bologna, Italy. [Go, Vay Liang W.; Pandol, Stephen J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Noss, Erika; Brenner, Michael B.] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA USA. [Pandol, Stephen J.] VA Greater Los Angeles Hlth Care Syst, Dept Vet Affairs, Los Angeles, CA USA. RP Wang, Q; Pandol, SJ (reprint author), Cedars Sinai Med Ctr, Dept Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM qiang.wang@cshs.org; stephen.pandol@cshs.org OI Wang, Qiang/0000-0001-9409-0251 FU Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute Developmental Funds for Liver Metastasis Team Grant Research Award "Colon, pancreas, and prostate cancer engraftment in the liver metastatic niche"; National Center for Advancing Translational Sciences UCLA CTSI grant [UL1TR000124]; Department of Veterans Affairs [I01BX001484, P01CA163200, P50 AA11999, P01DK098108] FX Supported by the Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute Developmental Funds for Liver Metastasis Team Grant Research Award "Colon, pancreas, and prostate cancer engraftment in the liver metastatic niche"; the National Center for Advancing Translational Sciences UCLA CTSI grant UL1TR000124 (Q.W.); the Department of Veterans Affairs grant I01BX001484 (S.J.P.); and NM grants P01CA163200, P50 AA11999, and P01DK098108 (S.J.P.). NR 63 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 2017 VL 187 IS 1 BP 146 EP 155 DI 10.1016/j.ajpath.2016.09.012 PG 10 WC Pathology SC Pathology GA EG1YC UT WOS:000390829300015 PM 27855278 ER PT J AU Al Hazzouri, AZ Elfassy, T Sidney, S Jacobs, D Stable, EJP Yaffe, K AF Al Hazzouri, Adina Zeki Elfassy, Tali Sidney, Stephen Jacobs, David Stable, Eliseo J. Perez Yaffe, Kristine TI Sustained Economic Hardship and Cognitive Function: The Coronary Artery Risk Development in Young Adults Study SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SOCIOECONOMIC POSITION; EDUCATIONAL-ATTAINMENT; MIDDLE-AGE; HEALTH; LIFE; INCOME; INEQUALITY; TRAJECTORIES; POPULATION; LIFECOURSE AB Introduction: The relationship between low income and worse health outcomes is evident, yet its association with cognitive outcomes is less explored. Most studies have measured income at one time and none have examined how sustained exposure to low income influences cognition in a relatively young cohort. This study examined the effect of sustained poverty and perceived financial difficulty on cognitive function in midlife. Methods: Income data were collected six times between 1985 and 2010 for 3,383 adults from the Coronary Artery Risk Development in Young Adults prospective cohort study. Sustained poverty was defined by the percentage of time participants' household income was <200% of the federal poverty level-"never" in poverty, "0< to <1/3," " >= 1/3 to <100%" or " all-time." In 2010, at a mean age of 50 years, participants underwent a cognitive battery. Data were analyzed in 2015. Results: In demographic-adjusted linear regression models, individuals with all-time poverty performed significantly worse than individuals never in poverty: 0.92 points worse on verbal memory (z-score, -0.28; 95% CI=-0.43, -0.13), 11.60 points worse on processing speed (z-score, -0.72; 95% CI=- 0.85, -0.58), and 3.50 points worse on executive function (z-score, -0.32; 95% CI=-0.47, -0.17). Similar results were observed with perceived financial difficulty. Findings were robust when restricted to highly educated participants, suggesting little evidence for reverse causation. Conclusions: Cumulative exposure to low income over 2 decades was strongly associated with worse cognitive function of a relatively young cohort. Poverty and perceived hardship may be important contributors to premature aging among disadvantaged populations. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Al Hazzouri, Adina Zeki; Elfassy, Tali] Univ Miami, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth Sci, Miami, FL 33136 USA. [Sidney, Stephen] Kaiser Permanente, Div Res, Oakland, CA USA. [Jacobs, David] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Stable, Eliseo J. Perez] Natl Inst Minor Hlth & Hlth Dispar, Bethesda, MD USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Al Hazzouri, AZ (reprint author), Univ Miami, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth Sci, Miami, FL 33136 USA. EM axz122@miami.edu FU NIH, National Institute on Aging (NIA) [K01AG047273]; NIH/NIA [k24AG031155]; T32 training grant from NIH, National Heart, Lung, and Blood Institute (NHLBI), "Behavioral Medicine Approaches to Cardiovascular Disease" [HL 007426]; University of California at San Francisco Center for Aging in Diverse Communities under "Resource Centers for Minority Aging Research program of the National Institute on Aging" [P30-AG15272]; NHLBI [HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268-201300028C, HHSN268201300029C, HHSN26820-0900041C, AG0005]; Intramural Research Program of NIA; NIA [AG0005] FX Dr. Zeki Al Hazzouri was supported by a grant from NIH, National Institute on Aging (NIA) (K01AG047273). Dr. Yaffe was supported by a grant from the NIH/NIA (k24AG031155). Tali Elfassy was supported by a T32 training grant from NIH, National Heart, Lung, and Blood Institute (NHLBI), "Behavioral Medicine Approaches to Cardiovascular Disease," (HL 007426). Funding for this study was supported in part by the University of California at San Francisco Center for Aging in Diverse Communities (P30-AG15272) under the "Resource Centers for Minority Aging Research program of the National Institute on Aging." The Coronary Artery Risk Development in Young Adults Study is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268-201300028C, HHSN268201300029C, and HHSN26820-0900041C from NHLBI, the Intramural Research Program of NIA, and an intra-agency agreement between NIA and NHLBI (AG0005). NR 41 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2017 VL 52 IS 1 BP 1 EP 9 DI 10.1016/j.amepre.2016.08.009 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EF9RM UT WOS:000390667400005 ER PT J AU Luedi, MM Doll, D Boggs, SD Stueber, F AF Luedi, Markus M. Doll, Dietrich Boggs, Steven D. Stueber, Frank TI Successful Personalities in Anesthesiology and Acute Care Medicine: Are We Selecting, Training, and Supporting the Best? SO ANESTHESIA AND ANALGESIA LA English DT Editorial Material ID EMOTIONAL INTELLIGENCE; RESIDENT PERFORMANCE; PHYSICIAN RESILIENCE; BURNOUT; PROMOTE; TRAITS C1 [Luedi, Markus M.; Stueber, Frank] Univ Bern, Univ Hosp Bern, Inselspital, Dept Anesthesiol & Pain Med, Bern, Switzerland. [Doll, Dietrich] Hannover Med Sch, Acad Teaching Hosp, St Marienhosp Vechta, Dept Gen Surg, Vechta, Germany. [Boggs, Steven D.] James J Peters VA Med Ctr, Dept Anesthesiol, New York, NY USA. [Boggs, Steven D.] Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY 10029 USA. RP Luedi, MM (reprint author), Univ Bern, Univ Hosp Bern, Inselspital, Dept Anesthesiol, Freiburgstr, CH-3010 Bern, Switzerland. EM markus.luedi2@insel.ch NR 33 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD JAN PY 2017 VL 124 IS 1 BP 359 EP 361 DI 10.1213/ANE.0000000000001714 PG 3 WC Anesthesiology SC Anesthesiology GA EF8WW UT WOS:000390613500039 PM 27861434 ER PT J AU Reinke, LF Feemster, LC McDowell, J Gunnink, E Tartaglione, EV Udris, E Curtis, JR Au, DH AF Reinke, Lynn F. Feemster, Laura C. McDowell, Jennifer Gunnink, Eric Tartaglione, Erica V. Udris, Edmunds Curtis, J. Randall Au, David H. TI The long term impact of an end-of-life communication intervention among veterans with COPD SO HEART & LUNG LA English DT Article DE End of life communication; Advance care planning; Chronic obstructive pulmonary disease (COPD); Clinician communication skills; Intervention ID INTENSIVE-CARE-UNIT; ADVANCE CARE; RANDOMIZED-TRIAL; DECISION-MAKING; ELDERLY-PATIENTS; PALLIATIVE CARE; OUTCOMES; HEALTH; FACILITATORS; PREFERENCES AB Objective: To assess if an end-of-life communication intervention with patients with COPD led to higher long-term documentation of advance care planning discussions at the end-of-life. Background: We previously demonstrated that providing clinicians a patient-specific feedback form about patients' communication preferences improved the occurrence and quality of clinician communication about end-of-life care. Methods: Among those individuals enrolled in the intervention study (2004-2007) who had died during the follow-up period (up to 2013), we assessed if patients in the intervention arm had more goals of care discussions and formal advance directives completed as compared to controls. We conducted logistic models accounting for provider level clustering, adjusting for age, FEVi, and race. Results: Among the 376 patients in the study, 157 died (76 in the intervention arm, 81 in the control arm). Over an average duration of 3.6 years (from the time of the first study appointment to death), 115 (73%) patients engaged in 451 unique end-of-life care discussions. The intervention was not associated with a higher percentage of patients with documented end-of-life conversations (I:C 75% vs 72%, p = 0.63) or completion of advance care directives (26% vs 29%, p = 0.55). Conclusions: Despite initially improving the occurrence of end-of-life conversations, the intervention did not increase the documentation of subsequent conversations about end-of-life care, nor did it improve documentation of advance directives. Future research should focus on testing multi-faceted, longitudinal, system-level interventions to enhance conversations about goals of care that promote goal-concurrent care. Published by Elsevier Inc. C1 [Reinke, Lynn F.; Feemster, Laura C.; McDowell, Jennifer; Gunnink, Eric; Tartaglione, Erica V.; Udris, Edmunds; Au, David H.] Puget Sound Hlth Care Syst, Hlth Serv R&D, Dept Vet Affairs, Seattle, WA USA. [Reinke, Lynn F.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Feemster, Laura C.; Curtis, J. Randall; Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Reinke, LF (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbia Way, Seattle, WA 98108 USA. EM reinkl@uw.edu FU Office of Nursing Services [10-004] FX This work was supported by a pilot project award from the Office of Nursing Services, #10-004, Reinke, LF (PI), from the United States (U.S.) Department of Veterans Affairs. NR 35 TC 0 Z9 0 U1 7 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 EI 1527-3288 J9 HEART LUNG JI Heart Lung PD JAN-FEB PY 2017 VL 46 IS 1 BP 30 EP 34 DI 10.1016/j.hrtlng.2016.10.003 PG 5 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA EG2AG UT WOS:000390834900007 PM 27989399 ER PT J AU Lusardi, TA Phillips, JI Wiedrick, JT Harrington, CA Lind, B Lapidus, JA Quinn, JF Saugstad, JA AF Lusardi, Theresa A. Phillips, Jay I. Wiedrick, Jack T. Harrington, Christina A. Lind, Babett Lapidus, Jodi A. Quinn, Joseph F. Saugstad, Julie A. TI MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; ApoE; biomarker; cerebrospinal fluid; microRNA; PCR ID EXPRESSION; TECHNOLOGIES; DIAGNOSIS; DEMENTIA; MARKERS; ALLELE; ADULTS AB Background: Currently available biomarkers of Alzheimer's disease (AD) include cerebrospinal fluid (CSF) protein analysis and amyloid PET imaging, each of which has limitations. The discovery of extracellular microRNAs (miRNAs) in CSF raises the possibility that miRNA may serve as novel biomarkers of AD. Objective: Investigate miRNAs in CSF obtained from living donors as biomarkers for AD. Methods: We profiled miRNAs in CSF from 50 AD patients and 49 controls using TaqMan (R) arrays. Replicate studies performed on a subset of 32 of the original CSF samples verified 20 high confidence miRNAs. Stringent data analysis using a four-step statistical selection process including log-rank and receiver operating characteristic (ROC) tests, followed by random forest tests, identified 16 additional miRNAs that discriminate AD from controls. Multimarker modeling evaluated linear combinations of these miRNAs via best-subsets logistic regression, and computed area under the ROC (AUC) curve ascertained classification performance. The influence of ApoE genotype on miRNA biomarker performance was also evaluated. Results: We discovered 36 miRNAs that discriminate AD from control CSF. 20 of these retested in replicate studies verified differential expression between AD and controls. Stringent statistical analysis also identified these 20 miRNAs, and 16 additional miRNA candidates. Top-performing linear combinations of 3 and 4 miRNAs have AUC of 0.80-0.82. Addition of ApoE genotype to the model improved performance, i.e., AUC of 3 miRNA plus ApoE4 improves to 0.84. Conclusions: CSF miRNAs can discriminate AD from controls. Combining miRNAs improves sensitivity and specificity of biomarker performance, and adding ApoE genotype improves classification. C1 [Lusardi, Theresa A.] Oregon Hlth & Sci Univ, Computat Biol Program, Portland, OR 97201 USA. [Phillips, Jay I.; Saugstad, Julie A.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,L459, Portland, OR 97239 USA. [Wiedrick, Jack T.; Lapidus, Jodi A.] Oregon Hlth & Sci Univ, Sch Publ Hlth, Biostat, Portland, OR 97201 USA. [Harrington, Christina A.] Oregon Hlth & Sci Univ, Integrated Genom Lab, Portland, OR 97201 USA. [Lind, Babett; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Layton Aging & Alzheimers Ctr, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. RP Saugstad, JA (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,L459, Portland, OR 97239 USA. EM saugstad@ohsu.edu FU NIH [NCATS UH2TR000903, NIA AG08017, NCATS UL1TR000128] FX These studies were supported by NIH grants NCATS UH2TR000903 (JAS, JFQ), NIA AG08017 (JFQ), and NCATS UL1TR000128 (Oregon Clinical and Translational Research Institute). We thank Dr. Steven Rekow for assistance in interpreting the Expression Suite data, and Dr. Shawn Westaway for the ApoE genotyping data. We also thank the OHSU Gene Profiling Shared Resource for technical advice and access to core instrumentation. NR 35 TC 1 Z9 1 U1 6 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2017 VL 55 IS 3 BP 1223 EP 1233 DI 10.3233/JAD-160835 PG 11 WC Neurosciences SC Neurosciences & Neurology GA EG1BN UT WOS:000390766600031 PM 27814298 ER PT J AU Pisapia, JM Nayak, NR Salinas, RD Macyszyn, L Lee, JYK Lucas, TH Malhotra, NR Chen, HI Schuster, JM AF Pisapia, Jared M. Nayak, Nikhil R. Salinas, Ryan D. Macyszyn, Luke Lee, John Y. K. Lucas, Timothy H. Malhotra, Neil R. Chen, H. Isaac Schuster, James M. TI Navigated odontoid screw placement using the O-arm: technical note and case series SO JOURNAL OF NEUROSURGERY-SPINE LA English DT Article DE odontoid; O-arm navigation; screw fixation; cervical spine ID SPINE SURGERY; IMAGE GUIDANCE; CERVICAL-SPINE; FRACTURES; FIXATION; MANAGEMENT; FLUOROSCOPY; SYSTEM; AXIS; DENS AB OBJECTIVE As odontoid process fractures become increasingly common in the aging population, a technical understanding of treatment approaches is critical. 3D image guidance can improve the safety of posterior cervical hardware placement, but few studies have explored its utility in anterior approaches. The authors present in a stepwise fashion the technique of odontoid screw placement using the Medtronic O-arm navigation system and describe their initial institutional experience with this surgical approach. METHODS The authors retrospectively reviewed all cases of anterior odontoid screw fixation for Type II fractures at an academic medical center between 2006 and 2015. Patients were identified from a prospectively collected institutional database of patients who had suffered spine trauma. A standardized protocol for navigated odontoid screw placement was generated from the collective experience at the authors' institution. Secondarily, the authors compared collected variables, including presenting symptoms, injury mechanism, surgical complications, blood loss, operative time, radiographically demonstrated nonunion rate, and clinical outcome at most recent follow-up, between navigated and nonnavigated cases. RESULTS Ten patients (three female; mean age 61) underwent odontoid screw placement. Most patients presented with neck pain without a neurological deficit after a fall. O-arm navigation was used in 8 patients. An acute neck hematoma and screw retraction, each requiring surgery, occurred in 2 patients in whom navigation was used. Partial vocal cord paralysis occurred after surgery in one patient in whom no navigation was used. There was no difference in blood loss or operative time with or without navigation. One patient from each group had radiographic nonunion. No patient reported.a worsening of symptoms at follow-up (mean duration 9 months). CONCLUSIONS The authors provide a detailed step-by-step guide to the navigated placement of an odontoid screw. Their surgical experience suggests that 0-arm assisted odontoid screw fixation is a viable approach. Future studies will be needed to rigorously compare the accuracy and efficiency of navigated versus nonnavigated odontoid screw placement. C1 [Pisapia, Jared M.; Nayak, Nikhil R.; Salinas, Ryan D.; Lee, John Y. K.; Lucas, Timothy H.; Malhotra, Neil R.; Chen, H. Isaac; Schuster, James M.] Univ Penn, Dept Neurosurg, 3400 Spruce St,3rd Fl Silverstein Pavil, Philadelphia, PA 19104 USA. [Macyszyn, Luke] Univ Calif Los Angeles, Med Ctr, Dept Neurosurg, Santa Monica, CA USA. [Macyszyn, Luke] Univ Calif Los Angeles, Med Ctr, Dept Orthoped, Santa Monica, CA USA. [Chen, H. Isaac] Philadelphia VA Med Ctr, Dept Neurosurg, Philadelphia, PA USA. RP Pisapia, JM (reprint author), Univ Penn, Dept Neurosurg, 3400 Spruce St,3rd Fl Silverstein Pavil, Philadelphia, PA 19104 USA. EM jared.pisapia@uphs.upenn.edu NR 29 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 1547-5654 EI 1547-5646 J9 J NEUROSURG-SPINE JI J. Neurosurg.-Spine PD JAN PY 2017 VL 26 IS 1 BP 10 EP 18 DI 10.3171/2016.5.SPINE151412 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA EG0LV UT WOS:000390725200004 PM 27517526 ER PT J AU Isaacs, K Mota, NP Tsai, J Harpaz-Rotem, I Cook, JM Kirwin, PD Krystal, JH Southwick, SM Pietrzak, RH AF Isaacs, Kayla Mota, Natalie P. Tsai, Jack Harpaz-Rotem, Ilan Cook, Joan M. Kirwin, Paul D. Krystal, John H. Southwick, Steven M. Pietrzak, Robert H. TI Psychological resilience in US military veterans: A 2-year, nationally representative prospective cohort study SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Resilience; Posttraumatic stress disorder; Veterans; Trauma; Depression; Epidemiology ID POSTTRAUMATIC-STRESS-DISORDER; SOCIAL SUPPORT; POTENTIAL TRAUMA; OLDER PERSONS; UNITED-STATES; DSM-IV; PTSD; LIFE; TRAJECTORIES; EXPOSURE AB Although many cross-sectional studies have examined the correlates of psychological resilience in U.S. military veterans, few longitudinal studies have identified long-term predictors of resilience in this population. The current prospective cohort study utilized data from a nationally representative sample of 2157 U.S. military veterans who completed web-based surveys in two waves (2011 and 2013) as part of the National Health and Resilience in Veterans Study (NHRVS). Cluster analysis of cumulative lifetime exposure to potentially traumatic events and Wave 2 measures of current symptoms of posttraumatic stress, major depressive, and generalized anxiety disorders was performed to characterize different profiles of current trauma-related psychological symptoms. Different profiles were compared with respect to sociodemographic, clinical, and psychosocial characteristics. A three-group cluster analysis revealed a Control group with low lifetime trauma exposure and low current psychological distress (59.5%), a Resilient group with high lifetime trauma and low current distress (27.4%), and a Distressed group with both high trauma exposure and current distress symptoms (13.1%). These results suggest that the majority of trauma-exposed veterans (67.7%) are psychologically resilient. Compared with the Distressed group, the Resilient group was younger, more likely to be Caucasian, and scored lower on measures of physical health difficulties, past psychiatric history, and substance abuse. Higher levels of emotional stability, extraversion, dispositional gratitude, purpose in life, and altruism, and lower levels of openness to experiences predicted resilient status. Prevention and treatment efforts designed to enhance modifiable factors such as gratitude, sense of purpose, and altruism may help promote resilience in highly trauma-exposed veterans. Published by Elsevier Ltd. C1 [Isaacs, Kayla; Tsai, Jack; Harpaz-Rotem, Ilan; Cook, Joan M.; Kirwin, Paul D.; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Dept Psychiat, Sch Med, 333 Cedar St, New Haven, CT 06510 USA. [Mota, Natalie P.] Univ Manitoba, Dept Clin Hlth Psychol, Coll Med, 771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada. [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, VA Connecticut Healthcare Syst, 950 Campbell Ave 161E, West Haven, CT 06516 USA. [Harpaz-Rotem, Ilan; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Cook, Joan M.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Evaluat Div, VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Kirwin, Paul D.] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. RP Pietrzak, RH (reprint author), US Dept Vet Affairs, Natl Ctr PTSD, Clin Neurosci Div, VA Connecticut Healthcare Syst, 950 Campbell Ave 161E, West Haven, CT 06516 USA. EM kayla.isaacs@yale.edu; natalie.mota@umanitoba.ca; jack.tsai@yale.edu; ilan.harpaz-rotem@yale.edu; joan.cook@yale.edu; paul.kirwin@yale.edu; john.krystal@yale.edu; steven.southwick@yale.edu; robert.pietrzak@yale.edu OI Tsai, Jack/0000-0002-0329-648X FU U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder FX The National Health and Resilience in Veterans Study was funded by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. This funding source did not play any role in the conduct or publication of the current study. NR 63 TC 0 Z9 0 U1 15 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2017 VL 84 BP 301 EP 309 DI 10.1016/j.jpsychires.2016.10.017 PG 9 WC Psychiatry SC Psychiatry GA EG0OW UT WOS:000390733100037 PM 27814502 ER PT J AU Bonora, G Mancini, M Carpinella, I Chiari, L Horak, FB Ferrarin, M AF Bonora, Gianluca Mancini, Martina Carpinella, Ilaria Chiari, Lorenzo Horak, Fay B. Ferrarin, Maurizio TI Gait initiation is impaired in subjects with Parkinson's disease in the OFF state: Evidence from the analysis of the anticipatory postural adjustments through wearable inertial sensors SO GAIT & POSTURE LA English DT Article DE Inertial sensors; Force plate; Accelerometry; Spatio-temporal parameters; APA phases; Levodopa ID STEP INITIATION; LEVODOPA; BALANCE AB People with Parkinson's disease (PD) typically demonstrate impaired anticipatory postural adjustments (APAs) that shift the body center of mass forward (imbalance) and over the stance leg (unloading) prior to gait initiation. APAs are known to be smallest when people with PD are in their OFF-medication state compared to ON-medication or healthy controls. The aim of this pilot study is to validate a previously developed method for the assessment of gait initiation on PD patients in OFF state with body-worn, inertial sensors. Ten subjects with mild-to-moderate idiopathic PD and twelve healthy controls of similar age performed three gait initiation trials. The spatio-temporal parameters of APAs were extracted from three wearable sensors, placed on the shins and on the lower back, and validated with two force plates. Temporal parameters extracted from sensors and force plates, as well as the trunk medio-lateral acceleration and the correspondent displacement of the center of pressure, were significantly correlated. Subjects with PD showed hypometric adjustments in the medio-lateral direction (p-value < 0.003) and increased duration of the unloading phase (p-value = 0.04). The unloading phase was significantly longer than the imbalance (p-value = 0.003) only in subjects with PD. The validity of the method of quantifying APAs from inertial sensors was confirmed in PD subjects by comparison with force plates. Sensitivity in discriminating PD patients from healthy controls was proven by both spatial and temporal parameters. Objective measures of gait initiation deficits with wearable technology provides valuable instrument for the assessment of gait initiation in clinical environments. (C) 2016 Elsevier B.V. All rights reserved. C1 [Bonora, Gianluca; Carpinella, Ilaria; Ferrarin, Maurizio] IRCCS Fdn Don Gnocchi Onlus, Biomed Technol Dept, Via Capecelatro 66, I-20148 Milan, Italy. [Mancini, Martina; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA. [Chiari, Lorenzo] Univ Bologna, Dept Elect Elect & Informat Engn Guglielmo Marcon, Viale Risorgimento 2, I-40136 Bologna, Italy. [Horak, Fay B.] Portland VA Med Ctr, Dept Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RP Carpinella, I (reprint author), IRCCS Fdn Don Gnocchi Onlus, Biomed Technol Dept, Via Capecelatro 66, I-20148 Milan, Italy. EM icarpinella@dongnocchi.it FU Italian Ministry of Health [Ricerca Corrente and Ricerca Finalizzata] [GR-2009-1604984]; NIH [RC1 NS068678, R42 HD071760-03] FX This publication was mainly funded by the Italian Ministry of Health [Ricerca Corrente and Ricerca Finalizzata: grant no. GR-2009-1604984] with the support from NIH [grant RC1 NS068678 and R42 HD071760-03] for data collection. NR 15 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2017 VL 51 BP 218 EP 221 DI 10.1016/j.gaitpost.2016.10.017 PG 4 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA EF6TF UT WOS:000390463000035 PM 27816900 ER PT J AU Eickhoff, SB Laird, AR Fox, PM Lancaster, JL Fox, PT AF Eickhoff, Simon B. Laird, Angela R. Fox, P. Mickle Lancaster, Jack L. Fox, Peter T. TI Implementation errors in the GingerALE Software: Description and recommendations SO HUMAN BRAIN MAPPING LA English DT Article DE fMRI; statistics; false positives; cluster inference; meta-analysis ID FALSE DISCOVERY RATE; PET IMAGES; METAANALYSIS; CONNECTIVITY; FMRI; NEUROSCIENCE; FAILURE; SCIENCE; SINGLE; POWER AB Neuroscience imaging is a burgeoning, highly sophisticated field the growth of which has been fostered by grant-funded, freely distributed software libraries that perform voxel-wise analyses in anatomically standardized three-dimensional space on multi-subject, whole-brain, primary datasets. Despite the ongoing advances made using these non-commercial computational tools, the replicability of individual studies is an acknowledged limitation. Coordinate-based meta-analysis offers a practical solution to this limitation and, consequently, plays an important role in filtering and consolidating the enormous corpus of functional and structural neuroimaging results reported in the peer-reviewed literature. In both primary data and meta-analytic neuroimaging analyses, correction for multiple comparisons is a complex but critical step for ensuring statistical rigor. Reports of errors in multiple-comparison corrections in primary-data analyses have recently appeared. Here, we report two such errors in GingerALE, a widely used, US National Institutes of Health (NIH)-funded, freely distributed software package for coordinate-based meta-analysis. These errors have given rise to published reports with more liberal statistical inferences than were specified by the authors. The intent of this technical report is threefold. First, we inform authors who used GingerALE of these errors so that they can take appropriate actions including re-analyses and corrective publications. Second, we seek to exemplify and promote an open approach to error management. Third, we discuss the implications of these and similar errors in a scientific environment dependent on third-party software. Hum Brain Mapp 38:7-11, 2017. (c) 2016 Wiley Periodicals, Inc. C1 [Eickhoff, Simon B.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Eickhoff, Simon B.] Heinrich Heine Univ, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Fox, P. Mickle; Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX USA. [Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Fox, PT (reprint author), 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM fox@uthscsa.edu FU US National Institute of Mental Health [RO1-MH074457]; Helmholtz Portfolio Theme "Supercomputing and Modelling for the Human Brain"; European Union [604102] FX Contract grant sponsor: US National Institute of Mental Health; Contract grant number: RO1-MH074457 (to P.T.F.); Contract grant sponsor: Helmholtz Portfolio Theme "Supercomputing and Modelling for the Human Brain" and the European Union Seventh Framework Program; Contract grant number: FP7/2007-2013 under grant agreement no. 604102. NR 35 TC 4 Z9 4 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JAN PY 2017 VL 38 IS 1 BP 7 EP 11 DI 10.1002/hbm.23342 PG 5 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA EF3XY UT WOS:000390259700001 PM 27511454 ER PT J AU Drawz, PE Pajewski, NM Bates, JT Bello, NA Cushman, WC Dwyer, JP Fine, LJ Goff, DC Haley, WE Krousel-Wood, M McWilliams, A Rifkin, DE Slinin, Y Taylor, A Townsend, R Wall, B Wright, JT Rahman, M AF Drawz, Paul E. Pajewski, Nicholas M. Bates, Jeffrey T. Bello, Natalie A. Cushman, William C. Dwyer, Jamie P. Fine, Lawrence J. Goff, David C., Jr. Haley, William E. Krousel-Wood, Marie McWilliams, Andrew Rifkin, Dena E. Slinin, Yelena Taylor, Addison Townsend, Raymond Wall, Barry Wright, Jackson T. Rahman, Mahboob TI Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study SO HYPERTENSION LA English DT Article DE blood pressure; circadian rhythm; goals; hypertension; stroke ID LEFT-VENTRICULAR HYPERTROPHY; SERVICES TASK-FORCE; RESISTANT HYPERTENSION; MASKED HYPERTENSION; EUROPEAN-SOCIETY; PROGNOSTIC VALUE; CKD; VARIABILITY; RECOMMENDATIONS; POPULATION AB The effect of clinic-based intensive hypertension treatment on ambulatory blood pressure (BP) is unknown. The goal of the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory BP ancillary study was to evaluate the effect of intensive versus standard clinic-based BP targets on ambulatory BP. Ambulatory BP was obtained within 3 weeks of the 27-month study visit in 897 SPRINT participants. Intensive treatment resulted in lower clinic systolic BP (mean difference between groups=16.0 mmHg; 95% confidence interval, 14.1-17.8 mmHg), nighttime systolic BP (mean difference=9.6 mmHg; 95% confidence interval, 7.7-11.5 mmHg), daytime systolic BP (mean difference=12.3 mmHg; 95% confidence interval, 10.6-13.9 mmHg), and 24-hour systolic BP (mean difference=11.2 mmHg; 95% confidence interval, 9.7-12.8 mmHg). The night/day systolic BP ratio was similar between the intensive (0.920.09) and standard-treatment groups (0.91 +/- 0.09). There was considerable lack of agreement within participants between clinic systolic BP and daytime ambulatory systolic BP with wide limits of agreement on Bland-Altman plots. In conclusion, targeting a systolic BP of <120 mmHg, when compared with <140 mmHg, resulted in lower nighttime, daytime, and 24-hour systolic BP, but did not change the night/day systolic BP ratio. Ambulatory BP monitoring may be required to assess the effect of targeted hypertension therapy on out of office BP. Further studies are needed to assess whether targeting hypertension therapy based on ambulatory BP improves clinical outcomes. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01835249. C1 [Drawz, Paul E.] Univ Minnesota, Div Renal Dis & Hypertens, 717 Delaware St SE,Suite 353, Minneapolis, MN 55414 USA. [Pajewski, Nicholas M.] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Bates, Jeffrey T.; Taylor, Addison] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Bates, Jeffrey T.] Baylor Coll Med, Div Gen Internal Med, Houston, TX 77030 USA. [Bello, Natalie A.] Cornell Univ, Med Ctr, Div Cardiol, New York, NY 10021 USA. [Cushman, William C.] Vet Affairs Med Ctr, Dept Med, Memphis, TN USA. [Dwyer, Jamie P.] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Nashville, TN USA. [Fine, Lawrence J.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA. [Goff, David C., Jr.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Haley, William E.] Mayo Clin, Div Nephrol & Hypertens, Jacksonville, FL 32224 USA. [Krousel-Wood, Marie] Tulane Univ, Dept Med, Ochsner Hlth Syst, New Orleans, LA 70118 USA. [Krousel-Wood, Marie] Tulane Univ, Dept Epidemiol, Ochsner Hlth Syst, New Orleans, LA 70118 USA. [McWilliams, Andrew] Carolinas HealthCare Syst, Dept Family Med, Charlotte, NC USA. [Rifkin, Dena E.] Vet Affairs Hlth Syst, Div Nephrol, San Diego, CA USA. [Rifkin, Dena E.] Univ Calif San Diego, San Diego, CA 92103 USA. [Slinin, Yelena] Vet Affairs Hlth Syst, Div Nephrol, Minneapolis, MN USA. [Slinin, Yelena] Univ Minnesota, Minneapolis, MN USA. [Taylor, Addison] Baylor Coll Med, Div Hypertens & Clin Pharmacol, Houston, TX 77030 USA. [Townsend, Raymond] Univ Penn, Med Ctr, Nephrol & Hypertens, Philadelphia, PA 19104 USA. [Wall, Barry] Vet Affairs Med Ctr, Memphis, TN USA. [Wall, Barry] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Wright, Jackson T.] Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Div Nephrol & Hypertens, Cleveland, OH 44106 USA. [Rahman, Mahboob] Case Western Reserve Univ, Div Nephrol & Hypertens, Univ Hosp Cleveland Med Ctr, Louis Stokes Cleveland VAMC, Cleveland, OH 44106 USA. RP Drawz, PE (reprint author), Univ Minnesota, Div Renal Dis & Hypertens, 717 Delaware St SE,Suite 353, Minneapolis, MN 55414 USA. EM draw0003@umn.edu FU National Institutes of Health (NIH) [R03DK100530, K12HD043451, K23DK091521, R03DK105314]; University of Minnesota Chronic Kidney Disease Research Fund; Federal funds from the NIH; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS) [HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN2682009 00049C]; Clinical and Translational Science Awards - National Center for Advancing Translational Sciences (NCATS)-Case Western Reserve University [UL1TR000439]; Ohio State University [UL1RR025755]; University of Pennsylvania [UL1RR024134, UL1TR000003]; University of Illinois [UL1TR000050]; University of Pittsburgh [UL1TR000005]; University of Texas Southwestern [9U54TR000017-06]; University of Utah [UL1TR000105-05]; Vanderbilt University [UL1TR000445]; George Washington University [UL1TR000075]; University of CA, Davis [UL1TR000002]; University of Florida [UL1TR000064]; University of Michigan [UL1TR000433]; Tulane University Center of Biomedical Research Excellence Award, National Institute of General Medical Sciences [P30GM103337]; [A-HL-13-002-001]; [UL1RR025771]; [UL1TR000093]; [UL1RR025752]; [UL1TR000073]; [UL1TR001064] FX The SPRINT ambulatory blood pressure ancillary study was supported by grants R03DK100530 (P.E. Drawz), K12HD043451 (M. Krousel-Wood), K23DK091521 (D.E. Rifkin), and R03DK105314 (D.E. Rifkin) from the National Institutes of Health (NIH) and funds from the University of Minnesota Chronic Kidney Disease Research Fund. The SPRINT (Systolic Blood Pressure Intervention Trial) is funded with Federal funds from the NIH, including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS), under Contract Numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN2682009 00049C, and Inter-Agency Agreement Number A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NHLBI, the US Department of Veterans Affairs, the US Department of Health and Human Services, the University of Minnesota, or the United States Government. We also acknowledge the support from the following: Clinical and Translational Science Awards funded by National Center for Advancing Translational Sciences (NCATS)-Case Western Reserve University: UL1TR000439; Ohio State University: UL1RR025755; University of Pennsylvania: UL1RR024134 and UL1TR000003; Boston: UL1RR025771; Stanford: UL1TR000093; Tufts: UL1RR025752, UL1TR000073, and UL1TR001064; University of Illinois: UL1TR000050; University of Pittsburgh: UL1TR000005; University of Texas Southwestern: 9U54TR000017-06; University of Utah: UL1TR000105-05; Vanderbilt University: UL1TR000445; George Washington University: UL1TR000075; University of CA, Davis: UL1TR000002; University of Florida: UL1TR000064; University of Michigan: UL1TR000433; and Tulane University: P30GM103337 Center of Biomedical Research Excellence Award, National Institute of General Medical Sciences. All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of article writing and revision were performed by the coauthors. Scientists at the National Institutes of Health participated in the design of the study and as a group had 1 vote on the steering committee of the trial. NR 30 TC 6 Z9 6 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD JAN PY 2017 VL 69 IS 1 BP 42 EP 50 DI 10.1161/HYPERTENSIONAHA.116.08076 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EF5IA UT WOS:000390362700009 PM 27849563 ER PT J AU Calverley, PM Eriksson, G Jenkins, CR Anzueto, AR Make, BJ Persson, A Fageras, M Postma, DS AF Calverley, Peter M. Eriksson, Goran Jenkins, Christine R. Anzueto, Antonio R. Make, Barry J. Persson, Anders Fageras, Malin Postma, Dirkje S. TI Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE bronchodilator agents; clinical respiratory medicine; clinical trials; COPD ID OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; FLUTICASONE PROPIONATE; CLINICAL-TRIAL; DOUBLE-BLIND; EXACERBATIONS; MANAGEMENT; TIOTROPIUM; FORMOTEROL; BUDESONIDE AB Background and objective: Large clinical trials have confirmed the long-term efficacy of inhaled corticosteroid/long-acting beta(2)-agonist combinations in patients with chronic obstructive pulmonary disease (COPD). It was hypothesized that significant treatment effects would already be present within 3 months after the initiation of treatment across a range of clinical outcomes, irrespective of COPD severity. Methods: Post hoc analysis of 3-month post-randomization outcomes, including exacerbation rates, dropouts, symptoms, reliever use, and lung function, from three studies with similar inclusion criteria of moderate-to-very-severe COPD. Patients (n=1,571) were treated with budesonide/formoterol (B/F) 320/9 mu g or placebo, twice daily; in one study, tiotropium 18 mu g once daily was also given. Results: Over the first 3 months of treatment, fewer patients randomized to B/F experienced exacerbations versus the placebo group (111 and 196 patients with >= 1 exacerbation, respectively). This was true in each COPD severity group. Compared with placebo, B/F treatment led to significantly lower 3-month exacerbation rates in the moderate and severe COPD severity groups (46% and 57% reduction, respectively), with a nonsignificant reduction (29%) in very severe COPD. Fewer dropouts occurred among patients treated with B/F versus placebo, this effect being greater with increasing COPD severity. B/F was associated with improved forced expiratory volume in 1 s, morning peak expiratory flow rate, total reliever use, and total symptom score versus placebo. Conclusion: Treatment with B/F decreased exacerbations in patients with moderate-to-very-severe COPD within 3 months of commencing treatment. This effect was paralleled by improved lung function, less reliever medication use, and fewer symptoms, irrespective of disease severity. C1 [Calverley, Peter M.] Aintree Univ Hosp NHS Fdn Trust, Pulm & Rehabil Res Grp, Liverpool, Merseyside, England. [Eriksson, Goran] Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden. [Jenkins, Christine R.] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia. [Jenkins, Christine R.] Concord Clin Sch, Sydney, NSW, Australia. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pulm Med & Allergol, San Antonio, TX 78229 USA. [Anzueto, Antonio R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Make, Barry J.] Univ Colorado, Natl Jewish Hlth, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Persson, Anders; Fageras, Malin] AstraZeneca R&D, Gothenburg, Sweden. [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pulm Med & TB, Groningen, Netherlands. RP Calverley, PM (reprint author), Aintree Univ Hosp NHS Fdn Trust, Pulm & Rehabil Res Grp, Liverpool, Merseyside, England.; Calverley, PM (reprint author), Aintree Univ Hosp NHS Fdn Trust, Dept Clin Sci, Inst Aging & Chron Dis, Lower Lane, Liverpool L9 7AL, Merseyside, England. EM pmcal@liverpool.ac.uk FU AstraZeneca; Chiesi FX The authors would like to thank Thomas Similowski and Ian Naya for their contributions to this manuscript. We also thank Katharine Williams and Ash Dunne of inScience Communications, Springer Healthcare, who provided medical writing support funded by AstraZeneca. The sponsor (AstraZeneca) funded this analysis and was involved in the analysis, design, and interpretation of the data, always in conjunction with the authors. The University of Groningen has received money for research by unrestricted educational grants from AstraZeneca and Chiesi. AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Nycomed have provided support for travel to meetings. NR 26 TC 0 Z9 0 U1 4 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2017 VL 12 BP 13 EP 25 DI 10.2147/COPD.S114209 PG 13 WC Respiratory System SC Respiratory System GA EF5NZ UT WOS:000390378200001 PM 28031707 ER PT J AU Simoni, JM Smith, L Oost, KM Lehavot, K Fredriksen-Goldsen, K AF Simoni, Jane M. Smith, Laramie Oost, Kathryn M. Lehavot, Keren Fredriksen-Goldsen, Karen TI Disparities in Physical Health Conditions Among Lesbian and Bisexual Women: A Systematic Review of Population-Based Studies SO JOURNAL OF HOMOSEXUALITY LA English DT Article DE Bisexual women; lesbian; LGBT; physical health disparities; systematic review ID SEXUAL MINORITY WOMEN; OF-THE-LITERATURE; RANDOMIZED-TRIALS; ORIENTATION; GAY; OVERWEIGHT; OBESITY; STRESS; MODEL AB We conducted a systematic review to assess evidence for disparities for lesbian and bisexual women (i.e., sexual minority women [SMW]) in comparison with heterosexual women across a range of nine physical health conditions. Among the k=11 studies meeting eligibility criteria, almost every comparison (i.e., heterosexual vs. (a) lesbian, (b) bisexual, or (c) both lesbian and bisexual women) was in a direction indicating SMW disparities. Despite limited power due to small samples of SMW, we found evidence of disparities as indicated by a statistically significant adjusted odds ratios for asthma (5 of 7 comparisons), obesity (8 of 12), arthritis (2 of 3), global ratings of physical health (4 of 7), and cardiovascular disease (1 of 1). Evidence was lacking for cancer (1 of 4), diabetes and hypertension (both 1 of 5), and high cholesterol (0 of 3). Future work should confirm findings in more diverse, larger samples and should examine potential explanatory factors. C1 [Simoni, Jane M.] Univ Washington, Dept Psychol, 3909 Stevens Way NE,Campus Box 351525, Seattle, WA 98195 USA. [Smith, Laramie] Univ Calif San Diego, Sch Med, Div Global Publ Hlth, San Diego, CA 92103 USA. [Oost, Kathryn M.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. [Lehavot, Keren] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Fredriksen-Goldsen, Karen] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. RP Simoni, JM (reprint author), Univ Washington, Dept Psychol, 3909 Stevens Way NE,Campus Box 351525, Seattle, WA 98195 USA. EM jsimoni@uw.edu FU NIA [R01AG026526]; VA Career Development Award from CSRD [1K2 CX000867]; [K24MH093243]; [P30AI27757] FX Simoni was supported by K24MH093243 and P30AI27757. Fredriksen-Goldsen was supported by NIA (R01AG026526). Smith was supported by the Fogarty International Center of NIH (D43TW008633) as a T32 postdoctoral fellow. Lehavot was supported by a VA Career Development Award from CSR&D (1K2 CX000867). NR 26 TC 0 Z9 0 U1 5 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0091-8369 EI 1540-3602 J9 J HOMOSEXUAL JI J. Homosex. PY 2017 VL 64 IS 1 BP 32 EP 44 DI 10.1080/00918369.2016.1174021 PG 13 WC Psychology, Multidisciplinary; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA EF2RH UT WOS:000390171500002 PM 27074088 ER PT J AU Osier, ND Bales, JW Pugh, B Shin, S Wyrobek, J Puccio, AM Okonkwo, DO Ren, DX Alexander, S Conley, YP Dixon, CE AF Osier, Nicole D. Bales, James W. Pugh, Bunny Shin, Samuel Wyrobek, Julie Puccio, Ava M. Okonkwo, David O. Ren, Dianxu Alexander, Sheila Conley, Yvette P. Dixon, C. Edward TI Variation in PPP3CC Genotype Is Associated with Long-Term Recovery after Severe Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE cognitive function; outcome measures; recovery; traumatic brain injury ID MITOCHONDRIAL PERMEABILITY TRANSITION; FLUID PERCUSSION INJURY; FULL-LENGTH HUMAN; CYCLOSPORINE-A; CALCINEURIN-A; GAMMA-SUBUNIT; CATALYTIC SUBUNIT; SYNAPTIC FUNCTION; RAT HIPPOCAMPUS; NEURONAL CELLS AB After experimental traumatic brain injury (TBI), calcineurin is upregulated; blocking calcineurin is associated with improved outcomes. In humans, variation in the calcineurin A-gamma gene (PPP3CC) has been associated with neuropsychiatric disorders, though any role in TBI recovery remains unknown. This study examines associations between PPP3CC genotype and mortality, as well as gross functional status assessed at admission using the Glasgow Coma Scale (GCS) and at 3, 6, and 12 months after severe TBI using the Glasgow Outcome Score (GOS). The following tagging single nucleotide polymorphisms (tSNPs) in PPP3CC were genotyped: rs2443504, rs2461491, rs2469749, and rs10108011. The rs2443504 AA genotype was univariately associated with GCS (p = 0.022), GOS at 3, 6, and 12 months (p = 0.002, p = 0.034, and p = 0.004, respectively), and mortality (p = 0.007). In multivariate analysis controlling for age, sex, and GCS, the AA genotype of rs2443504 was associated with GOS at 3 (p = 0.02), and 12 months (p = 0.01), with a trend toward significance at 6 months (p = 0.05); the AA genotype also was associated with mortality in the multivariate model (p = 0.04). Further work is warranted to better understand the role of calcineurin, as well as the genes encoding it and their relevance to outcomes after brain injury. C1 [Osier, Nicole D.; Pugh, Bunny; Shin, Samuel; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA. [Osier, Nicole D.; Ren, Dianxu; Alexander, Sheila; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Alexander, Sheila] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Bales, James W.] Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA. [Pugh, Bunny] Seton Hill Univ, Safar Ctr Resuscitat Res, Greensburg, PA USA. [Wyrobek, Julie] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA. [Puccio, Ava M.; Okonkwo, David O.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bales, James W.; Wyrobek, Julie] Univ Pittsburgh, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. RP Dixon, CE (reprint author), Univ Pittsburgh, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM dixonec@upmc.edu FU PPG Grant [30315, P50NS030318]; VA RRD [B6761R]; NIH [R01NR008424, R01NR13342, F31NR014957, T32NR009759]; Pittsburgh Foundation; Sigma Theta Tau International Eta Chapter; International Society for Nurses in Genetics; American Association of Neuroscience Nursing/Neuroscience Nursing Foundation FX This work was generously supported by several grants, including: PPG Grant 30315, P50NS030318, VA RR&D#B6761R, NIH R01NR008424, R01NR13342, F31NR014957, and T32NR009759. Additional support for this work was provided by grants from the following foundations and professional societies: the Pittsburgh Foundation, Sigma Theta Tau International Eta Chapter, the International Society for Nurses in Genetics, and the American Association of Neuroscience Nursing/Neuroscience Nursing Foundation. The authors would like to thank Marilyn K. Farmer, Amanda Savarese, and Lan Pham for their continued editorial support and Michael D. Farmer for his assistance with the figures. NR 81 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JAN 1 PY 2017 VL 34 IS 1 BP 86 EP 96 DI 10.1089/neu.2015.4343 PG 11 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA EF6DE UT WOS:000390420100011 PM 27225880 ER PT J AU Pederson, H Royer, EL Regen, D Ruan, A Pagoto, SL Dellavalle, RP AF Pederson, Hannah Royer, Eryn L. Regen, Donna Ruan, Allen Pagoto, Sherry L. Dellavalle, Robert P. TI A proactive approach to ending the use of university debit cards for indoor tanning SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter C1 [Pederson, Hannah; Royer, Eryn L.; Ruan, Allen] Univ Colorado, Sch Med, Aurora, CO USA. [Pagoto, Sherry L.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA USA. [Dellavalle, Robert P.] Univ Colorado Anschutz Med Campus, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado Anschutz Med Campus, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Dermatol Serv, Eastern Colorado Hlth Care Syst, Denver, CO USA. RP Dellavalle, RP (reprint author), Dept Vet Affairs Med Ctr, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu OI Pederson, Hannah/0000-0003-0240-8395 NR 5 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JAN PY 2017 VL 76 IS 1 BP E35 EP E36 DI 10.1016/j.jaad.2016.09.044 PG 2 WC Dermatology SC Dermatology GA EF0TC UT WOS:000390037900019 PM 27986162 ER PT J AU Czerniecki, JM Turner, AP Williams, RM Thompson, ML Landry, G Hakimi, K Speckman, R Norvell, DC AF Czerniecki, Joseph M. Turner, Aaron P. Williams, Rhonda M. Thompson, Mary Lou Landry, Greg Hakimi, Kevin Speckman, Rebecca Norvell, Daniel C. TI The development and validation of the AMPREDICT model for predicting mobility outcome after dysvascular lower extremity amputation SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID LOWER-LIMB AMPUTATION; SELF-RATED HEALTH; ACUTE MYOCARDIAL-INFARCTION; TRANSMETATARSAL AMPUTATIONS; FUNCTIONAL OUTCOMES; DISEASE; MORTALITY; AMPUTEES; DETERMINANTS; LIMITATIONS AB Objective: The objective of this study was the development of AMPREDICT-Mobility, a tool to predict the probability of independence in either basic or advanced (iBASIC or iADVANCED) mobility 1 year after dysvascular major lower extremity amputation. Methods: Two prospective cohort studies during consecutive 4-year periods (2005-2009 and 2010-2014) were conducted at seven medical centers. Multiple demographic and biopsychosocial predictors were collected in the periamputation period among individuals undergoing their first major amputation because of complications of peripheral arterial disease or diabetes. The primary outcomes were iBASIC and iADVANCED mobility, as measured by the Locomotor Capabilities Index. Combined data from both studies were used for model development and internal validation. Backwards stepwise logistic regression was used to develop the final prediction models. The discrimination and calibration of each model were assessed. Internal validity of each model was assessed with bootstrap sampling. Results: Twelve-month follow-up was reached by 157 of 200 (79%) participants. Among these, 54 (34%) did not achieve iBASIC mobility, 103 (66%) achieved at least iBASIC mobility, and 51 (32%) also achieved iADVANCED mobility. Predictive factors associated with reduced odds of achieving iBASIC mobility were increasing age, chronic obstructive pulmonary disease, dialysis, diabetes, prior history of treatment for depression or anxiety, and very poor to fair self-rated health. Those who were white, were married, and had at least a high-school degree had a higher probability of achieving iBASIC mobility. The odds of achieving iBASIC mobility increased with increasing body mass index up to 30 kg/m(2) and decreased with increasing body mass index thereafter. The prediction model of iADVANCED mobility included the same predictors with the exception of diabetes, chronic obstructive pulmonary disease, and education level. Both models showed strong discrimination with C statistics of 0.85 and 0.82, respectively. The mean difference in predicted probabilities for those who did and did not achieve iBASIC and iADVANCED mobility was 33% and 29%, respectively. Tests for calibration and observed vs predicted plots suggested good fit for both models; however, the precision of the estimates of the predicted probabilities was modest. Internal validation through bootstrapping demonstrated some overoptimism of the original model development, with the optimism-adjusted C statistic for iBASIC and iADVANCED mobility being 0.74 and 0.71, respectively, and the discrimination slope 19% and 16%, respectively. Conclusions: AMPREDICT-Mobility is a user-friendly prediction tool that can inform the patient undergoing a dysvascular amputation and the patient's provider about the probability of independence in either basic or advanced mobility at each major lower extremity amputation level. C1 [Czerniecki, Joseph M.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin; Speckman, Rebecca] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Czerniecki, Joseph M.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin; Speckman, Rebecca] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Thompson, Mary Lou] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Landry, Greg] Oregon Hlth & Sci Univ, Dept Surg, Div Vasc Surg, Portland, OR 97201 USA. [Norvell, Daniel C.] Spectrum Res Inc, 705 S 9th St,Ste 203, Tacoma, WA 98405 USA. RP Norvell, DC (reprint author), Spectrum Res Inc, 705 S 9th St,Ste 203, Tacoma, WA 98405 USA. EM dan@specri.com FU U.S. Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development [A41241]; [B4927W] FX This material is based on work supported by the U.S. Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development (Merit Review A41241 [J.M.C., principal investigator] and Career Development Award B4927W [A.P.T., principal investigator]). The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States government. NR 43 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2017 VL 65 IS 1 BP 162 EP + DI 10.1016/j.jvs.2016.08.078 PG 13 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EF0VT UT WOS:000390045100048 PM 27751738 ER PT J AU Stone, JA Lester, CA Aboneh, EA Phelan, CH Welch, LL Chui, MA AF Stone, Jamie A. Lester, Corey A. Aboneh, Ephrem A. Phelan, Cynthia H. Welch, Lauren L. Chui, Michelle A. TI A preliminary examination of over-the-counter medication misuse rates in older adults SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Drugs; Medication; Health; Sleep; Community pharmacy ID ADVERSE DRUG EVENTS; UNITED-STATES; CARE AB Background: Older adults are the largest consumers of over the counter (OTC) medications. Of the older adults who are at risk of a major adverse drug event, more than 50% of these events involve an OTC medication. Objective: To explore how older adults select and hypothetically use OTC medications and if the selected medications would be considered safe for use. Methods: Walking interviews were conducted with 20 community-dwelling older adults in a community pharmacy. Each participant selected an OTC medication for a hypothetical pain and sleep scenario. Data were analyzed for four types of misuse: drug drug interaction, drug disease interaction, drug age interaction, and excess usage. Results: At least one instance of potential misuse was found in 95% of participants. For sleep medications, drug-drug interactions and drug-age interactions were more common, affecting 50% and 65% of participants respectively. The most common type of misuse noted in the pain products selected was that of drug-drug interaction, with a total of 39 occurrences, affecting 60% of the participants. Conclusions: OTC misuse is common among older adults, and it is important for older adults to seek out resources, such as a pharmacist, to help them make safe OTC decisions. (C) 2016 Elsevier Inc. All rights reserved. C1 [Stone, Jamie A.; Lester, Corey A.; Aboneh, Ephrem A.; Chui, Michelle A.] Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA. [Phelan, Cynthia H.; Welch, Lauren L.] William S Middleton Mem Vet Adm Med Ctr, Dept Vet Affairs, 2500 Overlook Terrace, Madison, WI 53705 USA. RP Chui, MA (reprint author), Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA. EM michelle.chui@wisc.edu FU Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; U.S. Department of Veterans Affairs Clinical Science Research & Development Service [1K2CX000535] FX The project described was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427 and Career Development Award #1K2CX000535 from the U.S. Department of Veterans Affairs Clinical Science Research & Development Service (Phelan). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the U.S. Department of Veterans Affairs, or the United States Government. NR 17 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD JAN-FEB PY 2017 VL 13 IS 1 BP 187 EP 192 DI 10.1016/j.sapharm.2016.01.004 PG 6 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA EE8GM UT WOS:000389863700014 PM 26853833 ER PT J AU Butt, AA Ren, Y Marks, K Shaikh, OS Sherman, KE AF Butt, A. A. Ren, Y. Marks, K. Shaikh, O. S. Sherman, K. E. CA ERCHIVES Study TI Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID C VIRUS-INFECTION; CIRRHOSIS; DASABUVIR; ABT-450/R-OMBITASVIR; RIBAVIRIN; PARITAPREVIR; OMBITASVIR; RITONAVIR; SURVIVAL; THERAPY AB Background Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre-treatment cirrhosis, but this risk is not well defined. Aim To determine the incidence of hepatic decompensation, liver transplantation, death and worsening renal function in patients treated with a Paritaprevir/ritonavir, Ombitasvir, Dasabuvir (PrOD), sofosbuvir/simeprevir or sofosbuvir/ledipasvir regimen. Methods We followed ERCHIVES participants treated with the above regimens for up to 12 weeks post-treatment. We excluded those with HIV, HBsAg+ and pre-existing diagnosis of hepatic decompensation and hepatocellular carcinoma. Results Of 3728 persons on PrOD, 1578 on sofosbuvir/simeprevir and 10 440 on sofosbuvir/ledipasvir, incidence rates (95% CI) of hepatic decompensation/1000 patient-years were 10.6 (5.89-17.36) for the PrOD, 32.4 (20.74-48.16) for the sofosbuvir/simeprevir and 13.0 (9.74-17.10) for the sofosbuvir/ledipasvir. Among those with baseline cirrhosis, these rates were 36.9 (19.1-64.5), 61.8 (38.2-94.5) and 41.1 (29.9-55.2) respectively, while among those without cirrhosis at baseline, these rates were 2.7 (0.6-8.0), 7.5 (1.5-21.8) and 2.7 (1.2-5.4). Advanced fibrosis was associated with increased risk of hepatic decompensation in all groups [HR (95% CI) per 0.5 unit increase in FIB-4 score: PrOD 1.11 (1.07-1.16); sofosbuvir/simeprevir 1.03 (1.01-1.05); sofosbuvir/ledipasvir 1.02 (1.01-1.03)]. There were no deaths. Proportion of persons with eGFR decrease >30 ml/min/1.73 m(2) was higher among the PrOD group, but presence of cirrhosis did not appear to affect this. Conclusions The incidence of hepatic decompensation in persons treated with PrOD, up to 12 weeks after completion of treatment, was comparable to those treated with sofosbuvir/ledipasvir regimen, and was lower than among those treated with a sofosbuvir/simeprevir regimen. Such risk was predominantly observed in those with pre-treatment cirrhosis. C1 [Butt, A. A.; Ren, Y.; Shaikh, O. S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, A. A.] Weill Cornell Med Coll, Doha, Qatar. [Butt, A. A.] Weill Cornell Med Coll, New York, NY USA. [Butt, A. A.; Marks, K.] Hamad Med Corp, Hamad Healthcare Qual Inst, Doha, Qatar. [Shaikh, O. S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Sherman, K. E.] Univ Cincinnati, Cincinnati, OH USA. RP Butt, AA (reprint author), Univ Dr C,Bldg 30,Mailstop 151, Pittsburgh, PA 15240 USA. EM aab2005@qatar-med.cornell.edu FU AbbVie Inc.; Gilead; AbbVie FX This work was supported in part by an investigator initiated grant from AbbVie Inc. to Veterans Research Foundation of Pittsburgh (Principal Investigator Dr Butt). Dr Butt has received grant support (to the institution) from Gilead and AbbVie. Dr Shaikh has received grant support (to the institution) from Gilead. Dr Sherman reports grants from AbbVie, Anadys, Genentech, Gilead, Merck, Novartis, Vertex, personal fees from Bioline, MedImmune, Merck, Kadmon, personal fees from Janssen, MedPace, Synteract, outside the submitted work. Dr Marks and Ms. Ren have nothing to disclose. NR 30 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JAN PY 2017 VL 45 IS 1 BP 150 EP 159 DI 10.1111/apt.13837 PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA EE2UF UT WOS:000389439600015 PM 27813162 ER PT J AU Sonnenberg, A Turner, KO Spechler, SJ Genta, RM AF Sonnenberg, A. Turner, K. O. Spechler, S. J. Genta, R. M. TI The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ESOPHAGEAL ADENOCARCINOMA; UNITED-STATES; INFECTION; PREVALENCE; DIAGNOSIS; DISEASE; RISK; CLASSIFICATION; EPIDEMIOLOGY; METAANALYSIS AB Background Environmental risk factors associated with ethnicity may contribute to the occurrence of Barrett's metaplasia. Aim To investigate the interaction between ethnicity and Helicobacter pylori infection in the occurrence of Barrett's metaplasia among patients undergoing oesophago-gastro-duodenoscopy. Methods The Miraca Life Sciences Database is an electronic repository of histopathological patient records. A case-control study evaluated the influence of age, gender, ethnicity and histological diagnosis of H. pylori on the occurrence of Barrett's metaplasia. Results The total study population comprised 596 479 subjects, of whom 76 475 harboured a diagnosis of Barrett's metaplasia. Male sex, age and H. pylori infection in declining order exerted the strongest influence on the occurrence of BM. In comparison with the population comprising Caucasians and African Americans, Barrett's metaplasia was less common among subjects of African (OR = 0.09, 95% CI = 0.01-0.43), Middle Eastern (0.26, 0.20-0.34), East Asian (0.35, 0.31-0.40), Indian (0.39, 0.32-0.47), Hispanic (0.62, 0.59-0.64) or Jewish descent (0.50, 0.45-0.54), but more common among subjects of Northern European descent (1.14, 1.03-1.26). With the exception of Jews and Northern Europeans, all other ethnic subgroups were characterised by a higher prevalence of H. pylori than the comparison group. A low prevalence of H. pylori was significantly associated with a high prevalence of Barrett's metaplasia (R-2 = 0.82, P < 0.001), as well as dysplasia or oesophageal adenocarcinoma (R-2 = 0.81, P < 0.001). Conclusion Our analysis reveals an inverse relationship between the prevalence of Barrett's metaplasia and H. pylori gastritis among different ethnic groups within the United States. C1 [Sonnenberg, A.; Turner, K. O.; Genta, R. M.] Miraca Life Sci, Irving, TX USA. [Sonnenberg, A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Spechler, S. J.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Genta, R. M.] Baylor Coll Med, Houston, TX 77030 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 32 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JAN PY 2017 VL 45 IS 2 BP 283 EP 290 DI 10.1111/apt.13854 PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA EE2VA UT WOS:000389441900008 PM 27862104 ER PT J AU Beam, CA MacCallum, C Herold, KC Wherrett, DK Palmer, J Ludvigsson, J AF Beam, Craig A. MacCallum, Colleen Herold, Kevan C. Wherrett, Diane K. Palmer, Jerry Ludvigsson, Johnny CA Type 1 Diabet TrialNet Study Grp TI GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis SO DIABETOLOGIA LA English DT Article DE Bayes methods; Glutamic acid decarboxylase (GAD); Meta-analysis; Type 1 diabetes; Vaccine ID ANTIGEN-BASED THERAPY; C-PEPTIDE; T-CELLS; P-VALUE; MICE; TRIAL AB GAD is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. Randomised controlled clinical trials of a GAD + alum vaccine in human participants have so far given conflicting results. In this study, we sought to see whether a clearer answer to the question of whether GAD65 has an effect on C-peptide could be reached by combining individual-level data from the randomised controlled trials using Bayesian meta-analysis to estimate the probability of a positive biological effect (a reduction in C-peptide loss compared with placebo approximately 1 year after the GAD vaccine). We estimate that there is a 98% probability that 20 mu g GAD with alum administered twice yields a positive biological effect. The effect is probably a 15-20% reduction in the loss of C-peptide at approximately 1 year after treatment. This translates to an annual expected loss of between -0.250 and -0.235 pmol/ml in treated patients compared with an expected 2 h AUC loss of -0.294 pmol/ml at 1 year for untreated newly diagnosed patients. The biological effect of this vaccination should be developed further in order to reach clinically desirable reductions in insulin loss in patients recently diagnosed with type 1 diabetes. C1 [Beam, Craig A.; MacCallum, Colleen] Western Michigan Univ, Homer Stryker MD Sch Med, Div Epidemiol & Biostat, Dept Biomed Sci, 1000 Oakland Dr, Kalamazoo, MI 49008 USA. [Herold, Kevan C.] Yale Univ, Dept Immunobiol, New Haven, CT USA. [Herold, Kevan C.] Yale Univ, Dept Internal Med, New Haven, CT USA. [Wherrett, Diane K.] Hosp Sick Children, Dept Pediat, Toronto, ON, Canada. [Wherrett, Diane K.] Univ Toronto, Toronto, ON, Canada. [Palmer, Jerry] Univ Washington, Seattle, WA 98195 USA. [Palmer, Jerry] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Ludvigsson, Johnny] Linkoping Univ, Dept Clin & Expt Med, Div Pediat, Linkoping, Sweden. RP Beam, CA (reprint author), Western Michigan Univ, Homer Stryker MD Sch Med, Div Epidemiol & Biostat, Dept Biomed Sci, 1000 Oakland Dr, Kalamazoo, MI 49008 USA. EM craig.beam@med.wmich.edu OI Ludvigsson, Johnny/0000-0003-1695-5234 FU JDRF [1-INO-20140170-A-V] FX This work was supported by JDRF grant 1-INO-20140170-A-V. NR 18 TC 1 Z9 1 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2017 VL 60 IS 1 BP 43 EP 49 DI 10.1007/s00125-016-4122-1 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EE5GQ UT WOS:000389634000007 PM 27704166 ER PT J AU Irwin, D Grossman, M Weintraub, D Hurtig, HI Duda, JE Xie, SX Lee, EB Van Deerlin, VM Lopez, OL Kofler, JK Nelson, PT Jicha, GA Woltjer, R Quinn, JF Kaye, J Leverenz, JB Tsuang, D Longfellow, K Yearout, D Kukull, W Keene, CD Montine, TJ Zabetian, CP Trojanowski, JQ AF Irwin, David Grossman, Murray Weintraub, Daniel Hurtig, Howard I. Duda, John E. Xie, Sharon X. Lee, Edward B. Van Deerlin, Vivianna M. Lopez, Oscar L. Kofler, Julia K. Nelson, Peter T. Jicha, Gregory A. Woltjer, Randy Quinn, Joseph F. Kaye, Jeffery Leverenz, James B. Tsuang, Debby Longfellow, Katelan Yearout, Dora Kukull, Walter Keene, C. Dirk Montine, Thomas J. Zabetian, Cyrus P. Trojanowski, John Q. TI Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis SO LANCET NEUROLOGY LA English DT Article ID ALZHEIMERS ASSOCIATION GUIDELINES; PARKINSONS-DISEASE DEMENTIA; LEWY BODY; ALPHA-SYNUCLEIN; DIAGNOSTIC-CRITERIA; NATIONAL INSTITUTE; PATHOLOGY; TAU; PREVALENCE; BODIES AB Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synudeinopathies. We aimed to identify genetic and pathological markers that have the strongest association with these features of dinical heterogeneity in synudeinopathies. Methods In this retrospective study, we examined symptom onset, and genetic and neuropathological data from a cohort of patients with Lewy body disorders with autopsy-confirmed a synudeinopathy (as of Oct 1, 2015) who were previously induded in other studies from five academic institutions in five cities in the USA. We used histopathology techniques and markers to assess the burden of tau neurofibrillary tangles, neuritic plaques, alpha-synudein indusions, and other pathological changes in cortical regions. These samples were graded on an ordinal scale and genotyped for variants associated with synudeinopathies. We assessed the interval from onset of motor symptoms to onset of dementia, and overall survival in groups with varying levels of comorbid Alzheimer's disease pathology according to US National Institute on Aging Alzheimer's Association neuropathological criteria, and used multivariate regression to control for age at death and sex. Findings On the basis of data from 213 patients who had been followed up to autopsy and met inclusion criteria of Levey body disorder with autopsy-confirmed a synudeinopathy, we identified 49 (23%) patients with no Alzheimer's disease neuropathology, 56 (26%) with low-level Alzheimer's disease neuropathology, 45 (21%) with intermediate level Alzheimer's disease neuropathology, and 63 (30%) with high-level Alzheimer's disease neuropathology. As levels of Alzheimer's disease neuropathology increased, cerebral a-synudein scores were higher, and the interval between onset of motor and dementia symptoms and disease duration was shorter (p<0.0001 for all comparisons). Multivariate regression showed independent negative associations of cerebral tau neurofibrillary tangles score with the interval between onset of motor and dementia symptoms (beta -4.0, 95% CI -5.5 to -2.6; p<0.0001; R-2 0.22, p<0.0001) and with survival (-2.0, -3.2 to -0.8; 0.003; 0.15, <0.0001) in models that induded age at death, sex, cerebral neuritic plaque scores, cerebral alpha-synudein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genotype as covariates. Interpretation Alzheimer's disease neuropathology is common in synudeinopathies and confers a worse prognosis for each increasing level of neuropathological change. Cerebral neurofibrillary tangles burden, in addition to a-synudein pathology and amyloid plaque pathology, are the strongest pathological predictors of a shorter interval between onset of motor and dementia symptoms and survival. Diagnostic criteria based on reliable biomarkers for Alzheimer's disease neuropathology in synudeinopathies should help to identify the most appropriate patients for dinical trials of emerging therapies targeting tau, amyloid-beta or alpha synudein, and to stratify them by level of Alzheimer's disease neuropathology. C1 [Irwin, David; Grossman, Murray; Weintraub, Daniel; Hurtig, Howard I.; Xie, Sharon X.; Lee, Edward B.; Van Deerlin, Vivianna M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol, Philadelphia, PA 19104 USA. [Irwin, David; Grossman, Murray; Weintraub, Daniel; Hurtig, Howard I.; Xie, Sharon X.; Lee, Edward B.; Van Deerlin, Vivianna M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Lab Med, Morris K Udall Parkinsons Dis Ctr Excellence,Inst, Philadelphia, PA 19104 USA. [Irwin, David; Grossman, Murray; Weintraub, Daniel; Hurtig, Howard I.; Duda, John E.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Duda, John E.] Michael J Crescenz VA Med Ctr, Educ & Clin Ctr, Parkinsons Dis Res, Philadelphia, PA USA. [Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Kofler, Julia K.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Nelson, Peter T.; Jicha, Gregory A.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. [Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY USA. [Woltjer, Randy] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Quinn, Joseph F.; Kaye, Jeffery] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Leverenz, James B.] Cleveland Clin Fdn, Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Montine, Thomas J.] Standford Univ, Dept Pathol, Stanford, CA USA. [Kukull, Walter] Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA USA. [Tsuang, Debby] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Longfellow, Katelan; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Keene, C. Dirk] Univ Washington, Sch Med, Dept Pathol, Seattle, WA USA. [Quinn, Joseph F.; Leverenz, James B.; Yearout, Dora; Keene, C. Dirk; Montine, Thomas J.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Pacific Udall Ctr, Seattle, WA USA. [Tsuang, Debby; Yearout, Dora; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Longfellow, Katelan; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Northwest Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. RP Irwin, D (reprint author), Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol, Philadelphia, PA 19104 USA.; Irwin, D (reprint author), Univ Penn, Perelman Sch Med, Lab Med, Morris K Udall Parkinsons Dis Ctr Excellence,Inst, Philadelphia, PA 19104 USA.; Irwin, D (reprint author), Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.; Irwin, D (reprint author), Univ Penn, Hosp Univ Penn, Perelman Sch Med, Frontotemporal Degenerat Ctr, 3600 Spruce St, Philadelphia, PA 19104 USA.; Irwin, D (reprint author), Univ Penn, Hosp Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, 3600 Spruce St, Philadelphia, PA 19104 USA. EM dirwin@mail.med.upenn.edu FU US National Institutes of Health (National Institute on Aging); US National Institutes of Health (National Institute of Neurological Disorders and Stroke) FX US National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke). NR 30 TC 2 Z9 2 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD JAN PY 2017 VL 16 IS 1 BP 55 EP 65 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA EE8IP UT WOS:000389869200027 PM 27979356 ER PT J AU Schrag, A Siddiqui, UF Anastasiou, Z Weintraub, D Schott, JM AF Schrag, Anette Siddiqui, Uzma Faisal Anastasiou, Zacharias Weintraub, Daniel Schott, Jonathan M. TI Clinical variables and biomarkers in prediction of cognitive CrossMark impairment in patients with newly diagnosed Parkinson's disease: a cohort study SO LANCET NEUROLOGY LA English DT Article ID CEREBROSPINAL-FLUID; ALPHA-SYNUCLEIN; ALZHEIMER-DISEASE; DATATOP COHORT; AMYLOID-BETA; DEMENTIA; DECLINE; PROGRESSION; TAU; INSTRUMENT AB Background Parkinson's disease is associated with an increased incidence of cognitive impairment and dementia. Predicting who is at risk of cognitive decline early in the disease course has implications for clinical prognosis and for stratification of participants in clinical trials. We assessed the use of clinical information and biomarkers as predictive factors for cognitive decline in patients with newly diagnosed Parkinson's disease. Methods The Parkinson's Progression Markers Initiative (PPMI) study is a cohort study in patients with newly diagnosed Parkinson's disease. We evaluated cognitive performance (Montreal Cognitive Assessment [MoCA] scores), demographic and clinical data, APOE status, and biomarkers (CSF and dopamine transporter [DAT] imaging results). Using change in MoCA scores over 2 years, MoCA scores at 2 years' follow-up, and a diagnosis of cognitive impairment (combined mild cognitive impairment or dementia) at 2 years as outcome measures, we assessed the predictive values of baseline clinical variables and separate or combined additions of APOE status, DAT imaging, and CSF biomarkers. We did univariate and multivariate linear analyses with MoCA change scores between baseline and 2 years, and with MoCA scores at 2 years as dependent variables, using backwards linear regression analysis. Additionally, we constructed a prediction model for diagnosis of cognitive impairment using logistic regression analysis. Findings 390 patients with Parkinson's disease recruited between July 1,2010, and May 31,2013, and for whom data on MoCA scores at baseline and 2 years were available. In multivariate analyses, baseline age, University of Pennsylvania Smell Inventory Test (UP SIT) scores, CSF amyloid (A beta(42)) to t-tau ratio, and APOE status were associated with change in MoCA scores over time. Baseline age, MoCA and UPSIT scores, and CSF A beta(42) to t-tau ratio were associated with MoCA score at 2 years (using a backwards p-removal threshold of 0.1). Accuracy of prediction of cognitive impairment using age alone (area under the curve 0-68,95% CI 0.60-0.76) significantly improved by addition of clinical scores (UP SIT, Rapid Eye Movement Sleep Behaviour Disorder Screening Questionnaire [RBDSQ], Geriatric Depression Scale, and Movement Disorder Society Unified Parkinson's Disease Rating Scale motor scores; 0.76, 0.68-0.83), CSF variables (0.74, 0.68-0.81), or DAT imaging results (0.76, 0.68-0.83). In combination, the five variables showing the most significant associations with cognitive impairment (age, UP SIT, RBDSQ, CSF AR, and caudate uptake on DAT imaging) allowed prediction of cognitive impairment at 2 years (0.80, 0.74-0.87; p=0.0003 compared to age alone). Interpretation In newly diagnosed Parkinson's disease, the occurrence of cognitive impairment at 2 year follow-up can be predicted with good accuracy using a model combining information on age, non-motor assessments, DAT imaging, and CSF biomarkers. C1 [Schrag, Anette; Siddiqui, Uzma Faisal; Anastasiou, Zacharias] UCL, UCL Inst Neurol, Dept Clin Neurosci, Royal Free Campus, London NW3 2PF, England. [Schott, Jonathan M.] UCL, UCL Inst Neurol, Dementia Res Ctr, Dept Neurodegenerat Dis, London, England. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Schrag, A (reprint author), UCL, UCL Inst Neurol, Dept Clin Neurosci, Royal Free Campus, London NW3 2PF, England. EM a.schrag@ucl.ac.uk FU Michael J Fox Foundation for Parkinson's Research; AbbVie; Avid; Biogen; Bristol-Myers Squibb; Covance; GE Healthcare; Genentech; GlaxoSmithKline; Lilly; Lundbeck; Merck; Meso Scale Discovery; Pfizer; Piramal; Roche; Servier; Teva; UCB; National Institute for Health Research Queen Square Dementia Biomedical Research Unit; National Institute for Health Research University College London Hospital Biomedical Research Centre; Wolfson Foundation; Engineering and Physical Sciences Research Council [EP/J020990/1]; Medical Research Council [CSUB19166]; Arthritis Research UK [ARUK-Network 2012-6-ICE, ARUK-PG2014-1946]; European Union [666992] FX This project relied mainly on publicly available data without specific funding for the analysis. PPMI (a public-private partnership) is funded by the Michael J Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, Teva, and UCB. This study was not supported by additional funding. JMS was supported by the National Institute for Health Research Queen Square Dementia Biomedical Research Unit, the National Institute for Health Research University College London Hospital Biomedical Research Centre, Wolfson Foundation, Engineering and Physical Sciences Research Council (EP/J020990/1), Medical Research Council (CSUB19166), Arthritis Research UK (ARUK-Network 2012-6-ICE; ARUK-PG2014-1946), and the European Union's Horizon 2020 research and innovation programme (grant 666992). NR 36 TC 2 Z9 2 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD JAN PY 2017 VL 16 IS 1 BP 66 EP 75 DI 10.1016/S1474-4422(16)30328-3 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA EE8IP UT WOS:000389869200028 PM 27866858 ER PT J AU Egede, LE Gebregziabher, M Walker, RJ Payne, EH Acierno, R Frueh, BC AF Egede, Leonard E. Gebregziabher, Mulugeta Walker, Rebekah J. Payne, Elizabeth H. Acierno, Ron Frueh, B. Christopher TI Trajectory of cost overtime after psychotherapy for depression in older Veterans via telemedicine SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Telemedicine; Depression; Cost; Behavioral activation; Telepsychology; Elderly ID BEHAVIORAL ACTIVATION TREATMENT; COLLABORATIVE CARE; ADULTS; TRIAL; TELEPSYCHIATRY; DISORDER AB Background: Little evidence exists regarding the costs of telemedicine, especially considering changes over time. This analysis aimed to analyze trajectory of healthcare cost before, during, and after a behavioral activation intervention delivered via telepsychology and same-room delivery to elderly Veterans with depression. Methods: 241 participants were randomly assigned into one of two study groups: behavioral activation for depression via telemedicine or via same-room treatment. Patients received 8 weeks of weekly 60-min individual sessions of behavioral activation for depression. Primary outcomes were collected at 12-months. Inpatient, outpatient, pharmacy, and total costs were collected from VA Health Economics Resource Center (HERC) datasets for FY 1998-2014 and compared between the two treatment groups. Generalized mixed models were used to investigate the trajectories over time. Results: Overall cost, as well as, outpatient and pharmacy cost show increasing trend over time. Unadjusted and adjusted trajectories over time for any cost were not different between the two treatment groups. There was a significant overall increasing trend over time for outpatient (p < 0.001) and total cost (p < 0.001) but not for inpatient (p=0.543) or pharmacy cost (p=0.084). Limitations: Generalizability to younger, healthier populations may be limited due to inclusion criteria for study participants. Conclusion: Healthcare costs before, during, and after intervention did not differ between the telemedicine and in-person delivery methods. Outpatient costs accounted for most of the increasing trend of cost over time. These results support policies to use both telehealth and in-person treatment modalities to effectively and efficiently provide high quality care. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Walker, Rebekah J.; Payne, Elizabeth H.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. [Egede, Leonard E.; Walker, Rebekah J.] Med Univ South Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Payne, Elizabeth H.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Acierno, Ron] Med Univ South Carolina, Coll Nursing, Charleston, SC 29425 USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Dept Psychol, Houston, TX USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, 35 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU Veterans Affairs Health Services Research and Development (VA HSR D) program [IIR 04-421] FX This study was supported by Grant #IIR 04-421 funded by the Veterans Affairs Health Services Research and Development (VA HSR & D) program (PI: Leonard Egede). NR 30 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2017 VL 207 BP 157 EP 162 DI 10.1016/j.jad.2016.09.044 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ED7YM UT WOS:000389088600023 PM 27721190 ER PT J AU Post, RM Altshuler, LL Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Nolen, WA AF Post, Robert M. Altshuler, Lori L. Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E., Jr. Nolen, Willem A. TI Illnesses in siblings of US patients with bipolar disorder relate to multigenerational family history and patients severity of illness SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Depression; Alcohol abuse/dependence; Substance abuse/dependence; Suicide attempts; Anxiety disorder; Transgenerational vulnerability; Illness differences across countries ID PSYCHIATRIC-DISORDERS; UNITED-STATES; EARLY-ONSET; EARLY AGE; CLINICAL-FEATURES; SEXUAL-ABUSE; CHILDHOOD; PARENTS; RISK; ADOLESCENTS AB Background: Patients with bipolar disorder from the US have more early-onset illness and a greater familial loading for psychiatric problems than those from the Netherlands or Germany (abbreviated here as Europe). We hypothesized that these regional differences in illness burden would extend to the patients siblings. Methods: Outpatients with bipolar disorder gave consent for participation in a treatment outcome network and for filling out detailed questionnaires. This included a family history of unipolar depression, bipolar disorder, suicide attempt, alcohol abuse/dependence, drug abuse/dependence, and "other" illness elicited for the patients' grandparents, parents, spouses, offspring, and siblings. Problems in the siblings were examined as a function of parental and grandparental problems and the patients' adverse illness characteristics or poor prognosis factors (PPFs). Results: Each problem in the siblings was significantly (p < 0.001) more prevalent in those from the US than in those from Europe. In the US, problems in the parents and grandparents were almost uniformly associated with the same problems in the siblings, and sibling problems were related to the number of PPFs observed in the patients. Limitations: Family history was based on patient report. Conclusions: Increased familial loading for psychiatric problems extends through 4 generations of patients with bipolar disorder from the US compared to Europe, and appears to "breed true" into the siblings of the patients. In addition to early onset, a variety of PPFs are associated with the burden of psychiatric problems in the patients' siblings and offspring. Greater attention to the multigenerational prevalence of illness in patients from the US is indicated. C1 [Post, Robert M.; Rowe, Michael] Bipolar Collaborat Network, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Kupka, Ralph; Keck, Paul E., Jr.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Coll Med, Cincinnati, OH USA. [McElroy, Susan L.; Keck, Paul E., Jr.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Dept Psychiat & Psychotherapy, Salzburg, Austria. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr, Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, Bethesda, MD 20814 USA. OI Grunze, Heinz/0000-0003-4712-8979 NR 44 TC 0 Z9 0 U1 9 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2017 VL 207 BP 313 EP 319 DI 10.1016/j.jad.2016.09.042 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ED7YM UT WOS:000389088600044 PM 27741468 ER PT J AU Hom, MA Stanley, IH Gutierrezb, PM Joiner, TE AF Hom, Melanie A. Stanley, Ian H. Gutierrez, Peter M. Joiner, Thomas E., Jr. TI Exploring the association between exposure to suicide and suicide risk among military service members and veterans SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicide; Bereavement; Survivor; Military service member; Veteran ID INTERPERSONAL NEEDS QUESTIONNAIRE; FAMILIAL TRANSMISSION; BEREAVEMENT; VALIDITY; BEHAVIOR; RELIABILITY; PREVALENCE; PEER; ADOLESCENTS; POPULATION AB Background: Past research suggests that suicide has a profound impact on surviving family members and friends; yet, little is known about experiences with suicide bereavement among military populations. This study aimed to characterize experiences with suicide exposure and their associations with lifetime and current psychiatric symptoms among military service members and veterans. Methods: A sample of 1753 United States military service members and veterans completed self-report questionnaires assessing experiences with suicide exposure, lifetime history of suicidal thoughts and behaviors, current suicidal symptoms, and perceived likelihood of making a future suicide attempt. Results: The majority of participants (57.3%) reported knowing someone who had died by suicide, and of these individuals, most (53.1%) reported having lost a friend to suicide. Chi-square tests, one-way ANOVAs, and logistic regression analyses revealed that those who reported knowing a suicide decedent were more likely to report more severe current suicidal symptoms and a history of suicidal thoughts and behaviors compared to those who did not know a suicide decedent. Hierarchical linear regression analyses indicated that greater self reported interpersonal closeness to a suicide decedent predicted greater self-reported likelihood of a future suicide attempt, even after controlling for current suicidal symptoms and prior suicidal thoughts and behaviors. Limitations: This study utilized cross-sectional data, and information regarding degree of exposure to suicide was not collected. Conclusions: Military personnel and veterans who have been bereaved by suicide may themselves be at elevated risk for suicidal thoughts and behaviors. Additional work is needed to delineate the relationship between these experiences. C1 [Hom, Melanie A.; Stanley, Ian H.; Joiner, Thomas E., Jr.] Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32306 USA. [Gutierrez, Peter M.] Denver Vet Affairs Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA. RP Hom, MA (reprint author), Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32306 USA. EM hom@psy.fsu.edu OI Gutierrez, Peter/0000-0001-8981-8404 FU Department of Defense [W81XWH-10-2-0181, W81XWH-10-2-0178]; Office of the Assistant Secretary of Defense for Health Affairs FX This work was supported, in part, by grants awarded to Florida State University (W81XWH-10-2-0181) and the Rocky Mountain Mental Illness Research, Education and Clinical Center (W81XWH-10-2-0178) by the Department of Defense. The Department of Defense had no further role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The content of this paper is solely the responsibility of the authors and the views and opinions expressed do not necessarily represent those of the Military Suicide Research Consortium, Department of Defense, or the United States Government.; The authors would like to thank the Military Suicide Research Consortium (MSRC), an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs, for being the funding source of the provided data and to express their gratitude to the following principal investigators (PIs) for providing data used in this submission: Dr. Michael D. Anestis, PI of the study "Predicting Suicide Risk in a Military Population"; Dr. Sean M. Barnes, PI of the study "Behaviorally Assessing Suicide Risk"; Dr. Rebecca A. Bernert, PI of the study "Behavioral Sleep Intervention for the Prevention of Suicidal Behaviors in Military Veterans"; Dr. Nigel E. Bush, PI of the studies "Usability and Utility of a Virtual Hope Box (VHB) for Reducing Suicidal Ideation" and "Effectiveness of VHB Smartphone App in Enhancing Veterans' Coping with Suicidal Ideation"; Dr. Katherine A. Comtois, PI of the study "Continuity Contacts via Text Message: Testing a Brief Intervention to Prevent Suicidal Ideation and Behavior"; Drs. Peter M. Gutierrez and Thomas E. Joiner, PIs of the study "Toward a Gold Standard for Suicide Risk Assessment for Military Personnel"; Dr. Lori Johnson, PI of the study, "Suicide Risk Assessments within Suicide-Specific Group Therapy Treatment for Veterans"; Dr. Matthew K. Nock, PI of the study "Looking for Cognitive Differences in Suicidal Veterans"; Dr. Gina M. Signoracci, PI of the study "Assessment of Cognitive Functioning as It Relates to Risk for Suicide in Veterans with HIV/AIDS"; and Drs. Deborah A. Yurgelun-Todd and Perry F. Renshaw, PIs of the study "Neuroimaging Correlates of Suicide." This data is the property of the stated PIs and cannot be used without prior written approval. NR 49 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2017 VL 207 BP 327 EP 335 DI 10.1016/j.jad.2016.09.043 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ED7YM UT WOS:000389088600047 PM 27743535 ER PT J AU Kalkstein, S Scott, JC Biester, R Brownlow, JA Harpaz-Rotem, I Gur, RC AF Kalkstein, Solomon Scott, J. Cobb Biester, Rosette Brownlow, Janeese A. Harpaz-Rotem, Ilan Gur, Ruben C. TI Comparison of blast-exposed OEF/OIF veterans with and without a history of TBI symptoms on a brief computerized neuropsychological battery SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE Blast; cognitive; neuropsychological; posttraumatic stress disorder; traumatic brain injury ID TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; NEUROCOGNITIVE BATTERY; MILD TBI; METAANALYSIS; DISORDER; SEQUELAE; MODERATE; OUTCOMES AB Mild traumatic brain injuries (mild TBIs) resulting from exposure to Improvised Explosive Devices (IEDs) are highly prevalent among veterans of the wars in Iraq and Afghanistan. This exploratory study compared the neurocognitive performance of blast-exposed veterans with (n=19) and without (n=15) reported symptoms of mild TBI. All subjects had diagnoses of posttraumatic stress disorder (PTSD). Neurocognitive testing was administered using a well-established computerized battery, the Penn Computerized Neuropsychological Battery (CNB), and groups were well matched on age, race, education, and time since most recent blast exposure. Although differences were not observed on CNB accuracy scores, MANOVAs revealed slower processing speed in the mTBI group when answering correctly on tests of simple and sustained attention, with large effect sizes. Results suggest a potential speed-accuracy tradeoff in blast-related mild TBI, which should be further examined in larger samples. C1 [Kalkstein, Solomon; Scott, J. Cobb; Biester, Rosette; Brownlow, Janeese A.; Gur, Ruben C.] Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Kalkstein, Solomon; Scott, J. Cobb; Biester, Rosette; Brownlow, Janeese A.; Gur, Ruben C.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Scott, J. Cobb; Gur, Ruben C.] Philadelphia Vet Affairs Med Ctr, VISN4 Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Harpaz-Rotem, Ilan] Yale Univ, Sch Med, New Haven, CT USA. [Harpaz-Rotem, Ilan] Natl Ctr PTSD, Vet Affairs Connecticut Hlth Care Syst, Clin Neurosciences Div, West Haven, CT USA. RP Kalkstein, S (reprint author), Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM solomon.kalkstein@va.gov FU Philadelphia VA Parkinson's Disease Research, Education, & Clinical Center; Department of Veterans Affairs [IK2CX000772] FX This work was supported by a Pilot Project Award from the Philadelphia VA Parkinson's Disease Research, Education, & Clinical Center. Dr. Scott's participation was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772). NR 26 TC 0 Z9 0 U1 8 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PY 2017 VL 24 IS 1 BP 92 EP 97 DI 10.1080/23279095.2015.1119693 PG 6 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA EC3KW UT WOS:000388026000010 PM 27045712 ER PT J AU Banks, WA Kovac, A Majerova, P Bullock, KM Shi, M Zhang, J AF Banks, William A. Kovac, Andrej Majerova, Petra Bullock, Kristin M. Shi, Min Zhang, Jing TI Tau Proteins Cross the Blood-Brain Barrier SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; blood-brain barrier; tau protein; tauopathy ID PAIRED HELICAL FILAMENT; ALZHEIMERS-DISEASE; P-GLYCOPROTEIN; ALPHA-SYNUCLEIN; DISORDERED PROTEINS; CEREBROSPINAL-FLUID; EFFLUX TRANSPORT; CLEARANCE; PATHOLOGY; PEPTIDE AB Tauopathies are a hallmark of many neurodegenerative diseases, including Alzheimer's disease and traumatic brain injuries. It has been demonstrated that amyloid-beta peptides, alpha-synuclein, and prion proteins cross the blood-brain barrier (BBB), contributing to their abilities to induce disease. Very little is known about whether tau proteins can cross the BBB. Here we systematically characterized several key forms of tau proteins to cross the BBB, including Tau-441 (2N4R), Tau-410 (2N3R), truncated tau 151-391 (0N4R), and truncated tau 121-227. All of these tau proteins crossed the BBB readily and bidirectonally; however, only Tau-410 had a saturable component to its influx. The tau proteins also entered the blood after their injection into the brain, with Tau 121-227 having the slowest exit from brain. The tau proteins varied in regards to their enzymatic stability in brain and blood and in their peripheral pharmacokinetics. These results show that blood-borne tau proteins could contribute to brain tauopathies. The result also suggest that the CNS can contribute to blood levels of tau, raising the possibility that, as suggested for other misfolded proteins, blood levels of tau proteins could be used as a biomarker of CNS disease. C1 [Banks, William A.; Bullock, Kristin M.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kovac, Andrej; Majerova, Petra] Slovak Acad Sci, Inst Neuroimmunol, Bratislava, Slovakia. [Kovac, Andrej] Univ Vet Med & Pharm, Dept Pharmacol & Toxicol, Kosice, Slovakia. [Majerova, Petra] AXON Neurosci SE, Bratislava, Slovakia. [Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Zhang, Jing] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing, Peoples R China. [Zhang, Jing] Peking Univ, Hosp 3, Beijing, Peoples R China. RP Banks, WA (reprint author), VAPSHCS, 1660S ColumbianWay, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU NIH [R01 AG046619]; Alzheimer's Association grant [2015-NIRG-342009]; Veterans Affairs; APVV-14-0547 FX Supported by APVV-14-0547, Veterans Affairs, Alzheimer's Association grant 2015-NIRG-342009, and NIH R01 AG046619. NR 48 TC 0 Z9 0 U1 10 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2017 VL 55 IS 1 BP 411 EP 419 DI 10.3233/JAD-160542 PG 9 WC Neurosciences SC Neurosciences & Neurology GA EB8WI UT WOS:000387671600032 PM 27662303 ER PT J AU Sher, L Fisher, AM Kelliher, CH Penner, JD Goodman, M Koenigsberg, HW New, AS Siever, LJ Hazlett, EA AF Sher, Leo Fisher, Amanda M. Kelliher, Caitlin H. Penner, Justin D. Goodman, Marianne Koenigsberg, Harold W. New, Antonia S. Siever, Larry J. Hazlett, Erin A. TI Clinical features and psychiatric comorbidities of borderline personality disorder patients with versus without a history of suicide attempt SO PSYCHIATRY RESEARCH LA English DT Article DE Suicide; Borderline personality disorder; Narcissistic personality disorder; Depression; Affective lability ID SUBSTANCE USE DISORDERS; NONSUICIDAL SELF-INJURY; MAJOR DEPRESSIVE EPISODE; II COMPARISON SUBJECTS; NARCISSISTIC PERSONALITY; FUNCTIONAL IMPAIRMENT; EMOTIONAL PICTURES; BIPOLAR DISORDER; MOOD DISORDERS; YOUNG-ADULTS AB Patients with borderline personality disorder (BPD) are at high risk for suicidal behavior. However, many BPD patients do not engage in suicidal behavior. In this study, we compared clinical features of BPD patients with or without a history of suicide attempts and healthy volunteers. Compared with healthy volunteers, both BPD groups had higher Affective Lability Scale (ALS), ALS - Depression-Anxiety Subscale, Barratt Impulsivity Scale (BIS), and Lifetime History of Aggression (LHA) scores and were more likely to have a history of temper tantrums. BPD suicide attempters had higher ALS, ALS - Depression-Anxiety Subscale and LHA scores and were more likely to have a history of non-suicidal self-injury or temper tantrums compared to BPD nonattempters. Also, BPD suicide attempters were more likely to have a history of comorbid major depressive disorder and less likely to have comorbid narcissistic personality disorder (NPD) in comparison to BPD nonattempters. About 50% of study participants in each BPD group had a history of comorbid substance use disorder (SUD). Our study indicates that BPD patients with a history of suicide attempt are more aggressive, affectively dysregulated and less narcissistic than BPD suicide non-attempters. C1 [Sher, Leo; Fisher, Amanda M.; Kelliher, Caitlin H.; Penner, Justin D.; Goodman, Marianne; Koenigsberg, Harold W.; New, Antonia S.; Siever, Larry J.; Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Sher, Leo; Penner, Justin D.; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.] James J Peters VA Med Ctr, Inpatient & Outpatient Psychiat, Bronx, NY USA. [Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Penner, Justin D.; Goodman, Marianne; Siever, Larry J.; Hazlett, Erin A.] James J Peters VA Med Ctr, MIRECC, VISN South 2, Bronx, NY USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. EM leo.sher@mssm.edu FU VA Merit award [I01CX000609]; Mental Illness Research, Education, and Clinical Center (MIRECC; VISN 2 South) at the James J. Peters VA Medical Center FX This work was supported by a VA Merit award (I01CX000609) to EAH and the Mental Illness Research, Education, and Clinical Center (MIRECC; VISN 2 South) at the James J. Peters VA Medical Center. NR 76 TC 1 Z9 1 U1 14 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 30 PY 2016 VL 246 BP 261 EP 266 DI 10.1016/j.psychres.2016.10.003 PG 6 WC Psychiatry SC Psychiatry GA EG3TT UT WOS:000390968300039 PM 27728869 ER PT J AU Asch, DA Rosin, R AF Asch, David A. Rosin, Roy TI Engineering Social Incentives for Health SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID RANDOMIZED-TRIAL; FINANCIAL INCENTIVES C1 [Asch, David A.; Rosin, Roy] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA.; Asch, DA (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. NR 5 TC 0 Z9 0 U1 4 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 29 PY 2016 VL 375 IS 26 BP 2511 EP 2513 DI 10.1056/NEJMp1603978 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EG6SC UT WOS:000391175300002 PM 28029924 ER PT J AU Damien, P Lanham, HJ Parthasarathy, M Shah, NL AF Damien, Paul Lanham, Holly J. Parthasarathy, Murali Shah, Nikhil L. TI Assessing key cost drivers associated with caring for chronic kidney disease patients SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Chronic kidney disease; Total costs drivers; Co-morbid conditions ID STAGE RENAL-DISEASE; UNITED-STATES; HEALTH-CARE; TRADE-OFF; MEDICARE; PREVALENCE; QUALITY; PAYMENT; RATES AB Background: To examine key factors influencing chronic kidney disease (CKD) patients' total expenditure and offer recommendations on how to reduce total cost of CKD care without compromising quality. Methods: Using the 2002-2011 Medical Expenditure Panel Survey (MEPS) data, our cross-sectional study analyzed 197 patient records-79 patients with one record and 59 with two entries per patient (138 unique patients). We used three patient groups, based on international statistical classification of diseases version 9 code for condition (ICD9CODX) classification, to focus inference from the analysis: (a) non-dialysis dependent CKD, (b) dialysis and (c) transplant. Covariate information included region, demographic, co-morbid conditions and types of services. We used descriptive methods and multivariate generalized linear models to understand the impact of cost drivers. We compared actual and predicted CKD cost of care data using a hold-out sample of nine, randomly selected patients to validate the models. Results: Total costs were significantly affected by treatment type, with dialysis being significantly higher than non-dialysis and transplant groups. Costs were highest in the West region of the U.S. Average costs for patients with public insurance were significantly higher than patients with private insurance (p < .0743), and likewise, for patients with co-morbid conditions over those without co-morbid conditions (p < .001). Conclusions: Managing CKD patients both before and after the onset of dialysis treatment and managing co-morbid conditions in individuals with CKD are potential sources of substantial cost savings in the care of CKD patients. Comparing total costs pre and post the United States Affordable Care Act could provide invaluable insights into managing the cost-quality tradeoff in CKD care. C1 [Damien, Paul; Lanham, Holly J.] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [Lanham, Holly J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lanham, Holly J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Parthasarathy, Murali] Saaraa Med Solut, Whitehouse Stn, NJ USA. [Shah, Nikhil L.] Piedmont Clin, Atlanta, GA USA. [Shah, Nikhil L.] Georgia Inst Technol, Atlanta, GA 30332 USA. RP Lanham, HJ (reprint author), Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA.; Lanham, HJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.; Lanham, HJ (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM lanham@uthscsa.com FU Department of Information, Risk and Operations Management at the McCombs School of Business, The University of Texas at Austin FX The Department of Information, Risk and Operations Management at the McCombs School of Business, The University of Texas at Austin provided funding for PD. NR 29 TC 0 Z9 0 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD DEC 28 PY 2016 VL 16 AR 690 DI 10.1186/s12913-016-1922-4 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EH6LS UT WOS:000391885200001 PM 28031020 ER PT J AU Sandholm, J Lehtimaki, J Ishizu, T Velu, SE Clark, J Harkonen, P Jukkola-Vuorinen, A Schrey, A Harris, KW Tuomela, JM Selander, KS AF Sandholm, Jouko Lehtimaki, Jaakko Ishizu, Tamiko Velu, Sadanandan E. Clark, Jeremy Harkonen, Pirkko Jukkola-Vuorinen, Arja Schrey, Aleksi Harris, Kevin W. Tuomela, Johanna M. Selander, Katri S. TI Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo SO ONCOTARGET LA English DT Article DE breast cancer; bisphosphonate; biomarker; TLR9; ApppI ID NITROGEN-CONTAINING BISPHOSPHONATES; ADJUVANT ZOLEDRONIC ACID; MEVALONATE PATHWAY; NLRP3 INFLAMMASOME; CELLULAR INVASION; CELLS; MACROPHAGES; ALENDRONATE; ACTIVATION; CLODRONATE AB Bisphosphonates are standard treatments for bone metastases. When given in the adjuvant setting, they reduce breast cancer mortality and recurrence in bone but only among post-menopausal patients. Optimal drug use would require biomarker-based patient selection. Such biomarkers are not yet in clinical use. Based on the similarities in inflammatory responses to bisphosphonates and Toll-like receptor (TLR) agonists, we hypothesized that TLR9 expression may affect bisphosphonate responses in cells. We compared bisphosphonate effects in breast cancer cell lines with low or high TLR9 expression. We discovered that cells with decreased TLR9 expression are significantly more sensitive to the growth-inhibitory effects of bisphosphonates in vitro and in vivo. Furthermore, cancer growth-promoting effects seen with some bisphosphonates in some control shRNA cells were not detected in TLR9 shRNA cells. These differences were not associated with inhibition of Rap1A prenylation or p38 phosphorylation, which are known markers for bisphosphonate activity. However, TLR9 shRNA cells exhibited increased sensitivity to ApppI, a metabolite that accumulates in cells after bisphosphonate treatment. We conclude that decreased TLR9-expression sensitizes breast cancer cells to the growth inhibitory effects of bisphosphonates. Our results suggest that TLR9 should be studied as a potential biomarker for adjuvant bisphosphonate sensitivity among breast cancer patients. C1 [Sandholm, Jouko] Univ Turku, Turku Ctr Biotechnol, Cell Imaging Core, Turku, Finland. [Sandholm, Jouko] Abo Akad Univ, Turku, Finland. [Lehtimaki, Jaakko; Ishizu, Tamiko; Harkonen, Pirkko; Tuomela, Johanna M.] Univ Turku, Dept Cell Biol & Anat, Turku, Finland. [Ishizu, Tamiko] Univ Turku, Turku PET Ctr, MediCity Res Lab PET, Turku, Finland. [Velu, Sadanandan E.; Clark, Jeremy; Selander, Katri S.] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Jukkola-Vuorinen, Arja] Oulu Univ Hosp, Dept Oncol, Oulu, Finland. [Schrey, Aleksi] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland. [Harris, Kevin W.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Harris, Kevin W.] UAB, Ctr Comprehens Canc, Birmingham, AL USA. [Selander, Katri S.] Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland. RP Selander, KS (reprint author), Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA.; Selander, KS (reprint author), Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland. EM Katriselander@uabmc.edu OI Schrey, Aleksi/0000-0002-5985-0259; Tuomela, Johanna/0000-0003-4390-4563 FU DOD [W81XWH-10-1-0310, W81XWH-04-1-0479]; Jane and Aatos Erkko Foundation FX This research was funded by DOD grants W81XWH-10-1-0310 and W81XWH-04-1-0479 (K.S.S), and Jane and Aatos Erkko Foundation (J.T.). NR 65 TC 0 Z9 0 U1 2 U2 2 PU IMPACT JOURNALS LLC PI ORCHARD PARK PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 27 PY 2016 VL 7 IS 52 BP 87373 EP 87389 DI 10.18632/oncotarget.13570 PG 17 WC Oncology; Cell Biology SC Oncology; Cell Biology GA EG9ZT UT WOS:000391422500136 PM 27888633 ER PT J AU Bajaj, S Housley, SN Wu, D Dhamala, M James, GA Butler, AJ AF Bajaj, Sahil Housley, Stephen N. Wu, David Dhamala, Mukesh James, G. A. Butler, Andrew J. TI Dominance of the Unaffected Hemisphere Motor Network and Its Role in the Behavior of Chronic Stroke Survivors SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Article DE functional magnetic resonance imaging(fMRI); effective connectivity; dynamic causal modeling (DCM); motor task; stroke; affected hemisphere; unaffected hemisphere ID TEST-RETEST RELIABILITY; BAYESIAN MODEL SELECTION; FUGL-MEYER ASSESSMENT; CEREBRAL INFARCTION; FUNCTIONAL MRI; EFFECTIVE CONNECTIVITY; LONGITUDINAL FMRI; HAND MOVEMENTS; RECOVERY; ACTIVATION AB Balance of motor network activity between the two brain hemispheres after stroke is crucial for functional recovery. Several studies have extensively studied the role of the affected brain hemisphere to better understand changes in motor network activity following stroke. Very few studies have examined the role of the unaffected brain hemisphere and confirmed the testretest reliability of connectivity measures on unaffected hemisphere. We recorded blood oxygenation level dependent functional magnetic resonance imaging (fMRI) signals from nine stroke survivors with hemiparesis of the left or right hand. Participants performed a motor execution task with affected hand, unaffected hand, and both hands simultaneously. Participants returned for a repeat fMRI scan 1 week later. Using dynamic causal modeling (DCM), we evaluated effective connectivity among three motor areas: the primary motor area (M1), the premotor cortex (PMC) and the supplementary motor area for the affected and unaffected hemispheres separately. Five participants manual motor ability was assessed by Fugl-Meyer Motor Assessment scores and root-mean square error of participants tracking ability during a robot-assisted game. We found (i) that the task performance with the affected hand resulted in strengthening of the connectivity pattern for unaffected hemisphere, (ii) an identical network of the unaffected hemisphere when participants performed the task with their unaffected hand, and (iii) the pattern of directional connectivity observed in the affected hemisphere was identical for tasks using the affected hand only or both hands. Furthermore, paired t-test comparison found no significant differences in connectivity strength for any path when compared with one-week follow-up. Brain-behavior linear correlation analysis showed that the connectivity patterns in the unaffected hemisphere more accurately reflected the behavioral conditions than the connectivity patterns in the affected hemisphere. Above findings enrich our knowledge of unaffected brain hemisphere following stroke, which further strengthens our neurobiological understanding of stroke-affected brain and can help to effectively identify and apply stroke-treatments. C1 [Bajaj, Sahil; Dhamala, Mukesh] Georgia State Univ, Dept Phys & Astron, Atlanta, GA 30303 USA. [Bajaj, Sahil] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85721 USA. [Housley, Stephen N.; Wu, David; Butler, Andrew J.] Georgia State Univ, Byrdine F Lewis Sch Nursing & Hlth Profess, Atlanta, GA 30303 USA. [Dhamala, Mukesh] Georgia State Univ, Ctr Diagnost & Therapeut, Ctr Nanoopt, Joint Ctr Adv Brain Imaging,Ctr Behav Neurosci, Atlanta, GA USA. [Dhamala, Mukesh; Butler, Andrew J.] Georgia State Univ, Inst Neurosci, Atlanta, GA 30303 USA. [James, G. A.] Univ Arkansas Med Sci, Inst Psychiat Res, Little Rock, AR 72205 USA. [Butler, Andrew J.] US Dept Vet Affairs, Atlanta Rehabil Res & Dev Ctr Excellence, Decatur, GA USA. RP Bajaj, S (reprint author), Georgia State Univ, Dept Phys & Astron, Atlanta, GA 30303 USA.; Bajaj, S (reprint author), Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85721 USA. EM sahil.neuro@gmail.com FU U.S. Department of Veterans Affairs, Rehabilitation Research & Development Service [5I21RX000561 (B7676-P)] FX This study was supported by 5I21RX000561 (B7676-P) U.S. Department of Veterans Affairs, Rehabilitation Research & Development Service to AB. The authors would also like to thank Dr. Daniel Drake and Kimberly Richards for their assistance in data collection. NR 76 TC 0 Z9 0 U1 3 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD DEC 27 PY 2016 VL 10 AR 650 DI 10.3389/fnhum.2016.00650 PG 14 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA EG0VS UT WOS:000390751000001 PM 28082882 ER PT J AU Collier, JB Whitaker, RM Eblen, ST Schnellmann, RG AF Collier, Justin B. Whitaker, Ryan M. Eblen, Scott T. Schnellmann, Rick G. TI Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor gamma Coactivator-1 alpha by Extracellular Signal-Regulated Kinase 1/2 in Physiological and Pathological Conditions SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID GROWTH-FACTOR RECEPTOR; ACUTE KIDNEY INJURY; FOXO TRANSCRIPTION FACTORS; MITOCHONDRIAL DYSFUNCTION; FACTOR FKHR; IN-VITRO; PHOSPHORYLATION; CELLS; TRANSACTIVATION; PGC-1-ALPHA AB Previous studies have shown that extracellular signal-regulated kinase 1/2 (ERK1/2) directly inhibits mitochondrial function during cellular injury. We evaluated the role of ERK1/2 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene, a master regulator of mitochondrial function. The potent and specific MEK1/2 inhibitor trametinib rapidly blocked ERK1/2 phosphorylation, decreased cytosolic and nuclear FOXO3a/1 phosphorylation, and increased PGC-1 alpha gene expression and its downstream mitochondrial biogenesis (MB) targets under physiological conditions in the kidney cortex and in primary renal cell cultures. The epidermal growth factor receptor (EGFR) inhibitor erlotinib blocked ERK1/2 phosphorylation and increased PGC-1 alpha gene expression similar to treatment with trametinib, linking EGFR activation and FOXO3a/1 inactivation to the down-regulation of PGC-1 alpha and MB through ERK1/2. Pretreatment with trametinib blocked early ERK1/2 phosphorylation following ischemia/reperfusion kidney injury and attenuated the downregulation of PGC-1 alpha and downstream target genes. These results demonstrate that ERK1/2 rapidly regulates mitochondrial function through a novel pathway, EGFR/ERK1/2/FOXO3a/1/PGC-1 alpha, under physiological and pathological conditions. As such, ERK1/2 down-regulates mitochondrial function directly by phosphorylation of upstream regulators of PGC-1 alpha and subsequently decreasing MB. C1 [Collier, Justin B.; Whitaker, Ryan M.; Schnellmann, Rick G.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Eblen, Scott T.] Med Univ South Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. [Collier, Justin B.; Schnellmann, Rick G.] Univ Arizona, Drachman Hall,1295 N Martin Ave,POB 210202, Tucson, AZ 85721 USA. RP Schnellmann, RG (reprint author), Univ Arizona, Drachman Hall,1295 N Martin Ave,POB 210202, Tucson, AZ 85721 USA. EM schnell@pharmacy.arizona.edu FU National Institutes of Health National Center for Research Resources [C06-RR015455] FX Animal facilities were funded by the National Institutes of Health National Center for Research Resources (Grant C06-RR015455). NR 44 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 23 PY 2016 VL 291 IS 52 BP 26850 EP 26859 DI 10.1074/jbc.M116.754762 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EH2BE UT WOS:000391571400022 PM 27875304 ER PT J AU Cooney, JD Aguiar, RCT AF Cooney, Jeffrey D. Aguiar, Ricardo C. T. TI Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies SO BLOOD LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MICROVESSEL DENSITY; PDE4 INHIBITORS; TARGETING BTK; EXPRESSION; IDELALISIB; ROFLUMILAST; RECEPTOR AB Phosphodiesterase 4 (PDE4) inhibition restores the suppressive effects of 3',5'-cyclic adenosine monophosphate in lymphocytes. In this concise review, we detail how PDE4 inhibition downmodulates the B-cell receptor (BCR)-related kinases spleen tyrosine kinase and phosphatidylinositol 3-kinase and inhibits vascular endothelial growth factor A secretion by tumor cells, inducing cancer cell apoptosis and blocking angiogenesis in the microenvironment. We describe the successful clinical repurposing of PDE4 inhibitors in B-cell malignancies, and propose that given their anti-inflammatory/immunomodulatory activity, these agents will suppress BCR signals without the toxicity associated with other targeted biological doublets. C1 [Cooney, Jeffrey D.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Med Oncol, San Antonio, TX 78229 USA. [Cooney, Jeffrey D.] Univ Texas Hlth Sci Ctr San Antonio, MD PhD Program, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78284 USA. [Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] South Texas Vet Hlth Care Syst, Audie L Murphy Mem VA Hosp, San Antonio, TX USA. EM aguiarr@uthscsa.edu FU National Institutes of Health, National Cancer Institute [1F30CA206343-01]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP15077]; Owens' Foundation; Leukemia & Lymphoma Society [TRP-6524] FX J.D.C. was supported by the National Institutes of Health, National Cancer Institute (1F30CA206343-01). R.C.T.A. was supported in part by an award from the Cancer Prevention and Research Institute of Texas (CPRIT; RP15077), the Owens' Foundation, and the Leukemia & Lymphoma Society (TRP-6524). NR 54 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 22 PY 2016 VL 128 IS 25 BP 2886 EP 2890 DI 10.1182/blood-2016-09-737676 PG 5 WC Hematology SC Hematology GA EI7CO UT WOS:000392655100007 PM 27756749 ER PT J AU Lupo, F Tibaldi, E Matte, A Sharma, AK Brunati, AM Alper, SL Zancanaro, C Benati, D Siciliano, A Bertoldi, M Zonta, F Storch, A Walker, RH Danek, A Bader, B Hermann, A De Franceschi, L AF Lupo, Francesca Tibaldi, Elena Matte, Alessandro Sharma, Alok K. Brunati, Anna Maria Alper, Seth L. Zancanaro, Carlo Benati, Donatella Siciliano, Angela Bertoldi, Mariarita Zonta, Francesca Storch, Alexander Walker, Ruth H. Danek, Adrian Bader, Benedikt Hermann, Andreas De Franceschi, Lucia TI A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis SO BLOOD LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; ANION TRANSPORT ACTIVITY; RED-CELLS; NEUROACANTHOCYTOSIS SYNDROMES; MITOCHONDRIAL CLEARANCE; PROTEIN-PHOSPHORYLATION; MEMBRANE ASSOCIATION; SELECTIVE AUTOPHAGY; OXIDATIVE STRESS; MOUSE MODEL AB Chorea-acanthocytosis is one of the hereditary neurodegenerative disorders known as the neuroacanthocytoses. Chorea-acanthocytosis is characterized by circulating acanthocytes deficient in chorein, a protein of unknown function. We report here for the first time that chorea-acanthocytosis red-cells are characterized by impaired autophagy, with cytoplasmic accumulation of active Lyn and of autophagy-related proteins Ulk1, Atg7. In chorea-acanthocytosis erythrocytes, active Lyn is sequestered by HSP90-70 to form high-molecular-weight complexes that stabilize and protect Lyn from its proteasomal degradation, contributing to toxic Lyn accumulation. An interplay between accumulation of active Lyn and autophagy was found in chorea-acanthocytosis based on Lyn co-immunoprecipitation with Ulk1 and Atg7 and on the presence of Ulk1 in Lyn-containing high-molecular-weight complexes. In addition, chorein associated with Atg7 in healthy but not in chorea-acanthocytosis erythrocytes. Electron-microscopic detected multivesicular bodies and membrane remnants only in circulating chorea-acanthocytosis red cells. In addition, reticulocyte-enriched chorea-acanthocytosis red cell fractions exhibited delayed clearance of mitochondria and lysosomes, further supporting the impairment of authophagic flux. Since autophagy is also important in erythropoiesis, we studied in vitro CD34(+) derived erythroid precursors. In chorea-acanthocytosis, we found (1) dyserythropoiesis; (2) increased active Lyn, (3) accumulation of, a marker of autophagic flux and autolysososme degradation; (4) accumlation of Lamp1, a lysosmal membrane protein, and LAMP1 positive aggregates; (5) reduced clearance of lysosomes and mitochondria. Our results uncover in chorea-acanthocytosis erythroid cells an association between accumulation of active Lyn and impaired autophagy, suggesting a link between chorein and autophagic vesicle trafficking in erythroid maturation. C1 [Lupo, Francesca; Matte, Alessandro; Siciliano, Angela; De Franceschi, Lucia] Univ Verona, Dept Med, Verona, Italy. [Lupo, Francesca; Matte, Alessandro; Siciliano, Angela; De Franceschi, Lucia] Azienda Osped Univ Integrata Verona, Verona, Italy. [Tibaldi, Elena; Brunati, Anna Maria; Zonta, Francesca] Univ Padua, Dept Mol Med, Padua, Italy. [Sharma, Alok K.; Alper, Seth L.] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA. [Sharma, Alok K.; Alper, Seth L.] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA. [Sharma, Alok K.; Alper, Seth L.] Harvard Med Sch, Boston, MA USA. [Zancanaro, Carlo; Benati, Donatella; Bertoldi, Mariarita] Univ Verona, Dept Neurosci Biomed & Movement, Verona, Italy. [Storch, Alexander] Tech Univ Dresden, Ctr Regenerat Therapies, Dresden, Germany. [Storch, Alexander; Hermann, Andreas] Tech Univ Dresden, Div Neurodegenerat Dis, Dept Neurol, Dresden, Germany. [Storch, Alexander] Ctr Neurodegenerat Dis, Dresden, Germany. [Walker, Ruth H.] James J Peters VA Med Ctr, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. [Danek, Adrian; Bader, Benedikt] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany. EM lucia.defranceschi@univr.it RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 FU Telethon [GPP13005]; NA advocacy; Fondo Universitario di Ricerca; Federal Ministry of research and education Germany-European Multidisciplinary Initiative on Neuroacantocytosis (EMINA)-2 [ERARE12-081]; ERA-Net for Research on Rare Diseases; Doris Duke Charitable Foundation; European Agency-net E-Rare consortium EMINA [BMBF01 GM1003] FX This work was supported by Telethon grant GPP13005 (L.D.F.); an NA advocacy grant (L.D.F.); Fondo Universitario di Ricerca (L.D.F.); Federal Ministry of research and education Germany grant ERARE12-081-European Multidisciplinary Initiative on Neuroacantocytosis (EMINA)-2, under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases (A.H.); and the Doris Duke Charitable Foundation (S.L.A.). Western blot analysis of chorein was performed by G. Kwiatkowski and B. Bader, with financial support of NA advocacy and European Agency-net E-Rare consortium EMINA (BMBF01 GM1003) in the laboratories of H. Kretzschmar/A. Giese (Neuropathology) and A. Danek (Neurology) at Ludwing-Maximilians-Universitat Munich (Germany). NR 72 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 22 PY 2016 VL 128 IS 25 BP 2976 EP 2987 DI 10.1182/blood-2016-07727321 PG 12 WC Hematology SC Hematology GA EI7CO UT WOS:000392655100016 PM 27742708 ER PT J AU Benmansour, S Arroyo, LD Frazer, A AF Benmansour, Saloua Arroyo, Luis D. Frazer, Alan TI Comparison of the Antidepressant-Like Effects of Estradiol and That of Selective Serotonin Reuptake Inhibitors in Middle-Aged Ovariectomized Rats SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Article DE middle age; OVX rats; estradiol; SSRI; FST; SERT function; critical period ID ESTROGEN-RECEPTOR-ALPHA; LATE-LIFE DEPRESSION; POSTMENOPAUSAL WOMEN; FEMALE RATS; HUMAN-BRAIN; MENOPAUSAL TRANSITION; CONTROLLED-TRIAL; CREB PHOSPHORYLATION; IMIPRAMINE BINDING; ALZHEIMERS-DISEASE AB This study investigated the effect of age and that of the post-ovariectomy (OVX) time interval on the antidepressant (AD)-like effects of estradiol (E-2) and selective serotonin reuptake inhibitors (SSR1s) in middle-aged (10 month) OVX rats (10m-OVX). Acute or chronic effects of these treatments in 10m-OVX were compared with those (1) in young adult (4-month) OVX rats (4m-OVX) or with older (14-month) OVX rats (14m-OVX), at a short time: 2 weeks post-OVX (+2w) and (2) in 10m-OVX rats after a longer times: 4 or 8 months post-OVX (+4m or +8m). Using in vivo chronoamperometry in the CA3 region of the hippocampus. E-2 at 20 pmol, a dose shown previously to inhibit the serotonin transporter (SERT) in 4m-OVX, had no effect in 10m-OVX+2w. A higher dose of E-2 (40 pmol) increased T80 value, a measure of serotonin or 5-hydroxytryptamine (5 HT) clearance, and also blocked the ability of fluvoxamine to increase T80. By contrast, estradiol had no effects on SERT function in 10m-OVX+4m, even at a higher dose than 40 pmol. Fluvoxamine slowed 5-HT clearance in 10m-OVX at +2w, +4m and +8m post-OVX as it did in the 4m-OVX. Using the forced swim test, 2 weeks treatment with E-2 (5 mu g/day), a dose shown previously to induce AD-like effects in 4m-OVX, had no effect in 10m-OVX+2w. However, a higher dose (10 mu g/day) of E-2 induced an AD-like effect as demonstrated by significantly increased swimming behavior and decreased immobility. This effect was not seen in 10m-OVX+4m. By contrast, significant AD-like effects were obtained in 14m-OVX+2w, thereby demonstrating that the lack of an AD effect of E-2 is due to the 4-month hormone withdrawal and not to an age effect. After 2 weeks treatment with the SSRI sertraline, similar AD-like effects were obtained in 10m-OVX tested at +2w, +4m or +8m post-OVX as those found in 4m-OVX. Thus, the potency of estradiol to produce effects consistent with inhibition of the SERT was not only decreased in older rats but its effects were markedly diminished the longer hormonal depletion occurred. By contrast, the ability of SSRIs to inhibit the SERT was not affected either by age or the length of hormonal depletion. C1 [Benmansour, Saloua; Arroyo, Luis D.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. EM benmansour@uthscsa.edu FU NARSAD; Department of Veterans Affairs FX This research was supported by funds from NARSAD and the Department of Veterans Affairs. NR 88 TC 0 Z9 0 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD DEC 21 PY 2016 VL 8 AR 311 DI 10.3380/fnagi.2016.00311 PG 13 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA EF2JF UT WOS:000390150000001 PM 28066235 ER PT J AU Li, QL Yin, LJ Jones, LW Chu, GCY Wu, JBY Huang, JM Li, QL You, SY Kim, J Lu, YT Mrdenovic, S Wang, RX Freeman, MR Garraway, I Lewis, MS Chung, LWK Zhau, HE AF Li, Qinlong Yin, Lijuan Jones, Lawrence W. Chu, Gina C-Y Wu, Jason B-Y. Huang, Jen-Ming Li, Quanlin You, Sungyong Kim, Jayoung Lu, Yi-Tsung Mrdenovic, Stefan Wang, Ruoxiang Freeman, Michael R. Garraway, Isla Lewis, Michael S. Chung, Leland W. K. Zhau, Haiyen E. TI Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells SO ONCOTARGET LA English DT Article DE bone and brain metastases; RANKL-independent; targeting; biomarker; cell signal network ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; GENE-EXPRESSION; DIFFERENTIATION; CARCINOMA; PROGRESSION; INVASION; SURVIVAL; SITES AB Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients. Genetically enforced KRT13 expression in human prostate cancer cell lines drove metastases toward mouse bone, brain and soft tissues through a RANKLindependent mechanism, as KRT13 altered the expression of genes associated with EMT, stemness, neuroendocrine/neuromimicry, osteomimicry, development, and extracellular matrices, but not receptor activator NF-kappa B ligand (RANKL) signaling networks in prostate cancer cells. Our results suggest new inhibitors targeting RANKLindependent pathways should be developed for the treatment of prostate cancer bone and soft tissue metastases. C1 [Li, Qinlong; Yin, Lijuan; Chu, Gina C-Y; Wu, Jason B-Y.; Huang, Jen-Ming; Mrdenovic, Stefan; Wang, Ruoxiang; Chung, Leland W. K.; Zhau, Haiyen E.] Cedars Sinai Med Ctr, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA. [Jones, Lawrence W.] Huntington Mem Hosp, Huntington Med Res Inst, Urol Res, Pasadena, CA USA. [Li, Quanlin] Dept Med, Biostat & Bioinformat, Los Angeles, CA USA. [You, Sungyong; Kim, Jayoung; Freeman, Michael R.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA. [Lu, Yi-Tsung] Jr Hosp Cook Cty, Chicago, IL USA. [Garraway, Isla] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Garraway, Isla] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Garraway, Isla] Greater Los Angeles Vet Affairs Healthcare Syst, Div Urol, Los Angeles, CA 90073 USA. [Lewis, Michael S.] Sepulveda Res Corp, VA Med Ctr, Los Angeles, CA 90024 USA. [Li, Qinlong] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian, Shaanxi, Peoples R China. RP Chung, LWK; Zhau, HE (reprint author), Cedars Sinai Med Ctr, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA.; Garraway, I (reprint author), Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.; Garraway, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.; Garraway, I (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Div Urol, Los Angeles, CA 90073 USA.; Lewis, MS (reprint author), Sepulveda Res Corp, VA Med Ctr, Los Angeles, CA 90024 USA. EM igarraway@mednet.ucla.edu; michael.lewis8@va.gov; Leland.Chung@cshs.org; Haiyen.Zhau@cshs.org FU NCI NIH HHS [P01 CA098912] NR 51 TC 0 Z9 0 U1 3 U2 3 PU IMPACT JOURNALS LLC PI ORCHARD PARK PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 20 PY 2016 VL 7 IS 51 BP 84645 EP 84657 DI 10.18632/oncotarget.13175 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA EG9BT UT WOS:000391353200069 PM 27835867 ER PT J AU Deming, DA AF Deming, Dustin A. TI Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al SO JOURNAL FOR IMMUNOTHERAPY OF CANCER LA English DT Editorial Material ID DENSITY AB Colorectal cancer is a leading cause of cancer-related death in the United States, despite recent advances in treatment strategies. The immune system has been implicated in the pathogenesis of colorectal cancer, with numerous studies identifying either antagonistic or pro-tumorigenic effects of infiltrating immune cells. Therapeutic strategies harnessing the immune system to target cancers have evolved expediently over the last 5 years, especially the use of checkpoint inhibitors. Recently, a subset of patients whose colorectal cancers harbor a deficiency in mismatch repair proteins have demonstrated dramatic and durable response to checkpoint blockade. Unfortunately, the vast majority of colorectal cancers are mismatch repair proficient and resistant to these inhibitors. The tumor microenvironment has been implicated in the resistance to checkpoint block and ways to overcome these resistance mechanisms would be a major advance for the treatment of colorectal cancer. Here we provide commentary on a manuscript from Halama et al. examining CCL5/CCR5 as an immune biomarker and the potential role of anti-CCR5 agents for the treatment of patients with colorectal cancer. C1 [Deming, Dustin A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Madison, WI 53706 USA. [Deming, Dustin A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA. [Deming, Dustin A.] Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53705 USA. [Deming, Dustin A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Deming, DA (reprint author), Univ Wisconsin, Dept Med, Div Hematol & Oncol, Madison, WI 53706 USA.; Deming, DA (reprint author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA.; Deming, DA (reprint author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53705 USA.; Deming, DA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM ddeming@medicine.wisc.edu FU University of Wisconsin Carbone Cancer Center [NCI P30 CA014520] FX NCI P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center). NR 10 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-1426 J9 J IMMUNOTHER CANCER JI J. Immunother. Cancer PD DEC 20 PY 2016 VL 4 AR 93 DI 10.1186/s40425-016-0197-y PG 3 WC Oncology SC Oncology GA EG8WY UT WOS:000391339000002 PM 28031821 ER PT J AU Rowhani-Rahbar, A Fan, MD Simonetti, JA Lyons, VH Wang, J Zatzick, D Rivara, FP AF Rowhani-Rahbar, Ali Fan, Mary D. Simonetti, Joseph A. Lyons, Vivian H. Wang, Jin Zatzick, Douglas Rivara, Frederick P. TI Violence Perpetration Among Patients Hospitalized for Unintentional and Assault-Related Firearm Injury A Case-Control Study and a Cohort Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID URBAN EMERGENCY-DEPARTMENT; SUBSTANCE USE; RISK; YOUTH; INTERVENTION; ADOLESCENTS; CARE; VICTIMIZATION; MORTALITY; REINJURY AB Background: Hospital-based violence intervention programs typically focus on patients whose firearm injury occurred through interpersonal violence (assault). Knowledge of violence perpetration by victims of unintentional (accidental) firearm injury is limited. Objective: To examine violence perpetration before and after a patient becomes hospitalized for firearm injury according to injury intent (intentional [assault] or unintentional [accidental]). Design: A case-control study and a retrospective cohort study. Setting: Hospitals in Washington. Patients: Persons aged 15 years or older hospitalized for a firearm injury, other injuries, or a noninjury reason from 2006 to 2007. Measurements: In the case-control study, the odds of violencerelated arrest from 2001 through hospitalization by injury intent among 3 groups were compared. In the cohort study, the rates of violence-related arrest from hospitalization through 2011 by injury intent among 3 groups were compared. Results: Patients with unintentional firearm injuries (n = 180) were more likely than those with other unintentional injuries (n = 62 795; odds ratio [OR], 2.01 [95% Cl, 1.31 to 3.09]) and no injuries (n = 172 830; OR, 3.43 [Cl, 2.22 to 5.32]) to have been arrested for a violent crime before hospitalization. Prior violencerelated arrest did not differ between patients with assault-related firearm injuries (n = 339) and those with other assault-related injuries (n = 2342; OR, 1.10 [CI, 0.84 to 1.46). During follow-up, the cumulative incidence of violence-related arrest for patients with unintentional and assault-related firearm injuries was 10% and 15% (subhazard ratio, 1.88 [CI, 1.11 to 3.17] and 1.61 [CI, 1.08 to 2.44]), respectively, compared with 1% for those without injuries. Limitation: Exclusion of self-inflicted injuries, misclassification of intent, and ascertainment bias. Conclusion: Some firearm injuries classified as accidental may indicate involvement in the cycle of violence and present an opportunity for intervention. C1 [Rowhani-Rahbar, Ali] Univ Washington, Sch Publ Hlth, Dept Epidemiol, 1959 Northeast Pacific St,Hlth Sci Bldg,F-250D, Seattle, WA 98195 USA. [Zatzick, Douglas] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, 325 Ninth Ave,Box 359911, Seattle, WA 98104 USA. [Fan, Mary D.; Simonetti, Joseph A.; Lyons, Vivian H.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Seattle, WA 98195 USA. [Fan, Mary D.; Lyons, Vivian H.; Wang, Jin; Rivara, Frederick P.] Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA. [Simonetti, Joseph A.] Vet Affairs Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. RP Rowhani-Rahbar, A (reprint author), Univ Washington, Sch Publ Hlth, Dept Epidemiol, 1959 Northeast Pacific St,Hlth Sci Bldg,F-250D, Seattle, WA 98195 USA. EM rowhani@uw.edu FU City of Seattle [124195] FX Dr. Rivara reports grants from the City of Seattle during the conduct of the study. Dr. Zatzick reports a contract (number 124195) from the City of Seattle during the conduct of the study. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOflnterestForms.do?msNum=M16-159 6. NR 36 TC 1 Z9 1 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 20 PY 2016 VL 165 IS 12 BP 841 EP U150 DI 10.7326/M16-1596 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EG7OJ UT WOS:000391236900012 PM 27750282 ER PT J AU Kansagara, D Wilt, TJ Starkey, M Oaseem, A AF Kansagara, Devan Wilt, Timothy J. Starkey, Melissa Oaseem, Amir TI Management of Chronic Insomnia Disorder in Adults RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Kansagara, Devan] Portland Evidence Based Synth Program, Portland, OR 97239 USA. [Kansagara, Devan] Portland VA Med Ctr, Portland, OR 97239 USA. [Wilt, Timothy J.] Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Wilt, Timothy J.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Starkey, Melissa; Oaseem, Amir] Amer Coll Physicians, Philadelphia, PA USA. RP Kansagara, D (reprint author), Portland Evidence Based Synth Program, Portland, OR 97239 USA.; Kansagara, D (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 20 PY 2016 VL 165 IS 12 BP 892 EP 892 DI 10.7326/L16-0542 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EG7OJ UT WOS:000391236900029 PM 27992908 ER PT J AU Luo, SX Timbang, L Kim, JI Shang, YL Sandoval, K Tang, AA Whistler, JL Ding, JB Huang, EJ AF Luo, Sarah X. Timbang, Leah Kim, Jae-Ick Shang, Yulei Sandoval, Kadellyn Tang, Amy A. Whistler, Jennifer L. Ding, Jun B. Huang, Eric J. TI TGF-beta Signaling in Dopaminergic Neurons Regulates Dendritic Growth, Excitatory-Inhibitory Synaptic Balance, and Reversal Learning SO CELL REPORTS LA English DT Article ID IN-VIVO; MICE; NEUROGENESIS; EXPRESSION; SURVIVAL; DISRUPTION; RECEPTORS; BEHAVIOR; DEFECTS; APLYSIA AB Neural circuits involving midbrain dopaminergic (DA) neurons regulate reward and goal-directed behaviors. Although local GABAergic input is known to modulate DA circuits, the mechanism that controls excitatory/inhibitory synaptic balance in DA neurons remains unclear. Here, we show that DA neurons use autocrine transforming growth factor beta (TGF-beta) signaling to promote the growth of axons and dendrites. Surprisingly, removing TGF-beta type II receptor in DA neurons also disrupts the balance in TGF-beta 1 expression in DA neurons and neighboring GABAergic neurons, which increases inhibitory input, reduces excitatory synaptic input, and alters phasic firing patterns in DA neurons. Mice lacking TGF-beta signaling in DA neurons are hyperactive and exhibit inflexibility in relinquishing learned behaviors and re-establishing new stimulus-reward associations. These results support a role for TGF-beta in regulating the delicate balance of excitatory/inhibitory synaptic input in local microcircuits involving DA and GABAergic neurons and its potential contributions to neuropsychiatric disorders. C1 [Luo, Sarah X.; Timbang, Leah; Shang, Yulei; Sandoval, Kadellyn; Tang, Amy A.; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Luo, Sarah X.; Whistler, Jennifer L.; Huang, Eric J.] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA. [Kim, Jae-Ick; Ding, Jun B.] Stanford Univ, Dept Neurosurg, Palo Alto, CA 94304 USA. [Kim, Jae-Ick; Ding, Jun B.] Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA. [Whistler, Jennifer L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA. [Kim, Jae-Ick] Ulsan Natl Inst Sci & Technol, Sch Life Sci, Ulsan 44919, South Korea. RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.; Huang, EJ (reprint author), Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA.; Huang, EJ (reprint author), San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA. EM eric.huang2@ucsf.edu RI Ding, Jun/B-2513-2009 OI Ding, Jun/0000-0003-0690-1312 FU NIH [NS081485, NS098516, NS091144, DA037963]; Department of Veterans Affairs [BX001108, RX002133]; Klingenstein Foundation; state of California for medical research on alcohol and substance abuse through UCSF; A*STAR Scholar Program FX We thank Ivy Hsieh for help with the electron microscope (EM), Dr. Linda Noble and UCSF Neurobehavioral Core Facility for help with motor behavioral analyses, and Dr. Michael Kohn and Dr. Isabel Elaine Allen for statistical analyses. This work has been supported by grants from NIH NS081485 and NS098516 (E.J.H.), NS091144 (J.B.D.), DA037963 (J.L.W.), and from the Department of Veterans Affairs BX001108 and RX002133 (E.J.H.), the Klingenstein Foundation (J.B.D.), and funds provided by the state of California for medical research on alcohol and substance abuse through UCSF (J.L.W.). S.X.L. was supported by the A*STAR Scholar Program. NR 41 TC 0 Z9 0 U1 1 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD DEC 20 PY 2016 VL 17 IS 12 BP 3233 EP 3245 DI 10.1016/j.celrep.2016.11.068 PG 13 WC Cell Biology SC Cell Biology GA EG2SY UT WOS:000390895600014 PM 28009292 ER PT J AU Merchant, RM Volpp, KG Asch, DA AF Merchant, Raina M. Volpp, Kevin G. Asch, David A. TI Learning by Listening-Improving Health Care in the Era of Yelp SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PATIENT EXPERIENCE C1 [Merchant, Raina M.; Asch, David A.] Univ Penn, Perelman Sch Med, Penn Med Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Merchant, Raina M.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu NR 5 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 20 PY 2016 VL 316 IS 23 BP 2483 EP 2484 DI 10.1001/jama.2016.16754 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EG3QH UT WOS:000390959300011 PM 27997663 ER PT J AU Lee, JS Giesler, DL Fine, MJ AF Lee, Jonathan S. Giesler, Daniel L. Fine, Michael J. TI Duration of Antibiotic Therapy for Community-Acquired Pneumonia in the Era of Personalized Medicine SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID GUIDELINES AB IMPORTANCE The optimal duration of antibiotic treatment for community acquired pneumonia (CAP) has not been well established. OBJECTIVE To validate Infectious Diseases Society of America/American Thoracic Society guidelines for duration of antibiotic treatment in hospitalized patients with CAP. DESIGN, SETTING, AND PARTICIPANTS This study was a multicenter, noninferiority randomized clinical trial performed at 4 teaching hospitals in Spain from January 1, 2012, through August 31, 2013. A total of 312 hospitalized patients diagnosed as having CAP were studied. Data analysis was performed from January 1, 2014, through February 28, 2015. INTERVENTIONS Patients were randomized at day 5 to an intervention or control group. Those in the intervention group were treated with antibiotics for a minimum of 5 days, and the antibiotic treatment was stopped at this point if their body temperature was 37.8 degrees C or less for 48 hours and they had no more than 1 CAP-associated sign of clinical instability. Duration of antibiotic treatment in the control group was determined by physicians. MAIN OUTCOMES AND MEASURES Clinical success rate at days 10 and 30 since admission and CAP-related symptoms at days 5 and 10 measured with the 18-item CAP symptom questionnaire score range, 0-90; higher scores indicate more severe symptoms. RESULTS Of the 312 patients included, 150 and 162 were randomized to the control and intervention groups, respectively. The mean (SD) age of the patientswas 66.2 (17.9) years and 64.7 (18.7) years in the control and intervention groups, respectively. Therewere 95 men (63.3%) and 55women (36.7%) in the control group and 101 men (62.3%) and 61 women (37.7%) in the intervention group. In the intent-to-treat analysis, clinical success was 48.6%(71 of 150) in the control group and 56.3% (90 of 162) in the intervention group at day 10 (P =.18) and 88.6%(132 of 150) in the control group and 91.9%(147 of 162) in the intervention group at day 30 (P =.33). The mean (SD) CAP symptom questionnaire scoreswere 24.7 (11.4) vs 27.2 (12.5) at day 5 (P =.10) and 18.6 (9.0) vs 17.9 (7.6) at day 10 (P =.69). In the per-protocol analysis, clinical successwas 50.4%(67 of 137) in the control group and 59.7%(86 of 146) in the intervention group at day 10 (P =.12) and 92.7%(126 of 137) in the control group and 94.4%(136 of 146) in the intervention group at day 30 (P = .54). The mean (SD) CAP symptom questionnaire scores were 24.3 (11.4) vs 26.6 (12.1) at day 5 (P = .16) and 18.1 (8.5) vs 17.6 (7.4) at day 10 (P = .81). CONCLUSIONS AND RELEVANCE The Infectious Diseases Society of America/American Thoracic Society recommendations for duration of antibiotic treatment based on clinical stability criteria can be safely implemented in hospitalized patients with CAP. C1 [Lee, Jonathan S.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Giesler, Daniel L.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr,Bldg 30, Pittsburgh, PA 15240 USA. RP Fine, MJ (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr,Bldg 30, Pittsburgh, PA 15240 USA. EM michael.fine@va.gov NR 6 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 20 PY 2016 VL 316 IS 23 BP 2544 EP 2545 DI 10.1001/jamainternmed.2016.3633 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EG3QH UT WOS:000390959300022 PM 27997641 ER PT J AU Clark, NE Katolik, A Roberts, KM Taylor, AB Holloway, SP Schuermann, JP Montemayor, EJ Stevens, SW Fitzpatrick, PF Damha, MJ Hart, PJ AF Clark, Nathaniel E. Katolik, Adam Roberts, Kenneth M. Taylor, Alexander B. Holloway, Stephen P. Schuermann, Jonathan P. Montemayor, Eric J. Stevens, Scott W. Fitzpatrick, Paul F. Damha, Masad J. Hart, P. John TI Metal dependence and branched RNA cocrystal structures of the RNA lariat debranching enzyme Dbr1 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE RNA debranching; intron lariat; enzyme kinetics; X-ray crystallography; Dbr1 ID WAGR SYNDROME; MECHANISM; SITES; PHOSPHODIESTERASE; 5'-NUCLEOTIDASE; SPLICEOSOME; PROTEINS; TURNOVER; BINDING; REVEAL AB Intron lariats are circular, branched RNAs (bRNAs) produced during pre-mRNA splicing. Their unusual chemical and topological properties arise from branch-point nucleotides harboring vicinal 2', 5'- and 3', 5'-phosphodiester linkages. The 2', 5'-bonds must be hydrolyzed by the RNA debranching enzyme Dbr1 before spliced introns can be degraded or processed into small nucleolar RNA and microRNA derived from intronic RNA. Here, we measure the activity of Dbr1 from Entamoeba histolytica by using a synthetic, dark-quenched bRNA substrate that fluoresces upon hydrolysis. Purified enzyme contains nearly stoichiometric equivalents of Fe and Zn per polypeptide and demonstrates turnover rates of similar to 3 s(-1). Similar rates are observed when apo-Dbr1 is reconstituted with Fe(II)+Zn(II) under aerobic conditions. Under anaerobic conditions, a rate of similar to 4.0 s(-1) is observed when apoenzyme is reconstituted with Fe(II). In contrast, apo-Dbr1 reconstituted with Mn(II) or Fe(II) under aerobic conditions is inactive. Diffraction data from crystals of purified enzyme using X-rays tuned to the Fe absorption edge show Fe partitions primarily to the beta-pocket and Zn to the alpha-pocket. Structures of the catalytic mutant H91A in complex with 7-mer and 16-mer synthetic bRNAs reveal bona fide RNA branchpoints in the Dbr1 active site. A bridging hydroxide is in optimal position for nucleophilic attack of the scissile phosphate. The results clarify uncertainties regarding structure/function relationships in Dbr1 enzymes, and the fluorogenic probe permits high-throughput screening for inhibitors that may hold promise as treatments for retroviral infections and neurodegenerative disease. C1 [Clark, Nathaniel E.; Taylor, Alexander B.; Holloway, Stephen P.; Fitzpatrick, Paul F.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA. [Katolik, Adam; Damha, Masad J.] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada. [Roberts, Kenneth M.] Univ Southern Carolina Aiken, Dept Chem & Phys, Aiken, SC 29811 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Schuermann, Jonathan P.] Cornell Univ, Dept Chem & Chem Biol, Northeastern Collaborat Access Team, Ithaca, NY 14853 USA. [Montemayor, Eric J.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA. [Montemayor, Eric J.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA. [Stevens, Scott W.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA. [Stevens, Scott W.] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Clark, NE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA. EM clarkn@uthscsa.edu; fitzpatrickp@uthscsa.edu; masad.damha@mcgill.ca; pjh@biochem.uthscsa.edu FU US Department of Veterans Affairs, Biomedical Laboratory Research and Development Service, S. Texas Veterans Health Care System [I01 BX0025801]; Welch Foundation [AQ-1399, AQ-1245]; Judith and Jean Pape Adams Charitable Foundation; National Sciences and Engineering Research Council of Canada; National Institutes of Health (NIH) [GM084246]; NIH through the Barshop Institute for Longevity and Aging Studies [T-32 AG021890]; National Science Foundation [DBI-0905865]; US Department of Energy [DE-AC02-06CH11357]; Office of the Vice President for Research; San Antonio Cancer Institute [P30 CA054174]; National Center for Advancing Translational Sciences, NIH [UL1 TR001120]; NIH [P41 GM103403] FX P.J.H. was supported in part by Merit Review Award I01 BX0025801 from the US Department of Veterans Affairs, Biomedical Laboratory Research and Development Service, S. Texas Veterans Health Care System, and in part by a Welch Foundation Grant AQ-1399 and by the Judith and Jean Pape Adams Charitable Foundation. M.J.D. was supported by a Discovery Grant from the National Sciences and Engineering Research Council of Canada. S.W.S. was supported by National Institutes of Health (NIH) Grant GM084246. N.E.C. and E.J.M. were supported by NIH Grant T-32 AG021890 through the Barshop Institute for Longevity and Aging Studies. E.J.M. was supported by Grant DBI-0905865 through the National Science Foundation. P.F.F. and K.M.R. were supported by Grant AQ-1245 from The Welch Foundation. Support for NE-CAT beamline 24-ID-E is provided by NIH Grant P41 GM103403 and US Department of Energy Grant DE-AC02-06CH11357. The X-Ray Core Laboratory at University of Texas Health Science Center, San Antonio (UTHSCSA) is supported in part by the Office of the Vice President for Research and by San Antonio Cancer Institute Grant P30 CA054174. Equipment and technical expertise were provided by the Center for Innovative Drug Discovery and High Throughput Screening Facility at UTHSCSA, which is supported by Grant UL1 TR001120 from the National Center for Advancing Translational Sciences, NIH. NR 49 TC 1 Z9 1 U1 1 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 20 PY 2016 VL 113 IS 51 BP 14727 EP 14732 DI 10.1073/pnas.1612729114 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EF0VR UT WOS:000390044900061 PM 27930312 ER PT J AU Cortese, S Castellanos, FX Eickhoff, CR D'Acunto, G Masi, G Fox, PT Laird, AR Eickhoff, SB AF Cortese, Samuele Castellanos, F. Xavier Eickhoff, Claudia R. D'Acunto, Giulia Masi, Gabriele Fox, Peter T. Laird, Angela R. Eickhoff, Simon B. TI Functional Decoding and Meta-analytic Connectivity Modeling in Adult Attention-Deficit/Hyperactivity Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Adults; Attention-deficit/hyperactivity disorder; fMRI; Functional decoding; Meta-analysis; Meta-analytic connectivity modeling ID DEFICIT HYPERACTIVITY DISORDER; WORKING-MEMORY; REWARD ANTICIPATION; RESPONSE-INHIBITION; BRAIN ACTIVATION; INTERFERENCE INHIBITION; PREFRONTAL CORTEX; NEURAL ACTIVITY; GRAY-MATTER; FOLLOW-UP AB BACKGROUND: Task-based functional magnetic resonance imaging (fMRI) studies of adult attention-deficit/hyperactivity disorder (ADHD) have revealed various ADHD-related dysfunctional brain regions, with heterogeneous findings across studies. Here, we used novel meta-analytic data-driven approaches to characterize the function and connectivity profile of ADHD-related dysfunctional regions consistently detected across studies. METHODS: We first conducted an activation likelihood estimation meta-analysis of 24 task-based fMRI studies in adults with ADHD. Each ADHD-related dysfunctional region resulting from the activation likelihood estimation meta-analysis was then analyzed using functional decoding based on similar to 7500 fMRI experiments in the BrainMap database. This approach allows mapping brain regions to functions not necessarily tested in individual studies, thus suggesting possible novel functions for those regions. Additionally, ADHD-related dysfunctional regions were clustered based on their functional coactivation profiles across all the experiments stored in BrainMap (meta-analytic connectivity modeling). RESULTS: ADHD-related hypoactivation was found in the left putamen, left inferior frontal gyrus (pars opercularis), left temporal pole, and right caudate. Functional decoding mapped the left putamen to cognitive aspects of music perception/reproduction and the left temporal lobe to language semantics; both these regions clustered together on the basis of their meta-analytic functional connectivity. Left inferior gyrus mapped to executive function tasks; right caudate mapped to both executive function tasks and music-related processes. CONCLUSIONS: Our study provides meta-analytic support to the hypothesis that, in addition to well-known deficits in typical executive functions, impairment in processes related to music perception/reproduction and language semantics may be involved in the pathophysiology of adult ADHD. C1 [Cortese, Samuele] Univ Southampton, Fac Med, Dev Brain Behav Lab, Acad Unit Psychol, Southampton, Hants, England. [Cortese, Samuele] Univ Southampton, Fac Med, Clin & Expt Sci CNS & Psychiat, Southampton, Hants, England. [Castellanos, F. Xavier] NYU Langone Med Ctr, Hassenfeld Childrens Hosp New York, Ctr Child Study, New York, NY USA. [Castellanos, F. Xavier] Nathan S Kline Inst Psychiat Res, Orangeburg, NY USA. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Cortese, Samuele; D'Acunto, Giulia; Masi, Gabriele] IRCCS, Stella Maris Sci Inst Child Neurol & Psychiat, Calambrone, Italy. [Eickhoff, Claudia R.; Eickhoff, Simon B.] Res Ctr Julich GmbH, Inst Neurosci & Med INM 1, Julich, Germany. [Eickhoff, Claudia R.] Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany. [Eickhoff, Simon B.] Heinrich Heine Univ Duesseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. RP Cortese, S (reprint author), Univ Southampton, Dev Brain Behav Lab, Acad Unit Psychol, Southampton, Hants, England. EM samuele.cortese@gmail.com OI Castellanos, Francisco/0000-0001-9192-9437 FU Helmholtz Portfolio Theme "Supercomputing and Modeling for the Human Brain"; European Union Seventh Framework Programme (FP7) [604102]; Eli Lilly; Shire; [R01MH083246]; [R01MH074457] FX This work was supported by Grant Nos. R01MH083246 and R01MH074457, the Helmholtz Portfolio Theme "Supercomputing and Modeling for the Human Brain" and the European Union Seventh Framework Programme (FP7/2007-2013) under Grant No. 604102.; SC has received royalties from Argon Healthcare, Italy (2012-2014). GM was on the advisory boards for Eli Lilly, Shire, and Angelini; has received research grants from Eli Lilly and Shire; and has been a speaker for Eli Lilly, Shire, Lundbeck, and Otsuka. All other authors report no biomedical financial interests or potential conflicts of interest. NR 84 TC 1 Z9 1 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 2016 VL 80 IS 12 BP 896 EP 904 DI 10.1016/j.biopsych.2016.06.014 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EI8JZ UT WOS:000392754000005 PM 27569542 ER PT J AU Shields, RK Potoski, BA Haidar, G Hao, BH Doi, Y Chen, L Press, EG Kreiswirth, BN Clancy, CJ Nguyen, MH AF Shields, Ryan K. Potoski, Brian A. Haidar, Ghady Hao, Binghua Doi, Yohei Chen, Liang Press, Ellen G. Kreiswirth, Barry N. Clancy, Cornelius J. Hong Nguyen, M. TI Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE ceftazidime-avibactam resistance; carbapenem-resistant Enterobacteriaceae; Klebsiella pneumoniae carbapenemase ID KLEBSIELLA-PNEUMONIAE; BETA-LACTAMASES; BACTEREMIA AB Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures. C1 [Shields, Ryan K.; Potoski, Brian A.; Haidar, Ghady; Doi, Yohei; Press, Ellen G.; Clancy, Cornelius J.; Hong Nguyen, M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Potoski, Brian A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Shields, Ryan K.; Potoski, Brian A.; Hong Nguyen, M.] Univ Pittsburgh, Antibiot Management Program, Med Ctr, Pittsburgh, PA 15260 USA. [Shields, Ryan K.; Hao, Binghua; Clancy, Cornelius J.; Hong Nguyen, M.] Univ Pittsburgh, XDR Pathogen Lab, Med Ctr, Pittsburgh, PA 15260 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Chen, Liang; Kreiswirth, Barry N.] Rutgers State Univ, New Jersey Med Sch, TB Ctr, Publ Hlth Res Inst, Newark, NJ USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Med, 3550 Terrace St,S867 Scaife Hall, Pittsburgh, PA 15261 USA. EM cjc76@pitt.edu FU University of Pittsburgh Medical Center; NIH [K08AI114883, R21AI117338, R01AI090155, R21AI111037] FX This work was supported by funding provided to the XDR Pathogen Laboratory by the University of Pittsburgh Medical Center and the NIH (awards K08AI114883. R. K. S.; R21AI117338, L. C.; R01AI090155, B. N. K.; and R21AI111037, C. J. C.). NR 12 TC 5 Z9 5 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2016 VL 63 IS 12 BP 1615 EP 1618 DI 10.1093/cid/ciw636 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EI7WW UT WOS:000392716100013 PM 27624958 ER PT J AU Bajaj, NS Kalra, R Arora, P Ather, S Guichard, JL Lancaster, WJ Patel, N Raman, F Arora, G Al Solaiman, F Clark, DT Dell'Italia, LJ Leesar, MA Davies, JE McGiffin, DC Ahmed, MI AF Bajaj, Navkaranbir S. Kalra, Rajat Arora, Pankaj Ather, Sameer Guichard, Jason L. Lancaster, W. Jake Patel, Nirav Raman, Fabio Arora, Garima Al Solaiman, Firas Clark, D. Trey, III Dell'Italia, Louis J. Leesar, Massoud A. Davies, James E. McGiffin, David C. Ahmed, Mustafa I. TI Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Pulmonary embolism; Thrombolysis; Catheter-directed treatment ID ULTRASOUND-ACCELERATED THROMBOLYSIS; PERCUTANEOUS MECHANICAL THROMBECTOMY; ANGIOJET RHEOLYTIC THROMBECTOMY; PIGTAIL ROTATION CATHETER; DEEP-VEIN THROMBOSIS; ASSISTED THROMBOLYSIS; PLASMINOGEN-ACTIVATOR; MULTICENTER REGISTRY; HYBRID TREATMENT; FRAGMENTATION AB Background: We sought to estimate the efficacy and safety outcomes of catheter-directed treatment (CDT) for patients with acute pulmonary embolism (PE). Methods: We searched SCOPUS for studies reporting outcomes after CDT for acute PE. Studies were categorized in three groups for analyses due to heterogeneity in the classification of acute PE: 1) patients with PE causing right ventricular dysfunction and haemodynamic instability: unstable haemodynamic status, 2) patients with PE causing right ventricular dysfunction where study outcomes were not stratified by haemodynamic status: stable and unstable haemodynamic status, and 3) patients with PE causing right ventricular dysfunction who remained haemodynamically stable: stable haemodynamic status. Efficacy and safety outcomes were estimated and presented as point estimates with 95% confidence intervals. Results: In 35 studies with 1253 patients, 1277 CDTs were performed. The in-hospital mortality rates for the unstable haemodynamic status, stable and unstable haemodynamic status, and stable haemodynamic status groups were 18.1% (7.3-38.2%), 7.1% (5.0-10.1%), and 2.6% (0.8-7.3%), respectively. The major bleeding rates across the groups were estimated to be 4.5, 8.5 and 3.9 per 100 CDTs, respectively. Minor bleeding occurred in 6.2, 11.9 and 9.1 per 100 CDTs, respectively. After CDT, all groups had improvements in mean pulmonary artery pressure and right ventricular function. Conclusions: We provide descriptive measures of efficacy and safety for patients who underwent CDT for acute PE. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Bajaj, Navkaranbir S.; Arora, Pankaj; Ather, Sameer; Guichard, Jason L.; Patel, Nirav; Arora, Garima; Al Solaiman, Firas; Dell'Italia, Louis J.; Leesar, Massoud A.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL USA. [Bajaj, Navkaranbir S.] Univ Alabama Birmingham, Ryals Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA. [Kalra, Rajat; Lancaster, W. Jake] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Raman, Fabio] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Clark, D. Trey, III] Cleveland Clin, Dept Cardiol, Cleveland, OH 44106 USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Davies, James E.] Univ Alabama Birmingham, Dept Surg, Div Cardiothorac Surg, Birmingham, AL USA. [McGiffin, David C.] Alfred Hosp, Dept Surg, Div Cardiothorac Surg, Melbourne, Vic, Australia. [McGiffin, David C.] Monash Univ, Melbourne, Vic, Australia. [Ahmed, Mustafa I.] Baptist Princeton, Div Cardiol, 701 Princeton Ave SW, Birmingham, AL 35211 USA. [Bajaj, Navkaranbir S.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. [Bajaj, Navkaranbir S.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Bajaj, Navkaranbir S.] Harvard Med Sch, Boston, MA USA. [Kalra, Rajat] Univ Minnesota, Div Cardiovasc, Minneapolis, MN 55455 USA. RP Ahmed, MI (reprint author), Baptist Princeton, Struct Heart Program, 701 Princeton Ave SW, Birmingham, AL 35211 USA. EM musiahm@gmail.com NR 85 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD DEC 15 PY 2016 VL 225 BP 128 EP 139 DI 10.1016/j.ijcard.2016.09.036 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EF6WN UT WOS:000390472000031 PM 27718446 ER PT J AU Sheffrin, M Cenzer, IS Steinman, MA AF Sheffrin, Meera Cenzer, Irena Stijacic Steinman, Michael A. TI Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study SO ALZHEIMERS RESEARCH & THERAPY LA English DT Article DE Alzheimer's disease; Advance care planning; Attitudes and knowledge; Predictive testing ID PUBLIC-ATTITUDES; OLDER-ADULTS; RISK; PREVALENCE; DIRECTIVES; BEHAVIOR AB Background: It is unknown whether older adults in the United States would be willing to take a test predictive of future Alzheimer's disease, or whether testing would change behavior. Using a nationally representative sample, we explored who would take a free and definitive test predictive of Alzheimer's disease, and examined how using such a test may impact advance care planning. Methods: A cross-sectional study within the 2012 Health and Retirement Study of adults aged 65 years or older asked questions about a test predictive of Alzheimer's disease (N = 874). Subjects were asked whether they would want to take a hypothetical free and definitive test predictive of future Alzheimer's disease. Then, imagining they knew they would develop Alzheimer's disease, subjects rated the chance of completing advance care planning activities from 0 to 100. We classified a score > 50 as being likely to complete that activity. We evaluated characteristics associated with willingness to take a test for Alzheimer's disease, and how such a test would impact completing an advance directive and discussing health plans with loved ones. Results: Overall, 75% (N = 648) of the sample would take a free and definitive test predictive of Alzheimer's disease. Older adults willing to take the test had similar race and educational levels to those who would not, but were more likely to be <= 75 years old (odds ratio 0.71 (95% CI 0.53-0.94)). Imagining they knew they would develop Alzheimer's, 81% would be likely to complete an advance directive, although only 15% had done so already. Conclusions: In this nationally representative sample, 75% of older adults would take a free and definitive test predictive of Alzheimer's disease. Many participants expressed intent to increase activities of advance care planning with this knowledge. This confirms high public interest in predictive testing for Alzheimer's disease and suggests this may be an opportunity to engage patients in advance care planning discussions. C1 [Sheffrin, Meera] Stanford Univ, Sch Med, Div Gen Internal Med Disciplines, Geriatr Med Sect, Stanford, CA USA. [Cenzer, Irena Stijacic; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Cenzer, Irena Stijacic; Steinman, Michael A.] San Francisco VA Med Ctr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. RP Sheffrin, M (reprint author), Stanford Univ, Sch Med, Div Gen Internal Med Disciplines, Geriatr Med Sect, Stanford, CA USA. EM sheffrin@stanford.edu FU National Institute on Aging; American Federation on Aging Research [T32 AG000212-21, K23-AG030999, K24: K24AG049057, RC1-AG036377]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center [SDR 02-237, 98-004] FX This work was supported by grant funding from the National Institute on Aging and the American Federation on Aging Research (T32 AG000212-21, K23-AG030999, K24: K24AG049057, and RC1-AG036377). Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. NR 17 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PD DEC 13 PY 2016 VL 8 AR 55 DI 10.1186/s13195-016-0223-9 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EG9XK UT WOS:000391413500001 PM 27955707 ER PT J AU Woerman, AL Aoyagi, A Patel, S Kazmi, SA Lobach, I Grinberg, LT Mckee, AC Seeley, WW Olson, SH Prusiner, SB AF Woerman, Amanda L. Aoyagi, Atsushi Patel, Smita Kazmi, Sabeen A. Lobach, Iryna Grinberg, Lea T. McKee, Ann C. Seeley, William W. Olson, Steven H. Prusiner, Stanley B. TI Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE argyrophilic grain disease; corticobasal degeneration; Pick's disease; progressive supranuclear palsy; tauopathies ID MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; SHARE ANTIGENIC DETERMINANTS; FRONTOTEMPORAL DEMENTIA; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; PICKS-DISEASE; ABNORMAL PHOSPHORYLATION; BRAIN-INJURY; MOUSE-BRAIN AB Tau prions are thought to aggregate in the central nervous system, resulting in neurodegeneration. Among the tauopathies, Alzheimer's disease (AD) is the most common, whereas argyrophilic grain disease (AGD), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), Pick's disease (PiD), and progressive supranuclear palsy (PSP) are less prevalent. Brain extracts from deceased individuals with PiD, a neurodegenerative disorder characterized by three-repeat (3R) tau prions, were used to infect HEK293T cells expressing 3R tau fused to yellow fluorescent protein (YFP). Extracts from AGD, CBD, and PSP patient samples, which contain four-repeat (4R) tau prions, were transmitted to HEK293T cells expressing 4R tau fused to YFP. These studies demonstrated that prion propagation in HEK cells requires isoform pairing between the infecting prion and the recipient substrate. Interestingly, tau aggregates in AD and CTE, containing both 3R and 4R isoforms, were unable to robustly infect either 3R-or 4R-expressing cells. However, AD and CTE prions were able to replicate in HEK293T cells expressing both 3R and 4R tau. Unexpectedly, increasing the level of 4R isoform expression alone supported the propagation of both AD and CTE prions. These results allowed us to determine the levels of tau prions in AD and CTE brain extracts. C1 [Woerman, Amanda L.; Aoyagi, Atsushi; Patel, Smita; Kazmi, Sabeen A.; Olson, Steven H.; Prusiner, Stanley B.] Univ Calif San Francisco, Inst Neurodegenerat Dis, Weill Inst Neurosci, San Francisco, CA 94143 USA. [Woerman, Amanda L.; Grinberg, Lea T.; Seeley, William W.; Olson, Steven H.; Prusiner, Stanley B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Aoyagi, Atsushi] Daiichi Sankyo Co Ltd, Tokyo 1408710, Japan. [Lobach, Iryna] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Grinberg, Lea T.; Seeley, William W.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [McKee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, Alzheimers Dis Ctr, Boston, MA 02118 USA. [McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA. [McKee, Ann C.] US Dept Vet Affairs, Vet Affairs Boston Healthcare Syst, Jamaica Plain, MA 02130 USA. [McKee, Ann C.] US Dept Vet Affairs, Med Ctr, Bedford, MA 01730 USA. [Prusiner, Stanley B.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. RP Prusiner, SB (reprint author), Univ Calif San Francisco, Inst Neurodegenerat Dis, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Prusiner, SB (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Prusiner, SB (reprint author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. EM stanley.prusiner@ucsf.edu FU NIH [AG002132, AG031220, AG023501, AG19724]; Daiichi Sankyo; Dana Foundation; Glenn Foundation; Sherman Fairchild Foundation; Tau Consortium; Consortium for Frontotemporal Dementia Research; Department of Veterans Affairs, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering [NS086559]; National Institute on Aging, Boston University Alzheimer's Disease Center [AG13846, 0572063345-5]; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment, Inc FX We thank George A. Carlson for his thoughtful revisions and comments, and Brittany N. Dugger for microdissecting the CTE patient samples. This work was supported by NIH Grants AG002132 and AG031220, Daiichi Sankyo, Dana Foundation, Glenn Foundation, Sherman Fairchild Foundation, and a gift from the Rainwater Charitable Foundation. Control, AD, AGD, CBD, PiD, and PSP tissue samples were provided by the University of California, San Francisco, Neurodegenerative Disease Brain Bank, which is supported by NIH Grants AG023501 and AG19724 (to W.W.S.), Tau Consortium, and Consortium for Frontotemporal Dementia Research. CTE tissue samples were provided by the Boston University Alzheimer's Disease Center Chronic Traumatic Encephalopathy Center, which is supported by the Department of Veterans Affairs, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (NS086559), National Institute on Aging, Boston University Alzheimer's Disease Center (AG13846; Supplement 0572063345-5), Concussion Legacy Foundation, Andlinger Foundation, and World Wrestling Entertainment, Inc. Additional control samples were provided by the University of Miami Brain Endowment Bank. NR 71 TC 0 Z9 0 U1 15 U2 15 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 13 PY 2016 VL 113 IS 50 BP E8187 EP E8196 DI 10.1073/pnas.1616344113 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE6CQ UT WOS:000389696700022 PM 27911827 ER PT J AU Ikonomovic, MD Buckley, CJ Heurling, K Sherwin, P Jones, PA Zanette, M Mathis, CA Klunk, WE Chakrabarty, A Ironside, J Ismail, A Smith, C Thal, DR Beach, TG Farrar, G Smith, APL AF Ikonomovic, Milos D. Buckley, Chris J. Heurling, Kerstin Sherwin, Paul Jones, Paul A. Zanette, Michelle Mathis, Chester A. Klunk, William E. Chakrabarty, Aruna Ironside, James Ismail, Azzam Smith, Colin Thal, Dietmar R. Beach, Thomas G. Farrar, Gill Smith, Adrian P. L. TI Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection SO ACTA NEUROPATHOLOGICA COMMUNICATIONS LA English DT Article DE Flutemetamol; PET; Amyloid; Alzheimer's disease; Neuropathology (4-6 allowed) ID PITTSBURGH-COMPOUND-B; POSITRON-EMISSION-TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; NINDS NEUROPATHOLOGIC CRITERIA; ALZHEIMERS-DISEASE; LEWY BODIES; DIFFUSE PLAQUES; BINDING-SITES; HUMAN BRAIN; PATHOLOGY AB In vivo imaging of fibrillar beta-amyloid deposits may assist clinical diagnosis of Alzheimer's disease (AD), aid treatment selection for patients, assist clinical trials of therapeutic drugs through subject selection, and be used as an outcome measure. A recent phase III trial of [F-18]flutemetamol positron emission tomography (PET) imaging in 106 end-of-life subjects demonstrated the ability to identify fibrillar beta-amyloid by comparing in vivo PET to post-mortem histopathology. Post-mortem analyses demonstrated a broad and continuous spectrum of beta-amyloid pathology in AD and other dementing and non-dementing disease groups.The GE067-026 trial demonstrated 91% sensitivity and 90% specificity of [F-18] flutemetamol PET by majority read for the presence of moderate or frequent plaques. The probability of an abnormal [F-18] flutemetamol scan increased with neocortical plaque density and AD diagnosis. All dementia cases with non-AD neurodegenerative diseases and those without histopathological features of beta-amyloid deposits were [F-18] flutemetamol negative. Majority PET assessments accurately reflected the amyloid plaque burden in 90% of cases. However, ten cases demonstrated a mismatch between PET image interpretations and post-mortem findings. Although tracer retention was best associated with amyloid in neuritic plaques, amyloid in diffuse plaques and cerebral amyloid angiopathy best explain three [F-18] flutemetamol positive cases with mismatched (sparse) neuritic plaque burden. Advanced cortical atrophy was associated with the seven false negative [F-18] flutemetamol images. The interpretation of images from pathologically equivocal cases was associated with low reader confidence and inter-reader agreement. Our results support that amyloid in neuritic plaque burden is the primary form of beta-amyloid pathology detectable with [F-18] flutemetamol PET imaging. ClinicalTrials.gov NCT01165554. Registered June 21, 2010; NCT02090855. Registered March 11, 2014. C1 [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Buckley, Chris J.; Jones, Paul A.; Farrar, Gill; Smith, Adrian P. L.] GE Healthcare, Grove Ctr GC18,White Lion Rd, Amersham HP7 9LL, Bucks, England. [Heurling, Kerstin] GE Healthcare, S-75184 Uppsala, Sweden. [Heurling, Kerstin] Uppsala Univ, Dept Surg Sci, S-75185 Uppsala, Sweden. [Sherwin, Paul; Zanette, Michelle] GE Healthcare, Marlborough, MA 01752 USA. [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.; Klunk, William E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Chakrabarty, Aruna; Ismail, Azzam] St James Univ Hosp, Leeds Inst Mol Med, Pathol & Tumour Biol, Leeds, W Yorkshire, England. [Ironside, James] Univ Edinburgh, Western Gen Hosp, Natl CJD Res & Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland. [Smith, Colin] Ctr Clin Brain Sci, Acad Dept Neuropathol, Edinburgh EH16 4SB, Midlothian, Scotland. [Thal, Dietmar R.] Katholieke Univ Leuven, Neuropathol Lab, Dept Neurosci, Leuven, Belgium. [Beach, Thomas G.] Banner Sun Hlth Res Inst, Sun City, AZ 85351 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Thal, Dietmar R.] UZ Leuven, Dept Pathol, Leuven, Belgium. RP Smith, APL (reprint author), GE Healthcare, Grove Ctr GC18,White Lion Rd, Amersham HP7 9LL, Bucks, England. EM Adrian.Smith@ge.com FU GE Healthcare FX We wish to acknowledge Stacy Simpson Logan, CMPP, of Winfield Consulting, for her editorial assistance, funded by GE Healthcare and Dr Jan Wolber for critical manuscript review. This study was funded by GE Healthcare. NR 65 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-5960 J9 ACTA NEUROPATHOL COM JI Acta Neuropathol. Commun. PD DEC 12 PY 2016 VL 4 AR 130 DI 10.1186/s40478-016-0399-z PG 24 WC Neurosciences SC Neurosciences & Neurology GA EG2XJ UT WOS:000390907100001 PM 27955679 ER PT J AU Schwarzwalder, GM Scott, DR Vanderwal, CD AF Schwarzwalder, Gregg M. Scott, David R. Vanderwal, Christopher D. TI A Synthesis of Exiguaquinol Dessulfate SO CHEMISTRY-A EUROPEAN JOURNAL LA English DT Article DE antibiotics; epimers; Heck cyclization; natural product synthesis; sulfation ID PYLORI GLUTAMATE RACEMASE; SELECTIVE ANTIBACTERIAL AGENTS; HELICOBACTER-PYLORI; PYRIDODIAZEPINE AMINES; ALKALOID JAMTINE; GASTRIC-CANCER; MARINE SPONGE; CORE; 3,6-DIMETHOXYBENZOCYCLOBUTENONE; INHIBITORS AB A concise and stereoselective synthesis of exiguaquinol dessulfate is described. Sequential application of a Diels-Alder cycloaddition, a desymmetrizing aldol addition, and a reductive Heck cyclization established most of the architecture of exiguaquinol, and a carefully choreographed introduction of the polar substituents afforded the title compound; unfortunately, naphthoquinol sulfation could not be achieved to deliver exiguaquinol. Our hypothesis regarding the configurational preference of the N-acyl hemiaminal, which was based upon an analysis of internal hydrogen-bonding interactions with polar functional groups, was proven correct. A late-stage intermediate did not demonstrate bactericidal activity against H. pylori cultures. C1 [Schwarzwalder, Gregg M.; Vanderwal, Christopher D.] Univ Calif Irvine, Dept Chem, 1102 Nat Sci 2, Irvine, CA 92697 USA. [Scott, David R.] UC Los Angeles, Dept Physiol, VA Greater Los Angeles Healthcare Syst, 11310 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. RP Vanderwal, CD (reprint author), Univ Calif Irvine, Dept Chem, 1102 Nat Sci 2, Irvine, CA 92697 USA. EM cdv@uci.edu FU NIH [CA180568] FX We thank the NIH for an F31 predoctoral NRSA fellowship (CA180568) to G.M.S. We acknowledge the assistance of Dr. Greg Basarab (AstraZeneca) in our attempts to learn about the MurI inhibitory activity of our intermediates, and AstraZeneca for sharing a MurI plasmid and synthetic inhibitor. Professor Eduardo Garcia-Junceda (CSIC, Spain) is acknowledged for providing the plasmid encoding the aryl sulfotransferase enzyme from Haliangium ochraceum. We thank Jacob Milligan and Professor Sheryl Tsai (UCI) for helping to express MurI and the sulfotransferase enzyme and Dr. Hung Pham and Professor Ken Houk (UCLA) for the previously published but critical ground-state computations shown in Figure 2. NR 41 TC 1 Z9 1 U1 6 U2 6 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA POSTFACH 101161, 69451 WEINHEIM, GERMANY SN 0947-6539 EI 1521-3765 J9 CHEM-EUR J JI Chem.-Eur. J. PD DEC 12 PY 2016 VL 22 IS 50 BP 17953 EP 17957 DI 10.1002/chem.201604506 PG 5 WC Chemistry, Multidisciplinary SC Chemistry GA EF8UE UT WOS:000390604600012 PM 27673578 ER PT J AU Felicetti, P Trotta, F Bonetto, C Santuccio, C Pernus, YB Burgner, D Chandler, R Girolomoni, G Hadden, RDM Kochar, S Kucuku, M Monaco, G Ozen, S Pahud, B Phuong, L Bachtiar, NS Teeba, A Top, K Varricchio, F Wise, RP Zanoni, G Zivkovic, S Bonhoeffer, J AF Felicetti, Patrizia Trotta, Francesco Bonetto, Caterina Santuccio, Carmela Pernus, Yolanda Brauchli Burgner, David Chandler, Rebecca Girolomoni, Giampiero Hadden, Robert D. M. Kochar, Sonali Kucuku, Merita Monaco, Giuseppe Ozen, Seza Pahud, Barbara Phuong, Linny Bachtiar, Novilia Sjafri Teeba, Amina Top, Karina Varricchio, Frederick Wise, Robert P. Zanoni, Giovanna Zivkovic, Saga Bonhoeffer, Jan CA Brighton Collaboration Vasculitis TI Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases SO VACCINE LA English DT Article DE Vasculitis; Vaccines; Immunization; Adverse event following immunization (AEFI); Spontaneous reporting; Eudravigilance; VigiBase (R); VAERS; Pharmacovigilance ID SYSTEMIC VASCULITIDES; INFLUENZA VACCINATION; CONSENSUS CONFERENCE; KAWASAKI-DISEASE; CLASSIFICATION; CRITERIA; GRANULOMATOSIS; NOMENCLATURE AB Background: Vasculitides have been reported as adverse events following immunization (AEFI) following various vaccines. We describe reports of vasculitis to three international spontaneous reporting systems. Methods: All spontaneous reports of vasculitis following immunization between January 2003 and June 2014 were retrieved from Eudravigilance (EV), the Vaccine Adverse Event Reporting System (VAERS), and VigiBase (R). A Standard MedDRA Query (SMQ) for vasculitis was used and vaccine types were categorized using the Anatomical Therapeutic Chemical classification system. We performed a descriptive analysis by source, sex, age, country, time to onset, vaccine, and type of vasculitis. Results: We retrieved 1797 reports of vasculitis in EV, 1171 in VAERS, and 2606 in VigiBase (R). Vasculitis was predominantly reported in children aged 1-17 years, and less frequently in the elderly (>65 years). The generic term "vasculitis" was the most frequently reported AEFI" in this category across the three databases (range 21.9% to 27.5% of all reported vasculitis for vaccines). For the more specific terms, Henoch-Schoenlein Purpura (HSP) was most frequently reported, (19.1% on average), followed by Kawasaki disease (10) (16.1% on average) and polymyalgia rheumatica (PMR) (9.2% on average). Less frequently reported subtypes were cutaneous vasculitis (CuV), vasculitis of the central nervous system (CNS-V), and Behcet's syndrome (BS). HSP, PMR and CuV were more frequently reported with influenza vaccines: on average in 29.3% for HSP reports, 61.5% for PMR reports and in 39.2% for CuV reports KD was reported with pneumococcal vaccines in 32.0% of KD reports and with rotavirus vaccines in more than 20% of KD reports. BS was most frequently reported after hepatitis and HPV vaccines and CNS-V after HPV vaccines. Conclusion: Similar reporting patterns of vasculitides were observed in different databases. Implementation of standardized case definitions for specific vasculitides could improve overall data quality and comparability of reports. Published by Elsevier Ltd. C1 [Felicetti, Patrizia; Trotta, Francesco; Bonetto, Caterina; Santuccio, Carmela] Italian Med Agcy, Rome, Italy. [Pernus, Yolanda Brauchli; Bonhoeffer, Jan] Brighton Collaborat Fdn, Basel, Switzerland. [Burgner, David] Monash Childrens Hosp Clayton, Melbourne, Vic, Australia. [Burgner, David] Univ Melbourne, Dept Paediat, MCRI, Melbourne, Vic 3010, Australia. [Chandler, Rebecca] Uppsala Monitoring Ctr, Uppsala, Sweden. [Girolomoni, Giampiero] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy. [Hadden, Robert D. M.] Kings Coll Hosp London, London, England. [Kochar, Sonali] JSIPL, Deliver Project, USAID, New Delhi, India. [Kucuku, Merita] Natl Agcy Med & Med Devices, Dept Vaccines Control, Tirana, Albania. [Monaco, Giuseppe] Ctr Pharmacovigilance, Milan, Italy. [Ozen, Seza] Hacettepe Univ, Dept Pediat Rheumatol, Ankara, Turkey. [Pahud, Barbara] Childrens Mercy Hosp, Kansas City, MO 64108 USA. [Phuong, Linny] Monash Childrens Hosp, Melbourne, Vic, Australia. [Phuong, Linny] Royal Childrens Hosp, Melbourne, Vic, Australia. [Bachtiar, Novilia Sjafri] Bio Farma Vaccine Inst, Java, Indonesia. [Teeba, Amina] Ctr Natl Anti Poison & Pharmacovigilance, Rabat, Morocco. [Top, Karina] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada. [Wise, Robert P.] MedImmune AstraZeneca, Gaithersburg, MD USA. [Zanoni, Giovanna] Azienda Osped Univ Integrata Verona, Immunol Unit, Verona, Italy. [Zivkovic, Saga] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Zivkovic, Saga] VA Pittsburgh Healthcare Syst, MSL, Neurol Serv, Pittsburgh, PA USA. [Bonhoeffer, Jan] Univ Basel, Childrens Hosp, Basel, Switzerland. RP Felicetti, P (reprint author), Italian Med Agcy, Rome, Italy. EM contact@brightoncollaboration.org RI Trotta, Francesco/G-8702-2013 OI Trotta, Francesco/0000-0001-6889-8484 FU Italian Medicines Agency (AIFA) FX The Italian Medicines Agency (AIFA) financed the cost of the project "Working group for the Vasculitis case definition" performed by the Brighton Collaboration. NR 23 TC 2 Z9 2 U1 5 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD DEC 12 PY 2016 VL 34 IS 51 BP 6634 EP 6640 DI 10.1016/j.vaccine.2015.09.027 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EF7JO UT WOS:000390506100021 PM 26392009 ER PT J AU McLeod, CM Mauck, RL AF McLeod, Claire M. Mauck, Robert L. TI High fidelity visualization of cell-to-cell variation and temporal dynamics in nascent extracellular matrix formation SO SCIENTIFIC REPORTS LA English DT Article ID NEWLY SYNTHESIZED PROTEINS; NONCANONICAL AMINO-ACIDS; MESENCHYMAL STEM-CELLS; PERICELLULAR MATRIX; ARTICULAR-CARTILAGE; CLICK CHEMISTRY; IN-VIVO; ENGINEERED CARTILAGE; DEVELOPING ZEBRAFISH; AGAROSE CULTURE AB Extracellular matrix dynamics are key to tissue morphogenesis, homeostasis, injury, and repair. The spatiotemporal organization of this matrix has profound biological implications, but is challenging to monitor using standard techniques. Here, we address these challenges by using noncanonical amino acid tagging to fluorescently label extracellular matrix synthesized in the presence of bio-orthogonal methionine analogs. This strategy labels matrix proteins with high resolution, without compromising their distribution or mechanical function. We demonstrate that the organization and temporal dynamics of the proteinaceous matrix depend on the biophysical features of the microenvironment, including the biomaterial scaffold and the niche constructed by cells themselves. Pulse labeling experiments reveal that, in immature constructs, nascent matrix is highly fibrous and interdigitates with pre-existing matrix, while in more developed constructs, nascent matrix lacks fibrous organization and is retained in the immediate pericellular space. Inhibition of collagen crosslinking increases matrix synthesis, but compromises matrix organization. Finally, these data demonstrate marked cell-to-cell heterogeneity amongst both chondrocytes and mesenchymal stem cells undergoing chondrogenesis. Collectively, these results introduce fluorescent noncanonical amino acid tagging as a strategy to investigate spatiotemporal matrix organization, and demonstrate its ability to identify differences in phenotype, microenvironment, and matrix assembly at the single cell level. C1 [McLeod, Claire M.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [McLeod, Claire M.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [McLeod, Claire M.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu FU National Institutes of Health [R01 EB008722, T32 HL007954]; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX This work was funded by the National Institutes of Health (R01 EB008722, T32 HL007954) and the Penn Center for Musculoskeletal Disorders (P30 AR050950). We gratefully acknowledge Bhavana Mohanraj and Dr. George Dodge for their thoughtful discussion and input to this work. NR 46 TC 0 Z9 0 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 12 PY 2016 VL 6 AR 38852 DI 10.1038/srep38852 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE7PT UT WOS:000389816000001 PM 27941914 ER PT J AU Teerlink, JR Felker, GM McMurray, JJV Solomon, SD Adams, KF Cleland, JGF Ezekowitz, JA Goudev, A Macdonald, P Metra, M Mitrovic, V Ponikowski, P Serpytis, P Spinar, J Tomcsanyi, J Vandekerckhove, HJ Voors, AA Monsalvo, ML Johnston, J Malik, FI Honarpour, N AF Teerlink, John R. Felker, G. Michael McMurray, John J. V. Solomon, Scott D. Adams, Kirkwood F., Jr. Cleland, John G. F. Ezekowitz, Justin A. Goudev, Assen Macdonald, Peter Metra, Marco Mitrovic, Veselin Ponikowski, Piotr Serpytis, Pranas Spinar, Jindrich Tomcsanyi, Janos Vandekerckhove, Hans J. Voors, Adriaan A. Monsalvo, Maria Laura Johnston, James Malik, Fady I. Honarpour, Narimon CA COSMIC-HFf Investigators TI Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial SO LANCET LA English DT Article ID CARDIAC RESYNCHRONIZATION THERAPY; OMECAMTIV MECARBIL; TIME; MECHANISMS; PREDICTION; MORTALITY; EXERCISE; SAFETY AB Background Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and eff ects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. Methods In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials. gov, number NCT01786512. Findings From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fi xed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fi xed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean diff erences were as follows: systolic ejection time 25 ms (95% CI 18-32, p< 0.0001), stroke volume 3.6 mL (0.5-6.7, p= 0.0217), left ventricular end-systolic diameter -1.8 mm (-2.9 to -0.6, p= 0.0027), left ventricular end-diastolic diameter -1.3 mm, (-2.3 to 0.3, p= 0.0128), heart rate -3.0 beats per min (-5.1 to -0.8, p= 0.0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p= 0.0069). The frequency of adverse clinical events did not diff er between groups. Interpretation Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter. C1 [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. [Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA. [McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. [Solomon, Scott D.] Harvard Med Sch, Boston, MA USA. [Adams, Kirkwood F., Jr.] Univ North Carolina Chapel Hill, Div Cardiol, Chapel Hill, NC USA. [Cleland, John G. F.] Imperial Coll, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Cleland, John G. F.] Imperial Coll, Harefield Hosp, London, England. [Cleland, John G. F.] Univ Glasgow, Robertson Ctr Biostat & Clin Trials, Glasgow, Lanark, Scotland. [Ezekowitz, Justin A.] Univ Alberta, Dept Med, Edmonton, AB, Canada. [Goudev, Assen] Queen Giovanna Univ Hosp, Dept Cardiol, Sofia, Bulgaria. [Goudev, Assen] Med Univ Sofia, Sofia, Bulgaria. [Macdonald, Peter] St Vincents Hosp, Heart Transplant Unit, Sydney, NSW, Australia. [Macdonald, Peter] Victor Chang Cardiac Res Inst, Transplantat Res Lab, Sydney, NSW, Australia. [Macdonald, Peter] Univ New South Wales, Sydney, NSW, Australia. [Metra, Marco] Univ Brescia, Div Cardiol, Brescia, Italy. [Mitrovic, Veselin] Kerckhoff Klin Forsch Gesell, Frankfurt, Germany. [Mitrovic, Veselin] Goethe Univ Frankfurt, Mainz, Germany. [Ponikowski, Piotr] Med Univ, Dept Heart Dis, Wroclaw, Poland. [Ponikowski, Piotr] Mil Hosp, Ctr Heart Dis, Wroclaw, Poland. [Serpytis, Pranas] Vilnius Univ Hosp Santariskiu Klin, Emergency Ctr, Vilnius, Lithuania. [Serpytis, Pranas] Vilnius Univ, Vilnius, Lithuania. [Spinar, Jindrich] Univ Hosp Brno, Brno, Czech Republic. [Spinar, Jindrich] Masaryk Univ, Fac Med, Brno, Czech Republic. [Tomcsanyi, Janos] St John God Hosp, Dept Cardiol, Budapest, Hungary. [Vandekerckhove, Hans J.] AZ St Lucas, Dept Cardiol, Ghent, Belgium. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Monsalvo, Maria Laura; Johnston, James; Honarpour, Narimon] Amgen Inc, Thousand Oaks, CA USA. [Malik, Fady I.] Cytokinetics, San Francisco, CA USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu OI mcmurray, john/0000-0002-6317-3975 FU Amgen; Cytokinetics FX Amgen.; The COSMIC-HF study was funded and done by Amgen in collaboration with Cytokinetics. NR 23 TC 1 Z9 1 U1 11 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 10 PY 2016 VL 388 IS 10062 BP 2895 EP 2903 DI 10.1016/S0140-6736(16)32049-9 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA EE5FU UT WOS:000389631700034 PM 27914656 ER PT J AU Chen, HCI Burke, JF Cohen, AS AF Chen, Han-Chiao I. Burke, John F. Cohen, Akiva S. TI Editorial: Traumatic Brain Injury As a Systems Neuroscience Problem SO FRONTIERS IN SYSTEMS NEUROSCIENCE LA English DT Editorial Material DE traumatic brain injury; neural circuits; neural networks; systems neuroscience; neuromodulation C1 [Chen, Han-Chiao I.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA. [Chen, Han-Chiao I.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Burke, John F.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA. [Cohen, Akiva S.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA. [Cohen, Akiva S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA. RP Chen, HCI (reprint author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.; Chen, HCI (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM saac.chen@uphs.upenn.edu NR 10 TC 0 Z9 0 U1 3 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5137 J9 FRONT SYST NEUROSCI JI Front. Syst. Neurosci. PD DEC 9 PY 2016 VL 10 AR 100 DI 10.3339/fnsys.2016.00100 PG 3 WC Neurosciences SC Neurosciences & Neurology GA EE5UM UT WOS:000389673200001 PM 28018187 ER PT J AU Arffa, ML Zapf, MA Kothari, AN Chang, V Gupta, GN Ding, X Al-Gayyar, MM Syn, W Elsherbiny, NM Kuo, PC Mi, Z AF Arffa, M. L. Zapf, M. A. Kothari, A. N. Chang, V. Gupta, G. N. Ding, X. Al-Gayyar, M. M. Syn, W. Elsherbiny, N. M. Kuo, P. C. Mi, Z. TI Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis SO PLOS ONE LA English DT Article ID GREEN TEA CATECHINS; FATTY LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; NONALCOHOLIC STEATOHEPATITIS; OXIDATIVE STRESS; EXPRESSION; GALLATE; RNA; CELLS; MODEL AB Osteopontin (OPN) promotes hepatic fibrosis, and developing therapies targeting OPN expression in settings of hepatic injury holds promise. The polyphenol epigallocatechin-3-gallate (EGCG), found in high concentrations in green tea, downregulates OPN expression through OPN mRNA degradation, but the mechanism is unknown. Previous work has shown that microRNAs can decrease OPN mRNA levels, and other studies have shown that EGCG modulates the expression of multiple microRNAs. In our study, we first demonstrated that OPN induces hepatic stellate cells to transform into an activated state. We then identified three microRNAs which target OPN mRNA: miR-181a, miR-10b, and miR-221. In vitro results show that EGCG upregulates all three microRNAs, and all three microRNAs are capable of down regulating OPN mRNA when administered alone. Interestingly, only miR-221 is necessary for EGCG-mediated OPN mRNA degradation and miR-221 inhibition reduces the effects of EGCG on cell function. In vivo experiments show that thioacetamide (TAA)-induced cell cytotoxicity upregulates OPN expression; treatment with EGCG blocks the effects of TAA. Furthermore, chronic treatment of EGCG in vivo upregulates all three microRNAs equally, suggesting that in more chronic treatment all three microRNAs are involved in modulating OPN expression. We conclude that in in vitro and in vivo models of TAA-induced hepatic fibrosis, EGCG inhibits OPN-dependent injury and fibrosis. EGCG works primarily by upregulating miR-221 to accelerate OPN degradation. EGCG may therefore have utility as a protective agent in settings of liver injury. C1 [Arffa, M. L.; Zapf, M. A.; Kothari, A. N.; Chang, V.; Gupta, G. N.; Ding, X.; Kuo, P. C.; Mi, Z.] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA. [Al-Gayyar, M. M.; Elsherbiny, N. M.] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura, Egypt. [Syn, W.] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA. [Syn, W.] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. [Al-Gayyar, M. M.] Univ Tabuk, Dept Pharmaceut Chem, Tabuk, Saudi Arabia. RP Kuo, PC (reprint author), Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA. EM pkuo@lumc.edu OI Arffa, Matthew/0000-0002-9539-9100 NR 57 TC 0 Z9 0 U1 6 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 9 PY 2016 VL 11 IS 12 AR e0167435 DI 10.1371/journal.pone.0167435 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE4PU UT WOS:000389587100097 PM 27935974 ER PT J AU Ramratnam, M Salama, G Sharma, RK Wang, DWR Smith, SH Banerjee, SK Huang, XN Gifford, LM Pruce, ML Gabris, BE Saba, S Shroff, SG Ahmad, F AF Ramratnam, Mohun Salama, Guy Sharma, Ravi K. Wang, David Wen Rui Smith, Stephen H. Banerjee, Sanjay K. Huang, Xueyin N. Gifford, Lindsey M. Pruce, Michele L. Gabris, Bethann E. Saba, Samir Shroff, Sanjeev G. Ahmad, Ferhaan TI Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium Desensitization SO PLOS ONE LA English DT Article ID HEART-FAILURE; MOUSE HEARTS; MODEL; TRANSIENTS; PROTEINS AB Most studies of the mechanisms leading to hereditary dilated cardiomyopathy (DCM) have been performed in reconstituted in vitro systems. Genetically engineered murine models offer the opportunity to dissect these mechanisms in vivo. We generated a gene-targeted knock-in murine model of the autosomal dominant Arg141Trp (R141W) mutation in Tnnt2, which was first described in a human family with DCM. Mice heterozygous for the mutation (Tnnt2(R141W/+)) recapitulated the human phenotype, developing left ventricular dilation and reduced contractility. There was a gene dosage effect, so that the phenotype in Tnnt2(R141W/+) mice was attenuated by transgenic overexpression of wildtype Tnnt2 mRNA transcript. Male mice exhibited poorer survival than females. Biomechanical studies on skinned fibers from Tnnt2(R141W/+) hearts showed a significant decrease in pCa(50) (-log[Ca2+] required for generation of 50% of maximal force) relative to wildtype hearts, indicating Ca2+ desensitization. Optical mapping studies of Langendorff-perfused Tnnt2(R141W/+) hearts showed marked increases in diastolic and peak systolic intracellular Ca2+ ([Ca2+] i), and prolonged systolic rise and diastolic fall of [Ca2+] i. Perfused Tnnt2(R141W/+) hearts had slower intrinsic rates in sinus rhythm and reduced peak heart rates in response to isoproterenol. Tnnt2(R141W/+) hearts exhibited a reduction in phosphorylated phospholamban relative to wildtype mice. However, crossing Tnnt2(R141W/+) mice with phospholamban knockout (Pln(-/-)) mice, which exhibit increased Ca2+ transients and contractility, had no effect on the DCM phenotype. We conclude that the Tnnt2(R141W) mutation causes a Ca2+ desensitization and mice adapt by increasing Ca2+-transient amplitudes, which impairs Ca2+ handling dynamics, metabolism and responses to beta-adrenergic activation. C1 [Ramratnam, Mohun] Univ Wisconsin, Dept Med, Div Cardiovasc Med, Madison, WI USA. [Ramratnam, Mohun] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Cardiol Sect, Madison, WI USA. [Ramratnam, Mohun; Salama, Guy; Sharma, Ravi K.; Wang, David Wen Rui; Banerjee, Sanjay K.; Huang, Xueyin N.; Pruce, Michele L.; Gabris, Bethann E.; Saba, Samir; Ahmad, Ferhaan] Univ Pittsburgh, UPMC Heart & Vasc Inst, Pittsburgh, PA 15260 USA. [Ramratnam, Mohun; Salama, Guy; Sharma, Ravi K.; Wang, David Wen Rui; Banerjee, Sanjay K.; Huang, Xueyin N.; Pruce, Michele L.; Gabris, Bethann E.; Saba, Samir; Ahmad, Ferhaan] Univ Pittsburgh, Dept Med, Div Cardiol, Pittsburgh, PA 15260 USA. [Smith, Stephen H.; Shroff, Sanjeev G.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Gifford, Lindsey M.; Ahmad, Ferhaan] Univ Iowa, Dept Internal Med, Carver Coll Med, Div Cardiovasc Med, Iowa City, IA 52242 USA. [Gifford, Lindsey M.; Ahmad, Ferhaan] Univ Iowa, Abboud Cardiovasc Res Ctr, Iowa City, IA 52242 USA. [Banerjee, Sanjay K.] Translat Hlth Sci & Technol Inst, Gurgaon, India. RP Ahmad, F (reprint author), Univ Pittsburgh, UPMC Heart & Vasc Inst, Pittsburgh, PA 15260 USA.; Ahmad, F (reprint author), Univ Pittsburgh, Dept Med, Div Cardiol, Pittsburgh, PA 15260 USA.; Ahmad, F (reprint author), Univ Iowa, Dept Internal Med, Carver Coll Med, Div Cardiovasc Med, Iowa City, IA 52242 USA.; Ahmad, F (reprint author), Univ Iowa, Abboud Cardiovasc Res Ctr, Iowa City, IA 52242 USA. EM ferhaan-ahmad@uiowa.edu FU National Heart, Lung, and Blood Institute (US) [U01 HL108642]; Ferhaan Ahmad National Heart, Lung, and Blood Institute (US) [R21 HL1098121]; Ferhaan Ahmad American Heart Association (US) [053531N, 0725359U] FX National Heart, Lung, and Blood Institute (US) Award Number: U01 HL108642 vertical bar Recipient: Ferhaan Ahmad National Heart, Lung, and Blood Institute (US) Award Number: R21 HL1098121 vertical bar Recipient: Ferhaan Ahmad American Heart Association (US) Award Number: Scientist Development Grant 053531N vertical bar Recipient: Ferhaan Ahmad American Heart Association (US) Award Number: 0725359U vertical bar Recipient: Sanjay Banerjee NR 42 TC 1 Z9 1 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 9 PY 2016 VL 11 IS 12 AR e0167681 DI 10.1371/journal.pone.0167681 PG 23 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE4PU UT WOS:000389587100148 PM 27936050 ER PT J AU Liu, X Grogan, TR Hieronymus, H Hashimoto, T Mottahedeh, J Cheng, DH Zhang, LJ Huang, K Stoyanova, T Park, JW Shkhyan, RO Nowroozizadeh, B Rettig, MB Sawyers, CL Elashoff, D Horvath, S Huang, JT Witte, ON Goldstein, AS AF Liu, Xian Grogan, Tristan R. Hieronymus, Haley Hashimoto, Takao Mottahedeh, Jack Cheng, Donghui Zhang, Lijun Huang, Kevin Stoyanova, Tanya Park, Jung Wook Shkhyan, Ruzanna O. Nowroozizadeh, Behdokht Rettig, Matthew B. Sawyers, Charles L. Elashoff, David Horvath, Steve Huang, Jiaoti Witte, Owen N. Goldstein, Andrew S. TI Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome SO CELL REPORTS LA English DT Article ID BASAL-CELLS; STEM-CELL; MURINE PROSTATE; ACCELERATES INITIATION; RADICAL PROSTATECTOMY; IN-VITRO; ORIGIN; DIFFERENTIATION; METASTASIS; EPITHELIUM AB Inflammation is a risk factor for prostate cancer, but the mechanisms by which inflammation increases that risk are poorly understood. Here, we demonstrate that low expression of CD38 identifies a progenitor-like subset of luminal cells in the human prostate. CD38(lo) luminal cells are enriched in glands adjacent to inflammatory cells and exhibit epithelial nuclear factor kappa B (NF-kappa B) signaling. In response to oncogenic transformation, CD38(lo) luminal cells can initiate human prostate cancer in an in vivo tissue-regeneration assay. Finally, the CD38(lo) luminal phenotype and gene signature are associated with disease progression and poor outcome in prostate cancer. Our results suggest that prostate inflammation expands the pool of progenitor-like target cells susceptible to tumorigenesis. C1 [Liu, Xian; Hashimoto, Takao; Mottahedeh, Jack; Shkhyan, Ruzanna O.; Goldstein, Andrew S.] Univ Calif Los Angeles, Mol Cell & Dev Biol, Los Angeles, CA 90095 USA. [Zhang, Lijun; Huang, Kevin; Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Grogan, Tristan R.; Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med Stat Core, Los Angeles, CA 90095 USA. [Hieronymus, Haley; Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Program Human Oncol, New York, NY 10065 USA. [Hieronymus, Haley; Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Program Pathogenesis, New York, NY 10065 USA. [Cheng, Donghui; Huang, Jiaoti; Witte, Owen N.; Goldstein, Andrew S.] Univ Calif Los Angeles, Ctr Regenerat Med & Stem Cell Res, Eli & Edythe Broad, Los Angeles, CA 90095 USA. [Stoyanova, Tanya; Park, Jung Wook; Witte, Owen N.] Univ Calif Los Angeles, Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Nowroozizadeh, Behdokht; Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Pathol & Lab Med, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Rettig, Matthew B.; Goldstein, Andrew S.] Univ Calif Los Angeles, David Geffen Sch Med, Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew B.; Elashoff, David; Huang, Jiaoti; Witte, Owen N.; Goldstein, Andrew S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Human Genet, Los Angeles, CA 90095 USA. [Horvath, Steve] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA. [Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA. [Stoyanova, Tanya] Stanford Univ, Sch Med, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA. [Huang, Jiaoti] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA. RP Goldstein, AS (reprint author), Univ Calif Los Angeles, Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.; Goldstein, AS (reprint author), Univ Calif Los Angeles, Ctr Regenerat Med & Stem Cell Res, Eli & Edythe Broad, Los Angeles, CA 90095 USA.; Goldstein, AS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Urol, Los Angeles, CA 90095 USA.; Goldstein, AS (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. EM agoldstein@mednet.ucla.edu FU Department of Defense Idea Development Award [W81XWH-13-1-0470]; Prostate Cancer Foundation Young Investigator Award; Broad Stem Cell Research Center; AACR/PCF/Stand Up 2 Cancer West Coast Dream Team Award; National Institute of Health/National Cancer Institute grant [P50CA092131]; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI grant [UL1TR000124]; National Institute of Health/National Cancer Institute K99 Pathway to Independence Award [4R00CA184397]; Howard Hughes Medical Institute; Department of Defense [PC030686] FX This work was supported by Department of Defense Idea Development Award W81XWH-13-1-0470 (A.S.G. and S.H.), a Prostate Cancer Foundation Young Investigator Award (A.S.G. and T.S.), the Broad Stem Cell Research Center (A.S.G. and J.H.), an AACR/PCF/Stand Up 2 Cancer West Coast Dream Team Award (O.N.W., J.H., M.R., and A.S.G.), a National Institute of Health/National Cancer Institute grant (P50CA092131/UCLA SPORE in Prostate Cancer; D.E., S.H., O.N.W., J.H., M.R., and A.S.G), a NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI grant (UL1TR000124; T.R.G. and D.E.), a National Institute of Health/National Cancer Institute K99 Pathway to Independence Award (4R00CA184397; T.S.), and the Howard Hughes Medical Institute (O.N.W.). M.R. and funding for TMA creation were supported by the Department of Defense (PC030686). NR 54 TC 0 Z9 0 U1 2 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD DEC 6 PY 2016 VL 17 IS 10 BP 2596 EP 2606 DI 10.1016/j.celrep.2016.11.010 PG 11 WC Cell Biology SC Cell Biology GA EG2SK UT WOS:000390894200010 PM 27926864 ER PT J AU Zile, MR Claggett, BL Prescott, MF McMurray, JJV Packer, M Rouleau, JL Swedberg, K Desai, AS Gong, JJ Shi, VC Solomon, SD AF Zile, Michael R. Claggett, Brian L. Prescott, Margaret F. McMurray, John J. V. Packer, Milton Rouleau, Jean L. Swedberg, Karl Desai, Akshay S. Gong, Jianjian Shi, Victor C. Solomon, Scott D. TI Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE biomarker; chronic heart failure; natriuretic peptide; reduced ejection fraction ID GUIDED THERAPY; CARDIAC RESYNCHRONIZATION; NEPRILYSIN INHIBITION; RANDOMIZED-TRIAL; RELAX-AHF; VAL-HEFT; MORTALITY; MANAGEMENT; ENALAPRIL; BNP AB BACKGROUND Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is unclear. OBJECTIVES The authors assessed whether a reduction in N-terminal pro-B-type NP (NT-proBNP) was associated with a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients with HF and reduced ejection fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than enalapril, and whether the relationship between changes in NT-proBNP and changes in the primary endpoint were dependent on assigned treatment. METHODS In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial), baseline NT-proBNP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at 1 and 8 months. We related change in NT-proBNP to outcomes. RESULTS One month after randomization, 24% of the baseline NT-proBNP levels >1,000 pg/ml had fallen to <= 1,000 pg/ml. Risk of the primary endpoint was 59% lower in patients with a fall in NT-proBNP to <= 1,000 pg/ml than in those without such a fall. In sacubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after randomization than in enalapril-treated patients, and it fell to <= 1,000 pg/ml in 31% versus 17% of patients treated with sacubitril/valsartan and enalapril, respectively. There was no significant interaction between treatment and the relationship between change in NT-proBNP and the subsequent risk of the primary endpoint. CONCLUSIONS Patients who attained a significant reduction in NT-proBNP had a lower subsequent rate of cardiovascular death or HF hospitalization independent of the treatment group. Treatment with sacubitril/valsartan was nearly twice as likely as enalapril to reduce NT-proBNP to values <= 1,000 pg/ml. (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) [PARADIGM-HF]; NCT01035255.) (C) 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. C1 [Zile, Michael R.] Med Univ South Carolina, Charleston, SC USA. [Zile, Michael R.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Claggett, Brian L.; Desai, Akshay S.; Solomon, Scott D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Prescott, Margaret F.; Gong, Jianjian; Shi, Victor C.] Novartis Pharmaceut, E Hanover, NJ USA. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. [Packer, Milton] Baylor Univ, Med Ctr, Dallas, TX USA. [Rouleau, Jean L.] Montreal Heart Inst, Montreal, PQ, Canada. [Rouleau, Jean L.] Univ Montreal, Montreal, PQ, Canada. [Swedberg, Karl] Univ Gothenburg, Gothenburg, Sweden. RP Zile, MR (reprint author), Med Univ South Carolina, Charleston, SC USA.; Zile, MR (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.; Zile, MR (reprint author), Med Univ South Carolina, Div Cardiol, Dept Med, 114 Doughty St,Room 323, Charleston, SC 29425 USA. EM zilem@musc.edu OI mcmurray, john/0000-0002-6317-3975 FU Novartis; Servier FX This study was funded by Novartis. All authors have consulted for and received research support from Novartis, sponsor of the PARADIGM-HF trial. Drs. Prescott, Gong, and Shi are employees of Novartis. Professor McMurray's employer, University of Glasgow, was paid by Novartis for Professor McMurray's time spent as co-chairman of the PARADIGM-HF trial. Dr. Packer has served as a consultant for Admittance Technologies, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BioControl, CardioKinetix, CardioMEMS, Cardiorentis, Celyad, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda, and ZS Pharma. Dr. Swedberg has received honoraria from Novartis for sponsored lectures; has served as a consultant for AstraZeneca and Amgen and he has also received research support from Servier. Dr. Desai has served as a consultant for St. Jude Medical, Relypsa, Sanofi, and Merck. NR 46 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD DEC 6 PY 2016 VL 68 IS 22 BP 2425 EP 2436 DI 10.1016/j.jacc.2016.09.931 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EE4RF UT WOS:000389592000005 PM 27908347 ER PT J AU Pitts, R Gunzburger, E Ballantyne, CM Barter, PJ Kallend, D Leiter, LA Leitersdorf, E McMurray, JJV Nicholls, SJ Niesor, EJ Olsson, AG Shah, PK Tardif, JC Kittelson, J Schwartz, GG AF Pitts, Reynaria Gunzburger, Elise Ballantyne, Christie M. Barter, Philip J. Kallend, David Leiter, Lawrence A. Leitersdorf, Eran McMurray, John J. V. Nicholls, Stephen J. Niesor, Eric J. Olsson, Anders G. Shah, Prediman K. Tardif, Jean-Claude Kittelson, John Schwartz, Gregory G. TI Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Letter ID HDL C1 [Schwartz, Gregory G.] Denver VA Med Ctr, Cardiol Sect, 111B,1055 Clermont St, Denver, CO 80220 USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect, 111B,1055 Clermont St, Denver, CO 80220 USA. EM gregory.schwartz@va.gov OI mcmurray, john/0000-0002-6317-3975 NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD DEC 6 PY 2016 VL 68 IS 22 BP 2488 EP 2490 DI 10.1016/j.jacc.2016.09.932 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EE4RF UT WOS:000389592000014 PM 27908356 ER PT J AU Wray, CM Chaudhry, S Pincavage, A Miller, R DeCherrie, L Ouchida, K Arora, VM AF Wray, Charlie M. Chaudhry, Saima Pincavage, Amber Miller, Rachel DeCherrie, Linda Ouchida, Karin Arora, Vineet M. TI Resident Shift Handoff Strategies in US Internal Medicine Residency Programs SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Wray, Charlie M.] San Francisco VA Med Ctr, Div Hosp Med, San Francisco, CA USA. [Chaudhry, Saima] Mem Healthcare Syst, Off Acad Affairs, Ft Lauderdale, FL USA. [Arora, Vineet M.] Univ Chicago, Med Ctr, Gen Internal Med Sect, Chicago, IL 60637 USA. [Miller, Rachel] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [DeCherrie, Linda] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Ouchida, Karin] Weill Cornell Med Coll, Div Geriatr & Palliat Med, New York, NY USA. RP Wray, CM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM charlie.wray@ucsf.edu NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 6 PY 2016 VL 316 IS 21 BP 2273 EP 2275 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EE0YV UT WOS:000389307400014 PM 27923083 ER PT J AU Kwon, SH Oh, S Nacke, M Mostov, KE Lipschutz, JH AF Kwon, Sang-Ho Oh, Sekyung Nacke, Marisa Mostov, Keith E. Lipschutz, Joshua H. TI Adaptor Protein CD2AP and L-type Lectin LMAN2 Regulate Exosome Cargo Protein Trafficking through the Golgi Complex SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE endosome; extracellular vesicles; G protein-coupled receptor (GPCR); Golgi; membrane trafficking; CD2AP; exosomes; LMAN2; urinary proteins; multivesicular ID WNT-PRODUCING CELLS; MULTIVESICULAR ENDOSOMES; EXTRACELLULAR VESICLES; SECRETION; RETROMER; BIOGENESIS; WNTLESS; GPRC5B; VIP36; SITE AB Exosomes, 40-150-nm extracellular vesicles, transport biological macromolecules that mediate intercellular communications. Although exosomes are known to originate from maturation of endosomes into multivesicular endosomes (also known as multivesicular bodies) with subsequent fusion of the multivesicular endosomes with the plasma membrane, it remains unclear how cargos are selected for exosomal release. Using an inducible expression system for the exosome cargo protein GPRC5B and following its trafficking trajectory, we show here that newly synthesized GPRC5B protein accumulates in the Golgi complex prior to its release into exosomes. The L-type lectin LMAN2 (also known as VIP36) appears to be specifically required for the accumulation of GPRC5B in the Golgi complex and restriction of GPRC5B transport along the exosomal pathway. This may occur due to interference with the adaptor protein GGA1-mediated trans Golgi network-to-endosome transport of GPRC5B. The adaptor protein CD2AP-mediated internalization following cell surface delivery appears to contribute to the Golgi accumulation of GPRC5B, possibly in parallel with biosynthetic/secretory trafficking from the endoplasmic reticulum. Our data thus reveal a Golgi-traversing pathway for exosomal release of the cargo protein GPRC5B in which CD2AP facilitates the entry and LMAN2 impedes the exit of the flux, respectively. C1 [Kwon, Sang-Ho; Lipschutz, Joshua H.] Med Univ South Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. [Oh, Sekyung] Stanford Univ, Sch Med, Dept Radiol, Stanford Cardiovasc Inst, Stanford, CA 94305 USA. [Oh, Sekyung] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Nacke, Marisa; Mostov, Keith E.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA. [Nacke, Marisa; Mostov, Keith E.] Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC 29401 USA. RP Kwon, SH (reprint author), Med Univ South Carolina, Dept Med, 70 President St,Drug Discovery Bldg Rm 509, Charleston, SC 29425 USA. EM kwonk@musc.edu OI Oh, Sekyung/0000-0002-6880-5281 FU Medical University of South Carolina; American Society of Nephrology Gottschalk Research Scholar grant; National Institutes of Health [DK074398, DK091530, DK074038]; Veterans Affairs Merit Award [2I01BX000820] FX This work was supported by a start-up package from the Medical University of South Carolina and an American Society of Nephrology Gottschalk Research Scholar grant (to S.-H. K.), National Institutes of Health Grants DK074398 and DK091530 (to K. E. M.) and DK074038 (to J. H. L.), and Veterans Affairs Merit Award 2I01BX000820 (to J. H. L.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 62 TC 0 Z9 0 U1 6 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 2 PY 2016 VL 291 IS 49 BP 25462 EP 25475 DI 10.1074/jbc.M116.729202 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EF1OV UT WOS:000390095300016 PM 27765817 ER PT J AU Esson, D Mather, AE Scanlan, E Gupta, S de Vries, SPW Bailey, D Harris, SR McKinley, TJ Meric, G Berry, SK Mastroeni, P Sheppard, SK Christie, G Thomson, NR Parkhill, J Maskell, DJ Grant, AJ AF Esson, Diane Mather, Alison E. Scanlan, Eoin Gupta, Srishti de Vries, Stefan P. W. Bailey, David Harris, Simon R. McKinley, Trevelyan J. Meric, Guillaume Berry, Sophia K. Mastroeni, Pietro Sheppard, Samuel K. Christie, Graham Thomson, Nicholas R. Parkhill, Julian Maskell, Duncan J. Grant, Andrew J. TI Genomic variations leading to alterations in cell morphology of Campylobacter spp SO SCIENTIFIC REPORTS LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; FIELD GEL-ELECTROPHORESIS; PHASE-VARIABLE GENES; ESCHERICHIA-COLI; PEPTIDOGLYCAN HYDROLASES; NEISSERIA-MENINGITIDIS; PATHOGENIC BACTERIA; HELICOBACTER-PYLORI; MEMBRANE-PROTEIN; MISMATCH REPAIR AB Campylobacter jejuni, the most common cause of bacterial diarrhoeal disease, is normally helical. However, it can also adopt straight rod, elongated helical and coccoid forms. Studying how helical morphology is generated, and how it switches between its different forms, is an important objective for understanding this pathogen. Here, we aimed to determine the genetic factors involved in generating the helical shape of Campylobacter. A C. jejuni transposon (Tn) mutant library was screened for nonhelical mutants with inconsistent results. Whole genome sequence variation and morphological trends within this Tn library, and in various C. jejuni wild type strains, were compared and correlated to detect genomic elements associated with helical and rod morphologies. All rod-shaped C. jejuni Tn mutants and all rod-shaped laboratory, clinical and environmental C. jejuni and Campylobacter coli contained genetic changes within the pgp1 or pgp2 genes, which encode peptidoglycan modifying enzymes. We therefore confirm the importance of Pgp1 and Pgp2 in the maintenance of helical shape and extended this to a wide range of C. jejuni and C. coli isolates. Genome sequence analysis revealed variation in the sequence and length of homopolymeric tracts found within these genes, providing a potential mechanism of phase variation of cell shape. C1 [Esson, Diane; Mather, Alison E.; Scanlan, Eoin; Gupta, Srishti; de Vries, Stefan P. W.; McKinley, Trevelyan J.; Berry, Sophia K.; Mastroeni, Pietro; Maskell, Duncan J.; Grant, Andrew J.] Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge, England. [Mather, Alison E.; Harris, Simon R.; Thomson, Nicholas R.; Parkhill, Julian] Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England. [Bailey, David; Christie, Graham] Univ Cambridge, Dept Chem Engn & Biotechnol, New Museums Site,Pembroke St, Cambridge, England. [Meric, Guillaume; Sheppard, Samuel K.] Univ Bath, Dept Biol & Biotechnol, Milner Ctr Evolut, Claverton Down, Bath, Avon, England. [Thomson, Nicholas R.] London Sch Hyg & Trop Med, London, England. [Scanlan, Eoin] San Francisco VA Med Ctr, San Francisco, CA USA. [Scanlan, Eoin] Univ Calif San Francisco, San Francisco, CA 94143 USA. [McKinley, Trevelyan J.] Univ Exeter, Coll Engn Math & Phys Sci, Treliever Rd, Penryn, Cornwall, England. RP Grant, AJ (reprint author), Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge, England. EM ajg60@cam.ac.uk FU Wellcome Trust; Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge; BBSRC [BB/K004514/1, BB/ M014088/1]; Wellcome Trust [098051, 088786/C/09/Z]; Biotechnology and Biological Sciences Research Council [BB/I02464X/1]; Medical Research Council [MR/L015080/1]; National Institute for Social Care and Health Research Fellowship [HF-14-13] FX Scanning Electron Microscopy was kindly performed by Dr Jeremy Skepper (Cambridge Advanced Imaging Centre). This work was funded by The Wellcome Trust through a PhD training studentship awarded to DE, and was supported by an Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge joint research grant awarded to AJG. SG and SPWDV were funded by BBSRC grant BB/K004514/1. AEM, SH, NRT and JP were supported by the Wellcome Trust grant number 098051. AEM was also supported by BBSRC grant BB/ M014088/1. SKS was funded by Biotechnology and Biological Sciences Research Council grant BB/I02464X/1, Medical Research Council grant MR/L015080/1 and Wellcome Trust grant 088786/C/09/Z. GM was supported by a National Institute for Social Care and Health Research Fellowship (HF-14-13). NR 71 TC 1 Z9 1 U1 12 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 2 PY 2016 VL 6 AR 38303 DI 10.1038/srep38303 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA ED8LQ UT WOS:000389123400001 PM 27910897 ER PT J AU Tyler, JM Pang, PS Teerlink, JR AF Tyler, Jeffrey M. Pang, Peter S. Teerlink, John R. TI Serelaxin in the Treatment of Acute Heart Failure SO CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS LA English DT Article ID RELAX-AHF; TRIAL; OUTCOMES; POPULATION; MORTALITY; PREGNANCY; ASSOCIATION; MECHANISMS; DIURETICS; RECEPTORS C1 [Tyler, Jeffrey M.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Pang, Peter S.] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. [Pang, Peter S.] Indiana Univ, Regenstrief Inst, Indianapolis, IN 46204 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. EM john.teerlink@ucsf.edu FU Roche; Novartis; Amgen; Bayer; Cardio3 Bioscience; Cytokinetics; Mast Therapeutics; Medtronic; Relypsa; St. Jude; Trevena; ZS Pharma FX Dr. Tyler declares no conflict of interest. Dr. Pang is or has been over the past year a consultant for Janssen, Medtronic, Novartis, Trevena, sc Pharmaceuticals, Cardioxyl, Roche Diagnostics, and Relypsa and received honoraria from Palatin Technologies and Research Support from Roche and Novartis. Dr. Teerlink has received research grants and consulting fees from Amgen, Bayer, Cardio3 Bioscience, Cytokinetics, Mast Therapeutics, Medtronic, Novartis, Relypsa, St. Jude, Trevena, and ZS Pharma. NR 42 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2167-4884 J9 CURR EMERG HOSP ME R JI Curr. Emerg. Hosp. Med. Rep. PD DEC PY 2016 VL 4 IS 4 BP 213 EP 218 DI 10.1007/s40138-016-0114-1 PG 6 WC Emergency Medicine SC Emergency Medicine GA ER9DT UT WOS:000399125700009 ER PT J AU Roche, J Nasarre, P Gemmill, R Baldys, A Pontis, J Korch, C Guilhot, J Ait-Si-Ali, S Drabkin, H AF Roche, Joelle Nasarre, Patrick Gemmill, Robert Baldys, Aleksander Pontis, Julien Korch, Christopher Guilhot, Joelle Ait-Si-Ali, Slimane Drabkin, Harry TI Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells (vol 5, pg 334, 2013) SO CANCERS LA English DT Correction C1 [Roche, Joelle; Nasarre, Patrick; Gemmill, Robert; Drabkin, Harry] MUSC, Dept Med, Div Hematol Oncol, 96 Jonathan Lucas St, Charleston, SC 29425 USA. [Roche, Joelle] Univ Poitiers, CNRS, FRE 3511, 1 Rue Georges Bonnet, F-86022 Poitiers, France. [Baldys, Aleksander] Ralph H Johnson Vet Affairs Med Ctr, MUSC, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Pontis, Julien; Ait-Si-Ali, Slimane] Univ Paris Diderot, Sorbonne Paris Cite, CNRS, Epigenet & Destin Cellulaire,UMR 7216, F-75013 Paris, France. [Korch, Christopher] Univ Colorado, Sch Med, CU DNA Sequencing & Anal Core, 12801 E 17th Ave,Anschutz Med Campus, Aurora, CO 80045 USA. [Guilhot, Joelle] CHU Poitiers, INSERM, CIC 0802, F-86021 Poitiers, France. RP Roche, J (reprint author), MUSC, Dept Med, Div Hematol Oncol, 96 Jonathan Lucas St, Charleston, SC 29425 USA.; Roche, J (reprint author), Univ Poitiers, CNRS, FRE 3511, 1 Rue Georges Bonnet, F-86022 Poitiers, France. EM joelle.roche@univ-poitiers.fr; nasarre@musc.edu; gemmill@musc.edu; aleksander.baldys@siemens.com; julien.pontis@univ-paris-diderot.fr; Christopher.Korch@ucdenver.edu; joelle.guilhot-gaudeffroy@chu-poitiers.fr; slimane.aitsiali@univ-paris-diderot.fr; drabkin@musc.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2072-6694 J9 CANCERS JI Cancers PD DEC PY 2016 VL 8 IS 12 AR 114 DI 10.3390/cancers8120114 PG 1 WC Oncology SC Oncology GA EO7TC UT WOS:000396892000009 ER PT J AU Havran, M Scholten, JD Breuer, P Lundberg, J Kochersberger, G Newman, D Weiner, DK AF Havran, Mark Scholten, Joel D. Breuer, Paula Lundberg, Jennifer Kochersberger, Gary Newman, Dave Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step-by-Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part XII: Leg Length Discrepancy SO PAIN MEDICINE LA English DT Article DE Leg Length Discrepancy; Leg Length Inequality; Chronic Low Back Pain; Chronic Pain; Elderly; Older Adults ID TOTAL KNEE ARTHROPLASTY; LIMB LENGTH; INEQUALITY; JOINT; LIFT; OSTEOARTHRITIS; INTERVENTION; ASSOCIATION; DISPARITY; COHORT AB Objective. To present the last in a 12-part series designed to deconstruct chronic low back pain (CLBP) in older adults. This article focuses on leg length discrepancy (LLD) and presents an algorithm outlining approaches to diagnosis and management of LLD in older adults, along with a representative clinical case. Methods. Using a modified Delphi approach, the LLD evaluation and treatment algorithm was developed by a multidisciplinary expert panel representing expertise in physical therapy, geriatric medicine, and physical medicine and rehabilitation. The materials were subsequently refined through an iterative process of input from a primary care provider panel comprised of VA and non-VA providers. The clinical case was taken from one of the authors. Results. We present an algorithm and illustrative clinical case to help guide the care of older adults with LLD, which can be an important contributor to CLBP. Firstline assessment includes referral to physical therapy or orthopedics, depending on the context of the LLD. A variety of nonsurgical interventions may ensue depending on the etiology of the LLD, including shoe inserts, customized shoes, manual therapy, or a combination. Conclusions. To promote a patient-centered approach, providers should consider evaluating for leg length discrepancy when treating older adults with CLBP to help diminish pain and disability. C1 [Havran, Mark; Lundberg, Jennifer] VA Cent Iowa Hlth Care Syst, Extended Care & Rehab, De Moines, IA USA. [Havran, Mark; Scholten, Joel D.] Vet Hlth Adm, Rehabil Serv, Washington, DC USA. [Havran, Mark; Scholten, Joel D.] Vet Hlth Adm, Prosthet Serv, Washington, DC USA. [Scholten, Joel D.] Washington DC VA Med Ctr, Washington, DC USA. [Breuer, Paula] Univ Pittsburgh, Med Ctr, Ctr Rehab Serv, Pittsburgh, PA USA. [Kochersberger, Gary] VA Med Ctr, Canandaigua, NY USA. [Kochersberger, Gary] Univ Rochester, Sch Med & Dent, Div Geriatr, Rochester, NY USA. [Newman, Dave; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents of this report do not represent the views of the Department of Veterans Affairs or the US government. NR 45 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD DEC PY 2016 VL 17 IS 12 BP 2230 EP 2237 DI 10.1093/pm/pnw270 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA ER4DE UT WOS:000398748500008 PM 28025357 ER PT J AU Weiner, DK Marcum, Z Rodriguez, E AF Weiner, Debra K. Marcum, Zachary Rodriguez, Eric TI Deconstructing Chronic Low Back Pain in Older Adults: Summary Recommendations SO PAIN MEDICINE LA English DT Editorial Material ID EXPERT-BASED RECOMMENDATIONS; LUMBAR SPINAL STENOSIS; BY-STEP EVIDENCE; UNITED-STATES; PRIMARY-CARE; FIBROMYALGIA; PREVALENCE; COMPLICATIONS; EPIDEMIOLOGY; IMPAIRMENT C1 [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.; Rodriguez, Eric] Univ Pittsburgh, Div Geriatr Med, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Marcum, Zachary] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents of this report do not represent the views of the Department of Veterans Affairs or the US government. NR 35 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD DEC PY 2016 VL 17 IS 12 BP 2238 EP 2246 DI 10.1093/pm/pnw267 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA ER4DE UT WOS:000398748500009 PM 28025358 ER PT J AU Hu, QH Wang, M Cho, MS Wang, CY Nick, AM Thiagarajan, P Aung, FM Han, XL Sood, AK Afshar-Kharghan, V AF Hu, Qianghua Wang, Miao Cho, Min Soon Wang, Chunyan Nick, Alpa M. Thiagarajan, Perumal Aung, Fleur M. Han, Xianlin Sood, Anil K. Afshar-Kharghan, Vahid TI Lipid profile of platelets and platelet-derived microparticles in ovarian cancer SO BBA CLINICAL LA English DT Article DE Platelet; Lipidomics; Venous thrombosis; Hypercoagulability; Ovarian cancer; Lipid phosphate phosphatase 1 ID VENOUS THROMBOSIS; BLOOD-COAGULATION; MICROVESICLES; PHOSPHATIDYLETHANOLAMINE; LYSOPHOSPHATIDYLCHOLINE; INVASION; ACID AB Background: Ovarian cancer patients have a high risk of developing venous thrombosis. The membrane lipid bilayer of platelets and platelet-derived microparticles (PMP) provides a platform for assembly of coagulation proteins and generation of blood clots. Methods: We compared the lipid composition of platelets and PMPs in patients with ovarian cancer to those in healthy subjects. We used shotgun lipidomics to quantify 12 classes and 177 species of lipids. Results: We found a significant change in 2 classes of lipids in platelets and PMPs isolated from ovarian cancer patients: higher phosphatidylinositol and lower lyso-phosphatidylcholine. The level of 28 species of lipids was also significantly altered in the direction of an increase in the pro-coagulant and a reduction in the anticoagulant lipids. We found that cancer platelets expressed less lipid phosphate phosphatase 1 (LPP1), a key enzyme in phospholipid biosynthesis pathways, than normal platelets. The reduction in LPP1 might contribute to the changes in the lipid profile of cancer platelets. Conclusion: Our results support a procoagulant lipid profile of platelets in ovarian cancer patients that can play a role in the increased risk of venous thrombosis in these patients. General significance: As far as we are aware, our study is the first study on platelet lipidomics in ovarian cancer. The importance of our findings for the future studies are: 1) a similar change in lipid profile of platelets and PMP may be responsible for hypercoagulability in other cancers, and 2) plasma level of high-risk lipids for venous thrombosis may be useful biomarkers. (C) 2016 The Authors. Published by Elsevier B.V. C1 [Hu, Qianghua; Cho, Min Soon; Afshar-Kharghan, Vahid] Univ Texas MD Anderson Canc Ctr, Dept Benign Hematol, Houston, TX 77030 USA. [Wang, Miao; Wang, Chunyan; Han, Xianlin] Sanford Burnham Med Res Inst, Diabet & Obes Res Ctr, 6400 Sanger Rd, Orlando, FL 32827 USA. [Nick, Alpa M.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA. [Thiagarajan, Perumal] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA. [Aung, Fleur M.] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA. RP Afshar-Kharghan, V (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Benign Hematol, Houston, TX 77030 USA. EM vakharghan@mdanderson.org OI Thiagarajan, Perumal/0000-0003-2186-7036 FU Ovarian Cancer Research Fund [258813]; [R01CA177909] FX This work was supported in part by R01CA177909 (to V.A-K. and A.K.S.), Ovarian Cancer Research Fund (Grant number 258813 to V.A-K. and A.K.S). NR 29 TC 0 Z9 0 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2214-6474 J9 BBA CLIN JI BBA Clin. PD DEC PY 2016 VL 6 BP 76 EP 81 DI 10.1016/j.bbacli.2016.06.003 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EM4JW UT WOS:000395280300011 PM 27453821 ER PT J AU Gane, EJ Lawitz, E Pugatch, D Papatheodoridis, GV Brau, N Brown, AS Pol, S Leroy, V Persico, M Moreno, C Colombo, M Yoshida, EM Nelson, DR Lei, Y Kosloski, MP Mensa, FJ AF Gane, Edward J. Lawitz, Eric Pugatch, David Papatheodoridis, George V. Braeu, Norbert Brown, Ashley S. Pol, Stanislas Leroy, Vincent Persico, Marcello Moreno, Christophe Colombo, Massimo Yoshida, Eric M. Nelson, David R. Lei, Yang Kosloski, Matthew P. Mensa, Federico J. TI EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with renal impairment and Chronic Hepatitis C Virus Genotype 1-6 Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Pugatch, David; Lei, Yang; Kosloski, Matthew P.; Mensa, Federico J.] AbbVie, N Chicago, IL USA. [Lawitz, Eric] Univ Texas San Antonio, Hlth Sci Ctr, Texas Liver Inst, San Antonio, TX USA. [Gane, Edward J.] Auckland City Hosp, Liver Unit, Auckland, New Zealand. [Papatheodoridis, George V.] Univ Athens, Med Sch Natl & Kapodistrian, Athens, Greece. [Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Brown, Ashley S.] Imperial Coll Health care, London, England. [Pol, Stanislas] Groiupe Hosp Cochin St Vincent De Paul, Paris, France. [Leroy, Vincent] Ctr Hosp Univ Grenoble, Grenoble, France. [Persico, Marcello] Univ Salerno, Internal Med & Hepatol Unit, Salerno, Italy. [Moreno, Christophe] Univ Libre Bruxelles, CUB Hop Erasme, Brussels, Belgium. [Colombo, Massimo] Univ Milan, Osped Maggiore Policlin, Milan, Italy. [Yoshida, Eric M.] Univ British Columbia, Vancouver, BC, Canada. [Nelson, David R.] Univ Florida, Dept Med, Gainesville, FL 32611 USA. [Papatheodoridis, George V.] Laiko Gen Hosp Athens, Athens, Greece. [Braeu, Norbert] Icahn Sch Med Mt Sinai, New York, NY USA. FU AbbVie; Achillion Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmith-Kline; Idenix Pharmaceuticals; Intercept Pharmaceuticals; Janssen; Merck Co; Novartis; Nitto Denko; Theravance; Salix; Enanta; Roche; Gilead; Bristol-Meyer Squibb; MSD; Astellas; Merck Inc; Springbank; Jannsen Inc; Gilead Sciences Inc; Intercept; BMS; Merck FX Eric Lawitz - Advisory Committees or Review Panels: AbbVie, Achillion Pharmaceuticals, Regulus, Theravance, Enanta, Idenix Pharmaceuticals, Janssen, Merck & Co, Novartis, Gilead; Grant/Research Support: AbbVie, Achillion Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmith-Kline, Idenix Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Merck & Co, Novartis, Nitto Denko, Theravance, Salix, Enanta; Speaking and Teaching: Gilead, Janssen, AbbVie, Bristol Meyers Squibb, Merck, intercept; George V. Papatheodoridis - Advisory Committees or Review Panels: Merck Sharp & Dohme, Novartis, Abbvie, Boerhinger Ingelheim, Bristol-Meyer Squibb, Gilead, Roche, Janssen, GlaxoSmith Kleine; Grant/Research Support: Roche, Gilead, Bristol-Meyer Squibb, Abbvie, Janssen; Speaking and Teaching: Merck Sharp & Dohme, Bristol-Meyer Squibb, Gilead, Roche, Janssen, Abbvie; Stanislas Pol - Board Membership: Bristol- Myers-Squibb, Boehringer Ingelheim, Tibotec Janssen Cilag, Gilead, Glaxo Smith Kline, Roche, MSD, Novartis; Grant/Research Support: Gilead, Roche, MSD; Speaking and Teaching: Bristol- Myers-Squibb, Boehringer Ingelheim, Tibotec Janssen Cilag, Gilead, Roche, MSD, Novartis; Marcello Persico - Advisory Committees or Review Panels: abbvie; Grant/Research Support: gilead; Speaking and Teaching: Jansen, Bristol Myers Squibb, MSD; Christophe Moreno - Consulting: Abbvie, Janssen, Gilead, BMS, MSD; Grant/Research Support: Janssen, Gilead, Roche, Astellas, Abbvie; Eric M. Yoshida - Advisory Committees or Review Panels: Gilead Sciences Inc; Grant/Research Support: Abbvie, Merck Inc, Springbank, Jannsen Inc, Gilead Sciences Inc, Intercept; Speaking and Teaching: Gilead Sciences Inc, Merck Canada, Celgene Canada, Merck Inc; David R. Nelson - Grant/Research Support: Abbvie, BMS, Gilead, Merck, Janssen NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD DEC PY 2016 VL 64 IS 6 MA LB-11 BP 1125A EP 1125A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK4MF UT WOS:000393900200012 ER PT J AU Khan, N Patel, D Shah, Y Yang, YX AF Khan, Nabeel Patel, Dhruvan Shah, Yash Yang, Yu-Xiao TI Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE iron deficiency; ulcerative colitis; testing and treatment ID INFLAMMATORY-BOWEL-DISEASE; QUALITY-OF-LIFE; ULCERATIVE-COLITIS; EUROPEAN COUNTRIES; OLDER-ADULTS; MANAGEMENT; DIAGNOSIS; HEMOGLOBIN; HEALTH; IBD AB Background: Iron deficiency anemia (IDA) is an often unrecognized and undertreated complication of ulcerative colitis (UC). We conducted the first nationwide study in the United States to evaluate the prevalence of testing for iron deficiency (ID) in anemic UC patients and determine the frequency of treatment with iron supplementation in patients with IDA. Methods: Nationwide cohort of patients with newly diagnosed UC in the Veterans Affairs health care system was identified. Primary outcome was to evaluate if anemic UC patients were tested for ID and subsequently treated with iron replacement therapy if IDA is confirmed. Candidate parameters included factors that can impact testing and treatment of anemia including patients' demographics, severity of anemia, and endoscopic findings. Results: Of 836 newly diagnosed patients with UC, 585 patients (70%) developed anemia over the course of median 8 years of follow-up. Of 585 patients, 401 patients (68.6%) had iron study evaluation. Two hundred fifty-one patients (62.6%) were diagnosed with IDA, and among them, 191 patients (76.1%) were treated with oral iron therapy. None of the patient received intravenous iron therapy. In multivariate analysis, patients with mild/moderate anemia and patients from Midwest and South region were independent predictors of iron study evaluation in patients with anemia. Conclusions: More than a third of anemic UC patients were not tested for ID. Once tested, almost a quarter of the patients with IDA were not treated with iron replacement therapy. Testing for ID and subsequent treatment with iron replacement therapy should be considered among the quality process indicators in UC. C1 [Khan, Nabeel; Yang, Yu-Xiao] Univ Penn, Gastroenterol Sect, Philadelphia, PA 19104 USA. [Khan, Nabeel; Shah, Yash; Yang, Yu-Xiao] VA Med Ctr, Gastroenterol Sect, Philadelphia, PA USA. [Patel, Dhruvan] Mercy Catholic Med Ctr, Dept Internal Med, Darby, PA USA. RP Khan, N (reprint author), Univ Penn, Gastroenterol Sect, Perelman Sch Med, Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM nabeelk@mail.med.upenn.edu FU Luitpold pharmaceuticals FX The authors acknowledge Luitpold pharmaceuticals for providing an unrestricted research grant. NR 41 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2016 VL 22 IS 12 BP 2894 EP 2901 DI 10.1097/MIB.0000000000000947 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EK4JR UT WOS:000393893400014 PM 27763952 ER PT J AU Morrison, RS Dickman, E Hwang, U Akhtar, S Ferguson, T Huang, J Jeng, CL Nelson, BP Rosenblatt, MA Silverstein, JH Strayer, RJ Torrillo, TM Todd, KH AF Morrison, R. Sean Dickman, Eitan Hwang, Ula Akhtar, Saadia Ferguson, Taja Huang, Jennifer Jeng, Christina L. Nelson, Bret P. Rosenblatt, Meg A. Silverstein, Jeffrey H. Strayer, Reuben J. Torrillo, Toni M. Todd, Knox H. TI Regional Nerve Blocks Improve Pain and Functional Outcomes in Hip Fracture: A Randomized Controlled Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; hip fracture; functional recovery ID OLDER-ADULTS; EMERGENCY-DEPARTMENT; MANAGEMENT; ANALGESIA; NECK; IMPACT AB OBJECTIVES: To compared outcomes of regional nerve blocks with those of standard analgesics after hip fracture. DESIGN: Multisite randomized controlled trial from April 2009 to March 2013. SETTING: Three New York hospitals. PARTICIPANTS: Individuals with hip fracture (N = 161). INTERVENTION: Participants were randomized to receive an ultrasound-guided, single-injection, femoral nerve block administered by emergency physicians at emergency department (ED) admission followed by placement of a continuous fascia iliaca block by anesthesiologists within 24 hours (n = 79) or conventional analgesics (n = 82). MEASUREMENTS: Pain (0-10 scale), distance walked on Postoperative Day (POD) 3, walking ability 6 weeks after discharge, opioid side effects. RESULTS: Pain scores 2 hours after ED presentation favored the intervention group over controls (3.5 vs 5.3, P =.002). Pain scores on POD 3 were significantly better for the intervention than the control group for pain at rest (2.9 vs 3.8, P =.005), with transfers out of bed (4.7 vs 5.9, P =.005), and with walking (4.1 vs 4.8, P =.002). Intervention participants walked significantly further than controls in 2 minutes on POD 3 (170.6 feet, 95% confidence interval (CI) = 109.3-232 vs 100.0 feet, 95% CI = 65.1-134.9; P =.04). At 6 weeks, intervention participants reported better walking and stair climbing ability (mean Functional Independence Measure locomotion score of 10.3 (95% CI = 9.6-11.0) vs 9.1 (95% CI = 8.2-10.0), P =.04). Intervention participants were significantly less likely to report opioid side effects (3% vs 12.4%, P =.03) and required 33% to 40% fewer parenteral morphine sulfate equivalents. CONCLUSION: Femoral nerve blocks performed by emergency physicians followed by continuous fascia iliaca blocks placed by anesthesiologists are feasible and result in superior outcomes. C1 [Morrison, R. Sean; Rosenblatt, Meg A.; Silverstein, Jeffrey H.; Torrillo, Toni M.] Icahn Sch Med Mt Sinai, Dept Anesthesia, New York, NY 10029 USA. [Morrison, R. Sean; Hwang, Ula; Ferguson, Taja] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Morrison, R. Sean; Hwang, Ula] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Dickman, Eitan] Maimonides Hosp, Brooklyn, NY 11219 USA. [Hwang, Ula; Huang, Jennifer; Nelson, Bret P.; Strayer, Reuben J.] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. [Akhtar, Saadia; Todd, Knox H.] Mt Sinai Beth Israel, New York, NY USA. Icahn Sch Med Mt Sinai, Dept Orthoped, New York, NY 10029 USA. [Todd, Knox H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Morrison, RS (reprint author), Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU National Institute on Aging [R01AG030141]; Mid-Career Investigator Award in Patient-Oriented Research from the National Institute on Aging [AGK24AG022345]; Older Adult Independence Center Grant from the National Institute on Aging [5P30AG028741]; Mentored Patient-Oriented Research Career Development Award from the National Institute on Aging [K23AG031218] FX This project was supported by Grant R01AG030141 from the National Institute on Aging. Dr. Morrison was supported by Mid-Career Investigator Award in Patient-Oriented Research AGK24AG022345 and Older Adult Independence Center Grant 5P30AG028741 from the National Institute on Aging. Dr. Hwang was supported by Mentored Patient-Oriented Research Career Development Award K23AG031218 from the National Institute on Aging. NR 31 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2016 VL 64 IS 12 BP 2433 EP 2439 DI 10.1111/jgs.14386 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EK0AR UT WOS:000393589200020 PM 27787895 ER PT J AU Maust, DT Kales, HC Wiechers, IR Blow, FC Olfson, M AF Maust, Donovan T. Kales, Helen C. Wiechers, Ilse R. Blow, Frederic C. Olfson, Mark TI No End in Sight: Benzodiazepine Use in Older Adults in the United States SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE benzodiazepine; psychotropic; insomnia; anxiety ID COGNITIVE-BEHAVIORAL THERAPY; HEALTH MAINTENANCE ORGANIZATION; RANDOMIZED CONTROLLED-TRIALS; ANXIETY DISORDERS; METAANALYSIS; DISCONTINUATION; PREVALENCE; MEDICATION; RISK; PRESCRIPTIONS AB OBJECTIVES: To establish the rate of new and continuation of benzodiazepine use in older adults seen by nonpsychiatrist physicians and to identify subpopulations at risk of new and continuation benzodiazepine use. DESIGN: Cross-sectional analysis. SETTING: National Ambulatory Medical Care Survey (2007-10). PARTICIPANTS: Adults visiting office-based nonpsychiatrist physicians (n = 98,818) who were prescribed a benzodiazepine (new or continuation). MEASUREMENTS: Percentage of benzodiazepine visits of all outpatient encounters according to patient age and corresponding annual visit rate per 1,000 population. Analysis was then limited to adults aged 65 and older, demographic, clinical, and visits characteristics were used to compare visits of benzodiazepine users with those of nonusers and visits of continuation users with those of new users. RESULTS: The overall proportion of benzodiazepine visits ranged from 3.2% (95% confidence interval (CI) = 2.73.7) of those aged 18 to 34 to 6.6% (95% CI = 5.8-7.6) of those aged 80 and older, and the proportion of continuation visits increased with age, rising to 90.2% (95% CI = 86.2-93.1) of those aged 80 and older. The population-based visit rate ranged from 61.7 (95% CI = 50.7-72.7) per 1,000 persons in the youngest adults to 463.7 (95% CI = 385.4-542.0) in those aged 80 and older. Only 16.0% (95% CI = 13.5-18.8) of continuation users had any mental health diagnosis. Of all benzodiazepine users, fewer than 1% (95% CI =.4-1.8) were provided or referred to psychotherapy, and 10.0% (95% CI = 7. 2-13.3) were also prescribed an opioid. CONCLUSION: In the United States, few older adult benzodiazepine users receive a clinical mental health diagnosis, and almost none are provided or referred to psychotherapy. Prescribing to older adults continues despite decades of evidence documenting safety concerns, effective alternative treatments, and effective methods for tapering even chronic users. C1 [Maust, Donovan T.; Kales, Helen C.; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Maust, Donovan T.; Kales, Helen C.; Blow, Frederic C.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Maust, Donovan T.; Kales, Helen C.; Blow, Frederic C.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Wiechers, Ilse R.] US Dept Vet Affairs, Northeast Program Evaluat Ctr, Off Mental Hlth Operat, West Haven, CT USA. [Wiechers, Ilse R.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Olfson, Mark] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Maust, DT (reprint author), Dept Psychiat, 2800 Plymouth Rd,NCRC Bldg 16,Room 222W, Ann Arbor, MI 48109 USA. EM maustd@umich.edu FU Beeson Career Development Award Program (National Institute on Aging) [K08AG048321]; Beeson Career Development Award Program (AFAR); Beeson Career Development Award Program (John A. Hartford Foundation); Beeson Career Development Award Program (Atlantic Philanthropies) FX This work was supported by the 'Beeson Career Development Award Program (National Institute on Aging K08AG048321, AFAR, The John A. Hartford Foundation, and The Atlantic Philanthropies). NR 42 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2016 VL 64 IS 12 BP 2546 EP 2553 DI 10.1111/jgs.14379 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EK0AR UT WOS:000393589200036 PM 27879984 ER PT J AU Sheehan, OC Ritchie, CS Fathi, R Garrigues, SK Saliba, D Leff, B AF Sheehan, Orla C. Ritchie, Christine S. Fathi, Roya Garrigues, Sarah K. Saliba, Debra Leff, Bruce TI Development of Quality Indicators to Address Abuse and Neglect in Home-Based Primary Care and Palliative Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE abuse; neglect; quality indicators; home-based primary care; home-based palliative care ID ELDER ABUSE; REPORTING MISTREATMENT; PHYSICIANS; SET; STANDARDS AB OBJECTIVES: To develop candidate quality indicators (QIs) for the quality standard of "addressing abuse and neglect" in the setting of home-based medical care. DESIGN: Systematic literature review of both the peer-reviewed and gray literature. SETTING: Home-based primary and palliative care practices. PARTICIPANTS: Homebound community-dwelling older adults. MEASUREMENTS: Articles were identified to inform the development of candidate indicators of the quality by which home-based primary and palliative care practices addressed abuse and neglect. The literature guided the development of patient-level QIs and practice-level quality standards. A technical expert panel (TEP) representing exemplary home-based primary care and palliative care providers then participated in a modified Delphi process to assess the validity and feasibility of each measure and identify candidate QIs suitable for testing in the field. RESULTS: The literature review yielded 4,371 titles and abstracts that were reviewed; 25 publications met final inclusion criteria and informed development of nine candidate QIs. The TEP rated all but one of the nine candidate indicators as having high validity and feasibility. CONCLUSION: Translating the complex problem of addressing abuse and neglect into QIs may ultimately serve to improve care delivered to vulnerable home-limited adults who receive home-based medical care. C1 [Sheehan, Orla C.] Johns Hopkins Univ, Sch Med, Ctr Aging & Hlth, Div Geriatr Med & Gerontol, Baltimore, MD USA. [Ritchie, Christine S.; Fathi, Roya; Garrigues, Sarah K.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Fathi, Roya] San Francisco VA Med Ctr, Vet Affairs Qual Scholars Fellowship Program, San Francisco, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Los Angeles, CA USA. [Saliba, Debra] Jewish Home Borun Ctr, Los Angeles, CA USA. [Saliba, Debra] Vet Affairs Geriatr Res, Los Angeles, CA USA. [Leff, Bruce] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA. [Leff, Bruce] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Leff, Bruce] Johns Hopkins Univ, Sch Nursing, Dept Community & Publ Hlth, Baltimore, MD USA. RP Sheehan, OC (reprint author), Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Ctr Aging & Hlth, Baltimore, MD 21205 USA. EM osheeha1@jhmi.edu FU Commonwealth Fund FX This work was supported by the Commonwealth Fund. NR 45 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2016 VL 64 IS 12 BP 2577 EP 2584 DI 10.1111/jgs.14365 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EK0AR UT WOS:000393589200041 PM 27787878 ER PT J AU Levy, C Whitfield, EA AF Levy, Cari Whitfield, Emily A. TI Medical Foster Homes: Can the Adult Foster Care Model Substitute for Nursing Home Care? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE adult foster care; veteran; nursing home ID LONG-TERM-CARE; OF-LIFE ISSUES; DECISION-MAKING; RESIDENTS; DEMENTIA; VETERANS; PROGRAM; HEALTH; IMPACT; END AB OBJECTIVE: To compare characteristics, healthcare use, and costs of care of veterans in the rapidly expanding Veterans Health Administration (VHA) medical foster home (MFH) with those of three other VHA long-term care (LTC) programs. DESIGN: Descriptive, unmatched study. SETTING: VHA MFHs, home-based primary care (HBPC), community living centers (CLCs), and community nursing homes (CNHs). PARTICIPANTS: Veterans newly enrolled in one of the four LTC settings in calendar years 2010 or 2011. MEASUREMENTS: Using VA and Medicare data from fiscal years 2010 and 2011, demographic characteristics, healthcare use, and costs of 388 veterans in MFHs were compared with 26,037 of those in HBPC, 5,355 in CLCs, and 5,517 in CNHs in the year before and the year after enrollment. RESULTS: Veterans enrolled in the MFH program were more likely to be unmarried than those in other LTC programs and had higher levels of comorbidity and frailty than veterans receiving HBPC but had similar levels of comorbidity, frailty, and healthcare use as those in CLCs and CNHs. MFH veterans incurred lower costs than those in CNHs and CLCs. CONCLUSION: MFHs served a distinct subset of veterans with levels of comorbidity and frailty similar to those of veterans cared for in CLCs and CNHs at costs that were comparable to or lower than those of the VHA. Propensity-matched comparisons will be necessary to confirm these findings. C1 [Levy, Cari; Whitfield, Emily A.] Denver Vet Affairs Med Ctr, Denver Seattle Ctr Innovat, Denver, CO USA. [Levy, Cari] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. RP Levy, C (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM cari.levy@va.gov FU VHA HSRD FX VHA HSR&D provided funding for this study only. NR 43 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2016 VL 64 IS 12 BP 2585 EP 2592 DI 10.1111/jgs.14517 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EK0AR UT WOS:000393589200042 PM 27739060 ER PT J AU Fung, CH Vitiello, MV Alessi, CA Kuchel, GA AF Fung, Constance H. Vitiello, Michael V. Alessi, Cathy A. Kuchel, George A. CA AGS NIA Sleep Conference Planning TI Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Sleep, Circadian Rhythms, and Aging: New Avenues for Improving Brain Health, Physical Health, and Functioning SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aging; circadian; disorders; interventions; sleep ID EXCESSIVE DAYTIME SLEEPINESS; NURSING-HOME RESIDENTS; CONTROLLED COMPARATIVE EFFICACY; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE; ALL-CAUSE MORTALITY; OLDER-ADULTS; RISK-FACTORS; FOLLOW-UP AB The American Geriatrics Society, with support from the National Institute on Aging and other funders, held its eighth Bedside-to-Bench research conference, entitled "Sleep, Circadian Rhythms, and Aging: New Avenues for Improving Brain Health, Physical Health and Functioning," October 4 to 6, 2015, in Bethesda, Maryland. Part of a conference series addressing three common geriatric syndromes-delirium, sleep and circadian rhythm (SCR) disturbance, and voiding dysfunction-the series highlighted relationships and pertinent clinical and pathophysiological commonalities between these three geriatric syndromes. The conference provided a forum for discussing current sleep, circadian rhythm, and aging research; identifying gaps in knowledge; and developing a research agenda to inform future investigative efforts. The conference also promoted networking among developing researchers, leaders in the field of SCR and aging, and National Institutes of Health program personnel. C1 [Fung, Constance H.; Alessi, Cathy A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Fung, Constance H.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Vitiello, Michael V.] Univ Washington, Psychiat & Behav Sci, Seattle, WA 98195 USA. [Kuchel, George A.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA. RP Fung, CH (reprint author), Care of Mikhailovich A, Amer Geriatr Soc, Special Projects, 40 Fulton St,18th Floor, New York, NY 10038 USA. RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431; Irwin, Michael/0000-0001-5801-274X FU NIA, NIH [K23AG045937]; Beeson Career Development in Aging Research Award Program - NIA; Beeson Career Development in Aging Research Award Program - AFAR; Beeson Career Development in Aging Research Award Program - John A. Hartford Foundation; Beeson Career Development in Aging Research Award Program - Atlantic Philanthropies; NIA [NIA 5U13AG0-39151-02]; American Academy of Sleep Medicine; Pfizer; Philips Respironics FX Constance H. Fung has grant funding supported by the NIA, NIH (K23AG045937) and The Beeson Career Development in Aging Research Award Program (supported by NIA, AFAR, John A. Hartford Foundation, Atlantic Philanthropies). The grant focuses on one of the research aims proposed in the paper, "What are the optimal methods of developing and implementing an individualized approach to sleep/CR treatment, accounting for personal preferences and physiological differences in risk factor profiles among individuals?" She has received an honorarium to serve as a National Sleep Foundation expert panel on sleep quality, including sleep quality in older adults.; The NIA funded this conference (NIA 5U13AG0-39151-02). Additional funding for the conference was provided by the American Academy of Sleep Medicine, Pfizer, and Philips Respironics. We thank Marie A. Bernard, PhD, Basil Eldadah, MD, PhD, Nancy Lundebjerg, MPA, Miroslaw Mackiewicz, PhD, and all conference participants. We appreciate the excellent administrative support provided by Anna Mikhailovich and Alanna Goldstein, MPH, and the detailed program evaluation provided by Julie Robison, PhD. NR 142 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2016 VL 64 IS 12 BP E238 EP E247 DI 10.1111/jgs.14493 PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EK0AR UT WOS:000393589200001 PM 27858974 ER PT J AU Odden, MC Wu, CK Shlipak, MG Psaty, BM Katz, R Applegate, WB Harris, T Newman, AB Peralta, CA AF Odden, Michelle C. Wu, Chenkai Shlipak, Michael G. Psaty, Bruce M. Katz, Ronit Applegate, William B. Harris, Tamara Newman, Anne B. Peralta, Carmen A. CA Hlth ABC Study TI Blood Pressure Trajectory, Gait Speed, and Outcomes: The Health, Aging, and Body Composition Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Blood pressure; Epidemiology; Function; Gait speed; Hypertension ID OLDER-ADULTS; LEIDEN 85-PLUS; ASSOCIATION; MORTALITY; FRAILTY AB Background: The present study aimed to (i) evaluate previous observations that the association of blood pressure (BP) with outcomes varies by gait speed and (ii) evaluate the association of subsequent changes in BP and cardiovascular risk. Methods: Participants included 2,669 adults aged 70-79 years in the Health, Aging, and Body Composition (Health ABC) study. Gait speed was dichotomized at >= 1.0 m/s over a 20-m test at baseline. BP was measured at baseline, and changes in BP over 5 years were evaluated using (i) population-based trajectory models and (ii) intraindividual mean and slope. Results: Over a mean of 10 years, there were 1,366 deaths, 336 first myocardial infarctions, and 295 first strokes. There was a differential pattern of association between baseline systolic BP and diastolic BP and outcomes among brisk and moderate speed walkers. For example, the association between higher diastolic BP and mortality was in the protective direction for moderate speed walkers (hazard ratio = 0.75; 95% confidence interval: 0.63, 0.91) per 10 mmHg higher, whereas it was null in brisk walkers (hazard ratio = 1.05; 95% confidence interval: 0.98, 1.11), p value for interaction.01. The 5-year population-based trajectories did not add important information beyond baseline BP. Individual slopes in both systolic BP and diastolic BP did not appear to have important associations with the outcomes. Conclusions: In this study, we found that the overall level of BP was associated with myocardial infarction, stroke, and death, and this association differed by baseline gait speed, whereas changes in BP were not associated with these outcomes. C1 [Odden, Michelle C.; Wu, Chenkai] Oregon State Univ, Sch Biol & Populat Hlth Sci, 141B Milam Hall, Corvallis, OR 97331 USA. [Shlipak, Michael G.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Kidney Hlth Res Collaborat, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.; Peralta, Carmen A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Sci, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Katz, Ronit] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA. [Applegate, William B.] Wake Forest Univ, Baptist Med Ctr, Internal Med & Geriatr Med, Winston Salem, NC 27109 USA. [Harris, Tamara] NIA, Geriatr Epidemiol Sect, Bethesda, MD 20892 USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Odden, MC (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, 141B Milam Hall, Corvallis, OR 97331 USA. EM Michelle.Odden@oregonstate.edu FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, K01AG039387, R01AG46206]; NINR [R01-NR012459]; Intramural Research Program of the NIH, NIA FX The Health ABC study was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050; and NINR grant R01-NR012459, and in part by the Intramural Research Program of the NIH, NIA. Additional support for this research was provided by NIA (K01AG039387, R01AG46206). NR 15 TC 2 Z9 2 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2016 VL 71 IS 12 BP 1688 EP 1694 DI 10.1093/gerona/glw076 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EL2JW UT WOS:000394446900023 PM 27142696 ER PT J AU Odden, MC Wu, CK Shlipak, MG Psaty, BM Katz, R Applegate, WB Harris, T Newman, AB Peralta, CA AF Odden, Michelle C. Wu, Chenkai Shlipak, Michael G. Psaty, Bruce M. Katz, Ronit Applegate, William B. Harris, Tamara Newman, Anne B. Peralta, Carmen A. CA Hlth ABC Study TI Blood Pressure Trajectory, Gait Speed, and Outcomes: The Health, Aging, and Body Composition Study (vol 71, pg 1688, 2016) SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Correction C1 [Odden, Michelle C.; Wu, Chenkai] Oregon State Univ, Sch Biol & Populat Hlth Sci, 141B Milam Hall, Corvallis, OR 97331 USA. [Shlipak, Michael G.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Kidney Hlth Res Collaborat, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.; Peralta, Carmen A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Katz, Ronit] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA. [Applegate, William B.] Wake Forest Univ, Baptist Med Ctr, Internal Med & Geriatr Med, Winston Salem, NC 27109 USA. [Harris, Tamara] NIA, Geriatr Epidemiol Sect, Bethesda, MD 20892 USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Odden, MC (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, 141B Milam Hall, Corvallis, OR 97331 USA. EM Michelle.Odden@oregonstate.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2016 VL 71 IS 12 BP E1 EP E1 DI 10.1093/gerona/glw230 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EL2JW UT WOS:000394446900001 PM 27838648 ER PT J AU Pacor, JM Younus, A Malik, R Osondu, CU Aziz, M Ogunmoroti, O Younus, MA Aneni, EC Spatz, ES Humayun, C Virani, S Blaha, M Nasir, K AF Pacor, Justin M. Younus, Adnan Malik, Rehan Osondu, Chukwuemeka U. Aziz, Muhammad Ogunmoroti, Oluseye Younus, Muhammad Amir Aneni, Ehimen C. Spatz, Erica S. Humayun, Choudhry Virani, Salim Blaha, Michael Nasir, Khurram TI Prevalence of ideal cardiovascular health metrics in children & adolescents: A systematic review SO PROGRESS IN PEDIATRIC CARDIOLOGY LA English DT Review ID AMERICAN-HEART-ASSOCIATION; NATIONAL-HEALTH; YOUNG FINNS; DISEASE; RISK; CHILDHOOD; AGE AB Background: Although the prevalence of ideal cardiovascular health (CVH) has been extensively studied, its distribution in younger populations is not well established. In this systematic review we aggregated available evidence to examine prevalence of ideal CVH metrics in the adolescent and children population. Methods: A MEDLINE database search was conducted for studies published between January 2010 and July 2015. To be included in the study, studies had to report prevalence data on at least four of the seven metrics. Each study was meticulously reviewed by two independent reviewers, and studies with prevalence percentages across different percentiles were included. Results: Overall 6 studies met the inclusion and exclusion criteria. BMI and diet were the only metrics for which all 6 studies reported prevalence of ideal. Prevalence of ideal for fasting plasma glucose was reported least frequently, with 2 of the studies failing to assess it. A prevalence of >50% for ideal blood pressure or BMI was seen uniformly across all studies included in the review. By contrast, the healthy diet has the lowest prevalence among ideal CVH metrics ranging from 0 to 10%. Physical activity was the most variable with a range of 6.2-85.4%. Conclusion: Ideal diet and physical activity had the lowest prevalence among CVH metrics. Focused efforts on standardizing assessment of these metrics as well delineating strategies to achieve ideal CVH among children and adolescents are required. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Pacor, Justin M.; Younus, Adnan; Malik, Rehan; Osondu, Chukwuemeka U.; Aziz, Muhammad; Ogunmoroti, Oluseye; Younus, Muhammad Amir; Aneni, Ehimen C.; Humayun, Choudhry; Nasir, Khurram] Baptist Hlth South Florida, Ctr Healthcare Adv & Outcomes, Miami, FL USA. [Pacor, Justin M.] Marshall Univ, Joan C Edwards Sch Med, Huntington, WV USA. [Aneni, Ehimen C.] Mt Sinai Med Ctr, Dept Internal Med, Miami, FL USA. [Spatz, Erica S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA. [Virani, Salim] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Blaha, Michael; Nasir, Khurram] Johns Hopkins Univ Hosp, Ciccarone Prevent Cardiol Ctr, Baltimore, MD 21287 USA. [Nasir, Khurram] Florida Int Univ, Robert Stempel Coll Publ Hlth, Dept Epidemiol, Miami, FL 33199 USA. [Nasir, Khurram] Florida Int Univ, Herbert Wertheim Coll Med, Dept Med, Miami, FL 33199 USA. RP Nasir, K (reprint author), Baptist Hlth South Florida, Ctr Healthcare Adv & Outcomes, 1691 Michigan Ave Suite 500, Miami Beach, FL 33139 USA. EM KhurramN@baptisthealth.net OI Younus, Adnan/0000-0002-4915-1139 NR 14 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1058-9813 EI 1558-1519 J9 PROG PEDIATR CARDIOL JI Prog. Pediatr. Cardiol. PD DEC PY 2016 VL 43 BP 141 EP 146 DI 10.1016/j.ppedcard.2016.09.002 PG 6 WC Cardiac & Cardiovascular Systems; Pediatrics SC Cardiovascular System & Cardiology; Pediatrics GA EL5QU UT WOS:000394676700023 ER PT J AU Qu, HY Shewchuk, RM Alarcon, G Fraenkel, L Leong, A Dall'era, M Yazdany, J Singh, JA AF Qu, Haiyan Shewchuk, Richard M. Alarcon, Graciela Fraenkel, Liana Leong, Amye Dall'era, Maria Yazdany, Jinoos Singh, Jasvinder A. TI Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context SO ARTHRITIS CARE & RESEARCH LA English DT Article ID HEALTH-PROFESSIONALS PERCEPTIONS; CLINICAL-PRACTICE; SOCIOECONOMIC-STATUS; ERYTHEMATOSUS; NEPHRITIS; BARRIERS; CARE; COHORT; MORTALITY; ADHERENCE AB Objective. Numerous factors can impede or facilitate patients' medication decision-making and adherence to physicians' recommendations. Little is known about how patients and physicians jointly view issues that affect the decision-making process. Our objective was to derive an empirical framework of patient-identified facilitators to lupus medication decision-making from key stakeholders (including 15 physicians, 5 patients/patient advocates, and 8 medical professionals) using a patient-centered cognitive mapping approach. Methods. We used nominal group patient panels to identify facilitators to lupus treatment decision-making. Stakeholders independently sorted the identified facilitators (n=98) based on their similarities and rated the importance of each facilitator in patient decision-making. Data were analyzed using multidimensional scaling and hierarchical cluster analysis. Results. A cognitive map was derived that represents an empirical framework of facilitators for lupus treatment decisions from multiple stakeholders' perspectives. The facilitator clusters were 1) hope for a normal/healthy life, 2) understand benefits and effectiveness of taking medications, 3) desire to minimize side effects, 4) medication-related data, 5) medication effectiveness for "me," 6) family focus, 7) confidence in physician, 8) medication research, 9) reassurance about medication, and 10) medication economics. Conclusion. Consideration of how different stakeholders perceive the relative importance of lupus medication decision-making clusters is an important step toward improving patient-physician communication and effective shared decision-making. The empirically derived framework of medication decision-making facilitators can be used as a guide to develop a lupus decision aid that focuses on improving physician-patient communication. C1 [Qu, Haiyan; Shewchuk, Richard M.; Alarcon, Graciela; Singh, Jasvinder A.] Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Fraenkel, Liana] Yale Univ, Sch Med, New Haven, CT USA. [Leong, Amye] Hlth Motivat, Santa Barbara, CA USA. [Dall'era, Maria; Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Patient-Centered Outcomes Research Institute [CE-1304-6631] FX Supported by a research contract (CE-1304-6631) from the Patient-Centered Outcomes Research Institute. NR 43 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD DEC PY 2016 VL 68 IS 12 BP 1787 EP 1794 DI 10.1002/acr.22904 PG 8 WC Rheumatology SC Rheumatology GA EJ2GF UT WOS:000393027400007 PM 27059939 ER PT J AU Rosenthal, PA Lundy, KC Massoglia, DP Payne, EH Gilbert, G Gebregziabher, M AF Rosenthal, Peter A. Lundy, Katherine C. Massoglia, Dino P. Payne, Elizabeth H. Gilbert, Gregory Gebregziabher, Mulugeta TI Incidental paranasal sinusitis on routine brain magnetic resonance scans: association with atherosclerosis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE atherosclerosis; magnetic resonance; computed tomography; stroke; paranasal sinusitis; chronic rhinosinusitis ID AMERICAN-HEART-ASSOCIATION; COMPUTED-TOMOGRAPHY CBCT; MAXILLARY SINUS; CHRONIC RHINOSINUSITIS; PERIODONTAL-DISEASE; RADIOLOGICAL FINDINGS; RISK-FACTORS; STROKE; ABNORMALITIES; MORTALITY AB Background: Incidental paranasal sinusitis (IPS) is common on imaging for non-sinusitis disorders, usually without symptoms or obstructive features, and possibly arising from periodontitis (PD). PD associations with atherosclerosis have been widely reported. We test if IPS may also be associated with atherosclerosis. Methods: IPS was scored retrospectively in a random sample of 180 magnetic resonance (MR) brain scans and compared with chart review for atherosclerosis (all subtypes), rhinosinusitis, and related factors (smoking, asthma, and relevant surgery). IPS was scored out of 30, from all sinuses, with maxillary sinuses weighted double volumetrically. Significant IPS (Sig IPS) was designated as 6 or more out of 30. Bivariate logistic regression was used to test for associations of Sig IPS to the clinical data, with multivariate analysis then testing for potential confounders. Results: A total of 173 subjects were analyzed (7 exclusions). MR indications included suspected acute/prior stroke (22.0%). Sig IPS found in 20 (11.6%). Positive histories for atherosclerosis were cerebral, 57 (32.9%); coronary, 48 (27.7%); and peripheral arterial disease, 14 (8.1%). IPS >= 6 was strongly associated with cerebrovascular disease (odds ratio [OR] 6.0, p < 0.001), and less robustly to smoking (OR 2.9, p = 0.07) and rhinosinusitis (OR 2.4, p = 0.09). No associations with coronary or peripheral artery diseases were found. After controlling for smoking and rhinosinusitis, yielding significant subclinical sinusitis, the link of Sig IPS to cerebrovascular disease persisted (modified OR 5.2, p = 0.002). Conclusion: Significant incidental sinusitis, which is mostly subclinical sinusitis, is associated with cerebrovascular disease but not other atheroscleroses. This suggests possible common causation of both by PD. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. C1 [Rosenthal, Peter A.; Lundy, Katherine C.; Massoglia, Dino P.; Payne, Elizabeth H.; Gilbert, Gregory; Gebregziabher, Mulugeta] Ralph H Johnson VA Med Ctr, Bee St, Charleston, SC 29401 USA. [Payne, Elizabeth H.; Gebregziabher, Mulugeta] Med Univ South Carolina, Charleston, SC 29425 USA. [Payne, Elizabeth H.] Emmes Corp, Rockville, MD USA. RP Rosenthal, PA (reprint author), Ralph H Johnson VA Med Ctr, Bee St, Charleston, SC 29401 USA. EM Peter.Rosenthal@va.gov OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU Veterans Health Administration; Ralph H. Johnson VA Medical Center FX We acknowledge with gratitude the support of the Veterans Health Administration and the Ralph H. Johnson VA Medical Center for the conduct of this research. The study was unfunded. Thanks also for kind assistance from Michael E. Ullian, MD, Professor in Nephrology, and Jonathan Halford, MD, Associate Professor in Neurology, both at Medical University of South Carolina and Ralph H. Johnson VA Medical Center. NR 47 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD DEC PY 2016 VL 6 IS 12 BP 1253 EP 1263 DI 10.1002/alr.21824 PG 11 WC Otorhinolaryngology SC Otorhinolaryngology GA EJ2MN UT WOS:000393044400006 PM 27509266 ER PT J AU Egede, LE Acierno, R Knapp, RG Walker, RJ Payne, EH Frueh, BC AF Egede, Leonard E. Acierno, Ron Knapp, Rebecca G. Walker, Rebekah J. Payne, Elizabeth H. Frueh, B. Christopher TI Psychotherapy for Depression in Older Veterans Via Telemedicine: Effect on Quality of Life, Satisfaction, Treatment Credibility, and Service Delivery Perception SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID BEHAVIORAL ACTIVATION TREATMENT; HEALTH SURVEY QUESTIONNAIRE; COLLABORATIVE CARE; TELEMENTAL HEALTH; RANDOMIZED-TRIAL; ADULTS; SF-36; TELEPSYCHIATRY; EPIDEMIOLOGY; POPULATION AB Objective: To analyze the impact of telepsychology and same-room care on functioning, satisfaction, and perception of care based on a noninferiority trial of psychotherapy delivered via telemedicine or same-room care to elderly patients with depression. Methods: 241 elderly patients with depression (meeting DSM-IV diagnostic criteria) were randomly assigned to either telemedicine (n = 120) or same-room treatment (n = 121) between April 1, 2007, and July 31, 2011. The primary outcomes included quality of life (36-item Short Form Survey [SF-36]), satisfaction (Charleston Psychiatric Outpatient Satisfaction Scale), treatment credibility, and service delivery perception scores obtained at 4 weeks, 8 weeks, 3 months, and 12 months. Comparisons of intervention means were carried out at each time point using independent sample t tests and SAS Procedure MIANALYZE to combine results across the multiply imputed complete data sets. If significant differences were detected for a given outcome within a domain, a Bonferroni correction was applied to determine if significance was maintained. Results: None of the SF-36 scores showed a significant difference between the 2 treatment groups by the end of the study period, with little significance shown throughout the intermediate time points. Similarly, over all time points, there was no statistically significant difference in patient satisfaction or treatment credibility. Conclusions: This study found that telemedicine is a viable alternative modality for providing evidence-based psychotherapy for elderly patients with depression. Results provide evidence that quality of life and satisfaction with care are not adversely influenced by the decision to use a telehealth modality instead of in-person treatment, and, as a result, resources can be devoted to offering services in patients' homes through telemedicine. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Egede, Leonard E.; Acierno, Ron; Knapp, Rebecca G.; Walker, Rebekah J.; Payne, Elizabeth H.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. [Egede, Leonard E.; Walker, Rebekah J.] Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. [Egede, Leonard E.; Walker, Rebekah J.] Med Univ South Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC USA. [Acierno, Ron] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Knapp, Rebecca G.; Payne, Elizabeth H.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Dept Psychol, Houston, TX USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu FU US Veterans Affairs Health Services Research and Development program [IIR 04-421] FX This study was supported by grant IIR 04-421 funded by the US Veterans Affairs Health Services Research and Development program. NR 44 TC 0 Z9 0 U1 3 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2016 VL 77 IS 12 BP 1704 EP 1711 DI 10.4088/JCP.16m10951 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2EL UT WOS:000393022700027 PM 27835713 ER PT J AU Goodman, M Banthin, D Blair, NJ Mascitelli, KA Wilsnack, J Chen, J Messenger, JW Perez-Rodriguez, MM Triebwasser, J Koenigsberg, HW Goetz, RR Hazlett, EA New, AS AF Goodman, Marianne Banthin, David Blair, Nicholas J. Mascitelli, Kathryn A. Wilsnack, Jaime Chen, Jennifer Messenger, Julie W. Perez-Rodriguez, M. Mercedes Triebwasser, Joseph Koenigsberg, Harold W. Goetz, Raymond R. Hazlett, Erin A. New, Antonia S. TI A Randomized Trial of Dialectical Behavior Therapy in High-Risk Suicidal Veterans SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID BORDERLINE PERSONALITY-DISORDER; BINGE-EATING DISORDER; ADOLESCENTS; WOMEN; DEPRESSION; CARE; INTERVENTION; PREVENTION; INVENTORY; EFFICACY AB Objective: Despite advances in suicide prevention implemented throughout the US Department of Veterans Affairs (VA) including the hiring of Suicide Prevention Coordinators (SPCs) at every VA hospital, enhanced monitoring, and the availability of 24-hour crisis hotline services, suicide by veterans remains a critical problem affecting 20 veterans daily. Few empirically based treatment strategies for suicide prevention for postdeployment military personnel exist. This study aimed to test whether dialectical behavior therapy (DBT), one of the few psychosocial treatments with proven efficacy in diminishing suicidal behavior in individuals with personality disorder, can be applied to veterans irrespective of personality diagnosis. Methods: From January 2010 to December 2014, 91 nonpsychotic veterans at high risk for suicide (61 men, 30 women) were randomly assigned to a 6-month treatment trial at a veterans' medical center comparing standard DBT to treatment as usual (TAU) and followed for 6 months after trial completion. Primary outcome was suicide attempts, measured with the Columbia-Suicide Severity Rating Scale, and secondary outcomes were suicide ideation, depression, hopelessness, and anxiety. There were no exclusions pertaining to substance abuse, homelessness, or medical comorbidity. Results: Both DBT and TAU resulted in improvements in suicidal ideation, depression, and anxiety during the course of the 6-month treatment trial that did not differ between treatment arms. Survival analyses for suicide attempts and hospitalizations did not differ between treatment arms. However, DBT subjects utilized significantly more individual mental health services than TAU subjects (28.5 +/- 19.6 vs 14.7 +/- 10.9, F-1,F-77 = 11.60, P = .001). Conclusions: This study is the first to examine 6-month DBT in a mostly male, veteran population. Increased mental health treatment service delivery, which included enhanced monitoring, outreach, and availability of a designated SPC, did not yield statistically significant differences in outcome for veterans at risk for suicide in TAU as compared to the DBT treatment arm. However, both treatments had difficulty with initial engagement post-hospitalization. Future studies examining possible sex differences and strategies to boost retention in difficult-to-engage, homeless, and substance-abusing populations are indicated. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Goodman, Marianne; Perez-Rodriguez, M. Mercedes; Triebwasser, Joseph; Koenigsberg, Harold W.; Hazlett, Erin A.; New, Antonia S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Goodman, Marianne; Blair, Nicholas J.; Mascitelli, Kathryn A.; Wilsnack, Jaime; Chen, Jennifer; Messenger, Julie W.; Hazlett, Erin A.] James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 3, Bronx, NY USA. [Goodman, Marianne; Triebwasser, Joseph; Koenigsberg, Harold W.] James J Peters VA Med Ctr, Outpatient Psychiat, Bronx, NY USA. [Banthin, David] Mt Sinai St Lukes Roosevelt, Ctr Intens Treatment Personal Disorders, New York, NY USA. [Goetz, Raymond R.] New York State Psychiat Inst & Hosp, Div Clin Phenomenol, New York, NY 10032 USA. [Goetz, Raymond R.] Columbia Univ, Coll Phys & Surg, New York, NY USA. RP Goodman, M (reprint author), James J Peters VA Med Ctr, MIRECC, Room 6A-44, Bronx, NY 10468 USA. EM marianne.goodman@va.gov FU US Department of Defense Grant [WX81XWH-09-1-0722] FX This study was supported by US Department of Defense Grant WX81XWH-09-1-0722 (to Dr Goodman, principal investigator). NR 54 TC 2 Z9 2 U1 12 U2 12 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2016 VL 77 IS 12 BP E1591 EP E1600 DI 10.4088/JCP.15m10235 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2EL UT WOS:000393022700007 PM 27780335 ER PT J AU Weamer, EA DeMichele-Sweet, MAA Cloonan, YK Lopez, OL Sweet, RA AF Weamer, Elise A. DeMichele-Sweet, Mary Ann A. Cloonan, Yona K. Lopez, Oscar L. Sweet, Robert A. TI Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LAST 2 DECADES; NEUROPSYCHIATRIC SYMPTOMS; NATIONAL INSTITUTE; RISK-FACTORS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; FOLLOW-UP; DEMENTIA; HALLUCINATIONS AB Objective: To estimate the incidence of psychotic symptoms in Alzheimer's disease. Methods: The study consists of 776 elderly subjects presenting to the Alzheimer Disease Research Center at the University of Pittsburgh (Pittsburgh, Pennsylvania) between May 9, 2000, and August 19, 2014. All participants were diagnosed with mild cognitive impairment (National Institute on Aging-Alzheimer's Association workgroup criteria) or possible or probable Alzheimer's disease (National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria) and were without psychosis at entry. Psychotic symptoms were evaluated using the Consortium to Establish a Registry for Alzheimer's Disease Behavioral Rating Scale every 6 months. One-, 3- and 5-year cumulative incidences of psychosis were calculated. Results: The 1-year psychosis incidence was 10% (95% CI, 8%-12%), and this annual rate remained remarkably consistent at 3 and 5 years. Psychosis incidence was related to cognitive status at all time points. However, the incidence rate reached a plateau during the disease course. Cumulative psychosis incidence at 5 years was 61% (95% CI, 52%-69%) in individuals with moderate to severe Alzheimer's disease, not statistically significantly different from the cumulative incidence at 3 years in this group, which was 48% (95% CI, 40%-55%) or from the 5-year incidence in individuals who entered the study with mild Alzheimer's disease, which was 48% (95% CI, 41%-56%). Conclusions: Psychosis in Alzheimer's disease has been associated with a number of adverse clinical outcomes. We provide estimates of the risk of psychosis onset within clinically defined subgroups of individuals, a tool clinicians can use in treatment planning. Anticipating which subjects are at high risk for psychosis and the poor outcomes associated with it can help with family education and support decisions to implement nonpharmacologic strategies that may reduce or prevent symptoms. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Weamer, Elise A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. [DeMichele-Sweet, Mary Ann A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Cloonan, Yona K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU Veterans Health Administration Grant [BX000452]; National Institutes of Health Grants [AG027224, AG005133] FX This work was supported by Veterans Health Administration Grant BX000452 and National Institutes of Health Grants AG027224 and AG005133. NR 46 TC 1 Z9 1 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2016 VL 77 IS 12 BP E1564 EP + DI 10.4088/JCP.15m10617 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2EL UT WOS:000393022700003 PM 28086011 ER PT J AU Attridge, RT Frei, CR Pugh, MJV Lawson, KA Ryan, L Anzueto, A Metersky, ML Restrepo, MI Mortensen, EM AF Attridge, Russell T. Frei, Christopher R. Pugh, Mary Jo V. Lawson, Kenneth A. Ryan, Laurajo Anzueto, Antonio Metersky, Mark L. Restrepo, Marcos I. Mortensen, Eric M. TI Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes SO JOURNAL OF CRITICAL CARE LA English DT Article DE Pneumonia; Critical care; Guideline-concordant therapy; Health outcomes; Antibiotic therapy ID COMMUNITY-ACQUIRED PNEUMONIA; MULTIDRUG-RESISTANT PATHOGENS; CLINICAL-OUTCOMES; RISK-FACTORS; HOSPITALIZED-PATIENTS; THERAPY; EPIDEMIOLOGY; MULTICENTER; MORTALITY; METAANALYSIS AB Purpose: Recent data have not demonstrated improved outcomes when guideline-concordant (GC) antibiotics are given to patients with health care-associated pneumonia (HCAP). This study was designed to evaluate the relationship between health outcomes and GC therapy in patients admitted to an intensive care unit (ICU) with HCAP. Materials and methods: We performed a population-based cohort study of patients admitted to greater than 150 hospitals in the US Veterans Health Administration system to compare baseline characteristics, bacterial pathogens, and health outcomes in ICU patients with HCAP receiving GC-HCAP therapy, GC community acquired pneumonia (GC-CAP) therapy, or non-GC therapy. The primary outcome was 30-day patient mortality. Risk factors for the primary outcome were assessed in a multivariable logistic regression model. Results: A total of 3593 patients met inclusion criteria and received GC-HCAP therapy (26%), GC-CAP therapy (23%), or non-GC therapy (51%). Patients receiving GC-HCAP had higher 30-day patient mortality compared to GC-CAP patients (34% vs 22%; P<.0001). After controlling for confounders, risk factors for 30-day patient mortality were vasopressor use (odds ratio, 1.67; 95% confidence interval, 1.30-2.13), recent hospital admission (1.53; 1.15-2.02), and receipt of GC-HCAP therapy (1.51; 1.20-1.90). Conclusions: Our data do not demonstrate improved outcomes among ICU patients with HCAP who received GC-HCAP therapy. Published by Elsevier Inc. C1 [Attridge, Russell T.] Univ Incarnate Word, Feik Sch Pharm, 4301 Broadway,CPO 99, San Antonio, TX 78209 USA. [Attridge, Russell T.; Pugh, Mary Jo V.; Anzueto, Antonio; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Frei, Christopher R.; Lawson, Kenneth A.; Ryan, Laurajo] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Frei, Christopher R.; Ryan, Laurajo] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Ryan, Laurajo; Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Metersky, Mark L.] Univ Connecticut, Sch Med, Farmington, CT 06030 USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Gen Internal Med Sect, Dallas, TX 75216 USA. [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. RP Attridge, RT (reprint author), Univ Incarnate Word, Feik Sch Pharm, 4301 Broadway,CPO 99, San Antonio, TX 78209 USA. EM attridge@uiwtx.edu; freic@uthscsa.edu; pughm@uthscsa.edu; ken.lawson@austin.utexas.edu; ryanl@uthscsa.edu; anzueto@uthscsa.edu; Metersky@nso.uchc.edu; restrepom@uthscsa.edu; eric.mortensen@utsouthwestern.edu OI Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828]; Agency for Health Care Research and Quality [1R24HS022418-01]; National Heart, Lung, and Blood Institute [K23HL096054] FX This project was supported by grant number R01NR010828 from the National Institute of Nursing Research. Dr. Mortensenwas supported by Project Number 1R24HS022418-01 from the Agency for Health Care Research and Quality. Dr. Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health; the Department of Veterans Affairs; or the National Heart, Lung, and Blood Institute. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System and VA North Texas Health Care System. The funding agencies had no role in conducting the study or role in the preparation, review, or approval of the manuscript. NR 40 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 EI 1557-8615 J9 J CRIT CARE JI J. Crit. Care PD DEC PY 2016 VL 36 BP 265 EP 271 DI 10.1016/j.jcrc.2016.08.004 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA EJ2YS UT WOS:000393078100046 PM 27595461 ER PT J AU Morioka, C Meng, F Taira, R Sayre, J Zimmerman, P Ishimitsu, D Huang, J Shen, LY El-Saden, S AF Morioka, Craig Meng, Frank Taira, Ricky Sayre, James Zimmerman, Peter Ishimitsu, David Huang, Jimmy Shen, Luyao El-Saden, Suzie TI Automatic Classification of Ultrasound Screening Examinations of the Abdominal Aorta SO JOURNAL OF DIGITAL IMAGING LA English DT Article DE Classification; Coding; Natural language processing; Abdominal aortic aneurysm ID ANEURYSM; PROGRAM AB Our work facilitates the identification of veterans who may be at risk for abdominal aortic aneurysms (AAA) based on the 2007 mandate to screen all veteran patients that meet the screening criteria. The main research objective is to automatically index three clinical conditions: pertinent negative AAA, pertinent positive AAA, and visually unacceptable image exams. We developed and evaluated a ConText-based algorithm with the GATE (General Architecture for Text Engineering) development system to automatically classify 1402 ultrasound radiology reports for AAA screening. Using the results from JAPE (Java Annotation Pattern Engine) transducer rules, we developed a feature vector to classify the radiology reports with a decision table classifier. We found that ConText performed optimally on precision and recall for pertinent negative (0.99 (0.98-0.99), 0.99 (0.99-1.00)) and pertinent positive AAA detection (0.98 (0.95-1.00), 0.97 (0.92-1.00)), and respectably for determination of non-diagnostic image studies (0.85 (0.77-0.91), 0.96 (0.91-0.99)). In addition, our algorithm can determine the AAA size measurements for further characterization of abnormality. We developed and evaluated a regular expression based algorithm using GATE for determining the three contextual conditions: pertinent negative, pertinent positive, and non-diagnostic from radiology reports obtained for evaluating the presence or absence of abdominal aortic aneurysm. ConText performed very well at identifying the contextual features. Our study also discovered contextual trigger terms to detect sub-standard ultrasound image quality. Limitations of performance included unknown dictionary terms, complex sentences, and vague findings that were difficult to classify and properly code. C1 [Morioka, Craig; Zimmerman, Peter; Ishimitsu, David; Huang, Jimmy; El-Saden, Suzie] VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA. [Morioka, Craig; Meng, Frank; Taira, Ricky; Sayre, James; El-Saden, Suzie] Univ Calif Los Angeles, Med Imaging Informat, Los Angeles, CA USA. [Morioka, Craig; Meng, Frank; Taira, Ricky; Sayre, James; Zimmerman, Peter; Ishimitsu, David; Huang, Jimmy; Shen, Luyao; El-Saden, Suzie] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA. RP Morioka, C (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA.; Morioka, C (reprint author), Univ Calif Los Angeles, Med Imaging Informat, Los Angeles, CA USA.; Morioka, C (reprint author), Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA. EM Craig.Morioka@va.gov NR 23 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0897-1889 EI 1618-727X J9 J DIGIT IMAGING JI J. Digit. Imaging PD DEC PY 2016 VL 29 IS 6 BP 742 EP 748 DI 10.1007/s10278-016-9889-6 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EJ3KY UT WOS:000393112300015 PM 27400914 ER PT J AU Gemmell, LA Terhorst, L Jhamb, M Unruh, M Myaskovsky, L Kester, L Steel, JL AF Gemmell, Leigh A. Terhorst, Lauren Jhamb, Manisha Unruh, Mark Myaskovsky, Larissa Kester, Lauren Steel, Jennifer L. TI Gender and Racial Differences in Stress, Coping, and Health-Related Quality of Life in Chronic Kidney Disease SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Health-related quality of life; gender; chronic kidney disease; stress; coping ID DIALYSIS OUTCOMES; PRACTICE PATTERNS; MISSING DATA; SURVEY SF-36; HEMODIALYSIS; DEPRESSION; STRATEGIES; DOPPS AB Context. Living with chronic kidney disease can be stressful and influence an individual's health-related quality of life. Effective coping strategies may reduce stress and improve quality of life in individuals with chronic medical conditions. Objectives. Health-related quality of life (HRQOL) is an important outcome for patients living with chronic kidney disease (CKD), and it is necessary to better understand potential gender and racial differences and predictors associated with reduced HRQOL, so that effective interventions can be developed. Methods. Participants included 182 patients with CKD who were administered a battery of questions that included the Medical Outcomes Study Short-Form 36, Perceived Stress Scale, and the Brief COPE. Demographic and disease-specific information was abstracted from the patients' medical record. Results. No differences by race were observed with regard to stress, quality of life, or coping with the exception that minority patients reported use of religious coping more often (P = 0.001) and had higher levels of energy compared with nonminority patients with CKD (P = 0.27). Women with CKD tended to use self-distraction (P = 0.002), positive reframing (P = 0.035), venting (P = 0.024), and religious coping (P = 0 < 0.001) more often than men. No significant differences in perceived stress or domains of quality of life were observed between men and women with CKD. A link between coping strategies and HRQOL was observed in women (P = 0.001-0.02) but not men. Perceived stress was associated with poorer quality of life for men (P = 0.017 to < 0.001) and women (P = 0.001 to < 0.001), but more domains of men's quality of life were affected by perceived stress compared with women. Conclusions. The findings of the study suggest that the wider range of coping strategies used by women may be associated with buffering the link between perceived stress and quality of life. Men with CKD may benefit from interventions that not only reduce stress but also facilitate the use of a broader range of coping strategies to reduce stress and improve quality of life. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Gemmell, Leigh A.; Steel, Jennifer L.] Univ Pittsburgh, Sch Med, Dept Surg, 3459 Fifth Ave,Montefiore 7S, Pittsburgh, PA 15213 USA. [Terhorst, Lauren] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA 15260 USA. [Jhamb, Manisha; Unruh, Mark; Kester, Lauren] Univ Pittsburgh, Sch Med, Dept Renal Electrolyte Div, Pittsburgh, PA 15260 USA. [Myaskovsky, Larissa] Univ Pittsburgh, Sch Med, Dept Med & Psychiat, Pittsburgh, PA 15260 USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Steel, Jennifer L.] Univ Pittsburgh, Sch Med, Dept Surg, Psychiat & Psychol, Pittsburgh, PA 15260 USA. RP Steel, JL (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, 3459 Fifth Ave,Montefiore 7S, Pittsburgh, PA 15213 USA. EM steeljl@upmc.edu FU NIDDK NIH HHS [R01 DK077785] NR 22 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD DEC PY 2016 VL 52 IS 6 BP 806 EP 812 DI 10.1016/j.jpainsymman.2016.05.029 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EJ4KE UT WOS:000393184800317 PM 27697565 ER PT J AU Wang, SY Aldridge, MD Canavan, M Cherlin, E Bradley, E AF Wang, Shi-Yi Aldridge, Melissa D. Canavan, Maureen Cherlin, Emily Bradley, Elizabeth TI Continuous Home Care Reduces Hospice Disenrollment and Hospitalization After Hospice Enrollment SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Hospice; continuous home care; hospice disenrollment; end-of-life care ID MARKET-STRUCTURE; LIFE; PATTERNS; END AB Context. Among the four levels of hospice care, continuous home care (CHC) is the most expensive care, and infrequently provided in practice. Objectives. To identify hospice and patient characteristics associated with the use of CHC and to examine the associations between CHC utilization and hospice disenrollment or hospitalization after hospice enrollment. Methods. Using 100% fee-for-service Medicare claims data for beneficiaries aged 66 years or older who died between July and December 2011, we identified the percentage of hospice agencies in which patients used CHC in 2011 and determined hospice and patient characteristics associated with the use of CHC. Using multivariable analyses, we examined the associations between CHC utilization and hospice disenrollment and hospitalization after hospice enrollment, adjusted for hospice and patient characteristics. Results. Only 42.7% of hospices (1533 of 3592 hospices studied) provided CHC to at least one patient during the study period. Patients enrolled with for-profit, larger, and urban located hospices were more likely to use CHC (P < 0.001). Within these 1533 hospices, only 11.4% of patients used CHC. Patients who were white, had cancer, and had more comorbidities were more likely to use CHC. In multivariable models, compared with patients who did not use CHC, patients who used CHC were less likely to have hospice disenrollment (adjusted odds ratio 0.21; 95% CI 0.19, 0.23) and less likely to be hospitalized after hospice enrollment (adjusted odds ratio 0.37; 95% CI 0.34, 0.40). Conclusion. Although a minority of patients uses CHC, such services may be protective against hospice disenrollment and hospitalization after hospice enrollment. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Wang, Shi-Yi] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. [Wang, Shi-Yi] Yale Canc Ctr, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT USA. [Wang, Shi-Yi] Yale Univ, Sch Med, New Haven, CT USA. [Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Aldridge, Melissa D.] James J Peters VA Med Ctr, Bronx, NY USA. [Canavan, Maureen; Cherlin, Emily; Bradley, Elizabeth] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. RP Wang, SY (reprint author), Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St, New Haven, CT 06520 USA. EM shiyi.wang@yale.edu OI Wang, Shi-Yi/0000-0002-3294-5784 FU National Cancer Institute [1R01CA116398-01A2]; John D. Thompson Foundation; National Institute of Nursing Research [1R01NR013499-01A1]; Agency for Healthcare Research and Quality [1K01HS023900-01] FX This study was supported by grant 1R01CA116398-01A2 from the National Cancer Institute (Drs. Aldridge and Bradley); the John D. Thompson Foundation (Dr. Bradley); grant 1R01NR013499-01A1 from the National Institute of Nursing Research (Dr. Aldridge); and grant 1K01HS023900-01 from the Agency for Healthcare Research and Quality (Dr. Wang). NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD DEC PY 2016 VL 52 IS 6 BP 813 EP 821 DI 10.1016/j.jpainsymman.2016.05.031 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EJ4KE UT WOS:000393184800318 PM 27697564 ER PT J AU Hussain, AJ AF Hussain, Ali J. TI Alternative Scheduling Models: Improving Continuity of Care, Medical Outcomes, and Graduate Medical Education in Resident Ambulatory Training SO JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION LA English DT Article DE clinic scheduling models; continuity of care; graduate medical education; residency ID INTERNAL-MEDICINE; CLINIC HANDOFFS; REDESIGN; ASSOCIATION; BLOCK AB An association has been consistently made about continuity of care with improved quality of care and improved medical outcomes. However, resident ambulatory block scheduling prevents the optimization of continuity of care in ambulatory clinical education. The author performed a PubMed search for studies examining continuity of care and curriculum scheduling in US primary care residency clinics. These studies indicate the success of an X + Y scheduling model in resident ambulatory training. Additional benefits have also been noted, including improved clinical teaching and learning, increased sense of teamwork, increased resident satisfaction, improved recruitment and retention, improved patient satisfaction, and elimination of year-end patient care issues after graduation. Many allopathic institutions have begun to implement such curricular changes with demonstrated success. The author argues that osteopathic graduate medical education should embrace the X + Y scheduling model. C1 [Hussain, Ali J.] US Dept Vet Affairs, Washington, DC USA. RP Hussain, AJ (reprint author), 2361 S State St,L15, Chicago, IL 60616 USA. EM drajhussain@gmail.com NR 38 TC 0 Z9 0 U1 1 U2 1 PU AMER OSTEOPATHIC ASSN PI CHICAGO PA 142 EAST ONTARIO STREET, CHICAGO, IL 60611-2864 USA SN 0098-6151 EI 1945-1997 J9 J AM OSTEOPATH ASSOC JI J. Am. Osteopath. Assoc. PD DEC PY 2016 VL 116 IS 12 BP 794 EP 800 DI 10.7556/jaoa.2016.155 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EJ2OR UT WOS:000393050400006 PM 27893146 ER PT J AU McDonnell, MJ Aliberti, S Goeminne, PC Restrepo, MI Finch, S Pesci, A Dupont, LJ Fardon, TC Wilson, R Loebinger, MR Skrbic, D Obradovic, D De Soyza, A Ward, C Laffey, JG Rutherford, RM Chalmers, JD AF McDonnell, Melissa J. Aliberti, Stefano Goeminne, Pieter C. Restrepo, Marcos I. Finch, Simon Pesci, Alberto Dupont, Lieven J. Fardon, Thomas C. Wilson, Robert Loebinger, Michael R. Skrbic, Dusan Obradovic, Dusanka De Soyza, Anthony Ward, Chris Laffey, John G. Rutherford, Robert M. Chalmers, James D. TI Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study SO LANCET RESPIRATORY MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC FIBROSIS BRONCHIECTASIS; VALIDATION; STATEMENT; DIAGNOSIS; SEVERITY; REFLUX; CANCER; COPD AB Background Patients with bronchiectasis often have concurrent comorbidities, but the nature, prevalence, and impact of these comorbidities on disease severity and outcome are poorly understood. We aimed to investigate comorbidities in patients with bronchiectasis and establish their prognostic value on disease severity and mortality rate. Methods An international multicentre cohort analysis of outpatients with bronchiectasis from four European centres followed up for 5 years was done for score derivation. Eligible patients were those with bronchiectasis confirmed by high-resolution CT and a compatible clinical history. Comorbidity diagnoses were based on standardised definitions and were obtained from full review of paper and electronic medical records, prescriptions, and investigator definitions. Weibull parametric survival analysis was used to model the prediction of the 5 year mortality rate to construct the Bronchiectasis Aetiology Comorbidity Index (BACI). We tested the BACI as a predictor of outcomes and explored whether the BACI added further prognostic information when used alongside the Bronchiectasis Severity Index (BSI). The BACI was validated in two independent international cohorts from the UK and Serbia. Findings Between June 1, 2006, and Nov 22, 2013, 1340 patients with bronchiectasis were screened and 986 patients were analysed. Patients had a median of four comorbidities (IQR 2-6; range 0-20). 13 comorbidities independently predicting mortality rate were integrated into the BACI. The overall hazard ratio for death conferred by a one-point increase in the BACI was 1.18 (95% CI 1.14-1.23; p<0.0001). The BACI predicted 5 year mortality rate, hospital admissions, exacerbations, and health-related quality of life across all BSI risk strata (p<0.0001 for mortality and hospital admissions, p=0.03 for exacerbations, p=0.0008 for quality of life). When used in conjunction with the BSI, the combined model was superior to either model alone (p=0.01 for combined vs BACI; p=0.008 for combined vs BSI). Interpretation Multimorbidity is frequent in bronchiectasis and can negatively affect survival. The BACI complements the BSI in the assessment and prediction of mortality and disease outcomes in patients with bronchiectasis. C1 [McDonnell, Melissa J.; Rutherford, Robert M.] Galway Univ Hosp, Dept Resp Med, Galway H91 YR71, Ireland. [McDonnell, Melissa J.; De Soyza, Anthony; Ward, Chris] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne, Tyne & Wear, England. [McDonnell, Melissa J.; De Soyza, Anthony; Ward, Chris] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England. [McDonnell, Melissa J.; Laffey, John G.] Natl Univ Ireland, Lung Biol Grp, Galway, Ireland. [Aliberti, Stefano] Univ Milan, Dept Pathophysiol & Transplantat, Cardiothorac Unit, Milan, Italy. [Aliberti, Stefano] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cyst Fibrosis Adult Ctr, Milan, Italy. [Goeminne, Pieter C.; Dupont, Lieven J.] Univ Hosp Gasthuisberg, Dept Resp Med, Leuven, Belgium. [Goeminne, Pieter C.] AZ Nikolaas, Dept Resp Med, St Niklaas, Belgium. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Pesci, Alberto] Univ Milano Bicocca, Sch Med & Surg, Resp Unit, AO San Gerardo, Monza, Italy. [Finch, Simon; Fardon, Thomas C.; Chalmers, James D.] Univ Dundee, Scottish Ctr Resp Res, Dundee, Scotland. [Wilson, Robert; Loebinger, Michael R.] Royal Brompton Hosp, Host Def Unit, London, England. [Skrbic, Dusan; Obradovic, Dusanka] Inst Pulm Dis Vojvodina Sremska Kamenica, Sremska Kamenica, Serbia. [Skrbic, Dusan; Obradovic, Dusanka] Univ Novi Sad, Fac Med, Novi Sad, Serbia. [Laffey, John G.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Dept Anesthesia, Toronto, ON, Canada. RP McDonnell, MJ (reprint author), Galway Univ Hosp, Dept Resp Med, Galway H91 YR71, Ireland. EM melissajanefriel@gmail.com FU European Bronchiectasis Network (EMBARC) FX European Bronchiectasis Network (EMBARC). NR 30 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD DEC PY 2016 VL 4 IS 12 BP 969 EP 979 DI 10.1016/S2213-2600(16)30320-4 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EJ2GC UT WOS:000393027100017 PM 27864036 ER PT J AU Willis, AW Thibault, DP Schmidt, PN Dorsey, ER Weintraub, D AF Willis, Allison. W. Thibault, Dylan P. Schmidt, Peter N. Dorsey, E. Ray Weintraub, Daniel TI Hospital Care for Mental Health and Substance Abuse Conditions in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; suicide; psychiatry; addiction; epidemiology ID DEEP BRAIN-STIMULATION; GENDER-DIFFERENCES; ANXIETY DISORDERS; DEPRESSION; SUICIDE; FREQUENCY; DOPAMINE; DISPARITIES; DEMENTIA; VETERANS AB Objective: The objective of this study was to examine mental health conditions among hospitalized individuals with Parkinson's disease in the United States. Methods: This was a serial cross-sectional study of hospitalizations of individuals aged >= 60 identified in the Nationwide Inpatient Sample dataset from 2000 to 2010. We identified all hospitalizations with a diagnosis of PD, alcohol abuse, anxiety, bipolar disorder, depression, impulse control disorders, mania, psychosis, substance abuse, and attempted suicide/suicidal ideation. National estimates of each mental health condition were compared between hospitalized individuals with and without PD. Hierarchical logistic regression models determined which inpatient mental health diagnoses were associated with PD, adjusting for demographic, payer, geographic, and hospital characteristics. Results: We identified 3,918,703 mental health and substance abuse hospitalizations. Of these, 2.8% (n=104, 437) involved a person also diagnosed with PD. The majority of mental health and substance abuse patients were white (86.9% of PD vs 83.3% of non-PD). Women were more common than men in both groups (male: female prevalence ratio, PD: 0.78, 0.78-0.79, non-PD: 0.58, 0.57-0.58). Depression (adjusted odds ratio 1.32, 1.31-1.34), psychosis (adjusted odds ratio 1.25, 1.15-1.33), bipolar disorder (adjusted odds ratio 2.74, 2.69-2.79), impulse control disorders (adjusted odds ratio 1.51, 1.31-1.75), and mania (adjusted odds ratio 1.43, 1.18-1.74) were more likely among PD patients, alcohol abuse was less likely (adjusted odds ratio 0.26, 0.25-0.27). We found no PD-associated difference in suicide-related care. Conclusions: PD patients have unique patterns of acute care for mental health and substance abuse. Research is needed to guide PD treatment in individuals with pre-existing psychiatric illnesses, determine cross provider reliability of psychiatric diagnoses in PD patients, and inform efforts to improve psychiatric outcomes. (C) 2016 International Parkinson and Movement Disorder Society. C1 [Willis, Allison. W.; Thibault, Dylan P.; Weintraub, Daniel] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Willis, Allison. W.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Willis, Allison. W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Willis, Allison. W.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Schmidt, Peter N.] Natl Parkinsons Fdn, Miami, FL USA. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Willis, AW (reprint author), Blockley Hall 723,423 Guardian Dr, Philadelphia, PA 19104 USA. EM allison.willis@uphs.upenn.edu FU National Institutes of Health (NIH); National Institute of Neurological Disease and Stroke (NINDS) via a Mentored Career Development Award [K23NS081087]; University of Pennsylvania Perelman School of Medicine Department of Neurology Movement Disorders Division FX This study was funded primarily by the National Institutes of Health (NIH) and the National Institute of Neurological Disease and Stroke (NINDS) via a Mentored Career Development Award K23NS081087(PI-Willis) and the University of Pennsylvania Perelman School of Medicine Department of Neurology Movement Disorders Division. NR 39 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD DEC PY 2016 VL 31 IS 12 BP 1810 EP 1819 DI 10.1002/mds.26832 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA EJ3PD UT WOS:000393123200011 PM 27943472 ER PT J AU Bansal, N Katz, R Himmelfarb, J Afkarian, M Kestenbaum, B de Boer, IH Young, B AF Bansal, Nisha Katz, Ronit Himmelfarb, Jonathan Afkarian, Maryam Kestenbaum, Bryan de Boer, Ian H. Young, Bessie TI Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE African Americans; chronic kidney disease; echocardiogram; heart failure; left ventricular hypertrophy ID LEFT-VENTRICULAR HYPERTROPHY; PRESERVED EJECTION FRACTION; GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION; RACIAL-DIFFERENCES; YOUNG-ADULTS; CYSTATIN C; MASS INDEX; OUTCOMES; CKD AB Background. African Americans and patients with chronic kidney disease (CKD) are at high risk for clinical heart failure (HF). In this study, we aimed to determine the association of markers of kidney disease with subclinical HF (by echocardiogram) and risk of clinical HF among a large, well-characterized community-based cohort of African American patients. We also examined whether the association of markers of kidney disease with HF was attenuated with adjustment for echocardiographic measures. Methods. We studied participants in the Jackson Heart Study, a large community-based cohort of African Americans. Estimated glomerular filtration rate (eGFR) and urine albumin: creatinine ratio (ACR) were measured at baseline. We tested the association of eGFR and urine ACR with left ventricular mass (LVM), left ventricular ejection fraction (LVEF) and physician-adjudicated incident HF. Results. Among the 3332 participants in the study, 166 (5%) had eGFR <60 mL/min/1.73 m(2) and 405 (12%) had urine ACR >= 30 mg/g. In models adjusted for demographics, comorbidity and the alternative measure of kidney disease, lower eGFR and higher urine ACR were associated with higher LVM {beta-coefficient 1.54 [95% confidence interval (CI) 0.78-2.31] per 10 mL/min/1.73 m(2) decrease in eGFR and 2.87 (95% CI 1.85-3.88) per doubling of urine ACR}. There was no association of eGFR and urine ACR with LVEF [beta-coefficient -0.12 (95% CI -0.28-0.04) and -0.11 (95% CI -0.35-0.12), respectively]. There was no association of eGFR with the risk of incident HF [HR 1.02 (95% CI 0.91-1.14) per 10 mL/min/1.73 m(2) decrease], while there was a significant association of urine ACR [HR 2.22 (95% CI 1.29-3.84) per doubling of urine ACR]. This association was only modestly attenuated with adjustment for LVM [HR 1.95 (95% CI 1.09-3.49)]. Conclusions. Among a community-based cohort of African Americans, lower eGFR and higher ACR were associated with higher LVM. Furthermore, higher urine ACR was associated with incident HF, which was not entirely explained by the presence of left ventricular disease. C1 [Bansal, Nisha; Katz, Ronit; Himmelfarb, Jonathan; Afkarian, Maryam; Kestenbaum, Bryan; de Boer, Ian H.; Young, Bessie] Univ Washington, Div Nephrol, Kidney Res Inst, 908 Jefferson St,3rd Floor, Seattle, WA 98105 USA. [de Boer, Ian H.; Young, Bessie] Vet Affairs Puget Sound Hlth Care Syst, Nephrol Sect, Hosp & Specialty Med, Seattle, WA USA. RP Bansal, N (reprint author), Univ Washington, Div Nephrol, Kidney Res Inst, 908 Jefferson St,3rd Floor, Seattle, WA 98105 USA. EM nbansal@nephrology.washington.edu FU National Heart, Lung, and Blood Institute [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C]; National Institute on Minority Health and Health Disparities; Veterans Affairs Puget Sound Health Care System; [R01DK102134]; [K23DK088865] FX We thank all participants of the Jackson Heart Study for their time, effort and dedication toward this study. This study was supported by the following funding sources: R01DK102134 (B.Y.) and K23DK088865 (N.B.). The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C and HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. B.Y. and I.H.d.B. are also supported in part by funding from the Veterans Affairs Puget Sound Health Care System. NR 50 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD DEC PY 2016 VL 31 IS 12 BP 2057 EP 2064 DI 10.1093/ndt/gfw218 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA EJ2RV UT WOS:000393059700016 PM 27257276 ER PT J AU Arocho-Quinones, EV Pahapill, PA AF Arocho-Quinones, Elsa V. Pahapill, Peter A. TI Non-Infectious Peri-Electrode Edema and Contrast Enhancement Following Deep Brain Stimulation Surgery SO NEUROMODULATION LA English DT Article DE Brain edema; deep brain stimulation; gadolinium enhancement; peri-electrode; T2-weighted hyperintensity AB Background: Dramatic radiographic abnormalities seen after electrode placement (DRAAEP) in deep brain stimulation (DBS) surgery is rare and it has not been associated with infection or hemorrhage. It has consisted of peri-electrode low-attenuation signals on CT scans and extensive T2-hyperintense signals without associated contrast enhancement (CE) on MRI scans. Objective: Report on the management of a patient with Parkinson's disease (PD) presenting with a seizure and findings of DRAAEP with positive CE 12 days after the placement of a subthalamic nucleus (STN) DBS electrode. Methods: Head CT and contrasted brain MRI scans were completed on presentation. Standard laboratory work up was obtained to evaluate for infection. Operative exploration deep to the burr-hole site surrounding the electrode was performed and cultures were obtained. Serial contrasted MRI scans were completed to determine the abnormal signal duration. Results: A MRI revealed extensive T2-hyperintensity and positive CE concentrated around the burr-hole site surrounding the electrode. Intraoperative exploration revealed no evidence of infection and electrode revision was avoided. There was near resolution of the abnormal T2 signal and CE at six weeks from detection. The patient remained without signs of intracranial infection and responded well to DBS. Conclusion: To our knowledge, this is the first reported case of DRAAEP with positive gadolinium enhancement. Despite the extensive contrast enhancement, these DRAAEP appear to remain benign transient events that, in the absence of clinical signs of infection or neurologic decline, may warrant no further aggressive intervention such as hardware removal. C1 [Arocho-Quinones, Elsa V.; Pahapill, Peter A.] Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. [Arocho-Quinones, Elsa V.; Pahapill, Peter A.] US Dept Vet Affairs, Med Ctr, Dept Neurosurg, Milwaukee, WI USA. RP Arocho-Quinones, EV (reprint author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. EM earocho@mcw.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1094-7159 EI 1525-1403 J9 NEUROMODULATION JI Neuromodulation PD DEC PY 2016 VL 19 IS 8 BP 872 EP 876 DI 10.1111/ner.12432 PG 5 WC Medicine, Research & Experimental; Clinical Neurology SC Research & Experimental Medicine; Neurosciences & Neurology GA EI9IU UT WOS:000392822100021 PM 27098925 ER PT J AU Lusk, R Lyubkin, M Chermack, ST Sanborn, ML Bowersox, NW AF Lusk, Rebecca Lyubkin, Mark Chermack, Stephen T. Sanborn, Michelle L. Bowersox, Nicholas W. TI Quasi-Experimental Evaluation of the Impact of a Cognitive Behavioral Pretreatment Intervention for Veterans Seeking Psychotherapy SO PSYCHOTHERAPY LA English DT Article DE pretreatment intervention; cognitive-behavioral therapy; psychotherapy; veteran ID MENTAL-HEALTH TREATMENT; DEPRESSION TREATMENT; PREPARING CLIENTS; THERAPY; METAANALYSIS; PTSD; CARE; STRATEGIES; MOTIVATION; ATTENDANCE AB Pretreatment interventions have documented efficacy for reducing initial therapy refusal and early therapy departure. However, these interventions have not been well-studied in diagnostically diverse patient populations or within Veterans Affairs (VA) health care settings. We designed a manualized 4-session group cognitive-behavioral therapy-based pretreatment intervention (PTI) for a diagnostically diverse population of Veterans referred for psychotherapy in a general mental health clinic (MHC) in a large VA hospital. Retrospective record review was used to collect patient data over a period of 6 months after their completion of the PTI. A sample of 50 Veterans who were referred for care at the MHC prior to the implementation of the PTI was used for comparison (NoPTI). Two hundred sixty-six Veterans participated in the PTI. Veterans who participated in the PTI were equally as likely to attend at least one psychotherapy session as NoPTI Veterans, but had more individual and group therapy sessions during the 6-month therapy tracking period. PTI participants were also less likely to have a psychiatric hospitalization during the 6-month therapy tracking period. Study findings suggest that PTIs are a good fit to a VA general mental health setting and effective in bolstering therapy attendance. Limitations and future directions are discussed. C1 [Lusk, Rebecca; Lyubkin, Mark; Chermack, Stephen T.; Sanborn, Michelle L.; Bowersox, Nicholas W.] VA Ann Arbor Healthcare Syst, US Dept Vet Affairs, Ann Arbor, MI USA. [Lusk, Rebecca; Lyubkin, Mark; Chermack, Stephen T.; Sanborn, Michelle L.; Bowersox, Nicholas W.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Lusk, R (reprint author), VA Ann Arbor Healthcare Syst, 2215 Fuller Rd,116C, Ann Arbor, MI 48105 USA. EM rebecca.lusk@va.gov NR 48 TC 0 Z9 0 U1 2 U2 2 PU AMER PSYCHOLOGICAL ASSOC, DIV PSYCHOTHERAPY PI CORAL GABLES PA 1390 SOUTH DIXIE HIGHWAY, STE 2222, CORAL GABLES, FL 33146-2946 USA SN 0033-3204 EI 1939-1536 J9 PSYCHOTHERAPY JI Psychotherapy PD DEC PY 2016 VL 53 IS 4 SI SI BP 424 EP 432 DI 10.1037/pst0000088 PG 9 WC Psychology, Clinical SC Psychology GA EJ4VL UT WOS:000393215000005 PM 27918190 ER PT J AU Wick, MJ Loomis, ZL Harral, JW Le, M Wehling, CA Miller, YE Dempsey, EC AF Wick, Marilee J. Loomis, Zoe L. Harral, Julie W. Le, Mysan Wehling, Carol A. Miller, York E. Dempsey, Edward C. TI Protection against vascular leak in neprilysin transgenic mice with complex overexpression pattern SO TRANSGENIC RESEARCH LA English DT Article DE Neprilysin; Transgenic mouse; Vascular leak; Evans blue; Duodenum; Rosa26 promoter ID ANGIOTENSIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE; PLASMA EXTRAVASATION; SUBSTANCE-P; PERMEABILITY; EXPRESSION; PROTEOLYSIS; INHIBITION; BRADYKININ; PATHOLOGY AB Neprilysin (NEP) is a cell surface metallopeptidase found in many tissues. Based mostly on pharmacological manipulations, NEP has been thought to protect blood vessels from plasma extravasation. We have suggested that NEP may protect against pulmonary vascular injury. However, these prior studies did not utilize mice which overexpress NEP. The aims of the present investigation were to develop and characterize doubly transgenic (DT) mice that overexpress NEP universally and conditionally, and to investigate the protective effect that overexpressed NEP may have against plasma extravasation in the vasculature. The duodenum, which is often used to assess vascular permeability, and in which the NEP protein was overexpressed in our DT mice two-fold, was selected as our experimental preparation. We found that substance P-induced plasma extravasation was decreased substantially (3.5-fold) in the duodenums of our doxycycline-treated DT mice, giving independent evidence of NEP's protective effects against plasma extravasation. Transgenic lung NEP protein was not stably expressed in the DT mice, so we were not able to test the effect of NEP overexpression in the lung. Although initially overexpressed nearly nine-fold at that site, pulmonary NEP protein overexpression eventually dissipated. Surprisingly, at a time when there was no lung transgenic NEP protein overexpression, lung NEP mRNA expression was still increased 23-fold, indicating that the expression defect probably is not transcriptional. These studies help to characterize our complex transgenic model of NEP overexpression and further demonstrate NEP's protective effects against plasma extravasation. C1 [Wick, Marilee J.; Loomis, Zoe L.; Harral, Julie W.; Dempsey, Edward C.] Univ Colorado Denver, Cardiovasc Pulm Res Lab, RC-2,Box B-133,12700 E 19th Ave, Aurora, CO 80045 USA. [Wick, Marilee J.; Loomis, Zoe L.; Harral, Julie W.; Miller, York E.; Dempsey, Edward C.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Le, Mysan; Wehling, Carol A.; Miller, York E.; Dempsey, Edward C.] Denver VA Med Ctr, Denver, CO 80220 USA. RP Wick, MJ (reprint author), Univ Colorado Denver, Cardiovasc Pulm Res Lab, RC-2,Box B-133,12700 E 19th Ave, Aurora, CO 80045 USA.; Wick, MJ (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. EM Marilee.wick@ucdenver.edu FU National Heart, Lung and Blood Institute [NHLBI RO1 HL078929, PPG HL14985, RO3 HL095439]; Department of Veterans' Affairs; NCI [P50 CA058187, P30 CA046934] FX Supported by Grants received from the National Heart, Lung and Blood Institute (NHLBI RO1 HL078929, PPG HL14985 and RO3 HL095439) and the Department of Veterans' Affairs (Merit Review to ECD). YEM is supported by NCI P50 CA058187 and NCI P30 CA046934. The authors wish to thank Dr. James West (Vanderbilt University) for the FVB/N Rosa26- rtTA2-M2 singly transgenic mice, Dr. Lou Hersh (University of Kentucky) for the NEP-pCSC-SP-PW lentiviral vector, and Dr Jeffrey Whitsett (Cincinnati Children's Hospital) for the reengineered Tet-O-CMV vector and FVB/N SP-C-rtTA transgenic mice. The authors also wish to thank Sandra Walchak and Andy Poczobutt for expert technical and administrative assistance. NR 38 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-8819 EI 1573-9368 J9 TRANSGENIC RES JI Transgenic Res. PD DEC PY 2016 VL 25 IS 6 BP 773 EP 784 DI 10.1007/s11248-016-9969-x PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA EJ5AQ UT WOS:000393229300002 PM 27369050 ER PT J AU Baan, M Krentz, KJ Fontaine, DA Davis, DB AF Baan, Mieke Krentz, Kathleen J. Fontaine, Danielle A. Davis, Dawn Belt TI Successful in vitro fertilization and generation of transgenics in Black and Tan Brachyury (BTBR) mice SO TRANSGENIC RESEARCH LA English DT Article DE BTBR; In vitro fertilization; Embryo transfer; Transgenic mouse model; Diabetes mellitus; Autism ID METHYL-BETA-CYCLODEXTRIN; AUTISM SPECTRUM DISORDERS; C57BL/6 MOUSE SPERM; DIABETIC-NEPHROPATHY; CELL PROLIFERATION; OB/OB MICE; MODEL; EXPRESSION; FERTILITY; IMPROVES AB The Black and Tan Brachyury (BTBR) mouse strain is a valuable model for the study of long-term complications from obesity-induced type 2 diabetes mellitus and autism spectrum disorder. Due to technical difficulties with assisted reproduction, genetically modified animals on this background have previously been generated through extensive back-crossing, which is expensive and time-consuming. We successfully generated two separate transgenic mouse lines after direct zygote microinjection into this background strain. Additionally, we developed in vitro fertilization (IVF) methods for the BTBR mouse. We found low rates of fertilization and implantation in this strain, and identified the BTBR oocyte as the primary culprit of low success with BTBR IVF. We achieved an increase in live born pups from 5.9 to 35.6% with IVF in the BTBR strain by use of BTBR females at a younger age (18-25 days), collection of oocytes 15-17 h after superovulation, and the use of supplemented fertilization media. This method eliminates the need for time consuming assisted embryo manipulations that are otherwise required for success with BTBR oocytes. This advancement provides an exciting opportunity to directly generate BTBR transgenics and gene-edited mice using both traditional and emerging genomic editing techniques, such as CRISPR/Cas9. These methods also allow effective colony preservation and rederivation with these strains. To our knowledge, this is the first report describing embryo manipulations in BTBR mice. C1 [Baan, Mieke; Fontaine, Danielle A.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, 4147 MFCB,1685 Highland Ave, Madison, WI 53705 USA. [Krentz, Kathleen J.] Univ Wisconsin, Ctr Biotechnol, 425 Henry Mall, Madison, WI 53706 USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. RP Davis, DB (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, 4147 MFCB,1685 Highland Ave, Madison, WI 53705 USA.; Davis, DB (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM dbd@medicine.wisc.edu FU National Institutes of Health [T32 RR023916, T32 OD010423]; National Institute of Aging [T32 AG000213]; University of Wisconsin-Madison Science and Medicine Graduate Research Scholars Program; NIDDK [DK083442]; University of Wisconsin Department of Medicine FX This work was supported by the National Institutes of Health training grants T32 RR023916 and T32 OD010423 (MB). DAF was supported by National Institute of Aging Training Grant T32 AG000213 and by the University of Wisconsin-Madison Science and Medicine Graduate Research Scholars Program. DBD is supported by NIDDK DK083442 and the University of Wisconsin Department of Medicine. This work was performed with resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 37 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-8819 EI 1573-9368 J9 TRANSGENIC RES JI Transgenic Res. PD DEC PY 2016 VL 25 IS 6 BP 847 EP 854 DI 10.1007/s11248-016-9974-0 PG 8 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA EJ5AQ UT WOS:000393229300008 PM 27515175 ER PT J AU Grimes, BS Krysan, K Tran, LM Park, SJ Aberle, DR Spira, AE Dubinett, SM AF Grimes, Brandon S. Krysan, Kostyantyn Tran, Linh M. Park, Stacy J. Aberle, Denise R. Spira, Avrum E. Dubinett, Steven M. TI Indolence versus aggression in non-small cell lung cancer: defining heterogeneity to impact clinical outcomes SO TRANSLATIONAL CANCER RESEARCH LA English DT Editorial Material ID SURVIVAL PREDICTION; VALIDATION; EXPRESSION; ADENOCARCINOMA C1 [Grimes, Brandon S.; Krysan, Kostyantyn; Tran, Linh M.; Park, Stacy J.; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 10833 Le Conte Ave,37-131 CHS, Los Angeles, CA 90095 USA. [Krysan, Kostyantyn; Tran, Linh M.; Park, Stacy J.; Aberle, Denise R.; Dubinett, Steven M.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Aberle, Denise R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Spira, Avrum E.] Boston Univ, Dept Med, Pulm Ctr, Boston, MA 02215 USA. [Spira, Avrum E.] Boston Univ, Dept Pathol & Lab Med, Boston, MA 02215 USA. [Spira, Avrum E.] Boston Univ, Bioinformat Program, Boston, MA 02215 USA. [Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Dubinett, Steven M.] VA Greater Los Angeles Hlth Care Ctr, Los Angeles, CA USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 10833 Le Conte Ave,37-131 CHS, Los Angeles, CA 90095 USA. EM SDubinett@mednet.ucla.edu FU National Institutes of Health [1U01CA196408-01] FX Supported by the National Institutes of Health 1U01CA196408-01. NR 17 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2218-676X EI 2219-6803 J9 TRANSL CANCER RES JI Transl. Cancer Res. PD DEC PY 2016 VL 5 SU 7 BP S1315 EP S1319 DI 10.21037/tcr.2016.12.24 PG 5 WC Oncology SC Oncology GA EJ6KY UT WOS:000393329400003 ER PT J AU Holmes, SE Esterlis, I Mazure, CM Lim, YY Ames, D Rainey-Smith, S Martins, RN Salvado, O Dore, V Villemagne, VL Rowe, CC Laws, SM Masters, CL Maruff, P Pietrzak, RH AF Holmes, Sophie E. Esterlis, Irina Mazure, Carolyn M. Lim, Yen Ying Ames, David Rainey-Smith, Stephanie Martins, Ralph N. Salvado, Olivier Dore, Vincent Villemagne, Victor L. Rowe, Christopher C. Laws, Simon M. Masters, Colin L. Maruff, Paul Pietrzak, Robert H. CA Australian Imaging Biomarkers TI beta-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE amyloid; APOE; BDNF; depression; anxiety; elderly ID ALZHEIMERS-DISEASE; ALLELE AB Objective: To examine how beta-amyloid (A beta), APOE and BDNF genotypes, and cortisol relate to depressive and anxiety symptoms in cognitively normal older women and men. Methods: Cross-sectional data were analyzed from 423 older adults from the Australian Imaging Biomarkers and Lifestyle study. Analyses of covariance evaluated associations between A beta, APOE and BDNF genotype, and cortisol in relation to severity of depressive and anxiety symptoms. Results: Among-A beta+ older adults, APOE epsilon 4 carriage was associated with greater severity of anxiety symptoms (d = 0.55); and in the full sample, APOE epsilon 4 carriagewas linked togreater severity of depressive (d = 0.26) and anxiety (d = 0.21) symptoms. Among A beta+ women, epsilon 4 carriers reported greater anxiety symptoms than non-epsilon 4 carriers (d = 0.83), and female BDNF rs6265 Val66 Met allele carriers reported greater depressive symptoms (d = 0.29). Conclusion: Sex moderated the relationship between A beta, APOE genotype, and BDNF genotype in predicting severity of anxiety and depressive symptoms in cognitively normal older adults. C1 [Holmes, Sophie E.; Esterlis, Irina; Mazure, Carolyn M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Lim, Yen Ying; Villemagne, Victor L.; Masters, Colin L.; Maruff, Paul] Univ Melbourne, Florey Inst, Parkville, Vic, Australia. [Ames, David] Univ Melbourne, Dept Psychiat, St Vincents Hlth, Acad Unit Psychiat Old Age, Kew, Vic, Australia. [Ames, David] Natl Ageing Res Inst, Parkville, Vic, Australia. [Rainey-Smith, Stephanie; Martins, Ralph N.; Laws, Simon M.] Edith Cowan Univ, Sch Med & Hlth Sci, Ctr Excellence Alzheimers Dis Res & Care, Joondalup, WA, Australia. [Martins, Ralph N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Perth, WA, Australia. [Salvado, Olivier; Dore, Vincent] Commonwealth Sci & Ind Res Org, Canberra, ACT, Australia. [Dore, Vincent; Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia. [Dore, Vincent; Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia. [Laws, Simon M.] Curtin Univ, Curtin Hlth Innovat Res Inst, Fac Hlth Sci, Sch Biomed Sci, Perth, WA, Australia. [Maruff, Paul] Cogstate Ltd, Melbourne, Vic, Australia. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA. RP Holmes, SE (reprint author), Yale Translat Brain Imaging Program, 2 Church St South,Suite 511, New Haven, CT 06511 USA. EM sophie.holmes@yale.edu FU Commonwealth Scientific Industrial and research Organization; Edith Cowan University; Mental Health Research Institute; National Ageing Research Institute; Austin Health; CogState Ltd.; National Health and Medical Research Council Australia [APP1009292]; Science and Industry Endowment Fund; Cooperative Research Centre for Mental Health, an Australian Government Initiative; National Institutes of Health [5R01MH104459, 1K01MH092681]; U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder FX Funding for the study was provided in part by the study partners (Commonwealth Scientific Industrial and research Organization, Edith Cowan University, Mental Health Research Institute, National Ageing Research Institute, Austin Health, and CogState Ltd.). The study received support from the National Health and Medical Research Council Australia via a project grant (APP1009292) awarded to S.M.L. and R.N.M., the Science and Industry Endowment Fund, and the Cooperative Research Centre for Mental Health, an Australian Government Initiative. Drs. Holmes and Esterlis are supported by National Institutes of Health grants 5R01MH104459 and 1K01MH092681. Dr. Pietrzak is supported in part by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. NR 11 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2016 VL 24 IS 12 BP 1191 EP 1195 DI 10.1016/j.jagp.2016.08.007 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EI8AU UT WOS:000392727300010 PM 27742526 ER PT J AU Naples, JG Kotlarczyk, MP Perera, S Greenspan, SL Hanlon, JT AF Naples, Jennifer G. Kotlarczyk, Mary P. Perera, Subashan Greenspan, Susan L. Hanlon, Joseph T. TI Non-tricyclic and Non-selective Serotonin Reuptake Inhibitor Antidepressants and Recurrent Falls in Frail Older Women SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE antidepressants; older adults; recurrent falls; long-term care; frailty ID NURSING-HOME RESIDENTS; PRIMARY-CARE DATABASE; LONG-TERM-CARE; ELDERLY PATIENTS; RISK; DEPRESSION; PEOPLE; ADULTS; DRUGS; SAFETY AB Objective: To determine the risk of recurrent falls associated with antidepressants other than tricyclics (TCAs) and selective serotonin reuptake inhibitors (SSRIs) among frail older women. Methods: This is a secondary analysis of the Zoledronic acid in frail Elders to STrengthen bone, or ZEST, trial data treated as a longitudinal cohort in 181 frail, osteoporotic women aged >= 65 years in long-term care. The primary exposure was individual non-TCA/non-SSRI antidepressants (i.e., serotonin norepinephrine reuptake inhibitors, mirtazapine, trazodone, and bupropion) at baseline and 6 months. The main outcome was recurrent (at least two) falls within 6 months after antidepressant exposure. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were derived using a generalized estimating equations model. Results: At least 15% of women experienced recurrent falls between 0-6 and 6-12 months. At baseline and 6 months, 18.2% and 6.9% had a non-TCA/non-SSRI antidepressant, respectively. Adjusting for demographics, health status, and other drugs that increase risk of falls, non-TCA/non-SSRI antidepressant exposure significantly increased the risk of recurrent falls (AOR: 2.14; 95% CI: 1.01-4.54). Fall risk further increased after removing bupropion from the non-TCA/non-SSRI antidepressant group in sensitivity analyses (AOR: 2.73; 95% CI: 1.24-6.01). Conclusions: Other antidepressant classes may not be safer than TCAs/SSRIs with respect to recurrent falls in frail older women. C1 [Naples, Jennifer G.; Kotlarczyk, Mary P.; Perera, Subashan; Greenspan, Susan L.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Perera, Subashan] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Hanlon, JT (reprint author), Dept Med, Div Geriatr, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU National Institutes on Aging [R01-AG028086, R01-AG05123, T32-AG021885, P30-AG02482706]; Donoghue Foundation; Agency for Health Research and Quality [R18-HS023779]; Lilly; Amgen FX Supported in part by grants from the National Institutes on Aging (R01-AG028086, R01-AG05123, T32-AG021885, and P30-AG02482706), the Donoghue Foundation, and Agency for Health Research and Quality (R18-HS023779). The University of Pittsburgh receives grant funding from Lilly and Amgen for research. Dr. Greenspan is on an advisory board for Merck. For the remaining authors, no conflicts of interest were declared. NR 36 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2016 VL 24 IS 12 BP 1221 EP 1227 DI 10.1016/j.jagp.2016.08.008 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EI8AU UT WOS:000392727300015 PM 27743842 ER PT J AU Musuuza, JS Safdar, N AF Musuuza, Jackson S. Safdar, Nasia TI Every other day bathing with chlorhexidine gluconate: what is the evidence? SO ANNALS OF TRANSLATIONAL MEDICINE LA English DT Editorial Material ID CARE-ASSOCIATED INFECTIONS; ACQUIRED INFECTION; RANDOMIZED-TRIALS; PREVENTION; INTERVENTIONS; METAANALYSIS; STATEMENT; QUALITY; IMPACT; COSTS C1 [Musuuza, Jackson S.; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Musuuza, Jackson S.; Safdar, Nasia] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Infect Dis, Madison, WI USA. EM ns2@medicine.wisc.edu FU Agency for Healthcare Research and Quality [R18HS024039]; VA FX This work was supported by grant number R18HS024039 from the Agency for Healthcare Research and Quality. Nasia Safdar is also supported by a VA-funded Patient Safety Center of Inquiry. NR 26 TC 0 Z9 0 U1 1 U2 1 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2305-5839 EI 2305-5847 J9 ANN TRANSL MED JI ANN. TRANSL. MED. PD DEC PY 2016 VL 4 IS 24 AR 506 DI 10.21037/atm.2016.11.83 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EI7DE UT WOS:000392656900028 PM 28149868 ER PT J AU Soble, JR Sordahl, JA Critchfield, EA Highsmith, JM Gonzalez, DA Ashish, D Marceaux, JC O'Rourke, JJF McCoy, KJM AF Soble, Jason R. Sordahl, Jeffrey A. Critchfield, Edan A. Highsmith, Jonathan M. Gonzalez, David Andres Ashish, Dev Marceaux, Janice C. O'Rourke, Justin J. F. McCoy, Karin J. M. TI Slow and Steady Does Not Always Win the Race: Investigating the Effect of Processing Speed across Five Naming Tests SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Language and language disorders; Assessment; Intelligence ID FALSE DISCOVERY RATE; PERFORMANCE; ABILITY AB Objective: This retrospective study investigated the effect of processing speed on confrontation naming performance via five naming tests with varying time components. Method: The effect of processing speed, as measured by the Wechsler Adult Intelligence Scale-Fourth Edition Processing Speed Index (PSI), and cognitive impairment were examined using Boston Naming Test, Neuropsychological Assessment Battery Naming Test, Visual Naming Test (VNT), Auditory Naming Test (ANT), and Woodcock-Johnson III Rapid Picture Naming (RPN) performance among a mixed clinical sample of 115 outpatient veterans. Results: PSI scores accounted for 5%-26% of the total variance in naming test performances. Comparison of cognitively impaired versus unimpaired participants found significant differences and medium to large effect sizes (eta(2) = .08-.20) for all naming measures except ANT tip-of-the-tongue responses. After controlling for the effect processing speed, VNT tip-of-the-tongue responses also became non-significant, whereas significant group differences remained present for all other naming test scores, albeit with notably smaller effects sizes (eta(2) = .06-.10). Conclusions: Confrontation naming test performance is related to cognitive processing speed, although the magnitude of this effect varies by the demands of each naming test (i.e., largest for RPN; smallest for VNT). Thus, results argue that processing speed is important to consider for accurate clinical interpretation of naming tests, especially in the context of cognitive impairment. C1 [Soble, Jason R.; Critchfield, Edan A.; Highsmith, Jonathan M.; Gonzalez, David Andres; Ashish, Dev; Marceaux, Janice C.; O'Rourke, Justin J. F.; McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Sordahl, Jeffrey A.] Boise VA Med Ctr, Neuropsychol Clin, Boise, ID USA. RP Soble, JR (reprint author), South Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter, San Antonio, TX 78229 USA. EM Jason.Soble@va.gov NR 26 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD DEC PY 2016 VL 31 IS 8 BP 976 EP 982 DI 10.1093/arclin/acw073 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA EJ1MM UT WOS:000392974600014 ER PT J AU Bowles, DW Kochenderfer, M Cohn, A Sideris, L Nguyen, N Cline-Burkhardt, V Schnadig, I Choi, M Nabell, L Chaudhry, A Ruxer, R Ucar, A Hausman, D Walker, L Spira, A Jimeno, A AF Bowles, Daniel W. Kochenderfer, Mark Cohn, Allen Sideris, Lucas Nguyen, Nghia Cline-Burkhardt, Vivian Schnadig, Ian Choi, Minsig Nabell, Lisle Chaudhry, Arvind Ruxer, Robert Ucar, Antonio Hausman, Diana Walker, Luke Spira, Alexander Jimeno, Antonio TI A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma SO Clinical Colorectal Cancer LA English DT Article DE Combination therapy; EGFR; KRAS; PI3K; PIK3CA ID ADVANCED SOLID TUMORS; CELL LUNG-CANCER; OPEN-LABEL; MULTICENTER PHASE-1; PLUS IRINOTECAN; PI3K INHIBITORS; PIK3CA; MUTATIONS; PANITUMUMAB; RESISTANCE AB The phosphotidyinositol-3 kinase (PI3K) pathway in frequently activated on metastatic colorectal carcinoma (CRC). We combined a novel PI3K inhibitor, PX-866, with cetuximab for patients with KRAS codon 12 wide type metastatic CRC. Patients receiving PX-866 plus cetuximab did not improvement in response rate, progression-free survival, or overall survival compared to cetuximab alone. Toxicity, especially gastrointestinal, was higher in the combination arm. Background: The phosphotidylinositol-3 kinase (PI3K)/serine-threonine kinase/mammalian target of rapamycin signaling pathway is frequently altered in colorectal cancer (CRC). PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K. This randomized phase II study evaluated cetuximab with or without PX-866 in patients with metastatic, antiepidermal growth factor receptor-naive, KRAS codon 12 and 13 wild-type CRC. Patients and Methods: Patients with metastatic CRC who had received both oxaliplatin and irinotecan were randomized (1: 1) to cetuximab (400 mg/m(2) loading then 250 mg/m(2) weekly) with or without PX-866 (8 mg orally daily; arms A and B, respectively). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate, overall survival (OS), toxicity, and correlation of relevant biomarkers with efficacy outcomes. Results: A total of 85 patients were enrolled. The median PFS was 59 days versus 104 days for arms A (cetuximab + PX-866) and B (cetuximab alone), respectively (P = 77). OS between the 2 arms (266 vs. 333 days for arm A vs. B) were similar (P = 83). Overall toxicity, including treatment-related toxicity, was higher in arm A compared with arm B, especially in terms of all-grade nausea (66% vs. 37%), vomiting (50% vs. 29%), diarrhea (64% vs. 18%), and rash (66% vs. 37%). Grade 3 diarrhea occurred in 19% of patients in Arm A and 0% in Arm B. PIK3CA mutations and PTEN loss by immunohistochemistry were infrequently seen. Conclusion: The addition of PX-866 to cetuximab did not improve PFS, objective response rate, or OS in patients with metastatic CRC. The combination arm had greater toxicity and may have been harmful in this study. C1 [Bowles, Daniel W.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Bowles, Daniel W.; Jimeno, Antonio] Univ Colorado, Div Med Oncol, Sch Med, Aurora, CO USA. [Kochenderfer, Mark] Oncol & Hematol Associates SW Virginia, Roanoke, VA USA. [Cohn, Allen] Rocky Mt Canc Ctr, Denver, CO USA. [Sideris, Lucas] Maisonneuve Rosemont Hosp, Montreal, PQ, Canada. [Nguyen, Nghia] Champlin Charles LeMoyne, Ctr Sante & Serv Soc, Longueuil, PQ, Canada. [Cline-Burkhardt, Vivian] Texas Oncol, Austin, TX USA. [Schnadig, Ian] Northwest Canc Specialists, Vancouver, WA USA. [Choi, Minsig] Karmanos Canc Inst, Detroit, MI USA. [Nabell, Lisle] Univ Alabama Birmingham, Birmingham, AL USA. [Chaudhry, Arvind] Med Oncol Associates, Spokane, WA USA. [Ruxer, Robert] Texas Oncol Ft Worth, Ft Worth, TX USA. [Ucar, Antonio] Adv Med Specialties, Miami, FL USA. [Hausman, Diana; Walker, Luke] Oncothryeron Inc, Seattle, WA USA. [Spira, Alexander] Virginia Canc Specialists, Fairfax, VA USA. RP Bowles, DW (reprint author), Univ Colorado, Sch Med, Div Med Oncol, Med, 12801 East 17th Ave,MS8117, Aurora, CO 80045 USA. EM daniel.bowles@ucdenver.edu FU Oncothyreon Inc. FX This clinical trial was sponsored by Oncothyreon Inc. No funding was received from the National Institutes of Health, Wellcome Trust, or Howard Hughes Medical Institute. NR 40 TC 0 Z9 0 U1 0 U2 0 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1533-0028 EI 1938-0674 J9 CLIN COLORECTAL CANC JI Clin. Colorectal Canc. PD DEC PY 2016 VL 15 IS 4 BP 337 EP + DI 10.1016/j.dcc.2016.03.004 PG 10 WC Oncology SC Oncology GA EI7VQ UT WOS:000392712600021 PM 27118441 ER PT J AU Zullig, LL Smith, VA Jackson, GL Danus, S Schnell, M Lindquist, J Provenzale, D Weinberger, M Kelley, MJ Bosworth, HB AF Zullig, Leah L. Smith, Valerie A. Jackson, George L. Danus, Susanne Schnell, Merritt Lindquist, Jennifer Provenzale, Dawn Weinberger, Morris Kelley, Michael J. Bosworth, Hayden B. TI Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry SO Clinical Colorectal Cancer LA English DT Article DE Colorectal; Incidence; Mortality; Neoplasms; US Department of Veterans Affairs ID HEALTH-CARE-SYSTEM; REPORTING DELAY; PREVALENCE; QUALITY; IMPACT; VA AB We describe the patient and tumor characteristics of those with colorectal cancer (CRC) among Veterans Affairs (VA) healthcare system users. This is important because CRC is common and the VA data have not been uniformly included in national cancer reports. Using the VA Central Cancer Registry, we identified VA CRC cases and compared them with those in national data sources. We concluded that the incidence of CRC among VA users is similar to that in the U.S. CRC population. Background: Colorectal cancer (CRC) is a common and potentially deadly disease. Although the United States has robust cancer data reporting, information from the Department of Veterans Affairs (VA) healthcare system has often been underrepresented in national cancer data sources. We describe veterans with incident CRC in terms of their patient and tumor characteristics and mortality. Patients and Methods: Patients diagnosed or treated with CRC at any VA institution in the fiscal years 2009 to 2012 were identified using 3 data sources: (1) VA Central Cancer Registry (VACCR); (2) VA Corporate Data Warehouse; and (3) VA Reports and Measures Portal. The CRC frequencies within the VA population and survival curves were examined descriptively and compared with the national projections using Surveillance, Epidemiology, and End Results program data. Results: A total of 12,551 veterans with CRC were included in the present analysis. The median age at diagnosis was 65.5 years. Approximately 97% (n = 12,229) of the CRC cases were diagnosed among men. Approximately 44% (n = 5517) of the patients were diagnosed with localized disease. The 3-year survival rate was associated with age (P < .01) and stage (P < .01) at diagnosis. We identified a possible decrease in VA CRC incidence over time. Conclusion: Although the VA CRC patient population was heavily skewed toward the male gender, the patient and tumor characteristics were similar between the incident CRC cases reported by the VACCR and those reported to the Surveillance, Epidemiology, and End Results program. This suggests that research findings resulting from the VACCR might have applicability beyond the VA healthcare system setting. C1 [Zullig, Leah L.; Smith, Valerie A.; Jackson, George L.; Danus, Susanne; Schnell, Merritt; Lindquist, Jennifer; Provenzale, Dawn; Weinberger, Morris; Bosworth, Hayden B.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St 152, Durham, NC 27705 USA. [Zullig, Leah L.; Smith, Valerie A.; Jackson, George L.; Bosworth, Hayden B.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA. [Provenzale, Dawn] Epidemiol Ctr, Cooperat Studies Program, Durham, NC USA. [Provenzale, Dawn] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA. [Kelley, Michael J.] US Dept Vet Affairs, Off Patient Care Serv, Washington, DC USA. [Kelley, Michael J.] Durham Vet Affairs Med Ctr, Hematol Oncol Serv, Durham, NC USA. [Kelley, Michael J.] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Sch Nursing, Dept Psychiat & Behav Sci, Durham, NC USA. RP Zullig, LL (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St 152, Durham, NC 27705 USA. EM leah.zullig@va.gov FU Veterans Affairs Health Services Research and Development Career Development Award [CDA 13025]; Senior Research Career Scientist awards from Veterans Affairs Health Services Research and Development [RCS 08-027, RCS 91-408] FX Dr. Zullig is supported by a Veterans Affairs Health Services Research and Development Career Development Award (CDA 13025). Drs. Bosworth (RCS 08-027) and Weinberger (RCS 91-408) are supported by Senior Research Career Scientist awards from Veterans Affairs Health Services Research and Development. The views expressed in this article are those of the authors and do not necessarily represent the position or policy of the U.S. Department of Veterans Affairs of the United States Government. We thank the Veterans Affairs cancer registrars for their data collection and related efforts. NR 27 TC 2 Z9 2 U1 1 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1533-0028 EI 1938-0674 J9 CLIN COLORECTAL CANC JI Clin. Colorectal Canc. PD DEC PY 2016 VL 15 IS 4 BP E199 EP E204 DI 10.1016/j.clcc.2016.04.005 PG 6 WC Oncology SC Oncology GA EI7VQ UT WOS:000392712600008 PM 27301717 ER PT J AU Salinas, JL Rentsch, C Marconi, VC Tate, J Budoff, M Butt, AA Freiberg, MS Gibert, CL Goetz, MB Leaf, D Rodriguez-Barradas, MC Justice, AC Rimland, D AF Salinas, Jorge L. Rentsch, Christopher Marconi, Vincent C. Tate, Janet Budoff, Matthew Butt, Adeel A. Freiberg, Matthew S. Gibert, Cynthia L. Goetz, Matthew Bidwell Leaf, David Rodriguez-Barradas, Maria C. Justice, Amy C. Rimland, David TI Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE acute myocardial infarction; HIV; mortality; VACS Index ID VETERANS AGING COHORT; COMBINATION ANTIRETROVIRAL THERAPY; CARDIOVASCULAR-DISEASE; INFECTED PATIENTS; RISK-FACTORS; INDEX; IMMUNODEFICIENCY; HOSPITALIZATION; INDIVIDUALS; VIREMIA AB Background. After adjustment for cardiovascular risk factors and despite higher mortality, those with human immunodeficiency virus (HIV+) have a greater risk of acute myocardial infarction (AMI) than uninfected individuals. Methods. We included HIV+ individuals who started combination antiretroviral therapy (cART) in the Veterans Aging Cohort Study (VACS) from 1996 to 2012. We fit multivariable proportional hazards models for baseline, time-updated and cumulative measures of HIV-1 RNA, CD4 counts, and the VACS Index. We used the trapezoidal rule to build the following cumulative measures: viremia copy-years, CD4-years, and VACS Index score-years, captured 180 days after cART initiation until AMI, death, last clinic visit, or 30 September 2012. The primary outcomes were incident AMI (Medicaid, Medicare, and Veterans Affairs International Classification of Diseases-9 codes) and death. Results. A total of 8168 HIV+ individuals (53 861 person-years) were analyzed with 196 incident AMIs and 1710 deaths. Controlling for known cardiovascular risk factors, 6 of the 9 metrics predicted AMI and all metrics predicted mortality. Time-updated VACS Index had the lowest Akaike information criterion among all models for both outcomes. A time-updated VACS Index score of 55+ was associated with a hazard ratio (HR) of 3.31 (95% confidence interval [CI], 2.11-5.20) for AMI and a HR of 31.77 (95% CI, 26.17-38.57) for mortality. Conclusions. Time-updated VACS Index provided better AMI and mortality prediction than CD4 count and HIV-1 RNA, suggesting that current health determines risk more accurately than prior history and that risk assessment can be improved by biomarkers of organ injury. C1 [Salinas, Jorge L.; Marconi, Vincent C.; Rimland, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Salinas, Jorge L.; Marconi, Vincent C.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Rentsch, Christopher; Marconi, Vincent C.; Rimland, David] Atlanta Vet Affairs Med Ctr, Decatur, GA USA. [Rentsch, Christopher; Tate, Janet; Justice, Amy C.] West Haven Vet Adm, Med Ctr, New Haven, CT USA. [Rentsch, Christopher; Tate, Janet; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Rentsch, Christopher; Tate, Janet; Justice, Amy C.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Budoff, Matthew; Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Budoff, Matthew; Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Butt, Adeel A.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Butt, Adeel A.] Weill Cornell Med Coll, Doha, Qatar. [Butt, Adeel A.] Weill Cornell Med Coll, New York, NY USA. [Butt, Adeel A.] Hamad Med Corp, Hamad Healthcare Qual Inst, Doha, Qatar. [Freiberg, Matthew S.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. [Gibert, Cynthia L.] Wasington DC VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med, Washington, DC USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Justice, AC (reprint author), Yale Univ, Sch Med, VA Connecticut Healthcare Syst, 950 Campbell Ave,Bldg 35a Rm 2-212 11 ACSLG, West Haven, CT 06516 USA. EM amy.justice2@va.gov RI Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689 FU Agency for Healthcare Research and Quality [R01-HS018372]; National Institute on Alcohol Abuse and Alcoholism [U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U24-AA022001, U24 AA022007, U10 AA013566]; National Heart, Lung, and Blood Institute [R01HL095136, R01-HL090342]; National Institute of Allergy and Infectious Diseases [U01-A1069918]; Fogarty International Center [R25TW009337]; National Institute of Mental Health [P30-MH062294]; National Institute on Drug Abuse [R01DA035616]; National Cancer Institute [R01 CA173754]; Veterans Health Administration Office of Research and Development [VA REA 08-266]; Veterans Health Administration Office of Research and Development (VA IRR Merit Award); Office of Academic Affiliations (Medical Informatics Fellowship) FX This work was supported by the following: Agency for Healthcare Research and Quality (R01-HS018372); National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U24-AA022001, U24 AA022007, U10 AA013566 completed); National Heart, Lung, and Blood Institute (R01HL095136, R01-HL090342); National Institute of Allergy and Infectious Diseases (U01-A1069918); Fogarty International Center (R25TW009337); National Institute of Mental Health (P30-MH062294); National Institute on Drug Abuse (R01DA035616); National Cancer Institute (R01 CA173754), Veterans Health Administration Office of Research and Development (VA REA 08-266, VA IRR Merit Award), and Office of Academic Affiliations (Medical Informatics Fellowship). NR 32 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2016 VL 63 IS 11 BP 1423 EP 1430 DI 10.1093/cid/ciw564 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EI7WA UT WOS:000392713900005 PM 27539575 ER PT J AU Werling, D Reglodi, D Banks, WA Salameh, TS Kovacs, K Kvarik, T Vaczy, A Kovacs, L Mayer, F Danyadi, B Lokos, E Tamas, A Toth, G Biro, Z Atlasz, T AF Werling, Dora Reglodi, Dora Banks, William A. Salameh, Therese S. Kovacs, Krisztina Kvarik, Timea Vaczy, Alexandra Kovacs, Laszlo Mayer, Flora Danyadi, Bese Lokos, Emese Tamas, Andrea Toth, Gabor Biro, Zsolt Atlasz, Tamas TI Ocular Delivery of PACAP1-27 Protects the Retina From Ischemic Damage in Rodents SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE eye drops; ischemia; retina; neuropeptide ID CYCLASE-ACTIVATING POLYPEPTIDE; DIABETIC-RETINOPATHY; SIGNALING PATHWAYS; DEGENERATION; LESION; BRAIN; RATS; INVOLVEMENT; SECRETION; APOPTOSIS AB PURPOSE. Pituitary adenylate cyclase activating polypeptide (PACAP) is neuroprotective in neuronal injuries. Bilateral common carotid artery occlusion (BCCAO) causes chronic hypoperfusion-induced degeneration in the rat retina, where we proved the retinoprotective effect of intravitreal PACAP. Although this route of administration is a common clinical practice in several diseases, easier routes are clinically important. Our aim was to investigate the potential retinoprotective effects of PACAP eye drops in BCCAO-induced ischemic retinopathy. METHODS. After performing BCCAO in rats, the right eyes were treated with PACAP1-27 eye drops (1 mu g/drop, 2 3 1 drops/day for 5 days), containing different vehicles: saline, water for injections, thiomersal or benzalkonium solution for ophthalmic use (SOCB). Histology and immunohistochemistry were performed 2 weeks after surgery, while molecular analysis was performed 24 hours after BCCAO. Passage of PACAP1-27 through the ocular layers was tested with radioactive PACAP-SOCB in mice. RESULTS. Bilateral common carotid artery occlusion led to a severe degeneration of all retinal layers. Solution for ophthalmic use was the most effective vehicle for delivering PACAP (PACAP-SOCB), significantly ameliorating BCCAO-induced damage. The massive upregulation of GFAP was not observed in retinas treated with PACAP-SOCB eye drops. PACAP-SOCB treatment also increased activation of the protective Akt and ERK1/2 in hypoperfused retinas. The cytokine profile showing upregulation in different cytokines was attenuated by PACAP-SOCB. Radioactive PACAP reached the retina when delivered in SOCB-containing eye drops. CONCLUSIONS. PACAP1-27, delivered in the SOCB vehicle as eye drops, was retinoprotective in ischemic retinopathy, providing the basis for future therapeutic administration. C1 [Werling, Dora; Reglodi, Dora; Kvarik, Timea; Vaczy, Alexandra; Kovacs, Laszlo; Mayer, Flora; Danyadi, Bese; Lokos, Emese; Tamas, Andrea; Atlasz, Tamas] Univ Pecs, Dept Anat, Pecs, Hungary. [Werling, Dora; Biro, Zsolt] Univ Pecs, Dept Ophthalmol, Pecs, Hungary. [Banks, William A.; Salameh, Therese S.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.; Salameh, Therese S.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kovacs, Krisztina] Univ Pecs, Dept Biochem & Med Chem, Pecs, Hungary. [Toth, Gabor] Univ Szeged, Dept Med Chem, Szeged, Hungary. [Atlasz, Tamas] Univ Pecs, Dept Sportbiol, Pecs, Hungary. [Atlasz, Tamas] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary. RP Atlasz, T (reprint author), Univ Pecs, Fac Sci, Dept Sportbiol, Ifjusag St 6, H-7624 Pecs, Hungary. EM attam@gamma.ttk.pte.hu FU National Scientific Research Fund (OTKA, Budapest, Hungary) [K104984, K119759]; Arimura Foundation (New Orleans, LA, USA); Bolyai Scholarship of the Hungarian Academy of Sciences (Budapest, Hungary); PTE AOK KA Research Grant (Pecs, Hungary); National Brain Research Programme (Budapest, Hungary) [KTIA_13_NAP-A-III/5]; Centre for Neuroscience (Pecs, Hungary); New National Excellence Program of the Ministry of Human Capacites (Budapest, Hungary) [UNKP-16-3-IV, UNKP-16-4-III] FX Supported by grants from the National Scientific Research Fund (OTKA K104984, K119759; Budapest, Hungary), Arimura Foundation (New Orleans, LA, USA), Bolyai Scholarship of the Hungarian Academy of Sciences (Budapest, Hungary), PTE AOK KA Research Grant (Pecs, Hungary), National Brain Research Programme (KTIA_13_NAP-A-III/5; Budapest, Hungary), Centre for Neuroscience (Pecs, Hungary), and The UNKP-16-3-IV, UNKP-16-4-III New National Excellence Program of the Ministry of Human Capacites (Budapest, Hungary). NR 51 TC 0 Z9 0 U1 2 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD DEC PY 2016 VL 57 IS 15 BP 6683 EP 6691 DI 10.1167/iovs.16-20630 PG 9 WC Ophthalmology SC Ophthalmology GA EJ0VR UT WOS:000392929500024 PM 27936470 ER PT J AU Dean, SM Gilmore-Bykovskyi, A Buchanan, J Ehlenfeldt, B Kind, AJH AF Dean, Shannon M. Gilmore-Bykovskyi, Andrea Buchanan, Joel Ehlenfeldt, Brad Kind, Amy J. H. TI Design and Hospitalwide Implementation of a Standardized Discharge Summary in an Electronic Health Record SO Joint Commission Journal on Quality and Patient Safety LA English DT Article ID PATIENT OUTCOMES; CARE; PHYSICIANS; QUALITY; COMMUNICATION; MEDICINE; TRANSITIONS; TIMELINESS; CONTINUITY; PROVIDERS AB Background: The hospital discharge summary is the primary method used to communicate a patient's plan of care to the next provider(s). Despite the existence of regulations and guidelines outlining the optimal content for the discharge summary and its importance in facilitating an effective transition to posthospital care, incomplete discharge summaries remain a common problem that may contribute to poor posthospital outcomes. Electronic health records (EHRs) are regularly used as a platform on which standardization of content and format can be implemented. The feasibility of designing and implementing a standardized discharge summary hospitalwide using an EHR was examined-to the -authors' knowledge, for the first time. Methods: This large-scale project at the University of Wisconsin Hospital and Clinics was led by a task force that had been assembled to develop best practices for EHR notes. The evidence-based Replicating Effective Programs (REP) model was employed to guide the development and implementation during the project. REP outlines four stages in clinical health service intervention implementation: preconditions, preimplementation, implementation, and maintenance. Results: At 18 months postimplementation, 90% of all hospital discharge summaries were written using the standardized format. Hospital providers found the template helpful and easy to use, and recipient providers perceived an improvement in the quality of discharge summaries compared to those previously sent from the hospital. Conclusion: Discharge summaries can be standardized and implemented hospitalwide with both author and recipient provider satisfaction, particularly if evidence-based implementation strategies are employed. The use of EHR tools to guide clinicians in writing comprehensive discharge summaries holds promise in improving the existing deficits in communication at transitions of care. C1 [Dean, Shannon M.] Univ Wisconsin, Pediat, Div Hosp Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Dean, Shannon M.; Ehlenfeldt, Brad] UW Hlth, Madison, WI 53705 USA. [Gilmore-Bykovskyi, Andrea] William S Middleton Mem Vet Affairs Hosp, Madison, WI USA. [Gilmore-Bykovskyi, Andrea] Univ Wisconsin Madison, Sch Nursing, Madison, WI USA. [Buchanan, Joel] Univ Wisconsin, Med, Div Gen Internal Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Buchanan, Joel] Univ Wisconsin, Sch Med & Publ Hlth, Informat Technol Serv Strateg Projects, Madison, WI 53706 USA. [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Med, Div Geriatr, Madison, WI 53706 USA. [Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Dean, SM (reprint author), Univ Wisconsin, Pediat, Div Hosp Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.; Dean, SM (reprint author), UW Hlth, Madison, WI 53705 USA. EM SDean@uwhealth.org FU NCRR NIH HHS [UL1 RR025011]; NIA NIH HHS [K23 AG034551] NR 28 TC 0 Z9 0 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1553-7250 EI 1938-131X J9 JT COMM J QUAL PATIE JI Jt. Comm. J. Qual. Patient Saf. PD DEC PY 2016 VL 42 IS 12 BP 555 EP + PG 18 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EJ1NX UT WOS:000392978600005 PM 28334559 ER PT J AU Cohen, JR Danielson, CK Adams, ZW Ruggiero, KJ AF Cohen, Joseph R. Danielson, Carla Kmett Adams, Zachary W. Ruggiero, Kenneth J. TI Distress Tolerance and Social Support in Adolescence: Predicting Risk for Internalizing and Externalizing Symptoms Following a Natural Disaster SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Distress tolerance; Perceived social support; Natural disasters; Adolescence; Internalizing symptoms; Externalizing symptoms ID POSTTRAUMATIC-STRESS; REFUGEE ADOLESCENTS; HURRICANE-ANDREW; DEPRESSION; BEHAVIOR; TRAUMA; GENDER; ADULTS; PTSD; LIFE AB The purpose of the multi-measure, multi-wave, longitudinal study was to examine the interactive relation between behavioral distress tolerance (DT) and perceived social support (PSS) in 352 tornado-exposed adolescents aged 12-17 years (M = 14.44; SD = 1.74). At baseline, adolescents completed a computer-based task for DT, and self-report measures of PSS, depressed mood, posttraumatic stress disorder (PTSD), substance use, and interpersonal conflict. Symptoms also were assessed 4 and 12 months after baseline. Findings showed that lower levels of DT together with lower levels of PSS conferred risk for elevated symptoms of prospective depression (t(262) = -2.04, p = .04; r(effect size) = 0.13) and PTSD (t(195) = -2.08, p = .04; r(effect size) = 0.15) following a tornado. However, only PSS was significant in substance use t(139) = 2.20, p = .03; r(effect size=)0.18) and conflict (t(138) = -4.05, p < .0001; r(effect size=)0.33) in our sample. Implications regarding adolescent DT, the transdiagnostic nature of PSS, and the clinical applications of our findings in the aftermath of a natural disaster are discussed. C1 [Cohen, Joseph R.] Univ Illinois, Dept Psychol, Champaign, IL 61801 USA. [Danielson, Carla Kmett; Adams, Zachary W.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC 861,2nd Fl IOP South Bldg, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Med Univ South Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, 67 President St,MSC 861,2nd Fl IOP South Bldg, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VAMC, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. EM cohenj@illinois.edu FU National Institute of Mental Health [R01MH081056, R21MH086313]; [R01DA031285]; [K12-DA031794]; [T32MH18869] FX The National Institute of Mental Health supported this study and the team of collaborators: data collection occurred via grants R01MH081056 to KJR and R21MH086313 to CKD. The preparation of this manuscript was partially supported by grant R01DA031285 to CKD, grant K12-DA031794 which supports ZWA, and T32MH18869 which supported JRC. NR 60 TC 0 Z9 0 U1 6 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 EI 1573-3505 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD DEC PY 2016 VL 38 IS 4 BP 538 EP 546 DI 10.1007/s10862-016-9545-y PG 9 WC Psychology, Clinical SC Psychology GA EI5ET UT WOS:000392517600003 PM 28163364 ER PT J AU Wong, ML McMurry, TL Stukenborg, GJ Francescatti, AB Amato-Martz, C Schumacher, JR Chang, GJ Greenberg, CC Winchester, DP McKellar, DP Walter, LC Kozower, BD AF Wong, Melisa L. McMurry, Timothy L. Stukenborg, George J. Francescatti, Amanda B. Amato-Martz, Carla Schumacher, Jessica R. Chang, George J. Greenberg, Caprice C. Winchester, David P. McKellar, Daniel P. Walter, Louise C. Kozower, Benjamin D. TI Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study SO LUNG CANCER LA English DT Article DE Non-small cell lung cancer; Recurrence; Treatment; Geriatric oncology ID SUBSTANCE-ABUSE ISSUES; OLDER PATIENTS; EARLY-STAGE; PATIENT PREFERENCE; ELDERLY-PATIENTS; SEX-DIFFERENCES; UNITED-STATES; CHEMOTHERAPY; SURVIVAL; CARE AB Objective: Older patients with non-small cell lung cancer (NSCLC) are less likely to receive guideline recommended treatment at diagnosis, independent of comorbidity. However, national data on treatment of postoperative recurrence are limited. We evaluated the associations between age, comorbidity, and other patient factors and treatment of postoperative NSCLC recurrence in a national cohort. Materials and methods: We randomly selected 9001 patients with surgically resected stage I Ill NSCLC in 2006-2007 from the National Cancer Data Base. Patients were followed for 5 years or until first NSCLC recurrence, new primary cancer, or death, whichever came first. Perioperative comorbidities, first recurrence, treatment of recurrence, and survival were abstracted from medical records and merged with existing registry data. Factors associated with active treatment (chemotherapy, radiation, and/or surgery) versus supportive care only were analyzed using multivariable logistic regression. Results: Median age at initial diagnosis was 67; 69.7% had >1 comorbidity. At 5-year follow-up, 12.3% developed locoregional and 21.5% developed distant recurrence. Among patients with locoregional recurrence, 79.5% received active treatment. Older patients (OR 0.49 for age >75 compared with <55; 95% CI 0.27-0.88) and those with substance abuse (OR 0.43; 95% CI 0.23-0.81) were less likely to receive active treatment. Women (OR 0.62; 95% CI 0.43-0.89) and patients with symptomatic recurrence (OR 0.69; 95% CI 0.47-0.99) were also less likely to receive active treatment. Among those with distant recurrence, 77.3% received active treatment. Older patients (OR 0.42 for age >75 compared with <55; 95% CI 0.26-0.68) and those with any documented comorbidities (OR 0.59; 95% CI 0.38-0.89) were less likely to receive active treatment. Conclusion: Older patients independent of comorbidity, patients with substance abuse, and women were less likely to receive active treatment for postoperative NSCLC recurrence. Studies to further characterize these disparities in treatment of NSCLC recurrence are needed to identify barriers to treatment. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Wong, Melisa L.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, 505 Parnassus Ave,Mailbox 1270, San Francisco, CA 94143 USA. [Wong, Melisa L.] Univ Calif San Francisco, Dept Med, Div Geriatr, 505 Parnassus Ave,Mailbox 1270, San Francisco, CA 94143 USA. [Wong, Melisa L.] San Francisco VA Med Ctr, 505 Parnassus Ave,Mailbox 1270, San Francisco, CA 94143 USA. [McMurry, Timothy L.; Stukenborg, George J.] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, POB 800717, Charlottesville, VA 22908 USA. [Francescatti, Amanda B.] Amer Coll Surg, 633 N St Clair St, Chicago, IL 60611 USA. [Amato-Martz, Carla] Alliance Clin Trials Oncol, 125 S Wacker Dr,Suite 1600, Chicago, IL 60606 USA. [Schumacher, Jessica R.; Greenberg, Caprice C.] Univ Wisconsin, Dept Surg, 600 Highland Ave,BX7375 Clin Sci Ctr, Madison, WI 53792 USA. [Chang, George J.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Unit 444, Houston, TX 77030 USA. [Chang, George J.] Univ Texas MD Anderson Canc Ctr, Hlth Serv Res, 1515 Holcombe Blvd,Unit 444, Houston, TX 77030 USA. [Winchester, David P.] Amer Coll Surg, Canc Programs, 633 N St Clair St, Chicago, IL 60611 USA. [McKellar, Daniel P.] Amer Coll Surg, Commiss Canc, 633 N St Clair St, Chicago, IL 60611 USA. [Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, Dept Med, 4150 Clement,181G, San Francisco, CA 94121 USA. [Walter, Louise C.] San Francisco VA Med Ctr, 4150 Clement,181G, San Francisco, CA 94121 USA. [Kozower, Benjamin D.] Washington Univ, Dept Surg, Div Cardiothorac Surg, One Barnes Jewish Hosp Plaza,Suite 3108, St Louis, MO 63110 USA. EM melisa.wong@ucsf.edu; tlm6w@eservices.virginia.edu; gjs6r@eservices.virginia.edu; afrancescatti@facs.org; cmartz@alliancefoundationtrials.org; schumacher@surgery.wisc.edu; GChang@mdanderson.org; greenberg@surgery.wisc.edu; DWinchester@facs.org; d.mckellar1958@gmail.com; Louise.Walter@ucsf.edu; kozowerb@wudosis.wustl.edu FU Patient-Centered Outcomes Research Institute (PCORI) [CE-1306-00727]; National Institute on Aging [T32AG000212, K24AG041180]; National Cancer Institute [UG1CA189823] FX This work was supported by the Patient-Centered Outcomes Research Institute (PCORI; CE-1306-00727, Kozower), the National Institute on Aging (T32AG000212, Wong and K24AG041180, Walter), and the National Cancer Institute (UG1CA189823, Alliance for Clinical Trials in Oncology NCORP Research Base). NR 47 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD DEC PY 2016 VL 102 BP 108 EP 117 DI 10.1016/j.lungcan.2016.11.002 PG 10 WC Oncology; Respiratory System SC Oncology; Respiratory System GA EI5VT UT WOS:000392565100018 PM 27987578 ER PT J AU Badour, CL Gros, DF Szafranski, DD Acierno, R AF Badour, Christal L. Gros, Daniel F. Szafranski, Derek D. Acierno, Ron TI Sexual Problems Predict PTSD and Depression Symptom Change Among Male OEF/OIF Veterans Completing Exposure Therapy SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; TREATING ERECTILE DYSFUNCTION; MENTAL-HEALTH PROBLEMS; SOCIAL SUPPORT; DOUBLE-BLIND; AFGHANISTAN; IRAQ; PREVALENCE; ASSOCIATION; SILDENAFIL AB Objective: A growing literature documents frequent sexual problems among Operations Enduring/Iraqi Freedom (OEF/OIF) veterans with post-traumatic stress disorder (PTSD). However, there has been no examination of how (1) sexual problems may be affected by evidenced-based psychotherapy for PTSD or (2) how the presence of sexual problems might impact effectiveness of evidenced-based psychotherapy for PTSD. As such, the present study investigated associations among symptoms of PTSD, depression, and problems with sexual desire and arousal among 45 male OEF/OIF veterans receiving behavioral activation and therapeutic exposure (BA-TE), an evidence-based behavior therapy targeting co-occurring symptoms of PTSD and depression. Method: Participants completed clinical interviews and several questionnaires including measures of sexual arousal, sexual desire, PTSD symptoms, and depression symptoms at baseline and after completion of 8 sessions of BA-TE treatment. A records review was also conducted to assess for relevant medication use. Results: Overall, sexual desire and sexual arousal problems did not improve during the course of treatment. Moreover, veterans with co-occurring sexual problems at baseline evidenced significantly less improvement in symptoms of PTSD and depression across treatment as compared to veterans without sexual problems. Conclusions: These findings suggest that veterans with co-occurring symptoms of PTSD and sexual problems may require additional assessment and treatment considerations in order to improve their treatment outcomes for both primary psychiatric symptoms as well as sexual problems. Future research on combination treatments of medication for sexual problems and psychotherapy for PTSD is needed. C1 [Badour, Christal L.] Univ Kentucky, 106B Kastle Hall, Lexington, KY 40506 USA. [Gros, Daniel F.; Szafranski, Derek D.; Acierno, Ron] Med Univ South Carolina, Charleston, SC USA. [Gros, Daniel F.; Szafranski, Derek D.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Badour, CL (reprint author), Univ Kentucky, 106B Kastle Hall, Lexington, KY 40506 USA. EM Christal.badour@uky.edu FU Department of Defense [W81XWH-07-PTSD-IIRA]; Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award [CX000845]; South Carolina Clinical & Translational Research Institute; Medical University of South Carolina (NIH) [UL1 TR000062]; National Institute of Mental Health [T32 MH018869] FX This publication was supported, in part, by grants from the Department of Defense (W81XWH-07-PTSD-IIRA [PI: Acierno]), Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award (CX000845 [PI: Gros]), and the South Carolina Clinical & Translational Research Institute, with an academic home at the Medical University of South Carolina (NIH Grant Number UL1 TR000062 [PI: Brady]). Dr. Badour is supported by a grant from the National Institute of Mental Health (T32 MH018869). Several authors are also core and affiliate members of the Ralph H. Johnson VA Centers of Innovation (PI: Egede), Charleston Health Equity and Rural Outreach Innovation Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the National Institutes of Health, or the United States government. There are no conflicts of interest to disclose. NR 44 TC 0 Z9 0 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0033-2747 EI 1943-281X J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PD WIN PY 2016 VL 79 IS 4 BP 403 EP 417 DI 10.1080/00332747.2016.1142774 PG 15 WC Psychiatry SC Psychiatry GA EJ2BE UT WOS:000393014100013 PM 27997327 ER PT J AU Mohamed, NE Pisipati, S Lee, CT Goltz, HH Latini, DM Gilbert, FS Wittmann, D Knauer, CJ Mehrazin, R Sfakianos, JP McWilliams, GW Quale, DZ Hall, SJ AF Mohamed, Nihal E. Pisipati, Sailaja Lee, Cheryl T. Goltz, Heather H. Latini, David M. Gilbert, Francis S. Wittmann, Daniela Knauer, Cynthia J. Mehrazin, Reza Sfakianos, John P. McWilliams, Glen W. Quale, Diane Z. Hall, Simon J. TI Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Urothelial carcinoma of the urinary bladder; Muscle-invasive bladder cancer; Cystectomy; Urinary diversion; Unmet need ID RADICAL CYSTECTOMY; URINARY-DIVERSION; CHEMOTHERAPY; CARCINOMA; DISTRESS AB Purpose: Assessing the unmet needs of cancer patients can help providers tailor health care services to patients' specific needs. This study examines whether the unmet informational and supportive care needs of the patients with muscle-invasive bladder cancer vary by the patients' age, sex, or individual treatment choices. Methods and materials: Participants (N = 30 survivors; 73.3% men) were recruited from the Mount Sinai Medical Center and through advertisements posted on a national Bladder Cancer Advocacy Network website between December 2011 and September 2012. Data were collected through individual interviews and electronic medical record review. A prior qualitative study of this cohort, using immersion/crystallization approach, confirmed the prevalence of unmet needs across the disease trajectory. This is a secondary quantitative analysis of the initial interview data we collected (i.e., quantitative analyses of transformed qualitative data using Chi-square and Fisher exact tests) to examine differences in unmet needs based on the patient's age, sex, and treatment choices. Results: Younger patients (<60 y) were less satisfied with the treatment information received presurgery and more likely to report posttreatment complications, choose a neobladder, and seek and receive professional support regarding sexual function, than were older patients (P < 0.05). More women than men reported difficulties with self-care and relied on themselves in disease self-management as opposed to relying on spousal support (P < 0.05). Patients with neobladder were more likely to report difficulties with urinary incontinence and deterioration in sexual function, whereas patients with ileal conduit were more likely to require spousal help with self-care. Patients who received chemotherapy were significantly more likely to report changes in everyday life (P < 0.05). Lastly, regardless of age, sex, or treatment choice, up to 50% of patients reported feeling depressed before or after treatment. Conclusions: Unmet informational and supportive needs of patients with muscle-invasive bladder cancer during survivorship, and vary by age, sex, and treatment choices. Educational and psychological assessments as well as clinical interventions should be tailored to a patient's specific unmet needs, and to specific clinical and demographic characteristics. (C) 2016 Elsevier Inc. All rights reserved. C1 [Mohamed, Nihal E.; Knauer, Cynthia J.; Mehrazin, Reza; Sfakianos, John P.; McWilliams, Glen W.] Icahn Sch Med Mt Sinai, Dept Urol & Oncol Sci, New York, NY 10029 USA. [Lee, Cheryl T.; Wittmann, Daniela] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Goltz, Heather H.] Univ Houston Downtown, Social Work Program, Houston, TX USA. [Goltz, Heather H.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. [Goltz, Heather H.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. [Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. [McWilliams, Glen W.] James J Peters Vet Affairs Med Ctr, Dept Urol, Bronx, NY USA. [Quale, Diane Z.] Bladder Canc Advocacy Network, Washington, DC USA. [Hall, Simon J.] Northwell Hlth Syst, Smith Inst Urol, Lake Success, NY USA. EM nihal.mohamed@mountsinai.org FU American Cancer Society [121193-MRSG-11-103-01-CPPB]; National Cancer Institute [1R03CA165768-01A1] FX Supported by mentored research scholar grants from the American Cancer Society (121193-MRSG-11-103-01-CPPB) and the National Cancer Institute (1R03CA165768-01A1). NR 26 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 EI 1873-2496 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD DEC PY 2016 VL 34 IS 12 DI 10.1016/j.urolonc.2016.06.010 PG 8 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA EI6YL UT WOS:000392643500010 ER PT J AU Hayes, RA Dickey, MW Warren, T AF Hayes, Rebecca A. Dickey, Michael Walsh Warren, Tessa TI Looking for a Location: Dissociated Effects of Event-Related Plausibility and Verb-Argument Information on Predictive Processing in Aphasia SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY LA English DT Article ID ADULT AGE-DIFFERENCES; LANGUAGE COMPREHENSION; SENTENCE COMPREHENSION; EYE-MOVEMENTS; KNOWLEDGE ACTIVATION; SYNTACTIC AMBIGUITY; CONTEXT; TIME; INTEGRATION; BIAS AB Purpose: This study examined the influence of verb-argument information and event-related plausibility on prediction of upcoming event locations in people with aphasia, as well as older and younger, neurotypical adults. It investigated how these types of information interact during anticipatory processing and how the ability to take advantage of the different types of information is affected by aphasia. Method: This study used a modified visual-world task to examine eye movements and offline photo selection. Twelve adults with aphasia (aged 54-82 years) as well as 44 young adults (aged 18-31 years) and 18 older adults (aged 50-71 years) participated. Results: Neurotypical adults used verb argument status and plausibility information to guide both eye gaze (a measure of anticipatory processing) and image selection (a measure of ultimate interpretation). Argument status did not affect the behavior of people with aphasia in either measure. There was only limited evidence of interaction between these 2 factors in eye gaze data. Conclusions: Both event-related plausibility and verb-based argument status contributed to anticipatory processing of upcoming event locations among younger and older neurotypical adults. However, event-related likelihood had a much larger role in the performance of people with aphasia than did verb-based knowledge regarding argument structure. C1 [Hayes, Rebecca A.; Dickey, Michael Walsh; Warren, Tessa] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Hayes, RA (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM rahayes89@gmail.com FU National Institutes of Health [R01DC011520, UL1TR000005] FX This research was supported by the National Institutes of Health Grant R01DC011520 (awarded to Rebecca A. Hayes and Michael Walsh Dickey) and Grant UL1TR000005 (awarded to the Clinical and Translational Science Institute of the University of Pittsburgh, PA. This research was the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, PA. NR 84 TC 0 Z9 0 U1 3 U2 3 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA SN 1058-0360 EI 1558-9110 J9 AM J SPEECH-LANG PAT JI Am. J. Speech-Lang. Pathol. PD DEC PY 2016 VL 25 IS 4 SU S BP S758 EP S775 DI 10.1044/2016_AJSLP-15-0145 PG 18 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA EI1WC UT WOS:000392276100007 PM 27997951 ER PT J AU Luyster, FS Strollo, PJ Holguin, F Castro, M Dunican, EM Fahy, J Gaston, B Israel, E Jarjour, NN Mauger, DT Moore, WC Wenzel, SE AF Luyster, Faith S. Strollo, Patrick J., Jr. Holguin, Fernando Castro, Mario Dunican, Eleanor M. Fahy, John Gaston, Benjamin Israel, Elliot Jarjour, Nizar N. Mauger, David T. Moore, Wendy C. Wenzel, Sally E. TI Association Between Insomnia and Asthma Burden in the Severe Asthma Research Program (SARP) III SO CHEST LA English DT Article DE asthma; depression; health care utilization; insomnia; quality of life ID QUALITY-OF-LIFE; SLEEP DISTURBANCES; DEPRESSION SCALE; HOSPITAL ANXIETY; RISK-FACTORS; POPULATION; QUESTIONNAIRE; VALIDATION; SYMPTOMS; VALIDITY AB BACKGROUND: Sleep difficulties are commonly reported by patients with asthma; however, the prevalence of insomnia and its association with disease burden and well-being is unknown. We aimed to determine the prevalence of insomnia, defined as combined sleep-specific complaints with associated daytime symptoms, among a large sample of adults with asthma, and to compare well-being, asthma control, and asthma-related health care utilization in individuals with asthma and insomnia and those without insomnia. METHODS: Baseline data from adults with physician-confirmed asthma enrolled in the Severe Asthma Research Program III was used for analyses (N = 714). Participants completed the Insomnia Severity Index (ISI), Asthma Control Test, Asthma Quality of Life Questionnaire, and Hospital Anxiety and Depression Scale. RESULTS: Insomnia (ISI >= 10) was identified in 263 participants (37%). Presence of insomnia was associated with higher levels of depression and anxiety symptoms and poorer quality of life. Those with insomnia had a 2.4-fold increased risk for having not well-controlled asthma and a 1.5-fold increased risk for asthma-related health care utilization in the past year compared with those without insomnia. CONCLUSIONS: Insomnia is highly prevalent in asthma and is associated with adverse outcomes. Further studies are needed to gain a better understanding of the interaction between insomnia and asthma control. C1 [Luyster, Faith S.] Univ Pittsburgh, Sch Nursing, 3500 Vic St,Room 415, Pittsburgh, PA 15261 USA. [Strollo, Patrick J., Jr.; Holguin, Fernando; Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA. [Strollo, Patrick J., Jr.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA. [Dunican, Eleanor M.; Fahy, John] Univ Calif San Francisco, Sch Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Gaston, Benjamin] Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Div Pediat Allergy & Immunol, Cleveland, OH 44106 USA. [Israel, Elliot] Brigham & Womens Hosp, Pulm Div, Boston, MA 02115 USA. [Jarjour, Nizar N.] Univ Wisconsin, Sch Med, Div Allergy Pulm & Crit Care Med, Madison, WI USA. [Mauger, David T.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA. [Moore, Wendy C.] Wake Forest Univ, Sch Med, Dept Med, Div Pulm Crit Care Allergy & Immunol Med, Winston Salem, NC 27109 USA. RP Luyster, FS (reprint author), Univ Pittsburgh, Sch Nursing, 3500 Vic St,Room 415, Pittsburgh, PA 15261 USA. EM luysterfs@upmc.edu FU National Institutes of Health [NIH] [U10HL 109164, U10HL 109257, U10HL 109250, U10HL 109172, U10HL 109168, U10HL 109152, U10HL 109046]; National Heart, Lung, and Blood Institute (NHLBI) [K23 HL105887] FX This study was funded by the National Institutes of Health [NIH U10HL 109164, U10HL 109257, U10HL 109250, U10HL 109172, U10HL 109168, U10HL 109152, U10HL 109046, U10HL 109046]. Support for the first author was provided by the National Heart, Lung, and Blood Institute (NHLBI) K23 HL105887. NR 37 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2016 VL 150 IS 6 BP 1242 EP 1250 DI 10.1016/j.chest.2016.09.020 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EI1VQ UT WOS:000392274600024 PM 27720882 ER PT J AU Chen, XJ Al-Sheikh, M Chan, CK Hariri, AH Abraham, P Lalezary, M Lin, SG Sadda, S Sarraf, D AF Chen, Xuejing Al-Sheikh, Mayss Chan, Clement K. Hariri, Amir H. Abraham, Prema Lalezary, Maziar Lin, Steven G. Sadda, Srinivas Sarraf, David TI TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY A Prospective Study SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article; Proceedings Paper CT 4th Annual International Retinal Imaging Symposium (IRIS) CY MAR 17, 2016 CL Univ Calif, Los Angeles, Los Angeles, CA HO Univ Calif, Los Angeles DE aflibercept; age-related macular degeneration; imaging; intravitreal injection; optical coherence tomography; pigment epithelial detachment; retinal angiomatous proliferation; type 1 neovascularization; type 3 neovascularization; vascular endothelial growth factor ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL AFLIBERCEPT; VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; ANATOMICAL OUTCOMES; TREATMENT RESPONSE; RANIBIZUMAB; EYES; MACULOPATHY; SUBANALYSIS AB Purpose: To evaluate the response to aflibercept therapy for Type 1 and Type 3 neovascularization in pigment epithelial detachments associated with treatment-naive, neovascular age-related macular degeneration. Methods: In this multicentered, prospective study, eligible eyes underwent an intravitreal aflibercept injection protocol for 12 months. Visual acuity and morphologic features of the pigment epithelial detachments were compared at baseline and follow-up intervals between eyes with Type 1 versus Type 3 neovascularization. Results: Thirty-six eyes were analyzed. At 12 months, Type 1 lesions showed a 4.5 +/- 23 Early Treatment of Diabetic Retinopathy Study letter improvement (P = 0.1665) versus a 14 +/- 11 (P = 0.0072) letter improvement with Type 3 lesions. Both Type 1 and 3 eyes showed a significant decrease in pigment epithelial detachment size, subretinal fluid, and subretinal hyperreflective material; however, Type 3 eyes had a greater reduction in pigment epithelial detachment size and subretinal hyperreflective material, as well as a reduction in central retinal thickness. Type 1 eyes required an average of 1.636 (range, 1-4) injections to resolve fluid, which was greater than Type 3 eyes, which required an average of 1.143 (range, 1-2) injections (P = 0.0251). Conclusion: Intravitreal aflibercept injections were efficacious for pigment epithelial detachments, but baseline and follow-up anatomical and functional outcomes differed in Type 1 versus Type 3 neovascularization. The better response of Type 3 eyes with fewer injections suggests that differentiation of the neovascularization subtype at the initial diagnosis may allow for a more tailored, optimal therapy. C1 [Chen, Xuejing; Al-Sheikh, Mayss; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Stein Eye Inst, Los Angeles, CA 90095 USA. [Al-Sheikh, Mayss; Hariri, Amir H.; Sadda, Srinivas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Doheny Eye Inst, Los Angeles, CA 90095 USA. [Chan, Clement K.; Lalezary, Maziar; Lin, Steven G.] Southern Calif Desert Retina Consultants, Palm Desert, CA USA. [Chan, Clement K.] Loma Linda Univ, Inst Eye, Dept Ophthalmol, Loma Linda, CA 92350 USA. [Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD USA. [Sarraf, David] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Ophthalmol, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Regeneron; Genentech; NEI; Acucela; Ophthotech; Sequenom; Allergan; Theratechnologies; Juvenile Diabetes Research Foundation; Pfizer; Schering-Plough; Thrombogenics; Ophthotect; Optovue; Optos; Carl Zeiss Meditec FX Supported by a research grant from Regeneron. No support was received from the NIH, Wellcome Trust, or HHMI. C. K. Chan receives research support from Genentech, NEI, Acucela, Ophthotech, Sequenom, Regeneron, Allergan, and Theratechnologies. P. Abraham receives research support from Allergan, Genentech, NEI, Juvenile Diabetes Research Foundation, Ophthotech, Pfizer, Schering-Plough, and Thrombogenics. M. Lalezary and S. G. Lin receive research support from Allergan, Acucela, Regeneron, Genentech, Ophthotect, and NEI. D. Sarraf has research grants from Regeneron, Genentech, and Optovue. S. Sadda is a consultant for Optos, Carl Zeiss Meditec, Allergan, Genentech, Regeneron, Bayer, Novartis, and Iconic and receives research support from Optos, Carl Zeiss Meditec, Allergan, and Genentech. X. Chen, M. Al-Sheikh, and A. H. Hariri have no financial disclosures. NR 34 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD DEC PY 2016 VL 36 IS 12 SU 1 BP S50 EP S64 PG 15 WC Ophthalmology SC Ophthalmology GA EH7IP UT WOS:000391946700006 PM 28005663 ER PT J AU Falavarjani, KG Scott, AW Wang, K Han, IC Chen, XJ Klufas, M Hubschman, JP Schwartz, SD Sadda, SR Sarraf, D Tsui, I AF Falavarjani, Khalil Ghasemi Scott, Adrienne W. Wang, Kang Han, Ian C. Chen, Xuejing Klufas, Michael Hubschman, Jean-Pierre Schwartz, Steven D. Sadda, Srinivas R. Sarraf, David Tsui, Irena TI CORRELATION OF MULTIMODAL IMAGING IN SICKLE CELL RETINOPATHY SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article; Proceedings Paper CT 4th Annual International Retinal Imaging Symposium (IRIS) CY MAR 17, 2016 CL Univ Calif, Los Angeles, Los Angeles, CA HO Univ Calif, Los Angeles DE ischemic index; optical coherence tomography angiography; retinal imaging; sickle cell retinopathy; spectral domain optical coherence tomography; ultra-wide-field fluorescein angiography ID OPTICAL COHERENCE TOMOGRAPHY; ANGIOGRAPHY; DISEASE; HEMOGLOBINOPATHIES AB Purpose: To correlate macular findings on spectral domain optical coherence tomography (SDOCT) and optical coherence tomography angiography (OCTA) with quantitative ischemic index calculations on ultra-wide-field fluorescein angiography (UWFFA) in patients with sickle cell retinopathy. Methods: In this retrospective case series, SDOCT, OCTA, and UWFFA images of patients with sickle cell retinopathy were evaluated. Eyes were staged based on the Goldberg classification of proliferative sickle cell retinopathy. Focal areas of macular thinning were assessed on SDOCT, macular vessel density was derived from OCTA, and peripheral ischemic index was calculated from UWFFA. Results: Eighteen eyes of 10 patients were included. Mean age was 36.8 +/- 16.8 years, and 6 patients (11 eyes) were SS, 3 patients (5 eyes) were SC, and 1 patient (2 eyes) was Sb thalassemia in hemoglobin electrophoresis. Abnormal macular findings included inner retinal atrophy in 11 eyes (61%) on SDOCT, vascular remodeling and nonperfusion in the superficial and deep retinal capillary plexus in 12 eyes (67%) on OCTA, and macular microvascular abnormalities in 9 eyes (50%) on UWFFA. Sickle cell retinopathy Stage I was identified in 4 eyes (22.2%), Stage II in 8 eyes (44.4%), and Stage III in 6 eyes (33.3%). Mean ischemic index was 14.1 +/- 9.1%. Ischemic index was significantly correlated with hemoglobinopathy subtype (23.7 +/- 9.8%, 9.3 +/- 5.4%, and 16.3 +/- 3.2%, for SC, SS, and Sb thalassemia disease, respectively), stage of sickle cell retinopathy (22.5 +/- 9.2%, 12.5 +/- 4.9%, and 4.5 +/- 0.73% for Stages III, II, and I, respectively), and presence of retinal thinning on SDOCT (17.4 +/- 9.7% vs. 8.8 +/- 5.1%, respectively). Conclusion: Multimodal imaging can provide a more complete description of the microvascular and structural alterations associated with sickle retinopathy. The correlation between the severity of peripheral nonperfusion and stage and subtype of retinopathy suggests that UWF imaging may be a useful tool in the evaluation of these patients. C1 [Falavarjani, Khalil Ghasemi; Wang, Kang; Chen, Xuejing; Klufas, Michael; Hubschman, Jean-Pierre; Schwartz, Steven D.; Sadda, Srinivas R.; Sarraf, David; Tsui, Irena] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Tehran, Iran. [Scott, Adrienne W.; Han, Ian C.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Tsui, I (reprint author), Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM itsui@jsei.ucla.edu FU Optos; Genentech; Allergan; Carl Zeiss Meditec; Regeneron; Optovue FX S. R. Sadda is a consultant for Optos, Genentech, and Allergan and receives research support from Optos, Genentech, Allergan, and Carl Zeiss Meditec. D. Sarraf receives research grant from Genentech, Regeneron, and Optovue. The remaining authors have no financial/conflicting interests to disclose. NR 18 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD DEC PY 2016 VL 36 IS 12 SU 1 BP S111 EP S117 PG 7 WC Ophthalmology SC Ophthalmology GA EH7IP UT WOS:000391946700012 ER PT J AU Haug, SJ Wong, RW Day, S Choudhry, N Sneed, S Prasad, P Read, S McDonald, RH Agarwal, A Davis, J Sarraf, D AF Haug, Sara J. Wong, Robert W. Day, Shelley Choudhry, Netan Sneed, Scott Prasad, Pradeep Read, Sarah McDonald, Richard H. Agarwal, Anita Davis, Janet Sarraf, David TI DIDANOSINE RETINAL TOXICITY SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article; Proceedings Paper CT 4th Annual International Retinal Imaging Symposium (IRIS) CY MAR 17, 2016 CL Univ Calif, Los Angeles, Los Angeles, CA HO Univ Calif, Los Angeles DE toxic retinopathy; HIV; didanosine retinal toxicity ID HUMAN-IMMUNODEFICIENCY-VIRUS; MITOCHONDRIAL-DNA; OPHTHALMOPLEGIA; DIDEOXYINOSINE; ZIDOVUDINE; THERAPY; LESIONS; ADULTS AB Purpose: To report nine new cases of retinal degeneration secondary to didanosine toxicity and to summarize the previously reported cases in the literature. Methods: This was a multicenter, retrospective, observational case study from seven institutions. Medical records of patients who demonstrated well-demarcated severe midperipheral chorioretinal degeneration and who were previously treated with didanosine therapy were collected and the following information was reviewed: age, gender, medical history, detailed medication history including current and previous antiretroviral use, ocular and retinal examination findings, and multimodal imaging findings with optical coherence tomography, fundus photography, wide-field fundus autofluorescence, and wide-field fluorescein angiography. When available, findings with electrophysiology testing and automated perimetry were also collected and reviewed. A literature review was also performed to collect all reported cases of chorioretinal degeneration secondary to didanosine toxicity. Results: Nine patients were identified who had findings consistent with peripheral retinal toxicity secondary to didanosine use. Eight of the 9 patients were men, and the median age was 54 years at the time of presentation (mean: 55 years, range, 42-71 years). Snellen distance acuity ranged from 20/20 to 20/32. At least three of the cases in the series demonstrated progression of the peripheral retinal pigment epithelium and photoreceptor atrophy despite didanosine cessation. A review of the literature revealed 10 additional cases of didanosine toxicity. Seven of the 10 cases were in men (70%), and the average age was 26 years with a wide range (2-54 years). Chorioretinal findings were very similar to this cohort. Conclusion: Herein, we report the largest series of nine cases of peripheral chorioretinal degeneration secondary to didanosine toxicity in adults. When combined with the cases in the literature, 19 cases of didanosine toxicity, 4 of which occurred in children, were collected and analyzed. Three of the new cases presented showed clear progression of degeneration despite didanosine cessation. Newer nucleoside reverse transcriptase inhibitors may potentiate mitochondrial DNA damage and lead to continued chorioretinal degeneration. C1 [Haug, Sara J.; McDonald, Richard H.] West Coast Retina Med Grp, San Francisco, CA USA. [Wong, Robert W.; Day, Shelley] Austin Retina Associates, Austin, TX USA. [Choudhry, Netan] Herzig Eye Inst, Toronto, ON, Canada. [Sneed, Scott] Associated Retinal Consultants PC, Royal Oak, MI USA. [Prasad, Pradeep; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA. [Read, Sarah; Davis, Janet] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA. [Agarwal, Anita] Vanderbilt Univ, Vanderbilt Eye Inst, 221 Kirkland Hall, Nashville, TN 37235 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Allergan; Genentech; Regeneron; Optovue FX Dr. Sarraf has research grants from Allergan, Genentech, Regeneron and Optovue, is a consultant for Genentech and Optovue, and is a paid speaker for Optovue. None of the authors have any financial/conflicting interests to disclose. NR 16 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD DEC PY 2016 VL 36 IS 12 SU 1 BP S159 EP S167 PG 9 WC Ophthalmology SC Ophthalmology GA EH7IP UT WOS:000391946700017 PM 28005674 ER PT J AU Pichi, F Srvivastava, SK Chexal, S Lembo, A Lima, LH Neri, P Saitta, A Chhablani, J Albini, TA Nucci, P Freund, KB Chung, H Lowder, CY Sarraf, D AF Pichi, Francesco Srvivastava, Sunil K. Chexal, Saradha Lembo, Andrea Lima, Luiz H. Neri, Piergiorgio Saitta, Andrea Chhablani, Jay Albini, Thomas A. Nucci, Paolo Freund, K. Bailey Chung, Hyewon Lowder, Careen Y. Sarraf, David TI EN FACE OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF MULTIPLE EVANESCENT WHITE DOT SYNDROME New Insights Into Pathogenesis SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article; Proceedings Paper CT 4th Annual International Retinal Imaging Symposium (IRIS) CY MAR 17, 2016 CL Univ Calif, Los Angeles, Los Angeles, CA HO Univ Calif, Los Angeles DE MEWDS; en face OCT; OCT angiography ID INDOCYANINE GREEN ANGIOGRAPHY; FUNDUS AUTOFLUORESCENCE; CHOROIDAL THICKNESS; OUTER; UVEITIS; INNER AB Purpose: To localize the various levels of abnormalities in multiple evanescent white dot syndrome by comparing "en face" optical coherence tomography (OCT) and OCT angiography with various conventional imaging modalities. Methods: In this retrospective case series, multimodal imaging was performed in 9 retinal centers on 36 patients with multiple evanescent white dot syndrome and included widefield fundus autofluorescence (FAF), fluorescein angiography (FA), and indocyanine green angiography, and B-scan and "en face" C-scan enhanced depth imaging and spectral domain OCT. Optical coherence tomography angiography was also performed at the level of the superficial and deep retinal capillary plexus and choroid. Results: Multiple evanescent white dot syndrome lesions were more numerous and more easily detectable with FA and FAF. Two types of lesions were identified with FAF, FA, and indocyanine green angiography: larger widely scattered "spots" (approximately 200 mu in diameter) that were hyperfluorescent with FA, hyperautofluorescent with FAF, and hyporeflective in indocyanine green angiography, representing abnormalities primarily at the retinal pigment epithelium/photoreceptor junction; and punctate "dots" (less than 100 m in diameter) that were hyperfluorescent with FA, hyperautofluorescent, or isoautofluorescent with FAF, and hypofluorescent with indocyanine green angiography and that localized to the outer nuclear layer. These lesions colocalized with "en face" OCT. The larger confluent "spots" were hyporeflective and colocalized to the level of the ellipsoid zone, whereas smaller hyperreflective "dots" colocalized to the outer nuclear layer. The location of the "dots" in the outer nuclear layer was further confirmed by structural spectral domain optical coherence tomography which showed coalescence of the dots into hyperreflective lines extending from the external limiting membrane to the outer plexiform layer in certain cases. Optical coherence tomography angiography analysis of the retinal microvasculature and choriocapillaris and choroid were entirely unremarkable in 100% of our patients. Conclusion: By combining multimodal imaging, the authors propose that multiple evanescent white dot syndrome is primarily the result of inflammation at the outer photoreceptor level leading to a "photoreceptoritis" and causing loss of the inner and outer segments. Its evanescent nature suggests that the photoreceptor cell bodies remain intact ensuring complete recovery of the photoreceptor inner and outer segments in most cases, compatible with the clinical course of spontaneous resolution of white spots and dots. C1 [Pichi, Francesco; Lembo, Andrea; Nucci, Paolo] Univ Eye Clin, San Giuseppe Hosp, Milan, Italy. [Pichi, Francesco; Srvivastava, Sunil K.; Lowder, Careen Y.] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Chexal, Saradha] Retina Consultants Austin, Austin, TX USA. [Lima, Luiz H.] Fed Univ Sao Paulo UNIFESP, Sao Paulo, Brazil. [Neri, Piergiorgio; Saitta, Andrea] Polytech Univ Marche, Eye Clin, Ocular Immunol Serv, Ancona, Italy. [Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Hyderabad, Andhra Pradesh, India. [Albini, Thomas A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA. [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea. [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Pichi, F (reprint author), Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44106 USA. EM ilmiticopicchio@gmail.com FU Macula Foundation Inc, New York, NY FX Supported by the Macula Foundation Inc, New York, NY. NR 37 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD DEC PY 2016 VL 36 IS 12 SU 1 BP S178 EP S188 PG 11 WC Ophthalmology SC Ophthalmology GA EH7IP UT WOS:000391946700019 PM 28005676 ER PT J AU Su, D Lin, S Phasukkijwatana, N Chen, XJ Tan, A Freund, KB Sarraf, D AF Su, Daniel Lin, Shawn Phasukkijwatana, Nopasak Chen, Xuejing Tan, Anna Freund, K. Bailey Sarraf, David TI AN UPDATED STAGING SYSTEM OF TYPE 3 NEOVASCULARIZATION USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article; Proceedings Paper CT 4th Annual International Retinal Imaging Symposium (IRIS) CY MAR 17, 2016 CL Univ Calif, Los Angeles, Los Angeles, CA HO Univ Calif, Los Angeles DE age-related macular degeneration; intraretinal neovascularization; optical coherence tomography; pigment epithelial detachment; retinal angiomatous proliferation; staging system; Type 3 neovascularization; vascular endothelial growth factor ID RETINAL ANGIOMATOUS PROLIFERATION; OCCULT CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; HYPERREFLECTIVE FOCI; ANGIOGRAPHY; SUBTYPES; EYE; OCT; ASSOCIATION AB Purpose: To comprehensively investigate spectral domain optical coherence tomography features associated with Type 3 neovascularization and determine the prevalence of each feature and to develop an updated staging system for Type 3 neovascularization based on spectral domain optical coherence tomography findings. Methods: The authors retrospectively analyzed 34 eyes with new-onset Type 3 neovascularization. Spectral domain optical coherence tomography images at onset of Type 3 neovascularization, immediately after the first injection, and at the final quiescent visit were analyzed for the presence of specific optical coherence tomography features. In addition, when available, optical coherence tomography images from the visit before onset were studied. Results: Among 18 eyes with preonset optical coherence tomography, 77.8% had preexisting intraretinal hyperreflective foci (precursor lesion). In the same group of eyes, 44.4% and 27.8% exhibited outer plexiform layer disruption and outer plexiform layer downward deflection, respectively. At the onset of detectable Type 3 neovascularization, all 34 eyes demonstrated a hyperreflective focus with cystoid macular edema and 85.3% exhibited disruption of the retinal pigment epithelium. Serous pigment epithelial detachment and subretinal fluid were present in 67.6% and 23.5% of eyes at onset, respectively. The rate of cystoid macular edema decreased from 100% to 17.6% after a single injection. At the final quiescent visit, focal atrophy at the site of Type 3 lesions, as evidenced by outer retinal and retinal pigment epithelium disruption developed in 88.2% and 52.9% of eyes, respectively. Conclusion: An updated staging system of Type 3 lesions was developed based on spectral domain optical coherence tomography findings. A precursor stage consists of a punctate hyperreflective focus in the outer retina. The subtle detection of associated outer plexiform layer disruption and downward deflection may indicate that this precursor lesion is more likely to progress to an active Type 3 neovascular lesion. Stage 1 consists of a larger intraretinal hyperreflective lesion associated with cystoid macular edema but without outer retinal disruption. Stage 2 is notable for outer retinal disruption that occurs with retinal pigment epithelium disruption in most of the cases. Stage 3 is defined by an intraretinal hyperreflective lesion that extends through the retinal pigment epithelium to vascularize a drusenoid pigment epithelial detachment creating a serous component of the pigment epithelial detachment. C1 [Su, Daniel; Lin, Shawn; Phasukkijwatana, Nopasak; Chen, Xuejing; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA. [Tan, Anna] Singapore Eye Ctr, Singapore, Singapore. [Tan, Anna] Singapore Eye Res Inst, Singapore, Singapore. [Tan, Anna; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Tan, Anna; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA. [Sarraf, David] Greater Los Angeles Vet Adm Healthcare Ctr, Los Angeles, CA USA. [Sarraf, David] Kaiser Permanente, Dept Ophthalmol, Woodland Hills, CA USA. RP Sarraf, D (reprint author), UCLA Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Macula Foundation, Inc, New York, NY; Allergan; Genentech; Optovue; Regeneron FX Supported by the Macula Foundation, Inc, New York, NY.; K. B. Freund is a consultant for Genentech, Optovue, Optos, Bayer Healthcare, and Heidelberg Engineering. D. Sarraf is a consultant for Genentech and Optovue and receives research funding from Allergan, Genentech, Optovue and Regeneron. The remaining authors have no conflicting interests to disclose. NR 32 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD DEC PY 2016 VL 36 IS 12 SU 1 BP S40 EP S49 PG 10 WC Ophthalmology SC Ophthalmology GA EH7IP UT WOS:000391946700005 PM 28005662 ER PT J AU Wandling, MW Hungness, ES Pavey, ES Stulberg, JJ Schwab, B Yang, AD Shapiro, MB Bilimoria, KY Ko, CY Nathens, AB AF Wandling, Michael W. Hungness, Eric S. Pavey, Emily S. Stulberg, Jonah J. Schwab, Ben Yang, Anthony D. Shapiro, Michael B. Bilimoria, Karl Y. Ko, Clifford Y. Nathens, Avery B. TI Nationwide Assessment of Trends in Choledocholithiasis Management in the United States From 1998 to 2013 SO JAMA SURGERY LA English DT Article ID BILE-DUCT STONES; COMMON; EXPLORATION; TRIAL AB IMPORTANCE There are currently 2 widely accepted treatment strategies for patients presenting to the hospital with choledocholithiasis. However, the rate of use for each strategy in the United States has not been evaluated, and their trends over time have not been described. Furthermore, an optimal management strategy for choledocholithiasis has yet to be defined. OBJECTIVE To evaluate secular trends in the management of choledocholithiasis in the United States and to compare hospital length of stay between patients with choledocholithiasis treated with endoscopic retrograde cholangiopancreatography with laparoscopic cholecystectomy (ERCP+LC) vs laparoscopic common bile duct exploration with laparoscopic cholecystectomy (LCBDE+LC). DESIGN, SETTING, AND PARTICIPANTS In this cohort study, we studied patients with a primary diagnosis of choledocholithiasis that were included in the National Inpatient Sample between 1998 and 2013 from a representative sample of acute care hospitals in the United States. Patients with cholangitis or pancreatitis were excluded. MAIN OUTCOMES AND MEASURES Unadjusted and risk-adjusted median hospital length of stay. RESULTS Of the 37 207 patients included in our analysis, 36 0 48 (96.9%) were treated with ERCP+LC and 1159 (3.1%) were treated with LCBDE+LC. The mean (SD) age of patients treated with ERCP+LC was 50.7 (21.1) years and was 51.9 (20.9) years for those treated with LCBDE+LC; 25 788 (69.3%) were female. Analysis of the National Inpatient Sample data indicates that there are an average of 26 158 patients with choledocholithiasis admitted in the United States each year. The overall use of CBDE for patients with choledocholithiasis decreased from 39.8% of admissions in 1998 to 8.5% in 2013 (P < .001). A decrease was also seen for open CBDE (30.6% vs 5.5%; P < .001) and laparoscopic CBDE (9.2% vs 3.0%; P < .001) independently. Rates of management with LCBDE+LC decreased from 5.3% to 1.5% (P < .001), while rates of ERCP+LC increased from 52.8% to 85.7% (P < .001). The unadjusted median hospital length of stay was shorter for patients treated with LCBDE+LC than for those treated with ERCP+LC (3.0 vs 4.0 days; P < .001). After risk-adjustment, the median length of stay remained 0.5 days shorter for patients treated with LCBDE+LC than with ERCP+LC (3.5 vs 4.0 days; P < .001). CONCLUSIONS AND RELEVANCE This study highlights the marked decline in the use of both open and laparoscopic CBDE in the United States as well as the benefit to the length of stay LCBDE+LC has over ERCP+LC. Despite a persistent need for CBDE and the potential benefits of LCBDE+LC over ERCP+LC for managing choledocholithiasis, if current trends continue, CBDE may be at risk of disappearing from the surgical armamentarium. C1 [Wandling, Michael W.; Hungness, Eric S.; Pavey, Emily S.; Stulberg, Jonah J.; Schwab, Ben; Yang, Anthony D.; Shapiro, Michael B.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, 251E Huron St,Ste 3-150, Chicago, IL 60611 USA. [Wandling, Michael W.; Pavey, Emily S.; Stulberg, Jonah J.; Yang, Anthony D.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Surg Outcomes & Qual Improvement Ctr, Chicago, IL USA. [Wandling, Michael W.; Stulberg, Jonah J.; Yang, Anthony D.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL USA. [Wandling, Michael W.; Bilimoria, Karl Y.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Nathens, Avery B.] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. RP Wandling, MW (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Surg, 251E Huron St,Ste 3-150, Chicago, IL 60611 USA. EM m-wandling@northwestern.edu FU National Institute of General Medical Sciences of the National Institutes of Health [F32GM113513]; Department of Surgery at the Northwestern University Feinberg School of Medicine FX Research reported in this publication was supported by grant F32GM113513 from the National Institute of General Medical Sciences of the National Institutes of Health and by the Department of Surgery at the Northwestern University Feinberg School of Medicine. NR 11 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD DEC PY 2016 VL 151 IS 12 BP 1125 EP 1130 DI 10.1001/jamasurg.2016.2059 PG 6 WC Surgery SC Surgery GA EH1VQ UT WOS:000391556100008 PM 27556900 ER PT J AU Massarweh, NN Kougias, P Wilson, MA AF Massarweh, Nader N. Kougias, Panagiotis Wilson, Mark A. TI Complications and Failure to Rescue After Inpatient Noncardiac Surgery in the Veterans Affairs Health System SO JAMA SURGERY LA English DT Article ID QUALITY IMPROVEMENT PROGRAM; SURGICAL-CARE; AMERICAN-COLLEGE; HOSPITAL PARTICIPATION; MEDICARE BENEFICIARIES; PRIVATE-SECTOR; OLDER PATIENTS; OF-CARE; ASSOCIATION; OUTCOMES AB IMPORTANCE The quality of surgical care in the Veterans Health Administration improved markedly in the 1990s after implementation of the Veterans Affairs (VA) National Surgical Quality Improvement Program (now called the VA Surgical Quality Improvement Program). Although there have been many recent evaluations of surgical care in the private sector, to date, a contemporary global evaluation has not been performed within the VA health system. OBJECTIVE To provide a contemporaneous report of noncardiac postoperative outcomes in the VA health system during the past 15 years. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study was conducted using data from the VA Surgical Quality Improvement Program among veterans who underwent inpatient general, vascular, thoracic, genitourinary, neurosurgical, orthopedic, or spine surgery from October 1, 1999, through September 30, 2014. MAIN OUTCOMES AND MEASURES Rates of 30-day morbidity, mortality, and failure to rescue (FTR) over time. RESULTS Among 704 901 patients (mean [SD] age, 63.7 [11.8] years; 676 750 [96%] male) undergoing noncardiac surgical procedures at 143 hospitals, complications occurred in 97 836 patients (13.9%), major complications occurred in 66 816 (9.5%), FTR occurred in 12 648 of the 97 836 patients with complications (12.9%), FTR after major complications occurred in 12 223 of the 66 816 patients with major complications (18.3%), and 18 924 patients (2.7%) died within 30 days of surgery. There were significant decreases from 2000 to 2014 in morbidity (8202 of 59 421 [13.8%] vs 3368 of 32 785 [10.3%]), major complications (5832 of 59 421 [9.8%] vs 2284 of 32 785 [7%]), FTR (1445 of 8202 [17.6%] vs 351 of 3368 [10.4%]), and FTR after major complications (1388 of 5832 [23.8%] vs 343 of 2284 [15%]) (trend test, P<.001 for all). Although there were no clinically meaningful differences in rates of complications and major complications across hospital risk-adjusted mortality quintiles (any complications: lowest quintile, 20 945 of 147 721 [14.2%] vs highest quintile, 18 938 of 135 557 [14%]; major complications: lowest quintile, 14 044 of 147 721 [9.5%] vs highest quintile, 12 881 of 135 557 [9.5%]), FTR rates (any complications: lowest quintile, 2249 of 20 945 [10.7%] vs highest quintile, 2769 of 18 938 [14.6%]; major complications: lowest quintile, 2161 of 14 044 [15.4%] vs highest quintile, 2663 of 12 881 [20.7%]) were significantly higher with increasing quintile (P<.001). However, across hospital quintiles, there were significant decreases in morbidity (20.6%-29.9% decrease; trend test, P<.001 for all) and FTR (29.2%-50.6% decrease; trend test, P<.001 for all) during the study period. After hierarchical modeling, the odds of postoperative mortality, FTR, and FTR after a major complication were approximately 40% to 50% lower in the most recent study year compared with 15 years ago (P<.001 for all). CONCLUSIONS AND RELEVANCE For the past 15 years, morbidity, mortality, and FTR have improved within the VA health system. Other integrated health systems providing a high volume of surgical care for their enrollees may benefit by critically evaluating the system-level approaches of the VA health system to surgical quality improvement. C1 [Massarweh, Nader N.; Kougias, Panagiotis] Michael E DeBakey VA Med Ctr, Vet Affairs Hlth Serv, Res & Dev Ctr Innovat Qual, Houston, TX USA. [Massarweh, Nader N.; Kougias, Panagiotis] Baylor Coll Med, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,Operat Care Line 112, Houston, TX 77030 USA. [Wilson, Mark A.] Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA USA. RP Massarweh, NN (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,Operat Care Line 112, Houston, TX 77030 USA. EM massarwe@bcm.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development [CIN 13-413]; Department of Veterans Affairs, Center for Innovations in Quality, Effectiveness and Safety; Michael E. DeBakey Veterans Affairs Medical Center seed grant FX This study is based on work supported by grant CIN 13-413 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the Center for Innovations in Quality, Effectiveness and Safety and a Michael E. DeBakey Veterans Affairs Medical Center seed grant (Dr Massarweh). NR 28 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD DEC PY 2016 VL 151 IS 12 BP 1157 EP 1165 DI 10.1001/jamasurg.2016.2920 PG 9 WC Surgery SC Surgery GA EH1VQ UT WOS:000391556100015 PM 27653498 ER PT J AU Aguado, JM Silva, JT Samanta, P Singh, N AF Aguado, Jose M. Tiago Silva, Jose Samanta, Palash Singh, Nina TI Tuberculosis and Transplantation SO MICROBIOLOGY SPECTRUM LA English DT Article ID STEM-CELL TRANSPLANT; MULTIDRUG-RESISTANT TUBERCULOSIS; IMMUNE RECONSTITUTION SYNDROME; SOLID-ORGAN TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; GAMMA RELEASING ASSAY; MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; PULMONARY TUBERCULOSIS AB Mycobacterium tuberculosis is a major opportunistic pathogen in transplant recipients. Compared to that in the general population, the frequency of tuberculosis (TB) is 10 to 40 times higher in hematopoietic stem cell transplant (HSCT) recipients and 20 to 74 times higher in solid-organ transplant (SOT) recipients. Transplant recipients with TB are also more likely to develop disseminated disease, have longer time to definitive diagnosis, require more invasive diagnostic procedures, and experience greater anti-TB treatment-related toxicity than the general population. Specific risk factors for TB in SOT recipients include previous exposure to M. tuberculosis (positive tuberculin skin tests and/or residual TB lesions in pretransplant chest X ray) and the intensity of immunosuppression (use of antilymphocyte antibodies, type of basal immunosuppression, and intensification of immunosuppressive therapy for allograft rejection). Risk factors in HSCT recipients are allogeneic transplantation from an unrelated donor; chronic graft-versus-host disease treated with corticosteroids; unrelated or mismatched allograft; pretransplant conditioning using total body irradiation, busulfan, or cyclophosphamide; and type and stage of primary hematological disorder. Transplant recipients with evidence of prior exposure to M. tuberculosis should receive treatment appropriate for latent TB infection. Optimal management of active TB disease is particularly challenging due to significant drug interactions between the anti-TB agents and the immunosuppressive therapy. In this chapter, we address the epidemiology, clinical presentation, diagnostic considerations, and management strategies for TB in SOT and HSCT recipients. C1 [Aguado, Jose M.; Tiago Silva, Jose] Univ Hosp 12 Octubre, Infect Dis Unit, Madrid 28041, Spain. [Samanta, Palash; Singh, Nina] Univ Pittsburgh, Infect Dis Sect, Med Ctr, Pittsburgh, PA 15213 USA. [Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Singh, Nina] Univ Pittsburgh, Pittsburgh, PA 15240 USA. RP Aguado, JM (reprint author), Univ Hosp 12 Octubre, Infect Dis Unit, Madrid 28041, Spain. EM jaguadog1@gmail.com NR 126 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA EI 2165-0497 J9 MICROBIOL SPECTR JI Microbiol. Spectr. PD DEC PY 2016 VL 4 IS 6 AR UNSP TNMI7-0005-2016 DI 10.1128/microbiolspec.TNMI7-0005-2016 PG 14 WC Microbiology SC Microbiology GA EI1AU UT WOS:000392208200033 ER PT J AU Katiyar, SK AF Katiyar, Santosh K. TI Emerging Phytochemicals for the Prevention and Treatment of Head and Neck Cancer SO MOLECULES LA English DT Review DE head and neck cancer; epidermal growth factor receptor; phytochemical; cell migration; tumor growth ID SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; SEED PROANTHOCYANIDINS INHIBIT; GROWTH-FACTOR RECEPTOR; GREEN TEA POLYPHENOLS; EPITHELIAL-MESENCHYMAL TRANSITION; IN-VIVO INHIBITION; GRAPE SEEDS; DNA-REPAIR; TUMOR-GROWTH AB Despite the development of more advanced medical therapies, cancer management remains a problem. Head and neck squamous cell carcinoma (HNSCC) is a particularly challenging malignancy and requires more effective treatment strategies and a reduction in the debilitating morbidities associated with the therapies. Phytochemicals have long been used in ancient systems of medicine, and non-toxic phytochemicals are being considered as new options for the effective management of cancer. Here, we discuss the growth inhibitory and anti-cell migratory actions of proanthocyanidins from grape seeds (GSPs), polyphenols in green tea and honokiol, derived from the Magnolia species. Studies of these phytochemicals using human HNSCC cell lines from different sub-sites have demonstrated significant protective effects against HNSCC in both in vitro and in vivo models. Treatment of human HNSCC cell lines with GSPs, (-)-epigallocatechin-3-gallate (EGCG), a polyphenolic component of green tea or honokiol reduced cell viability and induced apoptosis. These effects have been associated with inhibitory effects of the phytochemicals on the epidermal growth factor receptor (EGFR), and cell cycle regulatory proteins, as well as other major tumor-associated pathways. Similarly, the cell migration capacity of HNSCC cell lines was inhibited. Thus, GSPs, honokiol and EGCG appear to be promising bioactive phytochemicals for the management of head and neck cancer. C1 [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35216 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr & Obes Res Ctr, Birmingham, AL 35216 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35216 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Nutr & Obes Res Ctr, Birmingham, AL 35216 USA.; Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. EM skatiyar@uab.edu FU National Cancer Institute/NIH [CA183869]; Veterans Administration [1I01BX001410] FX The work reported from the author's laboratory was supported by the funds from the National Cancer Institute/NIH (CA183869) and Veterans Administration Merit Review Award (1I01BX001410) to S.K.K. The content of this article does not necessarily reflect the views or policies of the funding agencies. Thanks to the staff members in the Author's laboratory for their outstanding contributions in the HNSCC studies. NR 82 TC 0 Z9 0 U1 3 U2 3 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1420-3049 J9 MOLECULES JI Molecules PD DEC PY 2016 VL 21 IS 12 AR 1610 DI 10.3390/molecules21121610 PG 13 WC Chemistry, Organic SC Chemistry GA EI0CQ UT WOS:000392140100005 ER PT J AU Pal, HC Katiyar, SK AF Pal, Harish C. Katiyar, Santosh K. TI Cryptolepine, a Plant Alkaloid, Inhibits the Growth of Non-Melanoma Skin Cancer Cells through Inhibition of Topoisomerase and Induction of DNA Damage SO MOLECULES LA English DT Article DE cryptolepine; skin cancer; topoisomerase; DNA damage; cell cycle; apoptosis ID DEPENDENT PROTEIN-KINASE; CYTOCHROME-C RELEASE; NF-KAPPA-B; IN-VITRO; MELANOMA-CELLS; CYCLE ARREST; SYNTHETIC CRYPTOLEPINE; INDUCED APOPTOSIS; P53; ACTIVATION AB Topoisomerases have been shown to have roles in cancer progression. Here, we have examined the effect of cryptolepine, a plant alkaloid, on the growth of human non-melanoma skin cancer cells (NMSCC) and underlying mechanism of action. For this purpose SCC-13 and A431 cell lines were used as an in vitro model. Our study reveals that SCC-13 and A431 cells express higher levels as well as activity of topoisomerase (Topo I and Topo II) compared with normal human epidermal keratinocytes. Treatment of NMSCC with cryptolepine (2.5, 5.0 and 7.5 mu M) for 24 h resulted in marked decrease in topoisomerase activity, which was associated with substantial DNA damage as detected by the comet assay. Cryptolepine induced DNA damage resulted in: (i) an increase in the phosphorylation of ATM/ATR, BRCA1, Chk1/Chk2 and gamma H2AX; (ii) activation of p53 signaling cascade, including enhanced protein expressions of p16 and p21; (iii) downregulation of cyclin-dependent kinases, cyclin D1, cyclin A, cyclin E and proteins involved in cell division (e.g., Cdc25a and Cdc25b) leading to cell cycle arrest at S-phase; and (iv) mitochondrial membrane potential was disrupted and cytochrome c released. These changes in NMSCC by cryptolepine resulted in significant reduction in cell viability, colony formation and increase in apoptotic cell death. C1 [Pal, Harish C.; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Environm Hlth Sci, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Pal, HC; Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Environm Hlth Sci, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. EM hcpal@uab.edu; skatiyar@uab.edu FU Veterans Administration Merit Review Award [1I01BX001410] FX This work was financially supported by the funds from Veterans Administration Merit Review Award (1I01BX001410 to S.K.K.). The content of this publication does not necessarily reflect the views or policies of the funding sources. The funding agency had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 0 Z9 0 U1 2 U2 2 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1420-3049 J9 MOLECULES JI Molecules PD DEC PY 2016 VL 21 IS 12 AR 1758 DI 10.3390/molecules21121758 PG 18 WC Chemistry, Organic SC Chemistry GA EI0CQ UT WOS:000392140100152 ER PT J AU Zaugg, TL Thielman, EJ Griest, S Henry, JA AF Zaugg, Tara L. Thielman, Emily J. Griest, Susan Henry, James A. TI Subjective Reports of Trouble Tolerating Sound in Daily Life versus Loudness Discomfort Levels SO AMERICAN JOURNAL OF AUDIOLOGY LA English DT Article ID TINNITUS AB Purpose: A retrospective analysis of tonal and speech loudness discomfort levels (LDLs) relative to a subjective report of sound tolerance (SRST) was performed to explore the relation between the 2 commonly used clinical measures. Method: Tonal LDLs and SRST were measured for 139 U.S. military veterans who were recruited into a study providing intervention for tinnitus. Spearman's rank correlation coefficients were computed to assess the relation between the tonal and speech LDLs and the SRST. Results: Only weak correlations were found between tonal LDLs and SRST and between speech LDLs and SRST. Conclusion: If LDLs ratings of SRST measured the same phenomenon, the measures would be strongly negatively correlated. The weak correlations found between the measures suggest that LDLs do not accurately represent a patient's ability to tolerate sound in daily life. C1 [Zaugg, Tara L.; Thielman, Emily J.; Griest, Susan; Henry, James A.] VA Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, Rehabil Res & Dev Serv, US Dept Vet Affairs, Portland, OR USA. [Griest, Susan; Henry, James A.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP Zaugg, TL (reprint author), VA Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, Rehabil Res & Dev Serv, US Dept Vet Affairs, Portland, OR USA. EM tara.zaugg@va.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA SN 1059-0889 EI 1558-9137 J9 AM J AUDIOL JI Am. J. Audiol. PD DEC PY 2016 VL 25 IS 4 BP 359 EP 363 DI 10.1044/2016_AJA-15-0034 PG 5 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA EG9QK UT WOS:000391394100004 PM 27768802 ER PT J AU Kroenke, K AF Kroenke, Kurt TI Somatic Symptoms Deserve Our Attention SO FAMILIES SYSTEMS & HEALTH LA English DT Editorial Material ID ILLNESS; DISEASE; BURDEN C1 [Kroenke, Kurt] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Kroenke, Kurt] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. RP Kroenke, K (reprint author), Regenstrief Inst Inc, Room 221,1101 West 10th St, Indianapolis, IN 46202 USA. EM kkroenke@regenstrief.org NR 10 TC 1 Z9 1 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD DEC PY 2016 VL 34 IS 4 BP 330 EP 333 DI 10.1037/fsh0000236 PG 4 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA EG9IW UT WOS:000391373300004 PM 27977289 ER PT J AU Misch, EA Safdar, N AF Misch, Elizabeth Ann Safdar, Nasia TI Updated guidelines for the diagnosis and management of aspergillosis SO JOURNAL OF THORACIC DISEASE LA English DT Article ID LIVER-TRANSPLANT RECIPIENTS; INFECTIOUS-DISEASES SOCIETY; INVASIVE FUNGAL-INFECTIONS; GALACTOMANNAN ANTIGEN; SERUM GALACTOMANNAN; ANTIFUNGAL THERAPY; AZOLE RESISTANCE; TRIAL; RISK; COMBINATION C1 [Misch, Elizabeth Ann; Safdar, Nasia] Univ Wisconsin, Dept Med, 5th Floor,1685 Highland Ave, Madison, WI 53705 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Misch, EA (reprint author), Univ Wisconsin, Dept Med, 5th Floor,1685 Highland Ave, Madison, WI 53705 USA. EM eamisch@medicine.wisc.edu FU Veteran's Administration-Patient Safety Center of Inquiry FX This work is supported by a Veteran's Administration-funded Patient Safety Center of Inquiry (N Safdar). NR 20 TC 0 Z9 0 U1 2 U2 2 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD DEC PY 2016 VL 8 IS 12 BP E1771 EP E1776 DI 10.21037/jtd.2016.12.76 PG 6 WC Respiratory System SC Respiratory System GA EG6SD UT WOS:000391175400055 PM 28149638 ER PT J AU Basman, C Agrawal, PR McRee, C Saravolatz, L Chen-Scarabelli, C Scarabelli, TM AF Basman, Craig Agrawal, Pratik R. McRee, Chad Saravolatz, Louis Chen-Scarabelli, Carol Scarabelli, Tiziano M. TI Diagnostic Approach to Myocarditis Mimicking Myocardial Infarction at Initial Presentation SO CARDIOLOGY RESEARCH LA English DT Article DE Myocarditis; Cardiac MRI; Endomyocardial biopsy ID VIRAL MYOCARDITIS; DILATED CARDIOMYOPATHY; BIOPSY AB We present a case of a 35-year-old male patient with a 12-hour history of sudden-onset, crushing chest pain and associated complaints of profuse diaphoresis, nausea and vomiting. The patient was transferred to our institution from an outside hospital for evaluation and possible emergent catheterization. Left heart catheterization was conclusive for normal coronary arteries and a ventriculogram revealed a left ventricular ejection fraction of approximately 45%. Due to a suspicion of myocarditis based on clinical history, pertinent serology tests were ordered, which were found to be negative. Cardiac magnetic resonance on delayed enhancement imaging showed typical sub-epicardial enhancement in a pattern most consistent with myocarditis. The patient was eventually diagnosed with myocarditis and discharged home later, without needing a myocardial biopsy. We present and discuss here the indications of myocardial biopsy and compare the relative utility of cardiac magnetic resonance imaging in formulating the diagnosis of myocarditis. C1 [Basman, Craig; Agrawal, Pratik R.; Saravolatz, Louis; Scarabelli, Tiziano M.] Wayne State Univ, Sch Med, St John Hosp & Med Ctr, Detroit, MI USA. [McRee, Chad; Scarabelli, Tiziano M.] Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA. [Chen-Scarabelli, Carol; Scarabelli, Tiziano M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Scarabelli, TM (reprint author), Wayne State Univ, Sch Med, Ctr Heart & Vessel Preclin Studies, Detroit, MI 48202 USA. EM tscarabelli@hotmail.com NR 15 TC 0 Z9 0 U1 1 U2 1 PU ELMER PRESS INC PI QUEBEC PA 9160 BOUL LEDUC, BUREAU 410, BROSSARD, QUEBEC, J4Y 0E3, CANADA SN 1923-2829 EI 1923-2837 J9 CARDIOL RES JI Cardiol. Res. PD DEC PY 2016 VL 7 IS 6 BP 209 EP 213 DI 10.14740/cr485w PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EG3JA UT WOS:000390938700004 PM 28197294 ER PT J AU Batur, P Schwarz, EB Walsh, JME Johnson, KM AF Batur, Pelin Schwarz, Eleanor Bimla Walsh, Judith M. E. Johnson, Kay M. TI Women's health 2016: An update for internists SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Review ID URINARY-TRACT-INFECTION; RANDOMIZED-CONTROLLED-TRIAL; ORAL-CONTRACEPTIVE USE; REPRODUCTIVE FACTORS; PROSPECTIVE COHORT; CANCER; MORTALITY; FRACTURE; RISK; OSTEOPOROSIS AB Internists are called upon on a daily basis to address a range of women's health issues. Staying up to date with the evidence in this wide field can be challenging. This article reviews important studies published in 2015 and early 2016 pertinent to urinary tract infection, osteoporosis, ovarian cancer screening, and contraception. C1 [Batur, Pelin] Cleveland Clin, Primary Care Womens Hlth, Cleveland, OH USA. [Batur, Pelin] Case Western Reserve Univ, Cleveland Clin Lerner, Coll Med, Cleveland, OH USA. [Batur, Pelin] Cleveland Clin, Journal Med, Cleveland, OH USA. [Schwarz, Eleanor Bimla] Univ Calif Davis, Med, Davis, CA 95616 USA. [Walsh, Judith M. E.] Univ Calif San Francisco, Ctr Excellence Womens Hlth, Div Gen Internal Med, San Francisco, CA 94143 USA. [Johnson, Kay M.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Div Gen Internal Med,Med, Seattle, WA 98195 USA. RP Batur, P (reprint author), Independence Family Hlth Ctr, 5001 Rockside Rd,Crown Ctr II, Independence, CA 44131 USA. EM baturp@ccf.org NR 48 TC 0 Z9 1 U1 3 U2 3 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD DEC PY 2016 VL 83 IS 12 BP 905 EP 913 DI 10.3949/ccjm.83a.16098 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA EG3ER UT WOS:000390927100008 PM 27938517 ER PT J AU Tsui, JI Williams, EC Green, PK Berry, K Su, F Ioannou, GN AF Tsui, Judith I. Williams, Emily C. Green, Pamela K. Berry, Kristin Su, Feng Ioannou, George N. TI Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Hepatitis c treatment; Direct antiviral agents; AUDIT-C ID OF-VETERANS-AFFAIRS; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; VIRAL-HEPATITIS; NATIONAL-HEALTH; LIVER-DISEASE; USE DISORDERS; PRIMARY-CARE; AUDIT-C; INFECTION AB Background: It is unclear whether alcohol use negatively impacts HCV treatment outcomes in the era of direct antiviral agents (DAAs). We aimed to evaluate the associations between current levels of drinking and treatment response among persons treated for HCV with DAAs in the national Veterans Affairs (VA) healthcare system. Methods: We identified patients who initiated HCV DAAs over 18 months (1/1/14-6/30/15) and had documented alcohol screening with the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaire within one year prior to initiating therapy. DAAs included: sofosbuvir (SOF), ledipasvir/sofosbuvir (LDV/SOF) or ombitasvir-paritaprevir-ritonavir, and dasabuvir (PrOD). AUDIT-C scores were categorized as 0 (abstinence), 1-3 (low-level drinking) and 4-12 (unhealthy drinking) in men or 0, 1-2 and 3-12 in women. Results: Among 17,487 patients who initiated DAAs, 15,151 (87%) completed AUDIT-C screening: 10,387 (68.5%) were categorized as abstinent, 3422 (22.6%) as low-level drinking and 1342 (8.9%) as unhealthy drinking. There were no significant differences in sustained virologic response (SVR) rates between abstinent (SVR 91%; 95% CI: 91-92%), low-level drinking (SVR 93%; 95% CI 92-94%) or unhealthy drinking (SVR 91%; 95% 89-92) categories in univariable analysis or in multivariable logistic regression models. However, after imputing missing SVR data, unhealthy drinkers were less likely to achieve SVR in multivariable analysis (AOR 0.75, 95% CI 0.60-0.92). Conclusion: Absolute SVR rates were uniformly high among all persons regardless of alcohol use, with only minor differences in those who report unhealthy drinking, which supports clinical guidelines that do not recommend excluding persons with alcohol use. Published by Elsevier Ireland Ltd. C1 [Tsui, Judith I.] Gen Internal Med, Seattle, WA USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Williams, Emily C.; Green, Pamela K.; Berry, Kristin; Ioannou, George N.] Hlth Serv Res & Dev, Seattle, WA USA. [Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Innovat Veteran Cent Value Driven Care COIN, Seattle, WA USA. [Su, Feng; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol Med, Seattle, WA USA. [Su, Feng; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro 1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 44 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 1 PY 2016 VL 169 BP 101 EP 109 DI 10.1016/j.drugalcdep.2016.10.021 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EG3SO UT WOS:000390965200016 PM 27810652 ER PT J AU Kaltenbach, T Soetikno, R AF Kaltenbach, Tonya Soetikno, Roy TI How to Create and Deliver an Effective Presentation SO GASTROENTEROLOGY LA English DT Editorial Material C1 [Kaltenbach, Tonya] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med,Dept Clin Med, Div Gastroenterol, San Francisco, CA 94143 USA. [Soetikno, Roy] Stanford Grad Sch Business, Stanford, CA USA. RP Kaltenbach, T (reprint author), Univ Calif San Francisco, San Francisco Vet Affair Med Ctr, Dept Med, Div Gastroenterol,Clin Med, 4150 Clement St VA111B,Bldg 203,2A-67, San Francisco, CA 94121 USA. EM endoresection@me.com NR 3 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2016 VL 151 IS 6 BP 1058 EP 1060 DI 10.1053/j.gastro.2016.10.009 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EG3OV UT WOS:000390955500011 PM 27765689 ER PT J AU Zabetian, CP AF Zabetian, Cyrus P. TI The Clinical Profile of GBA-Related Lewy Body Disorders SO JAMA NEUROLOGY LA English DT Editorial Material ID PARKINSONS-DISEASE; GLUCOCEREBROSIDASE MUTATIONS; METAANALYSIS; MULTICENTER; RISK C1 [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. RP Zabetian, CP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu NR 15 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD DEC 1 PY 2016 VL 73 IS 12 BP 1403 EP 1404 DI 10.1001/jamaneurol.2016.2546 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EG5ZB UT WOS:000391122200009 PM 27723881 ER PT J AU Admon, L Haefner, JK Kolenic, GE Chang, T Davis, MM Moniz, MH AF Admon, Lindsay Haefner, Jessica K. Kolenic, Giselle E. Chang, Tammy Davis, Matthew M. Moniz, Michelle H. TI Recruiting Pregnant Patients for Survey Research: A Head to Head Comparison of Social Media-Based Versus Clinic-Based Approaches SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE pregnant women; surveys and questionnaires; methods; social media ID HEALTH RESEARCH; FACEBOOK; WOMEN; SITE AB Background: Recruiting a diverse sample of pregnant women for clinical research is a challenging but crucial task for improving obstetric services and maternal and child health outcomes. Objective: To compare the feasibility and cost of recruiting pregnant women for survey research using social media-based and clinic-based approaches. Methods: Advertisements were used to recruit pregnant women from the social media website Facebook. In-person methods were used to recruit pregnant women from the outpatient clinic of a large, tertiary care center. In both approaches, potential respondents were invited to participate in a 15-minute Web-based survey. Each recruitment method was monitored for 1 month. Using bivariate statistics, we compared the number, demographic characteristics, and health characteristics of women recruited and the cost per completed survey for each recruitment method. Results: The social media-based approach recruited 1178 women and the clinic-based approach recruited 219 women. A higher proportion of subjects recruited through social media identified as African American (29.4%, 207/705 vs 11.2%, 20/179), reported household incomes 36 h of EEG yielding 10,404 h of data (mean age 57 years, 81 % arrested out-of-hospital, 33 % shockable rhythms, 31 % overall survival, 17 % discharged to home or acute rehabilitation). We identified 4 distinct SR trajectories associated with survival (62, 26, 12, and 0 %, P < 0.0001 across groups) and CPC (35, 10, 4, and 0 %, P < 0.0001 across groups). Adding trajectories significantly improved model performance compared to adding non-longitudinal data. Longitudinal analysis of continuous qEEG data using GBTM provides more predictive information than analysis of qEEG at single time-points after CA. C1 [Elmer, Jonathan; Shutter, Lori A.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA. [Elmer, Jonathan; Rittenberger, Jon C.; Faro, John; Callaway, Clifton W.] Univ Pittsburgh, Dept Emergency Med, Iroquois Bldg,Suite 400A,3600 Forbes Ave, Pittsburgh, PA 15213 USA. [Gianakas, John J.; Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Epidemiol Data Ctr, Pittsburgh, PA 15261 USA. [Baldwin, Maria E.] VA Pittsburgh Healthcare Syst, Dept Neurol, Pittsburgh, PA USA. [Plummer, Cheryl] Univ Pittsburgh, Med Ctr, Div Clin Neurophysiol, Pittsburgh, PA USA. [Shutter, Lori A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Shutter, Lori A.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA. [Wassel, Christina L.] Univ Vermont, Dept Pathol & Lab Med, Coll Med, Burlington, VT 05405 USA. RP Elmer, J (reprint author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Elmer, J (reprint author), Univ Pittsburgh, Dept Emergency Med, Iroquois Bldg,Suite 400A,3600 Forbes Ave, Pittsburgh, PA 15213 USA. EM elmerjp@upmc.edu FU NIH [5K12HL109068] FX Dr. Elmer's research time was supported by NIH Grant 5K12HL109068. NR 35 TC 0 Z9 0 U1 2 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 EI 1556-0961 J9 NEUROCRIT CARE JI Neurocrit. Care PD DEC PY 2016 VL 25 IS 3 BP 415 EP 423 DI 10.1007/s12028-016-0263-9 PG 9 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA EE9ZI UT WOS:000389984600011 PM 27033709 ER PT J AU Moore, DT Rosenheck, RA AF Moore, David Thomas Rosenheck, Robert A. TI Factors Affecting Emergency Department Use by a Chronically Homeless Population SO PSYCHIATRIC SERVICES LA English DT Article ID NEW-YORK-CITY; MENTAL-HEALTH-SERVICES; RISK-FACTORS; RANDOMIZED-TRIAL; FREQUENT USERS; MEDICAL-CARE; ADULTS; VETERANS; ILLNESS; PREDICTORS AB Objective: Homeless adults make extensive use of emergency department (ED) services. This study examined factors associated with moderate and high ED use in a cohort of chronically homeless individuals. Methods: A cross-sectional analysis identified factors related to ED use in a cohort of 755 individuals at 11 sites at entry into the Collaborative Initiative to Help End Chronic Homelessness (CICH). Bivariate analyses identified sociodemographic, housing status, health status, and servicerelated factors associated with moderate and high ED use. Independent risk factors were then identified by using a multivariate multinomial model. Hierarchical regression was used to compare the strengths of association between ED use and blocks of factors composed of sociodemographic, housing, health, and service-related characteristics. Results: In a three-month period, 30% of participants visited the ED one or two times (moderate ED use) and 12% visited three or more times (high-ED use). ED use was most strongly associated with poor health and utilization of other non-ED services and to a lesser extent with housing status. Conclusions: Increased ED utilization was associated with both general medical and psychiatric morbidity and greater use of non-ED services. Thus ED use was related to high need and acuity and was not ameliorated by use of other services. Housing instability and homelessness contributed less robustly to increased ED use. More coordinated services may better address the complex medical, housing, and psychosocial needs of chronically homeless individuals. C1 [Moore, David Thomas; Rosenheck, Robert A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Rosenheck, Robert A.] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. RP Moore, DT (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. EM david.moore@yale.edu FU Office of Research and Development, Veterans Health Administration; National Institute of Mental Health [5T32MH062994-13]; U.S. Department of Housing and Urban Development; U.S. Department of Health and Human Services; Department of Veterans Affairs FX The Collaborative Initiative to Help End Chronic Homelessness Funder's Group, representing the U.S. Department of Housing and Urban Development, the U.S. Department of Health and Human Services, and the Department of Veterans Affairs, provided support and guidance to this evaluation. This material is also based on work supported by the Office of Research and Development, Veterans Health Administration. Further financial support was provided by training grant 5T32MH062994-13 from the National Institute of Mental Health. The views presented here are those of the authors and do not represent the position of any federal agency or of the United States government. NR 44 TC 0 Z9 0 U1 7 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC 1 PY 2016 VL 67 IS 12 BP 1340 EP 1347 DI 10.1176/appi.ps.201500526 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EF1ZE UT WOS:000390122900015 PM 27417899 ER PT J AU Durisko, C McCue, M Doyle, PJ Dickey, MW Fiez, JA AF Durisko, Corrine McCue, Michael Doyle, Patrick J. Dickey, Michael Walsh Fiez, Julie A. TI A Flexible and Integrated System for the Remote Acquisition of Neuropsychological Data in Stroke Research SO TELEMEDICINE AND E-HEALTH LA English DT Article DE behavioral health; cardiology; cardiovascular disease; telemedicine; telepsychiatry; teleneurology ID COGNITIVE REHABILITATION; TELEHEALTH DELIVERY; CAMPERDOWN PROGRAM; ISCHEMIC-STROKE; TELEREHABILITATION; DEFICITS; APHASIA; INTERNET; TRIAL; CARE AB Background:Neuropsychological testing is a central aspect of stroke research because it provides critical information about the cognitive-behavioral status of stroke survivors, as well as the diagnosis and treatment of stroke-related disorders. Standard neuropsychological methods rely upon face-to-face interactions between a patient and researcher, which creates geographic and logistical barriers that impede research progress and treatment advances.Introduction:To overcome these barriers, we created a flexible and integrated system for the remote acquisition of neuropsychological data (RAND). The system we developed has a secure architecture that permits collaborative videoconferencing. The system supports shared audiovisual feeds that can provide continuous virtual interaction between a participant and researcher throughout a testing session. Shared presentation and computing controls can be used to deliver auditory and visual test items adapted from standard face-to-face materials or execute computer-based assessments. Spoken and manual responses can be acquired, and the components of the session can be recorded for offline data analysis.Materials and Methods:To evaluate its feasibility, our RAND system was used to administer a speech-language test battery to 16 stroke survivors with a variety of communication, sensory, and motor impairments. The sessions were initiated virtually without prior face-to-face instruction in the RAND technology or test battery.Results:Neuropsychological data were successfully acquired from all participants, including those with limited technology experience, and those with a communication, sensory, or motor impairment. Furthermore, participants indicated a high level of satisfaction with the RAND system and the remote assessment that it permits.Conclusions:The results indicate the feasibility of using the RAND system for virtual home-based neuropsychological assessment without prior face-to-face contact between a participant and researcher. Because our RAND system architecture uses off-the-shelf technology and software, it can be duplicated without specialized expertise or equipment. In sum, our RAND system offers a readily available and promising alternative to face-to-face neuropsychological assessment in stroke research. C1 [Durisko, Corrine; Fiez, Julie A.] Univ Pittsburgh, Learning Res & Dev Ctr, 3939 OHara St, Pittsburgh, PA 15260 USA. [McCue, Michael] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Doyle, Patrick J.; Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Doyle, Patrick J.; Dickey, Michael Walsh; Fiez, Julie A.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh; Fiez, Julie A.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Fiez, Julie A.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA. RP Fiez, JA (reprint author), Univ Pittsburgh, Learning Res & Dev Ctr, 3939 OHara St, Pittsburgh, PA 15260 USA. EM fiez@pitt.edu FU American Heart Association [AHA-RMT31010862]; National Institute of Deafness and Communication Disorders [NIH R21DC013568A] FX We gratefully acknowledge the support of American Heart Association (AHA-RMT31010862) and the National Institute of Deafness and Communication Disorders (NIH R21DC013568A). NR 55 TC 0 Z9 0 U1 5 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD DEC PY 2016 VL 22 IS 12 BP 1032 EP 1040 DI 10.1089/tmj.2015.0235 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EF5ZB UT WOS:000390407500010 PM 27214198 ER PT J AU Guihan, M Sohn, MW Bauman, WA Spungen, AM Powell-Cope, GM Thomason, SS Collins, JF Bates-Jensen, BM AF Guihan, Marylou Sohn, Min-Woong Bauman, William A. Spungen, Ann M. Powell-Cope, Gail M. Thomason, Susan S. Collins, Joseph F. Bates-Jensen, Barbara M. TI Difficulty in Identifying Factors Responsible for Pressure Ulcer Healing in Veterans With Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Pressure ulcer; Rehabilitation; Spinal cord injuries; Veterans ID NEUROPATHIC FOOT ULCERS; SURROGATE END-POINTS; RISK-FACTORS; MONITORING TOOL; HELP-SEEKING; WOUND AREA; IMPAIRMENT; PREVALENCE; PREDICTORS; DURATION AB Objective: To identify characteristics associated with pressure ulcer (PrU) healing for individuals with spinal cord injury (SCI). Design: Secondary analysis of a large clinical trial's data for healing PrUs in individuals with SCI; prospective Delphi process was conducted with SCI and/or PrU experts. Setting: Spinal cord injury centers. Participants: There were 629 screening and 162 treatment participants (N=791); 185 SCI clinicians/national PrU/wound care experts participated in the Delphi process. Interventions: None. Main Outcome Measure: PrU healing of 50% and 100% at weeks 4 and 12. Results: Poisson regression models using the top Delphi-recommended factors found that only ulcer stage consistently predicted 50% and 100% healing at weeks 4 and 12. Additionally, ischial/perineal location was associated with 33% higher likelihood of 50% healing at week 4. Patient noncompliance with treatment recommendations, the top-ranked Delphi factor, did not predict healing at week 4 or 12. Expanded models found that at week 4, baseline PrU size, PrU stage IV, PrU pain, and American Spinal Injury Association grade A significantly predicted 100% healing, while at week 12, only PrU stage (IV) significantly predicted 100% healing. Significant predictors of 50% healing at week 4 included baseline PrU size, stage, ischial/perianal location body mass index >30kg/m(2), foul odor, and signs of infection. At week 12, PrU duration, paraplegia predicted 50% healing. SCI center identifiers consistently showed 2- to 5-fold variation in predicting 50% PrU healing at weeks 4 and 12. Conclusions: Delphi panel-recommended factors (eg, patient compliance) did not predict PrU healing. Reducing center-level variability in wound healing by learning from best practices should be a health system goal. PrU healing in SCI is still poorly understood, and future studies should focus on as yet unidentified or underappreciated factors. Published by Elsevier Inc. on behalf of the American Congress of Rehabilitation Medicine C1 [Guihan, Marylou; Bates-Jensen, Barbara M.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Guihan, Marylou] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA. [Sohn, Min-Woong] Univ Virginia, Sch Med, Publ Hlth Sci, Charlottesville, VA USA. [Bauman, William A.; Spungen, Ann M.] James J Peters Vet Adm Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, Vet Adm Rehabil Res & Dev, Bronx, NY USA. [Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med & Rehabil Med, New York, NY 10029 USA. [Powell-Cope, Gail M.; Thomason, Susan S.] Ctr Innovat Disabil & Rehabil Res, Tampa, FL USA. [Powell-Cope, Gail M.] Univ S Florida, Sch Nursing, Tampa, FL USA. [Collins, Joseph F.] Perry Point Vet Adm Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [Bates-Jensen, Barbara M.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA USA. [Bates-Jensen, Barbara M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Guihan, M (reprint author), Edward Hines Jr Vet Adm Hosp 151H, Box 5000,5000 S 5th Ave, Hines, IL 60141 USA. EM Marylou.guihan@va.gov FU Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Quality Enhancement Research Initiative [RRP-11-376] FX Supported by the Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Quality Enhancement Research Initiative (grant no. RRP-11-376). NR 36 TC 0 Z9 0 U1 5 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 2016 VL 97 IS 12 BP 2085 EP 2094 DI 10.1016/j.apmr.2016.05.025 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA EE7GM UT WOS:000389783900008 PM 27373743 ER PT J AU Pyne, JM Constans, JI Wiederhold, MD Gibson, DP Kimbrell, T Kramer, TL Pitcock, JA Han, XT Williams, DK Chartrand, D Gevirtz, RN Spira, J Wiederhold, BK McCraty, R McCune, TR AF Pyne, Jeffrey M. Constans, Joseph I. Wiederhold, Mark D. Gibson, Douglas P. Kimbrell, Timothy Kramer, Teresa L. Pitcock, Jeffery A. Han, Xiaotong Williams, D. Keith Chartrand, Don Gevirtz, Richard N. Spira, James Wiederhold, Brenda K. McCraty, Rollin McCune, Thomas R. TI Heart rate variability: Pre-deployment predictor of post-deployment PTSD symptoms SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Post traumatic stress disorder (PTSD); military; risk factors; combat stress; prediction; longitudinal; heart rate variability ID POSTTRAUMATIC-STRESS-DISORDER; CARDIAC VAGAL TONE; SYMPATHOVAGAL BALANCE; VIETNAM VETERANS; COMBAT VETERANS; SELF-REGULATION; RISK-FACTORS; IRAQ; HEALTH; US AB Heart rate variability is a physiological measure associated with autonomic nervous system activity. This study hypothesized that lower pre-deployment HRV would be associated with higher post-deployment post-traumatic stress disorder (PTSD) symptoms. Three-hundred-forty-three Army National Guard soldiers enrolled in the Warriors Achieving Resilience (WAR) study were analyzed. The primary outcome was PTSD symptom severity using the PTSD Checklist Military version (PCL) measured at baseline, 3- and 12-month post-deployment. Heart rate variability predictor variables included: high frequency power (HF) and standard deviation of the normal cardiac inter-beat interval (SDNN). Generalized linear mixed models revealed that the pre-deployment PCL*ln(HF) interaction term was significant (p < 0.0001). Pre-deployment SDNN was not a significant predictor of post-deployment PCL. Covariates included age, pre-deployment PCL, race/ethnicity, marital status, tobacco use, childhood abuse, pre-deployment traumatic brain injury, and previous combat zone deployment. Pre-deployment heart rate variability predicts post-deployment PTSD symptoms in the context of higher pre-deployment PCL scores. Published by Elsevier B.V. C1 [Pyne, Jeffrey M.; Kimbrell, Timothy; Pitcock, Jeffery A.; Han, Xiaotong] Cent Arkansas Vet Healthcare Syst, Ctr Mental Hlth Outcomes Res, North Little Rock, AR 72114 USA. [Pyne, Jeffrey M.; Constans, Joseph I.; Kimbrell, Timothy; Han, Xiaotong] Cent Arkansas Vet Healthcare Syst, South Cent Mental Illness Educ & Clin Ctr, North Little Rock, AR 72114 USA. [Pyne, Jeffrey M.; Kramer, Teresa L.; Han, Xiaotong] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA. [Constans, Joseph I.] Southeastern Louisiana Vet Hlth Care Syst 629 11F, POB 61011, New Orleans, IA 70161 USA. [Constans, Joseph I.] Tulane Univ, New Orleans, LA 70118 USA. [Wiederhold, Mark D.; Wiederhold, Brenda K.] Virtual Real Med Ctr, 9565 Waples St,Suite 200, San Diego, CA 92121 USA. [Gibson, Douglas P.] Virginia Army Natl Guard, Off State Surgeon, BLDG 1310,Ft Pickett, Blackstone, VA 23824 USA. [Williams, D. Keith] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA. [Chartrand, Don] Ease Interactive Inc, San Diego, CA USA. [Gevirtz, Richard N.] Alliant Int Univ, 10455 Pomerado Rd, San Diego, CA 92131 USA. [Spira, James] Univ Hawaii, Sch Med, US Dept Vet Affairs, Natl Ctr PTSD, Honolulu, HI 96819 USA. [Spira, James] Univ Hawaii, Sch Med, Dept Psychiat, Honolulu, HI 96819 USA. [McCraty, Rollin] Inst HeartMath, 14700 West Pk Ave, Boulder Creek, CA 95006 USA. RP Pyne, JM (reprint author), 2200 Ft Roots Dr 152-NLR, North Little Rock, AR USA. EM jmpyne@uams.edu FU Military Operational Medical Research Program [PT074626]; South Central Mental Illness and Research Educational and Clinical Center (MIRECC); National Institutes of Health [P20 GM103425-09, UL1TR000039, KL2TR000063] FX This work was supported by grants from the Military Operational Medical Research Program (PT074626), South Central Mental Illness and Research Educational and Clinical Center (MIRECC), and National Institutes of Health (P20 GM103425-09, UL1TR000039, KL2TR000063). NR 62 TC 0 Z9 0 U1 11 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 EI 1873-6246 J9 BIOL PSYCHOL JI Biol. Psychol. PD DEC PY 2016 VL 121 BP 91 EP 98 DI 10.1016/j.biopsycho.2016.10.008 PN A PG 8 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA EE3SK UT WOS:000389518500011 PM 27773678 ER PT J AU Hoerster, KD Wilson, S Nelson, KM Reiber, GE Masheb, RM AF Hoerster, Katherine D. Wilson, Sarah Nelson, Karin M. Reiber, Gayle E. Masheb, Robin M. TI Diet quality is associated with mental health, social support, and neighborhood factors among Veterans SO EATING BEHAVIORS LA English DT Article DE Veterans; Diet quality; Ecological framework ID PHYSICAL-ACTIVITY; OVERWEIGHT; BEHAVIORS; DISEASE; RELIABILITY; DEPRESSION; MILITARY; PATTERNS; VALIDITY; SCALES AB United States Veterans have a higher prevalence of overweight and related chronic conditions compared to the general population. Although diet is a primary and modifiable contributor to these conditions, little is known about factors influencing diet quality among Veterans. The goal of this study is to examine individual, social environment, and physical environment correlates of general diet quality among Veterans. Study participants (N = 653) received care at an urban VA Medical Center in Seattle, WA and completed a mailed survey in 2012 and 2013. Diet quality was assessed with Starting the Conversation, an instrument that measures consumption of unhealthy snacks, fast food, desserts, sugar-sweetened beverages, and fats; fruits and vegetables; and healthy proteins. Variables significantly (p < 0.05) associated with diet quality in bivariate analyses were included in a multivariate regression. In the multivariate model, higher level of depressive symptom severity (Diff = 0.05; CI = 0.01, 0.09; p = 0.017); not having others eat healthy meals with the Veteran (Diff = -0.81; CI = -1.5, -0.1; p = 0.022); and reduced availability of low-fat foods in neighborhood stores where the Veteran shops (Diff = -0.37; CI = -0.6, -0.2; p < 0.001) were associated with poorer diet quality. Consistent with prior research in the general population, this study identified multiple domains associated with Veterans' diet quality, including psychological comorbidity, the social environment, and the physical environment. Findings from this study suggest that interventions aimed at mental health, social support, and neighborhood access to healthy foods are needed to improve Veteran diet quality. Published by Elsevier Ltd. C1 [Hoerster, Katherine D.; Nelson, Karin M.; Reiber, Gayle E.] VA Puget Sound Healthcare Syst, Seattle Div, Res & Dev Serv, 1660 South Columbian Way,S-152, Seattle, WA 98108 USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, 1959 NE Pacific St, Seattle, WA 98195 USA. [Wilson, Sarah] Vet Affairs Midatlantic Mental Illness Res Educ &, 508 Fulton St, Durham, NC 27705 USA. [Wilson, Sarah] Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA. [Nelson, Karin M.] VA Puget Sound Healthcare Syst, Gen Internal Med Serv, 1660 South Columbian Way, Seattle, WA 98108 USA. [Nelson, Karin M.] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv & Epidemiol, Sch Publ Hlth, 1959 NE Pacific St, Seattle, WA 98195 USA. [Masheb, Robin M.] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Masheb, Robin M.] Yale Sch Med, 301 Cedar St, New Haven, CT 06520 USA. RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, Res & Dev Serv, 1660 South Columbian Way,S-152, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov; Sarah.Wilson@duke.edu; Karin.Nelson@va.gov; greiber@uw.edu; Robin.Masheb@yale.edu FU VA Puget Sound Healthcare System (VAPS); VAPS Mental Illness Research, Education, and Clinical Center; VAPS Health Services Research and Development Center of Excellence; VA CDA [HSRD-12-263]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment FX This is the result of work supported by resources from VA Puget Sound Healthcare System (VAPS). Funding was provided by VAPS Mental Illness Research, Education, and Clinical Center and VAPS Health Services Research and Development Center of Excellence. Dr. Hoerster is supported by VA CDA HSR&D-12-263. Dr. Wilson was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment. Funding sources had no involvement in design, collection, analysis, or interpretation of data, writing the manuscript, nor the decision to submit the manuscript for publication. NR 32 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1471-0153 EI 1873-7358 J9 EAT BEHAV JI Eat. Behav. PD DEC PY 2016 VL 23 BP 168 EP 173 DI 10.1016/j.eatbeh.2016.10.003 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EF0EZ UT WOS:000389999800031 PM 27816854 ER PT J AU Kaltenbach, T McQuaid, KR Soetikno, R AF Kaltenbach, Tonya McQuaid, Kenneth R. Soetikno, Roy TI Outcomes of colitis-associated dysplasia after referral from the community to a tertiary center Response SO GASTROINTESTINAL ENDOSCOPY LA English DT Letter ID INFLAMMATORY-BOWEL-DISEASE C1 [Kaltenbach, Tonya; McQuaid, Kenneth R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Soetikno, Roy] Duke Natl Univ Singapore, Singapore Gen Hosp, Singapore, Singapore. RP Kaltenbach, T (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD DEC PY 2016 VL 84 IS 6 BP 1079 EP 1080 DI 10.1016/j.gie.2016.09.004 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EE4YN UT WOS:000389611900060 PM 27855796 ER PT J AU Orr, NM Boxer, RS Dolansky, MA Allen, LA Forman, DE AF Orr, Nicole M. Boxer, Rebecca S. Dolansky, Mary A. Allen, Larry A. Forman, Daniel E. TI Skilled Nursing Facility Care for Patients With Heart Failure: Can We Make It "Heart Failure Ready?" SO JOURNAL OF CARDIAC FAILURE LA English DT Review DE Skilled nursing facility; post-acute care; heart failure; transitions; systems of care; policy ID EMERGENCY-DEPARTMENT VISITS; RANDOMIZED CONTROLLED-TRIAL; TRANSITIONAL CARE; HOSPITAL READMISSIONS; POST-ACUTE; CARDIAC REHABILITATION; DISCHARGE SUMMARIES; 30-DAY READMISSION; CLINICAL-OUTCOMES; HOME RESIDENTS AB Skilled nursing facilities (SNFs) have emerged as an integral component of care for older adults with heart failure (HF). Despite their prominent role, poor clinical outcomes for the medically complex patients with HF managed in SNFs are common. Barriers to providing quality care include poor transitional care during hospital-to-SNF and SNF-to-community discharges, lack of HF training among SNF staff, and a lack of a standardized care process among SNF facilities. Although no evidence-based practice standards have been established, various measures and tools designed to improve HF management in SNFs are being investigated. In this review, we discuss the challenges of HF care in SNFs as well as potential targets and recommendations that can help improve care with respect to transitions, HF management within SNFs, and modifiable factors within facilities. Policy considerations that might help catalyze improvements in SNF-based HF management are also discussed. C1 [Orr, Nicole M.] Tufts Med Ctr, Div Cardiol & CardioVasc Ctr, Boston, MA USA. [Orr, Nicole M.] Postacute Cardiol Care, Wellesley, MA USA. [Boxer, Rebecca S.] Eastern Colorado Denver Vet Assoc GRECC, Denver, CO USA. [Boxer, Rebecca S.; Allen, Larry A.] Univ Colorado, Sch Med, Aurora, CO USA. [Dolansky, Mary A.] Frances Payne Bolton Sch Nursing, Cleveland, OH USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Orr, NM (reprint author), 95 Chapel St,Suite 2C, Norwood, MA 02062 USA. EM non@postacutecardiologycare.com FU NIA [P30 AG024827, 1R56AG051637-01A1]; PCORI [IH-1304678]; VA Office of Rehabilitation Research and Development [F0834-R] FX Dr. Forman is supported in part by NIA grants P30 AG024827 and 1R56AG051637-01A1, PCORI grant IH-1304678, and VA Office of Rehabilitation Research and Development grant F0834-R. NR 65 TC 0 Z9 0 U1 6 U2 6 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2016 VL 22 IS 12 BP 1004 EP 1014 DI 10.1016/j.cardfail.2016.10.009 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EE4IL UT WOS:000389565400010 PM 27769909 ER PT J AU Schopfer, DW Forman, DE AF Schopfer, David W. Forman, Daniel E. TI Growing Relevance of Cardiac Rehabilitation for an Older Population With Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Review DE Old age; heart failure; multimorbidity; frailty; disability; cardiac rehabilitation ID PRESERVED EJECTION FRACTION; RANDOMIZED CONTROLLED-TRIALS; FRAIL ELDERLY-PATIENTS; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; EXERCISE CAPACITY; THERAPEUTIC INTERVENTIONS; PULMONARY-REHABILITATION AB Cardiac rehabilitation (CR) is a comprehensive lifestyle program that can have particular benefit for older patients with heart failure (HF). Prevalence of HF is increasingly common among older adults. Mounting effects of cardiovascular risk factors in older age as well as the added effects of geriatric syndromes such as multimorbidity, frailty, and sedentariness contribute to the high incidence of HF as well as to management difficulty. CR can play a decisive role in improving function, quality of life, symptoms, morbidity, and mortality, and also address the idiosyncratic complexities of care that often arise in old age. Unfortunately, the current policies and practices regarding CR for patients with HF are limited to HF with reduced ejection fraction and do not extend to HF with preserved ejection fraction, which is likely undercutting its full potential to improve care for today's aging population. Despite the strong rationale for CR on important clinical outcomes, it remains underused, particularly among older patients with HF. In this review, we discuss both the potential and the limitations of contemporary CR for older adults with HF. C1 [Schopfer, David W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Schopfer, David W.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave, Pittsburgh, PA 15213 USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res & Clin Ctr, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave, Pittsburgh, PA 15213 USA. EM formand@pitt.edu OI Schopfer, David/0000-0002-7244-9857 FU National Center for Advancing Translational Sciences of the NIH [KL2TR000143]; NIA [P30 AG024827, 1R56AG051637-01A1]; PCORI [IH-1304678]; VA Rehabilitation Research and Development grant [F0834-R] FX Dr. Schopfer is supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143. Dr. Forman is supported in part by NIA grants P30 AG024827 and 1R56AG051637-01A1, PCORI grant IH-1304678, and VA Rehabilitation Research and Development grant F0834-R. NR 90 TC 0 Z9 0 U1 6 U2 6 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2016 VL 22 IS 12 BP 1015 EP 1022 DI 10.1016/j.cardfail.2016.10.010 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EE4IL UT WOS:000389565400011 PM 27769907 ER PT J AU Hebert, PL Hernandez, SE AF Hebert, Paul L. Hernandez, Susan E. TI Providing Patient-Centered Care to Veterans of All Races: Challenges and Evidence of Success SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID QUALITY-OF-CARE; BLACK PATIENTS; HEALTH SYSTEM; MEDICAL HOME; IMPLEMENTATION; ASSOCIATIONS; DISPARITIES; HOSPITALS C1 [Hebert, Paul L.; Hernandez, Susan E.] VA Puget Sound Hlth Care Syst, VA HSR&D Ctr Innovat Patient Ctr & Value Driven H, Seattle, WA 98108 USA. [Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, VA HSR&D Ctr Innovat Patient Ctr & Value Driven H, Seattle, WA 98108 USA. EM Paul.Hebert2@VA.gov NR 11 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2016 VL 31 IS 12 BP 1412 EP 1414 DI 10.1007/s11606-016-3866-0 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EE5DX UT WOS:000389626600004 PM 27704365 ER PT J AU Walker, RJ Egede, LE AF Walker, Rebekah J. Egede, Leonard E. TI Rationing of Care: Conceptual Ambiguity and Transparency in Data Collection and Synthesis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID HEALTH-CARE C1 [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. EM egedel@musc.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2016 VL 31 IS 12 BP 1415 EP 1416 DI 10.1007/s11606-016-3801-4 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EE5DX UT WOS:000389626600005 PM 27435252 ER PT J AU Jones, AL Mor, MK Cashy, JP Gordon, AJ Haas, GL Schaefer, JH Hausmann, LRM AF Jones, Audrey L. Mor, Maria K. Cashy, John P. Gordon, Adam J. Haas, Gretchen L. Schaefer, James H., Jr. Hausmann, Leslie R. M. TI Racial/Ethnic Differences in Primary Care Experiences in Patient-Centered Medical Homes among Veterans with Mental Health and Substance Use Disorders SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient-centered medical home; health care experience; race and ethnicity; mental health services ID ETHNIC-DIFFERENCES; PATIENTS ASSESSMENTS; DIAGNOSTIC PATTERNS; DISPARITIES; SATISFACTION; QUALITY; AFFAIRS; ILLNESS; ACCESS; RACE/ETHNICITY AB Patient-Centered Medical Homes (PCMH) may be effective in managing care for racial/ethnic minorities with mental health and/or substance use disorders (MHSUDs). How such patients experience care in PCMH settings is relatively unknown. We aimed to examine racial/ethnic differences in experiences with primary care in PCMH settings among Veterans with MHSUDs. We used multinomial regression methods to estimate racial/ethnic differences in PCMH experiences reported on a 2013 national survey of Veterans Affairs patients. Veterans with past-year MHSUD diagnoses (n = 65,930; 67 % White, 20 % Black, 11 % Hispanic, 1 % American Indian/Alaska Native[AI/AN], and 1 % Asian/Pacific Island[A/PI]). Positive and negative experiences from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) PCMH Survey. Veterans with MHSUDs reported the lowest frequency of positive experiences with access (22 %) and the highest frequency of negative experiences with self-management support (30 %) and comprehensiveness (16 %). Racial/ethnic differences (as compared to Whites) were observed in all seven healthcare domains (p values < 0.05). With access, Blacks and Hispanics reported more negative (Risk Differences [RDs] = 2 .0;3.6) and fewer positive (RDs = -2 .3;-2.3) experiences, while AI/ANs reported more negative experiences (RD = 5.7). In communication, Blacks reported fewer negative experiences (RD = -1.3); AI/ANs reported more negative (RD = 3.6) experiences; and AI/ANs and APIs reported fewer positive (RD = -6.5, -6.7) experiences. With office staff, Hispanics reported fewer positive experiences (RDs = -3.0); AI/ANs and A/PIs reported more negative experiences (RDs = 3.4; 3.7). For comprehensiveness, Blacks reported more positive experiences (RD = 3.6), and Hispanics reported more negative experiences (RD = 2.7). Both Blacks and Hispanics reported more positive (RDs = 2.3; 4.2) and fewer negative (RDs = -1.8; -1.9) provider ratings, and more positive experiences with decision making (RDs = 2.4; 3.0). Blacks reported more positive (RD = 3.9) and fewer negative (RD = -5.1) experiences with self-management support. In a national sample of Veterans with MHSUDs, potential deficiencies were observed in access, self-management support, and comprehensiveness. Racial/ethnic minorities reported worse experiences than Whites with access, comprehensiveness, communication, and office staff helpfulness/courtesy. C1 Vet Affairs Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Jones, Audrey L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot CHERP, Pittsburgh, PA 15240 USA. [Mor, Maria K.] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA. [Gordon, Adam J.; Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Haas, Gretchen L.] Vet Affairs Pittsburgh Healthcare Syst, VISN4 Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Det Psychiat, Pittsburgh, PA USA. [Schaefer, James H., Jr.] Dept Vet Affairs Off Analyt & Business Intelligen, Durham, NC USA. RP Jones, AL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot CHERP, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. EM Audrey.Jones3@va.gov FU VA Office of Academic Affiliations Associated Health Professions Post-doctoral Fellow in Health Services Research at the Center for Health Equity Research and Promotion (CHERP) at the VA Pittsburgh Healthcare System; Department of Veterans Affairs VISN4 CHERP Competitive Research Pilot Program [LIP 72-081] FX Dr. Jones is supported as a VA Office of Academic Affiliations Associated Health Professions Post-doctoral Fellow in Health Services Research at the Center for Health Equity Research and Promotion (CHERP) at the VA Pittsburgh Healthcare System. The work reported here was supported by the Department of Veterans Affairs VISN4 CHERP Competitive Research Pilot Program (LIP 72-081). The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 52 TC 2 Z9 2 U1 9 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2016 VL 31 IS 12 BP 1435 EP 1443 DI 10.1007/s11606-016-3776-1 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EE5DX UT WOS:000389626600008 PM 27325318 ER PT J AU Wong, ES Rosland, AM Fihn, SD Nelson, KM AF Wong, Edwin S. Rosland, Ann-Marie Fihn, Stephan D. Nelson, Karin M. TI Patient-Centered Medical Home Implementation in the Veterans Health Administration and Primary Care Use: Differences by Patient Comorbidity Burden SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient-centered medical home; multiple chronic conditions ID LOCAL-AREA UNEMPLOYMENT; SERVICES; COST; ASSOCIATION; PRINCIPLES; BURNOUT; DEMAND; ACCESS AB The patient-centered medical home (PCMH) model has several components to improve care for patients with high comorbidity, including greater access to face-to-face primary care. We examined whether high-comorbidity patients had larger increases in primary care provider (PCP) visits attributable to PCMH implementation in a large integrated health system relative to other patients enrolled in primary care. This longitudinal study examined a 1 % random sample of 9.3 million patients enrolled in the Veterans Health Administration (VHA) at any time between 2003 and 2013. Face-to-face visits with PCPs per quarter were identified through VHA administrative data. Comorbidity was measured using the Gagne index and patients with a weighted score of 2 were defined as high comorbidity. We applied interrupted time-series models to estimate marginal changes in PCP visits attributable to PCMH implementation. Differences in marginal changes were calculated across comorbidity groups (high vs. low). Analyses were stratified by age group to account for Medicare eligibility. Among age 65+ patients, PCMH was associated with greater PCP visits starting four and ten quarters following implementation for high- and low-comorbidity patients, respectively. Changes were larger for high-comorbidity patients (eight to 11 greater visits per 1000 patients per quarter). Among patients age < 65, PCMH was associated with greater visits for high-comorbidity patients starting eight quarters following implementation, but fewer visits for low-comorbidity patients in all quarters. The difference in visit changes across groups ranged from 18 to 67 visits per 1000 patients per quarter. Increases in PCP visits attributable to PCMH were greater among patients with higher comorbidity. Health systems implementing PCMH should account for population-level comorbidity burden when planning for PCMH-related changes in PCP utilization. C1 [Wong, Edwin S.; Nelson, Karin M.] Ctr Veteran Ctr & Value Driven Care, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Wong, Edwin S.; Nelson, Karin M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Rosland, Ann-Marie] VHA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Rosland, Ann-Marie] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Fihn, Stephan D.] Vet Hlth Adm, Off Analyt & Business Intelligence, Seattle, WA USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Wong, ES (reprint author), Ctr Veteran Ctr & Value Driven Care, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,MS S-152, Seattle, WA 98108 USA. EM edwin.wong@va.gov FU Veterans Health Administration Patient Aligned Care Team Demonstration Laboratory Coordination Center [XVA-61-041]; VA Health Services Research and Development Career Development Award [VA HSRD CDA 13-024]; VA HSRD CDA [10-209] FX This study was funded by the Veterans Health Administration Patient Aligned Care Team Demonstration Laboratory Coordination Center (XVA-61-041). Dr. Wong is supported by a VA Health Services Research and Development Career Development Award (VA HSR&D CDA 13-024). Dr. Rosland is supported by VA HSR&D CDA 10-209. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the University of Washington, the University of Michigan or the United States Government. The authors thank the deputy editor and three reviewers for their helpful comments. NR 27 TC 1 Z9 1 U1 5 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2016 VL 31 IS 12 BP 1467 EP 1474 DI 10.1007/s11606-016-3833-9 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EE5DX UT WOS:000389626600012 PM 27503440 ER PT J AU Thorp, J Dattalo, M Ghanem, K Christmas, C AF Thorp, Jonathon Dattalo, Melissa Ghanem, Khalil G. Christmas, Colleen TI Implementation of 2011 Duty Hours Regulations through a Workload Reduction Strategy and Impact on Residency Training SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE duty hour changes; ACGME; admission numbers; workload reduction; workload compression ID INTERNAL-MEDICINE RESIDENTS; PATIENT-CENTERED CARE; EXAMINATION PERFORMANCE; PROGRAM DIRECTORS; SLEEP DURATION; ASSOCIATION; REFORM; CONTINUITY; MORTALITY; EDUCATION AB Training programs have implemented the 2011 ACGME duty hour regulations (DHR) using "workload compression" (WLC) strategies, attempting to fit similar clinical responsibilities into fewer working hours, or workload reduction (WLR) approaches, reducing the number of patient encounters per trainee. Many have expressed concern that these strategies could negatively impact patient care and learner outcomes. This study evaluates the medical knowledge and clinical impact of a WLR intervention in a single institution. Nonrandomized intervention study with comparison to a historical control study among 58 PGY-1 internal medicine trainees in the 2 years after duty hour implementation [exposure cohort (EC), 7/1/2011-6/30/2013], compared to 2 years before implementation [comparison cohort (CC), 7/1/2009-6/30/2011]. Process outcomes were average inpatient encounters, average new inpatient admissions, and average scheduled outpatient encounters per PGY-1 year. Performance outcomes included trainee inpatient and outpatient days on service, In-Training Examination (ITE) scores as an objective surrogate of medical knowledge, Case-Mix Index (CMI), and quality of care measures (30-day readmission rate, 30-day mortality rate, and average length of stay). Baseline characteristics and average numbers of inpatient encounters per PGY-1 class were similar between the EC and CC. However, the EC experienced fewer new inpatient admissions (157.47 +/- 40.47 vs. 181.72 +/- 25.45; p < 0.01), more outpatient encounters (64.80 +/- 10.85 vs. 56.98 +/- 6.59; p < 0.01), and had similar ITE percentiles (p = 0.58). Patients of similar complexity cared for by the EC also had a greater reduction in readmissions (21.21 % to 19.08 %; p < 0.01) than the hospital baseline (12.07 to 11.14 %; p < 0.01). Our WLR resulted in a small decrease in the average number of new inpatient admissions and an increase in outpatient encounters. ITE and care quality outcomes were maintained or improved. While there is theoretical concern that reducing PGY-1 inpatient admissions volumes may negatively impact education and clinical care measures, this study found no evidence of such a trade-off. C1 [Thorp, Jonathon; Ghanem, Khalil G.; Christmas, Colleen] Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, 5200 Eastern Ave,Mason F Lord Bldg Ctr Tower,2nd, Baltimore, MD 21218 USA. [Dattalo, Melissa] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Dattalo, Melissa] Univ Wisconsin Madison, Div Geriatr & Gerontol, Madison, WI USA. RP Christmas, C (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, 5200 Eastern Ave,Mason F Lord Bldg Ctr Tower,2nd, Baltimore, MD 21218 USA. EM cchristm@jhmi.edu NR 30 TC 2 Z9 2 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2016 VL 31 IS 12 BP 1475 EP 1481 DI 10.1007/s11606-016-3840-x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EE5DX UT WOS:000389626600013 PM 27514539 ER PT J AU Brondfield, S Dhaliwal, G AF Brondfield, Sam Dhaliwal, Gurpreet TI Giant Inguinoscrotal Hernia SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Brondfield, Sam] Univ Calif San Francisco, Dept Med, 505 Parnassus Ave Rm 987, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Brondfield, S (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave Rm 987, San Francisco, CA 94143 USA. EM sam.brondfield@ucsf.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2016 VL 31 IS 12 BP 1537 EP 1537 DI 10.1007/s11606-016-3710-6 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EE5DX UT WOS:000389626600029 PM 27154730 ER PT J AU Madaras-Kelly, KJ Burk, M Caplinger, C Bohan, JG Neuhauser, MM Goetz, MB Zhang, R Cunningham, FE AF Madaras-Kelly, Karl J. Burk, Muriel Caplinger, Christina Bohan, Jefferson G. Neuhauser, Melinda M. Goetz, Matthew Bidwell Zhang, Rongping Cunningham, Francesca E. CA Pneumonia Duration Therapy Medica TI Total Duration of Antimicrobial Therapy in Veterans Hospitalized With Uncomplicated Pneumonia: Results of a National Medication Utilization Evaluation SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; CLOSTRIDIUM-DIFFICILE INFECTION; ANTIBIOTIC USE; DISEASES-SOCIETY; UNITED-STATES; CARE; STEWARDSHIP; METAANALYSIS; GUIDELINES; MANAGEMENT AB OBJECTIVE: Practice guidelines recommend the shortest duration of antimicrobial therapy appropriate to treat uncomplicated pneumonia be prescribed to reduce the emergence of resistant pathogens. A national evaluation was conducted to assess the duration of therapy for pneumonia. DESIGN: Retrospective medication utilization evaluation. SETTING: Thirty Veterans Affairs medical centers. PATIENTS: Inpatients discharged with a diagnosis of pneumonia. MEASUREMENTS: A manual review of electronic medical records of inpatients discharged with uncomplicated community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) was conducted. Appropriate CAP therapy duration was defined as at least 5 days, and up to 3 additional days beginning the first day the patient achieved clinical stability criteria; the appropriate HCAP therapy duration was defined as 8 days. The duration of antimicrobial therapy for intravenous (IV) and oral (PO) inpatient administration, PO therapy dispensed upon discharge, Clostridium difficile infection (CDI), hospital readmission, and death rates were measured. RESULTS: Of 3881 pneumonia admissions, 1739 met inclusion criteria (CAP [n = 1195]; HCAP [n = 544]). Overall, 13.9% of patients (CAP [6.9%], HCAP [29.0%]) received therapy duration consistent with guideline recommendations. The median (interquartile range) days of therapy were 4 days (3-6 days), 1 day (0-3 days), and 6 days (4-8 days) for inpatient IV, inpatient PO, and outpatient PO antimicrobials, respectively. CDI was rare but more common in patients who received therapy duration consistent with guidelines. Therapy duration was not associated with the readmission or mortality rate. CONCLUSIONS: Antimicrobials were commonly prescribed for a longer duration than guidelines recommend. The majority of excessive therapy was completed upon discharge, identifying the need for strategies to curtail unnecessary use postdischarge. (C) 2016 Society of Hospital Medicine C1 [Madaras-Kelly, Karl J.] Vet Affairs Med Ctr, Serv Pharm, Meridian, ID USA. [Madaras-Kelly, Karl J.] Idaho State Univ, Coll Pharm, Dept Pharm Practice, Meridian, ID USA. [Burk, Muriel; Zhang, Rongping; Cunningham, Francesca E.] Hines VA, Ctr Medicat Safety, Hines, IL USA. [Burk, Muriel; Neuhauser, Melinda M.; Cunningham, Francesca E.] Hines VA, VA Pharm Benefits Management Serv, Hines, IL USA. [Caplinger, Christina; Bohan, Jefferson G.] Vet Affairs Med Ctr, Serv Pharm, Boise, ID USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Hlth Care Syst, Infect Dis Sect, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Madaras-Kelly, KJ (reprint author), Vet Affairs Med Ctr, T111,500 West Ft St, Boise, ID 83713 USA. EM karl.madaras-kelly2@va.gov NR 38 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD DEC PY 2016 VL 11 IS 12 BP 832 EP 839 DI 10.1002/jhm.2648 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EE2NB UT WOS:000389420100003 PM 27527659 ER PT J AU Roalf, DR Moore, TM Wolk, DA Arnold, SE Mechanic-Hamilton, D Rick, J Kabadi, S Ruparel, K Chen-Plotkin, AS Chahine, LM Dahodwala, NA Duda, JE Weintraub, DA Moberg, PJ AF Roalf, David R. Moore, Tyler M. Wolk, David A. Arnold, Steven E. Mechanic-Hamilton, Dawn Rick, Jacqueline Kabadi, Sushila Ruparel, Kosha Chen-Plotkin, Alice S. Chahine, Lama M. Dahodwala, Nabila A. Duda, John E. Weintraub, Daniel A. Moberg, Paul J. TI Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID MINI-MENTAL-STATE; IMPAIRMENT HARMONIZATION STANDARDS; STROKE-CANADIAN STROKE; SCREENING INSTRUMENTS; PARKINSONS-DISEASE; NEUROPSYCHOLOGICAL BATTERY; NEUROLOGICAL DISORDERS; NATIONAL INSTITUTE; LINE ORIENTATION; PRIMARY-CARE AB Introduction Screening for cognitive deficits is essential in neurodegenerative disease. Screening tests, such as the Montreal Cognitive Assessment (MoCA), are easily administered, correlate with neuropsychological performance and demonstrate diagnostic utility. Yet, administration time is too long for many clinical settings. Methods Item response theory and computerised adaptive testing simulation were employed to establish an abbreviated MoCA in 1850 well-characterised community-dwelling individuals with and without neurodegenerative disease. Results 8 MoCA items with high item discrimination and appropriate difficulty were identified for use in a short form (s-MoCA). The s-MoCA was highly correlated with the original MoCA, showed robust diagnostic classification and cross-validation procedures substantiated these items. Discussion Early detection of cognitive impairment is an important clinical and public health concern, but administration of screening measures is limited by time constraints in demanding clinical settings. Here, we provide as-MoCA that is valid across neurological disorders and can be administered in approximately 5 min. C1 [Roalf, David R.; Moore, Tyler M.; Mechanic-Hamilton, Dawn; Kabadi, Sushila; Ruparel, Kosha; Weintraub, Daniel A.; Moberg, Paul J.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Wolk, David A.; Arnold, Steven E.; Chen-Plotkin, Alice S.; Chahine, Lama M.; Dahodwala, Nabila A.; Duda, John E.; Weintraub, Daniel A.; Moberg, Paul J.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Wolk, David A.; Arnold, Steven E.; Mechanic-Hamilton, Dawn; Moberg, Paul J.] Univ Penn, Perelman Sch Med, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. [Rick, Jacqueline; Weintraub, Daniel A.] Univ Penn, Perelman Sch Med, Udall Ctr Parkinsons Res, Philadelphia, PA 19104 USA. [Duda, John E.; Weintraub, Daniel A.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. RP Roalf, DR (reprint author), Hosp Univ Penn, Brain Behav Lab, Dept Psychiat, Neuropsychiat Sect, 10th Floor,Gates Bldg, Philadelphia, PA 19104 USA. EM roalf@upenn.edu FU NIA NIH HHS [K23 AG034236, P30 AG010124]; NIMH NIH HHS [K01 MH102609]; NINDS NIH HHS [U01 NS082134, P50 NS053488] NR 46 TC 2 Z9 2 U1 7 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 EI 1468-330X J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD DEC PY 2016 VL 87 IS 12 BP 1303 EP 1310 DI 10.1136/jnnp-2015-312723 PG 8 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA EE3FH UT WOS:000389472700250 PM 27071646 ER PT J AU Gerak, LR Collins, GT France, CP AF Gerak, Lisa R. Collins, Gregory T. France, Charles P. TI Effects of Lorcaserin on Cocaine and Methamphetamine Self-Administration and Reinstatement of Responding Previously Maintained by Cocaine in Rhesus Monkeys SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID RECEPTOR AGONISTS; REINFORCING EFFICACY; SQUIRREL-MONKEYS; SEEKING BEHAVIOR; 5-HT2C RECEPTORS; RATS; NICOTINE; ACTIVATION; FOOD AB Stimulant abuse is a serious public health issue for which there is no effective pharmacotherapy. The serotonin(2C) [5-hydroxytryptamine(2C) (5-HT2C)] receptor agonist lorcaserin decreases some abuse-related effects of cocaine in monkeys and might be useful for treating stimulant abuse. The current study investigated the effectiveness of lorcaserin to reduce self-administration of either cocaine or methamphetamine and cocaine-induced reinstatement of extinguished responding. Four rhesus monkeys responded under a progressive-ratio (PR) schedule in which the response requirement increased after each cocaine infusion (32-320 mu g/kg/infusion). A separate group of four monkeys responded under a fixed-ratio (FR) schedule for cocaine (32 mu g/kg/infusion) and reinstatement of extinguished responding was examined following administration of noncontingent infusions of cocaine (0.1-1 mg/kg) that were combined with response-contingent presentations of the drug-associated stimuli. Finally, three monkeys responded under a FR schedule for methamphetamine (0.32-100 mu g/kg/infusion). Lorcaserin (3.2 mg/kg) significantly decreased the final ratio completed (i.e., decreased break point) in monkeys responding under the PR schedule and reduced the reinstatement of responding for drug-associated stimuli following a noncontingent infusion of cocaine; these effects did not appear to change when lorcaserin was administered daily. The same dose of lorcaserin decreased responding for methamphetamine in two of the three monkeys, and the effect was maintained during daily lorcaserin administration; larger doses given acutely (10-17.8 mg/kg) significantly decreased responding for methamphetamine, although that effect was not sustained during daily lorcaserin administration. Together, these results indicate that lorcaserin might be effective in reducing cocaine and methamphetamine abuse and cocaine relapse at least in some individuals. C1 [Gerak, Lisa R.; Collins, Gregory T.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Dr,Mail Code 7764, San Antonio, TX 78229 USA. [France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP France, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM france@uthscsa.edu FU National Institutes of Health National Institute on Drug Abuse [U01 DA034992, K05 DA017918]; Welch Foundation [AQ-0039] FX This study was supported by the National Institutes of Health National Institute on Drug Abuse [Grants U01 DA034992 and K05 DA017918] and by the Welch Foundation [Grant AQ-0039]. NR 20 TC 1 Z9 1 U1 12 U2 12 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD DEC 1 PY 2016 VL 359 IS 3 BP 383 EP 391 DI 10.1124/jpet.116.236307 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EE4WH UT WOS:000389605800001 PM 27650954 ER PT J AU Salameh, TS Shah, GN Price, TO Hayden, MR Banks, WA AF Salameh, Therese S. Shah, Gul N. Price, Tulin O. Hayden, Melvin R. Banks, William A. TI Blood-Brain Barrier Disruption and Neurovascular Unit Dysfunction in Diabetic Mice: Protection with the Mitochondrial Carbonic Anhydrase Inhibitor Topiramate SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID MOUSE CEREBRAL PERICYTES; METABOLIC SYNDROME; PHARMACOLOGICAL INHIBITION; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; RATS; PERMEABILITY; MELLITUS; INSULIN AB All forms of diabetes mellitus are characterized by chronic hyperglycemia, resulting in the development of a number of microvascular and macrovascular pathologies. Diabetes is also associated with changes in brain microvasculature, leading to dysfunction and ultimately disruption of the blood-brain barrier (BBB). These changes are correlated with a decline in cognitive function. In diabetes, BBB damage is associated with increased oxidative stress and reactive oxygen species. This occurs because of the increased oxidative metabolism of glucose caused by hyperglycemia. Decreasing the production of bicarbonate with the use of a mitochondrial carbonic anhydrase inhibitor (mCAi) limits oxidative metabolism and the production of reactive oxygen species. In this study, we have demonstrated that 1) streptozotocin-induced diabetes resulted in BBB disruption, 2) ultrastructural studies showed a breakdown of the BBB and changes to the neurovascular unit (NVU), including a loss of brain pericytes and retraction of astrocytes, the two cell types that maintain the BBB, and 3) treatment with topiramate, a mCAi, attenuated the effects of diabetes on BBB disruption and ultrastructural changes in the neurovascular unit. C1 [Salameh, Therese S.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Seattle, WA USA. [Salameh, Therese S.; Banks, William A.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA USA. [Shah, Gul N.; Price, Tulin O.] St Louis Univ, Sch Med, Div Endocrinol, Dept Internal Med, St Louis, MO USA. [Hayden, Melvin R.] Univ Missouri, Dept Internal Med, Div Endocrinol Diabet & Metab, Columbia, MO USA. [Hayden, Melvin R.] Univ Missouri, Diabet & Cardiovasc Res Lab, Columbia, MO USA. RP Banks, WA (reprint author), VAPSHCS, 810A-1,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [RO1 DK083485]; Department of Veterans Affairs FX This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant RO1 DK083485] and the Department of Veterans Affairs. NR 34 TC 0 Z9 0 U1 4 U2 4 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD DEC 1 PY 2016 VL 359 IS 3 BP 452 EP 459 DI 10.1124/jpet.116.237057 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EE4WH UT WOS:000389605800008 PM 27729477 ER PT J AU Fisher, BT Vendetti, N Bryan, M Prasad, PA Localio, AR Damianos, A Coffin, SE Bell, LM Walsh, TJ Gross, R Zaoutis, TE AF Fisher, Brian T. Vendetti, Neika Bryan, Matthew Prasad, Priya A. Localio, A. Russell Damianos, Andreas Coffin, Susan E. Bell, Louis M. Walsh, Thomas J. Gross, Robert Zaoutis, Theoklis E. TI Central Venous Catheter Retention and Mortality in Children With Candidemia: A Retrospective Cohort Analysis SO JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY LA English DT Article DE candidemia; central catheter; mortality; pediatrics ID BLOOD-STREAM INFECTIONS; PEDIATRIC-PATIENTS; RISK-FACTORS; INVASIVE CANDIDIASIS; UNITED-STATES; EPIDEMIOLOGY; POPULATION; OUTCOMES; THERAPY; ADULTS AB Background. Candidemia causes significant morbidity and mortality among children. Removal of a central venous catheter (CVC) is often recommended for adults with candidemia to reduce persistent and metastatic infection. Pediatric-specific data on the impact of CVC retention are limited. Methods. A retrospective cohort study of inpatients <19 years with candidemia at the Children's Hospital of Philadelphia between 2000 and 2012 was performed. The final cohort included patients that had a CVC in place at time of blood culture and retained their CVC at least 1 day beyond the blood culture being positive. A structured data collection instrument was used to retrieve patient data. A discrete time failure model, adjusting for age and the complexity of clinical care before onset of candidemia, was used to assess the association of CVC retention and 30-day all-cause mortality. Results. Two hundred eighty-five patients with candidemia and a CVC in place at the time of blood culture were identified. Among these 285 patients, 30 (10%) died within 30 days. Central venous catheter retention was associated with a significant increased risk of death on a given day (odds ratio, 2.50; 95% confidence interval, 1.06-5.91). Conclusions. Retention of a CVC was associated with an increased risk of death after adjusting for age and complexity of care at candidemia onset. Although there is likely persistence of unmeasured confounding, given the strong association between catheter retention and death, our data suggest that early CVC removal should be strongly considered. C1 [Fisher, Brian T.; Vendetti, Neika; Damianos, Andreas; Coffin, Susan E.; Bell, Louis M.; Zaoutis, Theoklis E.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Bryan, Matthew; Localio, A. Russell; Bell, Louis M.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Fisher, Brian T.; Vendetti, Neika; Localio, A. Russell; Coffin, Susan E.; Zaoutis, Theoklis E.] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA. [Fisher, Brian T.; Bryan, Matthew; Localio, A. Russell; Coffin, Susan E.; Gross, Robert; Zaoutis, Theoklis E.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Prasad, Priya A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Walsh, Thomas J.] New York Presbyterian Hosp, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis, New York, NY USA. [Gross, Robert] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Fisher, BT (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, CHOP North, 34th & Civ Ctr Blvd,Suite 1515, Philadelphia, PA 19104 USA. EM fisherbria@email.chop.edu NR 19 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2048-7193 EI 2048-7207 J9 J PEDIATR INFECT DIS JI J. Pediatr. Infect. Dis. Soc. PD DEC PY 2016 VL 5 IS 4 BP 403 EP 408 DI 10.1093/jpids/piv048 PG 6 WC Infectious Diseases SC Infectious Diseases GA EE8EA UT WOS:000389856800008 PM 26407279 ER PT J AU Deng, J Mitsuki, Y Shen, GM Ray, JC Cicala, C Arthos, J Dustin, ML Hioe, CE AF Deng, Jing Mitsuki, Yu-ya Shen, Guomiao Ray, Jocelyn C. Cicala, Claudia Arthos, James Dustin, Michael L. Hioe, Catarina E. TI HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell Activation SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; VIROLOGICAL SYNAPSES; MONOCLONAL-ANTIBODIES; TYPE-1 INFECTION; DENDRITIC CELLS; STOP SIGNAL; MICROCLUSTERS; BINDING; ENV; SUBSETS AB HIV is transmitted most efficiently from cell to cell, and productive infection occurs mainly in activated CD4 T cells. It is postulated that HIV exploits immunological synapses formed between CD4 T cells and antigen-presenting cells to facilitate the targeting and infection of activated CD4 T cells. This study sought to evaluate how the presence of the HIV envelope (Env) in the CD4 T cell immunological synapse affects synapse formation and intracellular signaling to impact the downstream T cell activation events. CD4 T cells were applied to supported lipid bilayers that were reconstituted with HIV Env gp120, anti-T cell receptor (anti-TCR) monoclonal antibody, and ICAM-1 to represent the surface of HIV Env-bearing antigen-presenting cells. The results showed that the HIV Env did not disrupt immunological synapse formation. Instead, the HIV Env accumulated with TCR at the center of the synapse, altered the kinetics of TCR recruitment to the synapse and affected synapse morphology over time. The HIV Env also prolonged Lck phosphorylation at the synapse and enhanced TCR-induced CD69 upregulation, interleukin-2 secretion, and proliferation to promote virus infection. These results suggest that HIV uses the immunological synapse as a conduit not only for selective virus transmission to activated CD4 T cells but also for boosting the T cell activation state, thereby increasing its likelihood of undergoing productive replication in targeted CD4 T cells. IMPORTANCE There are about two million new HIV infections every year. A better understanding of how HIV is transmitted to susceptible cells is critical to devise effective strategies to prevent HIV infection. Activated CD4 T cells are preferentially infected by HIV, although how this is accomplished is not fully understood. This study examined whether HIV co-opts the normal T cell activation process through the so-called immunological synapse. We found that the HIV envelope is recruited to the center of the immunological synapse together with the T cell receptor and enhances the T cell receptor-induced activation of CD4 T cells. Heightened cellular activation promotes the capacity of CD4 T cells to support productive HIV replication. This study provides evidence of the exploitation of the normal immunological synapse and T cell activation process by HIV to boost the activation state of targeted CD4 T cells and promote the infection of these cells. C1 [Deng, Jing; Dustin, Michael L.] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY USA. [Deng, Jing; Shen, Guomiao; Dustin, Michael L.] NYU, Sch Med, Dept Pathol, New York, NY USA. [Mitsuki, Yu-ya; Hioe, Catarina E.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. [Ray, Jocelyn C.; Cicala, Claudia; Arthos, James] NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA. [Dustin, Michael L.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Kennedy Inst Rheumatol, Headington, England. [Hioe, Catarina E.] James J Peters Vet Affairs Med Ctr, Res Serv, Bronx, NY 10468 USA. RP Hioe, CE (reprint author), Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA.; Hioe, CE (reprint author), James J Peters Vet Affairs Med Ctr, Res Serv, Bronx, NY 10468 USA. EM catarina.hioe@mssm.edu FU U.S. Department of Veterans Affairs (VA); HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [AI093210, AI100151, AI102740, AI043542] FX This work, including the efforts of Catarina E. Hioe, was funded by U.S. Department of Veterans Affairs (VA) (Research Career Scientist Award). This work, including the efforts of Catarina E. Hioe, was funded by U.S. Department of Veterans Affairs (VA) (Merit Review Award). This work, including the efforts of Catarina E. Hioe, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (AI093210). This work, including the efforts of Catarina E. Hioe, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (AI100151). This work, including the efforts of Catarina E. Hioe, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (AI102740). This work, including the efforts of Michael L. Dustin, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (AI043542). NR 65 TC 1 Z9 1 U1 5 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD DEC PY 2016 VL 90 IS 23 BP 10513 EP 10526 DI 10.1128/JVI.01532-16 PG 14 WC Virology SC Virology GA EE8VL UT WOS:000389904500007 PM 27630246 ER PT J AU Bhagra, A Tierney, DM Sekiguchi, H Soni, NJ AF Bhagra, Anjali Tierney, David M. Sekiguchi, Hiroshi Soni, Nilam J. TI Point-of-Care Ultrasonography for Primary Care Physicians and General Internists SO MAYO CLINIC PROCEEDINGS LA English DT Review ID HAND-CARRIED ULTRASOUND; RIGHT ATRIAL PRESSURE; INFERIOR VENA-CAVA; LEFT-VENTRICULAR FUNCTION; CENTRAL VENOUS-PRESSURE; DEEP-VEIN THROMBOSIS; LUNG ULTRASOUND; DIAGNOSTIC-ACCURACY; BEDSIDE ULTRASOUND; CARDIAC ULTRASOUND AB Point-of-care ultrasonography (POCUS) is a safe and rapidly evolving diagnostic modality that is now utilized by health care professionals from nearly all specialties. Technological advances have improved the portability of equipment, enabling ultrasound imaging to be executed at the bedside and thereby allowing internists to make timely diagnoses and perform ultrasound-guided procedures. We reviewed the literature on the POCUS applications most relevant to the practice of internal medicine. The use of POCUS can immediately narrow differential diagnoses by building on the clinical information revealed by the traditional physical examination and refining clinical decision making for further management. We describe 2 common patient scenarios (heart failure and sepsis) to highlight the impact of POCUS performed by internists on efficiency, diagnostic accuracy, resource utilization, and radiation exposure. Using POCUS to guide procedures has been found to reduce procedure-related complications, along with costs and lengths of stay associated with these complications. Despite several undisputed advantages of POCUS, barriers to implementation must be considered. Most importantly, the utility of POCUS depends on the experience and skills of the operator, which are affected by the availability of training and the cost of ultrasound devices. Additional system barriers include availability of templates for documentation, electronic storage for image archiving, and policies and procedures for quality assurance and billing. Integration of POCUS into the practice of internal medicine is an inevitable change that will empower internists to improve the care of their patients at the bedside. (C) 2016 Mayo Foundation for Medical Education and Research C1 [Bhagra, Anjali] Mayo Clin, Dept Med, Div Gen Internal Med, Rochester, MN USA. [Sekiguchi, Hiroshi] Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Rochester, MN USA. [Tierney, David M.] Abbott NorthWeast Hosp, Med Educ Dept, Minneapolis, MN USA. [Soni, Nilam J.] Univ Texas San Antonio, Hlth Sci Ctr, South Texas Vet Hlth Care Syst, Sect Hosp Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. Univ Texas San Antonio, Hlth Sci Ctr, Div Pulm Dis & Crit Care Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. RP Bhagra, A (reprint author), Mayo Clin, Div Gen Internal Med, 200 First St SW, Rochester, MN 55905 USA. EM bhagra.anjali@mayo.edu NR 136 TC 0 Z9 0 U1 9 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD DEC PY 2016 VL 91 IS 12 BP 1811 EP 1827 DI 10.1016/j.mayocp.2016.08.023 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA EE3YW UT WOS:000389539500018 PM 27825617 ER PT J AU Chmelik, E Emtman, R Borisovskaya, A Borson, S AF Chmelik, Elizabeth Emtman, Reiko Borisovskaya, Anna Borson, Soo TI Communication in dementia care SO NEURODEGENERATIVE DISEASE MANAGEMENT LA English DT Article DE communication; dementia; prognosis ID NURSING-HOME PLACEMENT; PALLIATIVE CARE; COGNITIVE IMPAIRMENT; HOSPITAL ADMISSIONS; ALZHEIMERS-DISEASE; CAREGIVERS; DIAGNOSIS; PEOPLE; FAMILIES; SERVICES AB Dementia is a progressive neurodegenerative illness that affects a growing number of older adults in our country. We discuss ways to improve the management of persons with dementia within current healthcare models. Specifically, we argue that structured communication at regular intervals is essential for dementia care at all phases of illness. We emphasize the need for a single healthcare provider to take on a central role in organizing communication between patient, family and other healthcare providers in the outpatient setting. We also emphasize the need for healthcare providers to begin conversations about prognosis, care transitions and end of life early while balancing these difficult conversations with a hopeful attitude of realistic optimism that the disease can be managed. C1 [Chmelik, Elizabeth; Borisovskaya, Anna] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. [Chmelik, Elizabeth; Emtman, Reiko; Borisovskaya, Anna; Borson, Soo] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Borson, Soo] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA. RP Chmelik, E (reprint author), VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA.; Chmelik, E (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM Elizabeth.chmelik@va.gov NR 40 TC 0 Z9 0 U1 5 U2 5 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-2024 EI 1758-2032 J9 NEURODEGENER DIS MAN JI Neurodegener. Dis. Manag. PD DEC PY 2016 VL 6 IS 6 BP 479 EP 490 DI 10.2217/nmt-2016-0019 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA EE7BD UT WOS:000389768200005 PM 27855537 ER PT J AU De Gasperi, R Graham, ZA Harlow, LM Bauman, WA Qin, WP Cardozo, CP AF De Gasperi, Rita Graham, Zachary A. Harlow, Lauren M. Bauman, William A. Qin, Weiping Cardozo, Christopher P. TI The Signature of MicroRNA Dysregulation in Muscle Paralyzed by Spinal Cord Injury Includes Downregulation of MicroRNAs that Target Myostatin Signaling SO PLOS ONE LA English DT Article ID MESSENGER-RNA EXPRESSION; EMBRYONIC STEM-CELLS; SKELETAL-MUSCLE; GENE-EXPRESSION; ATROPHY; CITED2; MIR-145; PROTEIN; MICE; MASS AB Spinal cord injury (SCI) results in muscle atrophy, reduced force generation and an oxidative-to-glycolytic fiber type shift. The mechanisms responsible for these alterations remain incompletely understood. To gain new insights regarding mechanisms involved in deterioration of muscle after SCI, global expression profiles of miRs in paralyzed gastrocnemius muscle were compared between sham-operated (Sham) and spinal cord-transected (SCI) rats. Ingenuity Pathways Analysis of the altered miRs identified signaling via insulin, IGF-1, integrins and TGF-beta as being significantly enriched for target genes. By qPCR, miRs 23a, 23b, 27b, 145, and 206, were downregulated in skeletal muscle 56 days after SCI. Using FISH, miR-145, a miR not previously implicated in the function of skeletal muscle, was found to be localized to skeletal muscle fibers. One predicted target of miR-145 was Cited2, a transcriptional regulator that modulates signaling through NF-KB, Smad3 and other transcription factors. The 3' UTR of Cited2 mRNA contained a highly conserved miR-145 seed sequence. Luciferase reporter assays confirmed that miR-145 interacts with this seed sequence. However, Cited2 protein levels were similar between Sham and SCI groups, indicating a biochemical interaction that was not involved in the context of adaptations after SCI. Taken together, the findings indicate dysregulation of several highly expressed miRs in skeletal muscle after SCI and suggest that reduced expression of miR-23a, 145 and 206 may have roles in alteration in skeletal muscle mass and insulin responsiveness in muscle paralyzed by upper motor neuron injuries. C1 [De Gasperi, Rita; Graham, Zachary A.; Harlow, Lauren M.; Bauman, William A.; Qin, Weiping; Cardozo, Christopher P.] James J Peters Med Ctr, VA RR&D Serv Natl Ctr Med Consequences Spinal Cor, Bronx, NY 10468 USA. [De Gasperi, Rita] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Graham, Zachary A.; Bauman, William A.; Qin, Weiping; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA. [De Gasperi, Rita] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters Med Ctr, VA RR&D Serv Natl Ctr Med Consequences Spinal Cor, Bronx, NY 10468 USA.; Cardozo, CP (reprint author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.; Cardozo, CP (reprint author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.; Cardozo, CP (reprint author), Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA. EM chris.cardozo@mssm.edu FU VA Rehabilitation and Research Development Grant [B9212C] FX VA Rehabilitation and Research Development Grant B9212C to WAB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Funding was provided by Veterans Affairs RR&D Service National Center Grant B9212-C to W.A.B. NR 63 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 1 PY 2016 VL 11 IS 12 AR e0166189 DI 10.1371/journal.pone.0166189 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE3JC UT WOS:000389482700018 PM 27907012 ER PT J AU Hansoti, B Kellogg, DS Aberle, SJ Broccoli, MC Feden, J French, A Little, CM Moore, B Sabato, J Sheets, T Weinberg, R Elmes, P Kang, C AF Hansoti, Bhakti Kellogg, Dylan S. Aberle, Sara J. Broccoli, Morgan C. Feden, Jeffrey French, Arthur Little, Charles M. Moore, Brooks Sabato, Joseph, Jr. Sheets, Tara Weinberg, R. Elmes, Pat Kang, Christopher TI Preparing Emergency Physicians for Acute Disaster Response: A Review of Current Training Opportunities in the US SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Review DE disaster training; education; emergency physician ID HEALTH-CARE WORKERS; CORE COMPETENCES; PUBLIC-HEALTH; PREPAREDNESS; MEDICINE AB Study Objective: This study aimed to review available disaster training options for health care providers, and to provide specific recommendations for developing and delivering a disaster-response-training program for non-disaster-trained emergency physicians, residents, and trainees prior to acute deployment. Methods: A comprehensive review of the peer-reviewed and grey literature of the existing training options for health care providers was conducted to provide specific recommendations. Results: A comprehensive search of the Pubmed, Embase, Web of Science, Scopus, and Cochrane databases was performed to identify publications related to courses for disaster preparedness and response training for health care professionals. This search revealed 7,681 unique titles, of which 53 articles were included in the full review. A total of 384 courses were found through the grey literature search, and many of these were available online for no charge and could be completed in less than six hours. The majority of courses focused on management and disaster planning; few focused on clinical care and acute response. Conclusion: There is need for a course that is targeted toward emergency physicians and trainees without formal disaster training. This course should be available online and should utilize a mix of educational modalities, including lectures, scenarios, and virtual simulations. An ideal course should focus on disaster preparedness, and the clinical and nonclinical aspects of response, with a focus on an all-hazards approach, including both terrorism-related and environmental disasters. C1 [Hansoti, Bhakti; Kellogg, Dylan S.; Broccoli, Morgan C.] Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD 21218 USA. [Aberle, Sara J.] Mayo Clin, Emergency Med, Rochester, MN USA. [Feden, Jeffrey] Brown Univ, Emergency Med, Providence, RI 02912 USA. [French, Arthur] VA Puget Sound Hlth Care Syst, Emergency Med, Seattle Div, Seattle, WA USA. [Little, Charles M.] Univ Colorado, Emergency Med, Denver, CO 80202 USA. [Moore, Brooks] Emory Univ, Emergency Med, Atlanta, GA 30322 USA. [Sabato, Joseph, Jr.] Univ Florida, Emergency Med, Gainesville, FL USA. [Sheets, Tara] Baylor Coll Med, Emergency Med, Houston, TX 77030 USA. [Weinberg, R.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Elmes, Pat] ACEP, Irving, TX USA. [Kang, Christopher] Madigan Army Med Ctr, Emergency Med, Tacoma, WA 98431 USA. RP Hansoti, B (reprint author), Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD 21218 USA. EM bhakti.hansoti@gmail.com OI Hansoti, Bhakti/0000-0003-0188-9764 NR 28 TC 0 Z9 0 U1 5 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD DEC PY 2016 VL 31 IS 6 BP 643 EP 647 DI 10.1017/S1049023X16000820 PG 5 WC Emergency Medicine SC Emergency Medicine GA EE6DK UT WOS:000389698700011 PM 27640891 ER PT J AU Nishijima, Y Akamatsu, Y Yang, SY Lee, CC Baran, U Song, SZ Wang, RK Tominaga, T Liu, JL AF Nishijima, Yasuo Akamatsu, Yosuke Yang, Shih Yen Lee, Chih Cheng Baran, Utku Song, Shaozhen Wang, Ruikang K. Tominaga, Teiji Liu, Jialing TI Impaired Collateral Flow Compensation During Chronic Cerebral Hypoperfusion in the Type 2 Diabetic Mice SO STROKE LA English DT Article DE anastomosis; arteriogenesis; carotid occlusive disease; CCAO; doppler OCT; vascular remodeling ID CAROTID-ARTERY OCCLUSION; PENETRATING ARTERIOLES; STROKE; REACTIVITY; RISK; HYPERTENSION; CIRCULATION; ANGIOGRAPHY; MECHANISM; STENOSIS AB Background and Purpose-The presence of collaterals is associated with a reduced risk of stroke and transient ischemic attack in patients with steno-occlusive carotid artery disease. Although metabolic syndrome negatively impacts collateral status, it is unclear whether and to what extent type 2 diabetes mellitus affects cerebral collateral flow regulation during hypoperfusion. Methods-We examined the spatial and temporal changes of the leptomeningeal collateral flow and the flow dynamics of the penetrating arterioles in the distal middle cerebral artery and anterior cerebral artery branches over 2 weeks after unilateral common carotid artery occlusion (CCAO) using optical coherent tomography in db/+ and db/db mice. We also assessed the temporal adaptation of the circle of Willis after CCAO by measuring circle of Willis vessel diameters. Results-After unilateral CCAO, db/db mice exhibited diminished leptomeningeal collateral flow compensation compared with db/+ mice, which coincided with a reduced dilation of distal anterior cerebral artery branches, leading to reduced flow not only in pial vessels but also in penetrating arterioles bordering the distal middle cerebral artery and anterior cerebral artery. However, no apparent cell death was detected in either strain of mice during the first week after CCAO. db/db mice also experienced a more severe early reduction in the vessel diameters of several ipsilateral main feeding arteries in the circle of Willis, in addition to a delayed post-CCAO adaptive response by 1 to 2 weeks, compared with db/+ mice. Conclusions-Type 2 diabetes mellitus is an additional risk factor for hemodynamic compromise during cerebral hypoperfusion, which may increase the severity and the risk of stroke or transient ischemic attack. C1 [Nishijima, Yasuo; Akamatsu, Yosuke; Yang, Shih Yen; Lee, Chih Cheng; Liu, Jialing] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol Surg, 1700 Owens St, San Francisco, CA 94158 USA. [Nishijima, Yasuo; Akamatsu, Yosuke; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi, Japan. [Baran, Utku; Song, Shaozhen; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Dept Ophthalmol, Seattle, WA USA. RP Liu, JL (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol Surg, 1700 Owens St, San Francisco, CA 94158 USA. EM jialing.liu@ucsf.edu OI Baran, Utku/0000-0002-7740-4252 FU National Institutes of Health (NIH) [R01 NS071050]; Veterns Affairs merit award [I01RX000655, I01BX003335] FX This work was supported by National Institutes of Health (NIH) grant R01 NS071050 (Dr Liu) and Veterns Affairs merit award I01RX000655 and I01BX003335 (Dr Liu). NR 28 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD DEC PY 2016 VL 47 IS 12 BP 3014 EP 3021 DI 10.1161/STROKEAHA.116.014882 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA EE2ON UT WOS:000389424200034 PM 27834741 ER PT J AU Ayers, JI Diamond, J Sari, A Fromholt, S Galaleldeen, A Ostrow, LW Glass, JD Hart, PJ Borchelt, DR AF Ayers, Jacob I. Diamond, Jeffrey Sari, Adriana Fromholt, Susan Galaleldeen, Ahmad Ostrow, Lyle W. Glass, Jonathan D. Hart, P. John Borchelt, David R. TI Distinct conformers of transmissible misfolded SOD1 distinguish human SOD1-FALS from other forms of familial and sporadic ALS SO ACTA NEUROPATHOLOGICA LA English DT Article DE Amyotrophic lateral sclerosis; Superoxide dismutase-1; Prion; Strains; sALS; fALS ID AMYOTROPHIC-LATERAL-SCLEROSIS; PRION-LIKE PROPAGATION; MOTOR-NEURON DISEASE; SUPEROXIDE-DISMUTASE; MUTANT SOD1; WILD-TYPE; TRANSGENIC MICE; AGGREGATION; SCRAPIE; STRAINS AB Evidence of misfolded wild-type superoxide dismutase 1 (SOD1) has been detected in spinal cords of sporadic ALS (sALS) patients, suggesting an etiological relationship to SOD1-associated familial ALS (fALS). Given that there are currently a number of promising therapies under development that target SOD1, it is of critical importance to better understand the role of misfolded SOD1 in sALS. We previously demonstrated the permissiveness of the G85R-SOD1:YFP mouse model for MND induction following injection with tissue homogenates from paralyzed transgenic mice expressing SOD1 mutations. This prompted us to examine whether WT SOD1 can self-propagate misfolding of the G85R-SOD1:YFP protein akin to what has been observed with mutant SOD1. Using the G85R-SOD1:YFP mice, we demonstrate that misfolded conformers of recombinant WT SOD1, produced in vitro, induce MND with a distinct inclusion pathology. Furthermore, the distinct pathology remains upon successive passages in the G85R-SOD1:YFP mice, strongly supporting the notion for conformation-dependent templated propagation and SOD1 strains. To determine the presence of a similar misfolded WT SOD1 conformer in sALS tissue, we screened homogenates from patients diagnosed with sALS, fALS, and non-ALS disease in an organotypic spinal cord slice culture assay. Slice cultures from G85R-SOD1:YFP mice exposed to spinal homogenates from patients diagnosed with ALS caused by the A4V mutation in SOD1 developed robust inclusion pathology, whereas spinal homogenates from more than 30 sALS cases and various controls failed. These findings suggest that mutant SOD1 has prion-like attributes that do not extend to SOD1 in sALS tissues. C1 [Ayers, Jacob I.; Diamond, Jeffrey; Sari, Adriana; Fromholt, Susan; Borchelt, David R.] Univ Florida, Dept Neurosci, Ctr Translat Res Neurodegenerat Dis, Box 100159, Gainesville, FL 32610 USA. [Borchelt, David R.] Univ Florida, McKnight Brain Inst, SantaFe HealthCare Alzheimers Dis Res Ctr, Gainesville, FL 32610 USA. [Galaleldeen, Ahmad; Hart, P. John] St Marys Univ, Dept Biol Sci, San Antonio, TX 78228 USA. [Galaleldeen, Ahmad] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Galaleldeen, Ahmad] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Ostrow, Lyle W.] Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21205 USA. [Glass, Jonathan D.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Hart, P. John] South Texas Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Ayers, JI (reprint author), Univ Florida, Dept Neurosci, Ctr Translat Res Neurodegenerat Dis, Box 100159, Gainesville, FL 32610 USA. EM jayers.123ja@ufl.edu FU St. Mary's University Research Grant; Biaggini Research Program; NIH [S10OD020026]; National Institutes of Neurological Disease and Stroke [1R01NA092788-01]; Packard Center for ALS Research at Johns Hopkins University; Target ALS Multicenter Post-mortem Tissue Core FX We would like to thank the patients and family members who contributed tissue to the study; Drs. B. Giasson and J. Lewis for donating mouse tissue for the study; and Dr. C. Janus for his help on statistical analysis. A. G. was supported by St. Mary's University Research Grant and the Biaggini Research Program. This work was supported by an NIH Shared Instrumentation Grant (S10OD020026), a grant from the National Institutes of Neurological Disease and Stroke (1R01NA092788-01), and the Packard Center for ALS Research at Johns Hopkins University. Collection and characterization of human tissues provided by Johns Hopkins were funded by the Target ALS Multicenter Post-mortem Tissue Core. NR 40 TC 1 Z9 1 U1 5 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD DEC PY 2016 VL 132 IS 6 BP 827 EP 840 DI 10.1007/s00401-016-1623-4 PG 14 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA EC1DX UT WOS:000387844900005 PM 27704280 ER PT J AU Mounessa, J Buntinx-Krieg, T Qin, R Dunnick, CA Dellavalle, RP AF Mounessa, Jessica Buntinx-Krieg, Talayesa Qin, Rosie Dunnick, Cory A. Dellavalle, Robert P. TI Primary and Secondary Chemoprevention of Malignant Melanoma SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY LA English DT Review ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POLYPODIUM-LEUCOTOMOS EXTRACT; NONMELANOMA SKIN-CANCER; TOPICAL TRETINOIN; DYSPLASTIC NEVI; WOMENS HEALTH; PRIMARY PREVENTION; CLINICAL-TRIAL; ATYPICAL NEVI; RISK AB The incidence of malignant melanoma (MM) continues to rise in the United States. While sun protection and full body skin examinations remain the mainstay of preventative care, chemoprevention of the deadly disease has become an increasingly popular field of study. In this focused review, we discuss current findings and analyze the risks and benefits of various agents investigated for the primary and secondary chemoprevention of MM. Such agents include topical retinoids, vitamins, and supplements, Polypodium leucotomas extracts, non-steroidal anti-inflammatory agents (NSAIDs), statins, sunscreens, and field therapy with topical imiquimod for primary and secondary chemoprevention. We further identify a need for expanded high quality human research on the topic. C1 [Mounessa, Jessica] SUNY Stony Brook, Sch Med, 101 Nicolls Rd, Stony Brook, NY 11794 USA. [Mounessa, Jessica; Dunnick, Cory A.; Dellavalle, Robert P.] Univ Colorado Hosp, Dept Dermatol, 1665 Aurora Ct, Aurora, CO 80045 USA. [Buntinx-Krieg, Talayesa] Univ Cent Florida, Coll Med, 6850 Lake Nona Blvd, Orlando, FL 32827 USA. [Qin, Rosie] Univ San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA. [Dunnick, Cory A.; Dellavalle, Robert P.] Denver VA Med Ctr, Dept Dermatol, 1055 Clermont St 165, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado Hosp, Dept Dermatol, 1665 Aurora Ct, Aurora, CO 80045 USA.; Dellavalle, RP (reprint author), Denver VA Med Ctr, Dept Dermatol, 1055 Clermont St 165, Denver, CO 80220 USA. EM Robert.Dellavalle@ucdenver.edu NR 63 TC 0 Z9 0 U1 3 U2 3 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1175-0561 EI 1179-1888 J9 AM J CLIN DERMATOL JI Am. J. Clin. Dermatol. PD DEC PY 2016 VL 17 IS 6 BP 625 EP 634 DI 10.1007/s40257-016-0221-5 PG 10 WC Dermatology SC Dermatology GA EC0WO UT WOS:000387822500007 PM 27665299 ER PT J AU Caulfield, MD Zhu, DC McAuley, JD Servatius, RJ AF Caulfield, Meghan D. Zhu, David C. McAuley, J. Devin Servatius, Richard J. TI Cerebellar Response to Familiar and Novel Stimuli: An fMRI Study SO BEHAVIORAL NEUROSCIENCE LA English DT Article DE cerebellum; faces; scenes; familiar; novel ID INTRINSIC FUNCTIONAL CONNECTIVITY; POSTERIOR CINGULATE CORTEX; VERBAL WORKING-MEMORY; RECOGNITION MEMORY; PREFRONTAL CORTEX; SEX-DIFFERENCES; NEURAL SYSTEMS; MOTOR; NETWORKS; FACES AB Historically known for its key contribution to motor behavior, the cerebellum continues to break boundaries. Researchers have demonstrated the cerebellum also plays a role in learning, memory, and more recent evidence for contributions in language, attention, working memory, emotions, and social processes. Here, we present a study that adds to the list of nonmotor processes of the cerebellum. We used images of faces and outdoor scenes to examine the cerebellar response to familiar and novel stimuli. Participants were familiarized with a subset of stimuli, and then underwent functional MRI (fMRI) where they were presented with the previously stimuli and new stimuli while making "old" and "new" judgment. In a familiar versus novel contrast, familiar stimuli (faces and scenes combined) activated bilateral regions of the cerebellum including I-IV, V, VI, Crus I, and Crus II. When separated by type, familiar faces had greater activation of bilateral I-IV than novel faces. These results demonstrate the cerebellar role in determining familiarity and contribute to continuing research supporting cerebellar contributions to nonmotor processes. C1 [Caulfield, Meghan D.; Servatius, Richard J.] Stress & Motivated Behav Inst, E Orange, NJ USA. [Caulfield, Meghan D.] Kessler Fdn, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA. [Caulfield, Meghan D.] Lafayette Coll, Dept Psychol, Easton, PA USA. [Zhu, David C.] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA. [Zhu, David C.; McAuley, J. Devin] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. [Servatius, Richard J.] US Dept Vet Affairs, Vet Affairs Med Ctr, Syracuse, NY USA. RP Caulfield, MD (reprint author), Kessler Fdn, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM meghandcaulfield@gmail.com FU Stress and Motivated Behavior Institute; U.S. Department of Veterans Affairs; Graduate School of Biomedical Sciences; Department of Radiology at Michigan State University; Department of Psychology at Michigan State University FX This work was partially supported by the Stress and Motivated Behavior Institute, the U.S. Department of Veterans Affairs, the Foundations Fellowship of the Graduate School of Biomedical Sciences, and the Departments of Radiology and Psychology at Michigan State University. Scan support was provided by the Michigan State University Radiology Pilot Scan Program. We thank Scarlett Doyle for scanning support and Elizabeth Wieland for assistance in participant recruitment and data collection. We thank Glenn Wylie, Catherine Myers, and Elizabeth Tricomi for key input in early stages of this study. NR 62 TC 1 Z9 1 U1 2 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7044 EI 1939-0084 J9 BEHAV NEUROSCI JI Behav. Neurosci. PD DEC PY 2016 VL 130 IS 6 BP 585 EP 592 DI 10.1037/bne0000173 PG 8 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA ED3ID UT WOS:000388741900006 PM 27854447 ER PT J AU Turner, AP Alschuler, KN Hughes, AJ Beier, M Haselkorn, JK Sloan, AP Ehde, DM AF Turner, Aaron P. Alschuler, Kevin N. Hughes, Abbey J. Beier, Meghan Haselkorn, Jodie K. Sloan, Alicia P. Ehde, Dawn M. TI Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS LA English DT Review DE Multiple sclerosis; Depression; Anxiety; Bipolar disorder ID QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; MULTIPLE-SCLEROSIS PATIENTS; RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSION; INJECTION ANXIETY; PHYSICAL-ACTIVITY; SOCIAL SUPPORT; MOOD DISORDER; PSYCHIATRIC MORBIDITY AB Among individuals with multiple sclerosis (MS), mental health comorbidities play a significant role in contributing to secondary disability and detracting from quality of life. This review examines current evidence surrounding three mental health issues of particular relevance to MS: depression, anxiety, and bipolar disorder. We review what is known of the prevalence, correlates, screening mechanisms, and current treatment of each issue and provide recommendations for future areas of research. C1 [Turner, Aaron P.; Haselkorn, Jodie K.; Sloan, Alicia P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. [Turner, Aaron P.; Alschuler, Kevin N.; Haselkorn, Jodie K.; Ehde, Dawn M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Alschuler, Kevin N.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Hughes, Abbey J.; Beier, Meghan] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA.; Turner, AP (reprint author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. EM Aaron.Turner@va.gov NR 144 TC 0 Z9 0 U1 18 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1528-4042 EI 1534-6293 J9 CURR NEUROL NEUROSCI JI Curr. Neurol. Neurosci. Rep. PD DEC PY 2016 VL 16 IS 12 AR 106 DI 10.1007/s11910-016-0706-x PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ED4IU UT WOS:000388812100005 PM 27848174 ER PT J AU Werner, RM Skira, M Konetzka, RT AF Werner, Rachel M. Skira, Meghan Konetzka, R. Tamara TI An Evaluation of Performance Thresholds in Nursing Home Pay-for-Performance SO HEALTH SERVICES RESEARCH LA English DT Article DE Performance-based thresholds; quality of care; pay-for-performance; nursing home quality; long-term care ID RESIDENT ASSESSMENT INSTRUMENT; QUALITY; CARE; PAYMENT; MDS AB Objective. Performance thresholds are commonly used in pay-for-performance (P4P) incentives, where providers receive a bonus payment for achieving a prespecified target threshold but may produce discontinuous incentives, with providers just below the threshold having the strongest incentive to improve and providers either far below or above the threshold having little incentive. We investigate the effect of performance thresholds on provider response in the setting of nursing home P4P. Data Sources. The Minimum Data Set (MDS) and Online Survey, Certification, and Reporting (OSCAR) datasets. Study Setting and Design. Difference-in-differences design to test for changes in nursing home performance in three states that implemented threshold-based P4P (Colorado, Georgia, and Oklahoma) versus three comparator states (Arizona, Tennessee, and Arkansas) between 2006 and 2009. Principal Findings. We find that those farthest below the threshold (i.e., the worst-performing nursing homes) had the largest improvements under threshold-based P4P while those farthest above the threshold worsened. This effect did not vary with the percentage of Medicaid residents in a nursing home. Conclusions. Threshold-based P4P may provide perverse incentives for nursing homes above the performance threshold, but we do not find evidence to support concerns about the effects of performance thresholds on low-performing nursing homes. C1 [Werner, Rachel M.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Crescenz VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Skira, Meghan] Univ Georgia, Terry Coll Business, Dept Econ, Athens, GA 30602 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. RP Werner, RM (reprint author), Univ Penn, Perelman Sch Med, Div Gen Internal Med, 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu FU National Institute on Aging [R01-AG034182, K24-AG047908] FX This research was supported by grant R01-AG034182 from the National Institute on Aging. Rachel Werner is supported in part by grant K24-AG047908, also from the National Institute on Aging. NR 24 TC 1 Z9 1 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2016 VL 51 IS 6 BP 2282 EP 2304 DI 10.1111/1475-6773.12467 PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA ED8UP UT WOS:000389146700013 PM 26932527 ER PT J AU Barth, K Blasche, R Neisser, A Bramke, S Frank, JA Kasper, M AF Barth, K. Blaesche, R. Neisser, A. Bramke, S. Frank, J. A. Kasper, M. TI P2X7R-dependent regulation of glycogen synthase kinase 3 beta and claudin-18 in alveolar epithelial type I cells of mice lung SO HISTOCHEMISTRY AND CELL BIOLOGY LA English DT Article DE Mouse lung; Knockout; P2X7 receptor; GSK-3 beta; beta-catenin; claudin-18 ID JUNCTIONAL ADHESION MOLECULE; BARRIER FUNCTION; P2X(7) RECEPTORS; BETA-CATENIN; EXPRESSION; INJURY; FIBROSIS; PROTEIN; SIGNAL AB The purinergic receptor P2X7 represents an ATP-gated ionotropic receptor with a selective localization in alveolar epithelial type I cells of the lung. Despite the involvement of the receptor in inflammatory processes of the lung, it is not established whether this receptor plays a specific role in the alveolar epithelial cell biology. There is evidence that P2X7 receptor influences Wnt/beta-catenin signalling pathways in alveolar epithelial cells under conditions of injury. Here, we investigated the expression of GSK-3 beta, a potent protein kinase involved in alveolar epithelial barrier functions, and of tight junction molecules occludin, claudin-4 and claudin-18 in wild-type and P2X7(-/-) mice. Western blot analysis, immunohistochemistry and quantitative real-time RT-PCR revealed a remarkable increase in claudin-18 mRNA and protein in lungs of P2X7(-/-) mice animals. Furthermore, alveolar epithelial cells from P2X7(-/-) animals showed decreased levels of GSK-3 beta protein and its inactive form GSK-3 beta (pS9). Conversely, claudin-18 knockout mice exhibited decreased P2X7 mRNA transcript abundance as measured by mRNA expression microarray and quantitative PCR. Our data are consistent with the hypothesis that P2X7R contributes to alveolar epithelial barrier function through effects on GSK-3 beta. Furthermore, these data suggest a potential reciprocal regulation of claudin-18 and P2X7R in the alveolar epithelium. C1 [Barth, K.; Blaesche, R.; Neisser, A.; Bramke, S.; Kasper, M.] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Anat, Fetscherstr 74, D-01307 Dresden, Germany. [Frank, J. A.] Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA. RP Kasper, M (reprint author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Anat, Fetscherstr 74, D-01307 Dresden, Germany. EM michael.kasper@tu-dresden.de NR 34 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0948-6143 EI 1432-119X J9 HISTOCHEM CELL BIOL JI Histochem. Cell Biol. PD DEC PY 2016 VL 146 IS 6 BP 757 EP 768 DI 10.1007/s00418-016-1499-3 PG 12 WC Cell Biology; Microscopy SC Cell Biology; Microscopy GA EC0ST UT WOS:000387811700012 PM 27663455 ER PT J AU Sharma, A Ma, YF Scherzer, R Wheeler, AL Cohen, M Gustafson, DR Keating, SM Yin, MT Tien, PC AF Sharma, Anjali Ma, Yifei Scherzer, Rebecca Wheeler, Amber L. Cohen, Mardge Gustafson, Deborah R. Keating, Sheila M. Yin, Michael T. Tien, Phyllis C. TI Association of Adipokines With Bone Mineral Density in HIV-Infected and HIV-Uninfected Women SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE bone mineral density; adipokine; body composition; HIV ID INTERAGENCY HIV; SERUM LEPTIN; OLDER WOMEN; FAT MASS; ADIPONECTIN; MEN; LIPOATROPHY; POPULATION; MEDIATORS; INSULIN AB Background: HIV infection is associated with low bone mineral density (BMD) and alterations in adipokines, which may mediate the relationship between fat and bone. Objective: To evaluate the relationship of adiponectin and leptin with BMD in HIV-infected and uninfected women. Methods: We measured BMD over 5 years at the lumbar spine, total hip (TH), and femoral neck (FN) using dual-energy X-ray absorptiometry in 318 HIV-infected and 122 HIV-uninfected participants of the multicenter Women's Interagency HIV Study (WIHS). Total adiponectin and leptin were assayed on stored sera. Multivariable linear mixed models assessed the effects of adipokines and HIV status on BMD. Results: HIV-infected women had higher adiponectin (median 6.2 vs. 5.6 mg/mL,) but lower leptin (11.7 vs. 19.8 ng/mL) levels at baseline (both P, 0.05) compared with HIV-uninfected women. HIV infection was associated with lower BMD at the lumbar spine (20.074 g/cm(2)), FN (20.049 g/cm(2)), and TH (20.047 g/cm(2)) (all P, 0.05) after adjusting for demographic, behavioral, and metabolic factors. HIV infection remained associated with lower BMD at each site, with little change in the effect sizes after additional adjustment for adiponectin or leptin. Among HIV-infected women, higher adiponectin was associated with lower TH BMD (20.025 g/cm(2) per 10-fold increase, P = 0.035), whereas higher leptin was associated with higher BMD at FN (+ 0.027 g/cm(2) per 10-fold increase, P = 0.005) and TH (+ 0.019 g/cm(2), P = 0.028). After multivariable adjustment, the adipokines showed little association with BMD at any site (P>0.8 for adiponectin; P>0.2 for leptin). Conclusions: Alterations in serum adiponectin and leptin do not explain low BMD in HIV-infected women. C1 [Sharma, Anjali] Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave,Block Bldg 305, Bronx, NY 10461 USA. [Ma, Yifei] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Scherzer, Rebecca; Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wheeler, Amber L.; Tien, Phyllis C.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Cohen, Mardge] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL USA. [Gustafson, Deborah R.] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Keating, Sheila M.] Blood Syst Res Inst, San Francisco, CA USA. [Yin, Michael T.] Columbia Univ, Dept Med, New York, NY USA. RP Sharma, A (reprint author), Albert Einstein Coll Med, 1300 Morris Pk Ave,Block Bldg 305, Bronx, NY 10461 USA. EM anjali.sharma@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Cancer Institute (NCI); National Institute on Drug Abuse (NIDA); National Institute on Mental Health (NIMH); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute on Deafness and other Communication Disorders (NIDCD); NIH Office of Research on Women's Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [K23AR06199301]; National Institute of Allergy and Infectious Diseases [R01AI087176, K24AI108516] FX The Women's Interagency HIV Study (WIHS) is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA) and UL1-TR000454 (Atlanta CTSA). Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number K23AR06199301 (AS), and National Institute of Allergy and Infectious Diseases R01AI087176 and K24AI108516 (PCT). NR 26 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2016 VL 73 IS 4 BP 433 EP 437 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7LB UT WOS:000389044800012 PM 27792683 ER PT J AU Jayakumar, A Savic, RM Everett, CK Benator, D Alland, D Heilig, CM Weiner, M Friedrich, SO Martinson, NA Kerrigan, A Zamudio, C Goldberg, SV Whitworth, WC Davis, JL Nahid, P AF Jayakumar, A. Savic, R. M. Everett, C. K. Benator, D. Alland, D. Heilig, C. M. Weiner, M. Friedrich, S. O. Martinson, N. A. Kerrigan, A. Zamudio, C. Goldberg, S. V. Whitworth, W. C. Davis, J. L. Nahid, P. TI Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PULMONARY TUBERCULOSIS; BIOMARKER AB The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (C-T) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert C-T trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert C-T for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal C-T data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of C-T was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in C-T (P = 0.02). The estimated increase in C-T slope for every additional 100 mu g . h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 C-T/week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert C-T, indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response. C1 [Jayakumar, A.; Everett, C. K.; Nahid, P.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Savic, R. M.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. [Benator, D.] Washington DC VA Med Ctr, Washington, DC USA. [Benator, D.] George Washington Univ, Washington, DC USA. [Alland, D.] Rutgers New Jersey Med Sch, Newark, NJ USA. [Heilig, C. M.; Goldberg, S. V.; Whitworth, W. C.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Weiner, M.] Vet Adm Med Ctr, San Antonio, TX USA. [Weiner, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Friedrich, S. O.] Univ Stellenbosch, Fac Med & Hlth Sci, DST NRF Ctr Excellence Biomed TB Res, Div Med Physiol,MRC Ctr TB Res, Tygerberg, South Africa. [Martinson, N. A.] Univ Witwatersrand, MRC Soweto Matlosana Collaborating Ctr HIV AIDS &, Perinatal HIV Res Unit PHRU, Johannesburg, South Africa. [Kerrigan, A.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Zamudio, C.] Univ Peruana Cayetano Heredia, Lima, Peru. [Davis, J. L.] Yale Sch Publ Hlth, New Haven, CT USA. RP Nahid, P (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. EM pnahid@ucsf.edu OI Heilig, Charles/0000-0003-1075-1310; Zamudio, Carlos/0000-0001-7479-127X FU HHS \ National Institutes of Health (NIH) [5T32HL007185-37, AI097005]; HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [R01AI104589]; HHS \ Centers for Disease Control and Prevention (CDC) FX This work, including the efforts of Archana Jayakumar, was funded by HHS vertical bar National Institutes of Health (NIH) (5T32HL007185-37). This work, including the efforts of Charles K. Everett, was funded by HHS vertical bar National Institutes of Health (NIH) (AI097005). This work, including the efforts of Payam Nahid, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (R01AI104589). This work, including the efforts of Debra Benator, Charles M. Heilig, Marc Weiner, Neil Martinson, AmyKerrigan, Carlos Zamudio, Stefan V. Goldberg, William C. Whitworth, and Payam Nahid, was funded by HHS vertical bar Centers for Disease Control and Prevention (CDC). NR 19 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2016 VL 54 IS 12 BP 3028 EP 3033 DI 10.1128/JCM.01313-16 PG 6 WC Microbiology SC Microbiology GA ED9RF UT WOS:000389209600029 PM 27733634 ER PT J AU Ehlers, CL Kim, C Gilder, DA Stouffer, GM Caetano, R Yehuda, R AF Ehlers, Cindy L. Kim, Corinne Gilder, David A. Stouffer, Gina M. Caetano, Raul Yehuda, Rachel TI Lifetime history of traumatic events in a young adult Mexican American sample: Relation to substance dependence, affective disorder, acculturation stress, and PTSD SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Mexican American; PTSD; Substance dependence; Trauma ID NATIONAL-COMORBIDITY-SURVEY; R PSYCHIATRIC-DISORDERS; ALCOHOL SURVEY HABLAS; INDIAN RESERVATION POPULATIONS; POSTTRAUMATIC-STRESS; UNITED-STATES; MENTAL-HEALTH; EPIDEMIOLOGIC SURVEY; HOLOCAUST SURVIVORS; ANXIETY DISORDERS AB Mexican Americans comprise one of the most rapidly growing populations in the United States, and within this population, trauma and post-traumatic stress disorder (PTSD) are associated with physical and mental health problems. Therefore, efforts to delineate factors that may uniquely contribute to increased likelihood of trauma, PTSD, and substance use disorders over the lifetime in Mexican Americans are important to address health disparities and to develop treatment and prevention programs. Six hundred fourteen young adults (age 18-30 yrs) of Mexican American heritage, largely second generation, were recruited from the community and assessed with the Semi-Structured Assessment for the Genetics of Alcoholism and an acculturation stress scale. More males (51.2%) reported experiencing traumas than females (41.1%), however, a larger proportion of females received a PTSD diagnosis (15%) than males (8%). Alcohol dependence and affective disorders, but not anxiety disorders, antisocial disorders, nicotine, marijuana, or stimulant dependence, were significantly comorbid with PTSD. Endorsing higher levels of acculturation stress was also significantly associated with both trauma exposure and a diagnosis of PTSD. Logistic regression revealed that female gender, having an affective disorder, alcohol dependence, higher levels of acculturation stress, and lower levels of education were all predictors of PTSD status. Additionally, alcohol dependence generally occurred after the PTSD diagnosis in early adulthood in this high risk population. These studies suggest that treatment and prevention efforts should particularly focus on young adult second generation Mexican American women with higher levels of acculturation stress, who may be at higher risk for PTSD, affective disorder, and alcohol dependence following trauma exposure. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Ehlers, Cindy L.; Kim, Corinne; Gilder, David A.; Stouffer, Gina M.] Scripps Res Inst, Mol & Cellular Neurosci Dept, La Jolla, CA 92037 USA. [Caetano, Raul] Pacific Inst Res & Evaluat, Prevent Res Ctr, Oakland, CA USA. [Yehuda, Rachel] Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Studies Div, Dept Psychiat, Bronx, NY USA. RP Ehlers, CL (reprint author), Scripps Res Inst, 10550 North Torrey Pines Rd,SP30-1501, La Jolla, CA 92037 USA. EM cindye@scripps.edu FU National Institutes of Health (NIH) from the National Institute on Alcoholism and Alcohol Abuse (NIAAA) [AA006420] FX This research was supported by grants from the National Institutes of Health (NIH), from the National Institute on Alcoholism and Alcohol Abuse (NIAAA) grant AA006420 (CLE), the NIAAA, had no further role in study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. NR 82 TC 1 Z9 1 U1 10 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD DEC PY 2016 VL 83 BP 79 EP 85 DI 10.1016/j.jpsychires.2016.08.009 PG 7 WC Psychiatry SC Psychiatry GA ED8CW UT WOS:000389100600011 PM 27569652 ER PT J AU Horn, SR Pietrzak, RH Schechter, C Bromet, EJ Katz, CL Reissman, DB Kotov, R Crane, M Harrison, DJ Herbert, R Luft, BJ Moline, JM Stellman, JM Udasin, IG Landrigan, PJ Zvolensky, MJ Southwick, SM Feder, A AF Horn, Sarah R. Pietrzak, Robert H. Schechter, Clyde Bromet, Evelyn J. Katz, Craig L. Reissman, Dori B. Kotov, Roman Crane, Michael Harrison, Denise J. Herbert, Robin Luft, Benjamin J. Moline, Jacqueline M. Stellman, Jeanne M. Udasin, Iris G. Landrigan, Philip J. Zvolensky, Michael J. Southwick, Steven M. Feder, Adriana TI Latent typologies of posttraumatic stress disorder in World Trade Center responders SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Posttraumatic stress disorder (PTSD); World Trade Center (WTC); Latent class analysis (LCA); Typologies ID CENTER RESCUE; POLICE RESPONDERS; COMBAT VETERANS; CENTER DISASTER; SOCIAL SUPPORT; PTSD SYMPTOMS; RISK-FACTORS; LIFE EVENTS; BEHAVIORAL ACTIVATION; DISSOCIATIVE-SUBTYPE AB Posttraumatic stress disorder (PTSD) is a debilitating and often chronic psychiatric disorder. Following the 9/11/2001 World Trade Center (WTC) attacks, thousands of individuals were involved in rescue, recovery and clean-up efforts. While a growing body of literature has documented the prevalence and correlates of PTSD in WTC responders, no study has evaluated predominant typologies of PTSD in this population. Participants were 4352 WTC responders with probable WTC-related DSM-IV PTSD. Latent class analyses were conducted to identify predominant typologies of PTSD symptoms and associated correlates. A 3-class solution provided the optimal representation of latent PTSD symptom typologies. The first class, labeled "High-Symptom (n = 1,973, 45.3%)," was characterized by high probabilities of all PTSD symptoms. The second class, "Dysphoric (n = 1,371, 31.5%)," exhibited relatively high probabilities of emotional numbing and dysphoric arousal (e.g., sleep disturbance). The third class, "Threat (n = 1,008, 23.2%)," was characterized by high probabilities of re-experiencing, avoidance and anxious arousal (e.g., hypervigilance). Compared to the Threat class, the Dysphoric class reported a greater number of life stressors after 9/11/2001 (OR = 1.06). The High-Symptom class was more likely than the Threat class to have a positive psychiatric history before 9/11/2001 (OR = 1.7) and reported a greater number of life stressors after 9/11/2001 (OR = 1.1). The High-Symptom class was more likely than the Dysphoric class, which was more likely than the Threat class, to screen positive for depression (83% > 74% > 53%, respectively), and to report greater functional impairment (High-Symptom > Dysphoric [Cohen d = 0.19], Dysphoric > Threat [Cohen d = 0.24]). These results may help inform assessment, risk stratification, and treatment approaches for PTSD in WTC and disaster responders. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Horn, Sarah R.; Katz, Craig L.; Feder, Adriana] Icahn Sch Med, Dept Psychiat, New York, NY USA. [Pietrzak, Robert H.; Southwick, Steven M.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Schechter, Clyde] Yeshiva Univ, Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY USA. [Bromet, Evelyn J.] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [Reissman, Dori B.] NIOSH, Washington, DC USA. [Crane, Michael; Herbert, Robin; Landrigan, Philip J.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Harrison, Denise J.] NYU, Sch Med, Dept Environm Med, New York, NY USA. [Harrison, Denise J.] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Luft, Benjamin J.] SUNY Stony Brook, Div Infect Dis, Dept Med, Stony Book, NY USA. [Moline, Jacqueline M.] Hofstra North Shore Long Isl Jewish Sch Med, Dept Occupat Med Epidemiol & Prevent, Great Neck, NY USA. [Stellman, Jeanne M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY 10027 USA. [Udasin, Iris G.] UMDNJ, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Piscataway, NJ USA. [Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77004 USA. RP Horn, SR (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM shorn@uoregon.edu FU CDC/National Institute for Occupational Safety and Health (NIOSH) [200-2011-41919] FX This work was supported by the CDC/National Institute for Occupational Safety and Health (NIOSH) (A.F., R.H.P. and S.M.S., research contract # 200-2011-41919). The CDC/NIOSH did not contribute to study design; data collection, analysis or interpretation; writing of the report; or decision to submit the manuscript for publication. NR 75 TC 0 Z9 0 U1 16 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD DEC PY 2016 VL 83 BP 151 EP 159 DI 10.1016/j.jpsychires.2016.08.018 PG 9 WC Psychiatry SC Psychiatry GA ED8CW UT WOS:000389100600020 PM 27623049 ER PT J AU Copeland, LA Finley, EP Bollinger, MJ Amuan, ME Pugh, MJV AF Copeland, Laurel A. Finley, Erin P. Bollinger, Mary J. Amuan, Megan E. Pugh, Mary Jo V. TI Comorbidity Correlates of Death Among New Veterans of Iraq and Afghanistan Deployment SO MEDICAL CARE LA English DT Article DE Afghan campaign; comorbidity; Iraq war; mortality; veterans ID POLYTRAUMA-CLINICAL-TRIAD; TRAUMATIC BRAIN-INJURY; ADMINISTRATIVE DATA; PTSD; PAIN AB Background:Veterans of the wars in Iraq and Afghanistan who receive care in the Veterans Health Administration (VA) have high disease burden. Distinct comorbidity patterns have been shown to be differentially associated with adverse outcomes, including death. This study determined correlates of 5-year mortality.Materials and Methods:VA demographic, military, homelessness, and clinical measures informed this retrospective analysis. Previously constructed comorbidity classifications over 3 years of care were entered into a Cox proportional hazards model of death.Results:There were 164,933 veterans in the cohort, including African Americans (16%), Hispanics (11%), and whites (65%). Most were in their 20s at baseline (60%); 12% were women; 4% had attempted suicide; 4% had been homeless. Having clustered disorders of pain, posttraumatic stress disorder, and traumatic brain injury was associated with death [hazard ratio (HR)=2.0]. Mental disorders including substance abuse were similarly associated (HR=2.1). Prior suicide attempt (HR=2.2) or drug overdose (HR=3.0) considerably increased risk of death over 5 years.Conclusions:As congressional actions such as Veterans Choice Act offer more avenues to seek care outside of VA, coordination of care, and suicide prevention outreach for recent veterans may require innovative approaches to preserve life. C1 [Copeland, Laurel A.] UT Hlth Sci Ctr San Antonio, Ctr Appl Hlth Res, Cent Texas Vet Hlth Care Syst, San Antonio, TX USA. [Copeland, Laurel A.] UT Hlth Sci Ctr San Antonio, Ctr Appl Hlth Res, Baylor Scott & White Hlth, Dept Med, San Antonio, TX USA. [Copeland, Laurel A.] UT Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [Finley, Erin P.; Bollinger, Mary J.; Pugh, Mary Jo V.] UT Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Finley, Erin P.; Pugh, Mary Jo V.] UT Hlth Sci Ctr San Antonio, Div Clin Epidemiol, Dept Med, San Antonio, TX USA. [Bollinger, Mary J.] UT Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX USA. [Amuan, Megan E.] VA New England Hlth Care Syst, Bedford, MA USA. RP Pugh, MJV (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter 11c6, San Antonio, TX 78229 USA. EM maryjo.pugh2@va.gov OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209; Finley, Erin/0000-0003-4497-7721 FU South Texas Veterans Healthcare System/Audie L. Murphy Division; Edith Nourse Rogers VA Memorial Hospital FX The authors thank South Texas Veterans Healthcare System/Audie L. Murphy Division and the Edith Nourse Rogers VA Memorial Hospital. NR 16 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD DEC PY 2016 VL 55 IS 12 BP 1078 EP 1081 DI 10.1097/MLR.0000000000000588 PG 4 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA ED6JW UT WOS:000388962900010 PM 27367868 ER PT J AU Henao-Martinez, AF Gross, L Mcnair, B McCollister, B DeSanto, K Montoya, JG Shapiro, L Beckham, JD AF Henao-Martinez, Andres F. Gross, Lilyana Mcnair, Bryan McCollister, Bruce DeSanto, Kristen Montoya, Jose G. Shapiro, Leland Beckham, J. David TI Risk Factors for Cryptococcal Meningitis: A Single United States Center Experience SO MYCOPATHOLOGIA LA English DT Article DE Cryptococcal antigen; Cryptococcal meningitis; Cryptococcus neoformans; Fungemia; HIV; Risk factors ID ORGAN TRANSPLANT RECIPIENTS; PULMONARY CRYPTOCOCCOSIS; CLINICAL-FEATURES; HIV-INFECTION; MORTALITY; DISEASE; SMOKING AB Cryptococcal meningitis carries a high mortality. Further understanding of immune suppression factors associated with neuroinvasive infection will improve risk stratification and enhance early diagnosis and treatment with antifungal therapy. The aim of the study was to corroborate established or find novel clinical predictors for cryptococcal meningitis. We performed a matched case-control study of Cryptococcus infection in immunocompromised patients with or without cryptococcal meningitis. Data of all patients with a diagnosis of cryptococcal disease were collected at University of Colorado Hospital between 2000 and 2015 (n = 51). Thirty patients were diagnosed with cryptococcal meningitis. We built a logistic regression model for risk factors associated with cryptococcal meningitis. The single-predictor univariate model found that a positive blood culture, positive serum cryptococcal antigen, current malignancy, and headaches were significantly associated with cryptococcal meningitis (p = 0.02). In the adjusted multivariate model, central nervous system disease was significantly associated with a diagnosis of HIV infection (OR 24.45, 95 % CI 1.62-350.37; p = 0.022) and a positive serum cryptococcal antigen test (OR 42.92, 95 % CI 3.26-555.55; p = 0.0055). In patients with HIV infection or a positive serum cryptococcal antigen, the pretest probability of neuroinvasive Cryptococcus infection is increased and an aggressive diagnostic evaluation should be conducted to exclude infection and consider empiric therapy. C1 [Henao-Martinez, Andres F.; McCollister, Bruce; Beckham, J. David] Univ Colorado Denver, Div Infect Dis, Dept Med, 12700 E 19th Ave,Mail Stop B168, Aurora, CO 80045 USA. [Gross, Lilyana; Mcnair, Bryan] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [DeSanto, Kristen] Univ Colorado Denver, Hlth Sci Lib, Aurora, CO USA. [Montoya, Jose G.] Stanford Univ, Med Ctr, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA. [Shapiro, Leland] Denver Vet Affairs Med Ctr, Div Infect Dis, Dept Med, 1055 Clermont St,Box 111L, Denver, CO 80220 USA. RP Henao-Martinez, AF (reprint author), Univ Colorado Denver, Div Infect Dis, Dept Med, 12700 E 19th Ave,Mail Stop B168, Aurora, CO 80045 USA. EM andres.henaomartinez@ucdenver.edu; Lilyana.Gross@ucdenver.edu OI Henao-Martinez, Andres/0000-0001-7363-8652 FU University of Colorado Neurosciences Institute; NINDS [1R01NS097729] FX No funding agencies had any role in the preparation, review, or approval of this manuscript. We thank Daniela Garcia for her help in reviewing the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the University of Colorado Denver or Stanford University Medical Center. J.D.B receives research support from the University of Colorado Neurosciences Institute and NINDS 1R01NS097729. NR 30 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0301-486X EI 1573-0832 J9 MYCOPATHOLOGIA JI Mycopathologia PD DEC PY 2016 VL 181 IS 11-12 BP 807 EP 814 DI 10.1007/s11046-016-0048-x PG 8 WC Mycology SC Mycology GA ED6KM UT WOS:000388964500004 PM 27502502 ER PT J AU Qin, W Zhao, W Li, X Peng, Y Harlow, LM Li, J Qin, Y Pan, J Wu, Y Ran, L Ke, HZ Cardozo, CP Bauman, WA AF Qin, W. Zhao, W. Li, X. Peng, Y. Harlow, L. M. Li, J. Qin, Y. Pan, J. Wu, Y. Ran, L. Ke, H. Z. Cardozo, C. P. Bauman, W. A. TI Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bone formation; Bone mineral density; Mechanical unloading; Sclerostin; Spinal cord injury; Trabecular bone volume ID RAT MODEL; TARGETED DELETION; NERVOUS-SYSTEM; OSTEOPOROSIS; MARROW; MASS; DIFFERENTIATION; STRENGTH; ANTIBODY; DENSITY AB Bone loss after spinal cord injury (SCI) is rapid, severe, and refractory to interventions studied to date. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by SCI, further indicating pharmacological inhibition of sclerostin may represent a promising novel approach to this challenging medical problem. The bone loss secondary to spinal cord injury (SCI) is associated with several unique pathological features, including the permanent immobilization, neurological dysfunction, and systemic hormonal alternations. It remains unclear how these complex pathophysiological changes are linked to molecular alterations that influence bone metabolism in SCI. Sclerostin is a key negative regulator of bone formation and bone mass. We hypothesized that sclerostin could function as a major mediator of bone loss following SCI. To test this hypothesis, 10-week-old female sclerostin knockout (SOST KO) and wild type (WT) mice underwent complete spinal cord transection or laminectomy (Sham). At 8 weeks after SCI, substantial loss of bone mineral density was observed at the distal femur and proximal tibia in WT mice but not in SOST KO mice. By mu CT, trabecular bone volume of the distal femur was markedly decreased by 64 % in WT mice after SCI. In striking contrast, there was no significant reduction of bone volume in SOST KO/SCI mice compared with SOST KO/sham. Histomorphometric analysis of trabecular bone revealed that the significant reduction in bone formation rate following SCI was observed in WT mice but not in SOST KO mice. Moreover, SCI did not alter osteoblastogenesis of marrow stromal cells in SOST KO mice. Our findings demonstrate that SOST KO mice were protected from the major sublesional bone loss that invariably follows SCI. The evidence indicates that sclerostin is an important mediator of the marked sublesional bone loss after SCI, and that pharmacological inhibition of sclerostin may represent a promising novel approach to this challenging clinical problem. C1 [Qin, W.; Zhao, W.; Peng, Y.; Harlow, L. M.; Qin, Y.; Pan, J.; Cardozo, C. P.; Bauman, W. A.] Natl Ctr Med Consequences SCI, James J Peters VA Med Ctr, 130 West Kingsbridge Roa, Bronx, NY 10468 USA. [Qin, W.; Wu, Y.; Cardozo, C. P.; Bauman, W. A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Cardozo, C. P.; Bauman, W. A.] Icahn Sch Med Mt Sinai, Rehabil Med, New York, NY USA. [Cardozo, C. P.] Icahn Sch Med Mt Sinai, Pharmacol & Syst Therapeut, New York, NY USA. [Li, X.] Amgen Inc, Thousand Oaks, CA USA. [Li, J.] Indiana Univ Purdue Univ, Indianapolis, IN USA. [Wu, Y.; Ran, L.] Dalian Med Univ, Inst Gene Engn Anim Models Human Dis, Dalian, Peoples R China. [Ke, H. Z.] UCB Pharma, Slough, Berks, England. RP Qin, W (reprint author), Natl Ctr Med Consequences SCI, James J Peters VA Med Ctr, 130 West Kingsbridge Roa, Bronx, NY 10468 USA.; Qin, W (reprint author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. EM weiping.qin@mssm.edu FU Veterans Health Administration, Rehabilitation Research, and Development Service [5I01RX001313, 5I01RX000687, B9212-C, B2020-C]; Ministry of Science and Technology PRC grant [2014DFA32120]; Natural Science Foundation of China (NSFC) [81471000] FX This work was supported by the Veterans Health Administration, Rehabilitation Research, and Development Service (grants 5I01RX001313 and 5I01RX000687 to WQ; B9212-C and B2020-C to WAB). Ministry of Science and Technology PRC grant 2014DFA32120 and the Natural Science Foundation of China (NSFC) grant 81471000 to YW. Amgen Inc. provided SOST KO mice. Authors' roles: CPC, HK, XL, WAB, and WQ were responsible for study design and data analysis. YP, LH, WZ, JL, YQ, YW, LR, and WQ conducted the bone biology study. Jay Cao performed microCT analysis. The manuscript was written by WZ and WQ and was revised and approved by all authors. WQ takes responsibility for the integrity of the data analysis. NR 52 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD DEC PY 2016 VL 27 IS 12 BP 3627 EP 3636 DI 10.1007/s00198-016-3700-x PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ED6GI UT WOS:000388953700024 PM 27436301 ER PT J AU Kohli, P Naik, AN Farhood, Z Ong, AA Nguyen, SA Soler, ZM Schlosser, RJ AF Kohli, Preeti Naik, Akash N. Farhood, Zachary Ong, Adrian A. Nguyen, Shaun A. Soler, Zachary M. Schlosser, Rodney J. TI Olfactory Outcomes after Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A Meta-analysis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Review DE olfaction; smell; sinus surgery; chronic rhinosinusitis; sinusitis; meta-analysis ID OF-LIFE OUTCOMES; NASAL POLYPOSIS; DISEASE SEVERITY; IMPROVEMENT; SMELL; DYSFUNCTION; IRRIGATION; PREDICTORS; DISORDERS; IMPACT AB Objective. To use combined pre- and postsurgical olfactory outcomes to assess the impact of endoscopic sinus surgery on chronic rhinosinusitis-related olfactory impairment. Data Sources. CINAHL, Cochrane, OVID, EMBASE, PubMed, and SCOPUS. Each database was searched from inception up to October 2015. Review Methods. Studies were included that reported subjective or objective olfactory data in chronic rhinosinusitis patients before and after endoscopic sinus surgery. Results. Thirty-one studies were used in the meta-analysis. Weighted mean differences of olfactory measures demonstrated significant improvement in mixed CRS patients (those with and without polyps) through visual analog scales (20.83, P=.001), altered taste/smell item on Sinonasal Outcome Test (21.32, P <. 00001), 40-item Smell Identification Test (3.49, P =.0010), and Sniffin' Sticks identification (0.34, P =.03). Chronic rhinosinusitis mixed patients demonstrated nonsignificant improvements via Sniffin' Sticks threshold (1.60, P =.16) and Brief Smell Identification Test (0.20, P =.32). When separated, polyp patients and dysosmic patients experienced the highest levels of olfactory improvement. Polyp patients improved by 7.87 (P =.006) on the 40-item Smell Identification test, 11.54 (P <. 0001) with the Sniffin' Sticks total score, and 2.57 (P <. 00001) through Sniffin' Sticks identification. Dysosmic patients improved by 5.75 via the 40-item Smell Identification Test (P =.0001). Conclusion. Endoscopic sinus surgery improves nearly all subjective and objective measures of olfaction in chronic rhinosinusitis patients. Patients with nasal polyposis or preoperative olfactory dysfunction improve to a greater degree. C1 [Kohli, Preeti; Naik, Akash N.; Farhood, Zachary; Ong, Adrian A.; Nguyen, Shaun A.; Soler, Zachary M.; Schlosser, Rodney J.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Kohli, P (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM pkohli89@gmail.com FU National Institute on Deafness and Other Communication Disorders of the National Institutes of Health [R03 DC013651-01] FX National Institute on Deafness and Other Communication Disorders of the National Institutes of Health (R03 DC013651-01; principal investigator: Z.M.S.). NR 61 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD DEC PY 2016 VL 155 IS 6 BP 936 EP 948 DI 10.1177/0194599816664879 PG 13 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA ED8UN UT WOS:000389146500005 PM 27576679 ER PT J AU Davidson, EH Wang, EW Yu, JY Fernandez-Miranda, JC Wang, DJ Richards, N Miller, M Schuman, JS Washington, KM AF Davidson, Edward H. Wang, Eric W. Yu, Jenny Y. Fernandez-Miranda, Juan C. Wang, Dawn J. Richards, Nikisha Miller, Maxine Schuman, Joel S. Washington, Kia M. TI Total Human Eye Allotransplantation: Developing Surgical Protocols for Donor and Recipient Procedures SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID PERFUSED MAMMALIAN EYE; OPTIC-NERVE; OPHTHALMIC ARTERY; MAXILLARY ARTERY; REGENERATION; TRANSPLANTATION; RECOVERY; BRANCHES; SURGERY; ANATOMY AB Background: Vascularized composite allotransplantation of the eye is an appealing, novel method for reconstruction of the nonfunctioning eye. The authors' group has established the first orthotopic model for eye transplantation in the rat. With advancements in immunomodulation strategies together with new therapies in neuroregeneration, parallel development of human surgical protocols is vital for ensuring momentum toward eye transplantation in actual patients. Methods: Cadaveric donor tissue harvest (n = 8) was performed with orbital exenteration, combined open craniotomy, and endonasal approach to ligate the ophthalmic artery with a cuff of paraclival internal carotid artery, for transection of the optic nerve at the optic chiasm and transection of cranial nerves III to VI and the superior ophthalmic vein at the cavernous sinus. Candidate recipient vessels (superficial temporal/internal maxillary/facial artery and superficial temporal/facial vein) were exposed. Vein grafts were required for all anastomoses. Donor tissue was secured in recipient orbits followed by sequential venous and arterial anastomoses and nerve coaptation. Pedicle lengths and calibers were measured. All steps were timed, photographed, video recorded, and critically analyzed after each operative session. Results: The technical feasibility of cadaveric donor procurement and transplantation to cadaveric recipient was established. Mean measurements included optic nerve length (39 mm) and caliber (5 mm), donor artery length (33 mm) and caliber (3 mm), and superior ophthalmic vein length (15 mm) and caliber (0.5 mm). Recipient superficial temporal, internal maxillary artery, and facial artery calibers were 0.8, 2, and 2 mm, respectively; and superior temporal and facial vein calibers were 0.8 and 2.5 mm, respectively. Conclusion: This surgical protocol serves as a benchmark for optimization of technique, large-animal model development, and ultimately potentiating the possibility of vision restoration transplantation surgery. C1 Univ Pittsburgh, Dept Plast Surg, Sch Med, 3550 Terrace St Scaife Hall,Suite 668, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Otolaryngol, Sch Med, 3550 Terrace St Scaife Hall,Suite 668, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Ophthalmol, Sch Med, 3550 Terrace St Scaife Hall,Suite 668, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Neurosurg, Sch Med, 3550 Terrace St Scaife Hall,Suite 668, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Washington, KM (reprint author), Univ Pittsburgh, Dept Plast Surg, 3550 Terrace St Scaife Hall,Suite 668, Pittsburgh, PA 15261 USA. EM washingtonkm@upmc.edu FU NEI NIH HHS [R01 EY013178] NR 28 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD DEC PY 2016 VL 138 IS 6 BP 1297 EP 1308 DI 10.1097/PRS.0000000000002821 PG 12 WC Surgery SC Surgery GA ED7HQ UT WOS:000389033800050 PM 27879599 ER PT J AU Rodrigue, JR Schold, JD Mandelbrot, DA Taber, DJ Phan, V Baliga, PK AF Rodrigue, James R. Schold, Jesse D. Mandelbrot, Didier A. Taber, David J. Van Phan Baliga, Prabhakar K. TI Concern for Lost Income Following Donation Deters Some Patients From Talking to Potential Living Donors SO PROGRESS IN TRANSPLANTATION LA English DT Article DE kidney transplantation; transplant recipients; living donation; kidney donation; costs; barriers ID ORGAN DONATION; KIDNEY DONATION; UNITED-STATES; ATTITUDES; TRANSPLANTATION; DISINCENTIVES; INCENTIVES; SURGEONS; ADULTS AB Context: Some living kidney donors report lost income during recovery from surgery. Little is known about whether concern for living donor's lost income affects the decision to undergo donation evaluation and the willingness of transplant candidates to discuss living kidney donation (LKD) with others. Objective: To examine whether transplant patients were told by potential donors about lost income concerns and whether patients chose not to discuss LKD with others due to lost income concerns. Design, Setting, and Patients: Kidney transplant patients (185 wait-listed candidates, 171 deceased donor recipients, and 100 live donor recipients) at 2 centers completed a questionnaire to assess whether concern about donor's lost income was a consideration in discussion about LKD with others. Results: One-third (32%) were told by a family member/friend that they were willing to donate but were concerned about potential lost income. The majority of those who expressed financial concern (64%) did not initiate donation evaluation. Many patients (42%) chose not to discuss living donation with a family member/friend due to concern about the impact of lost income on the donor. In the multivariable model, lower annual household income was the only statistically significant predictor of both having a potential donor expressing lost income concern and choosing not to talk to someone because of lost income concern. Conclusion: Findings from the current study underscore how concern about income loss for living donors may affect decision-making by both transplant candidates and potential donors. C1 [Rodrigue, James R.] Beth Israel Deaconess Med Ctr, Ctr Transplant Outcomes & Qual Improvement, Transplant Inst, Boston, MA 02215 USA. [Rodrigue, James R.] Harvard Med Sch, Boston, MA USA. [Schold, Jesse D.] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA. [Mandelbrot, Didier A.] Univ Wisconsin, Dept Med, Madison, WI USA. [Taber, David J.; Van Phan; Baliga, Prabhakar K.] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VA Med Ctr, Dept Pharm, Charleston, SC USA. RP Rodrigue, JR (reprint author), Beth Israel Deaconess Med Ctr, Transplant Inst, 110 Francis St,7th Floor, Boston, MA 02215 USA. EM jrrodrig@bidmc.harvard.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK085185, R01DK098727]; Julie Henry Research Fund; Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Award No. R01DK085185 and R01DK098727 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The preparation of this manuscript was also supported, in part, by the Julie Henry Research Fund and the Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA. NR 27 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1526-9248 EI 2164-6708 J9 PROG TRANSPLANT JI Prog. Transplant. PD DEC PY 2016 VL 26 IS 4 BP 292 EP 298 DI 10.1177/1526924816661332 PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA ED4XR UT WOS:000388855800002 ER PT J AU Moore, TM Reise, SP Roalf, DR Satterthwaite, TD Davatzikos, C Bilker, WB Port, AM Jackson, CT Ruparel, K Savitt, AP Baron, RB Gur, RE Gur, RC AF Moore, Tyler M. Reise, Steven P. Roalf, David R. Satterthwaite, Theodore D. Davatzikos, Christos Bilker, Warren B. Port, Allison M. Jackson, Chad T. Ruparel, Kosha Savitt, Adam P. Baron, Robert B. Gur, Raquel E. Gur, Ruben C. TI Development of an Itemwise Efficiency Scoring Method: Concurrent, Convergent, Discriminant, and Neuroimaging-Based Predictive Validity Assessed in a Large Community Sample SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE neurocognitive efficiency; validity; computerized neurocognitive battery; psychometrics; Philadelphia Neurodevelopmental Cohort ID COMPUTERIZED NEUROCOGNITIVE BATTERY; CEREBRAL BLOOD-FLOW; SEX-DIFFERENCES; CORPUS-CALLOSUM; RESPONSE-TIMES; MENTAL ROTATION; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; COGNITIVE-PSYCHOLOGY; PSYCHOSIS SPECTRUM AB Traditional "paper-and-pencil" testing is imprecise in measuring speed and hence limited in assessing performance efficiency, but computerized testing permits precision in measuring itemwise response time. We present a method of scoring performance efficiency (combining information from accuracy and speed) at the item level. Using a community sample of 9,498 youths age 8-21, we calculated item-level efficiency scores on 4 neurocognitive tests, and compared the concurrent, convergent, discriminant, and predictive validity of these scores with simple averaging of standardized speed and accuracy-summed scores. Concurrent validity was measured by the scores' abilities to distinguish men from women and their correlations with age; convergent and discriminant validity were measured by correlations with other scores inside and outside of their neurocognitive domains; predictive validity was measured by correlations with brain volume in regions associated with the specific neurocognitive abilities. Results provide support for the ability of itemwise efficiency scoring to detect signals as strong as those detected by standard efficiency scoring methods. We find no evidence of superior validity of the itemwise scores over traditional scores, but point out several advantages of the former. The itemwise efficiency scoring method shows promise as an alternative to standard efficiency scoring methods, with overall moderate support from tests of 4 different types of validity. This method allows the use of existing item analysis methods and provides the convenient ability to adjust the overall emphasis of accuracy versus speed in the efficiency score, thus adjusting the scoring to the real-world demands the test is aiming to fulfill. C1 [Moore, Tyler M.; Roalf, David R.; Satterthwaite, Theodore D.; Port, Allison M.; Jackson, Chad T.; Ruparel, Kosha; Savitt, Adam P.; Baron, Robert B.; Gur, Raquel E.; Gur, Ruben C.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Reise, Steven P.] Univ Calif, Dept Psychol, Philadelphia, PA USA. [Davatzikos, Christos] Univ Penn, Sect Biomed Image Anal, Philadelphia, PA 19104 USA. [Bilker, Warren B.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Gur, Ruben C.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. RP Moore, TM (reprint author), Univ Penn, Perelman Sch Med, Brain Behav Lab, 3400 Spruce St,10th Floor Gates Pavil, Philadelphia, PA 19104 USA. EM tymoore@upenn.edu FU NIMH [MH089983, MH019112, MH096891]; Dowshen Program for Neuroscience FX Ruben C. Gur receives royalties from the Brain Resource Centre, Ultimo, New South Wales, Australia, and is an unpaid consultant on the Scientific Advisory Board of Lumosity, San Francisco, California. This work was supported by NIMH Grants MH089983, MH019112, MH096891 and the Dowshen Program for Neuroscience. NR 85 TC 0 Z9 0 U1 9 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD DEC PY 2016 VL 28 IS 12 BP 1529 EP 1542 DI 10.1037/pas0000284 PG 14 WC Psychology, Clinical SC Psychology GA EE0ZE UT WOS:000389308700001 PM 26866796 ER PT J AU Gutierrez, PM Pease, J Matarazzo, BB Monteith, LL Hernandez, T Osman, A AF Gutierrez, Peter M. Pease, James Matarazzo, Bridget B. Monteith, Lindsey L. Hernandez, Theresa Osman, Augustine TI Evaluating the Psychometric Properties of the Interpersonal Needs Questionnaire and the Acquired Capability for Suicide Scale in Military Veterans SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE Interpersonal Needs Questionnaire; Acquired Capability for Suicide Scale; veterans; psychometrics ID TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL THEORY; CONSTRUCT-VALIDITY; PERCEIVED BURDENSOMENESS; SCREENING-TEST; RISK-FACTORS; MISSING DATA; 2 SAMPLES; RELIABILITY; BEHAVIOR AB Joiner's (2005) interpersonal-psychological theory of suicide (IPTS) has become one of the most frequently studied in the field. Currently there are 2 primary measures designed to assess the 3 main constructs of the theory-the Interpersonal Needs Questionnaire (INQ; Van Orden, Witte, Gordon, Bender, & Joiner, 2008) and the Acquired Capability for Suicide Scale (ACSS; Van Orden et al., 2008). The psychometric properties of these 2 measures were evaluated in a sample of 477 U.S. military veterans. It was determined that the factor structure for both measures is consistent with the underlying theory and that all internal consistency reliability estimates are good. Acceptable convergent validity was found for the INQ, but not for the ACSS. Recommendations for refining the ACSS based on the results of the current analyses are provided. Comparisons of scale performance were made with data from participants with and without a history of 1 or more suicide attempts. Burdensomeness alone and the interaction between thwarted belongingness and burdensomeness were associated with prior suicide attempts. In conclusion, although some refinement may improve performance of the ACSS, both measures are appropriate and psychometrically sound for use in research and clinical applications with veterans of the U.S. military. C1 [Gutierrez, Peter M.; Pease, James; Matarazzo, Bridget B.; Monteith, Lindsey L.; Hernandez, Theresa] Denver Vet Affairs Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA. [Gutierrez, Peter M.; Pease, James; Matarazzo, Bridget B.; Monteith, Lindsey L.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA. [Hernandez, Theresa] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA. [Osman, Augustine] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA. RP Gutierrez, PM (reprint author), Denver Vet Affairs Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov OI Gutierrez, Peter/0000-0001-8981-8404 NR 65 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD DEC PY 2016 VL 28 IS 12 BP 1684 EP 1694 DI 10.1037/pas0000310 PG 11 WC Psychology, Clinical SC Psychology GA EE0ZE UT WOS:000389308700015 PM 26998894 ER PT J AU Rodriguez, F Lin, ST Maron, DJ Knowles, JW Virani, SS Heidenreich, PA AF Rodriguez, Fatima Lin, Shoutzu Maron, David J. Knowles, Joshua W. Virani, Salim S. Heidenreich, Paul A. TI Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines SO AMERICAN HEART JOURNAL LA English DT Article ID DENSITY-LIPOPROTEIN-CHOLESTEROL; PERIPHERAL ARTERIAL-DISEASE; CLINICAL-TRIALS; UNITED-STATES; THERAPY; IMPROVEMENT; DISCONTINUATION; DYSLIPIDEMIA; MANAGEMENT; PHYSICIANS AB Background The November 2013 American College of Cardiology/ American Heart Association cholesterol guidelines recommend the use of high-intensity statins for patients with atherosclerotic cardiovascular disease (ASCVD). We sought to determine how these guidelines are being adopted at the Veterans Affairs (VA) Health System and identify treatment gaps. Methods We examined administrative data from the VA 12 months prior to the index dates of April 1, 2013, and after April 1, 2014, to identify patients <= 75 years of age with >= 2 codes for ASCVD. We identified those on high-intensity statin therapy (atorvastatin 40 mg or 80 mg, rosuvastatin 20 mg or 40 mg, and simvastatin 80 mg) during the 6 months after the index date. Results The study sample included 331,927 and 326,759 eligible adults with ASCVD before and after the release of the new guidelines, respectively. Overall, high-intensity statin use increased from 28% to 35% after guideline release. High-intensity statin use was lowest in Hispanics and Native Americans, although all groups showed an increase over time. Among those on low-or moderate-intensity statin therapy, 15.6% were intensified to a high-intensity statin after guideline release. Groups less likely to undergo statin intensification were older adults (odds ratio = 0.78 for each 10-year increase, 95% CI 0.76-0.81), women (odds ratio = 0.86, 95% CI 0.75-0.99), and certain minority groups. Academic teaching hospitals and hospitals on the West Coast were more likely to intensify statins after release of the new guidelines. Conclusions High-intensity statin use increased in the VA following release of the American College of Cardiology/ American Heart Association cholesterol treatment guidelines, although disparities persist for certain patient groups including older adults, women, and certain minority groups. C1 [Rodriguez, Fatima; Maron, David J.; Knowles, Joshua W.; Heidenreich, Paul A.] Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA. [Rodriguez, Fatima; Maron, David J.; Knowles, Joshua W.; Heidenreich, Paul A.] Stanford Univ, Cardiovasc Inst, Stanford, CA 94305 USA. [Lin, Shoutzu; Heidenreich, Paul A.] Vet Affairs Hlth Syst, Palo Alto, CA USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA. RP Heidenreich, PA (reprint author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM heiden@stanford.edu NR 35 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD DEC PY 2016 VL 182 BP 97 EP 102 DI 10.1016/j.ahj.2016.09.007 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ED8QS UT WOS:000389136600012 PM 27914506 ER PT J AU Villarreal, G Hamner, MB Canive, JM Robert, S Calais, LA Durklaski, V Zhai, YS Qualls, C AF Villarreal, Gerardo Hamner, Mark B. Canive, Jose M. Robert, Sophie Calais, Lawrence A. Durklaski, Valerie Zhai, Yusheng Qualls, Clifford TI Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID OF-VETERANS-AFFAIRS; DOUBLE-BLIND; 2ND-GENERATION ANTIPSYCHOTICS; PTSD; SYMPTOMS; SCHIZOPHRENIA; COMORBIDITY; MEDICATIONS; AFGHANISTAN; OLANZAPINE AB Objective: This was a 12-week randomized, placebo-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic stress disorder (PTSD). Method: Eighty patients were randomly assigned to treatment with either quetiapine or placebo. The primary outcome measure was the Clinician-Administered PTSD Scale (CAPS). Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scales for severity of Illness and improvement, the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A). Safety measurements included adverse events, vital signs, the Abnormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizona Sexual Experiences Scale. Results: After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and increased to a maximum of 800 mg; the average was 258 mg (range, 50-800 mg). Reductions in CAPS total, re-experiencing, and hyperarousal scores were significantly greater for the quetiapine group than for the placebo group. Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales, HAM-A, and HAM-D than for placebo. Adverse events were generally mild and expected based on prior studies of quetiapine in this and other patient population. There were no differences in safety measures between groups. Conclusion: Quetiapine monotherapy was efficacious in the treatment of PTSD. These findings suggest quetiapine as a single agent is effective in treating military PTSD. C1 [Hamner, Mark B.] Raymond G Murphy VA Med Ctr, Behav Hlth Care Line, Albuquerque, NM 87108 USA. Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA. Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA. Biomed Res Inst New Mexico, Albuquerque, NM USA. Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ South Carolina, Dept Biometry & Biostat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Hamner, MB (reprint author), Raymond G Murphy VA Med Ctr, Behav Hlth Care Line, Albuquerque, NM 87108 USA. EM hamnermb@musc.edu FU AstraZeneca; Alkermes; Pfizer; Abbott; Bristol-Myers Squibb; Eli Lilly; Forest Laboratories; Janssen; Lundbeck; Organon; Sanofi-Synthlabo FX Funded by an investigator-initiated grant from AstraZeneca to Dr. Hamner.; Dr. Hamner has current research support from Alkermes and Pfizer; he has been the recipient of research grant support or honoraria and/or has served as a consultant for the following pharmaceutical companies: Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Janssen, Lundbeck, Organon, Otsuka, and Sanofi-Synthlabo Dr. Canive has received research grant support or honoraria and/or has served as a consultant for the following pharmaceutical companies: Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Organon, Otsuka, and Sanofi-Synthlabo. The other authors report no financial relationships with commercial interests. NR 35 TC 3 Z9 3 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD DEC PY 2016 VL 173 IS 12 BP 1205 EP 1212 DI 10.1176/appi.ajp.2016.15070967 PG 8 WC Psychiatry SC Psychiatry GA ED7CB UT WOS:000389012200010 PM 27418378 ER PT J AU Koselny, K Green, J DiDone, L Halterman, JP Fothergill, AW Wiederhold, NP Patterson, TF Cushion, MT Rappelye, C Wellington, M Krysan, DJ AF Koselny, Kristy Green, Julianne DiDone, Louis Halterman, Justin P. Fothergill, Annette W. Wiederhold, Nathan P. Patterson, Thomas F. Cushion, Melanie T. Rappelye, Chad Wellington, Melanie Krysan, Damian J. TI The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ACETYL-COA SYNTHETASE; CANDIDA-ALBICANS; FUNGAL-INFECTIONS; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; YEAST; NEOFORMANS; COMBINATION; MENINGITIS; COENZYME AB Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity of AR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. AR-12 inhibits fungal acetyl coenzyme A (acetyl-CoA) synthetase in vitro and is fungicidal at concentrations similar to those achieved in human plasma. AR-12 has a broad spectrum of activity, including activity against yeasts (e.g., Candida albicans, non-albicans Candida spp., Cryptococcus neoformans), molds (e.g., Fusarium, Mucor), and dimorphic fungi (Blastomyces, Histoplasma, and Coccidioides) with MICs of 2 to 4 mu g/ml. AR-12 is also active against azole- and echinocandin-resistant Candida isolates, and subinhibitory AR-12 concentrations increase the susceptibility of fluconazole- and echinocandin-resistant Candida isolates. Finally, AR-12 also increases the activity of fluconazole in a murine model of cryptococcosis. Taken together, these data indicate that AR-12 represents a promising class of small molecules with broad-spectrum antifungal activity. C1 [Koselny, Kristy; Green, Julianne; DiDone, Louis; Halterman, Justin P.; Wellington, Melanie; Krysan, Damian J.] Univ Rochester, Dept Pediat, Rochester, NY 14611 USA. [Krysan, Damian J.] Univ Rochester, Dept Immunol Microbiol, Rochester, NY 14611 USA. [Fothergill, Annette W.; Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Cushion, Melanie T.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Rappelye, Chad] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA. RP Krysan, DJ (reprint author), Univ Rochester, Dept Pediat, Rochester, NY 14611 USA. EM damian_krysan@urmc.rochester.edu FU HHS \ National Institutes of Health (NIH) [1R01AI097142, 5K12HD068373, HHS272201000018I] FX This work, including the efforts of Damian J. Krysan, was funded by HHS vertical bar National Institutes of Health (NIH) (1R01AI097142). This work, including the efforts of Julianne Green, was funded by HHS vertical bar National Institutes of Health (NIH) (5K12HD068373). This work, including the efforts of Thomas F. Patterson, was funded by HHS vertical bar National Institutes of Health (NIH) (HHS272201000018I). NR 55 TC 1 Z9 1 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 2016 VL 60 IS 12 BP 7115 EP 7127 DI 10.1128/AAC.01061-16 PG 13 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7QO UT WOS:000389064300012 PM 27645246 ER PT J AU Riggio, S Jagoda, A AF Riggio, Silvana Jagoda, Andy TI Concussion and its neurobehavioural sequelae SO INTERNATIONAL REVIEW OF PSYCHIATRY LA English DT Article DE Concussion; mild traumatic brain injury; post-concussive syndrome; head computed tomography; neuropsychologic testing ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN; PSYCHIATRIC-DISORDERS; HEAD-INJURY; ASSOCIATION; SYMPTOMS; RISK; CLASSIFICATION; ADOLESCENTS AB A concussion results from a force to the brain that results in a transient loss of connectivity within the brain. Sport psychiatrists are increasingly called to be part of the concussion team and need to be prepared to manage issues related to concussion and its behavioural sequelae. Objectively, the best evidence available suggests that deficits in attention and/or in balance are the most reliable objective findings that a concussion has occurred. Prognosis after a concussion is generally very good, although a sub-set of patients that are yet well defined seem pre-disposed to delayed recovery. Neither head CT nor MRI are sufficiently sensitive to diagnose the type of injuries that pre-dispose patients to the neurobehavioural sequelae that have been associated with a concussion; confounding this is the finding that many of these signs and symptoms associated with concussion occur in other types of non-head injuries. Brain biomarkers and functional MRI ( fMRI) hold promise in both diagnosis and prognosis of concussion, but are still research tools without validated clinical utility at this time. Finally, neurocognitive testing holds promise as a diagnostic criterion to demonstrate injury but, unfortunately, these tests are also limited in their prognostic utility and are of limited value. C1 [Riggio, Silvana] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Riggio, Silvana] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Riggio, Silvana] James J Peters Vet Adm, Dept Psychiat, Bronx, NY USA. [Jagoda, Andy] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. RP Riggio, S (reprint author), Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA. EM silvana.riggio@mssm.edu NR 37 TC 0 Z9 0 U1 7 U2 7 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0954-0261 EI 1369-1627 J9 INT REV PSYCHIATR JI Int. Rev. Psych. PD DEC PY 2016 VL 28 IS 6 SI SI BP 579 EP 586 DI 10.1080/09540261.2016.1220927 PG 8 WC Psychiatry SC Psychiatry GA ED1HM UT WOS:000388595900007 PM 27671123 ER PT J AU Chiotos, K Vendetti, N Zaoutis, TE Baddley, J Ostrosky-Zeichner, L Pappas, P Fisher, BT AF Chiotos, Kathleen Vendetti, Neika Zaoutis, Theoklis E. Baddley, John Ostrosky-Zeichner, Luis Pappas, Peter Fisher, Brian T. TI Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12) SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article ID INFECTIOUS-DISEASES SOCIETY; INVASIVE CANDIDIASIS; IMPACT; EPIDEMIOLOGY; MANAGEMENT; OUTCOMES; AMERICA; UPDATE AB Objectives: A polymorphism in the gene encoding beta-1,3-glucan synthase, the target of the echinocandin class of antifungals, results in increased in vitro MICs of the echinocandins. This has resulted in controversy surrounding use of the echinocandins for treatment of Candida parapsilosis candidaemia. We aimed to compare 30 day mortality in adults with C. parapsilosis candidaemia treated with echinocandins versus fluconazole. Methods: This is a retrospective observational cohort study. We used the Premier Perspective Database to identify adult patients with C. parapsilosis candidaemia treated with only fluconazole or only an echinocandin as definitive therapy. The primary outcome was 30 day mortality. Propensity scores were derived to estimate the probability the patient would have received either an echinocandin or fluconazole. Inverse probability of treatment weighting (IPTW) was used in a weighted logistic regression to calculate odds of 30 day mortality. Results: There were 307 unique patients with C. parapsilosis candidaemia. One hundred and twenty-six (41%) received fluconazole and 181 (59%) received an echinocandin. Age, gender, race, year of admission, need for ICU resources in the week prior to candidaemia onset, and receipt of vasopressors on the day of candidaemia onset were included in the propensity score model used to calculate inverse probability of treatment weights. Weighted logistic regression demonstrated no difference in 30 day mortality between patients receiving an echinocandin as compared with fluconazole (OR 0.82, 95% CI 0.33-2.07). Conclusions: Our result supports the 2016 IDSA invasive candidiasis guidelines, which no longer clearly favour treatment with fluconazole over an echinocandin for C. parapsilosis candidaemia. C1 [Chiotos, Kathleen; Vendetti, Neika; Zaoutis, Theoklis E.; Fisher, Brian T.] Childrens Hosp Philadelphia, Div Infect Dis, Abramson Res Bldg,Room 1202,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. [Chiotos, Kathleen] Childrens Hosp Philadelphia, Div Crit Care Med, Philadelphia, PA 19104 USA. [Chiotos, Kathleen; Vendetti, Neika; Zaoutis, Theoklis E.; Fisher, Brian T.] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA. [Zaoutis, Theoklis E.; Fisher, Brian T.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Baddley, John; Pappas, Peter] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Baddley, John] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. [Ostrosky-Zeichner, Luis] Univ Texas Med Sch, Div Infect Dis, Houston, TX USA. RP Chiotos, K (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, Abramson Res Bldg,Room 1202,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM chiotosk@email.chop.edu FU National Institutes of Health [T32HD060550] FX This work was supported by the National Institutes of Health (T32HD060550 to K. C.). NR 15 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD DEC PY 2016 VL 71 IS 12 BP 3536 EP 3539 DI 10.1093/jac/dkw305 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA ED4HT UT WOS:000388809300032 PM 27494929 ER PT J AU Balog, J Mehta, SL Vemuganti, R AF Balog, Justin Mehta, Suresh L. Vemuganti, Raghu TI Mitochondrial fission and fusion in secondary brain damage after CNS insults SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Review DE Apoptosis; fission; fusion; mitochondria; neuroprotection ID DYNAMIN-RELATED PROTEIN-1; OUTER-MEMBRANE PERMEABILIZATION; DOMINANT OPTIC ATROPHY; TRANSIENT CEREBRAL-ISCHEMIA; ALPHA-SYNUCLEIN; CELL-DEATH; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN AB Mitochondria are dynamically active organelles, regulated through fission and fusion events to continuously redistribute them across axons, dendrites, and synapses of neurons to meet bioenergetics requirements and to control various functions, including cell proliferation, calcium buffering, neurotransmission, oxidative stress, and apoptosis. However, following acute or chronic injury to CNS, altered expression and function of proteins that mediate fission and fusion lead to mitochondrial dynamic imbalance. Particularly, if the fission is abnormally increased through pro-fission mediators such as Drp1, mitochondrial function will be impaired and mitochondria will become susceptible to insertion of proapototic proteins. This leads to the formation of mitochondrial transition pore, which eventually triggers apoptosis. Thus, mitochondrial dysfunction is a major promoter of neuronal death and secondary brain damage after an insult. This review discusses the implications of mitochondrial dynamic imbalance in neuronal death after acute and chronic CNS insults. C1 [Balog, Justin; Mehta, Suresh L.; Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA. [Vemuganti, Raghu] Univ Wisconsin, Neurosci Training Program, Madison, WI USA. [Vemuganti, Raghu] Univ Wisconsin, Cellular & Mol Pathol Training Program, Madison, WI USA. [Mehta, Suresh L.; Vemuganti, Raghu] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Vemuganti, R (reprint author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA. EM vemuganti@neurosurgery.wisc.edu FU NIH [NS082957, NS083007, NS095192]; VA Merit Review Grant [I01BX002985] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by NIH grants NS082957, NS083007, NS095192 and VA Merit Review Grant I01BX002985. NR 147 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD DEC PY 2016 VL 36 IS 12 BP 2022 EP 2033 DI 10.1177/0271678X16671528 PG 12 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA ED8RI UT WOS:000389138200002 PM 27677674 ER PT J AU Cosgrove, BD Mui, KL Driscoll, TP Caliari, SR Mehta, KD Assoian, RK Burdick, JA Mauck, RL AF Cosgrove, Brian D. Mui, Keeley L. Driscoll, Tristan P. Caliari, Steven R. Mehta, Kush D. Assoian, Richard K. Burdick, Jason A. Mauck, Robert L. TI N-cadherin adhesive interactions modulate matrix mechanosensing and fate commitment of mesenchymal stem cells SO NATURE MATERIALS LA English DT Article ID ALPHA-CATENIN; RHO GTPASES; JUNCTIONS; HYDROGELS; CHONDROGENESIS; STIFFNESS; TENSION; YAP/TAZ; GROWTH; RAC AB During mesenchymal development, the microenvironment gradually transitions from one that is rich in cell-cell interactions to one that is dominated by cell-ECM (extracellular matrix) interactions. Because these cues cannot readily be decoupled in vitro or in vivo, how they converge to regulate mesenchymal stem cell (MSC) mechanosensing is not fully understood. Here, we show that a hyaluronic acid hydrogel system enables, across a physiological range of ECM stiffness, the independent co-presentation of the HAVDI adhesive motif from the EC1 domain of N-cadherin and the RGD adhesive motif from fibronectin. Decoupled presentation of these cues revealed that HAVDI ligation (at constant RGD ligation) reduced the contractile state and thereby nuclear YAP/TAZ localization in MSCs, resulting in altered interpretation of ECM stiffness and subsequent changes in downstream cell proliferation and differentiation. Our findings reveal that, in an evolving developmental context, HAVDI/N-cadherin interactions can alter stem cell perception of the stiffening extracellular microenvironment. C1 [Cosgrove, Brian D.; Driscoll, Tristan P.; Mehta, Kush D.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Cosgrove, Brian D.; Driscoll, Tristan P.; Caliari, Steven R.; Mehta, Kush D.; Burdick, Jason A.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Driscoll, Tristan P.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. [Assoian, Richard K.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu OI Driscoll, Tristan/0000-0002-2426-5551 FU National Institutes of Health [R01 EB008722, R01 HL115553]; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX The authors would like to thank C. McLeod for assistance with atomic force microscopy and curve fitting, C. Rodell for helpful discussions regarding MeHA synthesis and peptide conjugation, and M. Guvendiren for assistance with preliminary studies. This work was funded by the National Institutes of Health (R01 EB008722, R01 HL115553) and the Penn Center for Musculoskeletal Disorders (P30 AR050950). NR 53 TC 2 Z9 2 U1 24 U2 24 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1476-1122 EI 1476-4660 J9 NAT MATER JI Nat. Mater. PD DEC PY 2016 VL 15 IS 12 BP 1297 EP 1306 DI 10.1038/NMAT4725 PG 10 WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Materials Science; Physics GA ED8EI UT WOS:000389104400018 PM 27525568 ER PT J AU Parthasarathy, S Carskadon, MA Jean-Louis, G Owens, J Bramoweth, A Combs, D Hale, L Harrison, E Hart, CN Hasler, BP Honaker, SM Hertenstein, E Kuna, S Kushida, C Levenson, JC Murray, C Pack, AI Pillai, V Pruiksma, K Seixas, A Strollo, P Thosar, SS Williams, N Buysse, D AF Parthasarathy, Sairam Carskadon, Mary A. Jean-Louis, Girardin Owens, Judith Bramoweth, Adam Combs, Daniel Hale, Lauren Harrison, Elizabeth Hart, Chantelle N. Hasler, Brant P. Honaker, Sarah M. Hertenstein, Elisabeth Kuna, Samuel Kushida, Clete Levenson, Jessica C. Murray, Caitlin Pack, Allan I. Pillai, Vivek Pruiksma, Kristi Seixas, Azizi Strollo, Patrick Thosar, Saurabh S. Williams, Natasha Buysse, Daniel TI Implementation of Sleep and Circadian Science: Recommendations from the Sleep Research Society and National Institutes of Health Workshop SO SLEEP LA English DT Article ID POSITIVE AIRWAY PRESSURE; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; SCHOOL START TIMES; PATIENT-CENTERED OUTCOMES; RISK-TAKING BEHAVIOR; APNEA SYNDROME; PRIMARY-CARE; FOLLOW-UP; CARDIOVASCULAR-DISEASE C1 [Parthasarathy, Sairam; Combs, Daniel] Univ Arizona, UAHS Ctr Sleep & Circadian Sci, Tucson, AZ USA. [Carskadon, Mary A.] Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Med Sch, Providence, RI 02912 USA. [Carskadon, Mary A.] Univ South Australia, Sch Psychol Social Work & Social Policy, Ctr Sleep Res, Adelaide, SA, Australia. [Jean-Louis, Girardin; Seixas, Azizi; Williams, Natasha] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Owens, Judith] Boston Childrens Hosp, Boston, MA USA. [Bramoweth, Adam; Buysse, Daniel] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hale, Lauren] SUNY Stony Brook, Dept Family Populat & Prevent Med, Stony Brook, NY 11794 USA. [Harrison, Elizabeth] Univ San Diego, Ctr Circadian Biol, San Diego, CA 92110 USA. [Hart, Chantelle N.] Temple Univ, Social & Behav Sci & Ctr Obes Res & Educ, Coll Publ Hlth, Philadelphia, PA USA. [Hasler, Brant P.; Levenson, Jessica C.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA USA. [Honaker, Sarah M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA. [Hertenstein, Elisabeth] Univ Med Ctr Freiburg, Freiburg, Germany. [Kuna, Samuel; Pack, Allan I.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA USA. [Kushida, Clete] Stanford Univ, Palo Alto, CA 94304 USA. [Murray, Caitlin] Loyola Univ Chicago, Dept Psychol, Chicago, IL USA. [Pillai, Vivek] Henry Ford Hlth Syst, Sleep Disorders & Res Ctr, Detroit, MI USA. [Pruiksma, Kristi] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Thosar, Saurabh S.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Thosar, Saurabh S.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA. RP Parthasarathy, S (reprint author), Univ Arizona, Med, 1501 N Campbell Ave,UAHS Rm 2342D, Tucson, AZ 85724 USA. EM spartha1@email.arizona.edu RI Levenson, Jessica/O-5448-2015; Hasler, Brant/D-5989-2017 OI Hasler, Brant/0000-0002-3123-1106; Jean-Louis, Girardin/0000-0001-6777-2724 FU Sleep Research Society, Darien, IL; Merck; Purdue Pharma; Cereve; Emmi solutions; Philips Respironics; WebMD; CME Outfitters; Astellas; Servier; National Insitutes of Health; National Space Biomedical Research Institute [NCC 9-58, NIH/NHLBI R01 HL125893, NIH/NHLBI 1F32HL131308-01]; NIH/NICHD [HD073352]; NIH/NIA [AG036838]; NIH/NHLBI [HL122460] FX This was not an industry supported study. Funding was provided by the Sleep Research Society, Darien, IL. Dr. Parthasarathy reports grants from NIH/NHLBI (HL095799), grants from Patient Centered Outcomes Research Institute (IHS-1306-02505 and EAIN 3394-UoA), grants from US Department of Defense, grants from NIH (National Cancer Institute; R21CA184920), grants from Johrei Institute, personal fees from American Academy of Sleep Medicine, personal fees from American College of Chest Physicians, non-financial support from National Center for Sleep Disorders Research of the NIH (NHLBI), personal fees from UpToDate Inc., Philips-Respironics, Inc., and Vapotherm, Inc.; grants from Younes Sleep Technologies, Ltd., Niveus Medical Inc., and Philips-Respironics, Inc. outside the submitted work. In addition, Dr. Parthasarathy has a patent UA 14-018 U.S.S.N. 61/884,654; PTAS 502570970 (Home breathing device). The above-mentioned conflicts including the patent are unrelated to the topic of this paper. Dr. Buysse has served as a paid consultant to the following companies, over the past 5 years: Merck, Purdue Pharma, Cereve, Emmi solutions, Philips Respironics, WebMD, CME Outfitters. He has served as a paid speaker at educational conferences for Astellas and Servier. Dr. Buysse receives research grant support from the National Insitutes of Health. Dr. Thosar was supported by National Space Biomedical Research Institute through NCC 9-58, NIH/NHLBI R01 HL125893, NIH/NHLBI 1F32HL131308-01 during the writing of this manuscript. Dr. Hale reports current grant support from NIH/NICHD (HD073352), NIH/NIA (AG036838) and NIH/NHLBI (HL122460) and has served as a consultant to the BoomShop during the writing of this manuscript. Dr. Hale also sits on the Board of the Directors for the National Sleep Foundation and receives an honorarium for her role as Editor of Sleep Health. The other authors have indicated no financial conflicts of interest. NR 198 TC 0 Z9 0 U1 15 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD DEC 1 PY 2016 VL 39 IS 12 BP 2061 EP 2075 AR PII sp-00553-16 DI 10.5665/sleep.6300 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ED5ZK UT WOS:000388932700001 PM 27748248 ER PT J AU Ross, DA Ross, MN AF Ross, Donald A. Ross, Miner N. TI Diagnosis and Treatment of C4 Radiculopathy SO SPINE LA English DT Article DE asymptomatic C4 foraminal stenosis; C4 radiculopathy; C4 root block; facet mediated pain ID CERVICAL RADICULOPATHY; VERTEBRAL ARTERY; NECK PAIN; ROOT; INJECTIONS; DERMATOMES; ANATOMY; BLOCKS; C3 AB Study Design.Clinical case series.Objective.This study sought to clarify symptoms, diagnostic criteria, and treatment of C4 radiculopathy, and the role of diagnostic C4 root block in this entity.Summary of Background Data.Although well understood cervical dermatomal/myotomal syndromes have been described for symptoms originating from impingement on the C2, C3, C5, C6, C7, and C8 roots, less has been written about the syndrome(s) associated with the C4 root.Methods.The senior author reviewed surgical records and describes his personal experience with the diagnosis and treatment of C4 radiculopathy.Results.A total of 712 procedures for cervical radiculopathy without myelopathy were reviewed. Among that cohort, 13 procedures involved the C4 root only and five procedures involved two level procedures including the C4 root. Patients described pain as involving the axial cervical region, paraspinal muscles, trapezius muscle, and interscapular region. No patient described pain over the anterior chest wall or radiating distal to the shoulder, one described pain over the medial clavicle. All patients who were offered surgery had a positive response to a diagnostic C4 transforaminal single nerve root block. Thirteen patients underwent posterior foraminotomy (five at two levels) and five patients underwent an anterior discectomy and fusion at C3-4. Mean Oswestry Disability Index score significantly declined; preoperative score 24.3 (range 14-29), postoperative score 9.7 (range 2-18; P=0.003) at 3 months. Mean Short Form-36v2 score significantly increased; preoperative score 34.2 (range 20-40.2), postoperative score 73.7 (range 40.5-88.3, P=0.001) at 3 months.Conclusion.C4 root symptoms overlap those of the C3 and C5 roots and are very similar to facet mediated pain. Asymptomatic C4 foraminal stenosis may be a common imaging finding, it can be difficult to diagnose C4 radiculopathy clinically. Diagnostic C4 root block can make an accurate diagnosis and lead to successful surgical outcomes.Level of Evidence: 4 C1 [Ross, Donald A.] Oregon Hlth & Sci Univ, Dept Neurol Surg, 3303 SW Bond Ave,CH8N, Portland, OR 97239 USA. [Ross, Donald A.] Portland VA Med Ctr, Operat Care Div, Sect Neurol Surg, Portland, OR USA. [Ross, Miner N.] New York Med Coll, New York, NY USA. RP Ross, DA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3303 SW Bond Ave,CH8N, Portland, OR 97239 USA. EM rossdo@ohsu.edu NR 34 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD DEC 1 PY 2016 VL 41 IS 23 BP 1790 EP 1794 DI 10.1097/BRS.0000000000001620 PG 5 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA ED3CG UT WOS:000388726300013 PM 27054454 ER PT J AU Nuschke, A Rodrigues, M Wells, AW Sylakowski, K Wells, A AF Nuschke, Austin Rodrigues, Melanie Wells, Albin W. Sylakowski, Kyle Wells, Alan TI Mesenchymal stem cells/multipotent stromal cells (MSCs) are glycolytic and thus glucose is a limiting factor of in vitro models of MSC starvation SO STEM CELL RESEARCH & THERAPY LA English DT Article DE Multipotent stem cells; Mesenchymal stem cells; Glucose metabolism; Nutrient starvation; Stem cell survival ID SERUM DEPRIVATION; DIFFERENTIATION; HYPOXIA; PROLIFERATION; BIOENERGETICS; PLURIPOTENCY; SURVIVAL; CULTURE; NUMBER; GROWTH AB Background: Mesenchymal stem/multipotent stromal cells (MSCs) contribute to tissue repair but are challenged during wound healing when the blood supply is disrupted, thereby limiting nutrient delivery. Survival mechanisms against 'starvation' include autophagy, which we previously found to enhance differentiation efficiency. MSC response to models of in vitro nutrient deprivation are of great interest for improving MSC survival and therapeutic efficacy; however, the rate-limiting nutrients are unknown. Methods: MSC responses to culture nutrient and/or serum deprivations were assessed through light microscopy, cell survival, and measurements of metabolic levels. Glucose uptake was determined through conditioned media analyses over 3 days of culture. The Seahorse XF24 Flux analysis system was used to determine oxygen consumption and extracellular acidification for glycolytic metabolism. MSC autophagic response to these conditions was assessed via immunoblots for LC3-I and LC3-II, markers of autophagosome turnover. Results: We more closely examined limiting nutritional factors to MSC survival in vitro, finding that glucose is rapidly utilized/depleted whereas amino acids and other required nutrients were used sparingly. This finding concurred with metabolic analyses that showed a primarily glycolytic character to the MSCs at steady state. MSC autophagy, previously linked to MSC function through a unique accumulated autophagosome phenotype, also responded quickly to changes in glucose concentration, with drastic LC3-II changes within 24 h of glucose concentration shifts. Conclusions: Our results demonstrated a rapid uptake of glucose in MSC cultures that was due to a highly glycolytic phenotype for the cells; MSC starvation with serum or other nutrients appears to have a less notable effect on the cells. These findings highlight the importance of glucose and glucose metabolism on MSC function. The conditions and cellular responses outlined here may be essential in modeling MSC nutrient deprivation. C1 [Nuschke, Austin; Rodrigues, Melanie; Sylakowski, Kyle; Wells, Alan] Univ Pittsburgh, Dept Pathol, Sch Med, Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Nuschke, Austin; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, 450 Technol Dr, Pittsburgh, PA 15219 USA. [Wells, Alan] VA Pittsburgh Hlth Syst, Univ Dr A, Pittsburgh, PA 15261 USA. [Wells, Albin W.] Taylor Allderdice High Sch, 2409 Shady Ave, Pittsburgh, PA 15217 USA. [Rodrigues, Melanie] Stanford Univ, Dept Plast & Reconstruct Surg, Palo Alto, CA 94304 USA. RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, Sch Med, Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.; Wells, A (reprint author), Univ Pittsburgh, McGowan Inst Regenerat Med, 450 Technol Dr, Pittsburgh, PA 15219 USA.; Wells, A (reprint author), VA Pittsburgh Hlth Syst, Univ Dr A, Pittsburgh, PA 15261 USA. EM wellsa@upmc.edu FU NIH [GM063569, GM069668]; [T32s EB001026]; [CA175294] FX This project was supported by NIH grants GM063569 and GM069668, and support to AN from T32s EB001026 and CA175294. NR 21 TC 0 Z9 0 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1757-6512 J9 STEM CELL RES THER JI Stem Cell Res. Ther. PD DEC 1 PY 2016 VL 7 AR 179 DI 10.1186/s13287-016-0436-7 PG 9 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA ED7GD UT WOS:000389029300001 PM 27906055 ER PT J AU Wu, JJ Sun, Y Block, TJ Marinkovic, M Zhang, ZL Chen, R Yin, YX Song, JQ Dean, DD Lu, ZD Chen, XD AF Wu, Junjie Sun, Yun Block, Travis J. Marinkovic, Milos Zhang, Zhi-Liang Chen, Richard Yin, Yixia Song, Juquan Dean, David D. Lu, Zhongding Chen, Xiao-Dong TI Umbilical cord blood-derived non-hematopoietic stem cells retrieved and expanded on bone marrow-derived extracellular matrix display pluripotent characteristics SO STEM CELL RESEARCH & THERAPY LA English DT Article DE Umbilical cord blood; CD146-positive cells; Plastic non-adherent cells; Extracellular matrix-adherent cells; Pluripotent stem cells; Extracellular matrix; Three germ layer tissue formation in vivo ID MESENCHYMAL STEM/PROGENITOR CELLS; ADIPOSE-TISSUE; PROGENITOR CELLS; IN-VITRO; EX-VIVO; DIFFERENTIATION; CULTURE; LINES; TRANSPLANTATION; IDENTIFICATION AB Background: Umbilical cord blood (UCB) not only contains hematopoietic stem cells (HSCs), but also nonhematopoietic stem cells (NHSCs) that are able to differentiate into a number of distinct cell types. Based on studies published to date, the frequency of NHSCs in UCB is believed to be very low. However, the isolation of these cells is primarily based on their adhesion to tissue culture plastic surfaces. Methods and results: In the current study, we demonstrate that this approach overlooks some of the extremely immature NHSCs because they lack the ability to adhere to plastic. Using a native extracellular matrix (ECM), produced by bone marrow (BM) stromal cells, the majority of the UCB-NHSCs attached within 4 h. The colony-forming unit fibroblast frequency of these cells was 1.5 x 10(4)/10(8) mononuclear cells, which is at least 4000-fold greater than previously reported for UCB-NHSCs. The phenotype of these cells was fibroblast-like and different from those obtained by plastic adhesion; they formed embryonic body-like clusters that were OCT4-positive and expressed other human embryonic stem cell-related markers. Importantly, when implanted subcutaneously for 8 weeks into immunocompromised mice, these ECM-adherent and expanded NHSCs generated three germ layer-derived human tissues including muscle, fat, blood vessel, bone, gland, and nerve. Moreover, injection of these cells into muscle damaged by cryoinjury significantly accelerated muscle regeneration. Conclusions: These results indicate that UCB may be a virtually unlimited source of NHSCs when combined with isolation and expansion on ECM. NHSCs may be a practical alternative to embryonic stem cells for a number of therapeutic applications. C1 [Wu, Junjie; Sun, Yun; Block, Travis J.; Marinkovic, Milos; Zhang, Zhi-Liang; Chen, Richard; Yin, Yixia; Dean, David D.; Lu, Zhongding; Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Div Res, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Wu, Junjie] Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, Xian 710032, Shaanxi, Peoples R China. [Sun, Yun] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Ctr Reprod Med, Shanghai 200135, Peoples R China. [Block, Travis J.; Marinkovic, Milos; Dean, David D.] Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX 78249 USA. [Zhang, Zhi-Liang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Plast Surg, Sch Med, Shanghai, Peoples R China. [Yin, Yixia] Wuhan Univ Technol, Biomed Mat Engn Res Ctr, Wuhan, Peoples R China. [Song, Juquan] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Chen, Xiao-Dong] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Res Serv, San Antonio, TX 78229 USA. RP Lu, ZD; Chen, XD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Res, Dept Comprehens Dent, San Antonio, TX 78229 USA.; Chen, XD (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, Res Serv, San Antonio, TX 78229 USA. EM xwdlu@yahoo.com; chenx4@uthscsa.edu OI Dean, David/0000-0002-4512-9065 FU University Research Council Grants Program at the University of Texas Health Science Center at San Antonio (UTHSCSA); VA Merit Review [1 I01 BX000580]; UTHSCSA; NIH-NCI [P30 CA54174]; NIH-NIA [P30 AG013319, P01 AG19316] FX This work was supported by the University Research Council Grants Program at the University of Texas Health Science Center at San Antonio (UTHSCSA) (X-DC) and a VA Merit Review (X-DC) (1 I01 BX000580). The funding agencies did not participate in the design of the study, collecting, analyzing or interpreting the data, or writing the manuscript. Confocal images were generated in the Optical Imaging Core Facility which is supported by UTHSCSA, NIH-NCI P30 CA54174 (San Antonio Cancer Institute), NIH-NIA P30 AG013319 (Nathan Shock Center), and NIH-NIA P01 AG19316. NR 51 TC 0 Z9 0 U1 11 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1757-6512 J9 STEM CELL RES THER JI Stem Cell Res. Ther. PD DEC 1 PY 2016 VL 7 AR 176 DI 10.1186/s13287-016-0437-6 PG 14 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA ED7FZ UT WOS:000389028900001 PM 27906056 ER PT J AU Bandello, F Corvi, F La Spina, C Benatti, L Querques, L Capuano, V Naysan, J Chen, XJ Sarraf, D Parodi, MB Souied, E Freund, KB Querques, G AF Bandello, Francesco Corvi, Federico La Spina, Carlo Benatti, Lucia Querques, Lea Capuano, Vittorio Naysan, Jonathan Chen, Xuejing Sarraf, David Parodi, Maurizio Battaglia Souied, Eric Freund, K. Bailey Querques, Giuseppe TI Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB PLUS PROMPT; DEFERRED LASER; CHOROIDAL NEOVASCULARIZATION; TRAP-EYE; EDEMA; CLASSIFICATION; SEVERITY; ANCHOR AB Purpose To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR). Methods Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed. Results Forty-one eyes of 38 patients (21 male, 17 female; mean age 78 +/- 8 years) were enrolled. Median follow-up was 28 +/- 19 (12-72) months with a mean of 9.2 +/- 7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5 +/- 0.3 logMAR; it improved significantly at 1 year (0.3 +/- 0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6 +/- 0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408 +/- 150 mu m to 328 +/- 104 mu m at 1 year (p=0.021) and to 335 +/- 127 mu m at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51%) eyes, moderate NPDR in 14 (34%), severe NPDR in 4 (10%) and inactive proliferative DR in 2 (5%). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation. Conclusions Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up. C1 [Bandello, Francesco; Corvi, Federico; La Spina, Carlo; Benatti, Lucia; Querques, Lea; Parodi, Maurizio Battaglia; Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS San Raffaele Sci, Milan, Italy. [Capuano, Vittorio; Souied, Eric; Querques, Giuseppe] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France. [Naysan, Jonathan; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Naysan, Jonathan; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA. [Chen, Xuejing; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Querques, G (reprint author), Univ Vita Salute, Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy. EM giuseppe.querques@hotmail.it OI Corvi, Federico/0000-0002-2661-5500; Freund, K. Bailey/0000-0002-7888-9773 NR 31 TC 2 Z9 2 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 EI 1468-2079 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD DEC PY 2016 VL 100 IS 12 BP 1611 EP 1616 DI 10.1136/bjophthalmol-2016-308400 PG 6 WC Ophthalmology SC Ophthalmology GA EC7XD UT WOS:000388353500005 PM 26951773 ER EF